abs | rel | |
---|---|---|
Health | 1053 | 98.0% |
Medicine | 1039 | 96.7% |
Health sciences | 1015 | 94.5% |
Medical specialties | 996 | 92.7% |
Clinical medicine | 962 | 89.6% |
Health care | 923 | 85.9% |
Public health | 503 | 46.8% |
Diseases and disorders | 454 | 42.3% |
Risk | 345 | 32.1% |
Epidemiology | 338 | 31.5% |
Infection | 318 | 29.6% |
Disease | 294 | 27.4% |
Preventive healthcare | 274 | 25.5% |
Randomized controlled trial | 231 | 21.5% |
Clinical trial | 215 | 20.0% |
Evidence-based medicine | 215 | 20.0% |
Cancer | 211 | 19.6% |
Systematic review | 195 | 18.2% |
Medical diagnosis | 181 | 16.9% |
Cardiovascular disease | 171 | 15.9% |
Therapy | 166 | 15.5% |
Infectious diseases | 163 | 15.2% |
Meta-analysis | 160 | 14.9% |
HIV/AIDS | 158 | 14.7% |
Health economics | 157 | 14.6% |
Immunology | 155 | 14.4% |
Adherence (medicine) | 152 | 14.2% |
Medication | 147 | 13.7% |
Screening (medicine) | 147 | 13.7% |
Sensitivity and specificity | 147 | 13.7% |
Chronic condition | 146 | 13.6% |
Medical humanities | 145 | 13.5% |
Health policy | 143 | 13.3% |
Hospital | 143 | 13.3% |
Medical guideline | 139 | 12.9% |
Patient | 138 | 12.8% |
Surgery | 136 | 12.7% |
Hypertension | 134 | 12.5% |
Research | 134 | 12.5% |
Heart | 132 | 12.3% |
Biology | 131 | 12.2% |
Myocardial infarction | 128 | 11.9% |
Coronary artery disease | 123 | 11.5% |
Stroke | 119 | 11.1% |
Tuberculosis | 117 | 10.9% |
Health professional | 115 | 10.7% |
Life sciences | 113 | 10.5% |
Human activities | 111 | 10.3% |
Cardiovascular system | 109 | 10.1% |
Microbiology | 106 | 9.9% |
Vaccine | 104 | 9.7% |
Pregnancy | 101 | 9.4% |
Antimicrobial resistance | 100 | 9.3% |
Cardiology | 95 | 8.8% |
Cohort study | 94 | 8.8% |
Obesity | 93 | 8.7% |
Blood pressure | 85 | 7.9% |
Confidence interval | 84 | 7.8% |
Medical treatments | 80 | 7.4% |
Health system | 79 | 7.4% |
Childbirth | 78 | 7.3% |
Medical imaging | 78 | 7.3% |
Diabetes | 77 | 7.2% |
Nursing | 77 | 7.2% |
Breast cancer | 76 | 7.1% |
Virus | 76 | 7.1% |
Sexually transmitted infection | 75 | 7.0% |
Major depressive disorder | 73 | 6.8% |
Management of HIV/AIDS | 72 | 6.7% |
Statin | 72 | 6.7% |
Emergency department | 71 | 6.6% |
Cholesterol | 68 | 6.3% |
Human reproduction | 66 | 6.1% |
Low-density lipoprotein | 66 | 6.1% |
Blinded experiment | 65 | 6.1% |
Caregiver | 65 | 6.1% |
Evaluation | 65 | 6.1% |
Comorbidity | 63 | 5.9% |
Hepatitis | 63 | 5.9% |
Adverse effect | 62 | 5.8% |
Exercise | 62 | 5.8% |
Type 2 diabetes | 62 | 5.8% |
Drugs | 61 | 5.7% |
Quality-adjusted life year | 60 | 5.6% |
Transmission (medicine) | 60 | 5.6% |
Heart failure | 59 | 5.5% |
Pharmacy | 57 | 5.3% |
Public sphere | 57 | 5.3% |
Statistics | 57 | 5.3% |
Antibiotic | 56 | 5.2% |
COVID-19 pandemic | 56 | 5.2% |
Influenza | 56 | 5.2% |
Neoplasms | 56 | 5.2% |
High-density lipoprotein | 55 | 5.1% |
Physician | 55 | 5.1% |
CT scan | 54 | 5.0% |
Cost-effectiveness analysis | 54 | 5.0% |
Medicare (United States) | 54 | 5.0% |
Pneumonia | 54 | 5.0% |
Electronic health record | 53 | 4.9% |
Coronavirus disease 2019 | 52 | 4.8% |
Chemotherapy | 51 | 4.7% |
Receiver operating characteristic | 51 | 4.7% |
Colorectal cancer | 50 | 4.7% |
Tuberculosis management | 50 | 4.7% |
Anticoagulant | 49 | 4.6% |
Diagnosis of HIV/AIDS | 49 | 4.6% |
Internal medicine | 49 | 4.6% |
Pharmacology | 49 | 4.6% |
Chronic kidney disease | 48 | 4.5% |
Glycated hemoglobin | 48 | 4.5% |
HIV | 46 | 4.3% |
Dose (biochemistry) | 45 | 4.2% |
Medical test | 45 | 4.2% |
Thrombosis | 45 | 4.2% |
Venous thrombosis | 45 | 4.2% |
Risk assessment | 44 | 4.1% |
Lung cancer | 43 | 4.0% |
Physical therapy | 43 | 4.0% |
Radiology | 43 | 4.0% |
Self-care | 43 | 4.0% |
Vaccination | 43 | 4.0% |
Asthma | 42 | 3.9% |
General practitioner | 42 | 3.9% |
Primary care | 42 | 3.9% |
Radiation therapy | 42 | 3.9% |
Angina | 41 | 3.8% |
Multi-drug-resistant tuberculosis | 41 | 3.8% |
Renal function | 41 | 3.8% |
Angiology | 40 | 3.7% |
Atrial fibrillation | 40 | 3.7% |
Preterm birth | 39 | 3.6% |
Breastfeeding | 38 | 3.5% |
Cancer screening | 38 | 3.5% |
Hypercholesterolemia | 38 | 3.5% |
Immunodeficiency | 38 | 3.5% |
Mental disorder | 38 | 3.5% |
Osteoporosis | 38 | 3.5% |
Cervical cancer | 37 | 3.4% |
Positive and negative predictive values | 37 | 3.4% |
Severe acute respiratory syndrome coronavirus 2 | 37 | 3.4% |
Atherosclerosis | 36 | 3.4% |
Body mass index | 36 | 3.4% |
COVID-19 | 36 | 3.4% |
Circulatory system | 36 | 3.4% |
GeneXpert MTB/RIF | 36 | 3.4% |
Prostate cancer | 36 | 3.4% |
Antihypertensive drug | 35 | 3.3% |
Biomarker | 35 | 3.3% |
Chronic obstructive pulmonary disease | 35 | 3.3% |
Health informatics | 35 | 3.3% |
Percutaneous coronary intervention | 35 | 3.3% |
Aspirin | 34 | 3.2% |
Patient safety | 34 | 3.2% |
Sepsis | 34 | 3.2% |
Adjuvant therapy | 33 | 3.1% |
Diabetes management | 33 | 3.1% |
Magnetic resonance imaging | 33 | 3.1% |
Medicaid | 33 | 3.1% |
Transient ischemic attack | 33 | 3.1% |
Dementia | 32 | 3.0% |
Hospital readmission | 32 | 3.0% |
Men who have sex with men | 32 | 3.0% |
Mental health | 32 | 3.0% |
Pandemic | 32 | 3.0% |
Safety | 32 | 3.0% |
Shortness of breath | 32 | 3.0% |
Blood sugar level | 31 | 2.9% |
Data analysis | 31 | 2.9% |
Health care quality | 31 | 2.9% |
Medical prescription | 31 | 2.9% |
Placebo | 31 | 2.9% |
RTT | 31 | 2.9% |
Safe sex | 31 | 2.9% |
Biopsy | 30 | 2.8% |
Causes of death | 30 | 2.8% |
Dietary supplement | 30 | 2.8% |
Intensive care unit | 30 | 2.8% |
Maternal health | 30 | 2.8% |
Pain | 30 | 2.8% |
Personal protective equipment | 30 | 2.8% |
Smoking cessation | 30 | 2.8% |
Bias | 29 | 2.7% |
Extensively drug-resistant tuberculosis | 29 | 2.7% |
Gonorrhea | 29 | 2.7% |
Hepatitis C | 29 | 2.7% |
Infection prevention and control | 29 | 2.7% |
Mammography | 29 | 2.7% |
Prediabetes | 29 | 2.7% |
Prescription drug | 29 | 2.7% |
Psychiatry | 29 | 2.7% |
Artificial intelligence | 28 | 2.6% |
Echocardiography | 28 | 2.6% |
Isolation (health care) | 28 | 2.6% |
Medical record | 28 | 2.6% |
Prevention of HIV/AIDS | 28 | 2.6% |
Reporting bias | 28 | 2.6% |
Sensitivity analysis | 28 | 2.6% |
Tobacco smoking | 28 | 2.6% |
Warfarin | 28 | 2.6% |
Condom | 27 | 2.5% |
Deep vein thrombosis | 27 | 2.5% |
Diabetes mellitus | 27 | 2.5% |
Electrocardiography | 27 | 2.5% |
Pediatrics | 27 | 2.5% |
Regression analysis | 27 | 2.5% |
Science | 27 | 2.5% |
Antibody | 26 | 2.4% |
Antiviral drug | 26 | 2.4% |
Human papillomavirus infection | 26 | 2.4% |
Incremental cost-effectiveness ratio | 26 | 2.4% |
Infant | 26 | 2.4% |
Influenza pandemic | 26 | 2.4% |
MEDLINE | 26 | 2.4% |
Malaria | 26 | 2.4% |
Medical statistics | 26 | 2.4% |
Ovarian cancer | 26 | 2.4% |
Post-exposure prophylaxis | 26 | 2.4% |
Psychotherapy | 26 | 2.4% |
Technology | 26 | 2.4% |
Beta blocker | 25 | 2.3% |
Biotechnology | 25 | 2.3% |
Infection control | 25 | 2.3% |
Ischemia | 25 | 2.3% |
Kidney failure | 25 | 2.3% |
Metastasis | 25 | 2.3% |
Methicillin-resistant Staphylococcus aureus | 25 | 2.3% |
Prenatal development | 25 | 2.3% |
Telehealth | 25 | 2.3% |
Vein | 25 | 2.3% |
Women's health | 25 | 2.3% |
Behavior | 24 | 2.2% |
Best practice | 24 | 2.2% |
Confounding | 24 | 2.2% |
Dieting | 24 | 2.2% |
Dual-energy X-ray absorptiometry | 24 | 2.2% |
Health equity | 24 | 2.2% |
Innovation | 24 | 2.2% |
Physical examination | 24 | 2.2% |
Sampling (statistics) | 24 | 2.2% |
Sexual health | 24 | 2.2% |
Sexual intercourse | 24 | 2.2% |
Avian influenza | 23 | 2.1% |
Bone density | 23 | 2.1% |
Branches of science | 23 | 2.1% |
C-reactive protein | 23 | 2.1% |
Ebola virus disease | 23 | 2.1% |
Genetics | 23 | 2.1% |
Immunization | 23 | 2.1% |
Menopause | 23 | 2.1% |
Physiology | 23 | 2.1% |
Pre-exposure prophylaxis | 23 | 2.1% |
Saturated fat | 23 | 2.1% |
Urology | 23 | 2.1% |
ACE inhibitor | 22 | 2.0% |
Birth defect | 22 | 2.0% |
Bleeding | 22 | 2.0% |
Influenza A virus subtype H5N1 | 22 | 2.0% |
Laparoscopy | 22 | 2.0% |
Machine learning | 22 | 2.0% |
Non-communicable disease | 22 | 2.0% |
Palliative care | 22 | 2.0% |
Point of care | 22 | 2.0% |
Study heterogeneity | 22 | 2.0% |
Acute coronary syndrome | 21 | 2.0% |
Bone | 21 | 2.0% |
Cardiovascular diseases | 21 | 2.0% |
Creative Commons license | 21 | 2.0% |
Diabetes mellitus type 2 | 21 | 2.0% |
Fecal occult blood | 21 | 2.0% |
Hospital-acquired infection | 21 | 2.0% |
Immune system | 21 | 2.0% |
International Statistical Classification of Diseases and Related Health Problems | 21 | 2.0% |
Lymphoma | 21 | 2.0% |
Miscarriage | 21 | 2.0% |
Pathology | 21 | 2.0% |
Prothrombin time | 21 | 2.0% |
Respiratory disease | 21 | 2.0% |
Social programs | 21 | 2.0% |
Weight loss | 21 | 2.0% |
Anesthesia | 20 | 1.9% |
Antiplatelet drug | 20 | 1.9% |
Birth control | 20 | 1.9% |
Bone fracture | 20 | 1.9% |
COVID-19 vaccine | 20 | 1.9% |
Colonoscopy | 20 | 1.9% |
Coronary artery bypass surgery | 20 | 1.9% |
Dependent and independent variables | 20 | 1.9% |
Gene | 20 | 1.9% |
Genetic testing | 20 | 1.9% |
Health insurance | 20 | 1.9% |
Hormone replacement therapy | 20 | 1.9% |
Influenza vaccine | 20 | 1.9% |
Lentiviruses | 20 | 1.9% |
Leukemia | 20 | 1.9% |
Reproductive health | 20 | 1.9% |
Shared decision-making in medicine | 20 | 1.9% |
Sustainable Development Goals | 20 | 1.9% |
Artificial cardiac pacemaker | 19 | 1.8% |
Cardiothoracic surgery | 19 | 1.8% |
Disease surveillance | 19 | 1.8% |
Health technology | 19 | 1.8% |
Hepatitis B | 19 | 1.8% |
Inflammation | 19 | 1.8% |
Intravenous therapy | 19 | 1.8% |
Measles | 19 | 1.8% |
Medical Subject Headings | 19 | 1.8% |
Metabolic syndrome | 19 | 1.8% |
Obstetrics | 19 | 1.8% |
Organ transplantation | 19 | 1.8% |
Polymerase chain reaction | 19 | 1.8% |
Standard deviation | 19 | 1.8% |
Zidovudine | 19 | 1.8% |
Allergy | 18 | 1.7% |
Angiotensin II receptor blocker | 18 | 1.7% |
Bisphosphonate | 18 | 1.7% |
Cirrhosis | 18 | 1.7% |
Cochrane Library | 18 | 1.7% |
Community health | 18 | 1.7% |
Decision-making | 18 | 1.7% |
Disability | 18 | 1.7% |
Fetus | 18 | 1.7% |
Hematopoietic stem cell transplantation | 18 | 1.7% |
Hepatocellular carcinoma | 18 | 1.7% |
Kidney | 18 | 1.7% |
Logistic regression | 18 | 1.7% |
Neurology | 18 | 1.7% |
Preventive medicine | 18 | 1.7% |
Prostate-specific antigen | 18 | 1.7% |
Publication bias | 18 | 1.7% |
Signs and symptoms | 18 | 1.7% |
Survey methodology | 18 | 1.7% |
Vitamin D | 18 | 1.7% |
Adolescence | 17 | 1.6% |
Alzheimer's disease | 17 | 1.6% |
Angiography | 17 | 1.6% |
Arrhythmia | 17 | 1.6% |
Bipolar disorder | 17 | 1.6% |
Blood transfusion | 17 | 1.6% |
Cost–utility analysis | 17 | 1.6% |
ELISA | 17 | 1.6% |
Emergency medicine | 17 | 1.6% |
Epidemic | 17 | 1.6% |
Framingham Risk Score | 17 | 1.6% |
Human pregnancy | 17 | 1.6% |
Information | 17 | 1.6% |
Medical device | 17 | 1.6% |
Medical ultrasound | 17 | 1.6% |
Neonatal intensive care unit | 17 | 1.6% |
Pharmaceutical sciences | 17 | 1.6% |
Phases of clinical research | 17 | 1.6% |
Surgical mask | 17 | 1.6% |
Sustainability | 17 | 1.6% |
Urinary tract infection | 17 | 1.6% |
Vertically transmitted infection | 17 | 1.6% |
Atheroma | 16 | 1.5% |
Blood | 16 | 1.5% |
CD4 | 16 | 1.5% |
Cardiac surgery | 16 | 1.5% |
Cervical screening | 16 | 1.5% |
Chlamydia infection | 16 | 1.5% |
DNA sequencing | 16 | 1.5% |
Determinants of health | 16 | 1.5% |
Education | 16 | 1.5% |
HER2/neu | 16 | 1.5% |
Intensive care medicine | 16 | 1.5% |
Lipoprotein | 16 | 1.5% |
Lung | 16 | 1.5% |
Metformin | 16 | 1.5% |
Neoplasm | 16 | 1.5% |
Nervous system | 16 | 1.5% |
Nevirapine | 16 | 1.5% |
Occupational safety and health | 16 | 1.5% |
Poverty | 16 | 1.5% |
Pre-eclampsia | 16 | 1.5% |
Prediction | 16 | 1.5% |
Rifampicin | 16 | 1.5% |
Risk management | 16 | 1.5% |
Sexually transmitted diseases and infections | 16 | 1.5% |
Simvastatin | 16 | 1.5% |
Spirometry | 16 | 1.5% |
Substance abuse | 16 | 1.5% |
Syphilis | 16 | 1.5% |
Vagina | 16 | 1.5% |
Validity (statistics) | 16 | 1.5% |
Vitamin | 16 | 1.5% |
Animal viral diseases | 15 | 1.4% |
Aortic stenosis | 15 | 1.4% |
BRCA mutation | 15 | 1.4% |
Cardioversion | 15 | 1.4% |
Current Procedural Terminology | 15 | 1.4% |
DPT vaccine | 15 | 1.4% |
Dabigatran | 15 | 1.4% |
Gynaecology | 15 | 1.4% |
Hip fracture | 15 | 1.4% |
Hyperglycemia | 15 | 1.4% |
Insurance | 15 | 1.4% |
Osteopenia | 15 | 1.4% |
Placebo-controlled study | 15 | 1.4% |
Public services | 15 | 1.4% |
Pulmonary embolism | 15 | 1.4% |
Qualitative research | 15 | 1.4% |
Social distancing | 15 | 1.4% |
Surveillance | 15 | 1.4% |
Valvular heart disease | 15 | 1.4% |
Zoonosis | 15 | 1.4% |
Anti-diabetic medication | 14 | 1.3% |
Aortic valve | 14 | 1.3% |
Breast cancer screening | 14 | 1.3% |
Breastfeeding and HIV | 14 | 1.3% |
Cardiac catheterization | 14 | 1.3% |
Cardiac stress test | 14 | 1.3% |
Case–control study | 14 | 1.3% |
Clinical commissioning group | 14 | 1.3% |
Clinical pathology | 14 | 1.3% |
Clopidogrel | 14 | 1.3% |
Cognition | 14 | 1.3% |
Effect size | 14 | 1.3% |
Emergency management | 14 | 1.3% |
Environmental social science | 14 | 1.3% |
Familial hypercholesterolemia | 14 | 1.3% |
Fee-for-service | 14 | 1.3% |
Fever | 14 | 1.3% |
Gestational age | 14 | 1.3% |
Gestational diabetes | 14 | 1.3% |
Gynaecologic disorders | 14 | 1.3% |
Hyperlipidemia | 14 | 1.3% |
Hypoglycemia | 14 | 1.3% |
Influenza A virus | 14 | 1.3% |
Lamivudine | 14 | 1.3% |
Liver | 14 | 1.3% |
Medical history | 14 | 1.3% |
Medical tests | 14 | 1.3% |
Millennium Development Goals | 14 | 1.3% |
Nutrition | 14 | 1.3% |
Pain management | 14 | 1.3% |
Patient Protection and Affordable Care Act | 14 | 1.3% |
Peripheral neuropathy | 14 | 1.3% |
Personalized medicine | 14 | 1.3% |
Pharmacovigilance | 14 | 1.3% |
Prenatal testing | 14 | 1.3% |
Rivaroxaban | 14 | 1.3% |
Robot-assisted surgery | 14 | 1.3% |
Rubella | 14 | 1.3% |
Schizophrenia | 14 | 1.3% |
Triage | 14 | 1.3% |
Allocation concealment | 13 | 1.2% |
Animal diseases | 13 | 1.2% |
Assay | 13 | 1.2% |
Atrium (heart) | 13 | 1.2% |
BCG vaccine | 13 | 1.2% |
Caesarean section | 13 | 1.2% |
Cardiovascular physiology | 13 | 1.2% |
Cigarette | 13 | 1.2% |
Cognitive behavioral therapy | 13 | 1.2% |
Denosumab | 13 | 1.2% |
Diabetic retinopathy | 13 | 1.2% |
Diarrhea | 13 | 1.2% |
Disease management (health) | 13 | 1.2% |
Disorders of endocrine pancreas | 13 | 1.2% |
Endocrine system | 13 | 1.2% |
Epidemiology of HIV/AIDS | 13 | 1.2% |
Fat | 13 | 1.2% |
Global health | 13 | 1.2% |
Human diseases and disorders | 13 | 1.2% |
Hygiene | 13 | 1.2% |
Incidence (epidemiology) | 13 | 1.2% |
Influenza A virus subtype H1N1 | 13 | 1.2% |
Kidney disease | 13 | 1.2% |
Kidney transplantation | 13 | 1.2% |
Laboratory | 13 | 1.2% |
MMR vaccine | 13 | 1.2% |
Minimally invasive procedure | 13 | 1.2% |
Motherhood | 13 | 1.2% |
Nephrology | 13 | 1.2% |
Nicotine replacement therapy | 13 | 1.2% |
Organs (anatomy) | 13 | 1.2% |
Overdiagnosis | 13 | 1.2% |
Parameter | 13 | 1.2% |
Prenatal care | 13 | 1.2% |
Pyrazinamide | 13 | 1.2% |
Reference range | 13 | 1.2% |
Smoking | 13 | 1.2% |
Type I and type II errors | 13 | 1.2% |
Violence | 13 | 1.2% |
Visual impairment | 13 | 1.2% |
Zoledronic acid | 13 | 1.2% |
Atorvastatin | 12 | 1.1% |
Bacteria | 12 | 1.1% |
Birth weight | 12 | 1.1% |
CHA2DS2–VASc score | 12 | 1.1% |
Combined oral contraceptive pill | 12 | 1.1% |
Directly observed treatment, short-course | 12 | 1.1% |
Employment | 12 | 1.1% |
Ezetimibe | 12 | 1.1% |
Face masks during the COVID-19 pandemic | 12 | 1.1% |
False positives and false negatives | 12 | 1.1% |
Family planning | 12 | 1.1% |
Genetic counseling | 12 | 1.1% |
Geriatrics | 12 | 1.1% |
Governance | 12 | 1.1% |
Health promotion | 12 | 1.1% |
Healthy diet | 12 | 1.1% |
Hematology | 12 | 1.1% |
Hemodialysis | 12 | 1.1% |
Hysterectomy | 12 | 1.1% |
Informed consent | 12 | 1.1% |
Insulin (medication) | 12 | 1.1% |
Male genital disorders | 12 | 1.1% |
Maternal death | 12 | 1.1% |
Medical error | 12 | 1.1% |
Medical research | 12 | 1.1% |
Meningitis | 12 | 1.1% |
Mortality rate | 12 | 1.1% |
Multidrug-resistant tuberculosis | 12 | 1.1% |
Mutation | 12 | 1.1% |
Nicotine | 12 | 1.1% |
Pelvic inflammatory disease | 12 | 1.1% |
Percutaneous aortic valve replacement | 12 | 1.1% |
Peripheral artery disease | 12 | 1.1% |
Policy | 12 | 1.1% |
Positron emission tomography | 12 | 1.1% |
Postpartum period | 12 | 1.1% |
Psychology | 12 | 1.1% |
Raloxifene | 12 | 1.1% |
Relative risk | 12 | 1.1% |
Serology | 12 | 1.1% |
Sex worker | 12 | 1.1% |
Statistical classification | 12 | 1.1% |
Thorax (human anatomy) | 12 | 1.1% |
Tissues (biology) | 12 | 1.1% |
Traumatic brain injury | 12 | 1.1% |
Type 1 diabetes | 12 | 1.1% |
Viral hemorrhagic fever | 12 | 1.1% |
Viral load | 12 | 1.1% |
Accountable care organization | 11 | 1.0% |
Alcoholism | 11 | 1.0% |
Amiodarone | 11 | 1.0% |
Anaphylaxis | 11 | 1.0% |
Aortic valve replacement | 11 | 1.0% |
Bevacizumab | 11 | 1.0% |
Cancer immunotherapy | 11 | 1.0% |
Chest radiograph | 11 | 1.0% |
Clinic | 11 | 1.0% |
Clinical endpoint | 11 | 1.0% |
Creatinine | 11 | 1.0% |
Cytopathology | 11 | 1.0% |
Da Vinci Surgical System | 11 | 1.0% |
Down syndrome | 11 | 1.0% |
Expert | 11 | 1.0% |
Fall prevention | 11 | 1.0% |
Flu season | 11 | 1.0% |
Food | 11 | 1.0% |
Health insurance coverage in the United States | 11 | 1.0% |
Heart rate | 11 | 1.0% |
Hereditary nonpolyposis colorectal cancer | 11 | 1.0% |
Hierarchy of evidence | 11 | 1.0% |
Immunotherapy | 11 | 1.0% |
Implantable cardioverter-defibrillator | 11 | 1.0% |
Influenza A virus subtype H7N9 | 11 | 1.0% |
Insulin | 11 | 1.0% |
Managed care | 11 | 1.0% |
Management of atrial fibrillation | 11 | 1.0% |
Missing data | 11 | 1.0% |
Non-alcoholic fatty liver disease | 11 | 1.0% |
Omega-3 fatty acid | 11 | 1.0% |
P-value | 11 | 1.0% |
Pap test | 11 | 1.0% |
Pay for performance (healthcare) | 11 | 1.0% |
Platelet | 11 | 1.0% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 11 | 1.0% |
Radiography | 11 | 1.0% |
Respirator | 11 | 1.0% |
Rosuvastatin | 11 | 1.0% |
Teriparatide | 11 | 1.0% |
Transmission-based precautions | 11 | 1.0% |
Ventricular fibrillation | 11 | 1.0% |
Amniocentesis | 10 | 0.9% |
Analgesic | 10 | 0.9% |
Anesthesiology | 10 | 0.9% |
Antidepressant | 10 | 0.9% |
Antigen | 10 | 0.9% |
Apolipoprotein | 10 | 0.9% |
BRCA1 | 10 | 0.9% |
Biochemistry | 10 | 0.9% |
Cancer staging | 10 | 0.9% |
Central venous catheter | 10 | 0.9% |
Coagulation | 10 | 0.9% |
Coronavirus | 10 | 0.9% |
Dialysis | 10 | 0.9% |
Digoxin | 10 | 0.9% |
Disability-adjusted life year | 10 | 0.9% |
Emergency contraception | 10 | 0.9% |
Evidence-based practice | 10 | 0.9% |
Glucose tolerance test | 10 | 0.9% |
Hand washing | 10 | 0.9% |
Health technology in the United States | 10 | 0.9% |
Heart valve | 10 | 0.9% |
Hormonal contraception | 10 | 0.9% |
Human sexuality | 10 | 0.9% |
Indication (medicine) | 10 | 0.9% |
Influenza-like illness | 10 | 0.9% |
Insulin resistance | 10 | 0.9% |
Isoniazid | 10 | 0.9% |
Likelihood function | 10 | 0.9% |
Lung cancer screening | 10 | 0.9% |
MammaPrint | 10 | 0.9% |
Mantoux test | 10 | 0.9% |
Medroxyprogesterone acetate | 10 | 0.9% |
Monitoring (medicine) | 10 | 0.9% |
Natural reservoir | 10 | 0.9% |
Non-small-cell lung carcinoma | 10 | 0.9% |
Organ donation | 10 | 0.9% |
Outcomes research | 10 | 0.9% |
Pharmacogenomics | 10 | 0.9% |
Physical fitness | 10 | 0.9% |
Polio vaccine | 10 | 0.9% |
Primary health care | 10 | 0.9% |
Public health surveillance | 10 | 0.9% |
Quality of life | 10 | 0.9% |
Reverse-transcriptase inhibitor | 10 | 0.9% |
Selective serotonin reuptake inhibitor | 10 | 0.9% |
Severe acute respiratory syndrome | 10 | 0.9% |
Sleep apnea | 10 | 0.9% |
Tamoxifen | 10 | 0.9% |
Thrombocytopenia | 10 | 0.9% |
Urinary incontinence | 10 | 0.9% |
Vaginitis | 10 | 0.9% |
Variance | 10 | 0.9% |
Ventricle (heart) | 10 | 0.9% |
Accuracy and precision | 9 | 0.8% |
Antiarrhythmic agent | 9 | 0.8% |
Antipsychotic | 9 | 0.8% |
Apixaban | 9 | 0.8% |
Arthritis | 9 | 0.8% |
Atrial septal defect | 9 | 0.8% |
Audit | 9 | 0.8% |
Bladder cancer | 9 | 0.8% |
Blood donation | 9 | 0.8% |
Body fluids | 9 | 0.8% |
COVID-19 testing | 9 | 0.8% |
Cancer survivor | 9 | 0.8% |
Candidiasis | 9 | 0.8% |
Cardiac arrest | 9 | 0.8% |
Chikungunya | 9 | 0.8% |
Correlation and dependence | 9 | 0.8% |
Death | 9 | 0.8% |
Dexamethasone | 9 | 0.8% |
Diagnosis-related group | 9 | 0.8% |
Doppler ultrasonography | 9 | 0.8% |
Endometrial cancer | 9 | 0.8% |
Endoscopy | 9 | 0.8% |
Epilepsy | 9 | 0.8% |
Family medicine | 9 | 0.8% |
Fish oil | 9 | 0.8% |
Genome-wide association study | 9 | 0.8% |
HPV vaccine | 9 | 0.8% |
Heart arrhythmia | 9 | 0.8% |
Hematuria | 9 | 0.8% |
Infant mortality | 9 | 0.8% |
Influenza A virus subtype H3N2 | 9 | 0.8% |
Intention-to-treat analysis | 9 | 0.8% |
Mammalian pregnancy | 9 | 0.8% |
Maternal–fetal medicine | 9 | 0.8% |
Medical specialty | 9 | 0.8% |
Melanoma | 9 | 0.8% |
Midwife | 9 | 0.8% |
Nivolumab | 9 | 0.8% |
Nonsteroidal anti-inflammatory drug | 9 | 0.8% |
Ophthalmology | 9 | 0.8% |
Prevalence | 9 | 0.8% |
Programmed cell death protein 1 | 9 | 0.8% |
Prostate cancer screening | 9 | 0.8% |
Prostatectomy | 9 | 0.8% |
Quality of life (healthcare) | 9 | 0.8% |
Reliability (statistics) | 9 | 0.8% |
Reperfusion therapy | 9 | 0.8% |
Research methods | 9 | 0.8% |
Simulation | 9 | 0.8% |
Sotalol | 9 | 0.8% |
Stavudine | 9 | 0.8% |
Stomach cancer | 9 | 0.8% |
Symptom | 9 | 0.8% |
T cell | 9 | 0.8% |
Tetanus vaccine | 9 | 0.8% |
Thrombosis prevention | 9 | 0.8% |
Treatment of cancer | 9 | 0.8% |
Troponin | 9 | 0.8% |
Varenicline | 9 | 0.8% |
Virology | 9 | 0.8% |
2009 flu pandemic | 8 | 0.7% |
Abacavir | 8 | 0.7% |
Abdominal obesity | 8 | 0.7% |
Active surveillance of prostate cancer | 8 | 0.7% |
Acute myeloid leukemia | 8 | 0.7% |
Adverse event | 8 | 0.7% |
Ageing | 8 | 0.7% |
Anticonvulsant | 8 | 0.7% |
Antimicrobial | 8 | 0.7% |
Antimicrobial stewardship | 8 | 0.7% |
Assessment of kidney function | 8 | 0.7% |
Bacterial vaginosis | 8 | 0.7% |
Biosafety | 8 | 0.7% |
Blood lipids | 8 | 0.7% |
Blood plasma | 8 | 0.7% |
Breast milk | 8 | 0.7% |
Bronchodilator | 8 | 0.7% |
Bupropion | 8 | 0.7% |
Cancer prevention | 8 | 0.7% |
Carcinoma | 8 | 0.7% |
Cardiac muscle | 8 | 0.7% |
Cardiac rehabilitation | 8 | 0.7% |
Cardiotocography | 8 | 0.7% |
Case management (US health system) | 8 | 0.7% |
Cerebrovascular disease | 8 | 0.7% |
Cervical intraepithelial neoplasia | 8 | 0.7% |
Chickenpox | 8 | 0.7% |
Chlamydia | 8 | 0.7% |
Computer-aided diagnosis | 8 | 0.7% |
Copyright | 8 | 0.7% |
Coronary catheterization | 8 | 0.7% |
Cough | 8 | 0.7% |
Defibrillation | 8 | 0.7% |
Dengue fever | 8 | 0.7% |
Dentistry | 8 | 0.7% |
Disease burden | 8 | 0.7% |
Drug development | 8 | 0.7% |
Economics | 8 | 0.7% |
Eicosapentaenoic acid | 8 | 0.7% |
Emergency medical services | 8 | 0.7% |
Epidermal growth factor receptor | 8 | 0.7% |
Epidural administration | 8 | 0.7% |
Eradication of infectious diseases | 8 | 0.7% |
Fenofibrate | 8 | 0.7% |
Fertility | 8 | 0.7% |
Fluconazole | 8 | 0.7% |
Frailty syndrome | 8 | 0.7% |
Genomics | 8 | 0.7% |
Head and neck cancer | 8 | 0.7% |
Health data | 8 | 0.7% |
Health literacy | 8 | 0.7% |
Healthcare industry | 8 | 0.7% |
Healthcare quality | 8 | 0.7% |
Heart failure with preserved ejection fraction | 8 | 0.7% |
Hepatitis B vaccine | 8 | 0.7% |
Herpes simplex | 8 | 0.7% |
Human development | 8 | 0.7% |
Immunity (medical) | 8 | 0.7% |
Immunoglobulin G | 8 | 0.7% |
Immunosuppressive drug | 8 | 0.7% |
Interventional radiology | 8 | 0.7% |
Latent tuberculosis | 8 | 0.7% |
Linear regression | 8 | 0.7% |
Mathematical optimization | 8 | 0.7% |
Medical microbiology | 8 | 0.7% |
Medicare dual eligible | 8 | 0.7% |
Middle East respiratory syndrome | 8 | 0.7% |
N95 respirator | 8 | 0.7% |
Neutralizing antibody | 8 | 0.7% |
Nursing home | 8 | 0.7% |
Obstetric ultrasonography | 8 | 0.7% |
Obstructive sleep apnea | 8 | 0.7% |
Off-label use | 8 | 0.7% |
Osteoarthritis | 8 | 0.7% |
PCSK9 | 8 | 0.7% |
Passive smoking | 8 | 0.7% |
Pathogen | 8 | 0.7% |
Patient participation | 8 | 0.7% |
Pembrolizumab | 8 | 0.7% |
Pharmaceutical industry | 8 | 0.7% |
Pharmacist | 8 | 0.7% |
Prasugrel | 8 | 0.7% |
Privacy | 8 | 0.7% |
Procalcitonin | 8 | 0.7% |
Proteinuria | 8 | 0.7% |
Public Health Emergency of International Concern | 8 | 0.7% |
Random forest | 8 | 0.7% |
Respiratory droplet | 8 | 0.7% |
Rheumatoid arthritis | 8 | 0.7% |
Sample size determination | 8 | 0.7% |
Scientific method | 8 | 0.7% |
Stillbirth | 8 | 0.7% |
Thrombophilia | 8 | 0.7% |
Ticagrelor | 8 | 0.7% |
Trichomoniasis | 8 | 0.7% |
Veterinary medicine | 8 | 0.7% |
Western African Ebola virus epidemic | 8 | 0.7% |
Acute kidney injury | 7 | 0.7% |
Anatomical terms of motion | 7 | 0.7% |
Angioplasty | 7 | 0.7% |
Antimalarial medication | 7 | 0.7% |
Assumption | 7 | 0.7% |
Atrial flutter | 7 | 0.7% |
Atypical pneumonias | 7 | 0.7% |
Autoimmunity | 7 | 0.7% |
Bacteremia | 7 | 0.7% |
Balance (ability) | 7 | 0.7% |
Bariatric surgery | 7 | 0.7% |
Blood glucose monitoring | 7 | 0.7% |
Bone marrow | 7 | 0.7% |
Booster dose | 7 | 0.7% |
Canagliflozin | 7 | 0.7% |
Capacity building | 7 | 0.7% |
Cervix | 7 | 0.7% |
Chemicals in medicine | 7 | 0.7% |
Chronic lymphocytic leukemia | 7 | 0.7% |
Clinical decision support system | 7 | 0.7% |
Community health worker | 7 | 0.7% |
Computed tomography angiography | 7 | 0.7% |
Confidentiality | 7 | 0.7% |
Cystic fibrosis | 7 | 0.7% |
D-dimer | 7 | 0.7% |
Deep learning | 7 | 0.7% |
Delirium | 7 | 0.7% |
Diabetic ketoacidosis | 7 | 0.7% |
Diffuse large B-cell lymphoma | 7 | 0.7% |
Disinfectant | 7 | 0.7% |
EQ-5D | 7 | 0.7% |
Ejection fraction | 7 | 0.7% |
Errors and residuals | 7 | 0.7% |
Estrogen | 7 | 0.7% |
Experiment | 7 | 0.7% |
Fibrate | 7 | 0.7% |
Goal | 7 | 0.7% |
Harm reduction | 7 | 0.7% |
Hazard ratio | 7 | 0.7% |
Health care in the United States | 7 | 0.7% |
Homelessness | 7 | 0.7% |
Human sexual activity | 7 | 0.7% |
Immunoglobulin therapy | 7 | 0.7% |
Infertility | 7 | 0.7% |
Intrauterine device | 7 | 0.7% |
Labor induction | 7 | 0.7% |
Lassa fever | 7 | 0.7% |
Liraglutide | 7 | 0.7% |
Low molecular weight heparin | 7 | 0.7% |
Low-molecular-weight heparin | 7 | 0.7% |
Lung nodule | 7 | 0.7% |
MHealth | 7 | 0.7% |
Median | 7 | 0.7% |
Meningococcal disease | 7 | 0.7% |
Metabolic disorders | 7 | 0.7% |
Multiple myeloma | 7 | 0.7% |
Mycobacterium bovis | 7 | 0.7% |
Mycoplasma | 7 | 0.7% |
Myocardial perfusion imaging | 7 | 0.7% |
Neisseria meningitidis | 7 | 0.7% |
Nephrectomy | 7 | 0.7% |
Neutropenia | 7 | 0.7% |
Newborn screening | 7 | 0.7% |
Nuchal scan | 7 | 0.7% |
Nursing home care | 7 | 0.7% |
Odds ratio | 7 | 0.7% |
Old age | 7 | 0.7% |
Opioid | 7 | 0.7% |
Oseltamivir | 7 | 0.7% |
Osteonecrosis of the jaw | 7 | 0.7% |
Patient safety organization | 7 | 0.7% |
Physical activity | 7 | 0.7% |
Plasmodium vivax | 7 | 0.7% |
Platelet transfusion | 7 | 0.7% |
Pneumococcal conjugate vaccine | 7 | 0.7% |
Pneumococcal vaccine | 7 | 0.7% |
Polio | 7 | 0.7% |
Polyp (medicine) | 7 | 0.7% |
Precision medicine | 7 | 0.7% |
Psychosis | 7 | 0.7% |
Pulmonology | 7 | 0.7% |
Quality assurance | 7 | 0.7% |
Quantitative computed tomography | 7 | 0.7% |
Retinopathy | 7 | 0.7% |
Single-nucleotide polymorphism | 7 | 0.7% |
Sleep | 7 | 0.7% |
Specification (technical standard) | 7 | 0.7% |
Standard error | 7 | 0.7% |
Staphylococcus aureus | 7 | 0.7% |
Strontium ranelate | 7 | 0.7% |
Substance use disorder | 7 | 0.7% |
Sulfonylurea | 7 | 0.7% |
Survival analysis | 7 | 0.7% |
Tocilizumab | 7 | 0.7% |
Trastuzumab | 7 | 0.7% |
Tropical medicine | 7 | 0.7% |
Tuberculosis diagnosis | 7 | 0.7% |
Visual acuity | 7 | 0.7% |
Whole genome sequencing | 7 | 0.7% |
Wound | 7 | 0.7% |
Zika fever | 7 | 0.7% |
Abortion | 6 | 0.6% |
Addiction | 6 | 0.6% |
Airborne transmission | 6 | 0.6% |
Apolipoprotein B | 6 | 0.6% |
Attention | 6 | 0.6% |
BRCA2 | 6 | 0.6% |
Benzodiazepine | 6 | 0.6% |
Biosecurity | 6 | 0.6% |
Birth | 6 | 0.6% |
Bone resorption | 6 | 0.6% |
Brain natriuretic peptide | 6 | 0.6% |
Brain tumor | 6 | 0.6% |
Bronchiectasis | 6 | 0.6% |
Bronchitis | 6 | 0.6% |
Cardiac magnetic resonance imaging | 6 | 0.6% |
Cardiopulmonary resuscitation | 6 | 0.6% |
Casirivimab/imdevimab | 6 | 0.6% |
Catheter | 6 | 0.6% |
Catheter ablation | 6 | 0.6% |
Cattle | 6 | 0.6% |
Childhood | 6 | 0.6% |
Clostridioides difficile infection | 6 | 0.6% |
Contrast (vision) | 6 | 0.6% |
Coronary circulation | 6 | 0.6% |
Decision tree learning | 6 | 0.6% |
Diastole | 6 | 0.6% |
Diet (nutrition) | 6 | 0.6% |
Digital health | 6 | 0.6% |
Diltiazem | 6 | 0.6% |
Dronedarone | 6 | 0.6% |
Ductal carcinoma in situ | 6 | 0.6% |
Ebola | 6 | 0.6% |
Economic growth | 6 | 0.6% |
Educational assessment | 6 | 0.6% |
Emergency | 6 | 0.6% |
Endocrinology | 6 | 0.6% |
Endovascular aneurysm repair | 6 | 0.6% |
Erlotinib | 6 | 0.6% |
Exhaled nitric oxide | 6 | 0.6% |
Expanded Program on Immunization | 6 | 0.6% |
Eye care | 6 | 0.6% |
Federally Qualified Health Center | 6 | 0.6% |
Flecainide | 6 | 0.6% |
Formulary (pharmacy) | 6 | 0.6% |
Gene therapy | 6 | 0.6% |
Glomerular filtration rate | 6 | 0.6% |
Headache | 6 | 0.6% |
Health Insurance Portability and Accountability Act | 6 | 0.6% |
Hearing loss | 6 | 0.6% |
Heart diseases | 6 | 0.6% |
Human eye | 6 | 0.6% |
Implant (medicine) | 6 | 0.6% |
Indigenous Australians | 6 | 0.6% |
Intrauterine growth restriction | 6 | 0.6% |
Lipoprotein(a) | 6 | 0.6% |
Long-term care | 6 | 0.6% |
Low birth weight | 6 | 0.6% |
Malnutrition | 6 | 0.6% |
Mean | 6 | 0.6% |
Mechanical filter (respirator) | 6 | 0.6% |
Medicinal chemistry | 6 | 0.6% |
Memory | 6 | 0.6% |
Meningococcal vaccine | 6 | 0.6% |
Molecular biology | 6 | 0.6% |
Molecular diagnostics | 6 | 0.6% |
Motivational interviewing | 6 | 0.6% |
Multiple sclerosis | 6 | 0.6% |
Nausea | 6 | 0.6% |
Neglected tropical diseases | 6 | 0.6% |
Neisseria gonorrhoeae | 6 | 0.6% |
Neuroimaging | 6 | 0.6% |
Neuropathic pain | 6 | 0.6% |
Occupational therapist | 6 | 0.6% |
Oncology | 6 | 0.6% |
Pancreatic cancer | 6 | 0.6% |
Paracetamol | 6 | 0.6% |
Pericardium | 6 | 0.6% |
Perinatal mortality | 6 | 0.6% |
Pfizer–BioNTech COVID-19 vaccine | 6 | 0.6% |
Pharmacokinetics | 6 | 0.6% |
Phytosterol | 6 | 0.6% |
Plasmodium falciparum | 6 | 0.6% |
Positive airway pressure | 6 | 0.6% |
Posttraumatic stress disorder | 6 | 0.6% |
Prednisone | 6 | 0.6% |
Primary care physician | 6 | 0.6% |
Public health genomics | 6 | 0.6% |
Pulse | 6 | 0.6% |
Pulse oximetry | 6 | 0.6% |
QT interval | 6 | 0.6% |
Quantitative research | 6 | 0.6% |
Quarantine | 6 | 0.6% |
Radiofrequency ablation | 6 | 0.6% |
Rheumatic fever | 6 | 0.6% |
Rheumatology | 6 | 0.6% |
Selective estrogen receptor modulator | 6 | 0.6% |
Severe acute respiratory syndrome coronavirus | 6 | 0.6% |
Sigmoidoscopy | 6 | 0.6% |
Single-photon emission computed tomography | 6 | 0.6% |
Social work | 6 | 0.6% |
Specialty (medicine) | 6 | 0.6% |
Statistical significance | 6 | 0.6% |
Streptococcus agalactiae | 6 | 0.6% |
Systemic lupus erythematosus | 6 | 0.6% |
Tenofovir disoproxil | 6 | 0.6% |
Tetanus | 6 | 0.6% |
Training, validation, and test sets | 6 | 0.6% |
Transplant rejection | 6 | 0.6% |
Uncertainty | 6 | 0.6% |
Vaccine adverse event | 6 | 0.6% |
Vaginal discharge | 6 | 0.6% |
Vertebral augmentation | 6 | 0.6% |
Virtual colonoscopy | 6 | 0.6% |
Vision | 6 | 0.6% |
Vital signs | 6 | 0.6% |
Vitamin E | 6 | 0.6% |
Aboriginal Australians | 5 | 0.5% |
Aciclovir | 5 | 0.5% |
Adaptive immune system | 5 | 0.5% |
Adenoviridae | 5 | 0.5% |
Alanine transaminase | 5 | 0.5% |
Algorithm | 5 | 0.5% |
Alirocumab | 5 | 0.5% |
Alternative medicine | 5 | 0.5% |
Anatomy | 5 | 0.5% |
Aneurysm | 5 | 0.5% |
Angiotensin-converting enzyme | 5 | 0.5% |
Anxiety disorder | 5 | 0.5% |
Aorta | 5 | 0.5% |
Aortic aneurysm | 5 | 0.5% |
Aortic insufficiency | 5 | 0.5% |
Artesunate | 5 | 0.5% |
Ascending cholangitis | 5 | 0.5% |
Atezolizumab | 5 | 0.5% |
Attention deficit hyperactivity disorder | 5 | 0.5% |
B cell | 5 | 0.5% |
Back pain | 5 | 0.5% |
Benign tumor | 5 | 0.5% |
Beta-lactamase | 5 | 0.5% |
Biomarker (medicine) | 5 | 0.5% |
Biosimilar | 5 | 0.5% |
Blood-borne disease | 5 | 0.5% |
Bootstrapping (statistics) | 5 | 0.5% |
Brain | 5 | 0.5% |
COVID-19 pandemic in the United Kingdom | 5 | 0.5% |
CT pulmonary angiogram | 5 | 0.5% |
Cardiac electrophysiology | 5 | 0.5% |
Cataract | 5 | 0.5% |
Chlamydia trachomatis | 5 | 0.5% |
Cholecystectomy | 5 | 0.5% |
Colposcopy | 5 | 0.5% |
Compartmental models in epidemiology | 5 | 0.5% |
Consent | 5 | 0.5% |
Contact tracing | 5 | 0.5% |
Cost–benefit analysis | 5 | 0.5% |
DICOM | 5 | 0.5% |
Depression (mood) | 5 | 0.5% |
Diabetes mellitus type 1 | 5 | 0.5% |
Disseminated intravascular coagulation | 5 | 0.5% |
Docetaxel | 5 | 0.5% |
EHealth | 5 | 0.5% |
Econometrics | 5 | 0.5% |
Efavirenz | 5 | 0.5% |
Embolism | 5 | 0.5% |
Emergency medical technician | 5 | 0.5% |
End-of-life care | 5 | 0.5% |
Endocrine pancreas | 5 | 0.5% |
Endocrine, nutritional and metabolic diseases | 5 | 0.5% |
Esophagus | 5 | 0.5% |
Estimator | 5 | 0.5% |
External beam radiotherapy | 5 | 0.5% |
Fatigue | 5 | 0.5% |
Febrile neutropenia | 5 | 0.5% |
Fluvastatin | 5 | 0.5% |
Gastroenterology | 5 | 0.5% |
Gene expression | 5 | 0.5% |
Generic drug | 5 | 0.5% |
Genetic disorder | 5 | 0.5% |
Genital wart | 5 | 0.5% |
Glaucoma | 5 | 0.5% |
Global Outbreak Alert and Response Network | 5 | 0.5% |
Glucose test | 5 | 0.5% |
Glycemic index | 5 | 0.5% |
Gross domestic product | 5 | 0.5% |
Group B streptococcal infection | 5 | 0.5% |
HIV-positive people | 5 | 0.5% |
HIV/AIDS in Africa | 5 | 0.5% |
Health research | 5 | 0.5% |
Hib vaccine | 5 | 0.5% |
Histopathology | 5 | 0.5% |
Human chorionic gonadotropin | 5 | 0.5% |
Human female reproductive system | 5 | 0.5% |
Hypertrophic cardiomyopathy | 5 | 0.5% |
Hypogammaglobulinemia | 5 | 0.5% |
Incentive | 5 | 0.5% |
Insomnia | 5 | 0.5% |
International Classification of Diseases | 5 | 0.5% |
International Health Regulations | 5 | 0.5% |
Ionizing radiation | 5 | 0.5% |
Levonorgestrel | 5 | 0.5% |
License | 5 | 0.5% |
Likelihood ratios in diagnostic testing | 5 | 0.5% |
Lithium (medication) | 5 | 0.5% |
Liver function tests | 5 | 0.5% |
Liver transplantation | 5 | 0.5% |
Long QT syndrome | 5 | 0.5% |
Long-term effects of alcohol consumption | 5 | 0.5% |
Lymphadenectomy | 5 | 0.5% |
MMRV vaccine | 5 | 0.5% |
Macular degeneration | 5 | 0.5% |
Medical emergencies | 5 | 0.5% |
Medical school | 5 | 0.5% |
Metronidazole | 5 | 0.5% |
Middle East respiratory syndrome-related coronavirus | 5 | 0.5% |
Midwifery | 5 | 0.5% |
Mitral valve | 5 | 0.5% |
Model organism | 5 | 0.5% |
Moderna COVID-19 vaccine | 5 | 0.5% |
Mood disorder | 5 | 0.5% |
Mycobacteria | 5 | 0.5% |
Mycobacterium tuberculosis | 5 | 0.5% |
Myelodysplastic syndrome | 5 | 0.5% |
Neonatal infection | 5 | 0.5% |
Neurosurgery | 5 | 0.5% |
Non-governmental organization | 5 | 0.5% |
Non-pharmaceutical intervention (epidemiology) | 5 | 0.5% |
PD-L1 | 5 | 0.5% |
PHQ-9 | 5 | 0.5% |
Parkinson's disease | 5 | 0.5% |
Patient-reported outcome | 5 | 0.5% |
Perception | 5 | 0.5% |
Performance appraisal | 5 | 0.5% |
Periodontology | 5 | 0.5% |
Perioperative | 5 | 0.5% |
Personal genomics | 5 | 0.5% |
Pharmacogenetics | 5 | 0.5% |
Pleural effusion | 5 | 0.5% |
Polypharmacy | 5 | 0.5% |
Pravastatin | 5 | 0.5% |
Pre- and post-test probability | 5 | 0.5% |
Psychosocial | 5 | 0.5% |
Rabies | 5 | 0.5% |
Radiographer | 5 | 0.5% |
Rape | 5 | 0.5% |
Recovery approach | 5 | 0.5% |
Reliability engineering | 5 | 0.5% |
Remdesivir | 5 | 0.5% |
Residency (medicine) | 5 | 0.5% |
Reverse transcription polymerase chain reaction | 5 | 0.5% |
Ritonavir | 5 | 0.5% |
Rituximab | 5 | 0.5% |
SGLT2 inhibitor | 5 | 0.5% |
Selection bias | 5 | 0.5% |
Septic shock | 5 | 0.5% |
Severe combined immunodeficiency | 5 | 0.5% |
Shock (circulatory) | 5 | 0.5% |
Sievert | 5 | 0.5% |
Social determinants of health | 5 | 0.5% |
Statistical hypothesis testing | 5 | 0.5% |
Strength training | 5 | 0.5% |
Substance dependence | 5 | 0.5% |
Surface epithelial-stromal tumor | 5 | 0.5% |
Swine influenza | 5 | 0.5% |
Syncope (medicine) | 5 | 0.5% |
Systole | 5 | 0.5% |
Tachycardia | 5 | 0.5% |
Tax | 5 | 0.5% |
Thiazide | 5 | 0.5% |
Thorax | 5 | 0.5% |
Tooth decay | 5 | 0.5% |
Torsades de pointes | 5 | 0.5% |
Traffic collision | 5 | 0.5% |
Translational research | 5 | 0.5% |
Vaccines | 5 | 0.5% |
Ventricular natriuretic peptide | 5 | 0.5% |
Verification and validation | 5 | 0.5% |
Viral respiratory tract infections | 5 | 0.5% |
Viral vector | 5 | 0.5% |
World Wide Web | 5 | 0.5% |
3D printing | 4 | 0.4% |
Abdomen | 4 | 0.4% |
Adalimumab | 4 | 0.4% |
Adenoma | 4 | 0.4% |
Air pollution | 4 | 0.4% |
Airborne diseases | 4 | 0.4% |
Alcoholic drink | 4 | 0.4% |
Allergen | 4 | 0.4% |
Amoxicillin | 4 | 0.4% |
Amphotericin B | 4 | 0.4% |
Anal sex | 4 | 0.4% |
Analysis | 4 | 0.4% |
Anemia | 4 | 0.4% |
Animals and humans | 4 | 0.4% |
Anthracycline | 4 | 0.4% |
Antifungal | 4 | 0.4% |
Aortic dissection | 4 | 0.4% |
Aromatase inhibitor | 4 | 0.4% |
Artificial intelligence in healthcare | 4 | 0.4% |
Artificial neural network | 4 | 0.4% |
Asepsis | 4 | 0.4% |
Autism | 4 | 0.4% |
Bacteriuria | 4 | 0.4% |
Basic reproduction number | 4 | 0.4% |
Botulism | 4 | 0.4% |
Brachytherapy | 4 | 0.4% |
Brain metastasis | 4 | 0.4% |
CCR5 | 4 | 0.4% |
COVID-19 pandemic in Papua New Guinea | 4 | 0.4% |
Calcium channel blocker | 4 | 0.4% |
Cancer registry | 4 | 0.4% |
Cancer syndrome | 4 | 0.4% |
Carotid artery stenosis | 4 | 0.4% |
Cell-free fetal DNA | 4 | 0.4% |
Cerebral palsy | 4 | 0.4% |
Cerebrospinal fluid | 4 | 0.4% |
Child | 4 | 0.4% |
Chimeric antigen receptor T cell | 4 | 0.4% |
Choosing Wisely | 4 | 0.4% |
Chronic fatigue syndrome | 4 | 0.4% |
Chronic myelogenous leukemia | 4 | 0.4% |
Chronic pain | 4 | 0.4% |
Circumcision | 4 | 0.4% |
Clinical governance | 4 | 0.4% |
Clinical psychology | 4 | 0.4% |
Cloth face mask | 4 | 0.4% |
Coefficient of determination | 4 | 0.4% |
Common cold | 4 | 0.4% |
Community | 4 | 0.4% |
Community-acquired pneumonia | 4 | 0.4% |
Complete blood count | 4 | 0.4% |
Concussion | 4 | 0.4% |
Congenital heart defect | 4 | 0.4% |
Cornea | 4 | 0.4% |
Crizotinib | 4 | 0.4% |
Cryptococcosis | 4 | 0.4% |
Cystectomy | 4 | 0.4% |
Cystic fibrosis transmembrane conductance regulator | 4 | 0.4% |
Cystoscopy | 4 | 0.4% |
Demographic and Health Surveys | 4 | 0.4% |
Diabetes medication | 4 | 0.4% |
Diagnosis code | 4 | 0.4% |
Diagnosis of malaria | 4 | 0.4% |
Diagnostic and Statistical Manual of Mental Disorders | 4 | 0.4% |
Dietary fiber | 4 | 0.4% |
Diphtheria vaccine | 4 | 0.4% |
Docosahexaenoic acid | 4 | 0.4% |
Dog | 4 | 0.4% |
Doxorubicin | 4 | 0.4% |
Driving | 4 | 0.4% |
Dyslipidemia | 4 | 0.4% |
Eclampsia | 4 | 0.4% |
Elastography | 4 | 0.4% |
Electronic cigarette | 4 | 0.4% |
Embolization | 4 | 0.4% |
Emerging technologies | 4 | 0.4% |
Empagliflozin | 4 | 0.4% |
Endometriosis | 4 | 0.4% |
Essential health benefits | 4 | 0.4% |
Ethinylestradiol | 4 | 0.4% |
Exemestane | 4 | 0.4% |
Fatty liver disease | 4 | 0.4% |
Field Epidemiology Training Program | 4 | 0.4% |
Fine-needle aspiration | 4 | 0.4% |
Flavivirus | 4 | 0.4% |
Fluid replacement | 4 | 0.4% |
Folate | 4 | 0.4% |
Food and drink | 4 | 0.4% |
Foot | 4 | 0.4% |
Fraction (mathematics) | 4 | 0.4% |
Fresh frozen plasma | 4 | 0.4% |
Fundus photography | 4 | 0.4% |
Funnel plot | 4 | 0.4% |
Gastroesophageal reflux disease | 4 | 0.4% |
Gene expression profiling | 4 | 0.4% |
Genetic association | 4 | 0.4% |
Gene–environment interaction | 4 | 0.4% |
Gentamicin | 4 | 0.4% |
Gerontological nursing | 4 | 0.4% |
Good manufacturing practice | 4 | 0.4% |
HBsAg | 4 | 0.4% |
HIV and pregnancy | 4 | 0.4% |
Health human resources | 4 | 0.4% |
Health information technology | 4 | 0.4% |
Healthcare management | 4 | 0.4% |
Hela Province | 4 | 0.4% |
Helicobacter pylori | 4 | 0.4% |
Heparin | 4 | 0.4% |
Hepatectomy | 4 | 0.4% |
Hepatitis B virus | 4 | 0.4% |
Histoplasmosis | 4 | 0.4% |
Hives | 4 | 0.4% |
Homosexuality | 4 | 0.4% |
Hormonal therapy (oncology) | 4 | 0.4% |
Human anatomy | 4 | 0.4% |
Hypertriglyceridemia | 4 | 0.4% |
Hypopnea | 4 | 0.4% |
Hypothermia | 4 | 0.4% |
Hypothyroidism | 4 | 0.4% |
Immune thrombocytopenic purpura | 4 | 0.4% |
Information technology | 4 | 0.4% |
Injection (medicine) | 4 | 0.4% |
Institutional review board | 4 | 0.4% |
Insulin analog | 4 | 0.4% |
Inter-rater reliability | 4 | 0.4% |
Intraclass correlation | 4 | 0.4% |
Johnson & Johnson COVID-19 vaccine | 4 | 0.4% |
KRAS | 4 | 0.4% |
Laparoscopic radical prostatectomy | 4 | 0.4% |
Leadership | 4 | 0.4% |
Left atrial appendage occlusion | 4 | 0.4% |
Lenalidomide | 4 | 0.4% |
Levofloxacin | 4 | 0.4% |
Linezolid | 4 | 0.4% |
Listeriosis | 4 | 0.4% |
Liver biopsy | 4 | 0.4% |
Liver cancer | 4 | 0.4% |
Liver disease | 4 | 0.4% |
Local anesthetic | 4 | 0.4% |
Lower respiratory tract infection | 4 | 0.4% |
Lymphocyte | 4 | 0.4% |
Major trauma | 4 | 0.4% |
Management of hypertension | 4 | 0.4% |
Maturity onset diabetes of the young | 4 | 0.4% |
Medical equipment | 4 | 0.4% |
Medical home | 4 | 0.4% |
Medical physics | 4 | 0.4% |
Mediterranean diet | 4 | 0.4% |
Metered-dose inhaler | 4 | 0.4% |
Methodology | 4 | 0.4% |
Methylprednisolone | 4 | 0.4% |
Multiple birth | 4 | 0.4% |
Multiple drug resistance | 4 | 0.4% |
Musculoskeletal system | 4 | 0.4% |
National Lung Screening Trial | 4 | 0.4% |
Needle exchange programme | 4 | 0.4% |
Needlestick injury | 4 | 0.4% |
Neonatal alloimmune thrombocytopenia | 4 | 0.4% |
Nerve | 4 | 0.4% |
Neuroscience | 4 | 0.4% |
Neurostimulation | 4 | 0.4% |
Niacin | 4 | 0.4% |
Ordinary least squares | 4 | 0.4% |
Overactive bladder | 4 | 0.4% |
Oxaliplatin | 4 | 0.4% |
Oxygen therapy | 4 | 0.4% |
Pancreatitis | 4 | 0.4% |
Pandemics | 4 | 0.4% |
Paramedic | 4 | 0.4% |
Parathyroid hormone | 4 | 0.4% |
Performance indicator | 4 | 0.4% |
Pericardiocentesis | 4 | 0.4% |
Peritoneal dialysis | 4 | 0.4% |
Picture archiving and communication system | 4 | 0.4% |
Pioglitazone | 4 | 0.4% |
Placenta | 4 | 0.4% |
Plasmodium | 4 | 0.4% |
Plateletpheresis | 4 | 0.4% |
Pneumothorax | 4 | 0.4% |
Point-of-care testing | 4 | 0.4% |
Polio eradication | 4 | 0.4% |
Poliomyelitis | 4 | 0.4% |
Poliovirus | 4 | 0.4% |
Polysomnography | 4 | 0.4% |
Population health | 4 | 0.4% |
Potassium | 4 | 0.4% |
Poultry | 4 | 0.4% |
Prednisolone | 4 | 0.4% |
Pressure ulcer | 4 | 0.4% |
Prevention | 4 | 0.4% |
Primaquine | 4 | 0.4% |
Primary immunodeficiency | 4 | 0.4% |
Propensity score matching | 4 | 0.4% |
Puberty | 4 | 0.4% |
Pulmonary function testing | 4 | 0.4% |
Q fever | 4 | 0.4% |
Quality | 4 | 0.4% |
Race and ethnicity in the United States Census | 4 | 0.4% |
Radiosurgery | 4 | 0.4% |
Rare disease | 4 | 0.4% |
Real-time polymerase chain reaction | 4 | 0.4% |
Regulatory compliance | 4 | 0.4% |
Retina | 4 | 0.4% |
Revised National Tuberculosis Control Program | 4 | 0.4% |
Robust statistics | 4 | 0.4% |
Rosiglitazone | 4 | 0.4% |
SARS-CoV-2 | 4 | 0.4% |
Salt | 4 | 0.4% |
Sarbecovirus | 4 | 0.4% |
Sheep | 4 | 0.4% |
Shingles | 4 | 0.4% |
Sickle cell disease | 4 | 0.4% |
Sinusitis | 4 | 0.4% |
Sleep disorder | 4 | 0.4% |
Smoking ban | 4 | 0.4% |
Snellen chart | 4 | 0.4% |
Sofosbuvir | 4 | 0.4% |
Source control (respiratory disease) | 4 | 0.4% |
Spasticity | 4 | 0.4% |
Stanol ester | 4 | 0.4% |
Stem cell | 4 | 0.4% |
Sternum | 4 | 0.4% |
Superficial vein thrombosis | 4 | 0.4% |
Surgical procedures and techniques | 4 | 0.4% |
Symptoms of COVID-19 | 4 | 0.4% |
System | 4 | 0.4% |
T helper cell | 4 | 0.4% |
Test (assessment) | 4 | 0.4% |
Thrombus | 4 | 0.4% |
Tissue engineering | 4 | 0.4% |
Tissue plasminogen activator | 4 | 0.4% |
Trichomonas vaginalis | 4 | 0.4% |
Triglyceride | 4 | 0.4% |
Triple test | 4 | 0.4% |
Unintended pregnancy | 4 | 0.4% |
Urinary system | 4 | 0.4% |
Usability | 4 | 0.4% |
Valproate | 4 | 0.4% |
Vancomycin-resistant Enterococcus | 4 | 0.4% |
Variants of SARS-CoV-2 | 4 | 0.4% |
Ventricular tachycardia | 4 | 0.4% |
Verapamil | 4 | 0.4% |
Vertebral column | 4 | 0.4% |
Virtual reality | 4 | 0.4% |
Visual perception | 4 | 0.4% |
Vitamin D deficiency | 4 | 0.4% |
Web of Science | 4 | 0.4% |
Welfare | 4 | 0.4% |
West Nile fever | 4 | 0.4% |
West Nile virus | 4 | 0.4% |
Whooping cough | 4 | 0.4% |
Woman | 4 | 0.4% |
Working memory | 4 | 0.4% |
Youth | 4 | 0.4% |
Zika virus | 4 | 0.4% |
2019–20 coronavirus outbreak | 3 | 0.3% |
3D bioprinting | 3 | 0.3% |
Abdominal aortic aneurysm | 3 | 0.3% |
Abscess | 3 | 0.3% |
Abstract (summary) | 3 | 0.3% |
Accessibility | 3 | 0.3% |
Accountability | 3 | 0.3% |
Acromegaly | 3 | 0.3% |
Acupuncture | 3 | 0.3% |
Acute lymphoblastic leukemia | 3 | 0.3% |
Acute respiratory distress syndrome | 3 | 0.3% |
Adipose tissue | 3 | 0.3% |
Adverse drug reaction | 3 | 0.3% |
Aflibercept | 3 | 0.3% |
Alpha-fetoprotein | 3 | 0.3% |
Ambulance | 3 | 0.3% |
Aminoglycoside | 3 | 0.3% |
Ampicillin | 3 | 0.3% |
Amputation | 3 | 0.3% |
Analysis of variance | 3 | 0.3% |
Analytics | 3 | 0.3% |
Anatomical terms of location | 3 | 0.3% |
Animal anatomy | 3 | 0.3% |
Anthrax | 3 | 0.3% |
Antibiotic prophylaxis | 3 | 0.3% |
Antineoplastic and immunomodulating drugs | 3 | 0.3% |
Antineoplastic drugs | 3 | 0.3% |
Antioxidant | 3 | 0.3% |
Antiphospholipid syndrome | 3 | 0.3% |
Antiserum | 3 | 0.3% |
Anxiety | 3 | 0.3% |
Artemisinin | 3 | 0.3% |
Artery | 3 | 0.3% |
Atopy | 3 | 0.3% |
Atrophic vaginitis | 3 | 0.3% |
Audiology | 3 | 0.3% |
Augmented reality | 3 | 0.3% |
Australians | 3 | 0.3% |
Autism spectrum | 3 | 0.3% |
Autoimmune disease | 3 | 0.3% |
Automated external defibrillator | 3 | 0.3% |
Average treatment effect | 3 | 0.3% |
Azithromycin | 3 | 0.3% |
Baricitinib | 3 | 0.3% |
Bedaquiline | 3 | 0.3% |
Behavioural sciences | 3 | 0.3% |
Beta cell | 3 | 0.3% |
Bias of an estimator | 3 | 0.3% |
Big data | 3 | 0.3% |
Bilirubin | 3 | 0.3% |
Biobank | 3 | 0.3% |
Biopharmaceutical | 3 | 0.3% |
Bioterrorism | 3 | 0.3% |
Blood cell | 3 | 0.3% |
Blood culture | 3 | 0.3% |
Bloodstream infections | 3 | 0.3% |
Botulinum toxin | 3 | 0.3% |
Bovine spongiform encephalopathy | 3 | 0.3% |
Breakthrough infection | 3 | 0.3% |
Breast cancer classification | 3 | 0.3% |
Breast imaging | 3 | 0.3% |
Breathing | 3 | 0.3% |
CA-125 | 3 | 0.3% |
Cancer research | 3 | 0.3% |
Cancer treatments | 3 | 0.3% |
Cannabis (drug) | 3 | 0.3% |
Capitation (healthcare) | 3 | 0.3% |
Carbohydrate | 3 | 0.3% |
Carcinogen | 3 | 0.3% |
Carcinogenesis | 3 | 0.3% |
Cardiac imaging | 3 | 0.3% |
Cardiac resynchronization therapy | 3 | 0.3% |
Case management (US healthcare system) | 3 | 0.3% |
Census in Australia | 3 | 0.3% |
Central nervous system | 3 | 0.3% |
Cephalosporin | 3 | 0.3% |
Cerebral shunt | 3 | 0.3% |
Cetuximab | 3 | 0.3% |
Chagas disease | 3 | 0.3% |
Chancroid | 3 | 0.3% |
Chloroquine | 3 | 0.3% |
Chlortalidone | 3 | 0.3% |
Cholecalciferol | 3 | 0.3% |
Chorioamnionitis | 3 | 0.3% |
Cigar | 3 | 0.3% |
Ciprofloxacin | 3 | 0.3% |
Circumcision and HIV | 3 | 0.3% |
Clinical urine tests | 3 | 0.3% |
Clozapine | 3 | 0.3% |
Co-receptor | 3 | 0.3% |
Cognitive science | 3 | 0.3% |
Cold chain | 3 | 0.3% |
Common variable immunodeficiency | 3 | 0.3% |
Complication (medicine) | 3 | 0.3% |
Consensus decision-making | 3 | 0.3% |
Convolutional neural network | 3 | 0.3% |
Coronary CT calcium scan | 3 | 0.3% |
Corticosteroid | 3 | 0.3% |
Cotinine | 3 | 0.3% |
Cross-validation (statistics) | 3 | 0.3% |
Cryoablation | 3 | 0.3% |
Curriculum | 3 | 0.3% |
Cyclooxygenase | 3 | 0.3% |
Cystatin C | 3 | 0.3% |
Cytotoxic T cell | 3 | 0.3% |
DNA vaccination | 3 | 0.3% |
Dapagliflozin | 3 | 0.3% |
Daratumumab | 3 | 0.3% |
Database | 3 | 0.3% |
Diabetic nephropathy | 3 | 0.3% |
Diazepam | 3 | 0.3% |
Didanosine | 3 | 0.3% |
Dietitian | 3 | 0.3% |
Difference in differences | 3 | 0.3% |
Digestive system | 3 | 0.3% |
Drug injection | 3 | 0.3% |
Dual diagnosis | 3 | 0.3% |
Dummy variable (statistics) | 3 | 0.3% |
Dysmenorrhea | 3 | 0.3% |
Economic model | 3 | 0.3% |
Economics of service industries | 3 | 0.3% |
Ectopic pregnancy | 3 | 0.3% |
Electroencephalography | 3 | 0.3% |
Electronic prescribing | 3 | 0.3% |
Emergency Use Authorization | 3 | 0.3% |
Employee Retirement Income Security Act of 1974 | 3 | 0.3% |
Emtricitabine | 3 | 0.3% |
Endoscopic mucosal resection | 3 | 0.3% |
Enga Province | 3 | 0.3% |
Engineering controls | 3 | 0.3% |
Epigenetics | 3 | 0.3% |
Epileptic seizure | 3 | 0.3% |
Esophageal cancer | 3 | 0.3% |
Estradiol (medication) | 3 | 0.3% |
Evaluation methods | 3 | 0.3% |
Executive functions | 3 | 0.3% |
Exome sequencing | 3 | 0.3% |
FFP standards | 3 | 0.3% |
Fixed effects model | 3 | 0.3% |
Flucytosine | 3 | 0.3% |
Focus group | 3 | 0.3% |
Follicular lymphoma | 3 | 0.3% |
Forest plot | 3 | 0.3% |
Fractional flow reserve | 3 | 0.3% |
Frozen section procedure | 3 | 0.3% |
Furosemide | 3 | 0.3% |
Gabapentin | 3 | 0.3% |
Gardasil | 3 | 0.3% |
Gastrointestinal tract | 3 | 0.3% |
General anaesthesia | 3 | 0.3% |
Gestational trophoblastic disease | 3 | 0.3% |
Glioblastoma | 3 | 0.3% |
Glucagon-like peptide-1 | 3 | 0.3% |
Google Scholar | 3 | 0.3% |
Graft-versus-host disease | 3 | 0.3% |
Group A streptococcal infection | 3 | 0.3% |
Guido Imbens | 3 | 0.3% |
HAS-BLED | 3 | 0.3% |
Hand sanitizer | 3 | 0.3% |
Hazard | 3 | 0.3% |
Head injury | 3 | 0.3% |
Health Level 7 | 3 | 0.3% |
Health maintenance organization | 3 | 0.3% |
Health technology assessment | 3 | 0.3% |
Hepatitis C virus | 3 | 0.3% |
Hepatology | 3 | 0.3% |
Hip replacement | 3 | 0.3% |
Hispanic and Latino Americans | 3 | 0.3% |
Holter monitor | 3 | 0.3% |
Home care in the United States | 3 | 0.3% |
Hospital-acquired pneumonia | 3 | 0.3% |
Human cytomegalovirus | 3 | 0.3% |
Human respiratory syncytial virus | 3 | 0.3% |
Hyperkalemia | 3 | 0.3% |
Hypnotic | 3 | 0.3% |
Hypothesis | 3 | 0.3% |
Hypoxia (medical) | 3 | 0.3% |
ICD-10 | 3 | 0.3% |
Ibandronic acid | 3 | 0.3% |
Immigration | 3 | 0.3% |
Immunoglobulin E | 3 | 0.3% |
Immunohistochemistry | 3 | 0.3% |
Inflammatory bowel disease | 3 | 0.3% |
Infliximab | 3 | 0.3% |
Influenza A virus subtype H5N8 | 3 | 0.3% |
Information privacy | 3 | 0.3% |
Inhaler | 3 | 0.3% |
Innate immune system | 3 | 0.3% |
Inquiry | 3 | 0.3% |
Inspection | 3 | 0.3% |
Insulin pump | 3 | 0.3% |
Internet | 3 | 0.3% |
Interoperability | 3 | 0.3% |
Intima-media thickness | 3 | 0.3% |
Intracranial hemorrhage | 3 | 0.3% |
Intracranial pressure | 3 | 0.3% |
Intravitreal administration | 3 | 0.3% |
Jaundice | 3 | 0.3% |
Knee replacement | 3 | 0.3% |
Laser coagulation | 3 | 0.3% |
Lasso (statistics) | 3 | 0.3% |
Lead poisoning | 3 | 0.3% |
Life expectancy | 3 | 0.3% |
Light therapy | 3 | 0.3% |
Lipids | 3 | 0.3% |
Logistic function | 3 | 0.3% |
Loop diuretic | 3 | 0.3% |
Low back pain | 3 | 0.3% |
Low-carbohydrate diet | 3 | 0.3% |
Lumbar puncture | 3 | 0.3% |
Lutein | 3 | 0.3% |
Lyme disease | 3 | 0.3% |
Lymphatic system | 3 | 0.3% |
Lymphogranuloma venereum | 3 | 0.3% |
Macrophage | 3 | 0.3% |
Macula of retina | 3 | 0.3% |
Management | 3 | 0.3% |
Management of acute coronary syndrome | 3 | 0.3% |
Mania | 3 | 0.3% |
Marburg virus disease | 3 | 0.3% |
Mechanical ventilation | 3 | 0.3% |
Medical cannabis | 3 | 0.3% |
Medical education | 3 | 0.3% |
Medical genetics | 3 | 0.3% |
Medical sign | 3 | 0.3% |
Medicare Advantage | 3 | 0.3% |
Menstrual cycle | 3 | 0.3% |
Mesothelioma | 3 | 0.3% |
Mestranol | 3 | 0.3% |
Metastatic breast cancer | 3 | 0.3% |
Methylphenidate | 3 | 0.3% |
MicroRNA | 3 | 0.3% |
Microbicides for sexually transmitted diseases | 3 | 0.3% |
Microsatellite instability | 3 | 0.3% |
Microscopy | 3 | 0.3% |
Midazolam | 3 | 0.3% |
Middle East respiratory syndrome coronavirus | 3 | 0.3% |
Middle East respiratory syndrome–related coronavirus | 3 | 0.3% |
Mifepristone | 3 | 0.3% |
Migraine | 3 | 0.3% |
Misoprostol | 3 | 0.3% |
Mitral insufficiency | 3 | 0.3% |
Monoamine oxidase inhibitor | 3 | 0.3% |
Monoclonal antibody | 3 | 0.3% |
Morphine | 3 | 0.3% |
Mosquito | 3 | 0.3% |
Mosquito-borne disease | 3 | 0.3% |
Mumps | 3 | 0.3% |
Mycobacterium | 3 | 0.3% |
Near-sightedness | 3 | 0.3% |
Nebulizer | 3 | 0.3% |
Needs assessment | 3 | 0.3% |
Neonatal sepsis | 3 | 0.3% |
Neuron | 3 | 0.3% |
Nightmare | 3 | 0.3% |
Non-invasive ventilation | 3 | 0.3% |
Nuclear medicine | 3 | 0.3% |
Null hypothesis | 3 | 0.3% |
Number needed to treat | 3 | 0.3% |
Nurse practitioner | 3 | 0.3% |
Occupational therapy | 3 | 0.3% |
Omalizumab | 3 | 0.3% |
Ondansetron | 3 | 0.3% |
Oophorectomy | 3 | 0.3% |
Oral cancer | 3 | 0.3% |
Oral sex | 3 | 0.3% |
Oregon Medicaid health experiment | 3 | 0.3% |
Organisms | 3 | 0.3% |
Orthopedic surgery | 3 | 0.3% |
Orthotics | 3 | 0.3% |
Ovarian cyst | 3 | 0.3% |
Ovary | 3 | 0.3% |
Oxford–AstraZeneca COVID-19 vaccine | 3 | 0.3% |
Palbociclib | 3 | 0.3% |
Palpitations | 3 | 0.3% |
Pancreas | 3 | 0.3% |
Parenting | 3 | 0.3% |
Paresthesia | 3 | 0.3% |
Particulates | 3 | 0.3% |
Pathology of pregnancy, childbirth and the puerperium | 3 | 0.3% |
Pectus excavatum | 3 | 0.3% |
Pediatric nursing | 3 | 0.3% |
Penicillin | 3 | 0.3% |
Percentile | 3 | 0.3% |
Personal data | 3 | 0.3% |
Pharyngitis | 3 | 0.3% |
Placental abruption | 3 | 0.3% |
Pneumocystis pneumonia | 3 | 0.3% |
Poliomyelitis eradication | 3 | 0.3% |
Portal hypertension | 3 | 0.3% |
Post-thrombotic syndrome | 3 | 0.3% |
Power (statistics) | 3 | 0.3% |
Power of a test | 3 | 0.3% |
Powered air-purifying respirator | 3 | 0.3% |
Pregabalin | 3 | 0.3% |
Primary biliary cholangitis | 3 | 0.3% |
Prison | 3 | 0.3% |
Probability distribution | 3 | 0.3% |
Progestogen-only pill | 3 | 0.3% |
Propranolol | 3 | 0.3% |
Prostitution | 3 | 0.3% |
Protein | 3 | 0.3% |
Proteomics | 3 | 0.3% |
Pseudoaneurysm | 3 | 0.3% |
Psychiatric and mental health nursing | 3 | 0.3% |
Psychoactive drug | 3 | 0.3% |
Psychological concepts | 3 | 0.3% |
Ptosis (eyelid) | 3 | 0.3% |
Public hospital | 3 | 0.3% |
Pulmonary fibrosis | 3 | 0.3% |
Pyelonephritis | 3 | 0.3% |
QRISK | 3 | 0.3% |
Quality and Outcomes Framework | 3 | 0.3% |
Quality management | 3 | 0.3% |
QuantiFERON | 3 | 0.3% |
Quinolone antibiotic | 3 | 0.3% |
ROS1 | 3 | 0.3% |
Rabies vaccine | 3 | 0.3% |
Raltegravir | 3 | 0.3% |
Ranibizumab | 3 | 0.3% |
Readability | 3 | 0.3% |
Regenerative medicine | 3 | 0.3% |
Reinsurance | 3 | 0.3% |
Renal cell carcinoma | 3 | 0.3% |
Renin | 3 | 0.3% |
Reproduction in mammals | 3 | 0.3% |
Reproductive rights | 3 | 0.3% |
Respiratory system | 3 | 0.3% |
Robotics | 3 | 0.3% |
SARS-CoV-2 Beta variant | 3 | 0.3% |
SARS-CoV-2 Delta variant | 3 | 0.3% |
SOFA score | 3 | 0.3% |
Saxagliptin | 3 | 0.3% |
Scanning laser ophthalmoscopy | 3 | 0.3% |
Scientific Advice Mechanism | 3 | 0.3% |
Serosorting | 3 | 0.3% |
Sexuality | 3 | 0.3% |
Single-payer healthcare | 3 | 0.3% |
Skin cancer | 3 | 0.3% |
Social stigma | 3 | 0.3% |
Social support | 3 | 0.3% |
Sorafenib | 3 | 0.3% |
Spinal anaesthesia | 3 | 0.3% |
Spinal cord | 3 | 0.3% |
Spinal fusion | 3 | 0.3% |
Statistical model | 3 | 0.3% |
Stool guaiac test | 3 | 0.3% |
Stratified sampling | 3 | 0.3% |
Streptococcus | 3 | 0.3% |
Subacute sclerosing panencephalitis | 3 | 0.3% |
Sudden infant death syndrome | 3 | 0.3% |
Sugar | 3 | 0.3% |
Supplemental Nutrition Assistance Program | 3 | 0.3% |
Surrogate endpoint | 3 | 0.3% |
Systemic inflammatory response syndrome | 3 | 0.3% |
TNF inhibitor | 3 | 0.3% |
Telepharmacy | 3 | 0.3% |
Tetraplegia | 3 | 0.3% |
Thyroid hormones | 3 | 0.3% |
Tirofiban | 3 | 0.3% |
Tobacco control | 3 | 0.3% |
Tomography | 3 | 0.3% |
Tracheal intubation | 3 | 0.3% |
Traffic | 3 | 0.3% |
Training | 3 | 0.3% |
Transfusion-related acute lung injury | 3 | 0.3% |
Transitional care | 3 | 0.3% |
Translational medicine | 3 | 0.3% |
Transmissible spongiform encephalopathy | 3 | 0.3% |
Transmission of COVID-19 | 3 | 0.3% |
Treatment as prevention | 3 | 0.3% |
Tricyclic antidepressant | 3 | 0.3% |
Tuberculosis in relation to HIV | 3 | 0.3% |
Tumor necrosis factor alpha | 3 | 0.3% |
Typhoid fever | 3 | 0.3% |
Tyrosine kinase | 3 | 0.3% |
Ulcer (dermatology) | 3 | 0.3% |
Umbilical cord | 3 | 0.3% |
Unit of alcohol | 3 | 0.3% |
United States budget sequestration in 2013 | 3 | 0.3% |
Unlicensed assistive personnel | 3 | 0.3% |
Unwarranted variation | 3 | 0.3% |
Urine test strip | 3 | 0.3% |
Urological conditions | 3 | 0.3% |
Uterine prolapse | 3 | 0.3% |
Utility | 3 | 0.3% |
Vaccines for Children Program | 3 | 0.3% |
Vaginal yeast infection | 3 | 0.3% |
Valsartan | 3 | 0.3% |
Variant Creutzfeldt–Jakob disease | 3 | 0.3% |
Vector (epidemiology) | 3 | 0.3% |
Venlafaxine | 3 | 0.3% |
Ventilator | 3 | 0.3% |
Ventilator-associated pneumonia | 3 | 0.3% |
Ventricular assist device | 3 | 0.3% |
VigiBase | 3 | 0.3% |
Viral diseases | 3 | 0.3% |
Wart | 3 | 0.3% |
Waste | 3 | 0.3% |
Wearable technology | 3 | 0.3% |
Weight management | 3 | 0.3% |
Wheeze | 3 | 0.3% |
White blood cell | 3 | 0.3% |
Whole grain | 3 | 0.3% |
X-ray | 3 | 0.3% |
Zanamivir | 3 | 0.3% |
ABC (medicine) | 2 | 0.2% |
ABVD | 2 | 0.2% |
Abaloparatide | 2 | 0.2% |
Absorbed dose | 2 | 0.2% |
Abuse | 2 | 0.2% |
Acetylcysteine | 2 | 0.2% |
Activities of daily living | 2 | 0.2% |
Acute promyelocytic leukemia | 2 | 0.2% |
Adjustable gastric band | 2 | 0.2% |
Adverse selection | 2 | 0.2% |
Aedes aegypti | 2 | 0.2% |
Africa | 2 | 0.2% |
African Americans | 2 | 0.2% |
Agriculture | 2 | 0.2% |
Aid | 2 | 0.2% |
Aldosterone | 2 | 0.2% |
Allele | 2 | 0.2% |
Allergic rhinitis | 2 | 0.2% |
Alpha-Linolenic acid | 2 | 0.2% |
Amblyopia | 2 | 0.2% |
Ambulatory blood pressure | 2 | 0.2% |
Amos Tversky | 2 | 0.2% |
Amyloid beta | 2 | 0.2% |
Amyloidosis | 2 | 0.2% |
Amyotrophic lateral sclerosis | 2 | 0.2% |
Anaplastic lymphoma kinase | 2 | 0.2% |
Anastrozole | 2 | 0.2% |
Anatomical Therapeutic Chemical Classification System | 2 | 0.2% |
Aneuploidy | 2 | 0.2% |
Angiotensin | 2 | 0.2% |
Animal bacterial diseases | 2 | 0.2% |
Animal bite | 2 | 0.2% |
Animal testing | 2 | 0.2% |
Animal virology | 2 | 0.2% |
Ankle–brachial pressure index | 2 | 0.2% |
Anthropometry | 2 | 0.2% |
Anti-Müllerian hormone | 2 | 0.2% |
Anti-nuclear antibody | 2 | 0.2% |
Antibiotic sensitivity | 2 | 0.2% |
Antibiotics | 2 | 0.2% |
Antiretroviral drugs | 2 | 0.2% |
Antivenom | 2 | 0.2% |
Anti–vascular endothelial growth factor therapy | 2 | 0.2% |
Apheresis | 2 | 0.2% |
Apoptosis | 2 | 0.2% |
Appendectomy | 2 | 0.2% |
Appendicitis | 2 | 0.2% |
Appetite | 2 | 0.2% |
Applied behavior analysis | 2 | 0.2% |
Aripiprazole | 2 | 0.2% |
Arthroscopy | 2 | 0.2% |
Artificial kidney | 2 | 0.2% |
Asbestos | 2 | 0.2% |
Aspergillosis | 2 | 0.2% |
Assisted living | 2 | 0.2% |
Astigmatism | 2 | 0.2% |
Athetosis | 2 | 0.2% |
Auditor's report | 2 | 0.2% |
Autism therapies | 2 | 0.2% |
Autoimmune hepatitis | 2 | 0.2% |
Autologous chondrocyte implantation | 2 | 0.2% |
Autonomy | 2 | 0.2% |
Axon | 2 | 0.2% |
Baby Friendly Hospital Initiative | 2 | 0.2% |
Bareback (sex) | 2 | 0.2% |
Basal-cell carcinoma | 2 | 0.2% |
Basic life support | 2 | 0.2% |
Bayesian inference | 2 | 0.2% |
Behavior change method | 2 | 0.2% |
Behaviour therapy | 2 | 0.2% |
Bempedoic acid | 2 | 0.2% |
Bendamustine | 2 | 0.2% |
Benign prostatic hyperplasia | 2 | 0.2% |
Beta distribution | 2 | 0.2% |
Bethesda system | 2 | 0.2% |
Bibliometrics | 2 | 0.2% |
Biochemical cascade | 2 | 0.2% |
Bioequivalence | 2 | 0.2% |
Biological globalization | 2 | 0.2% |
Biomedical waste | 2 | 0.2% |
Biosafety level | 2 | 0.2% |
Birthing center | 2 | 0.2% |
Bivalirudin | 2 | 0.2% |
Blepharoplasty | 2 | 0.2% |
Blood lead level | 2 | 0.2% |
Blood pressure measurement | 2 | 0.2% |
Blood type | 2 | 0.2% |
Bone metastasis | 2 | 0.2% |
Borderline personality disorder | 2 | 0.2% |
Borrelia | 2 | 0.2% |
Bradycardia | 2 | 0.2% |
Brain damage | 2 | 0.2% |
Breast self-examination | 2 | 0.2% |
Broad-spectrum antibiotic | 2 | 0.2% |
Brucella | 2 | 0.2% |
Budesonide | 2 | 0.2% |
Budesonide/formoterol | 2 | 0.2% |
Bundled payment | 2 | 0.2% |
Business | 2 | 0.2% |
CD135 | 2 | 0.2% |
CD19 | 2 | 0.2% |
CE marking | 2 | 0.2% |
CHOP | 2 | 0.2% |
COVID-19 pandemic in the United States | 2 | 0.2% |
COX-2 inhibitor | 2 | 0.2% |
Calcitriol | 2 | 0.2% |
Calcium supplement | 2 | 0.2% |
Cancer pain | 2 | 0.2% |
Candida (fungus) | 2 | 0.2% |
Candida albicans | 2 | 0.2% |
Cannabidiol | 2 | 0.2% |
Cannabinoid | 2 | 0.2% |
Carbapenem | 2 | 0.2% |
Carbapenem-resistant enterobacteriaceae | 2 | 0.2% |
Carboplatin | 2 | 0.2% |
Carcinoembryonic antigen | 2 | 0.2% |
Cardiac marker | 2 | 0.2% |
Cardiac monitoring | 2 | 0.2% |
Cardiogenic shock | 2 | 0.2% |
Cardiopulmonary bypass | 2 | 0.2% |
Carotid endarterectomy | 2 | 0.2% |
Carotid stenting | 2 | 0.2% |
Cartilage | 2 | 0.2% |
Caspofungin | 2 | 0.2% |
Cataract surgery | 2 | 0.2% |
Causality | 2 | 0.2% |
Cefiderocol | 2 | 0.2% |
Ceftriaxone | 2 | 0.2% |
Cell signaling | 2 | 0.2% |
Cell therapy | 2 | 0.2% |
Cellulitis | 2 | 0.2% |
Central nervous system disorders | 2 | 0.2% |
Ceritinib | 2 | 0.2% |
Cervicitis | 2 | 0.2% |
Chest pain | 2 | 0.2% |
Child development | 2 | 0.2% |
Child mortality | 2 | 0.2% |
Childhood cancer | 2 | 0.2% |
Chlorhexidine | 2 | 0.2% |
Cholecystitis | 2 | 0.2% |
Choroidal neovascularization | 2 | 0.2% |
Chronic care | 2 | 0.2% |
Chronic myelomonocytic leukemia | 2 | 0.2% |
Circulating tumor DNA | 2 | 0.2% |
Citalopram | 2 | 0.2% |
Clinical engineering | 2 | 0.2% |
Clotrimazole | 2 | 0.2% |
Coccidioidomycosis | 2 | 0.2% |
Cohen's kappa | 2 | 0.2% |
Collaboration | 2 | 0.2% |
Coma | 2 | 0.2% |
Communication | 2 | 0.2% |
Complement system | 2 | 0.2% |
Comprehensive geriatric assessment | 2 | 0.2% |
Computerized physician order entry | 2 | 0.2% |
Conjoint analysis | 2 | 0.2% |
Contact lens | 2 | 0.2% |
Continuing medical education | 2 | 0.2% |
Continuous positive airway pressure | 2 | 0.2% |
CoronaVac | 2 | 0.2% |
Coronary CT angiography | 2 | 0.2% |
CpG site | 2 | 0.2% |
Creatine kinase | 2 | 0.2% |
Creutzfeldt–Jakob disease | 2 | 0.2% |
Crimean–Congo hemorrhagic fever | 2 | 0.2% |
Crohn's disease | 2 | 0.2% |
Culture | 2 | 0.2% |
Cure | 2 | 0.2% |
Cushing's disease | 2 | 0.2% |
Cytokine | 2 | 0.2% |
DNA | 2 | 0.2% |
DNA methylation | 2 | 0.2% |
Daclizumab | 2 | 0.2% |
Daniel Kahneman | 2 | 0.2% |
Dasatinib | 2 | 0.2% |
Data | 2 | 0.2% |
Data sharing | 2 | 0.2% |
Delphi method | 2 | 0.2% |
Dengue vaccine | 2 | 0.2% |
Dense breast tissue | 2 | 0.2% |
Deployment of COVID-19 vaccines | 2 | 0.2% |
Deprescribing | 2 | 0.2% |
Dermatitis | 2 | 0.2% |
Development aid | 2 | 0.2% |
Diabetic foot | 2 | 0.2% |
Diabetic foot ulcer | 2 | 0.2% |
Diabetic neuropathy | 2 | 0.2% |
Diffusion of innovations | 2 | 0.2% |
Digital pathology | 2 | 0.2% |
Diphtheria | 2 | 0.2% |
Discrete choice | 2 | 0.2% |
Discrete trial training | 2 | 0.2% |
Disease outbreaks | 2 | 0.2% |
Disease registry | 2 | 0.2% |
Domestic violence | 2 | 0.2% |
Domperidone | 2 | 0.2% |
Donabedian model | 2 | 0.2% |
Donepezil | 2 | 0.2% |
Dosimetry | 2 | 0.2% |
Doxycycline | 2 | 0.2% |
Dronabinol | 2 | 0.2% |
Drug | 2 | 0.2% |
Drug resistance | 2 | 0.2% |
Drug-induced QT prolongation | 2 | 0.2% |
Drugs acting on the nervous system | 2 | 0.2% |
Duchenne muscular dystrophy | 2 | 0.2% |
Eating | 2 | 0.2% |
Echinocandin | 2 | 0.2% |
Educational technology | 2 | 0.2% |
Egg allergy | 2 | 0.2% |
Elderly care | 2 | 0.2% |
Electroconvulsive therapy | 2 | 0.2% |
Embolic stroke of undetermined source | 2 | 0.2% |
Emerging infectious disease | 2 | 0.2% |
Empowerment | 2 | 0.2% |
Encephalitis | 2 | 0.2% |
Endometrium | 2 | 0.2% |
Endophthalmitis | 2 | 0.2% |
Endoscopic submucosal dissection | 2 | 0.2% |
Endothelium | 2 | 0.2% |
Enterococcus | 2 | 0.2% |
Enterovirus-associated diseases | 2 | 0.2% |
Epidemics | 2 | 0.2% |
Epigenomics | 2 | 0.2% |
Eptifibatide | 2 | 0.2% |
Equal opportunity | 2 | 0.2% |
Escherichia coli | 2 | 0.2% |
Esophagogastroduodenoscopy | 2 | 0.2% |
Estrogen (medication) | 2 | 0.2% |
Estrogen receptor | 2 | 0.2% |
Ethics | 2 | 0.2% |
Etomidate | 2 | 0.2% |
Etonogestrel | 2 | 0.2% |
Eur-Lex | 2 | 0.2% |
European Neighbourhood Policy | 2 | 0.2% |
Evaluation of binary classifiers | 2 | 0.2% |
Everolimus | 2 | 0.2% |
Evidence | 2 | 0.2% |
Exenatide | 2 | 0.2% |
Exercise prescription | 2 | 0.2% |
Exercise-induced bronchoconstriction | 2 | 0.2% |
Exhalation | 2 | 0.2% |
Exocrine system | 2 | 0.2% |
Externality | 2 | 0.2% |
Extracorporeal membrane oxygenation | 2 | 0.2% |
Eye protection | 2 | 0.2% |
Ezetimibe/simvastatin | 2 | 0.2% |
FRAX | 2 | 0.2% |
Factor H | 2 | 0.2% |
Factor V Leiden | 2 | 0.2% |
Factor X | 2 | 0.2% |
Familial adenomatous polyposis | 2 | 0.2% |
Fecal incontinence | 2 | 0.2% |
Federal Food, Drug, and Cosmetic Act | 2 | 0.2% |
Female condom | 2 | 0.2% |
Fentanyl | 2 | 0.2% |
Fetal movement | 2 | 0.2% |
Fibrinogen | 2 | 0.2% |
Five Year Forward View | 2 | 0.2% |
Fludeoxyglucose (18F) | 2 | 0.2% |
Fluoride varnish | 2 | 0.2% |
Fluoxetine | 2 | 0.2% |
Follicle-stimulating hormone | 2 | 0.2% |
Food fortification | 2 | 0.2% |
Food intolerance | 2 | 0.2% |
Food safety | 2 | 0.2% |
Foodborne illness | 2 | 0.2% |
Foot-and-mouth disease | 2 | 0.2% |
Forecasting | 2 | 0.2% |
Fraction | 2 | 0.2% |
Function (mathematics) | 2 | 0.2% |
Gastric bypass surgery | 2 | 0.2% |
Gastroenteritis | 2 | 0.2% |
Gastrointestinal bleeding | 2 | 0.2% |
Gender | 2 | 0.2% |
Gene expression profiling in cancer | 2 | 0.2% |
Gene signature | 2 | 0.2% |
Genealogy | 2 | 0.2% |
Generalized linear model | 2 | 0.2% |
Genetic engineering | 2 | 0.2% |
Genital herpes | 2 | 0.2% |
Genome | 2 | 0.2% |
Genotype | 2 | 0.2% |
Gestational hypertension | 2 | 0.2% |
Glands | 2 | 0.2% |
Glasses | 2 | 0.2% |
Gout | 2 | 0.2% |
Granulocyte colony-stimulating factor | 2 | 0.2% |
H-index | 2 | 0.2% |
HIV/AIDS research | 2 | 0.2% |
Health care industry | 2 | 0.2% |
Health care management | 2 | 0.2% |
Health disasters | 2 | 0.2% |
Health law | 2 | 0.2% |
Healthcare shortage area | 2 | 0.2% |
Hearing | 2 | 0.2% |
Hearing aid | 2 | 0.2% |
Heart-type fatty acid binding protein | 2 | 0.2% |
Heartburn | 2 | 0.2% |
Hemofiltration | 2 | 0.2% |
Hemolytic disease of the newborn | 2 | 0.2% |
Hepatitis A | 2 | 0.2% |
Herd immunity | 2 | 0.2% |
High-grade serous carcinoma | 2 | 0.2% |
High-risk pregnancy | 2 | 0.2% |
Hip | 2 | 0.2% |
History | 2 | 0.2% |
Hodgkin's lymphoma | 2 | 0.2% |
Human betaherpesvirus 5 | 2 | 0.2% |
Human leukocyte antigen | 2 | 0.2% |
Human orthopneumovirus | 2 | 0.2% |
Humoral immunity | 2 | 0.2% |
Hydronephrosis | 2 | 0.2% |
Hydroxychloroquine | 2 | 0.2% |
Hyperparathyroidism | 2 | 0.2% |
Hyperprolactinaemia | 2 | 0.2% |
Hyperthyroidism | 2 | 0.2% |
Hypodermic needle | 2 | 0.2% |
Hypokalemia | 2 | 0.2% |
Hypoxemia | 2 | 0.2% |
Iatrogenesis | 2 | 0.2% |
Ibrutinib | 2 | 0.2% |
Ibuprofen | 2 | 0.2% |
Idiopathic pulmonary fibrosis | 2 | 0.2% |
Image segmentation | 2 | 0.2% |
Immunoassay | 2 | 0.2% |
Immunoglobulin M | 2 | 0.2% |
Immunosuppression | 2 | 0.2% |
Imputation (statistics) | 2 | 0.2% |
In vitro fertilisation | 2 | 0.2% |
Incretin | 2 | 0.2% |
Index Medicus | 2 | 0.2% |
Indigestion | 2 | 0.2% |
Individualized Education Program | 2 | 0.2% |
Infant formula | 2 | 0.2% |
Infectious mononucleosis | 2 | 0.2% |
Infective endocarditis | 2 | 0.2% |
Inferior vena cava filter | 2 | 0.2% |
Inflammatory cytokine | 2 | 0.2% |
Influenza research | 2 | 0.2% |
Injuries | 2 | 0.2% |
Insect-borne diseases | 2 | 0.2% |
Insulin aspart | 2 | 0.2% |
Insulin degludec | 2 | 0.2% |
Insulin glargine | 2 | 0.2% |
Intellectual disability | 2 | 0.2% |
Intelligence quotient | 2 | 0.2% |
Intention | 2 | 0.2% |
Interferon | 2 | 0.2% |
Internal audit | 2 | 0.2% |
Internal control | 2 | 0.2% |
Internal validity | 2 | 0.2% |
International development | 2 | 0.2% |
Internet of things | 2 | 0.2% |
Interstitial cystitis | 2 | 0.2% |
Intracytoplasmic sperm injection | 2 | 0.2% |
Intramuscular injection | 2 | 0.2% |
Intraocular lens | 2 | 0.2% |
Invasive carcinoma of no special type | 2 | 0.2% |
Iodine deficiency | 2 | 0.2% |
Ipilimumab | 2 | 0.2% |
Iron overload | 2 | 0.2% |
Issues in ethics | 2 | 0.2% |
Ivabradine | 2 | 0.2% |
Janus kinase | 2 | 0.2% |
KIT (gene) | 2 | 0.2% |
Kaplan–Meier estimator | 2 | 0.2% |
Kaposi's sarcoma | 2 | 0.2% |
Kaposi's sarcoma-associated herpesvirus | 2 | 0.2% |
Kernicterus | 2 | 0.2% |
Kinase | 2 | 0.2% |
Knee | 2 | 0.2% |
Knowledge | 2 | 0.2% |
Lactobacillus | 2 | 0.2% |
Large for gestational age | 2 | 0.2% |
Learning | 2 | 0.2% |
Legionella | 2 | 0.2% |
Legionnaires' disease | 2 | 0.2% |
Leishmaniasis | 2 | 0.2% |
Lentigo maligna | 2 | 0.2% |
Leprosy | 2 | 0.2% |
Levothyroxine | 2 | 0.2% |
Licensure | 2 | 0.2% |
Lidocaine | 2 | 0.2% |
Likert scale | 2 | 0.2% |
Lineage B.1.1.7 | 2 | 0.2% |
Lineage B.1.351 | 2 | 0.2% |
Lisinopril | 2 | 0.2% |
Livestock | 2 | 0.2% |
Lixisenatide | 2 | 0.2% |
Li–Fraumeni syndrome | 2 | 0.2% |
Lobular carcinoma in situ | 2 | 0.2% |
Local average treatment effect | 2 | 0.2% |
Logic model | 2 | 0.2% |
Logistics | 2 | 0.2% |
Loss function | 2 | 0.2% |
Lovastatin | 2 | 0.2% |
Lower gastrointestinal series | 2 | 0.2% |
Lupus | 2 | 0.2% |
Lymph node | 2 | 0.2% |
Lymphatic vessel | 2 | 0.2% |
MRI contrast agent | 2 | 0.2% |
Macular telangiectasia | 2 | 0.2% |
Magnesium deficiency | 2 | 0.2% |
Magnetic resonance angiography | 2 | 0.2% |
Malignancy | 2 | 0.2% |
Mammalian sexuality | 2 | 0.2% |
Management of depression | 2 | 0.2% |
Mandibular advancement splint | 2 | 0.2% |
Marburg virus | 2 | 0.2% |
Mass drug administration | 2 | 0.2% |
Mastectomy | 2 | 0.2% |
Maximum likelihood estimation | 2 | 0.2% |
MedDRA | 2 | 0.2% |
Medical abortion | 2 | 0.2% |
Medical emergency | 2 | 0.2% |
Medical equipment management | 2 | 0.2% |
Medical laboratory | 2 | 0.2% |
Medical procedures | 2 | 0.2% |
Medical technology | 2 | 0.2% |
Medium-chain acyl-coenzyme A dehydrogenase deficiency | 2 | 0.2% |
Mefloquine | 2 | 0.2% |
Megakaryocyte | 2 | 0.2% |
Menstruation | 2 | 0.2% |
Mental states | 2 | 0.2% |
Mentorship | 2 | 0.2% |
Meta-regression | 2 | 0.2% |
Metabolomics | 2 | 0.2% |
Metastatic liver disease | 2 | 0.2% |
Methylenetetrahydrofolate reductase | 2 | 0.2% |
Metoprolol | 2 | 0.2% |
Microalbuminuria | 2 | 0.2% |
Microwave ablation | 2 | 0.2% |
Mid-level practitioner | 2 | 0.2% |
Miliary tuberculosis | 2 | 0.2% |
Minimally invasive procedures | 2 | 0.2% |
MitraClip | 2 | 0.2% |
Mitral valve replacement | 2 | 0.2% |
Mobile app | 2 | 0.2% |
Mobility aid | 2 | 0.2% |
Monitoring and evaluation | 2 | 0.2% |
Monocyte | 2 | 0.2% |
Monounsaturated fat | 2 | 0.2% |
Moral hazard | 2 | 0.2% |
Motivation | 2 | 0.2% |
Mouse | 2 | 0.2% |
Mucositis | 2 | 0.2% |
Multiple-criteria decision analysis | 2 | 0.2% |
Multisystem inflammatory syndrome in children | 2 | 0.2% |
Myc | 2 | 0.2% |
Myelofibrosis | 2 | 0.2% |
Myocarditis | 2 | 0.2% |
N-terminal prohormone of brain natriuretic peptide | 2 | 0.2% |
NIOSH air filtration rating | 2 | 0.2% |
Nabiximols | 2 | 0.2% |
National coverage determination | 2 | 0.2% |
Natural killer cell | 2 | 0.2% |
Neonatal jaundice | 2 | 0.2% |
Neonatology | 2 | 0.2% |
Neovascularization | 2 | 0.2% |
Neural tube defect | 2 | 0.2% |
Neurodegeneration | 2 | 0.2% |
Neurological disorders | 2 | 0.2% |
Neuromodulation (medicine) | 2 | 0.2% |
Nevus | 2 | 0.2% |
Nilotinib | 2 | 0.2% |
Non-Hodgkin lymphoma | 2 | 0.2% |
Norethisterone | 2 | 0.2% |
Normal distribution | 2 | 0.2% |
Norovirus | 2 | 0.2% |
Notifiable disease | 2 | 0.2% |
Notified body | 2 | 0.2% |
Nutrients | 2 | 0.2% |
OIE/FAO Network of Expertise on Animal Influenza | 2 | 0.2% |
Obeticholic acid | 2 | 0.2% |
Occam's razor | 2 | 0.2% |
Olanzapine | 2 | 0.2% |
Omega-3 acid ethyl esters | 2 | 0.2% |
Ongoing events | 2 | 0.2% |
Orbit (anatomy) | 2 | 0.2% |
Organic compounds | 2 | 0.2% |
Orphan drug | 2 | 0.2% |
Orthohantavirus | 2 | 0.2% |
Osimertinib | 2 | 0.2% |
Otitis media | 2 | 0.2% |
Otoacoustic emission | 2 | 0.2% |
Outlier | 2 | 0.2% |
Over-the-counter drug | 2 | 0.2% |
Overfitting | 2 | 0.2% |
Oxygen saturation (medicine) | 2 | 0.2% |
PET-CT | 2 | 0.2% |
Paclitaxel | 2 | 0.2% |
Pandemic H1N1/09 virus | 2 | 0.2% |
Panitumumab | 2 | 0.2% |
Parasitism | 2 | 0.2% |
Paroxetine | 2 | 0.2% |
Partner notification | 2 | 0.2% |
Patient education | 2 | 0.2% |
Patient-controlled analgesia | 2 | 0.2% |
Peer review | 2 | 0.2% |
Pegaptanib | 2 | 0.2% |
Pelvic examination | 2 | 0.2% |
Pelvis | 2 | 0.2% |
Pemphigus | 2 | 0.2% |
Pension | 2 | 0.2% |
Peptic ulcer disease | 2 | 0.2% |
Perfusion | 2 | 0.2% |
Pericarditis | 2 | 0.2% |
Perioperative mortality | 2 | 0.2% |
Perioperative nursing | 2 | 0.2% |
Peripherally inserted central catheter | 2 | 0.2% |
Peritoneum | 2 | 0.2% |
Pertuzumab | 2 | 0.2% |
Pervasive developmental disorder | 2 | 0.2% |
Pervasive developmental disorder not otherwise specified | 2 | 0.2% |
Pet | 2 | 0.2% |
Phagocyte | 2 | 0.2% |
Pharmacodynamics | 2 | 0.2% |
Phenylketonuria | 2 | 0.2% |
Philippine national identity card | 2 | 0.2% |
Physician Orders for Life-Sustaining Treatment | 2 | 0.2% |
Piperacillin | 2 | 0.2% |
Piperaquine | 2 | 0.2% |
Podiatrist | 2 | 0.2% |
Post-transplant lymphoproliferative disorder | 2 | 0.2% |
Post-traumatic amnesia | 2 | 0.2% |
Postoperative nausea and vomiting | 2 | 0.2% |
Predictive modelling | 2 | 0.2% |
Premature ventricular contraction | 2 | 0.2% |
Price | 2 | 0.2% |
Pricing | 2 | 0.2% |
Primary healthcare | 2 | 0.2% |
Primary sclerosing cholangitis | 2 | 0.2% |
Prion | 2 | 0.2% |
Probability | 2 | 0.2% |
Probiotic | 2 | 0.2% |
Problem solving | 2 | 0.2% |
Procedural sedation and analgesia | 2 | 0.2% |
Professional degrees of public health | 2 | 0.2% |
Projectional radiography | 2 | 0.2% |
Proof of concept | 2 | 0.2% |
Prostate biopsy | 2 | 0.2% |
Prosthesis | 2 | 0.2% |
Protein kinase | 2 | 0.2% |
Prothrombin G20210A | 2 | 0.2% |
Protocol (science) | 2 | 0.2% |
Protozoal diseases | 2 | 0.2% |
Provinces and territories of Canada | 2 | 0.2% |
Pseudomonas | 2 | 0.2% |
Pseudomonas aeruginosa | 2 | 0.2% |
Psoriasis | 2 | 0.2% |
Psoriatic arthritis | 2 | 0.2% |
Pulse wave velocity | 2 | 0.2% |
Quetiapine | 2 | 0.2% |
Quinidine | 2 | 0.2% |
RANKL | 2 | 0.2% |
Rabies virus | 2 | 0.2% |
Race (human categorization) | 2 | 0.2% |
Radiation protection | 2 | 0.2% |
Radon | 2 | 0.2% |
Ramucirumab | 2 | 0.2% |
Randomness | 2 | 0.2% |
Real world evidence | 2 | 0.2% |
Red blood cell | 2 | 0.2% |
Refractive surgery | 2 | 0.2% |
Registered nurse | 2 | 0.2% |
Regularization (mathematics) | 2 | 0.2% |
Remote patient monitoring | 2 | 0.2% |
Remote surgery | 2 | 0.2% |
Representativeness heuristic | 2 | 0.2% |
Respirator fit test | 2 | 0.2% |
Respiratory diseases | 2 | 0.2% |
Respiratory syncytial virus | 2 | 0.2% |
Respiratory tract infection | 2 | 0.2% |
Retinoblastoma | 2 | 0.2% |
Retinopathy of prematurity | 2 | 0.2% |
Retrovirus | 2 | 0.2% |
Revised Cardiac Risk Index | 2 | 0.2% |
Rhabdomyolysis | 2 | 0.2% |
Rhinitis | 2 | 0.2% |
Rhinovirus | 2 | 0.2% |
Rifapentine | 2 | 0.2% |
Rift Valley fever | 2 | 0.2% |
Risperidone | 2 | 0.2% |
Road traffic safety | 2 | 0.2% |
Robert Guthrie | 2 | 0.2% |
Robot | 2 | 0.2% |
SARS-CoV-2 Alpha variant | 2 | 0.2% |
SBAR | 2 | 0.2% |
Salbutamol | 2 | 0.2% |
Sarcoma | 2 | 0.2% |
Scenario analysis | 2 | 0.2% |
Scientific control | 2 | 0.2% |
Sedation | 2 | 0.2% |
Selective internal radiation therapy | 2 | 0.2% |
Self-insurance | 2 | 0.2% |
Self-report study | 2 | 0.2% |
Seroconversion | 2 | 0.2% |
Sertraline | 2 | 0.2% |
Sexology | 2 | 0.2% |
Sexual anatomy | 2 | 0.2% |
Sexual emotions | 2 | 0.2% |
Sexual violence | 2 | 0.2% |
Shoulder | 2 | 0.2% |
Sideroblastic anemia | 2 | 0.2% |
Sinopharm BIBP COVID-19 vaccine | 2 | 0.2% |
Skin condition | 2 | 0.2% |
Skull fracture | 2 | 0.2% |
Slum | 2 | 0.2% |
Small for gestational age | 2 | 0.2% |
Small-cell carcinoma | 2 | 0.2% |
Smallpox | 2 | 0.2% |
Smart city | 2 | 0.2% |
Snakebite | 2 | 0.2% |
Snowball sampling | 2 | 0.2% |
Social competence | 2 | 0.2% |
Social media | 2 | 0.2% |
Social protection | 2 | 0.2% |
Social science | 2 | 0.2% |
Socioeconomic status | 2 | 0.2% |
Sodium channel blocker | 2 | 0.2% |
Spanish flu | 2 | 0.2% |
Spermicide | 2 | 0.2% |
Spironolactone | 2 | 0.2% |
Spreadsheet | 2 | 0.2% |
Standardization | 2 | 0.2% |
Staphylococcus | 2 | 0.2% |
Statistical methods | 2 | 0.2% |
Sterilization (medicine) | 2 | 0.2% |
Strategic planning | 2 | 0.2% |
Stress (biology) | 2 | 0.2% |
Stress hyperglycemia | 2 | 0.2% |
Student's t-test | 2 | 0.2% |
Subarachnoid hemorrhage | 2 | 0.2% |
Subdural hematoma | 2 | 0.2% |
Substance-related disorders | 2 | 0.2% |
Superficial thrombophlebitis | 2 | 0.2% |
Supply chain management | 2 | 0.2% |
Supraventricular tachycardia | 2 | 0.2% |
Survival rate | 2 | 0.2% |
Targeted temperature management | 2 | 0.2% |
Technetium-99m | 2 | 0.2% |
Telecare | 2 | 0.2% |
Telecommuting | 2 | 0.2% |
Teledermatology | 2 | 0.2% |
Telenursing | 2 | 0.2% |
Terminal illness | 2 | 0.2% |
Testicular cancer | 2 | 0.2% |
Tetrahydrocannabinol | 2 | 0.2% |
Thematic analysis | 2 | 0.2% |
Thoracotomy | 2 | 0.2% |
Thrombin | 2 | 0.2% |
Thromboelastography | 2 | 0.2% |
Thromboelastometry | 2 | 0.2% |
Thrombolysis | 2 | 0.2% |
Thrombopoietin | 2 | 0.2% |
Thyroid | 2 | 0.2% |
Thyroid-stimulating hormone | 2 | 0.2% |
Time series | 2 | 0.2% |
Tisagenlecleucel | 2 | 0.2% |
Tourette syndrome | 2 | 0.2% |
Toxoplasmosis | 2 | 0.2% |
Tracheotomy | 2 | 0.2% |
Transcatheter arterial chemoembolization | 2 | 0.2% |
Transcranial magnetic stimulation | 2 | 0.2% |
Transcription (biology) | 2 | 0.2% |
Transfusion medicine | 2 | 0.2% |
Transtheoretical model | 2 | 0.2% |
Trauma center | 2 | 0.2% |
Trauma types | 2 | 0.2% |
Traumatology | 2 | 0.2% |
Trimethoprim/sulfamethoxazole | 2 | 0.2% |
Triple-negative breast cancer | 2 | 0.2% |
Tropical disease | 2 | 0.2% |
Tropical diseases | 2 | 0.2% |
Tumor microenvironment | 2 | 0.2% |
Tumors of the hematopoietic and lymphoid tissues | 2 | 0.2% |
Twin | 2 | 0.2% |
Twin-to-twin transfusion syndrome | 2 | 0.2% |
Ulipristal acetate | 2 | 0.2% |
Universal health care | 2 | 0.2% |
Universal precautions | 2 | 0.2% |
Unnecessary health care | 2 | 0.2% |
Ureter | 2 | 0.2% |
Urethra | 2 | 0.2% |
Urinary bladder | 2 | 0.2% |
Urination | 2 | 0.2% |
Ursodeoxycholic acid | 2 | 0.2% |
Uterine fibroid | 2 | 0.2% |
Uterus | 2 | 0.2% |
VKORC1 | 2 | 0.2% |
Vaccination schedule | 2 | 0.2% |
Vaccine-preventable diseases | 2 | 0.2% |
Vacuum aspiration | 2 | 0.2% |
Vaginal flora | 2 | 0.2% |
Vaginal lubrication | 2 | 0.2% |
Vancomycin | 2 | 0.2% |
Varicella vaccine | 2 | 0.2% |
Varicose veins | 2 | 0.2% |
Vascular surgery | 2 | 0.2% |
Vector control | 2 | 0.2% |
Venipuncture | 2 | 0.2% |
Ventricular hypertrophy | 2 | 0.2% |
Vertebra | 2 | 0.2% |
Very low-density lipoprotein | 2 | 0.2% |
Veterinarian | 2 | 0.2% |
Violence against women | 2 | 0.2% |
Viral infections of the central nervous system | 2 | 0.2% |
Virus-like particle | 2 | 0.2% |
Viruses | 2 | 0.2% |
Vitamin C | 2 | 0.2% |
Vocal cord dysfunction | 2 | 0.2% |
Volume expander | 2 | 0.2% |
WHO Framework Convention on Tobacco Control | 2 | 0.2% |
Water fluoridation | 2 | 0.2% |
Website | 2 | 0.2% |
Wolff–Parkinson–White syndrome | 2 | 0.2% |
Women | 2 | 0.2% |
Yellow fever | 2 | 0.2% |
Zeaxanthin | 2 | 0.2% |
Zygosity | 2 | 0.2% |
100,000 Genomes Project | 1 | 0.1% |
2,3,7,8-Tetrachlorodibenzodioxin | 1 | 0.1% |
2009 flu pandemic in the United Kingdom | 1 | 0.1% |
2009 swine flu pandemic | 1 | 0.1% |
3D modeling | 1 | 0.1% |
ALARP | 1 | 0.1% |
APACHE II | 1 | 0.1% |
ASA physical status classification system | 1 | 0.1% |
Abbreviated New Drug Application | 1 | 0.1% |
Aberrations of the eye | 1 | 0.1% |
Abidjan | 1 | 0.1% |
Abiraterone acetate | 1 | 0.1% |
Academic degree | 1 | 0.1% |
Access to COVID-19 Tools Accelerator | 1 | 0.1% |
Accidents | 1 | 0.1% |
Acetabular labrum | 1 | 0.1% |
Acinetobacter | 1 | 0.1% |
Aclidinium bromide | 1 | 0.1% |
Actigraphy | 1 | 0.1% |
Active ingredient | 1 | 0.1% |
Acupressure | 1 | 0.1% |
Acute exacerbation of chronic obstructive pulmonary disease | 1 | 0.1% |
Acute prostatitis | 1 | 0.1% |
Adaptive clinical trial | 1 | 0.1% |
Adenocarcinoma | 1 | 0.1% |
Adenosine | 1 | 0.1% |
Adiponectin | 1 | 0.1% |
Advance healthcare directive | 1 | 0.1% |
Advanced practice nurse | 1 | 0.1% |
Advanced practice registered nurse | 1 | 0.1% |
Advanced trauma life support | 1 | 0.1% |
Advertising | 1 | 0.1% |
Aedes albopictus | 1 | 0.1% |
Aegis Combat System | 1 | 0.1% |
Aerobic exercise | 1 | 0.1% |
Aerosol | 1 | 0.1% |
Affordable Care Act | 1 | 0.1% |
African trypanosomiasis | 1 | 0.1% |
Ailments of unknown cause | 1 | 0.1% |
Airborne disease | 1 | 0.1% |
Airline | 1 | 0.1% |
Airway management | 1 | 0.1% |
Alagille syndrome | 1 | 0.1% |
Albumin | 1 | 0.1% |
Alcohol advertising | 1 | 0.1% |
Alcohol and cancer | 1 | 0.1% |
Alcohol and pregnancy | 1 | 0.1% |
Alcoholic liver disease | 1 | 0.1% |
Alectinib | 1 | 0.1% |
Alemtuzumab | 1 | 0.1% |
Alkaline phosphatase | 1 | 0.1% |
Allergen immunotherapy | 1 | 0.1% |
Allergic bronchopulmonary aspergillosis | 1 | 0.1% |
Allergology | 1 | 0.1% |
Allied health professions | 1 | 0.1% |
Allopurinol | 1 | 0.1% |
Alma Ata Declaration | 1 | 0.1% |
Alteplase | 1 | 0.1% |
Alzheimer's disease biomarkers | 1 | 0.1% |
Ambulatory care | 1 | 0.1% |
Amenorrhea | 1 | 0.1% |
Amikacin | 1 | 0.1% |
Amlodipine | 1 | 0.1% |
Amnesia | 1 | 0.1% |
Amodiaquine | 1 | 0.1% |
Amoebiasis | 1 | 0.1% |
Ampicillin/sulbactam | 1 | 0.1% |
Amplicon | 1 | 0.1% |
Amyloid precursor protein | 1 | 0.1% |
Amyloid-beta precursor protein | 1 | 0.1% |
Anabolic steroid | 1 | 0.1% |
Anaerobic infection | 1 | 0.1% |
Anakinra | 1 | 0.1% |
Anal fissure | 1 | 0.1% |
Anaplastic oligodendroglioma | 1 | 0.1% |
Andrew Wakefield | 1 | 0.1% |
Androgen | 1 | 0.1% |
Androgen deprivation therapy | 1 | 0.1% |
Anecortave acetate | 1 | 0.1% |
Anesthetic | 1 | 0.1% |
Animal physiology | 1 | 0.1% |
Animal welfare | 1 | 0.1% |
Animals | 1 | 0.1% |
Anismus | 1 | 0.1% |
Ankle | 1 | 0.1% |
Anomaly scan | 1 | 0.1% |
Anosmia | 1 | 0.1% |
Anovulation | 1 | 0.1% |
Antenatal steroid | 1 | 0.1% |
Anterior chamber of eyeball | 1 | 0.1% |
Anterograde amnesia | 1 | 0.1% |
Anthropometry of the upper arm | 1 | 0.1% |
Anti-NMDA receptor encephalitis | 1 | 0.1% |
Anti-dsDNA antibodies | 1 | 0.1% |
Anti-inflammatory | 1 | 0.1% |
Anti-obesity medication | 1 | 0.1% |
Anti-social behaviour | 1 | 0.1% |
Anti-thymocyte globulin | 1 | 0.1% |
Antibody-drug conjugate | 1 | 0.1% |
Anticholinergic | 1 | 0.1% |
Antigen-presenting cell | 1 | 0.1% |
Antihistamine | 1 | 0.1% |
Antileukotriene | 1 | 0.1% |
Antimineralocorticoid | 1 | 0.1% |
Antiplatelet drugs | 1 | 0.1% |
Antithrombotic agents | 1 | 0.1% |
Anxiolytic | 1 | 0.1% |
Apnea | 1 | 0.1% |
Apolipoprotein A1 | 1 | 0.1% |
Apolipoprotein E | 1 | 0.1% |
Apolipoprotein L1 | 1 | 0.1% |
Application software | 1 | 0.1% |
Appropriations bill (United States) | 1 | 0.1% |
Apremilast | 1 | 0.1% |
Aqueous humour | 1 | 0.1% |
Arab world | 1 | 0.1% |
Arabs | 1 | 0.1% |
Arbovirus | 1 | 0.1% |
Areca nut | 1 | 0.1% |
Arm | 1 | 0.1% |
Aromatic compounds | 1 | 0.1% |
Arsenic trioxide | 1 | 0.1% |
Arthrogram | 1 | 0.1% |
Artificial heart valve | 1 | 0.1% |
Asbestos-related diseases | 1 | 0.1% |
Asbestosis | 1 | 0.1% |
Ascending aorta | 1 | 0.1% |
Ascites | 1 | 0.1% |
Asenapine | 1 | 0.1% |
Asian Americans | 1 | 0.1% |
Asperger syndrome | 1 | 0.1% |
Asset | 1 | 0.1% |
Assisted reproductive technology | 1 | 0.1% |
Astrocytoma | 1 | 0.1% |
Asystole | 1 | 0.1% |
Atelectasis | 1 | 0.1% |
Athletic heart syndrome | 1 | 0.1% |
Atmosphere of Earth | 1 | 0.1% |
Atopic dermatitis | 1 | 0.1% |
Atrial natriuretic peptide | 1 | 0.1% |
Attachment theory | 1 | 0.1% |
Attentional control | 1 | 0.1% |
Attenuated vaccine | 1 | 0.1% |
Attitude (psychology) | 1 | 0.1% |
Atypical pneumonia | 1 | 0.1% |
Auckland | 1 | 0.1% |
Australian Organ Donor Register | 1 | 0.1% |
AutoPulse | 1 | 0.1% |
Autoantibody | 1 | 0.1% |
Autocorrelation | 1 | 0.1% |
Autoimmune hemolytic anemia | 1 | 0.1% |
Automation | 1 | 0.1% |
Autonomic nervous system | 1 | 0.1% |
Autopsy | 1 | 0.1% |
Avascular necrosis | 1 | 0.1% |
Avelumab | 1 | 0.1% |
Axicabtagene ciloleucel | 1 | 0.1% |
Azacitidine | 1 | 0.1% |
Azathioprine | 1 | 0.1% |
Azo dye | 1 | 0.1% |
Aztreonam | 1 | 0.1% |
B1 cell | 1 | 0.1% |
BK virus | 1 | 0.1% |
Bachelor of Medicine, Bachelor of Surgery | 1 | 0.1% |
Bacillus anthracis | 1 | 0.1% |
Bacillus cereus | 1 | 0.1% |
Background radiation | 1 | 0.1% |
Bacterial adhesin | 1 | 0.1% |
Bacterial diseases | 1 | 0.1% |
Bacteriology | 1 | 0.1% |
Badger culling in the United Kingdom | 1 | 0.1% |
Bag valve mask | 1 | 0.1% |
Balanced Budget Act of 1997 | 1 | 0.1% |
Barbiturate | 1 | 0.1% |
Bariatrics | 1 | 0.1% |
Baroreflex | 1 | 0.1% |
Barrett's esophagus | 1 | 0.1% |
Basal metabolic rate | 1 | 0.1% |
Bayley Scales of Infant Development | 1 | 0.1% |
Bazedoxifene | 1 | 0.1% |
Beef cattle | 1 | 0.1% |
Belief | 1 | 0.1% |
Bellman equation | 1 | 0.1% |
Bempedoic acid/ezetimibe | 1 | 0.1% |
Benjamin Netanyahu | 1 | 0.1% |
Benzatropine | 1 | 0.1% |
Benznidazole | 1 | 0.1% |
Beta thalassemia | 1 | 0.1% |
Beta-Carotene | 1 | 0.1% |
Beta-Sitosterol | 1 | 0.1% |
Beta-catenin | 1 | 0.1% |
Beta-secretase 1 | 1 | 0.1% |
Beta2-adrenergic agonist | 1 | 0.1% |
Bicuspid aortic valve | 1 | 0.1% |
Bile duct | 1 | 0.1% |
Binimetinib | 1 | 0.1% |
Binomial distribution | 1 | 0.1% |
Biofilm | 1 | 0.1% |
Bioinformatics | 1 | 0.1% |
Biomechanics | 1 | 0.1% |
Biomedical engineering | 1 | 0.1% |
Biosafety cabinet | 1 | 0.1% |
Biosensor | 1 | 0.1% |
Bird migration | 1 | 0.1% |
Birds | 1 | 0.1% |
Birth rate | 1 | 0.1% |
Black Death | 1 | 0.1% |
Blast injury | 1 | 0.1% |
Blastocyst | 1 | 0.1% |
Blastoma | 1 | 0.1% |
Bleach | 1 | 0.1% |
Blinatumomab | 1 | 0.1% |
Blockchain | 1 | 0.1% |
Blood bank | 1 | 0.1% |
Blood disorders | 1 | 0.1% |
Blood film | 1 | 0.1% |
Blood vessel | 1 | 0.1% |
Blunt trauma | 1 | 0.1% |
Body composition | 1 | 0.1% |
Bone cyst | 1 | 0.1% |
Bone health | 1 | 0.1% |
Borna disease | 1 | 0.1% |
Bortezomib | 1 | 0.1% |
Bourbon virus | 1 | 0.1% |
Bovine leukemia virus | 1 | 0.1% |
Brachial plexus | 1 | 0.1% |
Brain abscess | 1 | 0.1% |
Brain ischemia | 1 | 0.1% |
Brassica | 1 | 0.1% |
Breast implant | 1 | 0.1% |
Breast reconstruction | 1 | 0.1% |
Brentuximab vedotin | 1 | 0.1% |
Brigatinib | 1 | 0.1% |
Brilacidin | 1 | 0.1% |
Brisbane Diamantina Health Partners | 1 | 0.1% |
British National Formulary | 1 | 0.1% |
Broccoli | 1 | 0.1% |
Bronchiolitis | 1 | 0.1% |
Bronchoscopy | 1 | 0.1% |
Brugada syndrome | 1 | 0.1% |
Bubonic plague | 1 | 0.1% |
Budget | 1 | 0.1% |
Bullous pemphigoid | 1 | 0.1% |
Bumetanide | 1 | 0.1% |
Bunyavirales | 1 | 0.1% |
Buprenorphine | 1 | 0.1% |
Buprenorphine/naloxone | 1 | 0.1% |
Burden of proof (law) | 1 | 0.1% |
Burkholderia | 1 | 0.1% |
Burkholderia mallei | 1 | 0.1% |
Burkholderia pseudomallei | 1 | 0.1% |
Burn | 1 | 0.1% |
CD20 | 1 | 0.1% |
CD4+ T cells and antitumor immunity | 1 | 0.1% |
CHEK2 | 1 | 0.1% |
CMA-ES | 1 | 0.1% |
COLD-PCR | 1 | 0.1% |
COVID-19 Surveillance | 1 | 0.1% |
COVID-19 drug development | 1 | 0.1% |
COVID-19 pandemic in New Jersey | 1 | 0.1% |
COVID-19 vaccination in the United Kingdom | 1 | 0.1% |
COX-3 | 1 | 0.1% |
Ca2+/calmodulin-dependent protein kinase II | 1 | 0.1% |
Cachexia | 1 | 0.1% |
Calcitonin | 1 | 0.1% |
Calcium | 1 | 0.1% |
Calibration | 1 | 0.1% |
California County Routes in zone G | 1 | 0.1% |
Canakinumab | 1 | 0.1% |
Cancer Drugs Fund | 1 | 0.1% |
Cancer biomarker | 1 | 0.1% |
Cancer rehabilitation | 1 | 0.1% |
Cancer-related fatigue | 1 | 0.1% |
Candesartan | 1 | 0.1% |
Candida glabrata | 1 | 0.1% |
Cangrelor | 1 | 0.1% |
Canon PowerShot G | 1 | 0.1% |
Carbamazepine | 1 | 0.1% |
Carbon tax | 1 | 0.1% |
Cardiac amyloidosis | 1 | 0.1% |
Cardiac cycle | 1 | 0.1% |
Cardiac fibrosis | 1 | 0.1% |
Cardiac tamponade | 1 | 0.1% |
Cardiomyopathy | 1 | 0.1% |
Cardiopulmonary rehabilitation | 1 | 0.1% |
Carfilzomib | 1 | 0.1% |
Caring for people with dementia | 1 | 0.1% |
Carlos Finlay | 1 | 0.1% |
Carrion crow | 1 | 0.1% |
Cataplexy | 1 | 0.1% |
Categorical variable | 1 | 0.1% |
Causes of cancer | 1 | 0.1% |
Cefaclor | 1 | 0.1% |
Cefazolin | 1 | 0.1% |
Cefotaxime | 1 | 0.1% |
Ceftazidime | 1 | 0.1% |
Celecoxib | 1 | 0.1% |
Cell (biology) | 1 | 0.1% |
Cell biology | 1 | 0.1% |
Cell culture | 1 | 0.1% |
Cell growth | 1 | 0.1% |
Cell-mediated immunity | 1 | 0.1% |
Cellular respiration | 1 | 0.1% |
Census | 1 | 0.1% |
Central limit theorem | 1 | 0.1% |
Cereal | 1 | 0.1% |
Cerebral cortex | 1 | 0.1% |
Cerebral hypoxia | 1 | 0.1% |
Certification | 1 | 0.1% |
Certified Registered Nurse Anesthetist | 1 | 0.1% |
Certified reference materials | 1 | 0.1% |
Cervical cerclage | 1 | 0.1% |
Chain of custody | 1 | 0.1% |
Chalazion | 1 | 0.1% |
Change management | 1 | 0.1% |
Checkpoint inhibitor | 1 | 0.1% |
Chemotherapy-induced nausea and vomiting | 1 | 0.1% |
Chest tube | 1 | 0.1% |
Child care | 1 | 0.1% |
Childhood obesity | 1 | 0.1% |
Childlessness | 1 | 0.1% |
Children's Health Insurance Program | 1 | 0.1% |
Chimbu Province | 1 | 0.1% |
Chimeric antigen receptor | 1 | 0.1% |
Chloride | 1 | 0.1% |
Chlorine dioxide | 1 | 0.1% |
Choice | 1 | 0.1% |
Choice modelling | 1 | 0.1% |
Choking | 1 | 0.1% |
Cholera | 1 | 0.1% |
Cholestasis | 1 | 0.1% |
Choosing Wisely Canada | 1 | 0.1% |
Chronic care management | 1 | 0.1% |
Chronic inflammatory demyelinating polyneuropathy | 1 | 0.1% |
Chronic thromboembolic pulmonary hypertension | 1 | 0.1% |
Chronotype | 1 | 0.1% |
Chrysotile | 1 | 0.1% |
Chylomicron | 1 | 0.1% |
Circadian rhythm | 1 | 0.1% |
Cisplatin | 1 | 0.1% |
Clavicle fracture | 1 | 0.1% |
Cleaning agent | 1 | 0.1% |
Clindamycin | 1 | 0.1% |
Clinical audit | 1 | 0.1% |
Clinical coder | 1 | 0.1% |
Clinical nurse specialist | 1 | 0.1% |
Clinical research | 1 | 0.1% |
ClinicalTrials.gov | 1 | 0.1% |
Clorazepate | 1 | 0.1% |
Closed-head injury | 1 | 0.1% |
Clostridial infections | 1 | 0.1% |
Clostridioides difficile (bacteria) | 1 | 0.1% |
Clostridium difficile infection | 1 | 0.1% |
Cloud computing | 1 | 0.1% |
Co-stimulation | 1 | 0.1% |
Codeine | 1 | 0.1% |
Coefficient of variation | 1 | 0.1% |
Coenzyme A | 1 | 0.1% |
Coenzyme Q10 | 1 | 0.1% |
Cognitive disorders | 1 | 0.1% |
Coitus interruptus | 1 | 0.1% |
Colesevelam | 1 | 0.1% |
Colestyramine | 1 | 0.1% |
Colorectal polyp | 1 | 0.1% |
Combination therapy | 1 | 0.1% |
Combined hormonal contraception | 1 | 0.1% |
Committee | 1 | 0.1% |
Common bile duct stone | 1 | 0.1% |
Common carotid artery | 1 | 0.1% |
Comparative genomic hybridization | 1 | 0.1% |
Competence (human resources) | 1 | 0.1% |
Competition | 1 | 0.1% |
Complexity | 1 | 0.1% |
Complications of diabetes | 1 | 0.1% |
Compounding | 1 | 0.1% |
Compression stockings | 1 | 0.1% |
Computer science | 1 | 0.1% |
Computer vision | 1 | 0.1% |
Conflict of interest | 1 | 0.1% |
Congenital cytomegalovirus infection | 1 | 0.1% |
Congenital hypothyroidism | 1 | 0.1% |
Congenital iodine deficiency syndrome | 1 | 0.1% |
Congenital pulmonary airway malformation | 1 | 0.1% |
Congenital syphilis | 1 | 0.1% |
Conjugate vaccine | 1 | 0.1% |
Conjugated estrogens | 1 | 0.1% |
Conjunctivitis | 1 | 0.1% |
Consolidated Omnibus Budget Reconciliation Act of 1985 | 1 | 0.1% |
Constipation | 1 | 0.1% |
Constraint-induced movement therapy | 1 | 0.1% |
Content analysis | 1 | 0.1% |
Continuous glucose monitor | 1 | 0.1% |
Contract | 1 | 0.1% |
Contrast-enhanced ultrasound | 1 | 0.1% |
Control chart | 1 | 0.1% |
Control of Substances Hazardous to Health Regulations 2002 | 1 | 0.1% |
Controlled ovarian hyperstimulation | 1 | 0.1% |
Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine | 1 | 0.1% |
Convulsion | 1 | 0.1% |
Coombs test | 1 | 0.1% |
Copanlisib | 1 | 0.1% |
Copeptin | 1 | 0.1% |
Coping (psychology) | 1 | 0.1% |
Copper IUDs | 1 | 0.1% |
Corneal pachymetry | 1 | 0.1% |
Corneal transplantation | 1 | 0.1% |
Coronary artery anomaly | 1 | 0.1% |
Coronary care unit | 1 | 0.1% |
Coronary stent | 1 | 0.1% |
Coronaviridae | 1 | 0.1% |
Coronavirus spike protein | 1 | 0.1% |
Coronavirus-associated diseases | 1 | 0.1% |
Correlation | 1 | 0.1% |
Corynebacterineae | 1 | 0.1% |
Cost estimate | 1 | 0.1% |
Counseling psychology | 1 | 0.1% |
Country of origin | 1 | 0.1% |
Crenezumab | 1 | 0.1% |
Criminalization | 1 | 0.1% |
Cross-reactivity | 1 | 0.1% |
Cross-sectional study | 1 | 0.1% |
Crossover study | 1 | 0.1% |
Croup | 1 | 0.1% |
Crown-rump length | 1 | 0.1% |
Crush syndrome | 1 | 0.1% |
Cryopreservation | 1 | 0.1% |
Cryptosporidiosis | 1 | 0.1% |
Crystallin | 1 | 0.1% |
Culex | 1 | 0.1% |
Current events | 1 | 0.1% |
Cushing's syndrome | 1 | 0.1% |
Custirsen | 1 | 0.1% |
Cutaneous leishmaniasis | 1 | 0.1% |
Cyberattack | 1 | 0.1% |
Cyclin-dependent kinase | 1 | 0.1% |
Cyclophosphamide | 1 | 0.1% |
Cyst | 1 | 0.1% |
Cystoisospora belli | 1 | 0.1% |
Cytogenetics | 1 | 0.1% |
DASH diet | 1 | 0.1% |
DNA microarray | 1 | 0.1% |
DNA vaccine | 1 | 0.1% |
DTaP-IPV/Hib vaccine | 1 | 0.1% |
Darbepoetin alfa | 1 | 0.1% |
Darunavir | 1 | 0.1% |
Data anonymization | 1 | 0.1% |
Data quality | 1 | 0.1% |
Debridement | 1 | 0.1% |
Debridement (dental) | 1 | 0.1% |
Declarative programming | 1 | 0.1% |
Decompression sickness | 1 | 0.1% |
Decriminalizing sex work | 1 | 0.1% |
Defecation | 1 | 0.1% |
Defensive medicine | 1 | 0.1% |
Deferasirox | 1 | 0.1% |
Deferiprone | 1 | 0.1% |
Defined daily dose | 1 | 0.1% |
Deformation (mechanics) | 1 | 0.1% |
Dehydration | 1 | 0.1% |
Dehydroepiandrosterone | 1 | 0.1% |
Demand | 1 | 0.1% |
Demcizumab | 1 | 0.1% |
Dementia with Lewy bodies | 1 | 0.1% |
Demography | 1 | 0.1% |
Demyelinating disease | 1 | 0.1% |
Dendritic cell | 1 | 0.1% |
Dengue virus | 1 | 0.1% |
Dental implant | 1 | 0.1% |
Dental public health | 1 | 0.1% |
Dental sealant | 1 | 0.1% |
Dermatology | 1 | 0.1% |
Dermatology Life Quality Index | 1 | 0.1% |
Dermatomyositis | 1 | 0.1% |
Dermatophytosis | 1 | 0.1% |
Dermatoscopy | 1 | 0.1% |
Desmopressin | 1 | 0.1% |
Desmoteplase | 1 | 0.1% |
Desogestrel | 1 | 0.1% |
Diabetic cardiomyopathy | 1 | 0.1% |
Diabetic hypoglycemia | 1 | 0.1% |
Diagnosis | 1 | 0.1% |
Diclofenac | 1 | 0.1% |
Digestive diseases | 1 | 0.1% |
Dihydrotestosterone | 1 | 0.1% |
Direct-to-consumer advertising | 1 | 0.1% |
Director general | 1 | 0.1% |
Disasters | 1 | 0.1% |
Disease-modifying antirheumatic drug | 1 | 0.1% |
Diseases of poverty | 1 | 0.1% |
Dislocated shoulder | 1 | 0.1% |
Disopyramide | 1 | 0.1% |
District nurse | 1 | 0.1% |
Diuretic | 1 | 0.1% |
Doctor of Medicine | 1 | 0.1% |
Doctor of Osteopathic Medicine | 1 | 0.1% |
Doctor of Philosophy | 1 | 0.1% |
Doctor–patient relationship | 1 | 0.1% |
Dofetilide | 1 | 0.1% |
Dolutegravir | 1 | 0.1% |
Dominance (genetics) | 1 | 0.1% |
Door-to-balloon | 1 | 0.1% |
Dopamine | 1 | 0.1% |
Dosimeter | 1 | 0.1% |
Doxepin | 1 | 0.1% |
Dravet syndrome | 1 | 0.1% |
Dried blood spot | 1 | 0.1% |
Drink | 1 | 0.1% |
Droperidol | 1 | 0.1% |
Drug brand names | 1 | 0.1% |
Drug discovery | 1 | 0.1% |
Drug education | 1 | 0.1% |
Drug eruption | 1 | 0.1% |
Drug liberalization | 1 | 0.1% |
Drug nomenclature | 1 | 0.1% |
Drug reaction with eosinophilia and systemic symptoms | 1 | 0.1% |
Drug tolerance | 1 | 0.1% |
Drug user | 1 | 0.1% |
Drug withdrawal | 1 | 0.1% |
Drug-eluting stent | 1 | 0.1% |
Drusen | 1 | 0.1% |
Duloxetine | 1 | 0.1% |
Duodenum | 1 | 0.1% |
Dura mater | 1 | 0.1% |
Dysentery | 1 | 0.1% |
Dysglycemia | 1 | 0.1% |
Dyspareunia | 1 | 0.1% |
Dysplastic nevus | 1 | 0.1% |
Dystonia | 1 | 0.1% |
ECTS grading scale | 1 | 0.1% |
Early childhood intervention | 1 | 0.1% |
Early-onset Alzheimer's disease | 1 | 0.1% |
Ebola vaccine | 1 | 0.1% |
Ebola virus | 1 | 0.1% |
Ebola virus epidemic in Liberia | 1 | 0.1% |
Echinococcus multilocularis | 1 | 0.1% |
Ecology | 1 | 0.1% |
Economic development | 1 | 0.1% |
Economic equilibrium | 1 | 0.1% |
Edema | 1 | 0.1% |
Edoxaban | 1 | 0.1% |
Efavirenz/emtricitabine/tenofovir | 1 | 0.1% |
Efficacy | 1 | 0.1% |
Eicosanoid | 1 | 0.1% |
Elastomeric respirator | 1 | 0.1% |
Elbow | 1 | 0.1% |
Elective surgery | 1 | 0.1% |
Electrical conduction system of the heart | 1 | 0.1% |
Electroblotting | 1 | 0.1% |
Electromyography | 1 | 0.1% |
Electrophysiology | 1 | 0.1% |
Elimination diet | 1 | 0.1% |
Embryo transfer | 1 | 0.1% |
Emic and etic | 1 | 0.1% |
Emotional eating | 1 | 0.1% |
Emphysema | 1 | 0.1% |
Empirical Bayes method | 1 | 0.1% |
Empiricism | 1 | 0.1% |
Emtricitabine/tenofovir | 1 | 0.1% |
Encephalopathy | 1 | 0.1% |
Encryption | 1 | 0.1% |
End Stage Renal Disease Program | 1 | 0.1% |
Endocrine diseases | 1 | 0.1% |
Endogeneity (econometrics) | 1 | 0.1% |
Endoplasmic reticulum | 1 | 0.1% |
Endoscopic retrograde cholangiopancreatography | 1 | 0.1% |
Enema | 1 | 0.1% |
Engineering | 1 | 0.1% |
Enoxaparin sodium | 1 | 0.1% |
Entamoeba | 1 | 0.1% |
Entecavir | 1 | 0.1% |
Enterococcus faecalis | 1 | 0.1% |
Enterovirus | 1 | 0.1% |
Enterovirus 71 | 1 | 0.1% |
Entrepreneurship | 1 | 0.1% |
Entropy | 1 | 0.1% |
Enuresis | 1 | 0.1% |
Envelope glycoprotein GP120 | 1 | 0.1% |
Environmental enrichment | 1 | 0.1% |
Environmental factor | 1 | 0.1% |
Environmental health | 1 | 0.1% |
Ependymoma | 1 | 0.1% |
Epididymis | 1 | 0.1% |
Epithelium | 1 | 0.1% |
Eplerenone | 1 | 0.1% |
Epstein–Barr virus | 1 | 0.1% |
Equation | 1 | 0.1% |
Equianalgesic | 1 | 0.1% |
Erectile dysfunction | 1 | 0.1% |
Ergocalciferol | 1 | 0.1% |
Error | 1 | 0.1% |
Erythrocyte sedimentation rate | 1 | 0.1% |
Erythropoietin | 1 | 0.1% |
Escitalopram | 1 | 0.1% |
Esophageal achalasia | 1 | 0.1% |
Esophageal varices | 1 | 0.1% |
Essential fatty acid | 1 | 0.1% |
Essential hypertension | 1 | 0.1% |
Estimand | 1 | 0.1% |
Estriol | 1 | 0.1% |
Estrous cycle | 1 | 0.1% |
Etanercept | 1 | 0.1% |
Eteplirsen | 1 | 0.1% |
Ethionamide | 1 | 0.1% |
Ethyl eicosapentaenoic acid | 1 | 0.1% |
Etoricoxib | 1 | 0.1% |
Eurasian beaver | 1 | 0.1% |
European polecat | 1 | 0.1% |
Evidence-based policy | 1 | 0.1% |
Excessive daytime sleepiness | 1 | 0.1% |
Exclusion of the null hypothesis | 1 | 0.1% |
Executive dysfunction | 1 | 0.1% |
Exophthalmos | 1 | 0.1% |
Exotic pet | 1 | 0.1% |
Expense | 1 | 0.1% |
Exponential distribution | 1 | 0.1% |
Expressed emotion | 1 | 0.1% |
External cephalic version | 1 | 0.1% |
External validity | 1 | 0.1% |
Extracellular matrix | 1 | 0.1% |
Eye | 1 | 0.1% |
Eye chart | 1 | 0.1% |
Eye neoplasm | 1 | 0.1% |
Eye surgery | 1 | 0.1% |
Eyelid | 1 | 0.1% |
FMR1 | 1 | 0.1% |
Face shield | 1 | 0.1% |
Facial trauma | 1 | 0.1% |
Factor VIII | 1 | 0.1% |
Factor analysis | 1 | 0.1% |
Failure mode and effects analysis | 1 | 0.1% |
Fallopian tube | 1 | 0.1% |
Falls in older adults | 1 | 0.1% |
False advertising | 1 | 0.1% |
False alarm | 1 | 0.1% |
Fascia | 1 | 0.1% |
Fatty acid | 1 | 0.1% |
Fax | 1 | 0.1% |
Febrile seizure | 1 | 0.1% |
Fee | 1 | 0.1% |
Feeling | 1 | 0.1% |
Felicia Cosman | 1 | 0.1% |
Fellatio | 1 | 0.1% |
Femoral artery | 1 | 0.1% |
Femoral fracture | 1 | 0.1% |
Femoroacetabular impingement | 1 | 0.1% |
Ferret | 1 | 0.1% |
Fertility preservation | 1 | 0.1% |
Fetal alcohol spectrum disorder | 1 | 0.1% |
Fibrin | 1 | 0.1% |
Fibrinolysis | 1 | 0.1% |
FibroTest | 1 | 0.1% |
Fibroadenoma | 1 | 0.1% |
Fibrocystic breast changes | 1 | 0.1% |
Fidaxomicin | 1 | 0.1% |
Field epidemiology | 1 | 0.1% |
Field triage | 1 | 0.1% |
Fifth disease | 1 | 0.1% |
Filariasis | 1 | 0.1% |
Filtering facepiece respirator | 1 | 0.1% |
Finance | 1 | 0.1% |
Financial audit | 1 | 0.1% |
Financial risk | 1 | 0.1% |
Finasteride | 1 | 0.1% |
Fixation (histology) | 1 | 0.1% |
Fixed asset | 1 | 0.1% |
Flexibility (anatomy) | 1 | 0.1% |
Fludarabine | 1 | 0.1% |
Fluorescence in situ hybridization | 1 | 0.1% |
Fluoride therapy | 1 | 0.1% |
Flurazepam | 1 | 0.1% |
Fluticasone propionate | 1 | 0.1% |
Flynn effect | 1 | 0.1% |
Focal segmental glomerulosclerosis | 1 | 0.1% |
Fondaparinux | 1 | 0.1% |
Food allergy | 1 | 0.1% |
Food and Drug Administration Amendments Act of 2007 | 1 | 0.1% |
Food defense | 1 | 0.1% |
Food energy | 1 | 0.1% |
Food frequency questionnaire | 1 | 0.1% |
Forearm | 1 | 0.1% |
Fosfomycin | 1 | 0.1% |
Fraction of inspired oxygen | 1 | 0.1% |
Fragile X syndrome | 1 | 0.1% |
Francis Collins | 1 | 0.1% |
Francisco Javier de Balmis | 1 | 0.1% |
Free flap breast reconstruction | 1 | 0.1% |
Frequentist inference | 1 | 0.1% |
Fructosamine | 1 | 0.1% |
Fruit | 1 | 0.1% |
Fulvestrant | 1 | 0.1% |
Functional groups | 1 | 0.1% |
Functional magnetic resonance imaging | 1 | 0.1% |
Functional neurological symptom disorder | 1 | 0.1% |
Funding of science | 1 | 0.1% |
Fusidic acid | 1 | 0.1% |
G2 phase | 1 | 0.1% |
GLUT1 | 1 | 0.1% |
Gadolinium | 1 | 0.1% |
Gait analysis | 1 | 0.1% |
Galactose-1-phosphate uridylyltransferase deficiency | 1 | 0.1% |
Galactosemia | 1 | 0.1% |
Galanin | 1 | 0.1% |
Gallbladder | 1 | 0.1% |
Gallstone | 1 | 0.1% |
Gametocyte | 1 | 0.1% |
Ganciclovir | 1 | 0.1% |
Gangrene | 1 | 0.1% |
Gardner's syndrome | 1 | 0.1% |
Gaza Strip | 1 | 0.1% |
Gefitinib | 1 | 0.1% |
Gemcitabine | 1 | 0.1% |
Gender equality | 1 | 0.1% |
Gene duplication | 1 | 0.1% |
Gene silencing | 1 | 0.1% |
General practice | 1 | 0.1% |
General surgery | 1 | 0.1% |
Generalized anxiety disorder | 1 | 0.1% |
Genetic carrier | 1 | 0.1% |
Genetic heterogeneity | 1 | 0.1% |
Genetic linkage | 1 | 0.1% |
Genetic marker | 1 | 0.1% |
Genome editing | 1 | 0.1% |
Genotoxicity | 1 | 0.1% |
Geriatric psychiatry | 1 | 0.1% |
Germline mutation | 1 | 0.1% |
Gestrinone | 1 | 0.1% |
Giant-cell arteritis | 1 | 0.1% |
Gilbert's syndrome | 1 | 0.1% |
Glasgow Coma Scale | 1 | 0.1% |
Gliflozin | 1 | 0.1% |
Glioma | 1 | 0.1% |
Global Burden of Disease Study | 1 | 0.1% |
Global warming | 1 | 0.1% |
Glomerulonephritis | 1 | 0.1% |
Glomerulus (kidney) | 1 | 0.1% |
Glove | 1 | 0.1% |
Glucocorticoid | 1 | 0.1% |
Glucose | 1 | 0.1% |
Glucose meter | 1 | 0.1% |
Glucose-6-phosphate dehydrogenase deficiency | 1 | 0.1% |
Glut1 deficiency | 1 | 0.1% |
Glutamate dehydrogenase | 1 | 0.1% |
Glutaric aciduria type 1 | 1 | 0.1% |
Glutathione | 1 | 0.1% |
Glycogen storage disease type II | 1 | 0.1% |
Goitre | 1 | 0.1% |
Government | 1 | 0.1% |
Gp41 | 1 | 0.1% |
Granuloma inguinale | 1 | 0.1% |
Graves' disease | 1 | 0.1% |
Graves' ophthalmopathy | 1 | 0.1% |
Gray (unit) | 1 | 0.1% |
Greater trochanteric pain syndrome | 1 | 0.1% |
Ground-glass opacity | 1 | 0.1% |
Group purchasing organization | 1 | 0.1% |
Growth hormone | 1 | 0.1% |
Gums | 1 | 0.1% |
Gun violence | 1 | 0.1% |
Gunshot wound | 1 | 0.1% |
HBB | 1 | 0.1% |
HELLP syndrome | 1 | 0.1% |
HEPA | 1 | 0.1% |
HERG | 1 | 0.1% |
HIV tropism | 1 | 0.1% |
HIV vaccine | 1 | 0.1% |
HPV-positive oropharyngeal cancer | 1 | 0.1% |
HTTPS | 1 | 0.1% |
Haemaphysalis longicornis | 1 | 0.1% |
Haematopoiesis | 1 | 0.1% |
Haemophilia | 1 | 0.1% |
Haemophilia B | 1 | 0.1% |
Hand | 1 | 0.1% |
Hand dryer | 1 | 0.1% |
Health Information Technology for Economic and Clinical Health Act | 1 | 0.1% |
Health and Social Care Act 2012 | 1 | 0.1% |
Health belief model | 1 | 0.1% |
Health care brands | 1 | 0.1% |
Health care prices in the United States | 1 | 0.1% |
Health claim | 1 | 0.1% |
Health education | 1 | 0.1% |
Health effects of sunlight exposure | 1 | 0.1% |
Health effects of tobacco | 1 | 0.1% |
Health insurance marketplace | 1 | 0.1% |
Health issues in pregnancy | 1 | 0.1% |
Health reimbursement account | 1 | 0.1% |
Health savings account | 1 | 0.1% |
Health security | 1 | 0.1% |
Health services research | 1 | 0.1% |
Healthcare Cost and Utilization Project | 1 | 0.1% |
Healthcare Effectiveness Data and Information Set | 1 | 0.1% |
Healthcare in Italy | 1 | 0.1% |
Healthcare in the Netherlands | 1 | 0.1% |
Healthcare reform in the United States | 1 | 0.1% |
Heart murmur | 1 | 0.1% |
Heart rate variability | 1 | 0.1% |
Heated humidified high-flow therapy | 1 | 0.1% |
Helicobacter | 1 | 0.1% |
Helminthiasis | 1 | 0.1% |
Hemiparesis | 1 | 0.1% |
Hemoglobin | 1 | 0.1% |
Hemoglobinopathy | 1 | 0.1% |
Hemophagocytic lymphohistiocytosis | 1 | 0.1% |
Hemorrhoid | 1 | 0.1% |
Hemosiderosis | 1 | 0.1% |
Hemostasis | 1 | 0.1% |
Hemothorax | 1 | 0.1% |
Henipavirus | 1 | 0.1% |
Heparin-induced thrombocytopenia | 1 | 0.1% |
Hepatic arterial infusion | 1 | 0.1% |
Hepatic encephalopathy | 1 | 0.1% |
Hepatitis E | 1 | 0.1% |
Hepatotoxicity | 1 | 0.1% |
Hernia | 1 | 0.1% |
Heteroscedasticity | 1 | 0.1% |
Heuristics in judgment and decision-making | 1 | 0.1% |
High-intensity focused ultrasound | 1 | 0.1% |
Hindsight bias | 1 | 0.1% |
Hip arthroscopy | 1 | 0.1% |
Hip dislocation | 1 | 0.1% |
Hip pain | 1 | 0.1% |
Hispanic paradox | 1 | 0.1% |
Histamine | 1 | 0.1% |
Histocompatibility | 1 | 0.1% |
Histology | 1 | 0.1% |
History of cancer chemotherapy | 1 | 0.1% |
Hodgkin lymphoma | 1 | 0.1% |
Home care | 1 | 0.1% |
Home hemodialysis | 1 | 0.1% |
Homoscedasticity | 1 | 0.1% |
Honiara | 1 | 0.1% |
Hookah | 1 | 0.1% |
Hormonal IUDs | 1 | 0.1% |
Hospice | 1 | 0.1% |
Hospice care in the United States | 1 | 0.1% |
Hospital-acquired condition | 1 | 0.1% |
Hot flash | 1 | 0.1% |
Household income in the United States | 1 | 0.1% |
Human | 1 | 0.1% |
Human Development Index | 1 | 0.1% |
Human body temperature | 1 | 0.1% |
Human decontamination | 1 | 0.1% |
Human gender and sexuality | 1 | 0.1% |
Human leg | 1 | 0.1% |
Human life stages | 1 | 0.1% |
Human metapneumovirus | 1 | 0.1% |
Human nature | 1 | 0.1% |
Human nutrition | 1 | 0.1% |
Human parainfluenza viruses | 1 | 0.1% |
Human resource management | 1 | 0.1% |
Human subject research | 1 | 0.1% |
Human tooth | 1 | 0.1% |
Humerus | 1 | 0.1% |
Hunger | 1 | 0.1% |
Hunger (physiology) | 1 | 0.1% |
Hydralazine | 1 | 0.1% |
Hydrocephalus | 1 | 0.1% |
Hydrops fetalis | 1 | 0.1% |
Hydroxyethyl starch | 1 | 0.1% |
Hyperalgesia | 1 | 0.1% |
Hypercapnia | 1 | 0.1% |
Hyperemesis gravidarum | 1 | 0.1% |
Hyperhidrosis | 1 | 0.1% |
Hyperinsulinemia | 1 | 0.1% |
Hyperkinetic disorder | 1 | 0.1% |
Hyperoxia | 1 | 0.1% |
Hyperparameter optimization | 1 | 0.1% |
Hypersomnia | 1 | 0.1% |
Hypertelorism | 1 | 0.1% |
Hypertensive disease of pregnancy | 1 | 0.1% |
Hyperthermia therapy | 1 | 0.1% |
Hyperuricemia | 1 | 0.1% |
Hypocalcemia | 1 | 0.1% |
Hypokinesia | 1 | 0.1% |
Hypopituitarism | 1 | 0.1% |
Hypotension | 1 | 0.1% |
Hypothalamus | 1 | 0.1% |
Hypovolemic shock | 1 | 0.1% |
IL17A | 1 | 0.1% |
ISM band | 1 | 0.1% |
ISO 9000 | 1 | 0.1% |
ISO/IEC 27001 | 1 | 0.1% |
Icodextrin | 1 | 0.1% |
Idiopathic hypersomnia | 1 | 0.1% |
Illicit cigarette trade | 1 | 0.1% |
Image scanner | 1 | 0.1% |
Imaging | 1 | 0.1% |
Imatinib | 1 | 0.1% |
Immune response | 1 | 0.1% |
Immune tolerance | 1 | 0.1% |
Immunization during pregnancy | 1 | 0.1% |
Immunocontraception | 1 | 0.1% |
Immunoelectrophoresis | 1 | 0.1% |
Immunoglobulin A | 1 | 0.1% |
Immunologic adjuvant | 1 | 0.1% |
Immunoprecipitation | 1 | 0.1% |
Immunosenescence | 1 | 0.1% |
Impact evaluation | 1 | 0.1% |
Impact factor | 1 | 0.1% |
Impetigo | 1 | 0.1% |
Improving Access to Psychological Therapies | 1 | 0.1% |
Incidental imaging finding | 1 | 0.1% |
Incubation period | 1 | 0.1% |
Index case | 1 | 0.1% |
Indiana vesiculovirus | 1 | 0.1% |
Indigenous health in Australia | 1 | 0.1% |
Indinavir | 1 | 0.1% |
Indo-Fijians | 1 | 0.1% |
Indole-3-carbinol | 1 | 0.1% |
Indoor tanning | 1 | 0.1% |
Industries | 1 | 0.1% |
Infancy | 1 | 0.1% |
Infant bed | 1 | 0.1% |
Inferior vena cava | 1 | 0.1% |
Inflation | 1 | 0.1% |
Influenza A virus subtype H7N7 | 1 | 0.1% |
Influenza A virus subtype H9N2 | 1 | 0.1% |
Influenza prevention | 1 | 0.1% |
Influenza treatment | 1 | 0.1% |
Infographic | 1 | 0.1% |
Information governance | 1 | 0.1% |
Information security | 1 | 0.1% |
Information security management | 1 | 0.1% |
Information system | 1 | 0.1% |
Infrared | 1 | 0.1% |
Infusion pump | 1 | 0.1% |
Instrumental variables estimation | 1 | 0.1% |
Insulin lispro | 1 | 0.1% |
Integrated disease surveillance program | 1 | 0.1% |
Intensive insulin therapy | 1 | 0.1% |
Interdisciplinarity | 1 | 0.1% |
Interest | 1 | 0.1% |
Interferon gamma | 1 | 0.1% |
Interleukin | 1 | 0.1% |
Interleukin 15 | 1 | 0.1% |
Interleukin 17 | 1 | 0.1% |
Interleukin 2 | 1 | 0.1% |
Interleukin 6 | 1 | 0.1% |
Interleukin-1 family | 1 | 0.1% |
Intermittent preventive therapy | 1 | 0.1% |
International Classification of Diseases for Oncology | 1 | 0.1% |
International Prognostic Index | 1 | 0.1% |
Internet of Military Things | 1 | 0.1% |
Interstitial lung disease | 1 | 0.1% |
Intervertebral disc | 1 | 0.1% |
Interview | 1 | 0.1% |
Intraductal papillary mucinous neoplasm | 1 | 0.1% |
Intraocular pressure | 1 | 0.1% |
Intrauterine hypoxia | 1 | 0.1% |
Intravenous pyelogram | 1 | 0.1% |
Intraventricular hemorrhage | 1 | 0.1% |
Invasive species | 1 | 0.1% |
Iodised salt | 1 | 0.1% |
Iron-deficiency anemia | 1 | 0.1% |
Irritable bowel syndrome | 1 | 0.1% |
Islet cell transplantation | 1 | 0.1% |
Isosporiasis | 1 | 0.1% |
Israeli settlement | 1 | 0.1% |
Itraconazole | 1 | 0.1% |
Ivacaftor | 1 | 0.1% |
Ivermectin | 1 | 0.1% |
JLENS | 1 | 0.1% |
Janssen COVID-19 vaccine | 1 | 0.1% |
Japanese encephalitis | 1 | 0.1% |
Jejunum | 1 | 0.1% |
Jerusalem | 1 | 0.1% |
Join (SQL) | 1 | 0.1% |
Joint dislocation | 1 | 0.1% |
Julie Gerberding | 1 | 0.1% |
Juvenile dermatomyositis | 1 | 0.1% |
Juvenile idiopathic arthritis | 1 | 0.1% |
Kangaroo care | 1 | 0.1% |
Kegel exercise | 1 | 0.1% |
Keloid | 1 | 0.1% |
Kennel cough | 1 | 0.1% |
Ketamine | 1 | 0.1% |
Ki-67 (protein) | 1 | 0.1% |
Kidney stone disease | 1 | 0.1% |
Klebsiella pneumoniae | 1 | 0.1% |
Klinefelter syndrome | 1 | 0.1% |
Kt/V | 1 | 0.1% |
Laboratory diagnosis of viral infections | 1 | 0.1% |
Laboratory information management system | 1 | 0.1% |
Laboratory rat | 1 | 0.1% |
Lactate dehydrogenase | 1 | 0.1% |
Lactobacillus acidophilus | 1 | 0.1% |
Lactobacillus fermentum | 1 | 0.1% |
Lactobacillus rhamnosus | 1 | 0.1% |
Lambert–Eaton myasthenic syndrome | 1 | 0.1% |
Laminoplasty | 1 | 0.1% |
Lamotrigine | 1 | 0.1% |
Language interpretation | 1 | 0.1% |
Laparotomy | 1 | 0.1% |
Lapatinib | 1 | 0.1% |
Laryngeal cancer | 1 | 0.1% |
Lateral flow test | 1 | 0.1% |
Law | 1 | 0.1% |
Law of Canada | 1 | 0.1% |
Laxative | 1 | 0.1% |
Le Fort fracture of skull | 1 | 0.1% |
Legislation | 1 | 0.1% |
Lennox–Gastaut syndrome | 1 | 0.1% |
Lens (anatomy) | 1 | 0.1% |
Lentivirus | 1 | 0.1% |
Lenvatinib | 1 | 0.1% |
Leptospirosis | 1 | 0.1% |
Leukorrhea | 1 | 0.1% |
Leukotriene | 1 | 0.1% |
Licensed behavior analyst | 1 | 0.1% |
Life satisfaction | 1 | 0.1% |
Life sciences industry | 1 | 0.1% |
Life-cycle assessment | 1 | 0.1% |
Lineage P.1 | 1 | 0.1% |
Linear no-threshold model | 1 | 0.1% |
Linkage disequilibrium | 1 | 0.1% |
Lipid disorders | 1 | 0.1% |
Lisdexamfetamine | 1 | 0.1% |
Listeria monocytogenes | 1 | 0.1% |
Literacy | 1 | 0.1% |
Lojze Peterle | 1 | 0.1% |
Long COVID | 1 | 0.1% |
Long non-coding RNA | 1 | 0.1% |
Long-acting beta-adrenoceptor agonist | 1 | 0.1% |
Long-acting reversible contraception | 1 | 0.1% |
Long-term effects of alcohol | 1 | 0.1% |
Lopinavir/ritonavir | 1 | 0.1% |
Loratadine | 1 | 0.1% |
Lorazepam | 1 | 0.1% |
Low-threshold treatment programs | 1 | 0.1% |
Lujo mammarenavirus | 1 | 0.1% |
Lumbar vertebrae | 1 | 0.1% |
Lumpectomy | 1 | 0.1% |
Lung disorders | 1 | 0.1% |
Luteinizing hormone | 1 | 0.1% |
Lymphadenopathy | 1 | 0.1% |
Lymphatic filariasis | 1 | 0.1% |
Lymphedema | 1 | 0.1% |
Lysosome | 1 | 0.1% |
MALT lymphoma | 1 | 0.1% |
MLH1 | 1 | 0.1% |
MMR vaccine and autism | 1 | 0.1% |
MRNA vaccine | 1 | 0.1% |
MRNA-1273 | 1 | 0.1% |
MSH2 | 1 | 0.1% |
MSH6 | 1 | 0.1% |
MTOR inhibitors | 1 | 0.1% |
MUC1 | 1 | 0.1% |
Macrogol | 1 | 0.1% |
Magnesium | 1 | 0.1% |
Magnetoencephalography | 1 | 0.1% |
Major histocompatibility complex | 1 | 0.1% |
Malaria antigen detection tests | 1 | 0.1% |
Malaria vaccine | 1 | 0.1% |
Malcolm B. Frost | 1 | 0.1% |
Mammal female reproductive system | 1 | 0.1% |
Mammaplasty | 1 | 0.1% |
Mammary tumor | 1 | 0.1% |
Management of COVID-19 | 1 | 0.1% |
Management of dehydration | 1 | 0.1% |
Management of obesity | 1 | 0.1% |
Management of schizophrenia | 1 | 0.1% |
Mandible | 1 | 0.1% |
Mandibular fracture | 1 | 0.1% |
Mani Menon | 1 | 0.1% |
Mantle cell lymphoma | 1 | 0.1% |
Manufacturing | 1 | 0.1% |
Manus Island | 1 | 0.1% |
Marfan syndrome | 1 | 0.1% |
Mark and recapture | 1 | 0.1% |
Market (economics) | 1 | 0.1% |
Marketing | 1 | 0.1% |
Marketing authorisation | 1 | 0.1% |
Marriage | 1 | 0.1% |
Mass media | 1 | 0.1% |
Mass-casualty incident | 1 | 0.1% |
Mastocytosis | 1 | 0.1% |
Mastopexy | 1 | 0.1% |
Matched filter | 1 | 0.1% |
Mathematical and quantitative methods (economics) | 1 | 0.1% |
Mathematical model | 1 | 0.1% |
Mathematics | 1 | 0.1% |
Maxilla | 1 | 0.1% |
McDonald criteria | 1 | 0.1% |
Mediastinitis | 1 | 0.1% |
Mediastinum | 1 | 0.1% |
Medical Priority Dispatch System | 1 | 0.1% |
Medical and health organizations | 1 | 0.1% |
Medical eligibility criteria for contraceptive use | 1 | 0.1% |
Medical laboratory scientist | 1 | 0.1% |
Medical prevention | 1 | 0.1% |
Medical privacy | 1 | 0.1% |
Medical simulation | 1 | 0.1% |
Medical ventilator | 1 | 0.1% |
Medicalization | 1 | 0.1% |
Medicare Part D | 1 | 0.1% |
Medicare Part D coverage gap | 1 | 0.1% |
Medulloblastoma | 1 | 0.1% |
Meige's syndrome | 1 | 0.1% |
Melanocytic nevus | 1 | 0.1% |
Melatonin | 1 | 0.1% |
Melioidosis | 1 | 0.1% |
Membrane-active molecules | 1 | 0.1% |
Memory B cell | 1 | 0.1% |
Memory T cell | 1 | 0.1% |
Men's health | 1 | 0.1% |
Meningioma | 1 | 0.1% |
Mental health professional | 1 | 0.1% |
Mental status examination | 1 | 0.1% |
Meralgia paraesthetica | 1 | 0.1% |
Mergers and acquisitions | 1 | 0.1% |
Mesenchymal stem cell | 1 | 0.1% |
Metabolic equivalent of task | 1 | 0.1% |
Metabolism | 1 | 0.1% |
Metastasectomy | 1 | 0.1% |
Methadone | 1 | 0.1% |
Methicillin | 1 | 0.1% |
Methods of birth control | 1 | 0.1% |
Methotrexate | 1 | 0.1% |
Methylnaltrexone | 1 | 0.1% |
Methyltestosterone | 1 | 0.1% |
Metoclopramide | 1 | 0.1% |
Metolazone | 1 | 0.1% |
Michael Osterholm | 1 | 0.1% |
Microcephaly | 1 | 0.1% |
Microglia | 1 | 0.1% |
Micronucleus | 1 | 0.1% |
Micronucleus test | 1 | 0.1% |
Micronutrient | 1 | 0.1% |
Microsimulation | 1 | 0.1% |
Microtia | 1 | 0.1% |
Microvascular angina | 1 | 0.1% |
Midostaurin | 1 | 0.1% |
Mild cognitive impairment | 1 | 0.1% |
Milk | 1 | 0.1% |
Milk allergy | 1 | 0.1% |
Mindfulness-based cognitive therapy | 1 | 0.1% |
Minimaze procedure | 1 | 0.1% |
Minneapolis–Saint Paul International Airport | 1 | 0.1% |
Mirtazapine | 1 | 0.1% |
Mitochondrion | 1 | 0.1% |
Mitral regurgitation | 1 | 0.1% |
Mitral stenosis | 1 | 0.1% |
Mitral valve annuloplasty | 1 | 0.1% |
Mitral valve repair | 1 | 0.1% |
Mitral valve stenosis | 1 | 0.1% |
Mobile device | 1 | 0.1% |
Moclobemide | 1 | 0.1% |
Modafinil | 1 | 0.1% |
Model for End-Stage Liver Disease | 1 | 0.1% |
Molecular imaging | 1 | 0.1% |
Monoclonal B-cell lymphocytosis | 1 | 0.1% |
Monoclonal antibody therapy | 1 | 0.1% |
Mood stabilizer | 1 | 0.1% |
Morobe Province | 1 | 0.1% |
Mother | 1 | 0.1% |
Motion sickness | 1 | 0.1% |
Motor skill | 1 | 0.1% |
Mouth | 1 | 0.1% |
Multidimensional signal processing | 1 | 0.1% |
Multifocal motor neuropathy | 1 | 0.1% |
Multilevel model | 1 | 0.1% |
Multimethodology | 1 | 0.1% |
Multinomial logistic regression | 1 | 0.1% |
Multiomics | 1 | 0.1% |
Multiple comparisons problem | 1 | 0.1% |
Multistakeholder governance | 1 | 0.1% |
Muriel Bowser | 1 | 0.1% |
Muromonab-CD3 | 1 | 0.1% |
Muscarinic antagonist | 1 | 0.1% |
Muscular dystrophy | 1 | 0.1% |
Musicians from Florida | 1 | 0.1% |
Mustelidae | 1 | 0.1% |
Mutagen | 1 | 0.1% |
Myasthenia gravis | 1 | 0.1% |
Mycophenolic acid | 1 | 0.1% |
Mycoplasma pneumoniae | 1 | 0.1% |
Myeloma protein | 1 | 0.1% |
Myeloproliferative neoplasm | 1 | 0.1% |
Myrosinase | 1 | 0.1% |
Māori people | 1 | 0.1% |
NHS dentistry | 1 | 0.1% |
NHS foundation trust | 1 | 0.1% |
NHS health check | 1 | 0.1% |
Nail biting | 1 | 0.1% |
Naive T cell | 1 | 0.1% |
Naldemedine | 1 | 0.1% |
Naltrexone | 1 | 0.1% |
Nandrolone | 1 | 0.1% |
Nanomedicine | 1 | 0.1% |
Nanotechnology | 1 | 0.1% |
Naproxen | 1 | 0.1% |
Narcolepsy | 1 | 0.1% |
Nasolacrimal duct obstruction | 1 | 0.1% |
Nasopharynx cancer | 1 | 0.1% |
Natalizumab | 1 | 0.1% |
National Health Interview Survey | 1 | 0.1% |
National Immunization Technical Advisory Group | 1 | 0.1% |
National TB Elimination Program (India) | 1 | 0.1% |
National security | 1 | 0.1% |
Naypyidaw | 1 | 0.1% |
Near-infrared spectroscopy | 1 | 0.1% |
Necrosis | 1 | 0.1% |
Necrotizing enterocolitis | 1 | 0.1% |
Necrotizing fasciitis | 1 | 0.1% |
Negative room pressure | 1 | 0.1% |
Nelfinavir | 1 | 0.1% |
Neonatal hypoglycemia | 1 | 0.1% |
Neonatal seizure | 1 | 0.1% |
Neonatal tetanus | 1 | 0.1% |
Nephrotic syndrome | 1 | 0.1% |
Nerve compression syndrome | 1 | 0.1% |
Nerve conduction study | 1 | 0.1% |
Neuralgia | 1 | 0.1% |
Neurological disorder | 1 | 0.1% |
Neuromyelitis optica | 1 | 0.1% |
Neuropathic arthropathy | 1 | 0.1% |
Neuropathology | 1 | 0.1% |
Neuroplasticity | 1 | 0.1% |
Neurotrauma | 1 | 0.1% |
Neutrophil | 1 | 0.1% |
New Britain | 1 | 0.1% |
New Drug Application | 1 | 0.1% |
Nicotine dependence | 1 | 0.1% |
Nidovirales | 1 | 0.1% |
Nifedipine | 1 | 0.1% |
Nifurtimox | 1 | 0.1% |
Nintedanib | 1 | 0.1% |
Nipple | 1 | 0.1% |
Niraparib | 1 | 0.1% |
Nirmatrelvir | 1 | 0.1% |
Nitrogen dioxide | 1 | 0.1% |
Nociceptor | 1 | 0.1% |
Non-Hispanic whites | 1 | 0.1% |
Nonoxynol-9 | 1 | 0.1% |
Nontuberculous mycobacteria | 1 | 0.1% |
Norethisterone enanthate | 1 | 0.1% |
Norgestimate | 1 | 0.1% |
Normal pressure hydrocephalus | 1 | 0.1% |
Nortriptyline | 1 | 0.1% |
Norwegian language | 1 | 0.1% |
Nuclear proliferation | 1 | 0.1% |
Nuclear safety and security | 1 | 0.1% |
Nucleic acid test | 1 | 0.1% |
Numeracy | 1 | 0.1% |
Nutri-Score | 1 | 0.1% |
Nutrient | 1 | 0.1% |
Nutritionist | 1 | 0.1% |
Nystatin | 1 | 0.1% |
Observation | 1 | 0.1% |
Obstetric labor complication | 1 | 0.1% |
Obstructive lung disease | 1 | 0.1% |
Occult fracture | 1 | 0.1% |
Occupational disease | 1 | 0.1% |
Octreotide | 1 | 0.1% |
Ocular tonometry | 1 | 0.1% |
Oculoplastics | 1 | 0.1% |
Olaparib | 1 | 0.1% |
Oligoastrocytoma | 1 | 0.1% |
Oligodendroglioma | 1 | 0.1% |
Omacetaxine mepesuccinate | 1 | 0.1% |
Omeprazole | 1 | 0.1% |
Omics | 1 | 0.1% |
Onchocerciasis | 1 | 0.1% |
Oncolytic virus | 1 | 0.1% |
Oncovirus | 1 | 0.1% |
Open access | 1 | 0.1% |
Operant conditioning | 1 | 0.1% |
Operation of computed tomography | 1 | 0.1% |
Opioid use disorder | 1 | 0.1% |
Opsoclonus myoclonus syndrome | 1 | 0.1% |
Optic disc | 1 | 0.1% |
Optic nerve | 1 | 0.1% |
Optic neuropathy | 1 | 0.1% |
Optical coherence tomography | 1 | 0.1% |
Optimism | 1 | 0.1% |
Optimism bias | 1 | 0.1% |
Optometry | 1 | 0.1% |
OraQuick | 1 | 0.1% |
Oral hygiene | 1 | 0.1% |
Oral rehydration therapy | 1 | 0.1% |
Orbital blowout fracture | 1 | 0.1% |
Oregon Health Plan | 1 | 0.1% |
Organ (anatomy) | 1 | 0.1% |
Organ (biology) | 1 | 0.1% |
Organ donation in Australia | 1 | 0.1% |
Organ procurement | 1 | 0.1% |
Organic, including symptomatic, mental disorders | 1 | 0.1% |
Orlistat | 1 | 0.1% |
Orthomyxoviridae | 1 | 0.1% |
Osilodrostat | 1 | 0.1% |
Ospemifene | 1 | 0.1% |
Osteoclast | 1 | 0.1% |
Osteocyte | 1 | 0.1% |
Osteopathy | 1 | 0.1% |
Osteotomy | 1 | 0.1% |
Otorhinolaryngology | 1 | 0.1% |
Ototoxicity | 1 | 0.1% |
Outbreak | 1 | 0.1% |
Outpatient surgery | 1 | 0.1% |
Ovarian follicle | 1 | 0.1% |
Ovarian hyperstimulation syndrome | 1 | 0.1% |
Ovarian reserve | 1 | 0.1% |
Overdispersion | 1 | 0.1% |
Ovulation | 1 | 0.1% |
Ovulation induction | 1 | 0.1% |
Ownership | 1 | 0.1% |
Oxazepam | 1 | 0.1% |
Oxidative stress | 1 | 0.1% |
Oxybutynin | 1 | 0.1% |
Ozone depletion | 1 | 0.1% |
P2Y12 | 1 | 0.1% |
P53 | 1 | 0.1% |
PANDAS | 1 | 0.1% |
PD-1 and PD-L1 inhibitors | 1 | 0.1% |
PMS2 | 1 | 0.1% |
PSEN1 | 1 | 0.1% |
PTEN (gene) | 1 | 0.1% |
PUVA therapy | 1 | 0.1% |
Packed red blood cells | 1 | 0.1% |
Palestinian territories | 1 | 0.1% |
Paliperidone | 1 | 0.1% |
Palivizumab | 1 | 0.1% |
Pancreatic islets | 1 | 0.1% |
Pancreatic mucinous cystic neoplasm | 1 | 0.1% |
Pancreaticoduodenectomy | 1 | 0.1% |
Pandemrix | 1 | 0.1% |
Panton–Valentine leukocidin | 1 | 0.1% |
Papillomaviridae | 1 | 0.1% |
Parasomnia | 1 | 0.1% |
Paratyphoid fever | 1 | 0.1% |
Parent | 1 | 0.1% |
Paromomycin | 1 | 0.1% |
Patau syndrome | 1 | 0.1% |
Patent ductus arteriosus | 1 | 0.1% |
Pathogenic Escherichia coli | 1 | 0.1% |
Patient choice | 1 | 0.1% |
Patiromer | 1 | 0.1% |
Paul Ridker | 1 | 0.1% |
Payment Card Industry Data Security Standard | 1 | 0.1% |
Peanut allergy | 1 | 0.1% |
Peer pressure | 1 | 0.1% |
Pelvic floor | 1 | 0.1% |
Pelvic floor dysfunction | 1 | 0.1% |
Pemetrexed | 1 | 0.1% |
Pemphigoid | 1 | 0.1% |
Penetrating trauma | 1 | 0.1% |
Penile cancer | 1 | 0.1% |
Pentavalent vaccine | 1 | 0.1% |
Peramivir | 1 | 0.1% |
Percentage | 1 | 0.1% |
Percutaneous tibial nerve stimulation | 1 | 0.1% |
Pericardial heart valves | 1 | 0.1% |
Periodic limb movement disorder | 1 | 0.1% |
Periodontal disease | 1 | 0.1% |
Peripheral nervous system | 1 | 0.1% |
Periventricular leukomalacia | 1 | 0.1% |
Peroxisome proliferator-activated receptor | 1 | 0.1% |
Peroxisome proliferator-activated receptor gamma | 1 | 0.1% |
Personal trainer | 1 | 0.1% |
Personality disorder | 1 | 0.1% |
Personally identifiable information | 1 | 0.1% |
Pertussis vaccine | 1 | 0.1% |
Pesticide | 1 | 0.1% |
Peter C. Gøtzsche | 1 | 0.1% |
Phacoemulsification | 1 | 0.1% |
Phagocytosis | 1 | 0.1% |
Phantom limb | 1 | 0.1% |
Pharmaceutical Benefits Scheme | 1 | 0.1% |
Pharmaceutical formulation | 1 | 0.1% |
Pharmaceutics | 1 | 0.1% |
Pharmacopoeia | 1 | 0.1% |
Pharmacy (shop) | 1 | 0.1% |
Pharmacy benefit management | 1 | 0.1% |
Pharmacy management system | 1 | 0.1% |
Phenobarbital | 1 | 0.1% |
Phenomenology (philosophy) | 1 | 0.1% |
Phenotype | 1 | 0.1% |
Phenytoin | 1 | 0.1% |
Phosphoinositide 3-kinase | 1 | 0.1% |
Photovoltaics | 1 | 0.1% |
Physical medicine and rehabilitation | 1 | 0.1% |
Physician assistant | 1 | 0.1% |
Physician supply | 1 | 0.1% |
Pirfenidone | 1 | 0.1% |
Piriformis syndrome | 1 | 0.1% |
Pitolisant | 1 | 0.1% |
Pituitary adenoma | 1 | 0.1% |
Pixantrone | 1 | 0.1% |
Plain language | 1 | 0.1% |
Plain tobacco packaging | 1 | 0.1% |
Plasma cell | 1 | 0.1% |
Plasmacytoma | 1 | 0.1% |
Plasmapheresis | 1 | 0.1% |
Plasmid | 1 | 0.1% |
Plasmodium knowlesi | 1 | 0.1% |
Plasmodium ovale | 1 | 0.1% |
Plastic surgery | 1 | 0.1% |
Pleural empyema | 1 | 0.1% |
Podiatry | 1 | 0.1% |
Poisson distribution | 1 | 0.1% |
Pollution | 1 | 0.1% |
Polyclonal B cell response | 1 | 0.1% |
Polyclonal antibodies | 1 | 0.1% |
Polycystic ovary syndrome | 1 | 0.1% |
Polycythemia vera | 1 | 0.1% |
Polypill | 1 | 0.1% |
Polystyrene sulfonate | 1 | 0.1% |
Population | 1 | 0.1% |
Population genetics | 1 | 0.1% |
Post-traumatic seizure | 1 | 0.1% |
Postgraduate education | 1 | 0.1% |
Postherpetic neuralgia | 1 | 0.1% |
Postterm pregnancy | 1 | 0.1% |
Potassium binder | 1 | 0.1% |
Potassium chloride | 1 | 0.1% |
Potassium-sparing diuretic | 1 | 0.1% |
Poultry diseases | 1 | 0.1% |
Pound (mass) | 1 | 0.1% |
Poverty threshold | 1 | 0.1% |
Powassan virus | 1 | 0.1% |
Pre-clinical development | 1 | 0.1% |
Prebiotic (nutrition) | 1 | 0.1% |
Precision and recall | 1 | 0.1% |
Preclinical development | 1 | 0.1% |
Predictive analytics | 1 | 0.1% |
Prelabor rupture of membranes | 1 | 0.1% |
Premature ovarian failure | 1 | 0.1% |
Premature rupture of membranes | 1 | 0.1% |
Premium tax credit | 1 | 0.1% |
Pretomanid | 1 | 0.1% |
Prevalence of tobacco use | 1 | 0.1% |
Prior probability | 1 | 0.1% |
Procainamide | 1 | 0.1% |
Procurement | 1 | 0.1% |
Production function | 1 | 0.1% |
Progestin | 1 | 0.1% |
Prognosis | 1 | 0.1% |
Program evaluation | 1 | 0.1% |
Program optimization | 1 | 0.1% |
Progressive familial intrahepatic cholestasis | 1 | 0.1% |
Progressive multifocal leukoencephalopathy | 1 | 0.1% |
Proguanil | 1 | 0.1% |
Prolactinoma | 1 | 0.1% |
Prolapse | 1 | 0.1% |
Proliferative index | 1 | 0.1% |
Prolotherapy | 1 | 0.1% |
Promoter (genetics) | 1 | 0.1% |
Propafenone | 1 | 0.1% |
Prophylactic salpingectomy | 1 | 0.1% |
Propofol | 1 | 0.1% |
Proportional hazards model | 1 | 0.1% |
Prostaglandin-endoperoxide synthase 2 | 1 | 0.1% |
Prostate | 1 | 0.1% |
Prostate disorders | 1 | 0.1% |
Prostatitis | 1 | 0.1% |
Protected health information | 1 | 0.1% |
Protein C | 1 | 0.1% |
Proton therapy | 1 | 0.1% |
Proton-pump inhibitor | 1 | 0.1% |
Pseudoexfoliation syndrome | 1 | 0.1% |
Psychiatric history | 1 | 0.1% |
Psychiatric hospital | 1 | 0.1% |
Psycho-oncology | 1 | 0.1% |
Psychoactive drugs | 1 | 0.1% |
Psychological evaluation | 1 | 0.1% |
Psychological resilience | 1 | 0.1% |
Psychological trauma | 1 | 0.1% |
Psychometrics | 1 | 0.1% |
Public health informatics | 1 | 0.1% |
Public policy | 1 | 0.1% |
Public–private partnership | 1 | 0.1% |
Pulmonary alveolus | 1 | 0.1% |
Pulmonary edema | 1 | 0.1% |
Pulmonary hypertension | 1 | 0.1% |
Pulmonary rehabilitation | 1 | 0.1% |
Pulmonary sequestration | 1 | 0.1% |
Pulse pressure | 1 | 0.1% |
Pyridoxine/doxylamine | 1 | 0.1% |
Quality (business) | 1 | 0.1% |
Quality Improvement Organizations (QIOs) in Medicare | 1 | 0.1% |
Quality management system | 1 | 0.1% |
Quantifier (logic) | 1 | 0.1% |
Quinine | 1 | 0.1% |
Quitline | 1 | 0.1% |
RET proto-oncogene | 1 | 0.1% |
RICE (medicine) | 1 | 0.1% |
RNA | 1 | 0.1% |
RNA-Seq | 1 | 0.1% |
RTS,S | 1 | 0.1% |
Rabbit haemorrhagic disease | 1 | 0.1% |
Rabies in animals | 1 | 0.1% |
Radio spectrum | 1 | 0.1% |
Radioallergosorbent test | 1 | 0.1% |
Radiomics | 1 | 0.1% |
Radiopharmaceutical | 1 | 0.1% |
Radius (bone) | 1 | 0.1% |
Rapid eye movement sleep | 1 | 0.1% |
Rapid eye movement sleep behavior disorder | 1 | 0.1% |
Rat | 1 | 0.1% |
Ratio | 1 | 0.1% |
Real-time computing | 1 | 0.1% |
Receptor antagonist | 1 | 0.1% |
Recombinant DNA | 1 | 0.1% |
Recovery model | 1 | 0.1% |
Rectal prolapse | 1 | 0.1% |
Rectocele | 1 | 0.1% |
Rectum | 1 | 0.1% |
Refrigerator | 1 | 0.1% |
Refugee | 1 | 0.1% |
Refugee children | 1 | 0.1% |
Regeneration (biology) | 1 | 0.1% |
Regulation | 1 | 0.1% |
Regulatory Flexibility Act | 1 | 0.1% |
Regulatory affairs | 1 | 0.1% |
Regurgitation (circulation) | 1 | 0.1% |
Reinforcement | 1 | 0.1% |
Relapse | 1 | 0.1% |
Religious Freedom Restoration Act | 1 | 0.1% |
Remifentanil | 1 | 0.1% |
Remote dispensing | 1 | 0.1% |
Renal sympathetic denervation | 1 | 0.1% |
Reperfusion injury | 1 | 0.1% |
Reproducibility | 1 | 0.1% |
Reproduction | 1 | 0.1% |
Reproductive medicine | 1 | 0.1% |
Republic | 1 | 0.1% |
Resampling (statistics) | 1 | 0.1% |
Research Excellence Framework | 1 | 0.1% |
Respiration | 1 | 0.1% |
Respiratory failure | 1 | 0.1% |
Respiratory therapist | 1 | 0.1% |
Respiratory tract | 1 | 0.1% |
Responsive web design | 1 | 0.1% |
Resting state fMRI | 1 | 0.1% |
Retirement | 1 | 0.1% |
Retrograde amnesia | 1 | 0.1% |
Retroviridae | 1 | 0.1% |
Reuptake inhibitor | 1 | 0.1% |
Reuse | 1 | 0.1% |
Reye syndrome | 1 | 0.1% |
Rhinorrhea | 1 | 0.1% |
Rhytidectomy | 1 | 0.1% |
Ribavirin | 1 | 0.1% |
Ribociclib | 1 | 0.1% |
Richter's transformation | 1 | 0.1% |
Rifamycin | 1 | 0.1% |
Risk ratio | 1 | 0.1% |
Risk–benefit ratio | 1 | 0.1% |
Rivastigmine | 1 | 0.1% |
Romosozumab | 1 | 0.1% |
Root-mean-square deviation | 1 | 0.1% |
Roseola | 1 | 0.1% |
Rotator cuff | 1 | 0.1% |
Rotavirus | 1 | 0.1% |
Rotavirus vaccine | 1 | 0.1% |
Route of administration | 1 | 0.1% |
Rubella vaccine | 1 | 0.1% |
Rural health | 1 | 0.1% |
Rural health clinic | 1 | 0.1% |
Russian language | 1 | 0.1% |
Ruxolitinib | 1 | 0.1% |
Ryanodine receptor 2 | 1 | 0.1% |
SARS-CoV-2 Omicron variant | 1 | 0.1% |
SGK1 | 1 | 0.1% |
SNOMED CT | 1 | 0.1% |
SWOT analysis | 1 | 0.1% |
Sacrum | 1 | 0.1% |
Sacubitril/valsartan | 1 | 0.1% |
Safe to Sleep | 1 | 0.1% |
Safety stock | 1 | 0.1% |
Saline (medicine) | 1 | 0.1% |
Salmeterol | 1 | 0.1% |
Salmonella | 1 | 0.1% |
Sample (statistics) | 1 | 0.1% |
Saquinavir | 1 | 0.1% |
Sarcopenia | 1 | 0.1% |
Scabies | 1 | 0.1% |
Scarlet fever | 1 | 0.1% |
Scatter plot | 1 | 0.1% |
Schistosomiasis | 1 | 0.1% |
Schizoaffective disorder | 1 | 0.1% |
Scintigraphy | 1 | 0.1% |
Sclerostin | 1 | 0.1% |
Scrub typhus | 1 | 0.1% |
Seat belt | 1 | 0.1% |
Secukinumab | 1 | 0.1% |
Sedative | 1 | 0.1% |
Sedentary lifestyle | 1 | 0.1% |
Seizure | 1 | 0.1% |
Selective laser sintering | 1 | 0.1% |
Self-administration | 1 | 0.1% |
Self-assessment | 1 | 0.1% |
Self-control | 1 | 0.1% |
Self-determination theory | 1 | 0.1% |
Self-disclosure | 1 | 0.1% |
Self-employment | 1 | 0.1% |
Self-esteem | 1 | 0.1% |
Self-harm | 1 | 0.1% |
Semaglutide | 1 | 0.1% |
Semen | 1 | 0.1% |
Semen analysis | 1 | 0.1% |
Senses | 1 | 0.1% |
Sensorineural hearing loss | 1 | 0.1% |
Sensory neuron | 1 | 0.1% |
Sentence (linguistics) | 1 | 0.1% |
Sequential analysis | 1 | 0.1% |
Serum amyloid A1 | 1 | 0.1% |
Serum free light-chain measurement | 1 | 0.1% |
Service industries | 1 | 0.1% |
Services sector of the economy | 1 | 0.1% |
Severe acute respiratory syndrome–related coronavirus | 1 | 0.1% |
Sex and drugs | 1 | 0.1% |
Sexual orientation | 1 | 0.1% |
Sexual reproduction | 1 | 0.1% |
Sham surgery | 1 | 0.1% |
Sharps waste | 1 | 0.1% |
Ship | 1 | 0.1% |
Shortages related to the COVID-19 pandemic | 1 | 0.1% |
Shoulder impingement syndrome | 1 | 0.1% |
Sibling | 1 | 0.1% |
Signal transduction | 1 | 0.1% |
Simeprevir | 1 | 0.1% |
Simian immunodeficiency virus | 1 | 0.1% |
Sinoatrial node | 1 | 0.1% |
Sirolimus | 1 | 0.1% |
Sisterhood method | 1 | 0.1% |
Sitosterolemia | 1 | 0.1% |
Sjögren syndrome | 1 | 0.1% |
Skeletal system | 1 | 0.1% |
Skin allergy test | 1 | 0.1% |
Skin grafting | 1 | 0.1% |
Skull | 1 | 0.1% |
Sleep and breathing | 1 | 0.1% |
Sleep medicine | 1 | 0.1% |
Slit lamp | 1 | 0.1% |
Small interfering RNA | 1 | 0.1% |
Small intestine | 1 | 0.1% |
Smokeless tobacco | 1 | 0.1% |
Smoking and pregnancy | 1 | 0.1% |
Social exclusion | 1 | 0.1% |
Social group | 1 | 0.1% |
Social influence | 1 | 0.1% |
Social innovation | 1 | 0.1% |
Social isolation | 1 | 0.1% |
Social marketing | 1 | 0.1% |
Social networking service | 1 | 0.1% |
Social services | 1 | 0.1% |
Societal collapse | 1 | 0.1% |
Sodium | 1 | 0.1% |
Soft drink | 1 | 0.1% |
Software | 1 | 0.1% |
Software testing | 1 | 0.1% |
Solanezumab | 1 | 0.1% |
Somatic symptom disorder | 1 | 0.1% |
Somatization | 1 | 0.1% |
South Yorkshire | 1 | 0.1% |
Southeast Asia | 1 | 0.1% |
Soy allergy | 1 | 0.1% |
Spasmodic torticollis | 1 | 0.1% |
Spastic cerebral palsy | 1 | 0.1% |
Special education | 1 | 0.1% |
Spermatozoon | 1 | 0.1% |
Sphygmomanometer | 1 | 0.1% |
Spina bifida | 1 | 0.1% |
Spinal disc herniation | 1 | 0.1% |
Spinal muscular atrophy | 1 | 0.1% |
Spontaneous bacterial peritonitis | 1 | 0.1% |
Sprain | 1 | 0.1% |
Sprained ankle | 1 | 0.1% |
Sputum | 1 | 0.1% |
Squamous cell carcinoma | 1 | 0.1% |
Staining | 1 | 0.1% |
Stakeholder (corporate) | 1 | 0.1% |
Standard score | 1 | 0.1% |
Staphylococcus saprophyticus | 1 | 0.1% |
Stargardt disease | 1 | 0.1% |
States and territories of Australia | 1 | 0.1% |
Stationary process | 1 | 0.1% |
Statistical analysis | 1 | 0.1% |
Statistical process control | 1 | 0.1% |
Statistical theory | 1 | 0.1% |
Stem cell factor | 1 | 0.1% |
Stenotrophomonas maltophilia | 1 | 0.1% |
Stereotactic surgery | 1 | 0.1% |
Stevens–Johnson syndrome | 1 | 0.1% |
Stimulant | 1 | 0.1% |
Stomach | 1 | 0.1% |
Stool test | 1 | 0.1% |
Strabismus | 1 | 0.1% |
Strain (injury) | 1 | 0.1% |
Strategic management | 1 | 0.1% |
Strategy | 1 | 0.1% |
Streptococcus pneumoniae | 1 | 0.1% |
Streptococcus pyogenes | 1 | 0.1% |
Streptomycin | 1 | 0.1% |
Stress incontinence | 1 | 0.1% |
Student-centered learning | 1 | 0.1% |
Subclavian artery | 1 | 0.1% |
Subcutaneous injection | 1 | 0.1% |
Subsidy | 1 | 0.1% |
Substance abuse prevention | 1 | 0.1% |
Substantia nigra | 1 | 0.1% |
Sudden unexpected death in epilepsy | 1 | 0.1% |
Suicide | 1 | 0.1% |
Sun tanning | 1 | 0.1% |
Sunitinib | 1 | 0.1% |
Superfund | 1 | 0.1% |
Supervised learning | 1 | 0.1% |
Supply chain | 1 | 0.1% |
Support-vector machine | 1 | 0.1% |
Supportive housing | 1 | 0.1% |
Suprachiasmatic nucleus | 1 | 0.1% |
Supraspinatus muscle | 1 | 0.1% |
Surfactant protein B | 1 | 0.1% |
Surgical specialties | 1 | 0.1% |
Swarm behaviour | 1 | 0.1% |
Sweetened beverage | 1 | 0.1% |
Sympathetic nervous system | 1 | 0.1% |
Symptoms and signs | 1 | 0.1% |
Symptoms and signs: General | 1 | 0.1% |
Synapse | 1 | 0.1% |
Syndemic | 1 | 0.1% |
Systematics | 1 | 0.1% |
SystmOne | 1 | 0.1% |
T-statistic | 1 | 0.1% |
TCF7L2 | 1 | 0.1% |
TIMI | 1 | 0.1% |
TLR4 | 1 | 0.1% |
TNM staging system | 1 | 0.1% |
Tablet (pharmacy) | 1 | 0.1% |
Tabubil | 1 | 0.1% |
Tacrolimus | 1 | 0.1% |
Tafamidis | 1 | 0.1% |
Tag SNP | 1 | 0.1% |
Takotsubo cardiomyopathy | 1 | 0.1% |
Talimogene laherparepvec | 1 | 0.1% |
Tattoo | 1 | 0.1% |
Teenage pregnancy | 1 | 0.1% |
Telecommunication | 1 | 0.1% |
Telemedicine | 1 | 0.1% |
Telepathology | 1 | 0.1% |
Teleradiology | 1 | 0.1% |
Telmisartan | 1 | 0.1% |
Temazepam | 1 | 0.1% |
Temozolomide | 1 | 0.1% |
Temporary Assistance for Needy Families | 1 | 0.1% |
Temporomandibular joint | 1 | 0.1% |
Temporomandibular joint dysfunction | 1 | 0.1% |
Tendinopathy | 1 | 0.1% |
Testosterone | 1 | 0.1% |
Testosterone (medication) | 1 | 0.1% |
Tetralogy of Fallot | 1 | 0.1% |
Thalassemia | 1 | 0.1% |
Thalidomide | 1 | 0.1% |
The European Semester | 1 | 0.1% |
The Hallmarks of Cancer | 1 | 0.1% |
The Midlands | 1 | 0.1% |
The New England Journal of Medicine | 1 | 0.1% |
Theiler's disease | 1 | 0.1% |
Theory of planned behavior | 1 | 0.1% |
Thiamine deficiency | 1 | 0.1% |
Thiomersal | 1 | 0.1% |
Thoracentesis | 1 | 0.1% |
Thoracic diaphragm | 1 | 0.1% |
Threshold limit value | 1 | 0.1% |
Thumb | 1 | 0.1% |
Thymoglobulin | 1 | 0.1% |
Thymus | 1 | 0.1% |
Thyroid disease | 1 | 0.1% |
Thyroid nodule | 1 | 0.1% |
Tibia | 1 | 0.1% |
Tibolone | 1 | 0.1% |
Tick | 1 | 0.1% |
Ticlopidine | 1 | 0.1% |
Tigecycline | 1 | 0.1% |
Till Roenneberg | 1 | 0.1% |
Time | 1 | 0.1% |
Timeline of the SARS outbreak | 1 | 0.1% |
Tiotropium bromide | 1 | 0.1% |
Tissue Doppler echocardiography | 1 | 0.1% |
Tobacco | 1 | 0.1% |
Toe | 1 | 0.1% |
Tofacitinib | 1 | 0.1% |
Toilet | 1 | 0.1% |
Toll-like receptor | 1 | 0.1% |
Tom Petty | 1 | 0.1% |
Tomosynthesis | 1 | 0.1% |
Toothpaste | 1 | 0.1% |
Tort reform | 1 | 0.1% |
Torticollis | 1 | 0.1% |
Tourism | 1 | 0.1% |
Tourniquet | 1 | 0.1% |
Toxic shock syndrome | 1 | 0.1% |
Toxicity | 1 | 0.1% |
Tozinameran | 1 | 0.1% |
Trabecula | 1 | 0.1% |
Traceability | 1 | 0.1% |
Trade-off | 1 | 0.1% |
Traditional Chinese medicine | 1 | 0.1% |
Tramadol | 1 | 0.1% |
Transcranial direct-current stimulation | 1 | 0.1% |
Transcriptomics technologies | 1 | 0.1% |
Transesophageal echocardiogram | 1 | 0.1% |
Transmission and infection of H5N1 | 1 | 0.1% |
Transposition of the great vessels | 1 | 0.1% |
Transthyretin | 1 | 0.1% |
Treatment | 1 | 0.1% |
Treatment and control groups | 1 | 0.1% |
Treatment and management of COVID-19 | 1 | 0.1% |
Treatment of bipolar disorder | 1 | 0.1% |
Treatment of lung cancer | 1 | 0.1% |
Tree of life (biology) | 1 | 0.1% |
Treponema pallidum | 1 | 0.1% |
Tretinoin | 1 | 0.1% |
Triatoma protracta | 1 | 0.1% |
Triatominae | 1 | 0.1% |
Tricuspid insufficiency | 1 | 0.1% |
Tricuspid valve | 1 | 0.1% |
Triiodothyronine | 1 | 0.1% |
Truck driver | 1 | 0.1% |
Truenat | 1 | 0.1% |
Trust (emotion) | 1 | 0.1% |
Trust (social science) | 1 | 0.1% |
Trypanosoma | 1 | 0.1% |
Trypanosoma cruzi | 1 | 0.1% |
Trypanosoma lewisi | 1 | 0.1% |
Tsetse fly | 1 | 0.1% |
Tuberculin | 1 | 0.1% |
Tubo-ovarian abscess | 1 | 0.1% |
Turner syndrome | 1 | 0.1% |
Ultrasound | 1 | 0.1% |
Ultraviolet | 1 | 0.1% |
Unfolded protein response | 1 | 0.1% |
Uniform distribution (continuous) | 1 | 0.1% |
United Nations Security Council Resolution 478 | 1 | 0.1% |
Universal neonatal hearing screening | 1 | 0.1% |
Unsafe abortion | 1 | 0.1% |
Unsaturated fat | 1 | 0.1% |
Unstable angina | 1 | 0.1% |
Unsupervised learning | 1 | 0.1% |
Upper gastrointestinal series | 1 | 0.1% |
Uracil-DNA glycosylase | 1 | 0.1% |
Urethritis | 1 | 0.1% |
Uric acid | 1 | 0.1% |
Urinary cast | 1 | 0.1% |
Urinary retention | 1 | 0.1% |
Urine | 1 | 0.1% |
Urogynecology | 1 | 0.1% |
Usability testing | 1 | 0.1% |
Use case | 1 | 0.1% |
Ustekinumab | 1 | 0.1% |
Uveitis | 1 | 0.1% |
VO2 max | 1 | 0.1% |
Vaccine Adverse Event Reporting System | 1 | 0.1% |
Vaccine Information Statement | 1 | 0.1% |
Vaccine efficacy | 1 | 0.1% |
Vaccine hesitancy | 1 | 0.1% |
Vaccinia | 1 | 0.1% |
Vaginal bleeding | 1 | 0.1% |
Vaginal ring | 1 | 0.1% |
Vandetanib | 1 | 0.1% |
Vaporized hydrogen peroxide | 1 | 0.1% |
Vascular dementia | 1 | 0.1% |
Vasospasm | 1 | 0.1% |
Vegetable | 1 | 0.1% |
Venereal Disease Research Laboratory test | 1 | 0.1% |
Venetoclax | 1 | 0.1% |
Venous access | 1 | 0.1% |
Ventricular escape beat | 1 | 0.1% |
Vibrio | 1 | 0.1% |
Video-assisted thoracoscopic surgery | 1 | 0.1% |
Viral load monitoring for HIV | 1 | 0.1% |
Viral replication | 1 | 0.1% |
Viral vector vaccine | 1 | 0.1% |
Virus latency | 1 | 0.1% |
Virus quantification | 1 | 0.1% |
Visceral leishmaniasis | 1 | 0.1% |
Visual field test | 1 | 0.1% |
Visual system | 1 | 0.1% |
Vitamin A | 1 | 0.1% |
Vitamin B12 | 1 | 0.1% |
Volunteering | 1 | 0.1% |
Vomiting | 1 | 0.1% |
Vulnerable plaque | 1 | 0.1% |
WASH | 1 | 0.1% |
WIC | 1 | 0.1% |
Waist–hip ratio | 1 | 0.1% |
Waitematā Harbour | 1 | 0.1% |
Weakness | 1 | 0.1% |
Weighted arithmetic mean | 1 | 0.1% |
Welfare economics | 1 | 0.1% |
West Bank | 1 | 0.1% |
Western blot | 1 | 0.1% |
White Americans | 1 | 0.1% |
White coat hypertension | 1 | 0.1% |
Whitehall Study | 1 | 0.1% |
Whole blood | 1 | 0.1% |
Wireless | 1 | 0.1% |
Wnt signaling pathway | 1 | 0.1% |
Working conditions | 1 | 0.1% |
Working group | 1 | 0.1% |
Workplace | 1 | 0.1% |
Wrist | 1 | 0.1% |
Wristband | 1 | 0.1% |
X-linked agammaglobulinemia | 1 | 0.1% |
X-linked severe combined immunodeficiency | 1 | 0.1% |
XYY syndrome | 1 | 0.1% |
Youth smoking | 1 | 0.1% |
Zebrafish | 1 | 0.1% |
Zileuton | 1 | 0.1% |
Zolpidem | 1 | 0.1% |
Zygomatic bone | 1 | 0.1% |
Β-lactam antibiotic | 1 | 0.1% |
ΔF508 | 1 | 0.1% |
abs | rel | |
---|---|---|
Adherence (medicine) | 1 | 100.0% |
Angina | 1 | 100.0% |
Back pain | 1 | 100.0% |
Clinical medicine | 1 | 100.0% |
Clinical trial | 1 | 100.0% |
Comorbidity | 1 | 100.0% |
Coronary artery disease | 1 | 100.0% |
Coronary care unit | 1 | 100.0% |
Diseases and disorders | 1 | 100.0% |
Emergency department | 1 | 100.0% |
Emergency medicine | 1 | 100.0% |
Evidence-based medicine | 1 | 100.0% |
Health | 1 | 100.0% |
Health care | 1 | 100.0% |
Health sciences | 1 | 100.0% |
Health services research | 1 | 100.0% |
Hospital | 1 | 100.0% |
Hospital readmission | 1 | 100.0% |
Intensive care unit | 1 | 100.0% |
Low back pain | 1 | 100.0% |
Medical guideline | 1 | 100.0% |
Medical specialties | 1 | 100.0% |
Medicine | 1 | 100.0% |
Myocardial infarction | 1 | 100.0% |
Pain | 1 | 100.0% |
Patient | 1 | 100.0% |
Physician | 1 | 100.0% |
Preventive healthcare | 1 | 100.0% |
Reliability engineering | 1 | 100.0% |
Research | 1 | 100.0% |
Risk | 1 | 100.0% |
Triage | 1 | 100.0% |
abs | rel | |
---|---|---|
Adolescence | 1 | 100.0% |
Asian Americans | 1 | 100.0% |
Birth rate | 1 | 100.0% |
Birth weight | 1 | 100.0% |
Birthing center | 1 | 100.0% |
Childbirth | 1 | 100.0% |
Doctor of Osteopathic Medicine | 1 | 100.0% |
Environmental social science | 1 | 100.0% |
Fertility | 1 | 100.0% |
Gestational age | 1 | 100.0% |
Health | 1 | 100.0% |
Health care | 1 | 100.0% |
Health sciences | 1 | 100.0% |
Hispanic and Latino Americans | 1 | 100.0% |
Human development | 1 | 100.0% |
Human pregnancy | 1 | 100.0% |
Human reproduction | 1 | 100.0% |
Large for gestational age | 1 | 100.0% |
Mammalian pregnancy | 1 | 100.0% |
Maternal health | 1 | 100.0% |
Medical specialties | 1 | 100.0% |
Midwife | 1 | 100.0% |
Mother | 1 | 100.0% |
Motherhood | 1 | 100.0% |
Multiple birth | 1 | 100.0% |
Non-Hispanic whites | 1 | 100.0% |
Pound (mass) | 1 | 100.0% |
Pregnancy | 1 | 100.0% |
Prenatal care | 1 | 100.0% |
Prenatal development | 1 | 100.0% |
Preterm birth | 1 | 100.0% |
Public health | 1 | 100.0% |
Race and ethnicity in the United States Census | 1 | 100.0% |
Teenage pregnancy | 1 | 100.0% |
Twin | 1 | 100.0% |
Women's health | 1 | 100.0% |
abs | rel | |
---|---|---|
Antibiotic | 1 | 100.0% |
Antimicrobial resistance | 1 | 100.0% |
Chronic condition | 1 | 100.0% |
Ciprofloxacin | 1 | 100.0% |
Clinical medicine | 1 | 100.0% |
Clinical trial | 1 | 100.0% |
Community-acquired pneumonia | 1 | 100.0% |
Comorbidity | 1 | 100.0% |
Cost-effectiveness analysis | 1 | 100.0% |
Disease | 1 | 100.0% |
Drugs | 1 | 100.0% |
Health | 1 | 100.0% |
Health care | 1 | 100.0% |
Health sciences | 1 | 100.0% |
Levofloxacin | 1 | 100.0% |
Lower respiratory tract infection | 1 | 100.0% |
Medical diagnosis | 1 | 100.0% |
Medical specialties | 1 | 100.0% |
Medication | 1 | 100.0% |
Medicine | 1 | 100.0% |
Meta-analysis | 1 | 100.0% |
Mycoplasma pneumoniae | 1 | 100.0% |
Pneumonia | 1 | 100.0% |
Public health | 1 | 100.0% |
Quinolone antibiotic | 1 | 100.0% |
Risk | 1 | 100.0% |
Sensitivity analysis | 1 | 100.0% |
Shortness of breath | 1 | 100.0% |
Streptococcus pneumoniae | 1 | 100.0% |
Therapy | 1 | 100.0% |
abs | rel | |
---|---|---|
Medical specialties | 3 | 100.0% |
Medicine | 3 | 100.0% |
Clinical medicine | 2 | 66.7% |
Health | 2 | 66.7% |
Health care | 2 | 66.7% |
Health sciences | 2 | 66.7% |
Surgery | 2 | 66.7% |
Adverse effect | 1 | 33.3% |
Anabolic steroid | 1 | 33.3% |
Androgen | 1 | 33.3% |
Aspirin | 1 | 33.3% |
Cardiothoracic surgery | 1 | 33.3% |
Da Vinci Surgical System | 1 | 33.3% |
Dementia | 1 | 33.3% |
Dihydrotestosterone | 1 | 33.3% |
Disease | 1 | 33.3% |
Drug tolerance | 1 | 33.3% |
Estrogen | 1 | 33.3% |
General practitioner | 1 | 33.3% |
Hospital | 1 | 33.3% |
Hypothalamus | 1 | 33.3% |
Laparoscopy | 1 | 33.3% |
Medical procedures | 1 | 33.3% |
Medical technology | 1 | 33.3% |
Medical treatments | 1 | 33.3% |
Medication | 1 | 33.3% |
Menstrual cycle | 1 | 33.3% |
Methyltestosterone | 1 | 33.3% |
Morphine | 1 | 33.3% |
Mortality rate | 1 | 33.3% |
Nandrolone | 1 | 33.3% |
Nursing | 1 | 33.3% |
Nursing home care | 1 | 33.3% |
Operant conditioning | 1 | 33.3% |
Pharmacology | 1 | 33.3% |
Pharmacy | 1 | 33.3% |
Physician | 1 | 33.3% |
Placebo-controlled study | 1 | 33.3% |
Prostate cancer | 1 | 33.3% |
Prostate-specific antigen | 1 | 33.3% |
Psychiatry | 1 | 33.3% |
Psychoactive drug | 1 | 33.3% |
Psychological trauma | 1 | 33.3% |
Psychology | 1 | 33.3% |
Radiology | 1 | 33.3% |
Reinforcement | 1 | 33.3% |
Remote surgery | 1 | 33.3% |
Reye syndrome | 1 | 33.3% |
Risk | 1 | 33.3% |
Robot-assisted surgery | 1 | 33.3% |
Self-administration | 1 | 33.3% |
Self-care | 1 | 33.3% |
Somatic symptom disorder | 1 | 33.3% |
Somatization | 1 | 33.3% |
Substance abuse | 1 | 33.3% |
Substance dependence | 1 | 33.3% |
Surgical procedures and techniques | 1 | 33.3% |
Systematic review | 1 | 33.3% |
Technology | 1 | 33.3% |
Testosterone | 1 | 33.3% |
abs | rel | |
---|---|---|
Clinical medicine | 9 | 100.0% |
Health | 9 | 100.0% |
Health sciences | 9 | 100.0% |
Medicine | 9 | 100.0% |
Health care | 8 | 88.9% |
Medical specialties | 8 | 88.9% |
Disease | 6 | 66.7% |
Epidemiology | 6 | 66.7% |
Public health | 6 | 66.7% |
Diseases and disorders | 5 | 55.6% |
Health policy | 4 | 44.4% |
Immunology | 4 | 44.4% |
Infection | 4 | 44.4% |
Infectious diseases | 4 | 44.4% |
Medical humanities | 4 | 44.4% |
Microbiology | 4 | 44.4% |
Emergency department | 3 | 33.3% |
Hospital | 3 | 33.3% |
Patient | 3 | 33.3% |
Preventive healthcare | 3 | 33.3% |
Bioterrorism | 2 | 22.2% |
Blood sugar level | 2 | 22.2% |
Candidiasis | 2 | 22.2% |
Cardiovascular system | 2 | 22.2% |
Chlamydia infection | 2 | 22.2% |
Coronary artery disease | 2 | 22.2% |
Coronavirus | 2 | 22.2% |
Gonorrhea | 2 | 22.2% |
HIV/AIDS | 2 | 22.2% |
Health economics | 2 | 22.2% |
Human activities | 2 | 22.2% |
Human reproduction | 2 | 22.2% |
Low-density lipoprotein | 2 | 22.2% |
Medical diagnosis | 2 | 22.2% |
Obesity | 2 | 22.2% |
Pandemic | 2 | 22.2% |
Pelvic inflammatory disease | 2 | 22.2% |
Polymerase chain reaction | 2 | 22.2% |
Public sphere | 2 | 22.2% |
Reproductive health | 2 | 22.2% |
Sensitivity and specificity | 2 | 22.2% |
Severe acute respiratory syndrome | 2 | 22.2% |
Surveillance | 2 | 22.2% |
Vaccine | 2 | 22.2% |
Virus | 2 | 22.2% |
Abdominal obesity | 1 | 11.1% |
Aciclovir | 1 | 11.1% |
Adherence (medicine) | 1 | 11.1% |
Adverse selection | 1 | 11.1% |
Airline | 1 | 11.1% |
Anthropometry | 1 | 11.1% |
Antimicrobial resistance | 1 | 11.1% |
Antiviral drug | 1 | 11.1% |
Apolipoprotein | 1 | 11.1% |
Apolipoprotein B | 1 | 11.1% |
Atherosclerosis | 1 | 11.1% |
Atorvastatin | 1 | 11.1% |
Azithromycin | 1 | 11.1% |
Bacterial vaginosis | 1 | 11.1% |
Biology | 1 | 11.1% |
COVID-19 pandemic | 1 | 11.1% |
CT scan | 1 | 11.1% |
Capitation (healthcare) | 1 | 11.1% |
Cardiology | 1 | 11.1% |
Cardiovascular disease | 1 | 11.1% |
Case management (US health system) | 1 | 11.1% |
Cervicitis | 1 | 11.1% |
Childbirth | 1 | 11.1% |
Chlamydia trachomatis | 1 | 11.1% |
Cholesterol | 1 | 11.1% |
Chronic condition | 1 | 11.1% |
Chronic kidney disease | 1 | 11.1% |
Clinical trial | 1 | 11.1% |
Comorbidity | 1 | 11.1% |
Coronary CT calcium scan | 1 | 11.1% |
Coronavirus disease 2019 | 1 | 11.1% |
Diabetes | 1 | 11.1% |
Diabetes management | 1 | 11.1% |
Diabetes mellitus | 1 | 11.1% |
Diabetes mellitus type 1 | 1 | 11.1% |
Diabetes mellitus type 2 | 1 | 11.1% |
Disease management (health) | 1 | 11.1% |
Disease surveillance | 1 | 11.1% |
Disinfectant | 1 | 11.1% |
Drugs | 1 | 11.1% |
Ectopic pregnancy | 1 | 11.1% |
Electronic health record | 1 | 11.1% |
Emergency | 1 | 11.1% |
Emergency management | 1 | 11.1% |
Employment | 1 | 11.1% |
Endocrinology | 1 | 11.1% |
Epidemic | 1 | 11.1% |
Evaluation | 1 | 11.1% |
Ezetimibe | 1 | 11.1% |
False positives and false negatives | 1 | 11.1% |
Fee-for-service | 1 | 11.1% |
Fluconazole | 1 | 11.1% |
Genital wart | 1 | 11.1% |
Glycated hemoglobin | 1 | 11.1% |
Granuloma inguinale | 1 | 11.1% |
Gynaecologic disorders | 1 | 11.1% |
Gynaecology | 1 | 11.1% |
Hand sanitizer | 1 | 11.1% |
Health informatics | 1 | 11.1% |
Health insurance | 1 | 11.1% |
Health maintenance organization | 1 | 11.1% |
Health professional | 1 | 11.1% |
Herpes simplex | 1 | 11.1% |
High-density lipoprotein | 1 | 11.1% |
Human female reproductive system | 1 | 11.1% |
Hypercholesterolemia | 1 | 11.1% |
Hypertension | 1 | 11.1% |
Imaging | 1 | 11.1% |
Infection control | 1 | 11.1% |
Infection prevention and control | 1 | 11.1% |
Inflation | 1 | 11.1% |
Influenza | 1 | 11.1% |
Influenza pandemic | 1 | 11.1% |
Influenza vaccine | 1 | 11.1% |
Insurance | 1 | 11.1% |
Isolation (health care) | 1 | 11.1% |
Julie Gerberding | 1 | 11.1% |
Life sciences | 1 | 11.1% |
Lipoprotein | 1 | 11.1% |
Lipoprotein(a) | 1 | 11.1% |
Lymphogranuloma venereum | 1 | 11.1% |
Male genital disorders | 1 | 11.1% |
Managed care | 1 | 11.1% |
Management | 1 | 11.1% |
Maternal death | 1 | 11.1% |
Medicaid | 1 | 11.1% |
Medical equipment | 1 | 11.1% |
Medical guideline | 1 | 11.1% |
Medical imaging | 1 | 11.1% |
Medical physics | 1 | 11.1% |
Medical test | 1 | 11.1% |
Medical tests | 1 | 11.1% |
Medicare (United States) | 1 | 11.1% |
Medication | 1 | 11.1% |
Metabolic disorders | 1 | 11.1% |
Metabolic syndrome | 1 | 11.1% |
Metformin | 1 | 11.1% |
Metronidazole | 1 | 11.1% |
Michael Osterholm | 1 | 11.1% |
Minneapolis–Saint Paul International Airport | 1 | 11.1% |
Multidimensional signal processing | 1 | 11.1% |
Nursing | 1 | 11.1% |
Nutrition | 1 | 11.1% |
Nystatin | 1 | 11.1% |
Operation of computed tomography | 1 | 11.1% |
Oral sex | 1 | 11.1% |
Pharmacy | 1 | 11.1% |
Physician | 1 | 11.1% |
Pneumonia | 1 | 11.1% |
Positive and negative predictive values | 1 | 11.1% |
Pregnancy | 1 | 11.1% |
Primary care | 1 | 11.1% |
Public health informatics | 1 | 11.1% |
Public health surveillance | 1 | 11.1% |
Quality-adjusted life year | 1 | 11.1% |
Quarantine | 1 | 11.1% |
RTT | 1 | 11.1% |
Risk | 1 | 11.1% |
Screening (medicine) | 1 | 11.1% |
Self-care | 1 | 11.1% |
Severe acute respiratory syndrome coronavirus 2 | 1 | 11.1% |
Sexual health | 1 | 11.1% |
Sexual intercourse | 1 | 11.1% |
Sexually transmitted infection | 1 | 11.1% |
Simvastatin | 1 | 11.1% |
Sisterhood method | 1 | 11.1% |
Smallpox | 1 | 11.1% |
Statin | 1 | 11.1% |
Syphilis | 1 | 11.1% |
Timeline of the SARS outbreak | 1 | 11.1% |
Transmission (medicine) | 1 | 11.1% |
Type 2 diabetes | 1 | 11.1% |
Vaccinia | 1 | 11.1% |
Vagina | 1 | 11.1% |
Vaginitis | 1 | 11.1% |
Women's health | 1 | 11.1% |
abs | rel | |
---|---|---|
Clinical medicine | 5 | 100.0% |
Health | 5 | 100.0% |
Health sciences | 5 | 100.0% |
Medical specialties | 5 | 100.0% |
Medicine | 5 | 100.0% |
Preventive healthcare | 4 | 80.0% |
Public health | 4 | 80.0% |
Cardiovascular disease | 3 | 60.0% |
Disease | 3 | 60.0% |
HIV/AIDS | 3 | 60.0% |
Health care | 3 | 60.0% |
Infection | 3 | 60.0% |
Antimicrobial resistance | 2 | 40.0% |
Biology | 2 | 40.0% |
Cancer | 2 | 40.0% |
Chronic condition | 2 | 40.0% |
Coronary artery disease | 2 | 40.0% |
Diseases and disorders | 2 | 40.0% |
HIV | 2 | 40.0% |
Hormone replacement therapy | 2 | 40.0% |
Life sciences | 2 | 40.0% |
Management of HIV/AIDS | 2 | 40.0% |
Obesity | 2 | 40.0% |
Pre-eclampsia | 2 | 40.0% |
Pregnancy | 2 | 40.0% |
Research | 2 | 40.0% |
Risk | 2 | 40.0% |
Type 2 diabetes | 2 | 40.0% |
Zidovudine | 2 | 40.0% |
ACE inhibitor | 1 | 20.0% |
Alcohol and pregnancy | 1 | 20.0% |
Amblyopia | 1 | 20.0% |
Ambulatory blood pressure | 1 | 20.0% |
Angina | 1 | 20.0% |
Angiology | 1 | 20.0% |
Angiotensin | 1 | 20.0% |
Angiotensin II receptor blocker | 1 | 20.0% |
Angiotensin-converting enzyme | 1 | 20.0% |
Antihypertensive drug | 1 | 20.0% |
Aspirin | 1 | 20.0% |
Asthma | 1 | 20.0% |
BRCA mutation | 1 | 20.0% |
BRCA1 | 1 | 20.0% |
BRCA2 | 1 | 20.0% |
Behavior | 1 | 20.0% |
Beta blocker | 1 | 20.0% |
Bioinformatics | 1 | 20.0% |
Biosensor | 1 | 20.0% |
Blood plasma | 1 | 20.0% |
Blood pressure | 1 | 20.0% |
Blood pressure measurement | 1 | 20.0% |
Brain | 1 | 20.0% |
Breast cancer | 1 | 20.0% |
Breastfeeding | 1 | 20.0% |
CD4 | 1 | 20.0% |
Caesarean section | 1 | 20.0% |
Calcium channel blocker | 1 | 20.0% |
Cardiovascular system | 1 | 20.0% |
Cataract | 1 | 20.0% |
Childbirth | 1 | 20.0% |
Chlortalidone | 1 | 20.0% |
Cholesterol | 1 | 20.0% |
Clinical trial | 1 | 20.0% |
Condom | 1 | 20.0% |
Cornea | 1 | 20.0% |
Crystallin | 1 | 20.0% |
Cystic fibrosis | 1 | 20.0% |
Cystic fibrosis transmembrane conductance regulator | 1 | 20.0% |
DASH diet | 1 | 20.0% |
Diabetic retinopathy | 1 | 20.0% |
Diagnosis of HIV/AIDS | 1 | 20.0% |
Diuretic | 1 | 20.0% |
Drug injection | 1 | 20.0% |
Drugs | 1 | 20.0% |
Eclampsia | 1 | 20.0% |
Epidemiology | 1 | 20.0% |
Epidemiology of HIV/AIDS | 1 | 20.0% |
Evaluation | 1 | 20.0% |
Evidence-based medicine | 1 | 20.0% |
Exercise | 1 | 20.0% |
FMR1 | 1 | 20.0% |
Fragile X syndrome | 1 | 20.0% |
Functional magnetic resonance imaging | 1 | 20.0% |
Gene | 1 | 20.0% |
Genetic carrier | 1 | 20.0% |
Genetic counseling | 1 | 20.0% |
Genetic testing | 1 | 20.0% |
Genetics | 1 | 20.0% |
Gene–environment interaction | 1 | 20.0% |
Genome | 1 | 20.0% |
Glaucoma | 1 | 20.0% |
HIV/AIDS in Africa | 1 | 20.0% |
Harm reduction | 1 | 20.0% |
Health economics | 1 | 20.0% |
Health equity | 1 | 20.0% |
Health policy | 1 | 20.0% |
Human reproduction | 1 | 20.0% |
Hypertension | 1 | 20.0% |
Immune system | 1 | 20.0% |
Infant mortality | 1 | 20.0% |
Infectious diseases | 1 | 20.0% |
Influenza | 1 | 20.0% |
Interstitial cystitis | 1 | 20.0% |
Kidney failure | 1 | 20.0% |
Lamivudine | 1 | 20.0% |
Lens (anatomy) | 1 | 20.0% |
Low-density lipoprotein | 1 | 20.0% |
Macular degeneration | 1 | 20.0% |
Magnetic resonance imaging | 1 | 20.0% |
Malaria | 1 | 20.0% |
Mammography | 1 | 20.0% |
Management of hypertension | 1 | 20.0% |
Medical humanities | 1 | 20.0% |
Medical imaging | 1 | 20.0% |
Medical record | 1 | 20.0% |
Medical research | 1 | 20.0% |
Medium-chain acyl-coenzyme A dehydrogenase deficiency | 1 | 20.0% |
Men who have sex with men | 1 | 20.0% |
Mental disorder | 1 | 20.0% |
Microbicides for sexually transmitted diseases | 1 | 20.0% |
Minimally invasive procedure | 1 | 20.0% |
Mutation | 1 | 20.0% |
Myocardial infarction | 1 | 20.0% |
Nanomedicine | 1 | 20.0% |
Near-sightedness | 1 | 20.0% |
Nevirapine | 1 | 20.0% |
Newborn screening | 1 | 20.0% |
Oophorectomy | 1 | 20.0% |
Ovarian cancer | 1 | 20.0% |
Pharmacogenomics | 1 | 20.0% |
Potassium-sparing diuretic | 1 | 20.0% |
Poverty | 1 | 20.0% |
Prenatal development | 1 | 20.0% |
Preterm birth | 1 | 20.0% |
Prevention of HIV/AIDS | 1 | 20.0% |
Prostitution | 1 | 20.0% |
Proteomics | 1 | 20.0% |
Public health genomics | 1 | 20.0% |
RTT | 1 | 20.0% |
Renin | 1 | 20.0% |
Retina | 1 | 20.0% |
Retinopathy | 1 | 20.0% |
Retinopathy of prematurity | 1 | 20.0% |
Retrovirus | 1 | 20.0% |
Safe sex | 1 | 20.0% |
Saturated fat | 1 | 20.0% |
Schizophrenia | 1 | 20.0% |
Science | 1 | 20.0% |
Screening (medicine) | 1 | 20.0% |
Sexual intercourse | 1 | 20.0% |
Sexually transmitted infection | 1 | 20.0% |
Simian immunodeficiency virus | 1 | 20.0% |
Single-nucleotide polymorphism | 1 | 20.0% |
Spironolactone | 1 | 20.0% |
Statin | 1 | 20.0% |
Stillbirth | 1 | 20.0% |
Strabismus | 1 | 20.0% |
Stroke | 1 | 20.0% |
Sudden infant death syndrome | 1 | 20.0% |
Surgery | 1 | 20.0% |
T helper cell | 1 | 20.0% |
Thiazide | 1 | 20.0% |
Tissue engineering | 1 | 20.0% |
Transcription (biology) | 1 | 20.0% |
Transient ischemic attack | 1 | 20.0% |
Transmission (medicine) | 1 | 20.0% |
Tuberculosis | 1 | 20.0% |
Urinary tract infection | 1 | 20.0% |
Vertically transmitted infection | 1 | 20.0% |
Virus | 1 | 20.0% |
Visual impairment | 1 | 20.0% |
Weight loss | 1 | 20.0% |
White coat hypertension | 1 | 20.0% |
abs | rel | |
---|---|---|
Clinical medicine | 3 | 100.0% |
Health | 3 | 100.0% |
Health care | 3 | 100.0% |
Health sciences | 3 | 100.0% |
Medical specialties | 3 | 100.0% |
Medicine | 3 | 100.0% |
Public health | 3 | 100.0% |
Diseases and disorders | 2 | 66.7% |
Epidemiology | 2 | 66.7% |
Preventive healthcare | 2 | 66.7% |
Accessibility | 1 | 33.3% |
Adalimumab | 1 | 33.3% |
Arthritis | 1 | 33.3% |
BCG vaccine | 1 | 33.3% |
Cardiovascular disease | 1 | 33.3% |
Cardiovascular system | 1 | 33.3% |
Caregiver | 1 | 33.3% |
Cholesterol | 1 | 33.3% |
Clinical nurse specialist | 1 | 33.3% |
Cohort study | 1 | 33.3% |
Coronary artery disease | 1 | 33.3% |
Dementia | 1 | 33.3% |
Etanercept | 1 | 33.3% |
Exercise | 1 | 33.3% |
Fall prevention | 1 | 33.3% |
Family medicine | 1 | 33.3% |
Geriatrics | 1 | 33.3% |
Gerontological nursing | 1 | 33.3% |
Health professional | 1 | 33.3% |
Health promotion | 1 | 33.3% |
Hepatitis | 1 | 33.3% |
High-density lipoprotein | 1 | 33.3% |
Hospital | 1 | 33.3% |
Human activities | 1 | 33.3% |
Hypercholesterolemia | 1 | 33.3% |
Immunology | 1 | 33.3% |
Infliximab | 1 | 33.3% |
Isoniazid | 1 | 33.3% |
Long-term care | 1 | 33.3% |
Mantoux test | 1 | 33.3% |
Medical guideline | 1 | 33.3% |
Medical prescription | 1 | 33.3% |
Medical treatments | 1 | 33.3% |
Medication | 1 | 33.3% |
Meta-analysis | 1 | 33.3% |
Myocardial infarction | 1 | 33.3% |
Nursing | 1 | 33.3% |
Nursing home care | 1 | 33.3% |
Obesity | 1 | 33.3% |
Occupational therapist | 1 | 33.3% |
Occupational therapy | 1 | 33.3% |
Osteoporosis | 1 | 33.3% |
Patient | 1 | 33.3% |
Pharmacy | 1 | 33.3% |
Physical fitness | 1 | 33.3% |
Physical therapy | 1 | 33.3% |
Provinces and territories of Canada | 1 | 33.3% |
Pyrazinamide | 1 | 33.3% |
Randomized controlled trial | 1 | 33.3% |
Rheumatoid arthritis | 1 | 33.3% |
Risk | 1 | 33.3% |
Simvastatin | 1 | 33.3% |
Statin | 1 | 33.3% |
Strength training | 1 | 33.3% |
TNF inhibitor | 1 | 33.3% |
Tuberculin | 1 | 33.3% |
Tuberculosis | 1 | 33.3% |
Tumor necrosis factor alpha | 1 | 33.3% |
abs | rel | |
---|---|---|
Health | 9 | 100.0% |
Health sciences | 8 | 88.9% |
Medicine | 8 | 88.9% |
Clinical medicine | 7 | 77.8% |
Medical specialties | 7 | 77.8% |
Diseases and disorders | 6 | 66.7% |
Health care | 6 | 66.7% |
Public health | 5 | 55.6% |
Epidemiology | 4 | 44.4% |
Therapy | 4 | 44.4% |
Cardiovascular disease | 3 | 33.3% |
Coronary artery disease | 3 | 33.3% |
HIV/AIDS | 3 | 33.3% |
Heart | 3 | 33.3% |
Hypertension | 3 | 33.3% |
Infection | 3 | 33.3% |
Infectious diseases | 3 | 33.3% |
Tuberculosis | 3 | 33.3% |
Adherence (medicine) | 2 | 22.2% |
Antimicrobial resistance | 2 | 22.2% |
Breastfeeding and HIV | 2 | 22.2% |
Cardiac stress test | 2 | 22.2% |
Cardiology | 2 | 22.2% |
Cardiovascular system | 2 | 22.2% |
Chlamydia infection | 2 | 22.2% |
Cholesterol | 2 | 22.2% |
Clinical trial | 2 | 22.2% |
Disease | 2 | 22.2% |
Drugs | 2 | 22.2% |
Evidence-based medicine | 2 | 22.2% |
Heart failure | 2 | 22.2% |
Human activities | 2 | 22.2% |
Human reproduction | 2 | 22.2% |
Hyperlipidemia | 2 | 22.2% |
Immunology | 2 | 22.2% |
Influenza | 2 | 22.2% |
Management of HIV/AIDS | 2 | 22.2% |
Medical guideline | 2 | 22.2% |
Medication | 2 | 22.2% |
Microbiology | 2 | 22.2% |
Myocardial infarction | 2 | 22.2% |
Pharmacology | 2 | 22.2% |
Preventive healthcare | 2 | 22.2% |
RTT | 2 | 22.2% |
Sexually transmitted infection | 2 | 22.2% |
Statin | 2 | 22.2% |
Survey methodology | 2 | 22.2% |
Vaccine | 2 | 22.2% |
ACE inhibitor | 1 | 11.1% |
Abacavir | 1 | 11.1% |
Abdominal obesity | 1 | 11.1% |
Adverse effect | 1 | 11.1% |
Amiodarone | 1 | 11.1% |
Antiarrhythmic agent | 1 | 11.1% |
Antihypertensive drug | 1 | 11.1% |
Apolipoprotein | 1 | 11.1% |
Apolipoprotein B | 1 | 11.1% |
Arrhythmia | 1 | 11.1% |
Atheroma | 1 | 11.1% |
Atherosclerosis | 1 | 11.1% |
Atorvastatin | 1 | 11.1% |
Atrial fibrillation | 1 | 11.1% |
Atrium (heart) | 1 | 11.1% |
Avian influenza | 1 | 11.1% |
Bacteria | 1 | 11.1% |
Bacterial adhesin | 1 | 11.1% |
Bacterial vaginosis | 1 | 11.1% |
Beta-lactamase | 1 | 11.1% |
Biology | 1 | 11.1% |
Birth control | 1 | 11.1% |
Birth defect | 1 | 11.1% |
Blood lipids | 1 | 11.1% |
Blood pressure | 1 | 11.1% |
Blood sugar level | 1 | 11.1% |
Body mass index | 1 | 11.1% |
Botulism | 1 | 11.1% |
C-reactive protein | 1 | 11.1% |
Candida (fungus) | 1 | 11.1% |
Candida albicans | 1 | 11.1% |
Candidiasis | 1 | 11.1% |
Cardiovascular diseases | 1 | 11.1% |
Cardiovascular physiology | 1 | 11.1% |
Cardioversion | 1 | 11.1% |
Cervical cancer | 1 | 11.1% |
Cervical intraepithelial neoplasia | 1 | 11.1% |
Childbirth | 1 | 11.1% |
Choice modelling | 1 | 11.1% |
Chronic condition | 1 | 11.1% |
Clinical pathology | 1 | 11.1% |
Condom | 1 | 11.1% |
Confidence interval | 1 | 11.1% |
Cost estimate | 1 | 11.1% |
Cytokine | 1 | 11.1% |
Declarative programming | 1 | 11.1% |
Demand | 1 | 11.1% |
Diabetes | 1 | 11.1% |
Diabetes management | 1 | 11.1% |
Diagnosis of HIV/AIDS | 1 | 11.1% |
Didanosine | 1 | 11.1% |
Dieting | 1 | 11.1% |
Discrete choice | 1 | 11.1% |
Disinfectant | 1 | 11.1% |
Disopyramide | 1 | 11.1% |
Dofetilide | 1 | 11.1% |
Dose (biochemistry) | 1 | 11.1% |
Dosimeter | 1 | 11.1% |
Dosimetry | 1 | 11.1% |
Echocardiography | 1 | 11.1% |
Efavirenz | 1 | 11.1% |
Electrocardiography | 1 | 11.1% |
Escherichia coli | 1 | 11.1% |
Estrogen | 1 | 11.1% |
Exercise | 1 | 11.1% |
Experiment | 1 | 11.1% |
Ezetimibe | 1 | 11.1% |
Family planning | 1 | 11.1% |
Fenofibrate | 1 | 11.1% |
Fibrate | 1 | 11.1% |
Flecainide | 1 | 11.1% |
Fluconazole | 1 | 11.1% |
Fluvastatin | 1 | 11.1% |
Forecasting | 1 | 11.1% |
General practitioner | 1 | 11.1% |
Glycated hemoglobin | 1 | 11.1% |
Gynaecology | 1 | 11.1% |
Health Level 7 | 1 | 11.1% |
Health informatics | 1 | 11.1% |
Heart diseases | 1 | 11.1% |
Hepatitis | 1 | 11.1% |
Hepatitis C | 1 | 11.1% |
High-density lipoprotein | 1 | 11.1% |
Hospital | 1 | 11.1% |
Hospital-acquired infection | 1 | 11.1% |
Human cytomegalovirus | 1 | 11.1% |
Human female reproductive system | 1 | 11.1% |
Human papillomavirus infection | 1 | 11.1% |
Hypercholesterolemia | 1 | 11.1% |
Hypertriglyceridemia | 1 | 11.1% |
Immune system | 1 | 11.1% |
Immunoglobulin G | 1 | 11.1% |
Indication (medicine) | 1 | 11.1% |
Indinavir | 1 | 11.1% |
Influenza A virus subtype H5N1 | 1 | 11.1% |
Influenza pandemic | 1 | 11.1% |
Information | 1 | 11.1% |
Internal medicine | 1 | 11.1% |
Kaposi's sarcoma | 1 | 11.1% |
Kaposi's sarcoma-associated herpesvirus | 1 | 11.1% |
Knowledge | 1 | 11.1% |
Lactobacillus | 1 | 11.1% |
Lamivudine | 1 | 11.1% |
Likelihood function | 1 | 11.1% |
Lipoprotein | 1 | 11.1% |
Lipoprotein(a) | 1 | 11.1% |
Listeria monocytogenes | 1 | 11.1% |
Listeriosis | 1 | 11.1% |
Logistic regression | 1 | 11.1% |
Logistics | 1 | 11.1% |
Long QT syndrome | 1 | 11.1% |
Lopinavir/ritonavir | 1 | 11.1% |
Lovastatin | 1 | 11.1% |
Low-density lipoprotein | 1 | 11.1% |
Lymphogranuloma venereum | 1 | 11.1% |
Mammal female reproductive system | 1 | 11.1% |
Medical humanities | 1 | 11.1% |
Medical treatments | 1 | 11.1% |
Metabolic disorders | 1 | 11.1% |
Metabolic syndrome | 1 | 11.1% |
Miscarriage | 1 | 11.1% |
Mortality rate | 1 | 11.1% |
Multinomial logistic regression | 1 | 11.1% |
Nevirapine | 1 | 11.1% |
Niacin | 1 | 11.1% |
Obesity | 1 | 11.1% |
Pathogenic Escherichia coli | 1 | 11.1% |
Patient | 1 | 11.1% |
Patient choice | 1 | 11.1% |
Pediatrics | 1 | 11.1% |
Pelvic inflammatory disease | 1 | 11.1% |
Pension | 1 | 11.1% |
Peripheral artery disease | 1 | 11.1% |
Physiology | 1 | 11.1% |
Placenta | 1 | 11.1% |
Post-exposure prophylaxis | 1 | 11.1% |
Pravastatin | 1 | 11.1% |
Prediabetes | 1 | 11.1% |
Pregnancy | 1 | 11.1% |
Preterm birth | 1 | 11.1% |
Prevention of HIV/AIDS | 1 | 11.1% |
Procainamide | 1 | 11.1% |
Procurement | 1 | 11.1% |
Propafenone | 1 | 11.1% |
Public sphere | 1 | 11.1% |
QT interval | 1 | 11.1% |
Quantifier (logic) | 1 | 11.1% |
Quinidine | 1 | 11.1% |
Renal function | 1 | 11.1% |
Resampling (statistics) | 1 | 11.1% |
Research | 1 | 11.1% |
Reverse-transcriptase inhibitor | 1 | 11.1% |
Risk | 1 | 11.1% |
Ritonavir | 1 | 11.1% |
Rosuvastatin | 1 | 11.1% |
SNOMED CT | 1 | 11.1% |
Safe sex | 1 | 11.1% |
Safety stock | 1 | 11.1% |
Saquinavir | 1 | 11.1% |
Saturated fat | 1 | 11.1% |
Screening (medicine) | 1 | 11.1% |
Sepsis | 1 | 11.1% |
Simvastatin | 1 | 11.1% |
Sotalol | 1 | 11.1% |
Spreadsheet | 1 | 11.1% |
Staphylococcus saprophyticus | 1 | 11.1% |
Statistics | 1 | 11.1% |
Stavudine | 1 | 11.1% |
Streptococcus agalactiae | 1 | 11.1% |
Stroke | 1 | 11.1% |
Supply chain | 1 | 11.1% |
Supply chain management | 1 | 11.1% |
Syphilis | 1 | 11.1% |
TLR4 | 1 | 11.1% |
Tablet (pharmacy) | 1 | 11.1% |
Technology | 1 | 11.1% |
Tenofovir disoproxil | 1 | 11.1% |
Toll-like receptor | 1 | 11.1% |
Torsades de pointes | 1 | 11.1% |
Toxoplasmosis | 1 | 11.1% |
Transtheoretical model | 1 | 11.1% |
Type 2 diabetes | 1 | 11.1% |
Ultrasound | 1 | 11.1% |
Urinary tract infection | 1 | 11.1% |
Utility | 1 | 11.1% |
Vagina | 1 | 11.1% |
Vaginal flora | 1 | 11.1% |
Vaginal yeast infection | 1 | 11.1% |
Ventricular fibrillation | 1 | 11.1% |
Zidovudine | 1 | 11.1% |
abs | rel | |
---|---|---|
Clinical medicine | 16 | 100.0% |
Health sciences | 16 | 100.0% |
Medical specialties | 16 | 100.0% |
Medicine | 16 | 100.0% |
Health | 15 | 93.8% |
Health care | 10 | 62.5% |
Diseases and disorders | 8 | 50.0% |
Cardiovascular system | 6 | 37.5% |
Preventive healthcare | 6 | 37.5% |
Angiology | 5 | 31.2% |
Anticoagulant | 5 | 31.2% |
Atrial fibrillation | 5 | 31.2% |
Cardiology | 5 | 31.2% |
Cardiovascular diseases | 5 | 31.2% |
Cardioversion | 5 | 31.2% |
Circulatory system | 5 | 31.2% |
Disease | 5 | 31.2% |
Epidemiology | 5 | 31.2% |
Heart | 5 | 31.2% |
Heart failure | 5 | 31.2% |
Infection | 5 | 31.2% |
Internal medicine | 5 | 31.2% |
Physiology | 5 | 31.2% |
Public health | 5 | 31.2% |
RTT | 5 | 31.2% |
Ventricular fibrillation | 5 | 31.2% |
Atrium (heart) | 4 | 25.0% |
Beta blocker | 4 | 25.0% |
Cancer | 4 | 25.0% |
Cardiovascular physiology | 4 | 25.0% |
Coronary artery disease | 4 | 25.0% |
Digoxin | 4 | 25.0% |
Heart diseases | 4 | 25.0% |
Heart rate | 4 | 25.0% |
Management of atrial fibrillation | 4 | 25.0% |
Risk | 4 | 25.0% |
Stroke | 4 | 25.0% |
Amiodarone | 3 | 18.8% |
Antiarrhythmic agent | 3 | 18.8% |
Arrhythmia | 3 | 18.8% |
Cardiac electrophysiology | 3 | 18.8% |
Cardiovascular disease | 3 | 18.8% |
Chronic condition | 3 | 18.8% |
Clinical trial | 3 | 18.8% |
Evidence-based medicine | 3 | 18.8% |
Flecainide | 3 | 18.8% |
Health economics | 3 | 18.8% |
Health policy | 3 | 18.8% |
Medical humanities | 3 | 18.8% |
Randomized controlled trial | 3 | 18.8% |
Systematic review | 3 | 18.8% |
Warfarin | 3 | 18.8% |
Aspirin | 2 | 12.5% |
Atrial flutter | 2 | 12.5% |
Breast cancer | 2 | 12.5% |
Calcium channel blocker | 2 | 12.5% |
Cardiac surgery | 2 | 12.5% |
Cardiopulmonary bypass | 2 | 12.5% |
Clinical engineering | 2 | 12.5% |
Colorectal cancer | 2 | 12.5% |
Diltiazem | 2 | 12.5% |
Evaluation | 2 | 12.5% |
HIV/AIDS | 2 | 12.5% |
Human activities | 2 | 12.5% |
Human reproduction | 2 | 12.5% |
Immunology | 2 | 12.5% |
Infectious diseases | 2 | 12.5% |
Influenza | 2 | 12.5% |
Major depressive disorder | 2 | 12.5% |
Medication | 2 | 12.5% |
Meta-analysis | 2 | 12.5% |
Percutaneous coronary intervention | 2 | 12.5% |
Prothrombin time | 2 | 12.5% |
Public health genomics | 2 | 12.5% |
Research | 2 | 12.5% |
Screening (medicine) | 2 | 12.5% |
Selective serotonin reuptake inhibitor | 2 | 12.5% |
Sensitivity and specificity | 2 | 12.5% |
Sexually transmitted infection | 2 | 12.5% |
Sodium channel blocker | 2 | 12.5% |
Sotalol | 2 | 12.5% |
Transient ischemic attack | 2 | 12.5% |
Tuberculosis | 2 | 12.5% |
Vaccine | 2 | 12.5% |
Validity (statistics) | 2 | 12.5% |
Valvular heart disease | 2 | 12.5% |
Venous thrombosis | 2 | 12.5% |
Accuracy and precision | 1 | 6.2% |
Aciclovir | 1 | 6.2% |
Active ingredient | 1 | 6.2% |
Acute kidney injury | 1 | 6.2% |
Adolescence | 1 | 6.2% |
Allergen | 1 | 6.2% |
Allergology | 1 | 6.2% |
Allergy | 1 | 6.2% |
Anaphylaxis | 1 | 6.2% |
Antibiotic | 1 | 6.2% |
Antidepressant | 1 | 6.2% |
Antimicrobial resistance | 1 | 6.2% |
Antiplatelet drug | 1 | 6.2% |
Appropriations bill (United States) | 1 | 6.2% |
Atopic dermatitis | 1 | 6.2% |
Atopy | 1 | 6.2% |
Autism | 1 | 6.2% |
Avian influenza | 1 | 6.2% |
Azithromycin | 1 | 6.2% |
BRCA mutation | 1 | 6.2% |
Biology | 1 | 6.2% |
Bioterrorism | 1 | 6.2% |
Birth defect | 1 | 6.2% |
Bleeding | 1 | 6.2% |
Bradycardia | 1 | 6.2% |
Breastfeeding | 1 | 6.2% |
Candidiasis | 1 | 6.2% |
Certification | 1 | 6.2% |
Cervicitis | 1 | 6.2% |
Chemotherapy | 1 | 6.2% |
Chlamydia infection | 1 | 6.2% |
Chlamydia trachomatis | 1 | 6.2% |
Chronic kidney disease | 1 | 6.2% |
Chronic obstructive pulmonary disease | 1 | 6.2% |
Clopidogrel | 1 | 6.2% |
Coronary artery bypass surgery | 1 | 6.2% |
Cost-effectiveness analysis | 1 | 6.2% |
Data anonymization | 1 | 6.2% |
Defibrillation | 1 | 6.2% |
Dermatitis | 1 | 6.2% |
Diabetes | 1 | 6.2% |
Diagnosis of HIV/AIDS | 1 | 6.2% |
Dialysis | 1 | 6.2% |
Disability | 1 | 6.2% |
Disease surveillance | 1 | 6.2% |
Drugs | 1 | 6.2% |
Echocardiography | 1 | 6.2% |
Ectopic pregnancy | 1 | 6.2% |
Educational assessment | 1 | 6.2% |
Electrocardiography | 1 | 6.2% |
Elimination diet | 1 | 6.2% |
Encryption | 1 | 6.2% |
Engineering | 1 | 6.2% |
Epidemic | 1 | 6.2% |
Extensively drug-resistant tuberculosis | 1 | 6.2% |
Fallopian tube | 1 | 6.2% |
Familial adenomatous polyposis | 1 | 6.2% |
Fluconazole | 1 | 6.2% |
Folate | 1 | 6.2% |
Food allergy | 1 | 6.2% |
Food and drink | 1 | 6.2% |
Food intolerance | 1 | 6.2% |
Funnel plot | 1 | 6.2% |
Genealogy | 1 | 6.2% |
Genetic testing | 1 | 6.2% |
Genetics | 1 | 6.2% |
Gene–environment interaction | 1 | 6.2% |
Genomics | 1 | 6.2% |
Genotype | 1 | 6.2% |
Global health | 1 | 6.2% |
Goal | 1 | 6.2% |
Gonorrhea | 1 | 6.2% |
Gynaecology | 1 | 6.2% |
HEPA | 1 | 6.2% |
Health insurance | 1 | 6.2% |
Health promotion | 1 | 6.2% |
Hemodialysis | 1 | 6.2% |
Hemofiltration | 1 | 6.2% |
Hepatitis | 1 | 6.2% |
Hepatitis B | 1 | 6.2% |
Hepatitis B vaccine | 1 | 6.2% |
Hereditary nonpolyposis colorectal cancer | 1 | 6.2% |
History | 1 | 6.2% |
Hospice care in the United States | 1 | 6.2% |
Hospital | 1 | 6.2% |
Human female reproductive system | 1 | 6.2% |
Hypertension | 1 | 6.2% |
Immunoglobulin E | 1 | 6.2% |
Infertility | 1 | 6.2% |
Influenza A virus subtype H5N1 | 1 | 6.2% |
Influenza pandemic | 1 | 6.2% |
Influenza vaccine | 1 | 6.2% |
Information | 1 | 6.2% |
Insurance | 1 | 6.2% |
Intensive care medicine | 1 | 6.2% |
Intensive care unit | 1 | 6.2% |
Ischemia | 1 | 6.2% |
Isolation (health care) | 1 | 6.2% |
Kidney | 1 | 6.2% |
Kidney failure | 1 | 6.2% |
Lead poisoning | 1 | 6.2% |
Life expectancy | 1 | 6.2% |
Life sciences | 1 | 6.2% |
Li–Fraumeni syndrome | 1 | 6.2% |
Long QT syndrome | 1 | 6.2% |
Measles | 1 | 6.2% |
Medical diagnosis | 1 | 6.2% |
Medical history | 1 | 6.2% |
Medical prescription | 1 | 6.2% |
Medical record | 1 | 6.2% |
Medical treatments | 1 | 6.2% |
Meningococcal disease | 1 | 6.2% |
Mental disorder | 1 | 6.2% |
Methicillin-resistant Staphylococcus aureus | 1 | 6.2% |
Methylenetetrahydrofolate reductase | 1 | 6.2% |
Metronidazole | 1 | 6.2% |
Microbiology | 1 | 6.2% |
Milk | 1 | 6.2% |
Milk allergy | 1 | 6.2% |
Myocardial infarction | 1 | 6.2% |
Neisseria meningitidis | 1 | 6.2% |
Nephrology | 1 | 6.2% |
Newborn screening | 1 | 6.2% |
Nontuberculous mycobacteria | 1 | 6.2% |
Occupational safety and health | 1 | 6.2% |
Oncology | 1 | 6.2% |
Ovarian cancer | 1 | 6.2% |
Peanut allergy | 1 | 6.2% |
Pelvic inflammatory disease | 1 | 6.2% |
Phenotype | 1 | 6.2% |
Physician | 1 | 6.2% |
Primary care | 1 | 6.2% |
Prostate cancer | 1 | 6.2% |
Psychiatry | 1 | 6.2% |
Public sphere | 1 | 6.2% |
Publication bias | 1 | 6.2% |
Quality-adjusted life year | 1 | 6.2% |
Quarantine | 1 | 6.2% |
Quinidine | 1 | 6.2% |
Radiation therapy | 1 | 6.2% |
Radioallergosorbent test | 1 | 6.2% |
Respirator | 1 | 6.2% |
Risk assessment | 1 | 6.2% |
Severe combined immunodeficiency | 1 | 6.2% |
Single-nucleotide polymorphism | 1 | 6.2% |
Skin allergy test | 1 | 6.2% |
Soy allergy | 1 | 6.2% |
Statistics | 1 | 6.2% |
Syphilis | 1 | 6.2% |
Tachycardia | 1 | 6.2% |
Therapy | 1 | 6.2% |
Thrombosis prevention | 1 | 6.2% |
Torsades de pointes | 1 | 6.2% |
Tuberculosis management | 1 | 6.2% |
VKORC1 | 1 | 6.2% |
Vaccination | 1 | 6.2% |
Vagina | 1 | 6.2% |
Vaginitis | 1 | 6.2% |
Ventricular assist device | 1 | 6.2% |
Verapamil | 1 | 6.2% |
Virus | 1 | 6.2% |
Wolff–Parkinson–White syndrome | 1 | 6.2% |
Women's health | 1 | 6.2% |
abs | rel | |
---|---|---|
Health | 13 | 100.0% |
Health sciences | 13 | 100.0% |
Medicine | 12 | 92.3% |
Medical specialties | 11 | 84.6% |
Clinical medicine | 10 | 76.9% |
Health care | 9 | 69.2% |
Public health | 9 | 69.2% |
Diseases and disorders | 4 | 30.8% |
Infection | 4 | 30.8% |
Angiology | 3 | 23.1% |
Cardiology | 3 | 23.1% |
Cardiovascular system | 3 | 23.1% |
Clinical trial | 3 | 23.1% |
Disease | 3 | 23.1% |
Epidemiology | 3 | 23.1% |
HIV/AIDS | 3 | 23.1% |
Heart | 3 | 23.1% |
Immunology | 3 | 23.1% |
Internal medicine | 3 | 23.1% |
Patient safety | 3 | 23.1% |
Risk | 3 | 23.1% |
Safety | 3 | 23.1% |
Sexually transmitted infection | 3 | 23.1% |
Adverse effect | 2 | 15.4% |
Angina | 2 | 15.4% |
Biology | 2 | 15.4% |
Blood transfusion | 2 | 15.4% |
Cardiovascular diseases | 2 | 15.4% |
Childbirth | 2 | 15.4% |
Condom | 2 | 15.4% |
Coronary artery disease | 2 | 15.4% |
Death | 2 | 15.4% |
Diagnosis of HIV/AIDS | 2 | 15.4% |
Diarrhea | 2 | 15.4% |
Federal Food, Drug, and Cosmetic Act | 2 | 15.4% |
Health care quality | 2 | 15.4% |
Health professional | 2 | 15.4% |
Hospital | 2 | 15.4% |
Human activities | 2 | 15.4% |
Infectious diseases | 2 | 15.4% |
Life sciences | 2 | 15.4% |
Medical error | 2 | 15.4% |
Medical humanities | 2 | 15.4% |
Medical record | 2 | 15.4% |
Medication | 2 | 15.4% |
Methicillin-resistant Staphylococcus aureus | 2 | 15.4% |
Microbiology | 2 | 15.4% |
Myocardial infarction | 2 | 15.4% |
Nursing | 2 | 15.4% |
Patient | 2 | 15.4% |
Patient safety organization | 2 | 15.4% |
Pharmacy | 2 | 15.4% |
Pneumonia | 2 | 15.4% |
Prevention of HIV/AIDS | 2 | 15.4% |
Preventive healthcare | 2 | 15.4% |
Research | 2 | 15.4% |
Risk management | 2 | 15.4% |
Safe sex | 2 | 15.4% |
Sexual intercourse | 2 | 15.4% |
Surgery | 2 | 15.4% |
Systematic review | 2 | 15.4% |
Abbreviated New Drug Application | 1 | 7.7% |
Abortion | 1 | 7.7% |
Acute coronary syndrome | 1 | 7.7% |
Adherence (medicine) | 1 | 7.7% |
Adverse event | 1 | 7.7% |
Anesthesia | 1 | 7.7% |
Anthrax | 1 | 7.7% |
Aortic insufficiency | 1 | 7.7% |
Aortic stenosis | 1 | 7.7% |
Aortic valve | 1 | 7.7% |
Aortic valve replacement | 1 | 7.7% |
Asthma | 1 | 7.7% |
Atrium (heart) | 1 | 7.7% |
Avian influenza | 1 | 7.7% |
Biotechnology | 1 | 7.7% |
Birthing center | 1 | 7.7% |
Blood donation | 1 | 7.7% |
Bone | 1 | 7.7% |
Bone density | 1 | 7.7% |
Booster dose | 1 | 7.7% |
Botulism | 1 | 7.7% |
Breast milk | 1 | 7.7% |
Breastfeeding | 1 | 7.7% |
Breastfeeding and HIV | 1 | 7.7% |
CE marking | 1 | 7.7% |
Cardiac marker | 1 | 7.7% |
Cardiothoracic surgery | 1 | 7.7% |
Cardiovascular disease | 1 | 7.7% |
Causality | 1 | 7.7% |
Cholesterol | 1 | 7.7% |
Chronic condition | 1 | 7.7% |
Chronic obstructive pulmonary disease | 1 | 7.7% |
Circulatory system | 1 | 7.7% |
Coccidioidomycosis | 1 | 7.7% |
Community | 1 | 7.7% |
Comorbidity | 1 | 7.7% |
Complete blood count | 1 | 7.7% |
Complication (medicine) | 1 | 7.7% |
Compounding | 1 | 7.7% |
Congenital heart defect | 1 | 7.7% |
Consent | 1 | 7.7% |
Copyright | 1 | 7.7% |
Counseling psychology | 1 | 7.7% |
DPT vaccine | 1 | 7.7% |
DTaP-IPV/Hib vaccine | 1 | 7.7% |
Data analysis | 1 | 7.7% |
Deep vein thrombosis | 1 | 7.7% |
Diagnosis-related group | 1 | 7.7% |
Diastole | 1 | 7.7% |
Disability | 1 | 7.7% |
Drugs | 1 | 7.7% |
Emergency department | 1 | 7.7% |
Encephalitis | 1 | 7.7% |
Endocrine system | 1 | 7.7% |
Endocrinology | 1 | 7.7% |
Endovascular aneurysm repair | 1 | 7.7% |
Error | 1 | 7.7% |
Evaluation | 1 | 7.7% |
Evidence-based medicine | 1 | 7.7% |
Failure mode and effects analysis | 1 | 7.7% |
Familial hypercholesterolemia | 1 | 7.7% |
Family planning | 1 | 7.7% |
Food | 1 | 7.7% |
Food and Drug Administration Amendments Act of 2007 | 1 | 7.7% |
Food defense | 1 | 7.7% |
Food safety | 1 | 7.7% |
Foodborne illness | 1 | 7.7% |
Generic drug | 1 | 7.7% |
HIV | 1 | 7.7% |
Health economics | 1 | 7.7% |
Health policy | 1 | 7.7% |
Health system | 1 | 7.7% |
Health technology in the United States | 1 | 7.7% |
Healthcare reform in the United States | 1 | 7.7% |
Heart valve | 1 | 7.7% |
Hib vaccine | 1 | 7.7% |
Hindsight bias | 1 | 7.7% |
Hormone replacement therapy | 1 | 7.7% |
Hospital-acquired infection | 1 | 7.7% |
Hospital-acquired pneumonia | 1 | 7.7% |
Human reproduction | 1 | 7.7% |
Hypercholesterolemia | 1 | 7.7% |
Hypertension | 1 | 7.7% |
Iatrogenesis | 1 | 7.7% |
Immunization | 1 | 7.7% |
Infant | 1 | 7.7% |
Infant formula | 1 | 7.7% |
Infection control | 1 | 7.7% |
Influenza | 1 | 7.7% |
Influenza A virus | 1 | 7.7% |
Influenza A virus subtype H1N1 | 1 | 7.7% |
Influenza A virus subtype H3N2 | 1 | 7.7% |
Influenza A virus subtype H5N1 | 1 | 7.7% |
Influenza pandemic | 1 | 7.7% |
Influenza treatment | 1 | 7.7% |
Influenza-like illness | 1 | 7.7% |
Intensive care medicine | 1 | 7.7% |
Intensive care unit | 1 | 7.7% |
Intention | 1 | 7.7% |
International Statistical Classification of Diseases and Related Health Problems | 1 | 7.7% |
Ischemia | 1 | 7.7% |
Listeriosis | 1 | 7.7% |
MEDLINE | 1 | 7.7% |
Magnetic resonance imaging | 1 | 7.7% |
Malaria | 1 | 7.7% |
Medical Subject Headings | 1 | 7.7% |
Medical device | 1 | 7.7% |
Medical diagnosis | 1 | 7.7% |
Medical prescription | 1 | 7.7% |
Medicare (United States) | 1 | 7.7% |
Men who have sex with men | 1 | 7.7% |
Menopause | 1 | 7.7% |
Metabolic disorders | 1 | 7.7% |
Musculoskeletal system | 1 | 7.7% |
Natural reservoir | 1 | 7.7% |
Non-governmental organization | 1 | 7.7% |
Norovirus | 1 | 7.7% |
Number needed to treat | 1 | 7.7% |
Nursing home care | 1 | 7.7% |
Osteoporosis | 1 | 7.7% |
Parent | 1 | 7.7% |
Pediatrics | 1 | 7.7% |
Percutaneous aortic valve replacement | 1 | 7.7% |
Pericardial heart valves | 1 | 7.7% |
Pharmaceutical sciences | 1 | 7.7% |
Pharmacology | 1 | 7.7% |
Pneumococcal conjugate vaccine | 1 | 7.7% |
Pneumococcal vaccine | 1 | 7.7% |
Point of care | 1 | 7.7% |
Point-of-care testing | 1 | 7.7% |
Polio vaccine | 1 | 7.7% |
Positive and negative predictive values | 1 | 7.7% |
Pregnancy | 1 | 7.7% |
Prescription drug | 1 | 7.7% |
Pressure ulcer | 1 | 7.7% |
Preventive medicine | 1 | 7.7% |
Protocol (science) | 1 | 7.7% |
Psychotherapy | 1 | 7.7% |
Pulmonary embolism | 1 | 7.7% |
Randomized controlled trial | 1 | 7.7% |
Reliability (statistics) | 1 | 7.7% |
Residency (medicine) | 1 | 7.7% |
Rift Valley fever | 1 | 7.7% |
Rotavirus vaccine | 1 | 7.7% |
Self-disclosure | 1 | 7.7% |
Sensitivity and specificity | 1 | 7.7% |
Sepsis | 1 | 7.7% |
Sex worker | 1 | 7.7% |
Staphylococcus aureus | 1 | 7.7% |
Statin | 1 | 7.7% |
Statistical classification | 1 | 7.7% |
Swine influenza | 1 | 7.7% |
System | 1 | 7.7% |
Tetralogy of Fallot | 1 | 7.7% |
Thiamine deficiency | 1 | 7.7% |
Thorax (human anatomy) | 1 | 7.7% |
Thrombosis | 1 | 7.7% |
Tobacco smoking | 1 | 7.7% |
Toxic shock syndrome | 1 | 7.7% |
Trimethoprim/sulfamethoxazole | 1 | 7.7% |
Troponin | 1 | 7.7% |
Truck driver | 1 | 7.7% |
Tuberculosis | 1 | 7.7% |
Ulcer (dermatology) | 1 | 7.7% |
Unstable angina | 1 | 7.7% |
Vaccination | 1 | 7.7% |
Vaccine | 1 | 7.7% |
Vaccines | 1 | 7.7% |
Valvular heart disease | 1 | 7.7% |
Vein | 1 | 7.7% |
Venous thrombosis | 1 | 7.7% |
Ventilator-associated pneumonia | 1 | 7.7% |
Ventricle (heart) | 1 | 7.7% |
Verification and validation | 1 | 7.7% |
Vibrio | 1 | 7.7% |
Virus | 1 | 7.7% |
Wound | 1 | 7.7% |
Zoonosis | 1 | 7.7% |
abs | rel | |
---|---|---|
Clinical medicine | 18 | 100.0% |
Health | 18 | 100.0% |
Health sciences | 18 | 100.0% |
Medical specialties | 18 | 100.0% |
Medicine | 18 | 100.0% |
Health care | 17 | 94.4% |
Public health | 9 | 50.0% |
Diseases and disorders | 8 | 44.4% |
Epidemiology | 7 | 38.9% |
Cardiovascular disease | 5 | 27.8% |
Disease | 5 | 27.8% |
Preventive healthcare | 5 | 27.8% |
Risk | 5 | 27.8% |
Screening (medicine) | 5 | 27.8% |
Biology | 4 | 22.2% |
Cancer | 4 | 22.2% |
Cardiovascular system | 4 | 22.2% |
Coronary artery disease | 4 | 22.2% |
Heart | 4 | 22.2% |
High-density lipoprotein | 4 | 22.2% |
Hypertension | 4 | 22.2% |
Infectious diseases | 4 | 22.2% |
Life sciences | 4 | 22.2% |
Medical treatments | 4 | 22.2% |
Myocardial infarction | 4 | 22.2% |
Stroke | 4 | 22.2% |
Vaccine | 4 | 22.2% |
Avian influenza | 3 | 16.7% |
Cardiology | 3 | 16.7% |
Cholesterol | 3 | 16.7% |
Chronic condition | 3 | 16.7% |
Clinical trial | 3 | 16.7% |
Cost-effectiveness analysis | 3 | 16.7% |
Exercise | 3 | 16.7% |
Immunology | 3 | 16.7% |
Infection | 3 | 16.7% |
Influenza | 3 | 16.7% |
Influenza A virus subtype H5N1 | 3 | 16.7% |
Internal medicine | 3 | 16.7% |
Low-density lipoprotein | 3 | 16.7% |
Medication | 3 | 16.7% |
Microbiology | 3 | 16.7% |
Obesity | 3 | 16.7% |
Research | 3 | 16.7% |
Saturated fat | 3 | 16.7% |
Statin | 3 | 16.7% |
Abdominal obesity | 2 | 11.1% |
Adherence (medicine) | 2 | 11.1% |
Anticoagulant | 2 | 11.1% |
Antihypertensive drug | 2 | 11.1% |
Antimicrobial resistance | 2 | 11.1% |
Antiviral drug | 2 | 11.1% |
Apolipoprotein B | 2 | 11.1% |
Atrial fibrillation | 2 | 11.1% |
Body mass index | 2 | 11.1% |
C-reactive protein | 2 | 11.1% |
CHA2DS2–VASc score | 2 | 11.1% |
Cancer screening | 2 | 11.1% |
Cardiovascular diseases | 2 | 11.1% |
Colonoscopy | 2 | 11.1% |
Colorectal cancer | 2 | 11.1% |
Diabetes | 2 | 11.1% |
Disease surveillance | 2 | 11.1% |
Drugs | 2 | 11.1% |
Electrocardiography | 2 | 11.1% |
Fat | 2 | 11.1% |
Fecal occult blood | 2 | 11.1% |
Framingham Risk Score | 2 | 11.1% |
General practitioner | 2 | 11.1% |
HIV/AIDS | 2 | 11.1% |
Health economics | 2 | 11.1% |
Health policy | 2 | 11.1% |
Heart failure | 2 | 11.1% |
Human activities | 2 | 11.1% |
Hypercholesterolemia | 2 | 11.1% |
Influenza pandemic | 2 | 11.1% |
Lipoprotein | 2 | 11.1% |
Medical humanities | 2 | 11.1% |
Metabolic syndrome | 2 | 11.1% |
Oseltamivir | 2 | 11.1% |
Pharmacology | 2 | 11.1% |
Pharmacy | 2 | 11.1% |
Polyp (medicine) | 2 | 11.1% |
Pregnancy | 2 | 11.1% |
Prescription drug | 2 | 11.1% |
Public sphere | 2 | 11.1% |
Randomized controlled trial | 2 | 11.1% |
Renal function | 2 | 11.1% |
Sensitivity analysis | 2 | 11.1% |
Sensitivity and specificity | 2 | 11.1% |
Sexually transmitted infection | 2 | 11.1% |
Stool guaiac test | 2 | 11.1% |
Systematic review | 2 | 11.1% |
Virus | 2 | 11.1% |
Vitamin D | 2 | 11.1% |
Adenoma | 1 | 5.6% |
Adiponectin | 1 | 5.6% |
Adjuvant therapy | 1 | 5.6% |
Adverse effect | 1 | 5.6% |
Allergy | 1 | 5.6% |
Alzheimer's disease | 1 | 5.6% |
Angioplasty | 1 | 5.6% |
Anti-diabetic medication | 1 | 5.6% |
Antibiotic | 1 | 5.6% |
Antibody | 1 | 5.6% |
Antigen | 1 | 5.6% |
Antiplatelet drug | 1 | 5.6% |
Apolipoprotein | 1 | 5.6% |
Areca nut | 1 | 5.6% |
Asthma | 1 | 5.6% |
Atheroma | 1 | 5.6% |
Atherosclerosis | 1 | 5.6% |
Atorvastatin | 1 | 5.6% |
B cell | 1 | 5.6% |
Bacteria | 1 | 5.6% |
Bariatric surgery | 1 | 5.6% |
Behavior | 1 | 5.6% |
Beta blocker | 1 | 5.6% |
Biomarker | 1 | 5.6% |
Biotechnology | 1 | 5.6% |
Birth weight | 1 | 5.6% |
Blastocyst | 1 | 5.6% |
Brain natriuretic peptide | 1 | 5.6% |
Breast cancer | 1 | 5.6% |
CD20 | 1 | 5.6% |
COVID-19 pandemic | 1 | 5.6% |
CT scan | 1 | 5.6% |
Cardiac catheterization | 1 | 5.6% |
Cardiac stress test | 1 | 5.6% |
Cardiogenic shock | 1 | 5.6% |
Cardiothoracic surgery | 1 | 5.6% |
Chemotherapy | 1 | 5.6% |
Childbirth | 1 | 5.6% |
Cholecystectomy | 1 | 5.6% |
Chronic kidney disease | 1 | 5.6% |
Cigarette | 1 | 5.6% |
Circulatory system | 1 | 5.6% |
Cohort study | 1 | 5.6% |
Coronary artery bypass surgery | 1 | 5.6% |
Coronary stent | 1 | 5.6% |
Cost–benefit analysis | 1 | 5.6% |
Cost–utility analysis | 1 | 5.6% |
Creatinine | 1 | 5.6% |
Current Procedural Terminology | 1 | 5.6% |
Cystatin C | 1 | 5.6% |
Cytokine | 1 | 5.6% |
DNA methylation | 1 | 5.6% |
DNA microarray | 1 | 5.6% |
DNA vaccination | 1 | 5.6% |
DPT vaccine | 1 | 5.6% |
Da Vinci Surgical System | 1 | 5.6% |
Determinants of health | 1 | 5.6% |
Diabetes management | 1 | 5.6% |
Diabetes mellitus | 1 | 5.6% |
Diabetes mellitus type 2 | 1 | 5.6% |
Diet (nutrition) | 1 | 5.6% |
Dietary fiber | 1 | 5.6% |
Dieting | 1 | 5.6% |
Door-to-balloon | 1 | 5.6% |
Emergency department | 1 | 5.6% |
Emergency management | 1 | 5.6% |
Emergency medical services | 1 | 5.6% |
Epigenetics | 1 | 5.6% |
Estrogen | 1 | 5.6% |
Evidence-based practice | 1 | 5.6% |
Ezetimibe | 1 | 5.6% |
Family medicine | 1 | 5.6% |
Fenofibrate | 1 | 5.6% |
Fetus | 1 | 5.6% |
Fibrate | 1 | 5.6% |
Flu season | 1 | 5.6% |
Fluvastatin | 1 | 5.6% |
Gastroenterology | 1 | 5.6% |
Gene | 1 | 5.6% |
Genetic disorder | 1 | 5.6% |
Gene–environment interaction | 1 | 5.6% |
Glucose tolerance test | 1 | 5.6% |
Glycated hemoglobin | 1 | 5.6% |
HIV | 1 | 5.6% |
Health equity | 1 | 5.6% |
Health insurance coverage in the United States | 1 | 5.6% |
Health professional | 1 | 5.6% |
Health promotion | 1 | 5.6% |
Health technology | 1 | 5.6% |
Health technology assessment | 1 | 5.6% |
Healthy diet | 1 | 5.6% |
Hospital | 1 | 5.6% |
Human nutrition | 1 | 5.6% |
Hyperglycemia | 1 | 5.6% |
Hyperlipidemia | 1 | 5.6% |
Hypertriglyceridemia | 1 | 5.6% |
Hysterectomy | 1 | 5.6% |
Immune system | 1 | 5.6% |
Immune tolerance | 1 | 5.6% |
Immunization | 1 | 5.6% |
Incremental cost-effectiveness ratio | 1 | 5.6% |
Inflammation | 1 | 5.6% |
Inflammatory cytokine | 1 | 5.6% |
Influenza A virus subtype H3N2 | 1 | 5.6% |
Influenza vaccine | 1 | 5.6% |
Innate immune system | 1 | 5.6% |
Insulin resistance | 1 | 5.6% |
Interferon | 1 | 5.6% |
Kidney disease | 1 | 5.6% |
Laparoscopic radical prostatectomy | 1 | 5.6% |
Laparoscopy | 1 | 5.6% |
Lipoprotein(a) | 1 | 5.6% |
Lymphoma | 1 | 5.6% |
MEDLINE | 1 | 5.6% |
MMR vaccine | 1 | 5.6% |
MMRV vaccine | 1 | 5.6% |
Macrophage | 1 | 5.6% |
MammaPrint | 1 | 5.6% |
Maturity onset diabetes of the young | 1 | 5.6% |
Medical guideline | 1 | 5.6% |
Medical history | 1 | 5.6% |
Medical prescription | 1 | 5.6% |
Medical procedures | 1 | 5.6% |
Medical record | 1 | 5.6% |
Medical tests | 1 | 5.6% |
Medicare (United States) | 1 | 5.6% |
Microglia | 1 | 5.6% |
Minimally invasive procedures | 1 | 5.6% |
Model organism | 1 | 5.6% |
Molecular biology | 1 | 5.6% |
Monoclonal antibody | 1 | 5.6% |
Neisseria gonorrhoeae | 1 | 5.6% |
Nephrectomy | 1 | 5.6% |
Niacin | 1 | 5.6% |
Non-pharmaceutical intervention (epidemiology) | 1 | 5.6% |
Nursing | 1 | 5.6% |
Nutrition | 1 | 5.6% |
Osteoporosis | 1 | 5.6% |
Pandemic | 1 | 5.6% |
Patient | 1 | 5.6% |
Percutaneous coronary intervention | 1 | 5.6% |
Peripheral artery disease | 1 | 5.6% |
Peroxisome proliferator-activated receptor | 1 | 5.6% |
Peroxisome proliferator-activated receptor gamma | 1 | 5.6% |
Pharmaceutical sciences | 1 | 5.6% |
Physical fitness | 1 | 5.6% |
Placenta | 1 | 5.6% |
Plasmid | 1 | 5.6% |
Pneumonia | 1 | 5.6% |
Polymerase chain reaction | 1 | 5.6% |
Post-exposure prophylaxis | 1 | 5.6% |
Pravastatin | 1 | 5.6% |
Prediabetes | 1 | 5.6% |
Primary care | 1 | 5.6% |
Prion | 1 | 5.6% |
Prostatectomy | 1 | 5.6% |
Puberty | 1 | 5.6% |
Quality of life (healthcare) | 1 | 5.6% |
Quality-adjusted life year | 1 | 5.6% |
Rabies | 1 | 5.6% |
Rabies vaccine | 1 | 5.6% |
Radiology | 1 | 5.6% |
Reperfusion therapy | 1 | 5.6% |
Reverse transcription polymerase chain reaction | 1 | 5.6% |
Rhinovirus | 1 | 5.6% |
Rituximab | 1 | 5.6% |
Robot-assisted surgery | 1 | 5.6% |
Rosuvastatin | 1 | 5.6% |
Self-care | 1 | 5.6% |
Serology | 1 | 5.6% |
Sheep | 1 | 5.6% |
Shock (circulatory) | 1 | 5.6% |
Sigmoidoscopy | 1 | 5.6% |
Simulation | 1 | 5.6% |
Simvastatin | 1 | 5.6% |
Smoking cessation | 1 | 5.6% |
Social distancing | 1 | 5.6% |
Social programs | 1 | 5.6% |
Statistics | 1 | 5.6% |
Surgery | 1 | 5.6% |
Surgical procedures and techniques | 1 | 5.6% |
Surrogate endpoint | 1 | 5.6% |
T cell | 1 | 5.6% |
TCF7L2 | 1 | 5.6% |
Tamoxifen | 1 | 5.6% |
Therapy | 1 | 5.6% |
Tobacco smoking | 1 | 5.6% |
Transient ischemic attack | 1 | 5.6% |
Translational medicine | 1 | 5.6% |
Translational research | 1 | 5.6% |
Triage | 1 | 5.6% |
Triglyceride | 1 | 5.6% |
Tumor microenvironment | 1 | 5.6% |
Type 1 diabetes | 1 | 5.6% |
Type 2 diabetes | 1 | 5.6% |
Urology | 1 | 5.6% |
Vaccination | 1 | 5.6% |
Vaccines for Children Program | 1 | 5.6% |
Validity (statistics) | 1 | 5.6% |
Venous thrombosis | 1 | 5.6% |
Ventricular fibrillation | 1 | 5.6% |
Virtual colonoscopy | 1 | 5.6% |
Vitamin | 1 | 5.6% |
Vitamin C | 1 | 5.6% |
WIC | 1 | 5.6% |
Warfarin | 1 | 5.6% |
Zanamivir | 1 | 5.6% |
abs | rel | |
---|---|---|
Health | 23 | 100.0% |
Health sciences | 23 | 100.0% |
Medical specialties | 23 | 100.0% |
Clinical medicine | 22 | 95.7% |
Medicine | 22 | 95.7% |
Health care | 21 | 91.3% |
Public health | 13 | 56.5% |
Disease | 10 | 43.5% |
Epidemiology | 10 | 43.5% |
Evidence-based medicine | 9 | 39.1% |
Preventive healthcare | 9 | 39.1% |
Biology | 8 | 34.8% |
Clinical trial | 8 | 34.8% |
Diseases and disorders | 8 | 34.8% |
Risk | 8 | 34.8% |
Adherence (medicine) | 7 | 30.4% |
Cancer | 7 | 30.4% |
Randomized controlled trial | 7 | 30.4% |
Research | 7 | 30.4% |
Genetic testing | 6 | 26.1% |
Science | 6 | 26.1% |
Evaluation | 5 | 21.7% |
Gene | 5 | 21.7% |
Genetics | 5 | 21.7% |
Major depressive disorder | 5 | 21.7% |
Medical diagnosis | 5 | 21.7% |
Personal genomics | 5 | 21.7% |
Screening (medicine) | 5 | 21.7% |
Self-care | 5 | 21.7% |
Behavior | 4 | 17.4% |
Chronic condition | 4 | 17.4% |
Evidence-based practice | 4 | 17.4% |
Genetic association | 4 | 17.4% |
Genome-wide association study | 4 | 17.4% |
HIV/AIDS | 4 | 17.4% |
Heart | 4 | 17.4% |
Hepatitis | 4 | 17.4% |
Influenza | 4 | 17.4% |
Life sciences | 4 | 17.4% |
Medication | 4 | 17.4% |
Meta-analysis | 4 | 17.4% |
Obesity | 4 | 17.4% |
Pharmacogenomics | 4 | 17.4% |
Risk assessment | 4 | 17.4% |
Sensitivity and specificity | 4 | 17.4% |
Validity (statistics) | 4 | 17.4% |
Warfarin | 4 | 17.4% |
Cardiovascular disease | 3 | 13.0% |
Chronic obstructive pulmonary disease | 3 | 13.0% |
Comorbidity | 3 | 13.0% |
Disease surveillance | 3 | 13.0% |
Health economics | 3 | 13.0% |
Health policy | 3 | 13.0% |
Human activities | 3 | 13.0% |
Infection | 3 | 13.0% |
Infectious diseases | 3 | 13.0% |
Influenza A virus subtype H1N1 | 3 | 13.0% |
Influenza pandemic | 3 | 13.0% |
Information | 3 | 13.0% |
Medical history | 3 | 13.0% |
Medical humanities | 3 | 13.0% |
Medical treatments | 3 | 13.0% |
Mutation | 3 | 13.0% |
Myocardial infarction | 3 | 13.0% |
Outcomes research | 3 | 13.0% |
Pain | 3 | 13.0% |
Pharmacogenetics | 3 | 13.0% |
Physical examination | 3 | 13.0% |
Pneumonia | 3 | 13.0% |
Public sphere | 3 | 13.0% |
Receiver operating characteristic | 3 | 13.0% |
Scientific method | 3 | 13.0% |
Sexually transmitted infection | 3 | 13.0% |
Shortness of breath | 3 | 13.0% |
Spirometry | 3 | 13.0% |
Surgery | 3 | 13.0% |
Therapy | 3 | 13.0% |
Vaccine | 3 | 13.0% |
Virus | 3 | 13.0% |
Adverse effect | 2 | 8.7% |
Allergen | 2 | 8.7% |
Allergic rhinitis | 2 | 8.7% |
Allergy | 2 | 8.7% |
Analgesic | 2 | 8.7% |
Antiviral drug | 2 | 8.7% |
Asthma | 2 | 8.7% |
Avian influenza | 2 | 8.7% |
Biosecurity | 2 | 8.7% |
Breast cancer | 2 | 8.7% |
Bronchodilator | 2 | 8.7% |
Cardiovascular system | 2 | 8.7% |
Caregiver | 2 | 8.7% |
Chest radiograph | 2 | 8.7% |
Childbirth | 2 | 8.7% |
Chlamydia infection | 2 | 8.7% |
Colorectal cancer | 2 | 8.7% |
Cough | 2 | 8.7% |
Emergency department | 2 | 8.7% |
Exercise-induced bronchoconstriction | 2 | 8.7% |
Field Epidemiology Training Program | 2 | 8.7% |
Gastroesophageal reflux disease | 2 | 8.7% |
Genetic counseling | 2 | 8.7% |
Gonorrhea | 2 | 8.7% |
Heartburn | 2 | 8.7% |
Human reproduction | 2 | 8.7% |
Hypertension | 2 | 8.7% |
Immunology | 2 | 8.7% |
Influenza A virus | 2 | 8.7% |
Influenza A virus subtype H5N1 | 2 | 8.7% |
Influenza vaccine | 2 | 8.7% |
Influenza-like illness | 2 | 8.7% |
Lung | 2 | 8.7% |
Medical guideline | 2 | 8.7% |
Medicare (United States) | 2 | 8.7% |
Microbiology | 2 | 8.7% |
Obstructive sleep apnea | 2 | 8.7% |
Patient | 2 | 8.7% |
Pregnancy | 2 | 8.7% |
Psychiatry | 2 | 8.7% |
Psychotherapy | 2 | 8.7% |
Pulmonary function testing | 2 | 8.7% |
Pulmonology | 2 | 8.7% |
Rhinitis | 2 | 8.7% |
Sinusitis | 2 | 8.7% |
Sleep apnea | 2 | 8.7% |
Stroke | 2 | 8.7% |
Surveillance | 2 | 8.7% |
Tuberculosis | 2 | 8.7% |
Vocal cord dysfunction | 2 | 8.7% |
Wheeze | 2 | 8.7% |
2009 flu pandemic | 1 | 4.3% |
Abortion | 1 | 4.3% |
Acupuncture | 1 | 4.3% |
Acute myeloid leukemia | 1 | 4.3% |
Ageing | 1 | 4.3% |
Alcoholism | 1 | 4.3% |
Allergic bronchopulmonary aspergillosis | 1 | 4.3% |
Alternative medicine | 1 | 4.3% |
Alzheimer's disease | 1 | 4.3% |
Anatomical terms of motion | 1 | 4.3% |
Anesthesia | 1 | 4.3% |
Anesthesiology | 1 | 4.3% |
Angiology | 1 | 4.3% |
Animal bacterial diseases | 1 | 4.3% |
Antibiotic | 1 | 4.3% |
Anticonvulsant | 1 | 4.3% |
Antileukotriene | 1 | 4.3% |
Antimicrobial resistance | 1 | 4.3% |
Antiphospholipid syndrome | 1 | 4.3% |
Aortic stenosis | 1 | 4.3% |
Aortic valve | 1 | 4.3% |
Aortic valve replacement | 1 | 4.3% |
Artificial cardiac pacemaker | 1 | 4.3% |
Atopy | 1 | 4.3% |
Atrial fibrillation | 1 | 4.3% |
Attention | 1 | 4.3% |
Automated external defibrillator | 1 | 4.3% |
BRCA mutation | 1 | 4.3% |
Bariatric surgery | 1 | 4.3% |
Best practice | 1 | 4.3% |
Beta2-adrenergic agonist | 1 | 4.3% |
Biosafety | 1 | 4.3% |
Birth control | 1 | 4.3% |
Blinded experiment | 1 | 4.3% |
Blood pressure | 1 | 4.3% |
Bone marrow | 1 | 4.3% |
Breastfeeding | 1 | 4.3% |
Bronchitis | 1 | 4.3% |
Cancer syndrome | 1 | 4.3% |
Cardiac arrest | 1 | 4.3% |
Cardiac resynchronization therapy | 1 | 4.3% |
Cardiology | 1 | 4.3% |
Cardiopulmonary resuscitation | 1 | 4.3% |
Case–control study | 1 | 4.3% |
Cervical cancer | 1 | 4.3% |
Chemicals in medicine | 1 | 4.3% |
Chemotherapy | 1 | 4.3% |
Chest pain | 1 | 4.3% |
Chronic myelomonocytic leukemia | 1 | 4.3% |
Circulatory system | 1 | 4.3% |
Cirrhosis | 1 | 4.3% |
Cognitive behavioral therapy | 1 | 4.3% |
Cohort study | 1 | 4.3% |
Combined oral contraceptive pill | 1 | 4.3% |
Community | 1 | 4.3% |
Community health | 1 | 4.3% |
Condom | 1 | 4.3% |
Continuing medical education | 1 | 4.3% |
Contrast (vision) | 1 | 4.3% |
Coronary artery disease | 1 | 4.3% |
Coronavirus disease 2019 | 1 | 4.3% |
Cystic fibrosis | 1 | 4.3% |
Cystic fibrosis transmembrane conductance regulator | 1 | 4.3% |
DPT vaccine | 1 | 4.3% |
Deep vein thrombosis | 1 | 4.3% |
Defibrillation | 1 | 4.3% |
Delirium | 1 | 4.3% |
Dementia | 1 | 4.3% |
Diabetes | 1 | 4.3% |
Diabetes mellitus | 1 | 4.3% |
Diagnosis of HIV/AIDS | 1 | 4.3% |
Dietary supplement | 1 | 4.3% |
Direct-to-consumer advertising | 1 | 4.3% |
Disability | 1 | 4.3% |
Disease management (health) | 1 | 4.3% |
Down syndrome | 1 | 4.3% |
Driving | 1 | 4.3% |
Drug | 1 | 4.3% |
Drugs | 1 | 4.3% |
Electronic health record | 1 | 4.3% |
Emergency contraception | 1 | 4.3% |
Endometrial cancer | 1 | 4.3% |
Epidural administration | 1 | 4.3% |
Eradication of infectious diseases | 1 | 4.3% |
Etomidate | 1 | 4.3% |
Executive dysfunction | 1 | 4.3% |
Exercise | 1 | 4.3% |
Exhaled nitric oxide | 1 | 4.3% |
Eye chart | 1 | 4.3% |
Factor V Leiden | 1 | 4.3% |
False advertising | 1 | 4.3% |
Flu season | 1 | 4.3% |
Food | 1 | 4.3% |
Food safety | 1 | 4.3% |
Foodborne illness | 1 | 4.3% |
Genetic marker | 1 | 4.3% |
Gestational trophoblastic disease | 1 | 4.3% |
Glaucoma | 1 | 4.3% |
Global Outbreak Alert and Response Network | 1 | 4.3% |
Goal | 1 | 4.3% |
Headache | 1 | 4.3% |
Health claim | 1 | 4.3% |
Health equity | 1 | 4.3% |
Health informatics | 1 | 4.3% |
Health professional | 1 | 4.3% |
Health research | 1 | 4.3% |
Health system | 1 | 4.3% |
Heart arrhythmia | 1 | 4.3% |
Heart failure | 1 | 4.3% |
Heart rate | 1 | 4.3% |
Hematopoietic stem cell transplantation | 1 | 4.3% |
Hepatocellular carcinoma | 1 | 4.3% |
Hormonal contraception | 1 | 4.3% |
Hospital | 1 | 4.3% |
Hypoglycemia | 1 | 4.3% |
ISM band | 1 | 4.3% |
Immunization | 1 | 4.3% |
Implantable cardioverter-defibrillator | 1 | 4.3% |
Infection control | 1 | 4.3% |
Inflammatory bowel disease | 1 | 4.3% |
Influenza A virus subtype H3N2 | 1 | 4.3% |
Intensive care medicine | 1 | 4.3% |
Intensive care unit | 1 | 4.3% |
Internal medicine | 1 | 4.3% |
Internal validity | 1 | 4.3% |
International Health Regulations | 1 | 4.3% |
Intracranial pressure | 1 | 4.3% |
Isoniazid | 1 | 4.3% |
Laboratory | 1 | 4.3% |
Lamotrigine | 1 | 4.3% |
Leukemia | 1 | 4.3% |
Leukotriene | 1 | 4.3% |
Levonorgestrel | 1 | 4.3% |
Logic model | 1 | 4.3% |
MMR vaccine | 1 | 4.3% |
Management of HIV/AIDS | 1 | 4.3% |
Maternal health | 1 | 4.3% |
Measles | 1 | 4.3% |
Medical device | 1 | 4.3% |
Medical error | 1 | 4.3% |
Medical statistics | 1 | 4.3% |
Medicinal chemistry | 1 | 4.3% |
Medroxyprogesterone acetate | 1 | 4.3% |
Memory | 1 | 4.3% |
Menopause | 1 | 4.3% |
Mental disorder | 1 | 4.3% |
Mental health | 1 | 4.3% |
Metered-dose inhaler | 1 | 4.3% |
Mid-level practitioner | 1 | 4.3% |
Miscarriage | 1 | 4.3% |
Monitoring and evaluation | 1 | 4.3% |
Mycobacteria | 1 | 4.3% |
Myelodysplastic syndrome | 1 | 4.3% |
Nebulizer | 1 | 4.3% |
Neoplasms | 1 | 4.3% |
Nervous system | 1 | 4.3% |
Neurology | 1 | 4.3% |
Newborn screening | 1 | 4.3% |
Nursing | 1 | 4.3% |
OIE/FAO Network of Expertise on Animal Influenza | 1 | 4.3% |
Old age | 1 | 4.3% |
Omalizumab | 1 | 4.3% |
Opioid | 1 | 4.3% |
Oseltamivir | 1 | 4.3% |
Pain management | 1 | 4.3% |
Pandemic | 1 | 4.3% |
Patient-controlled analgesia | 1 | 4.3% |
Pelvic inflammatory disease | 1 | 4.3% |
Percutaneous aortic valve replacement | 1 | 4.3% |
Performance indicator | 1 | 4.3% |
Personalized medicine | 1 | 4.3% |
Pharmaceutical sciences | 1 | 4.3% |
Pharmacology | 1 | 4.3% |
Pharmacy | 1 | 4.3% |
Physical therapy | 1 | 4.3% |
Physician | 1 | 4.3% |
Placebo | 1 | 4.3% |
Placebo-controlled study | 1 | 4.3% |
Pneumococcal conjugate vaccine | 1 | 4.3% |
Pneumococcal vaccine | 1 | 4.3% |
Point of care | 1 | 4.3% |
Positive airway pressure | 1 | 4.3% |
Prenatal testing | 1 | 4.3% |
Prevention of HIV/AIDS | 1 | 4.3% |
Privacy | 1 | 4.3% |
Procedural sedation and analgesia | 1 | 4.3% |
Proteinuria | 1 | 4.3% |
Prothrombin G20210A | 1 | 4.3% |
Pyrazinamide | 1 | 4.3% |
RTT | 1 | 4.3% |
Race (human categorization) | 1 | 4.3% |
Radio spectrum | 1 | 4.3% |
Registered nurse | 1 | 4.3% |
Remifentanil | 1 | 4.3% |
Reproductive health | 1 | 4.3% |
Rifampicin | 1 | 4.3% |
Road traffic safety | 1 | 4.3% |
Safety | 1 | 4.3% |
Scientific control | 1 | 4.3% |
Sedation | 1 | 4.3% |
Sexual health | 1 | 4.3% |
Sham surgery | 1 | 4.3% |
Sideroblastic anemia | 1 | 4.3% |
Sleep disorder | 1 | 4.3% |
Snellen chart | 1 | 4.3% |
Specialty (medicine) | 1 | 4.3% |
Substance abuse | 1 | 4.3% |
Superfund | 1 | 4.3% |
Syncope (medicine) | 1 | 4.3% |
Syndemic | 1 | 4.3% |
Syphilis | 1 | 4.3% |
Systemic lupus erythematosus | 1 | 4.3% |
Technology | 1 | 4.3% |
Telecommunication | 1 | 4.3% |
Telehealth | 1 | 4.3% |
Test (assessment) | 1 | 4.3% |
Thorax (human anatomy) | 1 | 4.3% |
Thrombophilia | 1 | 4.3% |
Thrombosis | 1 | 4.3% |
Traditional Chinese medicine | 1 | 4.3% |
Traffic collision | 1 | 4.3% |
Transmission (medicine) | 1 | 4.3% |
Transmission and infection of H5N1 | 1 | 4.3% |
Traumatic brain injury | 1 | 4.3% |
Tuberculosis management | 1 | 4.3% |
Type 2 diabetes | 1 | 4.3% |
Vaccination | 1 | 4.3% |
Vaccine-preventable diseases | 1 | 4.3% |
Vaccines for Children Program | 1 | 4.3% |
Valvular heart disease | 1 | 4.3% |
Venous thrombosis | 1 | 4.3% |
Ventricular tachycardia | 1 | 4.3% |
Visual acuity | 1 | 4.3% |
Visual impairment | 1 | 4.3% |
Vital signs | 1 | 4.3% |
Weight loss | 1 | 4.3% |
Wireless | 1 | 4.3% |
Women's health | 1 | 4.3% |
Working memory | 1 | 4.3% |
World Wide Web | 1 | 4.3% |
Zileuton | 1 | 4.3% |
ΔF508 | 1 | 4.3% |
abs | rel | |
---|---|---|
Health sciences | 28 | 100.0% |
Medicine | 28 | 100.0% |
Health | 27 | 96.4% |
Health care | 25 | 89.3% |
Medical specialties | 25 | 89.3% |
Clinical medicine | 23 | 82.1% |
Public health | 16 | 57.1% |
Risk | 16 | 57.1% |
Diseases and disorders | 13 | 46.4% |
Epidemiology | 13 | 46.4% |
Disease | 11 | 39.3% |
Preventive healthcare | 11 | 39.3% |
Evidence-based medicine | 10 | 35.7% |
Cancer | 7 | 25.0% |
Cardiovascular disease | 7 | 25.0% |
Dietary supplement | 7 | 25.0% |
Human activities | 7 | 25.0% |
Infection | 7 | 25.0% |
Medical guideline | 7 | 25.0% |
Obesity | 7 | 25.0% |
Randomized controlled trial | 7 | 25.0% |
Research | 7 | 25.0% |
Systematic review | 7 | 25.0% |
Vaccine | 7 | 25.0% |
Biology | 6 | 21.4% |
Medical humanities | 6 | 21.4% |
Screening (medicine) | 6 | 21.4% |
Sensitivity and specificity | 6 | 21.4% |
Stroke | 6 | 21.4% |
Adjuvant therapy | 5 | 17.9% |
Cholesterol | 5 | 17.9% |
Clinical trial | 5 | 17.9% |
Coronary artery disease | 5 | 17.9% |
Evaluation | 5 | 17.9% |
Health policy | 5 | 17.9% |
Influenza | 5 | 17.9% |
Myocardial infarction | 5 | 17.9% |
Risk assessment | 5 | 17.9% |
Body mass index | 4 | 14.3% |
Breast cancer | 4 | 14.3% |
Cardiovascular system | 4 | 14.3% |
Chronic condition | 4 | 14.3% |
Diabetes | 4 | 14.3% |
Evidence-based practice | 4 | 14.3% |
Exercise | 4 | 14.3% |
Health economics | 4 | 14.3% |
Hierarchy of evidence | 4 | 14.3% |
High-density lipoprotein | 4 | 14.3% |
Hypertension | 4 | 14.3% |
Infectious diseases | 4 | 14.3% |
Life sciences | 4 | 14.3% |
Medical imaging | 4 | 14.3% |
Medication | 4 | 14.3% |
Saturated fat | 4 | 14.3% |
Science | 4 | 14.3% |
Therapy | 4 | 14.3% |
Transmission (medicine) | 4 | 14.3% |
Virus | 4 | 14.3% |
Weight loss | 4 | 14.3% |
ACE inhibitor | 3 | 10.7% |
Adherence (medicine) | 3 | 10.7% |
Aspirin | 3 | 10.7% |
Beta blocker | 3 | 10.7% |
Bevacizumab | 3 | 10.7% |
Blood pressure | 3 | 10.7% |
CT scan | 3 | 10.7% |
Cardiology | 3 | 10.7% |
Chemotherapy | 3 | 10.7% |
Colorectal cancer | 3 | 10.7% |
Diabetes mellitus | 3 | 10.7% |
Eicosapentaenoic acid | 3 | 10.7% |
Fish oil | 3 | 10.7% |
Genetic counseling | 3 | 10.7% |
Genetic testing | 3 | 10.7% |
HIV/AIDS | 3 | 10.7% |
Health professional | 3 | 10.7% |
Heart | 3 | 10.7% |
Immunology | 3 | 10.7% |
MMR vaccine | 3 | 10.7% |
Measles | 3 | 10.7% |
Medical diagnosis | 3 | 10.7% |
Medical treatments | 3 | 10.7% |
Meningococcal disease | 3 | 10.7% |
Meta-analysis | 3 | 10.7% |
Microbiology | 3 | 10.7% |
Neoplasms | 3 | 10.7% |
Omega-3 fatty acid | 3 | 10.7% |
Ovarian cancer | 3 | 10.7% |
Patient | 3 | 10.7% |
Pre-eclampsia | 3 | 10.7% |
Prediabetes | 3 | 10.7% |
Radiation therapy | 3 | 10.7% |
Statin | 3 | 10.7% |
Type 2 diabetes | 3 | 10.7% |
Acute coronary syndrome | 2 | 7.1% |
Angiotensin II receptor blocker | 2 | 7.1% |
Anthrax | 2 | 7.1% |
Antihypertensive drug | 2 | 7.1% |
Assumption | 2 | 7.1% |
Atherosclerosis | 2 | 7.1% |
Atrial fibrillation | 2 | 7.1% |
BRCA mutation | 2 | 7.1% |
Bisphosphonate | 2 | 7.1% |
Bone | 2 | 7.1% |
C-reactive protein | 2 | 7.1% |
Cancer syndrome | 2 | 7.1% |
Cognition | 2 | 7.1% |
Dabigatran | 2 | 7.1% |
Dengue fever | 2 | 7.1% |
Denosumab | 2 | 7.1% |
Diabetes mellitus type 2 | 2 | 7.1% |
Dieting | 2 | 7.1% |
Drugs | 2 | 7.1% |
Dual-energy X-ray absorptiometry | 2 | 7.1% |
Epidemic | 2 | 7.1% |
Exemestane | 2 | 7.1% |
Expert | 2 | 7.1% |
Fetus | 2 | 7.1% |
Framingham Risk Score | 2 | 7.1% |
Gene | 2 | 7.1% |
Genetics | 2 | 7.1% |
Health care quality | 2 | 7.1% |
Health equity | 2 | 7.1% |
Health informatics | 2 | 7.1% |
Healthy diet | 2 | 7.1% |
Heart failure | 2 | 7.1% |
Hispanic and Latino Americans | 2 | 7.1% |
Inquiry | 2 | 7.1% |
Listeriosis | 2 | 7.1% |
Low-density lipoprotein | 2 | 7.1% |
Magnetic resonance imaging | 2 | 7.1% |
Major depressive disorder | 2 | 7.1% |
Medical test | 2 | 7.1% |
Metabolic syndrome | 2 | 7.1% |
Neisseria meningitidis | 2 | 7.1% |
Neoplasm | 2 | 7.1% |
Nursing | 2 | 7.1% |
Osteoporosis | 2 | 7.1% |
Pay for performance (healthcare) | 2 | 7.1% |
Performance appraisal | 2 | 7.1% |
Point of care | 2 | 7.1% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 2 | 7.1% |
Pregnancy | 2 | 7.1% |
Prostate cancer | 2 | 7.1% |
Quality | 2 | 7.1% |
Quality-adjusted life year | 2 | 7.1% |
Radiology | 2 | 7.1% |
Reference range | 2 | 7.1% |
Research methods | 2 | 7.1% |
Reverse transcription polymerase chain reaction | 2 | 7.1% |
Risk management | 2 | 7.1% |
Rubella | 2 | 7.1% |
SBAR | 2 | 7.1% |
Subacute sclerosing panencephalitis | 2 | 7.1% |
Surgery | 2 | 7.1% |
Surveillance | 2 | 7.1% |
Tamoxifen | 2 | 7.1% |
Teriparatide | 2 | 7.1% |
Testicular cancer | 2 | 7.1% |
Thiazide | 2 | 7.1% |
Tuberculosis | 2 | 7.1% |
Uncertainty | 2 | 7.1% |
Validity (statistics) | 2 | 7.1% |
Viral hemorrhagic fever | 2 | 7.1% |
Vitamin D | 2 | 7.1% |
Whole grain | 2 | 7.1% |
Zoledronic acid | 2 | 7.1% |
ALARP | 1 | 3.6% |
Absorbed dose | 1 | 3.6% |
Accuracy and precision | 1 | 3.6% |
Adenoviridae | 1 | 3.6% |
Adverse effect | 1 | 3.6% |
Aedes aegypti | 1 | 3.6% |
Aedes albopictus | 1 | 3.6% |
Anastrozole | 1 | 3.6% |
Angina | 1 | 3.6% |
Angiography | 1 | 3.6% |
Angiology | 1 | 3.6% |
Angiotensin-converting enzyme | 1 | 3.6% |
Anti-diabetic medication | 1 | 3.6% |
Antibody | 1 | 3.6% |
Antimalarial medication | 1 | 3.6% |
Antimicrobial resistance | 1 | 3.6% |
Antioxidant | 1 | 3.6% |
Antiplatelet drug | 1 | 3.6% |
Antiplatelet drugs | 1 | 3.6% |
Antithrombotic agents | 1 | 3.6% |
Antiviral drug | 1 | 3.6% |
Anti–vascular endothelial growth factor therapy | 1 | 3.6% |
Arbovirus | 1 | 3.6% |
Aromatase inhibitor | 1 | 3.6% |
Artesunate | 1 | 3.6% |
Asthma | 1 | 3.6% |
Attention | 1 | 3.6% |
Automated external defibrillator | 1 | 3.6% |
BRCA1 | 1 | 3.6% |
BRCA2 | 1 | 3.6% |
Bariatric surgery | 1 | 3.6% |
Behavior | 1 | 3.6% |
Best practice | 1 | 3.6% |
Biobank | 1 | 3.6% |
Biochemistry | 1 | 3.6% |
Biomarker | 1 | 3.6% |
Biopsy | 1 | 3.6% |
Biotechnology | 1 | 3.6% |
Bird migration | 1 | 3.6% |
Birth defect | 1 | 3.6% |
Bladder cancer | 1 | 3.6% |
Bleeding | 1 | 3.6% |
Blood lipids | 1 | 3.6% |
Blood sugar level | 1 | 3.6% |
Bone density | 1 | 3.6% |
Bone metastasis | 1 | 3.6% |
Bone resorption | 1 | 3.6% |
Branches of science | 1 | 3.6% |
Bunyavirales | 1 | 3.6% |
CA-125 | 1 | 3.6% |
Caesarean section | 1 | 3.6% |
Cancer survivor | 1 | 3.6% |
Cangrelor | 1 | 3.6% |
Carbohydrate | 1 | 3.6% |
Cardiac arrest | 1 | 3.6% |
Cardiac rehabilitation | 1 | 3.6% |
Cardiovascular diseases | 1 | 3.6% |
Caregiver | 1 | 3.6% |
Carrion crow | 1 | 3.6% |
Cataract | 1 | 3.6% |
Cereal | 1 | 3.6% |
Chikungunya | 1 | 3.6% |
Childbirth | 1 | 3.6% |
Chloroquine | 1 | 3.6% |
Cholecalciferol | 1 | 3.6% |
Choroidal neovascularization | 1 | 3.6% |
Chronic kidney disease | 1 | 3.6% |
Chronic obstructive pulmonary disease | 1 | 3.6% |
Clinical audit | 1 | 3.6% |
Clinical commissioning group | 1 | 3.6% |
Clopidogrel | 1 | 3.6% |
Colonoscopy | 1 | 3.6% |
Community | 1 | 3.6% |
Community health | 1 | 3.6% |
Comorbidity | 1 | 3.6% |
Complement system | 1 | 3.6% |
Computed tomography angiography | 1 | 3.6% |
Confidence interval | 1 | 3.6% |
Contact tracing | 1 | 3.6% |
Contrast (vision) | 1 | 3.6% |
Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine | 1 | 3.6% |
Cost-effectiveness analysis | 1 | 3.6% |
Cost–benefit analysis | 1 | 3.6% |
Crimean–Congo hemorrhagic fever | 1 | 3.6% |
Crown-rump length | 1 | 3.6% |
Culex | 1 | 3.6% |
Culture | 1 | 3.6% |
Curriculum | 1 | 3.6% |
Cutaneous leishmaniasis | 1 | 3.6% |
DNA sequencing | 1 | 3.6% |
DNA vaccination | 1 | 3.6% |
DPT vaccine | 1 | 3.6% |
Data sharing | 1 | 3.6% |
Database | 1 | 3.6% |
Death | 1 | 3.6% |
Dengue vaccine | 1 | 3.6% |
Dengue virus | 1 | 3.6% |
Determinants of health | 1 | 3.6% |
Diabetes management | 1 | 3.6% |
Diarrhea | 1 | 3.6% |
Dietary fiber | 1 | 3.6% |
Dietitian | 1 | 3.6% |
Diffusion of innovations | 1 | 3.6% |
Director general | 1 | 3.6% |
Down syndrome | 1 | 3.6% |
Doxycycline | 1 | 3.6% |
Drusen | 1 | 3.6% |
ELISA | 1 | 3.6% |
Ebola virus disease | 1 | 3.6% |
Echocardiography | 1 | 3.6% |
Ecology | 1 | 3.6% |
Economic model | 1 | 3.6% |
Education | 1 | 3.6% |
Electronic health record | 1 | 3.6% |
Embryo transfer | 1 | 3.6% |
Emergency department | 1 | 3.6% |
Empiricism | 1 | 3.6% |
Employment | 1 | 3.6% |
Empowerment | 1 | 3.6% |
Epigenetics | 1 | 3.6% |
Epilepsy | 1 | 3.6% |
Errors and residuals | 1 | 3.6% |
Ethics | 1 | 3.6% |
Extensively drug-resistant tuberculosis | 1 | 3.6% |
Eye care | 1 | 3.6% |
Factor H | 1 | 3.6% |
False positives and false negatives | 1 | 3.6% |
Family medicine | 1 | 3.6% |
Fixation (histology) | 1 | 3.6% |
Flu season | 1 | 3.6% |
Fruit | 1 | 3.6% |
Fundus photography | 1 | 3.6% |
General practitioner | 1 | 3.6% |
Genomics | 1 | 3.6% |
Gestational age | 1 | 3.6% |
Gestational diabetes | 1 | 3.6% |
Global health | 1 | 3.6% |
Glucose test | 1 | 3.6% |
Glucose tolerance test | 1 | 3.6% |
Glycated hemoglobin | 1 | 3.6% |
Glycemic index | 1 | 3.6% |
Goal | 1 | 3.6% |
Gonorrhea | 1 | 3.6% |
HER2/neu | 1 | 3.6% |
HIV | 1 | 3.6% |
HIV vaccine | 1 | 3.6% |
Headache | 1 | 3.6% |
Health care management | 1 | 3.6% |
Health human resources | 1 | 3.6% |
Health insurance coverage in the United States | 1 | 3.6% |
Health literacy | 1 | 3.6% |
Health system | 1 | 3.6% |
Healthcare in the Netherlands | 1 | 3.6% |
Healthcare management | 1 | 3.6% |
Healthcare quality | 1 | 3.6% |
Hematuria | 1 | 3.6% |
Hepatitis | 1 | 3.6% |
Hepatitis B vaccine | 1 | 3.6% |
Hereditary nonpolyposis colorectal cancer | 1 | 3.6% |
Hip fracture | 1 | 3.6% |
Hispanic paradox | 1 | 3.6% |
History | 1 | 3.6% |
Hormonal therapy (oncology) | 1 | 3.6% |
Hormone replacement therapy | 1 | 3.6% |
Hospital | 1 | 3.6% |
Human eye | 1 | 3.6% |
Human pregnancy | 1 | 3.6% |
Human reproduction | 1 | 3.6% |
Hypercholesterolemia | 1 | 3.6% |
Hyperglycemia | 1 | 3.6% |
Immunization | 1 | 3.6% |
Immunohistochemistry | 1 | 3.6% |
In vitro fertilisation | 1 | 3.6% |
Incremental cost-effectiveness ratio | 1 | 3.6% |
Index case | 1 | 3.6% |
Infant mortality | 1 | 3.6% |
Influenza A virus subtype H3N2 | 1 | 3.6% |
Influenza pandemic | 1 | 3.6% |
Influenza prevention | 1 | 3.6% |
Influenza vaccine | 1 | 3.6% |
Information | 1 | 3.6% |
Information technology | 1 | 3.6% |
Infusion pump | 1 | 3.6% |
Innovation | 1 | 3.6% |
Institutional review board | 1 | 3.6% |
Insulin resistance | 1 | 3.6% |
Interdisciplinarity | 1 | 3.6% |
Internal medicine | 1 | 3.6% |
Internet | 1 | 3.6% |
Intima-media thickness | 1 | 3.6% |
Intracytoplasmic sperm injection | 1 | 3.6% |
Intravitreal administration | 1 | 3.6% |
Ionizing radiation | 1 | 3.6% |
Japanese encephalitis | 1 | 3.6% |
Ki-67 (protein) | 1 | 3.6% |
Laboratory | 1 | 3.6% |
Laser coagulation | 1 | 3.6% |
Lassa fever | 1 | 3.6% |
Law | 1 | 3.6% |
Leadership | 1 | 3.6% |
Learning | 1 | 3.6% |
Leishmaniasis | 1 | 3.6% |
Life expectancy | 1 | 3.6% |
Linear no-threshold model | 1 | 3.6% |
Liraglutide | 1 | 3.6% |
Literacy | 1 | 3.6% |
Lujo mammarenavirus | 1 | 3.6% |
Lumbar vertebrae | 1 | 3.6% |
Lung cancer | 1 | 3.6% |
Lutein | 1 | 3.6% |
Lymphadenectomy | 1 | 3.6% |
MEDLINE | 1 | 3.6% |
Macula of retina | 1 | 3.6% |
Macular degeneration | 1 | 3.6% |
Macular telangiectasia | 1 | 3.6% |
Malaria | 1 | 3.6% |
Malaria vaccine | 1 | 3.6% |
Mammalian pregnancy | 1 | 3.6% |
Management | 1 | 3.6% |
Management of acute coronary syndrome | 1 | 3.6% |
Marburg virus | 1 | 3.6% |
Marburg virus disease | 1 | 3.6% |
Marketing | 1 | 3.6% |
Maternal health | 1 | 3.6% |
Maternal–fetal medicine | 1 | 3.6% |
Medicaid | 1 | 3.6% |
Medical and health organizations | 1 | 3.6% |
Medical device | 1 | 3.6% |
Medical genetics | 1 | 3.6% |
Medical physics | 1 | 3.6% |
Medical record | 1 | 3.6% |
Medical ultrasound | 1 | 3.6% |
Meningitis | 1 | 3.6% |
Meningococcal vaccine | 1 | 3.6% |
Menopause | 1 | 3.6% |
Mental health | 1 | 3.6% |
Metastasis | 1 | 3.6% |
Metastatic breast cancer | 1 | 3.6% |
Metformin | 1 | 3.6% |
Missing data | 1 | 3.6% |
Mosquito | 1 | 3.6% |
Mosquito-borne disease | 1 | 3.6% |
Motherhood | 1 | 3.6% |
Multiple birth | 1 | 3.6% |
NHS foundation trust | 1 | 3.6% |
Natural reservoir | 1 | 3.6% |
Needs assessment | 1 | 3.6% |
Neonatal intensive care unit | 1 | 3.6% |
Neovascularization | 1 | 3.6% |
Neurology | 1 | 3.6% |
Newborn screening | 1 | 3.6% |
Nuclear proliferation | 1 | 3.6% |
Nutrition | 1 | 3.6% |
Nutritionist | 1 | 3.6% |
Obstetric ultrasonography | 1 | 3.6% |
Obstetrics | 1 | 3.6% |
Ophthalmology | 1 | 3.6% |
Organisms | 1 | 3.6% |
Orthohantavirus | 1 | 3.6% |
Osteonecrosis of the jaw | 1 | 3.6% |
Osteopenia | 1 | 3.6% |
Outcomes research | 1 | 3.6% |
Oxaliplatin | 1 | 3.6% |
Palliative care | 1 | 3.6% |
Pandemic | 1 | 3.6% |
Paromomycin | 1 | 3.6% |
Patient Protection and Affordable Care Act | 1 | 3.6% |
Patient safety | 1 | 3.6% |
Pegaptanib | 1 | 3.6% |
Perception | 1 | 3.6% |
Percutaneous coronary intervention | 1 | 3.6% |
Personalized medicine | 1 | 3.6% |
Pharmacogenomics | 1 | 3.6% |
Pharmacology | 1 | 3.6% |
Pharmacy | 1 | 3.6% |
Physical activity | 1 | 3.6% |
Physician | 1 | 3.6% |
Pioglitazone | 1 | 3.6% |
Plasmodium | 1 | 3.6% |
Plasmodium falciparum | 1 | 3.6% |
Plasmodium vivax | 1 | 3.6% |
Policy | 1 | 3.6% |
Population health | 1 | 3.6% |
Positron emission tomography | 1 | 3.6% |
Post-exposure prophylaxis | 1 | 3.6% |
Prasugrel | 1 | 3.6% |
Premature rupture of membranes | 1 | 3.6% |
Prenatal care | 1 | 3.6% |
Prenatal development | 1 | 3.6% |
Preterm birth | 1 | 3.6% |
Primaquine | 1 | 3.6% |
Privacy | 1 | 3.6% |
Proliferative index | 1 | 3.6% |
Prosthesis | 1 | 3.6% |
Protocol (science) | 1 | 3.6% |
Psychiatry | 1 | 3.6% |
Public health genomics | 1 | 3.6% |
Public sphere | 1 | 3.6% |
Quantitative computed tomography | 1 | 3.6% |
RTS,S | 1 | 3.6% |
Race and ethnicity in the United States Census | 1 | 3.6% |
Radiation protection | 1 | 3.6% |
Raloxifene | 1 | 3.6% |
Ranibizumab | 1 | 3.6% |
Rare disease | 1 | 3.6% |
Regression analysis | 1 | 3.6% |
Renal cell carcinoma | 1 | 3.6% |
Retina | 1 | 3.6% |
Rift Valley fever | 1 | 3.6% |
Root-mean-square deviation | 1 | 3.6% |
Rosiglitazone | 1 | 3.6% |
Scanning laser ophthalmoscopy | 1 | 3.6% |
Scientific method | 1 | 3.6% |
Scrub typhus | 1 | 3.6% |
Selective estrogen receptor modulator | 1 | 3.6% |
Severe acute respiratory syndrome | 1 | 3.6% |
Severe acute respiratory syndrome coronavirus | 1 | 3.6% |
Sexually transmitted infection | 1 | 3.6% |
Sheep | 1 | 3.6% |
Sibling | 1 | 3.6% |
Sievert | 1 | 3.6% |
Smoking cessation | 1 | 3.6% |
Social marketing | 1 | 3.6% |
Social science | 1 | 3.6% |
Socioeconomic status | 1 | 3.6% |
Staining | 1 | 3.6% |
Stakeholder (corporate) | 1 | 3.6% |
Standard deviation | 1 | 3.6% |
Strontium ranelate | 1 | 3.6% |
Subarachnoid hemorrhage | 1 | 3.6% |
Surface epithelial-stromal tumor | 1 | 3.6% |
Surgical mask | 1 | 3.6% |
Survey methodology | 1 | 3.6% |
Symptom | 1 | 3.6% |
Syphilis | 1 | 3.6% |
Technology | 1 | 3.6% |
Ticagrelor | 1 | 3.6% |
Tourniquet | 1 | 3.6% |
Transient ischemic attack | 1 | 3.6% |
Translational medicine | 1 | 3.6% |
Translational research | 1 | 3.6% |
Twin | 1 | 3.6% |
Typhoid fever | 1 | 3.6% |
Urology | 1 | 3.6% |
Usability | 1 | 3.6% |
Usability testing | 1 | 3.6% |
Vaccination | 1 | 3.6% |
Vasospasm | 1 | 3.6% |
Vector (epidemiology) | 1 | 3.6% |
Vegetable | 1 | 3.6% |
Vertebral augmentation | 1 | 3.6% |
Vision | 1 | 3.6% |
Visual acuity | 1 | 3.6% |
Visual impairment | 1 | 3.6% |
Visual system | 1 | 3.6% |
Vitamin | 1 | 3.6% |
Vitamin E | 1 | 3.6% |
Warfarin | 1 | 3.6% |
Weight management | 1 | 3.6% |
West Nile fever | 1 | 3.6% |
West Nile virus | 1 | 3.6% |
Whole genome sequencing | 1 | 3.6% |
Women's health | 1 | 3.6% |
World Wide Web | 1 | 3.6% |
Yellow fever | 1 | 3.6% |
Zeaxanthin | 1 | 3.6% |
Zoonosis | 1 | 3.6% |
abs | rel | |
---|---|---|
Medical specialties | 63 | 100.0% |
Medicine | 63 | 100.0% |
Health | 62 | 98.4% |
Health sciences | 61 | 96.8% |
Clinical medicine | 59 | 93.7% |
Health care | 54 | 85.7% |
Public health | 36 | 57.1% |
Diseases and disorders | 32 | 50.8% |
Infection | 25 | 39.7% |
Preventive healthcare | 24 | 38.1% |
Epidemiology | 21 | 33.3% |
Risk | 20 | 31.7% |
Disease | 16 | 25.4% |
HIV/AIDS | 16 | 25.4% |
Infectious diseases | 15 | 23.8% |
Immunology | 14 | 22.2% |
Medical humanities | 14 | 22.2% |
Myocardial infarction | 13 | 20.6% |
Evidence-based medicine | 12 | 19.0% |
Health economics | 12 | 19.0% |
Health professional | 12 | 19.0% |
Sensitivity and specificity | 12 | 19.0% |
Adherence (medicine) | 11 | 17.5% |
Health policy | 11 | 17.5% |
Microbiology | 11 | 17.5% |
Sexually transmitted infection | 11 | 17.5% |
Tuberculosis | 11 | 17.5% |
Biology | 10 | 15.9% |
Cardiovascular disease | 10 | 15.9% |
Coronary artery disease | 10 | 15.9% |
Hypertension | 10 | 15.9% |
Medical diagnosis | 10 | 15.9% |
Randomized controlled trial | 10 | 15.9% |
Antimicrobial resistance | 9 | 14.3% |
Cancer | 9 | 14.3% |
Cardiovascular system | 9 | 14.3% |
Human reproduction | 9 | 14.3% |
Pneumonia | 9 | 14.3% |
Pregnancy | 9 | 14.3% |
Surgery | 9 | 14.3% |
Systematic review | 9 | 14.3% |
Therapy | 9 | 14.3% |
Chronic condition | 8 | 12.7% |
Heart | 8 | 12.7% |
Management of HIV/AIDS | 8 | 12.7% |
Blood pressure | 7 | 11.1% |
Cardiology | 7 | 11.1% |
Human activities | 7 | 11.1% |
Medical guideline | 7 | 11.1% |
Meta-analysis | 7 | 11.1% |
Research | 7 | 11.1% |
Sexual health | 7 | 11.1% |
Stroke | 7 | 11.1% |
Antibiotic | 6 | 9.5% |
Diagnosis of HIV/AIDS | 6 | 9.5% |
Gonorrhea | 6 | 9.5% |
Life sciences | 6 | 9.5% |
Low-density lipoprotein | 6 | 9.5% |
Patient | 6 | 9.5% |
Percutaneous coronary intervention | 6 | 9.5% |
Screening (medicine) | 6 | 9.5% |
Women's health | 6 | 9.5% |
Childbirth | 5 | 7.9% |
Cholesterol | 5 | 7.9% |
Clinical trial | 5 | 7.9% |
Drugs | 5 | 7.9% |
Health system | 5 | 7.9% |
Hospital | 5 | 7.9% |
Immunodeficiency | 5 | 7.9% |
Obesity | 5 | 7.9% |
Public sphere | 5 | 7.9% |
RTT | 5 | 7.9% |
Statin | 5 | 7.9% |
Tropical medicine | 5 | 7.9% |
Acute coronary syndrome | 4 | 6.3% |
Adverse effect | 4 | 6.3% |
Anticoagulant | 4 | 6.3% |
Antihypertensive drug | 4 | 6.3% |
Breast cancer | 4 | 6.3% |
C-reactive protein | 4 | 6.3% |
CT scan | 4 | 6.3% |
Caregiver | 4 | 6.3% |
Clinical pathology | 4 | 6.3% |
Confidence interval | 4 | 6.3% |
Diabetes | 4 | 6.3% |
Electronic health record | 4 | 6.3% |
Emergency department | 4 | 6.3% |
Evaluation | 4 | 6.3% |
Fertility | 4 | 6.3% |
HIV | 4 | 6.3% |
Health informatics | 4 | 6.3% |
Health insurance coverage in the United States | 4 | 6.3% |
High-density lipoprotein | 4 | 6.3% |
Hypercholesterolemia | 4 | 6.3% |
Lentiviruses | 4 | 6.3% |
Malaria | 4 | 6.3% |
Medical statistics | 4 | 6.3% |
Medicare (United States) | 4 | 6.3% |
Nursing | 4 | 6.3% |
Quality-adjusted life year | 4 | 6.3% |
Safe sex | 4 | 6.3% |
Self-care | 4 | 6.3% |
Sepsis | 4 | 6.3% |
Transmission (medicine) | 4 | 6.3% |
Tuberculosis management | 4 | 6.3% |
Urology | 4 | 6.3% |
Vaccine | 4 | 6.3% |
Animal viral diseases | 3 | 4.8% |
Antibody | 3 | 4.8% |
Antimalarial medication | 3 | 4.8% |
Asthma | 3 | 4.8% |
Birth control | 3 | 4.8% |
Blinded experiment | 3 | 4.8% |
Blood transfusion | 3 | 4.8% |
Cervical cancer | 3 | 4.8% |
Chemotherapy | 3 | 4.8% |
Chlamydia infection | 3 | 4.8% |
Chronic obstructive pulmonary disease | 3 | 4.8% |
Clinical decision support system | 3 | 4.8% |
Cohort study | 3 | 4.8% |
Colorectal cancer | 3 | 4.8% |
Comorbidity | 3 | 4.8% |
Condom | 3 | 4.8% |
Diagnosis of malaria | 3 | 4.8% |
Diarrhea | 3 | 4.8% |
Dieting | 3 | 4.8% |
Directly observed treatment, short-course | 3 | 4.8% |
Disability | 3 | 4.8% |
ELISA | 3 | 4.8% |
Emergency contraception | 3 | 4.8% |
Exercise | 3 | 4.8% |
Family planning | 3 | 4.8% |
Fever | 3 | 4.8% |
Gynaecologic disorders | 3 | 4.8% |
Health information technology | 3 | 4.8% |
Heart failure | 3 | 4.8% |
Herpes simplex | 3 | 4.8% |
Hormonal contraception | 3 | 4.8% |
Human sexuality | 3 | 4.8% |
Infant | 3 | 4.8% |
Infertility | 3 | 4.8% |
Internal medicine | 3 | 4.8% |
Male genital disorders | 3 | 4.8% |
Medical test | 3 | 4.8% |
Medical treatments | 3 | 4.8% |
Medication | 3 | 4.8% |
Miscarriage | 3 | 4.8% |
Neisseria gonorrhoeae | 3 | 4.8% |
Nutrition | 3 | 4.8% |
Pharmacology | 3 | 4.8% |
Pharmacy | 3 | 4.8% |
Physician | 3 | 4.8% |
Plasmodium falciparum | 3 | 4.8% |
Plasmodium vivax | 3 | 4.8% |
Polymerase chain reaction | 3 | 4.8% |
Prediabetes | 3 | 4.8% |
Procalcitonin | 3 | 4.8% |
Rape | 3 | 4.8% |
Reporting bias | 3 | 4.8% |
Reproductive health | 3 | 4.8% |
Risk assessment | 3 | 4.8% |
Sexual intercourse | 3 | 4.8% |
Sexually transmitted diseases and infections | 3 | 4.8% |
Social programs | 3 | 4.8% |
Syphilis | 3 | 4.8% |
Trichomoniasis | 3 | 4.8% |
Type 2 diabetes | 3 | 4.8% |
Zidovudine | 3 | 4.8% |
Abortion | 2 | 3.2% |
Angina | 2 | 3.2% |
Angiology | 2 | 3.2% |
Angioplasty | 2 | 3.2% |
Angiotensin II receptor blocker | 2 | 3.2% |
Animals and humans | 2 | 3.2% |
Antiplatelet drug | 2 | 3.2% |
Aortic insufficiency | 2 | 3.2% |
Aortic stenosis | 2 | 3.2% |
Aortic valve | 2 | 3.2% |
Aortic valve replacement | 2 | 3.2% |
Apolipoprotein | 2 | 3.2% |
Artesunate | 2 | 3.2% |
Asepsis | 2 | 3.2% |
Aspirin | 2 | 3.2% |
Atrial fibrillation | 2 | 3.2% |
Atrium (heart) | 2 | 3.2% |
Bacteremia | 2 | 3.2% |
Bacterial vaginosis | 2 | 3.2% |
Balance (ability) | 2 | 3.2% |
Benzodiazepine | 2 | 3.2% |
Biomarker | 2 | 3.2% |
Biopsy | 2 | 3.2% |
Birth defect | 2 | 3.2% |
Blood donation | 2 | 3.2% |
Blood lipids | 2 | 3.2% |
Blood sugar level | 2 | 3.2% |
Breastfeeding | 2 | 3.2% |
Bronchitis | 2 | 3.2% |
Caesarean section | 2 | 3.2% |
Cardiac catheterization | 2 | 3.2% |
Cardiothoracic surgery | 2 | 3.2% |
Causes of death | 2 | 3.2% |
Central nervous system disorders | 2 | 3.2% |
Chickenpox | 2 | 3.2% |
Chlamydia trachomatis | 2 | 3.2% |
Circulatory system | 2 | 3.2% |
Clopidogrel | 2 | 3.2% |
Combined oral contraceptive pill | 2 | 3.2% |
Concussion | 2 | 3.2% |
Coronary artery bypass surgery | 2 | 3.2% |
Cost-effectiveness analysis | 2 | 3.2% |
Cystectomy | 2 | 3.2% |
Da Vinci Surgical System | 2 | 3.2% |
Depression (mood) | 2 | 3.2% |
Determinants of health | 2 | 3.2% |
Dietary supplement | 2 | 3.2% |
Disease management (health) | 2 | 3.2% |
Echocardiography | 2 | 3.2% |
Electrocardiography | 2 | 3.2% |
Environmental social science | 2 | 3.2% |
Epileptic seizure | 2 | 3.2% |
Foot-and-mouth disease | 2 | 3.2% |
Glycated hemoglobin | 2 | 3.2% |
HIV/AIDS in Africa | 2 | 3.2% |
Hand washing | 2 | 3.2% |
Head injury | 2 | 3.2% |
Health care quality | 2 | 3.2% |
Health technology in the United States | 2 | 3.2% |
Hepatitis | 2 | 3.2% |
Hepatitis A | 2 | 3.2% |
Hospital-acquired infection | 2 | 3.2% |
Human chorionic gonadotropin | 2 | 3.2% |
Human diseases and disorders | 2 | 3.2% |
Human sexual activity | 2 | 3.2% |
Hygiene | 2 | 3.2% |
Hysterectomy | 2 | 3.2% |
Incremental cost-effectiveness ratio | 2 | 3.2% |
Infection prevention and control | 2 | 3.2% |
Inflammation | 2 | 3.2% |
Influenza | 2 | 3.2% |
Injuries | 2 | 3.2% |
International Statistical Classification of Diseases and Related Health Problems | 2 | 3.2% |
Isolation (health care) | 2 | 3.2% |
Laboratory | 2 | 3.2% |
Lamivudine | 2 | 3.2% |
Laparoscopy | 2 | 3.2% |
Leukemia | 2 | 3.2% |
Lipoprotein | 2 | 3.2% |
Lymphoma | 2 | 3.2% |
Major depressive disorder | 2 | 3.2% |
Maternal health | 2 | 3.2% |
Measles | 2 | 3.2% |
Medicaid | 2 | 3.2% |
Medical record | 2 | 3.2% |
Men who have sex with men | 2 | 3.2% |
Meningitis | 2 | 3.2% |
Metabolic syndrome | 2 | 3.2% |
Methicillin-resistant Staphylococcus aureus | 2 | 3.2% |
Microscopy | 2 | 3.2% |
Midwife | 2 | 3.2% |
Mifepristone | 2 | 3.2% |
Minimally invasive procedure | 2 | 3.2% |
Multi-drug-resistant tuberculosis | 2 | 3.2% |
Nephrectomy | 2 | 3.2% |
Nervous system | 2 | 3.2% |
Neurological disorders | 2 | 3.2% |
Neurology | 2 | 3.2% |
Neutropenia | 2 | 3.2% |
Nevirapine | 2 | 3.2% |
Obstetrics | 2 | 3.2% |
Osteoporosis | 2 | 3.2% |
Ovarian cancer | 2 | 3.2% |
Parasitism | 2 | 3.2% |
Patient safety | 2 | 3.2% |
Pelvic inflammatory disease | 2 | 3.2% |
Percutaneous aortic valve replacement | 2 | 3.2% |
Personal protective equipment | 2 | 3.2% |
Plasmodium | 2 | 3.2% |
Positive and negative predictive values | 2 | 3.2% |
Post-traumatic amnesia | 2 | 3.2% |
Postpartum period | 2 | 3.2% |
Prasugrel | 2 | 3.2% |
Prenatal development | 2 | 3.2% |
Prenatal testing | 2 | 3.2% |
Preterm birth | 2 | 3.2% |
Prevention of HIV/AIDS | 2 | 3.2% |
Primary care | 2 | 3.2% |
Primary care physician | 2 | 3.2% |
Prostate cancer | 2 | 3.2% |
Prostatectomy | 2 | 3.2% |
Public services | 2 | 3.2% |
Radiation therapy | 2 | 3.2% |
Receiver operating characteristic | 2 | 3.2% |
Remote patient monitoring | 2 | 3.2% |
Reperfusion therapy | 2 | 3.2% |
Respiratory droplet | 2 | 3.2% |
Robot-assisted surgery | 2 | 3.2% |
Saturated fat | 2 | 3.2% |
Sheep | 2 | 3.2% |
Specialty (medicine) | 2 | 3.2% |
Staphylococcus aureus | 2 | 3.2% |
Surgical mask | 2 | 3.2% |
Survey methodology | 2 | 3.2% |
Tamoxifen | 2 | 3.2% |
Technology | 2 | 3.2% |
Telehealth | 2 | 3.2% |
Telepharmacy | 2 | 3.2% |
Thrombosis | 2 | 3.2% |
Ticagrelor | 2 | 3.2% |
Transmission-based precautions | 2 | 3.2% |
Trauma types | 2 | 3.2% |
Traumatic brain injury | 2 | 3.2% |
Traumatology | 2 | 3.2% |
Trichomonas vaginalis | 2 | 3.2% |
Unintended pregnancy | 2 | 3.2% |
Vaccination | 2 | 3.2% |
Vagina | 2 | 3.2% |
Vaginal discharge | 2 | 3.2% |
Vaginitis | 2 | 3.2% |
Valvular heart disease | 2 | 3.2% |
Vancomycin-resistant Enterococcus | 2 | 3.2% |
Vein | 2 | 3.2% |
Vertically transmitted infection | 2 | 3.2% |
Veterinarian | 2 | 3.2% |
Veterinary medicine | 2 | 3.2% |
Virus | 2 | 3.2% |
Weight loss | 2 | 3.2% |
2009 flu pandemic | 1 | 1.6% |
ABVD | 1 | 1.6% |
ACE inhibitor | 1 | 1.6% |
Abdominal obesity | 1 | 1.6% |
Accidents | 1 | 1.6% |
Aciclovir | 1 | 1.6% |
Acute myeloid leukemia | 1 | 1.6% |
Acute promyelocytic leukemia | 1 | 1.6% |
Adaptive immune system | 1 | 1.6% |
Adipose tissue | 1 | 1.6% |
Adjustable gastric band | 1 | 1.6% |
Adjuvant therapy | 1 | 1.6% |
Adolescence | 1 | 1.6% |
African Americans | 1 | 1.6% |
Airborne disease | 1 | 1.6% |
Airborne transmission | 1 | 1.6% |
Allocation concealment | 1 | 1.6% |
Alpha-fetoprotein | 1 | 1.6% |
Amiodarone | 1 | 1.6% |
Amnesia | 1 | 1.6% |
Amniocentesis | 1 | 1.6% |
Amodiaquine | 1 | 1.6% |
Anal sex | 1 | 1.6% |
Anaphylaxis | 1 | 1.6% |
Anaplastic oligodendroglioma | 1 | 1.6% |
Aneurysm | 1 | 1.6% |
Animal anatomy | 1 | 1.6% |
Animal diseases | 1 | 1.6% |
Anterograde amnesia | 1 | 1.6% |
Anthracycline | 1 | 1.6% |
Anthropometry | 1 | 1.6% |
Antibiotic prophylaxis | 1 | 1.6% |
Antidepressant | 1 | 1.6% |
Antigen | 1 | 1.6% |
Antineoplastic and immunomodulating drugs | 1 | 1.6% |
Antineoplastic drugs | 1 | 1.6% |
Aorta | 1 | 1.6% |
Aortic aneurysm | 1 | 1.6% |
Aortic dissection | 1 | 1.6% |
Aromatase inhibitor | 1 | 1.6% |
Artemisinin | 1 | 1.6% |
Artery | 1 | 1.6% |
Ascending aorta | 1 | 1.6% |
Astrocytoma | 1 | 1.6% |
Atherosclerosis | 1 | 1.6% |
Atrial septal defect | 1 | 1.6% |
Attention deficit hyperactivity disorder | 1 | 1.6% |
Audit | 1 | 1.6% |
Avian influenza | 1 | 1.6% |
B cell | 1 | 1.6% |
BRCA mutation | 1 | 1.6% |
BRCA1 | 1 | 1.6% |
Baby Friendly Hospital Initiative | 1 | 1.6% |
Background radiation | 1 | 1.6% |
Bareback (sex) | 1 | 1.6% |
Bariatric surgery | 1 | 1.6% |
Behavior | 1 | 1.6% |
Benznidazole | 1 | 1.6% |
Best practice | 1 | 1.6% |
Beta blocker | 1 | 1.6% |
Bevacizumab | 1 | 1.6% |
Bicuspid aortic valve | 1 | 1.6% |
Biomechanics | 1 | 1.6% |
Bisphosphonate | 1 | 1.6% |
Bivalirudin | 1 | 1.6% |
Bleeding | 1 | 1.6% |
Blood cell | 1 | 1.6% |
Blood glucose monitoring | 1 | 1.6% |
Blood plasma | 1 | 1.6% |
Blood pressure measurement | 1 | 1.6% |
Blood-borne disease | 1 | 1.6% |
Blunt trauma | 1 | 1.6% |
Bone | 1 | 1.6% |
Bone density | 1 | 1.6% |
Bone fracture | 1 | 1.6% |
Bone marrow | 1 | 1.6% |
Bone resorption | 1 | 1.6% |
Brain damage | 1 | 1.6% |
Brain natriuretic peptide | 1 | 1.6% |
Brain tumor | 1 | 1.6% |
Breast milk | 1 | 1.6% |
Breastfeeding and HIV | 1 | 1.6% |
CD4 | 1 | 1.6% |
Calcitonin | 1 | 1.6% |
Calcitriol | 1 | 1.6% |
Cancer pain | 1 | 1.6% |
Cancer prevention | 1 | 1.6% |
Cancer registry | 1 | 1.6% |
Cancer staging | 1 | 1.6% |
Cancer treatments | 1 | 1.6% |
Candidiasis | 1 | 1.6% |
Carboplatin | 1 | 1.6% |
Carcinoma | 1 | 1.6% |
Cardiac cycle | 1 | 1.6% |
Cardiac muscle | 1 | 1.6% |
Cardiac stress test | 1 | 1.6% |
Cardiac surgery | 1 | 1.6% |
Cardiovascular diseases | 1 | 1.6% |
Cardiovascular physiology | 1 | 1.6% |
Cardioversion | 1 | 1.6% |
Case management (US health system) | 1 | 1.6% |
Catheter | 1 | 1.6% |
Catheter ablation | 1 | 1.6% |
Central nervous system | 1 | 1.6% |
Central venous catheter | 1 | 1.6% |
Cervical screening | 1 | 1.6% |
Cervix | 1 | 1.6% |
Cetuximab | 1 | 1.6% |
Chagas disease | 1 | 1.6% |
Chancroid | 1 | 1.6% |
Childlessness | 1 | 1.6% |
Chlamydia | 1 | 1.6% |
Chlorhexidine | 1 | 1.6% |
Chloroquine | 1 | 1.6% |
Cholecystectomy | 1 | 1.6% |
Chronic kidney disease | 1 | 1.6% |
Chronic myelogenous leukemia | 1 | 1.6% |
Cirrhosis | 1 | 1.6% |
Clinic | 1 | 1.6% |
Closed-head injury | 1 | 1.6% |
Clostridioides difficile infection | 1 | 1.6% |
Coccidioidomycosis | 1 | 1.6% |
Cognition | 1 | 1.6% |
Coitus interruptus | 1 | 1.6% |
Coma | 1 | 1.6% |
Community health | 1 | 1.6% |
Community health worker | 1 | 1.6% |
Community-acquired pneumonia | 1 | 1.6% |
Confidentiality | 1 | 1.6% |
Conflict of interest | 1 | 1.6% |
Confounding | 1 | 1.6% |
Congenital syphilis | 1 | 1.6% |
Contrast-enhanced ultrasound | 1 | 1.6% |
Copper IUDs | 1 | 1.6% |
Coronary catheterization | 1 | 1.6% |
Cost–utility analysis | 1 | 1.6% |
Cough | 1 | 1.6% |
Creatinine | 1 | 1.6% |
Cryoablation | 1 | 1.6% |
Cryptococcosis | 1 | 1.6% |
Cryptosporidiosis | 1 | 1.6% |
Cystoisospora belli | 1 | 1.6% |
Cytotoxic T cell | 1 | 1.6% |
DNA | 1 | 1.6% |
DPT vaccine | 1 | 1.6% |
Dabigatran | 1 | 1.6% |
Data analysis | 1 | 1.6% |
Delirium | 1 | 1.6% |
Dementia | 1 | 1.6% |
Demographic and Health Surveys | 1 | 1.6% |
Denosumab | 1 | 1.6% |
Diabetes management | 1 | 1.6% |
Diabetes mellitus | 1 | 1.6% |
Diabetes mellitus type 2 | 1 | 1.6% |
Diabetic ketoacidosis | 1 | 1.6% |
Diabetic retinopathy | 1 | 1.6% |
Diagnostic and Statistical Manual of Mental Disorders | 1 | 1.6% |
Diastole | 1 | 1.6% |
Disorders of endocrine pancreas | 1 | 1.6% |
Docetaxel | 1 | 1.6% |
Domestic violence | 1 | 1.6% |
Doppler ultrasonography | 1 | 1.6% |
Dose (biochemistry) | 1 | 1.6% |
Down syndrome | 1 | 1.6% |
Doxorubicin | 1 | 1.6% |
Doxycycline | 1 | 1.6% |
Dual-energy X-ray absorptiometry | 1 | 1.6% |
Education | 1 | 1.6% |
Efavirenz | 1 | 1.6% |
Effect size | 1 | 1.6% |
Ejection fraction | 1 | 1.6% |
Electrical conduction system of the heart | 1 | 1.6% |
Emergency medicine | 1 | 1.6% |
Endocrine system | 1 | 1.6% |
Endocrine, nutritional and metabolic diseases | 1 | 1.6% |
Endogeneity (econometrics) | 1 | 1.6% |
Endometrial cancer | 1 | 1.6% |
Endometrium | 1 | 1.6% |
Endothelium | 1 | 1.6% |
Endovascular aneurysm repair | 1 | 1.6% |
Enterovirus-associated diseases | 1 | 1.6% |
Envelope glycoprotein GP120 | 1 | 1.6% |
Ependymoma | 1 | 1.6% |
Epidermal growth factor receptor | 1 | 1.6% |
Epidural administration | 1 | 1.6% |
Epilepsy | 1 | 1.6% |
Eptifibatide | 1 | 1.6% |
Eradication of infectious diseases | 1 | 1.6% |
Estriol | 1 | 1.6% |
Ethionamide | 1 | 1.6% |
Evidence-based policy | 1 | 1.6% |
Exocrine system | 1 | 1.6% |
Fall prevention | 1 | 1.6% |
Familial hypercholesterolemia | 1 | 1.6% |
Family medicine | 1 | 1.6% |
Fat | 1 | 1.6% |
Febrile neutropenia | 1 | 1.6% |
Fellatio | 1 | 1.6% |
Female condom | 1 | 1.6% |
Fenofibrate | 1 | 1.6% |
Fertility preservation | 1 | 1.6% |
Flu season | 1 | 1.6% |
Fludarabine | 1 | 1.6% |
Folate | 1 | 1.6% |
Food and drink | 1 | 1.6% |
Food fortification | 1 | 1.6% |
Frailty syndrome | 1 | 1.6% |
Framingham Risk Score | 1 | 1.6% |
Functional neurological symptom disorder | 1 | 1.6% |
Gametocyte | 1 | 1.6% |
Gastric bypass surgery | 1 | 1.6% |
Gastroenteritis | 1 | 1.6% |
Gefitinib | 1 | 1.6% |
Genetic counseling | 1 | 1.6% |
Genetic testing | 1 | 1.6% |
Genital herpes | 1 | 1.6% |
Genital wart | 1 | 1.6% |
Gentamicin | 1 | 1.6% |
Geriatrics | 1 | 1.6% |
Gestational age | 1 | 1.6% |
Gestational diabetes | 1 | 1.6% |
Gestrinone | 1 | 1.6% |
Glasgow Coma Scale | 1 | 1.6% |
Glioblastoma | 1 | 1.6% |
Glucose test | 1 | 1.6% |
Glucose tolerance test | 1 | 1.6% |
Gp41 | 1 | 1.6% |
Group B streptococcal infection | 1 | 1.6% |
Gynaecology | 1 | 1.6% |
HER2/neu | 1 | 1.6% |
HIV and pregnancy | 1 | 1.6% |
Hand sanitizer | 1 | 1.6% |
Hazard ratio | 1 | 1.6% |
Head and neck cancer | 1 | 1.6% |
Headache | 1 | 1.6% |
Health Information Technology for Economic and Clinical Health Act | 1 | 1.6% |
Health Insurance Portability and Accountability Act | 1 | 1.6% |
Health care in the United States | 1 | 1.6% |
Health insurance | 1 | 1.6% |
Health technology | 1 | 1.6% |
Health technology assessment | 1 | 1.6% |
Heart arrhythmia | 1 | 1.6% |
Heart murmur | 1 | 1.6% |
Heart rate | 1 | 1.6% |
Heart valve | 1 | 1.6% |
Hematopoietic stem cell transplantation | 1 | 1.6% |
Hemodialysis | 1 | 1.6% |
Hepatocellular carcinoma | 1 | 1.6% |
Hepatology | 1 | 1.6% |
Hereditary nonpolyposis colorectal cancer | 1 | 1.6% |
Hierarchy of evidence | 1 | 1.6% |
Histoplasmosis | 1 | 1.6% |
History of cancer chemotherapy | 1 | 1.6% |
Hodgkin lymphoma | 1 | 1.6% |
Homosexuality | 1 | 1.6% |
Hormonal therapy (oncology) | 1 | 1.6% |
Hormone replacement therapy | 1 | 1.6% |
Hospital-acquired pneumonia | 1 | 1.6% |
Human anatomy | 1 | 1.6% |
Human cytomegalovirus | 1 | 1.6% |
Human female reproductive system | 1 | 1.6% |
Human papillomavirus infection | 1 | 1.6% |
Human pregnancy | 1 | 1.6% |
Human subject research | 1 | 1.6% |
Humoral immunity | 1 | 1.6% |
Hyperglycemia | 1 | 1.6% |
Hyperparathyroidism | 1 | 1.6% |
Hypertriglyceridemia | 1 | 1.6% |
Hypnotic | 1 | 1.6% |
Hypoglycemia | 1 | 1.6% |
Hypokalemia | 1 | 1.6% |
Hypothyroidism | 1 | 1.6% |
Immune system | 1 | 1.6% |
Immunization | 1 | 1.6% |
Immunocontraception | 1 | 1.6% |
Infant formula | 1 | 1.6% |
Infection control | 1 | 1.6% |
Influenza A virus subtype H1N1 | 1 | 1.6% |
Influenza A virus subtype H3N2 | 1 | 1.6% |
Influenza A virus subtype H5N1 | 1 | 1.6% |
Influenza pandemic | 1 | 1.6% |
Influenza research | 1 | 1.6% |
Influenza vaccine | 1 | 1.6% |
Informed consent | 1 | 1.6% |
Insect-borne diseases | 1 | 1.6% |
Insulin | 1 | 1.6% |
Insulin pump | 1 | 1.6% |
Insulin resistance | 1 | 1.6% |
Intensive care medicine | 1 | 1.6% |
Intensive care unit | 1 | 1.6% |
Inter-rater reliability | 1 | 1.6% |
Interventional radiology | 1 | 1.6% |
Intraclass correlation | 1 | 1.6% |
Intracranial hemorrhage | 1 | 1.6% |
Intrauterine device | 1 | 1.6% |
Intravenous therapy | 1 | 1.6% |
Ischemia | 1 | 1.6% |
Isoniazid | 1 | 1.6% |
Isosporiasis | 1 | 1.6% |
KRAS | 1 | 1.6% |
Kaposi's sarcoma | 1 | 1.6% |
Labor induction | 1 | 1.6% |
Laparoscopic radical prostatectomy | 1 | 1.6% |
Lapatinib | 1 | 1.6% |
Lenalidomide | 1 | 1.6% |
Leukorrhea | 1 | 1.6% |
Levonorgestrel | 1 | 1.6% |
Levothyroxine | 1 | 1.6% |
Liver | 1 | 1.6% |
Low birth weight | 1 | 1.6% |
Low-carbohydrate diet | 1 | 1.6% |
Lower respiratory tract infection | 1 | 1.6% |
Lung cancer | 1 | 1.6% |
Lymph node | 1 | 1.6% |
Lymphatic system | 1 | 1.6% |
Lymphocyte | 1 | 1.6% |
MEDLINE | 1 | 1.6% |
MMR vaccine | 1 | 1.6% |
MRI contrast agent | 1 | 1.6% |
Macrophage | 1 | 1.6% |
Magnesium deficiency | 1 | 1.6% |
Magnetic resonance imaging | 1 | 1.6% |
Malaria antigen detection tests | 1 | 1.6% |
Malnutrition | 1 | 1.6% |
Mammalian sexuality | 1 | 1.6% |
Mammography | 1 | 1.6% |
Management of acute coronary syndrome | 1 | 1.6% |
Management of atrial fibrillation | 1 | 1.6% |
Management of hypertension | 1 | 1.6% |
Marfan syndrome | 1 | 1.6% |
Mass drug administration | 1 | 1.6% |
Maternal death | 1 | 1.6% |
Medical abortion | 1 | 1.6% |
Medical emergencies | 1 | 1.6% |
Medical equipment | 1 | 1.6% |
Medical equipment management | 1 | 1.6% |
Medical history | 1 | 1.6% |
Medical imaging | 1 | 1.6% |
Medical physics | 1 | 1.6% |
Medical prescription | 1 | 1.6% |
Medical specialty | 1 | 1.6% |
Medical tests | 1 | 1.6% |
Medical ultrasound | 1 | 1.6% |
Medroxyprogesterone acetate | 1 | 1.6% |
Medulloblastoma | 1 | 1.6% |
Mefloquine | 1 | 1.6% |
Memory | 1 | 1.6% |
Menopause | 1 | 1.6% |
Menstrual cycle | 1 | 1.6% |
Mental disorder | 1 | 1.6% |
Mental status examination | 1 | 1.6% |
Metabolic disorders | 1 | 1.6% |
Metastasis | 1 | 1.6% |
Metformin | 1 | 1.6% |
Methylenetetrahydrofolate reductase | 1 | 1.6% |
Midwifery | 1 | 1.6% |
Misoprostol | 1 | 1.6% |
Mitral insufficiency | 1 | 1.6% |
Mitral valve | 1 | 1.6% |
Mitral valve annuloplasty | 1 | 1.6% |
Mitral valve stenosis | 1 | 1.6% |
Molecular biology | 1 | 1.6% |
Monocyte | 1 | 1.6% |
Mortality rate | 1 | 1.6% |
Mucositis | 1 | 1.6% |
Multiple myeloma | 1 | 1.6% |
Mycobacterium | 1 | 1.6% |
Mycoplasma | 1 | 1.6% |
Myelodysplastic syndrome | 1 | 1.6% |
Myeloma protein | 1 | 1.6% |
Myocardial perfusion imaging | 1 | 1.6% |
N95 respirator | 1 | 1.6% |
National Health Interview Survey | 1 | 1.6% |
National coverage determination | 1 | 1.6% |
Natural reservoir | 1 | 1.6% |
Nausea | 1 | 1.6% |
Needlestick injury | 1 | 1.6% |
Needs assessment | 1 | 1.6% |
Negative room pressure | 1 | 1.6% |
Neglected tropical diseases | 1 | 1.6% |
Neonatal infection | 1 | 1.6% |
Neonatal sepsis | 1 | 1.6% |
Neoplasms | 1 | 1.6% |
Neural tube defect | 1 | 1.6% |
Neurosurgery | 1 | 1.6% |
Neurotrauma | 1 | 1.6% |
Niacin | 1 | 1.6% |
Nicotine | 1 | 1.6% |
Nifurtimox | 1 | 1.6% |
Non-communicable disease | 1 | 1.6% |
Nonoxynol-9 | 1 | 1.6% |
Nuchal scan | 1 | 1.6% |
Nurse practitioner | 1 | 1.6% |
Nursing home care | 1 | 1.6% |
Obstetric ultrasonography | 1 | 1.6% |
Occupational safety and health | 1 | 1.6% |
Oligoastrocytoma | 1 | 1.6% |
Oligodendroglioma | 1 | 1.6% |
Opioid | 1 | 1.6% |
Organ transplantation | 1 | 1.6% |
Organs (anatomy) | 1 | 1.6% |
Orthopedic surgery | 1 | 1.6% |
Osteopenia | 1 | 1.6% |
Outcomes research | 1 | 1.6% |
Outlier | 1 | 1.6% |
P2Y12 | 1 | 1.6% |
Paclitaxel | 1 | 1.6% |
Pain | 1 | 1.6% |
Pain management | 1 | 1.6% |
Palliative care | 1 | 1.6% |
Pancreatic cancer | 1 | 1.6% |
Parathyroid hormone | 1 | 1.6% |
Pathology | 1 | 1.6% |
Payment Card Industry Data Security Standard | 1 | 1.6% |
Pediatrics | 1 | 1.6% |
Pelvic examination | 1 | 1.6% |
Performance indicator | 1 | 1.6% |
Peripheral neuropathy | 1 | 1.6% |
Peripherally inserted central catheter | 1 | 1.6% |
Phagocyte | 1 | 1.6% |
Phagocytosis | 1 | 1.6% |
Pharmaceutical formulation | 1 | 1.6% |
Phases of clinical research | 1 | 1.6% |
Physical therapy | 1 | 1.6% |
Physician assistant | 1 | 1.6% |
Physiology | 1 | 1.6% |
Plasma cell | 1 | 1.6% |
Plasmacytoma | 1 | 1.6% |
Pneumocystis pneumonia | 1 | 1.6% |
Point of care | 1 | 1.6% |
Polio vaccine | 1 | 1.6% |
Poliomyelitis | 1 | 1.6% |
Poliomyelitis eradication | 1 | 1.6% |
Post-exposure prophylaxis | 1 | 1.6% |
Post-traumatic seizure | 1 | 1.6% |
Pre-eclampsia | 1 | 1.6% |
Prenatal care | 1 | 1.6% |
Prevention | 1 | 1.6% |
Preventive medicine | 1 | 1.6% |
Pricing | 1 | 1.6% |
Primaquine | 1 | 1.6% |
Progressive multifocal leukoencephalopathy | 1 | 1.6% |
Proguanil | 1 | 1.6% |
Protein | 1 | 1.6% |
Protozoal diseases | 1 | 1.6% |
Psychometrics | 1 | 1.6% |
Psychosis | 1 | 1.6% |
Psychotherapy | 1 | 1.6% |
Public health genomics | 1 | 1.6% |
Public health surveillance | 1 | 1.6% |
Pulmonary hypertension | 1 | 1.6% |
Pyrazinamide | 1 | 1.6% |
QRISK | 1 | 1.6% |
Quality assurance | 1 | 1.6% |
Quality of life | 1 | 1.6% |
Quality of life (healthcare) | 1 | 1.6% |
Quantitative computed tomography | 1 | 1.6% |
Quinine | 1 | 1.6% |
RANKL | 1 | 1.6% |
RNA | 1 | 1.6% |
Race and ethnicity in the United States Census | 1 | 1.6% |
Radiofrequency ablation | 1 | 1.6% |
Radiology | 1 | 1.6% |
Raloxifene | 1 | 1.6% |
Real-time polymerase chain reaction | 1 | 1.6% |
Rectal prolapse | 1 | 1.6% |
Red blood cell | 1 | 1.6% |
Relative risk | 1 | 1.6% |
Reliability (statistics) | 1 | 1.6% |
Respiratory tract infection | 1 | 1.6% |
Retirement | 1 | 1.6% |
Retrograde amnesia | 1 | 1.6% |
Retrovirus | 1 | 1.6% |
Reverse-transcriptase inhibitor | 1 | 1.6% |
Rheumatic fever | 1 | 1.6% |
Rifampicin | 1 | 1.6% |
Risk management | 1 | 1.6% |
Ritonavir | 1 | 1.6% |
Rubella | 1 | 1.6% |
Rubella vaccine | 1 | 1.6% |
Sarcoma | 1 | 1.6% |
Scatter plot | 1 | 1.6% |
Scientific control | 1 | 1.6% |
Sedative | 1 | 1.6% |
Selective estrogen receptor modulator | 1 | 1.6% |
Septic shock | 1 | 1.6% |
Serology | 1 | 1.6% |
Severe acute respiratory syndrome | 1 | 1.6% |
Sexology | 1 | 1.6% |
Sexual emotions | 1 | 1.6% |
Sexual orientation | 1 | 1.6% |
Sexual violence | 1 | 1.6% |
Sexuality | 1 | 1.6% |
Shingles | 1 | 1.6% |
Sievert | 1 | 1.6% |
Sinoatrial node | 1 | 1.6% |
Skull fracture | 1 | 1.6% |
Small-cell carcinoma | 1 | 1.6% |
Smoking cessation | 1 | 1.6% |
Social stigma | 1 | 1.6% |
Spermatozoon | 1 | 1.6% |
Spermicide | 1 | 1.6% |
Sphygmomanometer | 1 | 1.6% |
Stanol ester | 1 | 1.6% |
Statistics | 1 | 1.6% |
Stavudine | 1 | 1.6% |
Sterilization (medicine) | 1 | 1.6% |
Streptococcus | 1 | 1.6% |
Streptococcus agalactiae | 1 | 1.6% |
Strontium ranelate | 1 | 1.6% |
Study heterogeneity | 1 | 1.6% |
Subdural hematoma | 1 | 1.6% |
Substance abuse | 1 | 1.6% |
Surface epithelial-stromal tumor | 1 | 1.6% |
Surgical specialties | 1 | 1.6% |
Surveillance | 1 | 1.6% |
Systole | 1 | 1.6% |
T cell | 1 | 1.6% |
T helper cell | 1 | 1.6% |
Temozolomide | 1 | 1.6% |
Teriparatide | 1 | 1.6% |
Tetanus | 1 | 1.6% |
Tetanus vaccine | 1 | 1.6% |
Thorax (human anatomy) | 1 | 1.6% |
Thymus | 1 | 1.6% |
Toxoplasmosis | 1 | 1.6% |
Transient ischemic attack | 1 | 1.6% |
Trastuzumab | 1 | 1.6% |
Triage | 1 | 1.6% |
Triatominae | 1 | 1.6% |
Tricuspid insufficiency | 1 | 1.6% |
Tricuspid valve | 1 | 1.6% |
Triple test | 1 | 1.6% |
Tropical diseases | 1 | 1.6% |
Troponin | 1 | 1.6% |
Trypanosoma | 1 | 1.6% |
Trypanosoma cruzi | 1 | 1.6% |
Trypanosoma lewisi | 1 | 1.6% |
Type 1 diabetes | 1 | 1.6% |
Universal precautions | 1 | 1.6% |
Unsafe abortion | 1 | 1.6% |
Urinary incontinence | 1 | 1.6% |
Urological conditions | 1 | 1.6% |
Uterine prolapse | 1 | 1.6% |
Uterus | 1 | 1.6% |
Vacuum aspiration | 1 | 1.6% |
Validity (statistics) | 1 | 1.6% |
Vector (epidemiology) | 1 | 1.6% |
Venous access | 1 | 1.6% |
Venous thrombosis | 1 | 1.6% |
Ventilator-associated pneumonia | 1 | 1.6% |
Ventricle (heart) | 1 | 1.6% |
Violence | 1 | 1.6% |
Violence against women | 1 | 1.6% |
Viral infections of the central nervous system | 1 | 1.6% |
Viral load | 1 | 1.6% |
Viral respiratory tract infections | 1 | 1.6% |
Virology | 1 | 1.6% |
Vitamin D | 1 | 1.6% |
Wart | 1 | 1.6% |
Western blot | 1 | 1.6% |
White Americans | 1 | 1.6% |
White blood cell | 1 | 1.6% |
Whitehall Study | 1 | 1.6% |
Woman | 1 | 1.6% |
Wound | 1 | 1.6% |
X-ray | 1 | 1.6% |
Zoledronic acid | 1 | 1.6% |
abs | rel | |
---|---|---|
Health | 40 | 97.6% |
Health sciences | 36 | 87.8% |
Medicine | 36 | 87.8% |
Medical specialties | 35 | 85.4% |
Clinical medicine | 34 | 82.9% |
Health care | 29 | 70.7% |
Public health | 18 | 43.9% |
Disease | 13 | 31.7% |
Preventive healthcare | 13 | 31.7% |
Diseases and disorders | 12 | 29.3% |
Infection | 12 | 29.3% |
Risk | 12 | 29.3% |
Cancer | 11 | 26.8% |
Epidemiology | 11 | 26.8% |
Medical guideline | 10 | 24.4% |
Health economics | 8 | 19.5% |
Health system | 8 | 19.5% |
Randomized controlled trial | 8 | 19.5% |
Clinical trial | 7 | 17.1% |
Cohort study | 7 | 17.1% |
Evidence-based medicine | 7 | 17.1% |
Health professional | 7 | 17.1% |
Hospital | 7 | 17.1% |
Meta-analysis | 7 | 17.1% |
Patient | 7 | 17.1% |
Research | 7 | 17.1% |
Screening (medicine) | 7 | 17.1% |
Biology | 6 | 14.6% |
Chronic condition | 6 | 14.6% |
Heart | 6 | 14.6% |
Medical diagnosis | 6 | 14.6% |
Systematic review | 6 | 14.6% |
Cancer screening | 5 | 12.2% |
Cardiology | 5 | 12.2% |
Cardiovascular disease | 5 | 12.2% |
Community health | 5 | 12.2% |
Emergency department | 5 | 12.2% |
HIV/AIDS | 5 | 12.2% |
Health policy | 5 | 12.2% |
Infectious diseases | 5 | 12.2% |
Medicare (United States) | 5 | 12.2% |
Myocardial infarction | 5 | 12.2% |
Pain | 5 | 12.2% |
Physician | 5 | 12.2% |
Surgery | 5 | 12.2% |
Therapy | 5 | 12.2% |
Tuberculosis | 5 | 12.2% |
Antimicrobial resistance | 4 | 9.8% |
Cardiovascular system | 4 | 9.8% |
Colorectal cancer | 4 | 9.8% |
Coronary artery disease | 4 | 9.8% |
GeneXpert MTB/RIF | 4 | 9.8% |
Hospital readmission | 4 | 9.8% |
Human activities | 4 | 9.8% |
Internal medicine | 4 | 9.8% |
Medical humanities | 4 | 9.8% |
Medication | 4 | 9.8% |
Microbiology | 4 | 9.8% |
Palliative care | 4 | 9.8% |
Patient safety | 4 | 9.8% |
Primary care | 4 | 9.8% |
Sensitivity and specificity | 4 | 9.8% |
Statistics | 4 | 9.8% |
Substance abuse | 4 | 9.8% |
Adverse effect | 3 | 7.3% |
Angiology | 3 | 7.3% |
Angiotensin II receptor blocker | 3 | 7.3% |
Best practice | 3 | 7.3% |
Bias | 3 | 7.3% |
Biomarker | 3 | 7.3% |
Blinded experiment | 3 | 7.3% |
Breast cancer | 3 | 7.3% |
Cardiovascular physiology | 3 | 7.3% |
Clinic | 3 | 7.3% |
Comorbidity | 3 | 7.3% |
Confidence interval | 3 | 7.3% |
Evaluation | 3 | 7.3% |
Exercise | 3 | 7.3% |
HIV | 3 | 7.3% |
Health care quality | 3 | 7.3% |
Health informatics | 3 | 7.3% |
Hepatitis C | 3 | 7.3% |
Human reproduction | 3 | 7.3% |
Hypertension | 3 | 7.3% |
Immunology | 3 | 7.3% |
Medical imaging | 3 | 7.3% |
Medical treatments | 3 | 7.3% |
Mental health | 3 | 7.3% |
Multi-drug-resistant tuberculosis | 3 | 7.3% |
Nursing | 3 | 7.3% |
Pregnancy | 3 | 7.3% |
Prostate cancer | 3 | 7.3% |
Psychiatry | 3 | 7.3% |
Receiver operating characteristic | 3 | 7.3% |
Sampling (statistics) | 3 | 7.3% |
Sexually transmitted infection | 3 | 7.3% |
ACE inhibitor | 2 | 4.9% |
Acute coronary syndrome | 2 | 4.9% |
Acute kidney injury | 2 | 4.9% |
Adherence (medicine) | 2 | 4.9% |
Analgesic | 2 | 4.9% |
Angina | 2 | 4.9% |
Animal viral diseases | 2 | 4.9% |
Antiplatelet drug | 2 | 4.9% |
Arrhythmia | 2 | 4.9% |
Artificial cardiac pacemaker | 2 | 4.9% |
Aspirin | 2 | 4.9% |
Asthma | 2 | 4.9% |
Audit | 2 | 4.9% |
Behavior | 2 | 4.9% |
Blood donation | 2 | 4.9% |
Blood pressure | 2 | 4.9% |
Brain natriuretic peptide | 2 | 4.9% |
Cancer prevention | 2 | 4.9% |
Cancer survivor | 2 | 4.9% |
Cardiovascular diseases | 2 | 4.9% |
Caregiver | 2 | 4.9% |
Childbirth | 2 | 4.9% |
Cholesterol | 2 | 4.9% |
Chronic kidney disease | 2 | 4.9% |
Circulatory system | 2 | 4.9% |
Clinical pathology | 2 | 4.9% |
Clopidogrel | 2 | 4.9% |
Cochrane Library | 2 | 4.9% |
Colonoscopy | 2 | 4.9% |
Confounding | 2 | 4.9% |
Correlation and dependence | 2 | 4.9% |
Dentistry | 2 | 4.9% |
Diabetes | 2 | 4.9% |
Diagnosis of HIV/AIDS | 2 | 4.9% |
Directly observed treatment, short-course | 2 | 4.9% |
ELISA | 2 | 4.9% |
Electronic health record | 2 | 4.9% |
Emergency medicine | 2 | 4.9% |
Extensively drug-resistant tuberculosis | 2 | 4.9% |
Fecal occult blood | 2 | 4.9% |
Flavivirus | 2 | 4.9% |
Fluoride varnish | 2 | 4.9% |
General practitioner | 2 | 4.9% |
Glycated hemoglobin | 2 | 4.9% |
Gynaecologic disorders | 2 | 4.9% |
Health equity | 2 | 4.9% |
Health insurance coverage in the United States | 2 | 4.9% |
Health promotion | 2 | 4.9% |
Healthcare shortage area | 2 | 4.9% |
Heart failure | 2 | 4.9% |
Hepatitis | 2 | 4.9% |
High-density lipoprotein | 2 | 4.9% |
Hyperthyroidism | 2 | 4.9% |
Immunodeficiency | 2 | 4.9% |
Inflammation | 2 | 4.9% |
Information | 2 | 4.9% |
Innovation | 2 | 4.9% |
Kidney | 2 | 4.9% |
Kidney failure | 2 | 4.9% |
Knee replacement | 2 | 4.9% |
Lentiviruses | 2 | 4.9% |
Life sciences | 2 | 4.9% |
Low-density lipoprotein | 2 | 4.9% |
Lung cancer | 2 | 4.9% |
Malaria | 2 | 4.9% |
Male genital disorders | 2 | 4.9% |
Mammography | 2 | 4.9% |
Management of HIV/AIDS | 2 | 4.9% |
Medicaid | 2 | 4.9% |
Medical home | 2 | 4.9% |
Medical test | 2 | 4.9% |
Mental disorder | 2 | 4.9% |
Neonatal intensive care unit | 2 | 4.9% |
Neoplasms | 2 | 4.9% |
Nonsteroidal anti-inflammatory drug | 2 | 4.9% |
Obesity | 2 | 4.9% |
Odds ratio | 2 | 4.9% |
Pain management | 2 | 4.9% |
Paracetamol | 2 | 4.9% |
Parameter | 2 | 4.9% |
Pathology | 2 | 4.9% |
Percutaneous coronary intervention | 2 | 4.9% |
Periodontology | 2 | 4.9% |
Peripheral neuropathy | 2 | 4.9% |
Pharmacy | 2 | 4.9% |
Physical therapy | 2 | 4.9% |
Physiology | 2 | 4.9% |
Positive and negative predictive values | 2 | 4.9% |
Poverty | 2 | 4.9% |
Prison | 2 | 4.9% |
Prostate-specific antigen | 2 | 4.9% |
Public hospital | 2 | 4.9% |
Renal function | 2 | 4.9% |
Reporting bias | 2 | 4.9% |
Respiratory disease | 2 | 4.9% |
Sensitivity analysis | 2 | 4.9% |
Sexual health | 2 | 4.9% |
Sexually transmitted diseases and infections | 2 | 4.9% |
Statin | 2 | 4.9% |
Stroke | 2 | 4.9% |
Tax | 2 | 4.9% |
Telehealth | 2 | 4.9% |
Tooth decay | 2 | 4.9% |
Transmission (medicine) | 2 | 4.9% |
Tuberculosis in relation to HIV | 2 | 4.9% |
Tuberculosis management | 2 | 4.9% |
Variance | 2 | 4.9% |
Vein | 2 | 4.9% |
Venous thrombosis | 2 | 4.9% |
Water fluoridation | 2 | 4.9% |
West Nile fever | 2 | 4.9% |
West Nile virus | 2 | 4.9% |
Abacavir | 1 | 2.4% |
Accountable care organization | 1 | 2.4% |
Acetylcysteine | 1 | 2.4% |
Acromegaly | 1 | 2.4% |
Acupuncture | 1 | 2.4% |
Addiction | 1 | 2.4% |
Adolescence | 1 | 2.4% |
Adverse event | 1 | 2.4% |
Aldosterone | 1 | 2.4% |
Allocation concealment | 1 | 2.4% |
Alternative medicine | 1 | 2.4% |
Alzheimer's disease | 1 | 2.4% |
Amiodarone | 1 | 2.4% |
Amphotericin B | 1 | 2.4% |
Anemia | 1 | 2.4% |
Anesthesia | 1 | 2.4% |
Anesthesiology | 1 | 2.4% |
Antiarrhythmic agent | 1 | 2.4% |
Anticoagulant | 1 | 2.4% |
Antimalarial medication | 1 | 2.4% |
Antiretroviral drugs | 1 | 2.4% |
Antiviral drug | 1 | 2.4% |
Apolipoprotein A1 | 1 | 2.4% |
Aromatase inhibitor | 1 | 2.4% |
Artemisinin | 1 | 2.4% |
Artesunate | 1 | 2.4% |
Assay | 1 | 2.4% |
Atherosclerosis | 1 | 2.4% |
Atrial fibrillation | 1 | 2.4% |
Atrial flutter | 1 | 2.4% |
Autocorrelation | 1 | 2.4% |
Autoimmune disease | 1 | 2.4% |
BRCA mutation | 1 | 2.4% |
Balance (ability) | 1 | 2.4% |
Bareback (sex) | 1 | 2.4% |
Bellman equation | 1 | 2.4% |
Benign prostatic hyperplasia | 1 | 2.4% |
Beta blocker | 1 | 2.4% |
Big data | 1 | 2.4% |
Binomial distribution | 1 | 2.4% |
Biobank | 1 | 2.4% |
Biomarker (medicine) | 1 | 2.4% |
Biomedical engineering | 1 | 2.4% |
Biopsy | 1 | 2.4% |
Biotechnology | 1 | 2.4% |
Birth | 1 | 2.4% |
Bivalirudin | 1 | 2.4% |
Blood | 1 | 2.4% |
Blood film | 1 | 2.4% |
Blood sugar level | 1 | 2.4% |
Botulism | 1 | 2.4% |
Bradycardia | 1 | 2.4% |
C-reactive protein | 1 | 2.4% |
CHA2DS2–VASc score | 1 | 2.4% |
CMA-ES | 1 | 2.4% |
Cachexia | 1 | 2.4% |
Caesarean section | 1 | 2.4% |
Calcium channel blocker | 1 | 2.4% |
Cancer pain | 1 | 2.4% |
Cancer registry | 1 | 2.4% |
Cardiac arrest | 1 | 2.4% |
Cardiac electrophysiology | 1 | 2.4% |
Cardiac rehabilitation | 1 | 2.4% |
Cardiac resynchronization therapy | 1 | 2.4% |
Cardiotocography | 1 | 2.4% |
Cardioversion | 1 | 2.4% |
Case management (US health system) | 1 | 2.4% |
Case–control study | 1 | 2.4% |
Catheter ablation | 1 | 2.4% |
Central limit theorem | 1 | 2.4% |
Cervical cancer | 1 | 2.4% |
Cervical screening | 1 | 2.4% |
Chemotherapy | 1 | 2.4% |
Childhood | 1 | 2.4% |
Childhood cancer | 1 | 2.4% |
Chlamydia | 1 | 2.4% |
Chloride | 1 | 2.4% |
Choking | 1 | 2.4% |
Chronic care | 1 | 2.4% |
Chronic pain | 1 | 2.4% |
Cigarette | 1 | 2.4% |
Cirrhosis | 1 | 2.4% |
Clinical commissioning group | 1 | 2.4% |
Codeine | 1 | 2.4% |
Cohen's kappa | 1 | 2.4% |
Collaboration | 1 | 2.4% |
Communication | 1 | 2.4% |
Community health worker | 1 | 2.4% |
Computer science | 1 | 2.4% |
Congenital iodine deficiency syndrome | 1 | 2.4% |
Consensus decision-making | 1 | 2.4% |
Coronary artery bypass surgery | 1 | 2.4% |
Crizotinib | 1 | 2.4% |
Cross-sectional study | 1 | 2.4% |
Curriculum | 1 | 2.4% |
DNA sequencing | 1 | 2.4% |
Dabigatran | 1 | 2.4% |
Decision-making | 1 | 2.4% |
Deep vein thrombosis | 1 | 2.4% |
Dementia | 1 | 2.4% |
Dental sealant | 1 | 2.4% |
Dependent and independent variables | 1 | 2.4% |
Determinants of health | 1 | 2.4% |
Dexamethasone | 1 | 2.4% |
Diagnosis of malaria | 1 | 2.4% |
Dialysis | 1 | 2.4% |
Diastole | 1 | 2.4% |
Diclofenac | 1 | 2.4% |
Digital health | 1 | 2.4% |
Digoxin | 1 | 2.4% |
Diltiazem | 1 | 2.4% |
Disability | 1 | 2.4% |
Disease management (health) | 1 | 2.4% |
District nurse | 1 | 2.4% |
Dose (biochemistry) | 1 | 2.4% |
Dronedarone | 1 | 2.4% |
Drug discovery | 1 | 2.4% |
Drug education | 1 | 2.4% |
Drug-eluting stent | 1 | 2.4% |
Drugs | 1 | 2.4% |
Economic model | 1 | 2.4% |
Economics | 1 | 2.4% |
Education | 1 | 2.4% |
Elective surgery | 1 | 2.4% |
Electrocardiography | 1 | 2.4% |
Electronic prescribing | 1 | 2.4% |
Employment | 1 | 2.4% |
Endoscopy | 1 | 2.4% |
Entrepreneurship | 1 | 2.4% |
Environmental social science | 1 | 2.4% |
Epidemic | 1 | 2.4% |
Epidemiology of HIV/AIDS | 1 | 2.4% |
Epidural administration | 1 | 2.4% |
Eptifibatide | 1 | 2.4% |
Errors and residuals | 1 | 2.4% |
Esophagus | 1 | 2.4% |
Essential hypertension | 1 | 2.4% |
Estimator | 1 | 2.4% |
Exercise prescription | 1 | 2.4% |
Expert | 1 | 2.4% |
Fall prevention | 1 | 2.4% |
False alarm | 1 | 2.4% |
Fatigue | 1 | 2.4% |
Fertility | 1 | 2.4% |
Fetus | 1 | 2.4% |
Fever | 1 | 2.4% |
Flexibility (anatomy) | 1 | 2.4% |
Fluid replacement | 1 | 2.4% |
Flynn effect | 1 | 2.4% |
Fondaparinux | 1 | 2.4% |
Food fortification | 1 | 2.4% |
Framingham Risk Score | 1 | 2.4% |
Funnel plot | 1 | 2.4% |
Furosemide | 1 | 2.4% |
Gabapentin | 1 | 2.4% |
Genetic counseling | 1 | 2.4% |
Genetic testing | 1 | 2.4% |
Genomics | 1 | 2.4% |
Goitre | 1 | 2.4% |
Gonorrhea | 1 | 2.4% |
Governance | 1 | 2.4% |
Graves' disease | 1 | 2.4% |
Health information technology | 1 | 2.4% |
Health insurance | 1 | 2.4% |
Health literacy | 1 | 2.4% |
Health technology | 1 | 2.4% |
Healthcare industry | 1 | 2.4% |
Heart rate | 1 | 2.4% |
Hematology | 1 | 2.4% |
Hepatitis B | 1 | 2.4% |
Hepatocellular carcinoma | 1 | 2.4% |
Hereditary nonpolyposis colorectal cancer | 1 | 2.4% |
High-risk pregnancy | 1 | 2.4% |
Hookah | 1 | 2.4% |
Hormonal therapy (oncology) | 1 | 2.4% |
Hospice | 1 | 2.4% |
Human development | 1 | 2.4% |
Human life stages | 1 | 2.4% |
Human pregnancy | 1 | 2.4% |
Human sexuality | 1 | 2.4% |
Hydronephrosis | 1 | 2.4% |
Hyperalgesia | 1 | 2.4% |
Hypothyroidism | 1 | 2.4% |
Ibuprofen | 1 | 2.4% |
Immune system | 1 | 2.4% |
Implantable cardioverter-defibrillator | 1 | 2.4% |
Incidence (epidemiology) | 1 | 2.4% |
Infancy | 1 | 2.4% |
Infant | 1 | 2.4% |
Infant bed | 1 | 2.4% |
Infant mortality | 1 | 2.4% |
Infection control | 1 | 2.4% |
Inflammatory bowel disease | 1 | 2.4% |
Influenza | 1 | 2.4% |
Influenza vaccine | 1 | 2.4% |
Informed consent | 1 | 2.4% |
Insurance | 1 | 2.4% |
Intelligence quotient | 1 | 2.4% |
Intensive care unit | 1 | 2.4% |
Inter-rater reliability | 1 | 2.4% |
Internet | 1 | 2.4% |
Intraclass correlation | 1 | 2.4% |
Intrauterine growth restriction | 1 | 2.4% |
Iodine deficiency | 1 | 2.4% |
Iodised salt | 1 | 2.4% |
Ketamine | 1 | 2.4% |
Kidney disease | 1 | 2.4% |
Labor induction | 1 | 2.4% |
Laboratory | 1 | 2.4% |
Lamivudine | 1 | 2.4% |
Left atrial appendage occlusion | 1 | 2.4% |
Lidocaine | 1 | 2.4% |
Lipoprotein | 1 | 2.4% |
Lipoprotein(a) | 1 | 2.4% |
Lisinopril | 1 | 2.4% |
Liver | 1 | 2.4% |
Local anesthetic | 1 | 2.4% |
Logistic regression | 1 | 2.4% |
Lojze Peterle | 1 | 2.4% |
Loop diuretic | 1 | 2.4% |
Low molecular weight heparin | 1 | 2.4% |
Low-threshold treatment programs | 1 | 2.4% |
Lymphedema | 1 | 2.4% |
Major depressive disorder | 1 | 2.4% |
Mammalian pregnancy | 1 | 2.4% |
Mammalian sexuality | 1 | 2.4% |
Management of atrial fibrillation | 1 | 2.4% |
Mass media | 1 | 2.4% |
Matched filter | 1 | 2.4% |
Maternal health | 1 | 2.4% |
Mathematical model | 1 | 2.4% |
Mathematics | 1 | 2.4% |
Maturity onset diabetes of the young | 1 | 2.4% |
Mean | 1 | 2.4% |
Medical Subject Headings | 1 | 2.4% |
Medical equipment management | 1 | 2.4% |
Medical error | 1 | 2.4% |
Medical prescription | 1 | 2.4% |
Medical record | 1 | 2.4% |
Medical research | 1 | 2.4% |
Medical statistics | 1 | 2.4% |
Medicare Part D | 1 | 2.4% |
Medicare Part D coverage gap | 1 | 2.4% |
Medicare dual eligible | 1 | 2.4% |
Men who have sex with men | 1 | 2.4% |
Micronutrient | 1 | 2.4% |
Microscopy | 1 | 2.4% |
Millennium Development Goals | 1 | 2.4% |
Morphine | 1 | 2.4% |
Mosquito | 1 | 2.4% |
Motherhood | 1 | 2.4% |
Motivational interviewing | 1 | 2.4% |
Multistakeholder governance | 1 | 2.4% |
Mycoplasma | 1 | 2.4% |
Nephrology | 1 | 2.4% |
Nerve | 1 | 2.4% |
Nervous system | 1 | 2.4% |
Neurology | 1 | 2.4% |
Neuropathic pain | 1 | 2.4% |
Neurosurgery | 1 | 2.4% |
Nevirapine | 1 | 2.4% |
Nociceptor | 1 | 2.4% |
Non-communicable disease | 1 | 2.4% |
Non-small-cell lung carcinoma | 1 | 2.4% |
Normal distribution | 1 | 2.4% |
Obstetrics | 1 | 2.4% |
Occupational safety and health | 1 | 2.4% |
Oncology | 1 | 2.4% |
Opioid | 1 | 2.4% |
Organ donation | 1 | 2.4% |
Organ transplantation | 1 | 2.4% |
Osteoporosis | 1 | 2.4% |
Ovarian cancer | 1 | 2.4% |
P-value | 1 | 2.4% |
Pancreatic cancer | 1 | 2.4% |
Pap test | 1 | 2.4% |
Paresthesia | 1 | 2.4% |
Patient Protection and Affordable Care Act | 1 | 2.4% |
Patient safety organization | 1 | 2.4% |
Pediatrics | 1 | 2.4% |
Peer pressure | 1 | 2.4% |
Pelvic inflammatory disease | 1 | 2.4% |
Perinatal mortality | 1 | 2.4% |
Personal trainer | 1 | 2.4% |
Personalized medicine | 1 | 2.4% |
Pharmaceutical industry | 1 | 2.4% |
Physical examination | 1 | 2.4% |
Physical fitness | 1 | 2.4% |
Placebo | 1 | 2.4% |
Placebo-controlled study | 1 | 2.4% |
Plasmodium falciparum | 1 | 2.4% |
Plasmodium vivax | 1 | 2.4% |
Pneumonia | 1 | 2.4% |
Podiatrist | 1 | 2.4% |
Point of care | 1 | 2.4% |
Policy | 1 | 2.4% |
Post-exposure prophylaxis | 1 | 2.4% |
Potassium | 1 | 2.4% |
Potassium chloride | 1 | 2.4% |
Poverty threshold | 1 | 2.4% |
Prasugrel | 1 | 2.4% |
Prediction | 1 | 2.4% |
Pregabalin | 1 | 2.4% |
Prenatal development | 1 | 2.4% |
Prenatal testing | 1 | 2.4% |
Prescription drug | 1 | 2.4% |
Preterm birth | 1 | 2.4% |
Prevalence | 1 | 2.4% |
Primary health care | 1 | 2.4% |
Prostate | 1 | 2.4% |
Prostate biopsy | 1 | 2.4% |
Prostate disorders | 1 | 2.4% |
Prothrombin time | 1 | 2.4% |
Psycho-oncology | 1 | 2.4% |
Psychological concepts | 1 | 2.4% |
Psychology | 1 | 2.4% |
Psychotherapy | 1 | 2.4% |
Public health surveillance | 1 | 2.4% |
Public sphere | 1 | 2.4% |
Publication bias | 1 | 2.4% |
Quality Improvement Organizations (QIOs) in Medicare | 1 | 2.4% |
Quality of life (healthcare) | 1 | 2.4% |
RICE (medicine) | 1 | 2.4% |
Radiography | 1 | 2.4% |
Radiology | 1 | 2.4% |
Real-time computing | 1 | 2.4% |
Recovery model | 1 | 2.4% |
Reference range | 1 | 2.4% |
Regression analysis | 1 | 2.4% |
Relative risk | 1 | 2.4% |
Renin | 1 | 2.4% |
Reperfusion therapy | 1 | 2.4% |
Reverse-transcriptase inhibitor | 1 | 2.4% |
Risk assessment | 1 | 2.4% |
Rosuvastatin | 1 | 2.4% |
Safe to Sleep | 1 | 2.4% |
Safety | 1 | 2.4% |
Science | 1 | 2.4% |
Selection bias | 1 | 2.4% |
Sensory neuron | 1 | 2.4% |
Serology | 1 | 2.4% |
Sexology | 1 | 2.4% |
Sexual emotions | 1 | 2.4% |
Sexuality | 1 | 2.4% |
Shared decision-making in medicine | 1 | 2.4% |
Shock (circulatory) | 1 | 2.4% |
Signs and symptoms | 1 | 2.4% |
Smoking | 1 | 2.4% |
Smoking cessation | 1 | 2.4% |
Snowball sampling | 1 | 2.4% |
Social competence | 1 | 2.4% |
Social influence | 1 | 2.4% |
Social media | 1 | 2.4% |
Social networking service | 1 | 2.4% |
Social services | 1 | 2.4% |
Sodium | 1 | 2.4% |
Sotalol | 1 | 2.4% |
Specialty (medicine) | 1 | 2.4% |
Sprain | 1 | 2.4% |
Sprained ankle | 1 | 2.4% |
Standard deviation | 1 | 2.4% |
Standard error | 1 | 2.4% |
Standardization | 1 | 2.4% |
States and territories of Australia | 1 | 2.4% |
Stationary process | 1 | 2.4% |
Statistical hypothesis testing | 1 | 2.4% |
Statistical theory | 1 | 2.4% |
Stomach cancer | 1 | 2.4% |
Stratified sampling | 1 | 2.4% |
Strength training | 1 | 2.4% |
Substance abuse prevention | 1 | 2.4% |
Sudden infant death syndrome | 1 | 2.4% |
Survey methodology | 1 | 2.4% |
Symptom | 1 | 2.4% |
SystmOne | 1 | 2.4% |
TIMI | 1 | 2.4% |
Thoracotomy | 1 | 2.4% |
Thrombophilia | 1 | 2.4% |
Thrombosis | 1 | 2.4% |
Thyroid | 1 | 2.4% |
Thyroid hormones | 1 | 2.4% |
Ticagrelor | 1 | 2.4% |
Time | 1 | 2.4% |
Time series | 1 | 2.4% |
Tirofiban | 1 | 2.4% |
Tobacco smoking | 1 | 2.4% |
Transient ischemic attack | 1 | 2.4% |
Transitional care | 1 | 2.4% |
Translational medicine | 1 | 2.4% |
Treatment of cancer | 1 | 2.4% |
Triage | 1 | 2.4% |
Troponin | 1 | 2.4% |
Twin-to-twin transfusion syndrome | 1 | 2.4% |
Type I and type II errors | 1 | 2.4% |
United States budget sequestration in 2013 | 1 | 2.4% |
Ureter | 1 | 2.4% |
Urinary system | 1 | 2.4% |
Urology | 1 | 2.4% |
Utility | 1 | 2.4% |
Vaccine | 1 | 2.4% |
Valvular heart disease | 1 | 2.4% |
Venipuncture | 1 | 2.4% |
Venlafaxine | 1 | 2.4% |
Ventricular fibrillation | 1 | 2.4% |
Ventricular tachycardia | 1 | 2.4% |
Verapamil | 1 | 2.4% |
Vertically transmitted infection | 1 | 2.4% |
Viral load | 1 | 2.4% |
Virology | 1 | 2.4% |
Virus | 1 | 2.4% |
Vitamin | 1 | 2.4% |
Volume expander | 1 | 2.4% |
Website | 1 | 2.4% |
Whole genome sequencing | 1 | 2.4% |
Wolff–Parkinson–White syndrome | 1 | 2.4% |
Women's health | 1 | 2.4% |
Youth | 1 | 2.4% |
Youth smoking | 1 | 2.4% |
Zidovudine | 1 | 2.4% |
abs | rel | |
---|---|---|
Health | 61 | 98.4% |
Medicine | 59 | 95.2% |
Health sciences | 58 | 93.5% |
Medical specialties | 58 | 93.5% |
Clinical medicine | 55 | 88.7% |
Health care | 52 | 83.9% |
Risk | 27 | 43.5% |
Public health | 26 | 41.9% |
Diseases and disorders | 19 | 30.6% |
Preventive healthcare | 18 | 29.0% |
Randomized controlled trial | 18 | 29.0% |
Epidemiology | 16 | 25.8% |
Infection | 15 | 24.2% |
Meta-analysis | 15 | 24.2% |
Patient | 15 | 24.2% |
Clinical trial | 14 | 22.6% |
Confidence interval | 14 | 22.6% |
Disease | 14 | 22.6% |
Medical diagnosis | 14 | 22.6% |
Systematic review | 14 | 22.6% |
Therapy | 14 | 22.6% |
Evidence-based medicine | 13 | 21.0% |
Adherence (medicine) | 11 | 17.7% |
Cardiology | 11 | 17.7% |
Cardiovascular system | 11 | 17.7% |
Coronary artery disease | 11 | 17.7% |
Hospital | 11 | 17.7% |
Myocardial infarction | 11 | 17.7% |
Research | 11 | 17.7% |
Screening (medicine) | 11 | 17.7% |
Surgery | 11 | 17.7% |
Cancer | 10 | 16.1% |
Cardiovascular disease | 10 | 16.1% |
Heart | 10 | 16.1% |
Medication | 10 | 16.1% |
Sensitivity and specificity | 10 | 16.1% |
Stroke | 10 | 16.1% |
HIV/AIDS | 9 | 14.5% |
Medical guideline | 9 | 14.5% |
Virus | 9 | 14.5% |
Childbirth | 8 | 12.9% |
Cohort study | 8 | 12.9% |
Health policy | 8 | 12.9% |
Life sciences | 8 | 12.9% |
Management of HIV/AIDS | 8 | 12.9% |
Medical imaging | 8 | 12.9% |
Biology | 7 | 11.3% |
Blinded experiment | 7 | 11.3% |
Health economics | 7 | 11.3% |
Hypertension | 7 | 11.3% |
Infectious diseases | 7 | 11.3% |
Medicare (United States) | 7 | 11.3% |
Pregnancy | 7 | 11.3% |
Statin | 7 | 11.3% |
Statistics | 7 | 11.3% |
Adverse effect | 6 | 9.7% |
Antimicrobial resistance | 6 | 9.7% |
Caregiver | 6 | 9.7% |
Cholesterol | 6 | 9.7% |
Chronic condition | 6 | 9.7% |
Emergency department | 6 | 9.7% |
Evaluation | 6 | 9.7% |
Immunology | 6 | 9.7% |
Low-density lipoprotein | 6 | 9.7% |
Microbiology | 6 | 9.7% |
Angina | 5 | 8.1% |
Atherosclerosis | 5 | 8.1% |
Blood pressure | 5 | 8.1% |
Breast cancer | 5 | 8.1% |
Electronic health record | 5 | 8.1% |
Health professional | 5 | 8.1% |
Hospital readmission | 5 | 8.1% |
Human reproduction | 5 | 8.1% |
Internal medicine | 5 | 8.1% |
Magnetic resonance imaging | 5 | 8.1% |
Medical humanities | 5 | 8.1% |
Medical record | 5 | 8.1% |
Medical treatments | 5 | 8.1% |
Mental disorder | 5 | 8.1% |
Patient safety | 5 | 8.1% |
Positive and negative predictive values | 5 | 8.1% |
Preterm birth | 5 | 8.1% |
Radiation therapy | 5 | 8.1% |
Regression analysis | 5 | 8.1% |
Standard deviation | 5 | 8.1% |
Transmission (medicine) | 5 | 8.1% |
Angiology | 4 | 6.5% |
Anticoagulant | 4 | 6.5% |
Atrial fibrillation | 4 | 6.5% |
Birth defect | 4 | 6.5% |
Breastfeeding | 4 | 6.5% |
CT scan | 4 | 6.5% |
Condom | 4 | 6.5% |
Dependent and independent variables | 4 | 6.5% |
Diagnosis of HIV/AIDS | 4 | 6.5% |
Dietary supplement | 4 | 6.5% |
ELISA | 4 | 6.5% |
HIV | 4 | 6.5% |
Health system | 4 | 6.5% |
Heart failure | 4 | 6.5% |
Hepatitis | 4 | 6.5% |
High-density lipoprotein | 4 | 6.5% |
Human activities | 4 | 6.5% |
Infant | 4 | 6.5% |
Intensive care unit | 4 | 6.5% |
Ischemia | 4 | 6.5% |
Major depressive disorder | 4 | 6.5% |
Medicaid | 4 | 6.5% |
Medical Subject Headings | 4 | 6.5% |
Medical test | 4 | 6.5% |
Nursing | 4 | 6.5% |
Pharmacy | 4 | 6.5% |
Physical therapy | 4 | 6.5% |
Prenatal development | 4 | 6.5% |
Prescription drug | 4 | 6.5% |
Prevention of HIV/AIDS | 4 | 6.5% |
Radiology | 4 | 6.5% |
Risk assessment | 4 | 6.5% |
Safe sex | 4 | 6.5% |
Sampling (statistics) | 4 | 6.5% |
Self-care | 4 | 6.5% |
Sexually transmitted infection | 4 | 6.5% |
Thrombosis | 4 | 6.5% |
Transient ischemic attack | 4 | 6.5% |
Tuberculosis | 4 | 6.5% |
Variance | 4 | 6.5% |
Viral load | 4 | 6.5% |
Adjuvant therapy | 3 | 4.8% |
Allergy | 3 | 4.8% |
Amiodarone | 3 | 4.8% |
Apixaban | 3 | 4.8% |
Aspirin | 3 | 4.8% |
Beta blocker | 3 | 4.8% |
Biopsy | 3 | 4.8% |
Biotechnology | 3 | 4.8% |
Bisphosphonate | 3 | 4.8% |
Body mass index | 3 | 4.8% |
Bone | 3 | 4.8% |
Bone density | 3 | 4.8% |
Cardiac stress test | 3 | 4.8% |
Cardiac surgery | 3 | 4.8% |
Cardioversion | 3 | 4.8% |
Colorectal cancer | 3 | 4.8% |
Comorbidity | 3 | 4.8% |
Confounding | 3 | 4.8% |
Coronary artery bypass surgery | 3 | 4.8% |
Cost-effectiveness analysis | 3 | 4.8% |
Dabigatran | 3 | 4.8% |
Determinants of health | 3 | 4.8% |
Diabetes | 3 | 4.8% |
Digoxin | 3 | 4.8% |
Dronedarone | 3 | 4.8% |
Drugs | 3 | 4.8% |
Dual-energy X-ray absorptiometry | 3 | 4.8% |
Ebola virus disease | 3 | 4.8% |
Echocardiography | 3 | 4.8% |
Emergency medicine | 3 | 4.8% |
Errors and residuals | 3 | 4.8% |
Exercise | 3 | 4.8% |
False positives and false negatives | 3 | 4.8% |
Fever | 3 | 4.8% |
General practitioner | 3 | 4.8% |
Gonorrhea | 3 | 4.8% |
Health insurance | 3 | 4.8% |
Insurance | 3 | 4.8% |
International Statistical Classification of Diseases and Related Health Problems | 3 | 4.8% |
Lung cancer | 3 | 4.8% |
MEDLINE | 3 | 4.8% |
Mean | 3 | 4.8% |
Mental health | 3 | 4.8% |
Neurology | 3 | 4.8% |
Osteoporosis | 3 | 4.8% |
Overdiagnosis | 3 | 4.8% |
Patient Protection and Affordable Care Act | 3 | 4.8% |
Patient participation | 3 | 4.8% |
Pharmacology | 3 | 4.8% |
Placebo | 3 | 4.8% |
Primary care | 3 | 4.8% |
Prothrombin time | 3 | 4.8% |
Psychotherapy | 3 | 4.8% |
Qualitative research | 3 | 4.8% |
Quality-adjusted life year | 3 | 4.8% |
Radiofrequency ablation | 3 | 4.8% |
Renal function | 3 | 4.8% |
Reporting bias | 3 | 4.8% |
Rivaroxaban | 3 | 4.8% |
Selective serotonin reuptake inhibitor | 3 | 4.8% |
Sensitivity analysis | 3 | 4.8% |
Sepsis | 3 | 4.8% |
Sexual intercourse | 3 | 4.8% |
Simulation | 3 | 4.8% |
Sotalol | 3 | 4.8% |
Standard error | 3 | 4.8% |
Study heterogeneity | 3 | 4.8% |
Tuberculosis management | 3 | 4.8% |
Type 2 diabetes | 3 | 4.8% |
Venous thrombosis | 3 | 4.8% |
Warfarin | 3 | 4.8% |
Zidovudine | 3 | 4.8% |
Abacavir | 2 | 3.2% |
Adverse drug reaction | 2 | 3.2% |
Allocation concealment | 2 | 3.2% |
Alzheimer's disease | 2 | 3.2% |
Anaphylaxis | 2 | 3.2% |
Aneurysm | 2 | 3.2% |
Angiography | 2 | 3.2% |
Angioplasty | 2 | 3.2% |
Antiarrhythmic agent | 2 | 3.2% |
Antibiotic | 2 | 3.2% |
Antibody | 2 | 3.2% |
Antidepressant | 2 | 3.2% |
Antiplatelet drug | 2 | 3.2% |
Antipsychotic | 2 | 3.2% |
Aripiprazole | 2 | 3.2% |
Artificial cardiac pacemaker | 2 | 3.2% |
Asthma | 2 | 3.2% |
Atrial flutter | 2 | 3.2% |
Bacteremia | 2 | 3.2% |
Bias | 2 | 3.2% |
Biochemistry | 2 | 3.2% |
Bioequivalence | 2 | 3.2% |
Biomarker | 2 | 3.2% |
Birth control | 2 | 3.2% |
Birth weight | 2 | 3.2% |
Bleeding | 2 | 3.2% |
Bone fracture | 2 | 3.2% |
Cancer screening | 2 | 3.2% |
Cancer staging | 2 | 3.2% |
Cardiovascular diseases | 2 | 3.2% |
Catheter ablation | 2 | 3.2% |
Cerebral shunt | 2 | 3.2% |
Chemotherapy | 2 | 3.2% |
Circulatory system | 2 | 3.2% |
Clinical pathology | 2 | 3.2% |
Cognitive behavioral therapy | 2 | 3.2% |
Consent | 2 | 3.2% |
Cyclooxygenase | 2 | 3.2% |
DNA sequencing | 2 | 3.2% |
Decision-making | 2 | 3.2% |
Deep vein thrombosis | 2 | 3.2% |
Dementia | 2 | 3.2% |
Diagnostic and Statistical Manual of Mental Disorders | 2 | 3.2% |
Diazepam | 2 | 3.2% |
Dieting | 2 | 3.2% |
Difference in differences | 2 | 3.2% |
Donepezil | 2 | 3.2% |
Dose (biochemistry) | 2 | 3.2% |
Efavirenz | 2 | 3.2% |
Effect size | 2 | 3.2% |
Eicosapentaenoic acid | 2 | 3.2% |
Employment | 2 | 3.2% |
Emtricitabine | 2 | 3.2% |
Epidemiology of HIV/AIDS | 2 | 3.2% |
Exome sequencing | 2 | 3.2% |
Fee-for-service | 2 | 3.2% |
Fetus | 2 | 3.2% |
Fixed effects model | 2 | 3.2% |
Flecainide | 2 | 3.2% |
Fluoxetine | 2 | 3.2% |
Framingham Risk Score | 2 | 3.2% |
Funnel plot | 2 | 3.2% |
Gene | 2 | 3.2% |
Genetic testing | 2 | 3.2% |
Genetics | 2 | 3.2% |
Genomics | 2 | 3.2% |
Health care in the United States | 2 | 3.2% |
Health care quality | 2 | 3.2% |
Health informatics | 2 | 3.2% |
Health technology in the United States | 2 | 3.2% |
Healthcare quality | 2 | 3.2% |
Heart arrhythmia | 2 | 3.2% |
Hepatitis B | 2 | 3.2% |
Hepatitis C | 2 | 3.2% |
Hip fracture | 2 | 3.2% |
Hormone replacement therapy | 2 | 3.2% |
Hospital-acquired infection | 2 | 3.2% |
Human sexual activity | 2 | 3.2% |
Human sexuality | 2 | 3.2% |
Hypercholesterolemia | 2 | 3.2% |
Immunoglobulin E | 2 | 3.2% |
Infection control | 2 | 3.2% |
Information | 2 | 3.2% |
Informed consent | 2 | 3.2% |
Institutional review board | 2 | 3.2% |
Lamivudine | 2 | 3.2% |
Laparoscopy | 2 | 3.2% |
Lentiviruses | 2 | 3.2% |
Linear regression | 2 | 3.2% |
Lipoprotein | 2 | 3.2% |
Logistic regression | 2 | 3.2% |
Lymphoma | 2 | 3.2% |
Managed care | 2 | 3.2% |
Maternal health | 2 | 3.2% |
Medical prescription | 2 | 3.2% |
Medical tests | 2 | 3.2% |
Medicare Advantage | 2 | 3.2% |
Men who have sex with men | 2 | 3.2% |
Menopause | 2 | 3.2% |
Metastasis | 2 | 3.2% |
Methicillin-resistant Staphylococcus aureus | 2 | 3.2% |
Microbicides for sexually transmitted diseases | 2 | 3.2% |
Multi-drug-resistant tuberculosis | 2 | 3.2% |
Nausea | 2 | 3.2% |
Neonatal intensive care unit | 2 | 3.2% |
Neoplasms | 2 | 3.2% |
Neuroimaging | 2 | 3.2% |
Nevirapine | 2 | 3.2% |
Nicotine | 2 | 3.2% |
Nicotine replacement therapy | 2 | 3.2% |
Nonsteroidal anti-inflammatory drug | 2 | 3.2% |
Nutrition | 2 | 3.2% |
Obesity | 2 | 3.2% |
Omega-3 fatty acid | 2 | 3.2% |
Osteopenia | 2 | 3.2% |
Ovarian cancer | 2 | 3.2% |
P-value | 2 | 3.2% |
Pain | 2 | 3.2% |
Palliative care | 2 | 3.2% |
Parameter | 2 | 3.2% |
Paroxetine | 2 | 3.2% |
Pathology | 2 | 3.2% |
Penicillin | 2 | 3.2% |
Personal protective equipment | 2 | 3.2% |
Pharmaceutical sciences | 2 | 3.2% |
Physician | 2 | 3.2% |
Pre-exposure prophylaxis | 2 | 3.2% |
Prevalence | 2 | 3.2% |
Prostate cancer | 2 | 3.2% |
Psychiatry | 2 | 3.2% |
Psychosocial | 2 | 3.2% |
Quality of life (healthcare) | 2 | 3.2% |
Raloxifene | 2 | 3.2% |
Receiver operating characteristic | 2 | 3.2% |
Reinsurance | 2 | 3.2% |
Reproductive health | 2 | 3.2% |
Reverse-transcriptase inhibitor | 2 | 3.2% |
Rifampicin | 2 | 3.2% |
Risperidone | 2 | 3.2% |
Sample size determination | 2 | 3.2% |
Saturated fat | 2 | 3.2% |
Selection bias | 2 | 3.2% |
Sertraline | 2 | 3.2% |
Sex worker | 2 | 3.2% |
Sexual health | 2 | 3.2% |
Sexually transmitted diseases and infections | 2 | 3.2% |
Shortness of breath | 2 | 3.2% |
Smoking cessation | 2 | 3.2% |
Social stigma | 2 | 3.2% |
Social support | 2 | 3.2% |
Staphylococcus aureus | 2 | 3.2% |
Stavudine | 2 | 3.2% |
Stratified sampling | 2 | 3.2% |
Surveillance | 2 | 3.2% |
Syphilis | 2 | 3.2% |
Tenofovir disoproxil | 2 | 3.2% |
Tobacco smoking | 2 | 3.2% |
Tricyclic antidepressant | 2 | 3.2% |
Type I and type II errors | 2 | 3.2% |
Unnecessary health care | 2 | 3.2% |
Urology | 2 | 3.2% |
Validity (statistics) | 2 | 3.2% |
Venlafaxine | 2 | 3.2% |
Vertically transmitted infection | 2 | 3.2% |
Viral hemorrhagic fever | 2 | 3.2% |
Vitamin | 2 | 3.2% |
Welfare | 2 | 3.2% |
2009 flu pandemic | 1 | 1.6% |
Abdominal aortic aneurysm | 1 | 1.6% |
Accountable care organization | 1 | 1.6% |
Accuracy and precision | 1 | 1.6% |
Active surveillance of prostate cancer | 1 | 1.6% |
Activities of daily living | 1 | 1.6% |
Acupuncture | 1 | 1.6% |
Adenoma | 1 | 1.6% |
Adolescence | 1 | 1.6% |
Advanced practice registered nurse | 1 | 1.6% |
Adverse selection | 1 | 1.6% |
Aerobic exercise | 1 | 1.6% |
Aflibercept | 1 | 1.6% |
Alanine transaminase | 1 | 1.6% |
Alternative medicine | 1 | 1.6% |
Amniocentesis | 1 | 1.6% |
Amoxicillin | 1 | 1.6% |
Ampicillin | 1 | 1.6% |
Amputation | 1 | 1.6% |
Anal sex | 1 | 1.6% |
Analysis of variance | 1 | 1.6% |
Anatomy | 1 | 1.6% |
Anecortave acetate | 1 | 1.6% |
Anemia | 1 | 1.6% |
Anesthesia | 1 | 1.6% |
Animal anatomy | 1 | 1.6% |
Animal bacterial diseases | 1 | 1.6% |
Animal viral diseases | 1 | 1.6% |
Anti-inflammatory | 1 | 1.6% |
Antibiotics | 1 | 1.6% |
Anticholinergic | 1 | 1.6% |
Anticonvulsant | 1 | 1.6% |
Antigen | 1 | 1.6% |
Antihypertensive drug | 1 | 1.6% |
Antiviral drug | 1 | 1.6% |
Anti–vascular endothelial growth factor therapy | 1 | 1.6% |
Anxiety | 1 | 1.6% |
Anxiety disorder | 1 | 1.6% |
Aortic aneurysm | 1 | 1.6% |
Aortic dissection | 1 | 1.6% |
Aortic stenosis | 1 | 1.6% |
Aortic valve | 1 | 1.6% |
Aortic valve replacement | 1 | 1.6% |
Apheresis | 1 | 1.6% |
Apolipoprotein | 1 | 1.6% |
Apolipoprotein B | 1 | 1.6% |
Asenapine | 1 | 1.6% |
Atrium (heart) | 1 | 1.6% |
Attention deficit hyperactivity disorder | 1 | 1.6% |
Audit | 1 | 1.6% |
Avian influenza | 1 | 1.6% |
Azithromycin | 1 | 1.6% |
BRCA mutation | 1 | 1.6% |
Back pain | 1 | 1.6% |
Bacteria | 1 | 1.6% |
Bacterial diseases | 1 | 1.6% |
Bacteriology | 1 | 1.6% |
Balance (ability) | 1 | 1.6% |
Bazedoxifene | 1 | 1.6% |
Behavior | 1 | 1.6% |
Behavior change method | 1 | 1.6% |
Benzatropine | 1 | 1.6% |
Benzodiazepine | 1 | 1.6% |
Best practice | 1 | 1.6% |
Beta-lactamase | 1 | 1.6% |
Bevacizumab | 1 | 1.6% |
Biosafety | 1 | 1.6% |
Biosecurity | 1 | 1.6% |
Bipolar disorder | 1 | 1.6% |
Bladder cancer | 1 | 1.6% |
Blood | 1 | 1.6% |
Blood donation | 1 | 1.6% |
Blood lipids | 1 | 1.6% |
Blood plasma | 1 | 1.6% |
Blood transfusion | 1 | 1.6% |
Blood type | 1 | 1.6% |
Body fluids | 1 | 1.6% |
Bone metastasis | 1 | 1.6% |
Brachytherapy | 1 | 1.6% |
Brain tumor | 1 | 1.6% |
Branches of science | 1 | 1.6% |
Breast cancer screening | 1 | 1.6% |
Breast imaging | 1 | 1.6% |
Broad-spectrum antibiotic | 1 | 1.6% |
Bronchodilator | 1 | 1.6% |
Buprenorphine | 1 | 1.6% |
Buprenorphine/naloxone | 1 | 1.6% |
Bupropion | 1 | 1.6% |
C-reactive protein | 1 | 1.6% |
CCR5 | 1 | 1.6% |
CD4 | 1 | 1.6% |
CHA2DS2–VASc score | 1 | 1.6% |
COLD-PCR | 1 | 1.6% |
COX-2 inhibitor | 1 | 1.6% |
Caesarean section | 1 | 1.6% |
Capitation (healthcare) | 1 | 1.6% |
Carbapenem | 1 | 1.6% |
Carcinoembryonic antigen | 1 | 1.6% |
Carcinoma | 1 | 1.6% |
Cardiac catheterization | 1 | 1.6% |
Cardiac imaging | 1 | 1.6% |
Cardiac rehabilitation | 1 | 1.6% |
Cardiotocography | 1 | 1.6% |
Case management (US health system) | 1 | 1.6% |
Case management (US healthcare system) | 1 | 1.6% |
Case–control study | 1 | 1.6% |
Cefaclor | 1 | 1.6% |
Celecoxib | 1 | 1.6% |
Cell-free fetal DNA | 1 | 1.6% |
Census | 1 | 1.6% |
Central venous catheter | 1 | 1.6% |
Cephalosporin | 1 | 1.6% |
Cerebral palsy | 1 | 1.6% |
Cervical cancer | 1 | 1.6% |
Chagas disease | 1 | 1.6% |
Chemicals in medicine | 1 | 1.6% |
Chemotherapy-induced nausea and vomiting | 1 | 1.6% |
Chlamydia | 1 | 1.6% |
Chlamydia infection | 1 | 1.6% |
Cholecystectomy | 1 | 1.6% |
Cholecystitis | 1 | 1.6% |
Choosing Wisely | 1 | 1.6% |
Choosing Wisely Canada | 1 | 1.6% |
Chorioamnionitis | 1 | 1.6% |
Choroidal neovascularization | 1 | 1.6% |
Chronic kidney disease | 1 | 1.6% |
Chronic obstructive pulmonary disease | 1 | 1.6% |
Cigarette | 1 | 1.6% |
Citalopram | 1 | 1.6% |
Clinic | 1 | 1.6% |
Clinical coder | 1 | 1.6% |
Clinical commissioning group | 1 | 1.6% |
Clopidogrel | 1 | 1.6% |
Clozapine | 1 | 1.6% |
Co-receptor | 1 | 1.6% |
Coagulation | 1 | 1.6% |
Cochrane Library | 1 | 1.6% |
Colonoscopy | 1 | 1.6% |
Colorectal polyp | 1 | 1.6% |
Complement system | 1 | 1.6% |
Complete blood count | 1 | 1.6% |
Computed tomography angiography | 1 | 1.6% |
Computer-aided diagnosis | 1 | 1.6% |
Computerized physician order entry | 1 | 1.6% |
Conjugated estrogens | 1 | 1.6% |
Constraint-induced movement therapy | 1 | 1.6% |
Contact tracing | 1 | 1.6% |
Contrast (vision) | 1 | 1.6% |
Control chart | 1 | 1.6% |
Coombs test | 1 | 1.6% |
Coping (psychology) | 1 | 1.6% |
Coronary catheterization | 1 | 1.6% |
Coronary circulation | 1 | 1.6% |
Correlation | 1 | 1.6% |
Correlation and dependence | 1 | 1.6% |
Corticosteroid | 1 | 1.6% |
Corynebacterineae | 1 | 1.6% |
Cost–utility analysis | 1 | 1.6% |
Cotinine | 1 | 1.6% |
Creatine kinase | 1 | 1.6% |
Criminalization | 1 | 1.6% |
Cryopreservation | 1 | 1.6% |
Current Procedural Terminology | 1 | 1.6% |
Cytogenetics | 1 | 1.6% |
D-dimer | 1 | 1.6% |
DNA | 1 | 1.6% |
Da Vinci Surgical System | 1 | 1.6% |
Data analysis | 1 | 1.6% |
Death | 1 | 1.6% |
Defensive medicine | 1 | 1.6% |
Dehydroepiandrosterone | 1 | 1.6% |
Demyelinating disease | 1 | 1.6% |
Denosumab | 1 | 1.6% |
Desmoteplase | 1 | 1.6% |
Diabetes mellitus | 1 | 1.6% |
Diabetic foot | 1 | 1.6% |
Diabetic foot ulcer | 1 | 1.6% |
Diarrhea | 1 | 1.6% |
Didanosine | 1 | 1.6% |
Diltiazem | 1 | 1.6% |
Discrete choice | 1 | 1.6% |
Disease registry | 1 | 1.6% |
Disease surveillance | 1 | 1.6% |
Docosahexaenoic acid | 1 | 1.6% |
Down syndrome | 1 | 1.6% |
Doxepin | 1 | 1.6% |
Dried blood spot | 1 | 1.6% |
Drug eruption | 1 | 1.6% |
Drug injection | 1 | 1.6% |
Drug reaction with eosinophilia and systemic symptoms | 1 | 1.6% |
Drug resistance | 1 | 1.6% |
Drugs acting on the nervous system | 1 | 1.6% |
Ductal carcinoma in situ | 1 | 1.6% |
Dummy variable (statistics) | 1 | 1.6% |
EQ-5D | 1 | 1.6% |
Ebola | 1 | 1.6% |
Eclampsia | 1 | 1.6% |
Econometrics | 1 | 1.6% |
Economics | 1 | 1.6% |
Education | 1 | 1.6% |
Efavirenz/emtricitabine/tenofovir | 1 | 1.6% |
Electrocardiography | 1 | 1.6% |
Electroencephalography | 1 | 1.6% |
Electronic prescribing | 1 | 1.6% |
Embolism | 1 | 1.6% |
Emergency management | 1 | 1.6% |
Emic and etic | 1 | 1.6% |
Empirical Bayes method | 1 | 1.6% |
Employee Retirement Income Security Act of 1974 | 1 | 1.6% |
Encephalopathy | 1 | 1.6% |
End-of-life care | 1 | 1.6% |
Endometrial cancer | 1 | 1.6% |
Endometriosis | 1 | 1.6% |
Endovascular aneurysm repair | 1 | 1.6% |
Engineering controls | 1 | 1.6% |
Epidermal growth factor receptor | 1 | 1.6% |
Epilepsy | 1 | 1.6% |
Epileptic seizure | 1 | 1.6% |
Equation | 1 | 1.6% |
Erectile dysfunction | 1 | 1.6% |
Escitalopram | 1 | 1.6% |
Essential health benefits | 1 | 1.6% |
Estimator | 1 | 1.6% |
Estradiol (medication) | 1 | 1.6% |
Estrogen (medication) | 1 | 1.6% |
Etoricoxib | 1 | 1.6% |
Exhaled nitric oxide | 1 | 1.6% |
Extensively drug-resistant tuberculosis | 1 | 1.6% |
Eye care | 1 | 1.6% |
Factor H | 1 | 1.6% |
Factor X | 1 | 1.6% |
Fat | 1 | 1.6% |
Fatigue | 1 | 1.6% |
Febrile neutropenia | 1 | 1.6% |
Febrile seizure | 1 | 1.6% |
Fecal occult blood | 1 | 1.6% |
Felicia Cosman | 1 | 1.6% |
Fenofibrate | 1 | 1.6% |
Fibrate | 1 | 1.6% |
Fibrin | 1 | 1.6% |
Fibrinolysis | 1 | 1.6% |
Five Year Forward View | 1 | 1.6% |
Flu season | 1 | 1.6% |
Fludeoxyglucose (18F) | 1 | 1.6% |
Focus group | 1 | 1.6% |
Food and drink | 1 | 1.6% |
Food intolerance | 1 | 1.6% |
Forest plot | 1 | 1.6% |
Formulary (pharmacy) | 1 | 1.6% |
Fusidic acid | 1 | 1.6% |
Gabapentin | 1 | 1.6% |
Gender | 1 | 1.6% |
Gene duplication | 1 | 1.6% |
Gene expression | 1 | 1.6% |
GeneXpert MTB/RIF | 1 | 1.6% |
Generic drug | 1 | 1.6% |
Genetic counseling | 1 | 1.6% |
Genetic disorder | 1 | 1.6% |
Genetic heterogeneity | 1 | 1.6% |
Genome-wide association study | 1 | 1.6% |
Gentamicin | 1 | 1.6% |
Gestational age | 1 | 1.6% |
Gestational diabetes | 1 | 1.6% |
Gestational hypertension | 1 | 1.6% |
Glioblastoma | 1 | 1.6% |
Glioma | 1 | 1.6% |
Gynaecologic disorders | 1 | 1.6% |
Gynaecology | 1 | 1.6% |
HAS-BLED | 1 | 1.6% |
HER2/neu | 1 | 1.6% |
Harm reduction | 1 | 1.6% |
Health Insurance Portability and Accountability Act | 1 | 1.6% |
Health care industry | 1 | 1.6% |
Health insurance coverage in the United States | 1 | 1.6% |
Health insurance marketplace | 1 | 1.6% |
Health maintenance organization | 1 | 1.6% |
Health research | 1 | 1.6% |
Healthy diet | 1 | 1.6% |
Heart failure with preserved ejection fraction | 1 | 1.6% |
Hepatocellular carcinoma | 1 | 1.6% |
Herpes simplex | 1 | 1.6% |
Heteroscedasticity | 1 | 1.6% |
Hip | 1 | 1.6% |
Hives | 1 | 1.6% |
Home care | 1 | 1.6% |
Home care in the United States | 1 | 1.6% |
Homoscedasticity | 1 | 1.6% |
Homosexuality | 1 | 1.6% |
Human decontamination | 1 | 1.6% |
Human diseases and disorders | 1 | 1.6% |
Human eye | 1 | 1.6% |
Human leukocyte antigen | 1 | 1.6% |
Human nature | 1 | 1.6% |
Human pregnancy | 1 | 1.6% |
Hydrocephalus | 1 | 1.6% |
Hygiene | 1 | 1.6% |
Hyperkinetic disorder | 1 | 1.6% |
Hyperprolactinaemia | 1 | 1.6% |
Hypnotic | 1 | 1.6% |
Hypodermic needle | 1 | 1.6% |
Hysterectomy | 1 | 1.6% |
ICD-10 | 1 | 1.6% |
Iatrogenesis | 1 | 1.6% |
Immigration | 1 | 1.6% |
Immunization | 1 | 1.6% |
Immunization during pregnancy | 1 | 1.6% |
Immunoassay | 1 | 1.6% |
Immunodeficiency | 1 | 1.6% |
Immunoelectrophoresis | 1 | 1.6% |
Immunohistochemistry | 1 | 1.6% |
Incentive | 1 | 1.6% |
Incidence (epidemiology) | 1 | 1.6% |
Incidental imaging finding | 1 | 1.6% |
Incremental cost-effectiveness ratio | 1 | 1.6% |
Infection prevention and control | 1 | 1.6% |
Inflammation | 1 | 1.6% |
Influenza | 1 | 1.6% |
Influenza A virus | 1 | 1.6% |
Influenza A virus subtype H1N1 | 1 | 1.6% |
Influenza A virus subtype H3N2 | 1 | 1.6% |
Influenza A virus subtype H5N1 | 1 | 1.6% |
Influenza A virus subtype H7N7 | 1 | 1.6% |
Influenza pandemic | 1 | 1.6% |
Injection (medicine) | 1 | 1.6% |
Insomnia | 1 | 1.6% |
Instrumental variables estimation | 1 | 1.6% |
Insulin resistance | 1 | 1.6% |
Intention-to-treat analysis | 1 | 1.6% |
Interest | 1 | 1.6% |
Intraclass correlation | 1 | 1.6% |
Intracranial hemorrhage | 1 | 1.6% |
Intracranial pressure | 1 | 1.6% |
Intravenous therapy | 1 | 1.6% |
Intravitreal administration | 1 | 1.6% |
Invasive carcinoma of no special type | 1 | 1.6% |
Isoniazid | 1 | 1.6% |
KRAS | 1 | 1.6% |
Kidney failure | 1 | 1.6% |
Labor induction | 1 | 1.6% |
Laser coagulation | 1 | 1.6% |
Latent tuberculosis | 1 | 1.6% |
Leadership | 1 | 1.6% |
Left atrial appendage occlusion | 1 | 1.6% |
Leukemia | 1 | 1.6% |
Likelihood function | 1 | 1.6% |
Likelihood ratios in diagnostic testing | 1 | 1.6% |
Linezolid | 1 | 1.6% |
Lisdexamfetamine | 1 | 1.6% |
Lithium (medication) | 1 | 1.6% |
Liver | 1 | 1.6% |
Long-term care | 1 | 1.6% |
Low birth weight | 1 | 1.6% |
Lower gastrointestinal series | 1 | 1.6% |
Lung | 1 | 1.6% |
Lung cancer screening | 1 | 1.6% |
Lung disorders | 1 | 1.6% |
Lung nodule | 1 | 1.6% |
Lutein | 1 | 1.6% |
Macula of retina | 1 | 1.6% |
Macular degeneration | 1 | 1.6% |
Macular telangiectasia | 1 | 1.6% |
Male genital disorders | 1 | 1.6% |
MammaPrint | 1 | 1.6% |
Mammalian pregnancy | 1 | 1.6% |
Mammography | 1 | 1.6% |
Management of atrial fibrillation | 1 | 1.6% |
Management of hypertension | 1 | 1.6% |
Management of schizophrenia | 1 | 1.6% |
Mania | 1 | 1.6% |
Mantoux test | 1 | 1.6% |
Mark and recapture | 1 | 1.6% |
Maternal death | 1 | 1.6% |
Maternal–fetal medicine | 1 | 1.6% |
Mathematical optimization | 1 | 1.6% |
McDonald criteria | 1 | 1.6% |
Median | 1 | 1.6% |
Medical genetics | 1 | 1.6% |
Medical history | 1 | 1.6% |
Medical home | 1 | 1.6% |
Medical laboratory | 1 | 1.6% |
Medical school | 1 | 1.6% |
Medical simulation | 1 | 1.6% |
Medical specialty | 1 | 1.6% |
Medicalization | 1 | 1.6% |
Medicinal chemistry | 1 | 1.6% |
Melatonin | 1 | 1.6% |
Meningioma | 1 | 1.6% |
Meningitis | 1 | 1.6% |
Mental states | 1 | 1.6% |
Meta-regression | 1 | 1.6% |
Metabolic syndrome | 1 | 1.6% |
Methadone | 1 | 1.6% |
Methicillin | 1 | 1.6% |
Methodology | 1 | 1.6% |
Methylphenidate | 1 | 1.6% |
Metoprolol | 1 | 1.6% |
Microsatellite instability | 1 | 1.6% |
Mild cognitive impairment | 1 | 1.6% |
Minimally invasive procedure | 1 | 1.6% |
Minimaze procedure | 1 | 1.6% |
Mirtazapine | 1 | 1.6% |
Miscarriage | 1 | 1.6% |
Moclobemide | 1 | 1.6% |
Molecular biology | 1 | 1.6% |
Monoamine oxidase inhibitor | 1 | 1.6% |
Motherhood | 1 | 1.6% |
Motivational interviewing | 1 | 1.6% |
Mucositis | 1 | 1.6% |
Multiple drug resistance | 1 | 1.6% |
Multiple sclerosis | 1 | 1.6% |
Muscarinic antagonist | 1 | 1.6% |
Musculoskeletal system | 1 | 1.6% |
Mutation | 1 | 1.6% |
Mycobacteria | 1 | 1.6% |
Mycoplasma | 1 | 1.6% |
Myelodysplastic syndrome | 1 | 1.6% |
Myocardial perfusion imaging | 1 | 1.6% |
Nail biting | 1 | 1.6% |
Necrosis | 1 | 1.6% |
Needle exchange programme | 1 | 1.6% |
Neonatal seizure | 1 | 1.6% |
Neonatology | 1 | 1.6% |
Neoplasm | 1 | 1.6% |
Neovascularization | 1 | 1.6% |
Nervous system | 1 | 1.6% |
Neurological disorder | 1 | 1.6% |
Neuromyelitis optica | 1 | 1.6% |
Neuropathology | 1 | 1.6% |
Neutropenia | 1 | 1.6% |
Non-small-cell lung carcinoma | 1 | 1.6% |
Normal pressure hydrocephalus | 1 | 1.6% |
Nortriptyline | 1 | 1.6% |
Null hypothesis | 1 | 1.6% |
Numeracy | 1 | 1.6% |
Nursing home care | 1 | 1.6% |
OIE/FAO Network of Expertise on Animal Influenza | 1 | 1.6% |
Observation | 1 | 1.6% |
Obstetrics | 1 | 1.6% |
Occupational safety and health | 1 | 1.6% |
Odds ratio | 1 | 1.6% |
Olanzapine | 1 | 1.6% |
Ophthalmology | 1 | 1.6% |
OraQuick | 1 | 1.6% |
Oral sex | 1 | 1.6% |
Ordinary least squares | 1 | 1.6% |
Osteoarthritis | 1 | 1.6% |
Osteonecrosis of the jaw | 1 | 1.6% |
Overfitting | 1 | 1.6% |
Pain management | 1 | 1.6% |
Paliperidone | 1 | 1.6% |
Pandemic | 1 | 1.6% |
Passive smoking | 1 | 1.6% |
Patient-reported outcome | 1 | 1.6% |
Paul Ridker | 1 | 1.6% |
Pediatrics | 1 | 1.6% |
Pegaptanib | 1 | 1.6% |
Percutaneous aortic valve replacement | 1 | 1.6% |
Percutaneous coronary intervention | 1 | 1.6% |
Perinatal mortality | 1 | 1.6% |
Peripheral artery disease | 1 | 1.6% |
Peripheral neuropathy | 1 | 1.6% |
Periventricular leukomalacia | 1 | 1.6% |
Personalized medicine | 1 | 1.6% |
Personally identifiable information | 1 | 1.6% |
Pharmacist | 1 | 1.6% |
Pharmacogenomics | 1 | 1.6% |
Phenobarbital | 1 | 1.6% |
Phenomenology (philosophy) | 1 | 1.6% |
Phenytoin | 1 | 1.6% |
Physical examination | 1 | 1.6% |
Physical fitness | 1 | 1.6% |
Physical medicine and rehabilitation | 1 | 1.6% |
Platelet | 1 | 1.6% |
Pleural effusion | 1 | 1.6% |
Pneumonia | 1 | 1.6% |
Point of care | 1 | 1.6% |
Polymerase chain reaction | 1 | 1.6% |
Polyp (medicine) | 1 | 1.6% |
Polypharmacy | 1 | 1.6% |
Positron emission tomography | 1 | 1.6% |
Post-exposure prophylaxis | 1 | 1.6% |
Postterm pregnancy | 1 | 1.6% |
Poultry | 1 | 1.6% |
Power (statistics) | 1 | 1.6% |
Prasugrel | 1 | 1.6% |
Pre- and post-test probability | 1 | 1.6% |
Pre-eclampsia | 1 | 1.6% |
Prediabetes | 1 | 1.6% |
Prediction | 1 | 1.6% |
Prednisolone | 1 | 1.6% |
Prednisone | 1 | 1.6% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 1 | 1.6% |
Pregabalin | 1 | 1.6% |
Prenatal testing | 1 | 1.6% |
Prevention | 1 | 1.6% |
Price | 1 | 1.6% |
Probability | 1 | 1.6% |
Probability distribution | 1 | 1.6% |
Production function | 1 | 1.6% |
Prognosis | 1 | 1.6% |
Propensity score matching | 1 | 1.6% |
Propranolol | 1 | 1.6% |
Prostaglandin-endoperoxide synthase 2 | 1 | 1.6% |
Prostate-specific antigen | 1 | 1.6% |
Prostatectomy | 1 | 1.6% |
Prostitution | 1 | 1.6% |
Pseudomonas | 1 | 1.6% |
Pseudomonas aeruginosa | 1 | 1.6% |
Psychiatric and mental health nursing | 1 | 1.6% |
Psychiatric hospital | 1 | 1.6% |
Psychoactive drugs | 1 | 1.6% |
Psychological concepts | 1 | 1.6% |
Psychology | 1 | 1.6% |
Psychosis | 1 | 1.6% |
Public hospital | 1 | 1.6% |
Public sphere | 1 | 1.6% |
Publication bias | 1 | 1.6% |
Pulmonary embolism | 1 | 1.6% |
Pyrazinamide | 1 | 1.6% |
QRISK | 1 | 1.6% |
Quality assurance | 1 | 1.6% |
Quality of life | 1 | 1.6% |
Quantitative computed tomography | 1 | 1.6% |
Quetiapine | 1 | 1.6% |
RTT | 1 | 1.6% |
Randomness | 1 | 1.6% |
Ranibizumab | 1 | 1.6% |
Rape | 1 | 1.6% |
Readability | 1 | 1.6% |
Red blood cell | 1 | 1.6% |
Registered nurse | 1 | 1.6% |
Relative risk | 1 | 1.6% |
Renal cell carcinoma | 1 | 1.6% |
Research methods | 1 | 1.6% |
Residency (medicine) | 1 | 1.6% |
Respiratory disease | 1 | 1.6% |
Retina | 1 | 1.6% |
Reverse transcription polymerase chain reaction | 1 | 1.6% |
Rifamycin | 1 | 1.6% |
Rifapentine | 1 | 1.6% |
Rivastigmine | 1 | 1.6% |
Robot-assisted surgery | 1 | 1.6% |
Robust statistics | 1 | 1.6% |
Safety | 1 | 1.6% |
Salbutamol | 1 | 1.6% |
Scanning laser ophthalmoscopy | 1 | 1.6% |
Schizophrenia | 1 | 1.6% |
Self-insurance | 1 | 1.6% |
Self-report study | 1 | 1.6% |
Semen | 1 | 1.6% |
Semen analysis | 1 | 1.6% |
Serosorting | 1 | 1.6% |
Sexuality | 1 | 1.6% |
Shared decision-making in medicine | 1 | 1.6% |
Sievert | 1 | 1.6% |
Signs and symptoms | 1 | 1.6% |
Single-nucleotide polymorphism | 1 | 1.6% |
Single-photon emission computed tomography | 1 | 1.6% |
Skeletal system | 1 | 1.6% |
Smoking | 1 | 1.6% |
Smoking ban | 1 | 1.6% |
Snowball sampling | 1 | 1.6% |
Social media | 1 | 1.6% |
Spasticity | 1 | 1.6% |
Spina bifida | 1 | 1.6% |
Spirometry | 1 | 1.6% |
Standard score | 1 | 1.6% |
Staphylococcus | 1 | 1.6% |
Statistical hypothesis testing | 1 | 1.6% |
Statistical model | 1 | 1.6% |
Statistical significance | 1 | 1.6% |
Stenotrophomonas maltophilia | 1 | 1.6% |
Stevens–Johnson syndrome | 1 | 1.6% |
Stillbirth | 1 | 1.6% |
Strontium ranelate | 1 | 1.6% |
Student's t-test | 1 | 1.6% |
Substance abuse | 1 | 1.6% |
Substance dependence | 1 | 1.6% |
Surgical mask | 1 | 1.6% |
Swine influenza | 1 | 1.6% |
T-statistic | 1 | 1.6% |
Tamoxifen | 1 | 1.6% |
Telehealth | 1 | 1.6% |
Teriparatide | 1 | 1.6% |
Tetraplegia | 1 | 1.6% |
Thorax | 1 | 1.6% |
Thrombin | 1 | 1.6% |
Thrombus | 1 | 1.6% |
Thyroid hormones | 1 | 1.6% |
Thyroid nodule | 1 | 1.6% |
Ticagrelor | 1 | 1.6% |
Tirofiban | 1 | 1.6% |
Tissue plasminogen activator | 1 | 1.6% |
Tissues (biology) | 1 | 1.6% |
Tomosynthesis | 1 | 1.6% |
Tort reform | 1 | 1.6% |
Tourism | 1 | 1.6% |
Treatment | 1 | 1.6% |
Treatment of bipolar disorder | 1 | 1.6% |
Treponema pallidum | 1 | 1.6% |
Triage | 1 | 1.6% |
Triatoma protracta | 1 | 1.6% |
Trichomoniasis | 1 | 1.6% |
Triglyceride | 1 | 1.6% |
Triiodothyronine | 1 | 1.6% |
Tuberculosis diagnosis | 1 | 1.6% |
Uncertainty | 1 | 1.6% |
Uniform distribution (continuous) | 1 | 1.6% |
Uterine fibroid | 1 | 1.6% |
Uterine prolapse | 1 | 1.6% |
Vaccine | 1 | 1.6% |
Vagina | 1 | 1.6% |
Vaginal lubrication | 1 | 1.6% |
Valproate | 1 | 1.6% |
Valvular heart disease | 1 | 1.6% |
Varenicline | 1 | 1.6% |
Vascular dementia | 1 | 1.6% |
Vein | 1 | 1.6% |
Venereal Disease Research Laboratory test | 1 | 1.6% |
Verapamil | 1 | 1.6% |
Verification and validation | 1 | 1.6% |
Vertebral column | 1 | 1.6% |
Violence | 1 | 1.6% |
Virtual colonoscopy | 1 | 1.6% |
Vision | 1 | 1.6% |
Visual acuity | 1 | 1.6% |
Vitamin B12 | 1 | 1.6% |
Vitamin D | 1 | 1.6% |
Vitamin D deficiency | 1 | 1.6% |
Vitamin E | 1 | 1.6% |
Weight loss | 1 | 1.6% |
Western African Ebola virus epidemic | 1 | 1.6% |
Whole genome sequencing | 1 | 1.6% |
Whooping cough | 1 | 1.6% |
Wristband | 1 | 1.6% |
Zeaxanthin | 1 | 1.6% |
Zoledronic acid | 1 | 1.6% |
Zolpidem | 1 | 1.6% |
Zoonosis | 1 | 1.6% |
Β-lactam antibiotic | 1 | 1.6% |
abs | rel | |
---|---|---|
Health | 85 | 98.8% |
Medicine | 84 | 97.7% |
Health sciences | 83 | 96.5% |
Medical specialties | 79 | 91.9% |
Clinical medicine | 71 | 82.6% |
Health care | 71 | 82.6% |
Public health | 52 | 60.5% |
Diseases and disorders | 36 | 41.9% |
Infection | 35 | 40.7% |
Epidemiology | 32 | 37.2% |
Risk | 28 | 32.6% |
Disease | 27 | 31.4% |
Preventive healthcare | 25 | 29.1% |
Evidence-based medicine | 21 | 24.4% |
HIV/AIDS | 20 | 23.3% |
Medical humanities | 19 | 22.1% |
Health economics | 18 | 20.9% |
Health policy | 17 | 19.8% |
Chronic condition | 16 | 18.6% |
Management of HIV/AIDS | 15 | 17.4% |
Medical guideline | 15 | 17.4% |
Randomized controlled trial | 15 | 17.4% |
Adherence (medicine) | 14 | 16.3% |
Infectious diseases | 14 | 16.3% |
Medical diagnosis | 14 | 16.3% |
Tuberculosis | 14 | 16.3% |
Human activities | 13 | 15.1% |
Systematic review | 13 | 15.1% |
Cancer | 12 | 14.0% |
Cardiovascular disease | 12 | 14.0% |
Ebola virus disease | 12 | 14.0% |
Immunology | 12 | 14.0% |
Meta-analysis | 12 | 14.0% |
Stroke | 12 | 14.0% |
Clinical trial | 11 | 12.8% |
Evaluation | 11 | 12.8% |
Health professional | 11 | 12.8% |
Screening (medicine) | 11 | 12.8% |
Confidence interval | 10 | 11.6% |
Hospital | 10 | 11.6% |
Microbiology | 10 | 11.6% |
Public sphere | 10 | 11.6% |
Sensitivity and specificity | 10 | 11.6% |
Statistics | 10 | 11.6% |
Cohort study | 9 | 10.5% |
Hepatitis | 9 | 10.5% |
Medication | 9 | 10.5% |
Patient | 9 | 10.5% |
Research | 9 | 10.5% |
Sexually transmitted infection | 9 | 10.5% |
Therapy | 9 | 10.5% |
Antimicrobial resistance | 8 | 9.3% |
Childbirth | 8 | 9.3% |
Exercise | 8 | 9.3% |
General practitioner | 8 | 9.3% |
Osteoporosis | 8 | 9.3% |
Virus | 8 | 9.3% |
Best practice | 7 | 8.1% |
Biology | 7 | 8.1% |
Blood pressure | 7 | 8.1% |
Cholesterol | 7 | 8.1% |
Coronary artery disease | 7 | 8.1% |
Emergency department | 7 | 8.1% |
Health system | 7 | 8.1% |
Heart | 7 | 8.1% |
Human reproduction | 7 | 8.1% |
Myocardial infarction | 7 | 8.1% |
Nursing | 7 | 8.1% |
Obesity | 7 | 8.1% |
Pregnancy | 7 | 8.1% |
Thrombosis | 7 | 8.1% |
Anticoagulant | 6 | 7.0% |
Breast cancer | 6 | 7.0% |
Cardiovascular system | 6 | 7.0% |
Cost-effectiveness analysis | 6 | 7.0% |
Data analysis | 6 | 7.0% |
Emergency management | 6 | 7.0% |
GeneXpert MTB/RIF | 6 | 7.0% |
HIV | 6 | 7.0% |
Hypertension | 6 | 7.0% |
Infection control | 6 | 7.0% |
Influenza | 6 | 7.0% |
Low-density lipoprotein | 6 | 7.0% |
Medical treatments | 6 | 7.0% |
Medicare (United States) | 6 | 7.0% |
Multi-drug-resistant tuberculosis | 6 | 7.0% |
Reproductive health | 6 | 7.0% |
Safe sex | 6 | 7.0% |
Surgery | 6 | 7.0% |
Tuberculosis management | 6 | 7.0% |
Vaccine | 6 | 7.0% |
Atrial fibrillation | 5 | 5.8% |
Avian influenza | 5 | 5.8% |
Birth control | 5 | 5.8% |
Breastfeeding | 5 | 5.8% |
Breastfeeding and HIV | 5 | 5.8% |
Colorectal cancer | 5 | 5.8% |
Comorbidity | 5 | 5.8% |
Condom | 5 | 5.8% |
Deep vein thrombosis | 5 | 5.8% |
Diagnosis of HIV/AIDS | 5 | 5.8% |
Disability-adjusted life year | 5 | 5.8% |
Extensively drug-resistant tuberculosis | 5 | 5.8% |
Influenza pandemic | 5 | 5.8% |
Lung cancer | 5 | 5.8% |
Patient safety | 5 | 5.8% |
Pharmacy | 5 | 5.8% |
Physician | 5 | 5.8% |
Primary care | 5 | 5.8% |
Qualitative research | 5 | 5.8% |
Quality-adjusted life year | 5 | 5.8% |
Renal function | 5 | 5.8% |
Risk management | 5 | 5.8% |
Statin | 5 | 5.8% |
Venous thrombosis | 5 | 5.8% |
Western African Ebola virus epidemic | 5 | 5.8% |
Zoonosis | 5 | 5.8% |
Adjuvant therapy | 4 | 4.7% |
Adolescence | 4 | 4.7% |
Antibiotic | 4 | 4.7% |
Antihypertensive drug | 4 | 4.7% |
Antiviral drug | 4 | 4.7% |
Asthma | 4 | 4.7% |
Bias | 4 | 4.7% |
Bone density | 4 | 4.7% |
CD4 | 4 | 4.7% |
Caregiver | 4 | 4.7% |
Chronic kidney disease | 4 | 4.7% |
Cochrane Library | 4 | 4.7% |
Diabetes | 4 | 4.7% |
Disease burden | 4 | 4.7% |
Drugs | 4 | 4.7% |
Dual-energy X-ray absorptiometry | 4 | 4.7% |
Epidemiology of HIV/AIDS | 4 | 4.7% |
Family planning | 4 | 4.7% |
Global Outbreak Alert and Response Network | 4 | 4.7% |
Harm reduction | 4 | 4.7% |
High-density lipoprotein | 4 | 4.7% |
Hip fracture | 4 | 4.7% |
Hospital readmission | 4 | 4.7% |
Inflammation | 4 | 4.7% |
Influenza A virus subtype H7N9 | 4 | 4.7% |
Life sciences | 4 | 4.7% |
MEDLINE | 4 | 4.7% |
Medicaid | 4 | 4.7% |
Medroxyprogesterone acetate | 4 | 4.7% |
Menopause | 4 | 4.7% |
Mental disorder | 4 | 4.7% |
Millennium Development Goals | 4 | 4.7% |
Neoplasms | 4 | 4.7% |
Physical therapy | 4 | 4.7% |
Pneumonia | 4 | 4.7% |
Prescription drug | 4 | 4.7% |
Quantitative research | 4 | 4.7% |
Reliability engineering | 4 | 4.7% |
Risk assessment | 4 | 4.7% |
Sampling (statistics) | 4 | 4.7% |
Sexual intercourse | 4 | 4.7% |
Shortness of breath | 4 | 4.7% |
Survey methodology | 4 | 4.7% |
Transmission (medicine) | 4 | 4.7% |
Type 2 diabetes | 4 | 4.7% |
2009 flu pandemic | 3 | 3.5% |
Adverse effect | 3 | 3.5% |
Animal diseases | 3 | 3.5% |
Antidepressant | 3 | 3.5% |
Antimicrobial | 3 | 3.5% |
Audit | 3 | 3.5% |
Benzodiazepine | 3 | 3.5% |
Beta blocker | 3 | 3.5% |
Blinded experiment | 3 | 3.5% |
Body mass index | 3 | 3.5% |
Bone | 3 | 3.5% |
Bone fracture | 3 | 3.5% |
Case–control study | 3 | 3.5% |
Chemotherapy | 3 | 3.5% |
Chikungunya | 3 | 3.5% |
Combined oral contraceptive pill | 3 | 3.5% |
Decision-making | 3 | 3.5% |
Dementia | 3 | 3.5% |
Dependent and independent variables | 3 | 3.5% |
Disease surveillance | 3 | 3.5% |
Echocardiography | 3 | 3.5% |
Emergency contraception | 3 | 3.5% |
Employment | 3 | 3.5% |
Fee-for-service | 3 | 3.5% |
Flu season | 3 | 3.5% |
Glycated hemoglobin | 3 | 3.5% |
Google Scholar | 3 | 3.5% |
Gross domestic product | 3 | 3.5% |
HER2/neu | 3 | 3.5% |
Health care quality | 3 | 3.5% |
Hepatitis C | 3 | 3.5% |
Hormonal contraception | 3 | 3.5% |
Hormone replacement therapy | 3 | 3.5% |
Incidence (epidemiology) | 3 | 3.5% |
Infant | 3 | 3.5% |
Influenza A virus subtype H5N1 | 3 | 3.5% |
Levonorgestrel | 3 | 3.5% |
Linear regression | 3 | 3.5% |
Major depressive disorder | 3 | 3.5% |
Medical prescription | 3 | 3.5% |
Medical test | 3 | 3.5% |
Men who have sex with men | 3 | 3.5% |
Metastasis | 3 | 3.5% |
Middle East respiratory syndrome-related coronavirus | 3 | 3.5% |
Mortality rate | 3 | 3.5% |
Nevirapine | 3 | 3.5% |
Non-communicable disease | 3 | 3.5% |
Peripheral neuropathy | 3 | 3.5% |
Pharmacology | 3 | 3.5% |
Polio | 3 | 3.5% |
Post-exposure prophylaxis | 3 | 3.5% |
Postpartum period | 3 | 3.5% |
Prevention of HIV/AIDS | 3 | 3.5% |
Pulse | 3 | 3.5% |
Quality assurance | 3 | 3.5% |
Radiation therapy | 3 | 3.5% |
Reliability (statistics) | 3 | 3.5% |
Reproductive rights | 3 | 3.5% |
Selective serotonin reuptake inhibitor | 3 | 3.5% |
Self-care | 3 | 3.5% |
Sensitivity analysis | 3 | 3.5% |
Sex worker | 3 | 3.5% |
Sexual health | 3 | 3.5% |
Spirometry | 3 | 3.5% |
Variance | 3 | 3.5% |
Vein | 3 | 3.5% |
Vertically transmitted infection | 3 | 3.5% |
Violence | 3 | 3.5% |
Viral hemorrhagic fever | 3 | 3.5% |
Vitamin D | 3 | 3.5% |
Warfarin | 3 | 3.5% |
ACE inhibitor | 2 | 2.3% |
Abacavir | 2 | 2.3% |
Abdominal obesity | 2 | 2.3% |
Aid | 2 | 2.3% |
Allergy | 2 | 2.3% |
Allocation concealment | 2 | 2.3% |
Amniocentesis | 2 | 2.3% |
Amputation | 2 | 2.3% |
Angiology | 2 | 2.3% |
Angiotensin II receptor blocker | 2 | 2.3% |
Ankle–brachial pressure index | 2 | 2.3% |
Arthritis | 2 | 2.3% |
Assay | 2 | 2.3% |
Assumption | 2 | 2.3% |
Atherosclerosis | 2 | 2.3% |
Athetosis | 2 | 2.3% |
Auditor's report | 2 | 2.3% |
Bibliometrics | 2 | 2.3% |
Bilirubin | 2 | 2.3% |
Biochemistry | 2 | 2.3% |
Blood sugar level | 2 | 2.3% |
Bootstrapping (statistics) | 2 | 2.3% |
Bronchodilator | 2 | 2.3% |
CCR5 | 2 | 2.3% |
CHA2DS2–VASc score | 2 | 2.3% |
Cancer screening | 2 | 2.3% |
Capacity building | 2 | 2.3% |
Cardiology | 2 | 2.3% |
Central venous catheter | 2 | 2.3% |
Chronic obstructive pulmonary disease | 2 | 2.3% |
Circumcision | 2 | 2.3% |
Clinical governance | 2 | 2.3% |
Clinical pathology | 2 | 2.3% |
Co-receptor | 2 | 2.3% |
Confidentiality | 2 | 2.3% |
Confounding | 2 | 2.3% |
Conjoint analysis | 2 | 2.3% |
Data | 2 | 2.3% |
Decision tree learning | 2 | 2.3% |
Delphi method | 2 | 2.3% |
Dentistry | 2 | 2.3% |
Diabetes management | 2 | 2.3% |
Diabetes mellitus | 2 | 2.3% |
Diabetes mellitus type 2 | 2 | 2.3% |
Directly observed treatment, short-course | 2 | 2.3% |
Disability | 2 | 2.3% |
Dose (biochemistry) | 2 | 2.3% |
Down syndrome | 2 | 2.3% |
Economic growth | 2 | 2.3% |
Electronic health record | 2 | 2.3% |
Emergency | 2 | 2.3% |
Emergency medicine | 2 | 2.3% |
Epidemic | 2 | 2.3% |
Erlotinib | 2 | 2.3% |
Ethinylestradiol | 2 | 2.3% |
Etonogestrel | 2 | 2.3% |
European Neighbourhood Policy | 2 | 2.3% |
Expert | 2 | 2.3% |
Fall prevention | 2 | 2.3% |
Focus group | 2 | 2.3% |
Framingham Risk Score | 2 | 2.3% |
Goal | 2 | 2.3% |
Gonorrhea | 2 | 2.3% |
Group B streptococcal infection | 2 | 2.3% |
H-index | 2 | 2.3% |
HIV/AIDS research | 2 | 2.3% |
Health Insurance Portability and Accountability Act | 2 | 2.3% |
Health promotion | 2 | 2.3% |
Healthcare industry | 2 | 2.3% |
Healthcare quality | 2 | 2.3% |
Heart failure | 2 | 2.3% |
Hemolytic disease of the newborn | 2 | 2.3% |
Hepatitis B | 2 | 2.3% |
Hepatocellular carcinoma | 2 | 2.3% |
Homosexuality | 2 | 2.3% |
Hospital-acquired infection | 2 | 2.3% |
Human pregnancy | 2 | 2.3% |
Hyperlipidemia | 2 | 2.3% |
Immunodeficiency | 2 | 2.3% |
Incremental cost-effectiveness ratio | 2 | 2.3% |
Influenza A virus | 2 | 2.3% |
Influenza A virus subtype H1N1 | 2 | 2.3% |
Internal audit | 2 | 2.3% |
Internal control | 2 | 2.3% |
Internal medicine | 2 | 2.3% |
International Statistical Classification of Diseases and Related Health Problems | 2 | 2.3% |
Intrauterine device | 2 | 2.3% |
Ischemia | 2 | 2.3% |
Jaundice | 2 | 2.3% |
Kernicterus | 2 | 2.3% |
Kidney | 2 | 2.3% |
Kidney disease | 2 | 2.3% |
Kidney failure | 2 | 2.3% |
Leukemia | 2 | 2.3% |
Light therapy | 2 | 2.3% |
Likert scale | 2 | 2.3% |
Logistic regression | 2 | 2.3% |
Low birth weight | 2 | 2.3% |
Malaria | 2 | 2.3% |
Maternal death | 2 | 2.3% |
Maternal health | 2 | 2.3% |
Mathematical optimization | 2 | 2.3% |
Measles | 2 | 2.3% |
Medical error | 2 | 2.3% |
Medical statistics | 2 | 2.3% |
Mental health | 2 | 2.3% |
Mestranol | 2 | 2.3% |
Methodology | 2 | 2.3% |
Miscarriage | 2 | 2.3% |
Mood disorder | 2 | 2.3% |
Multiple-criteria decision analysis | 2 | 2.3% |
Neonatal infection | 2 | 2.3% |
Neonatal jaundice | 2 | 2.3% |
Obstetrics | 2 | 2.3% |
Osteopenia | 2 | 2.3% |
Ovarian cancer | 2 | 2.3% |
Overdiagnosis | 2 | 2.3% |
Pain | 2 | 2.3% |
Pandemic | 2 | 2.3% |
Patient safety organization | 2 | 2.3% |
Performance appraisal | 2 | 2.3% |
Pharmacovigilance | 2 | 2.3% |
Phases of clinical research | 2 | 2.3% |
Physical examination | 2 | 2.3% |
Point of care | 2 | 2.3% |
Poverty | 2 | 2.3% |
Prediabetes | 2 | 2.3% |
Preterm birth | 2 | 2.3% |
Prevalence | 2 | 2.3% |
Progestogen-only pill | 2 | 2.3% |
Proteinuria | 2 | 2.3% |
Psychiatry | 2 | 2.3% |
Public Health Emergency of International Concern | 2 | 2.3% |
Publication bias | 2 | 2.3% |
Pulse oximetry | 2 | 2.3% |
Quality and Outcomes Framework | 2 | 2.3% |
Raltegravir | 2 | 2.3% |
Receiver operating characteristic | 2 | 2.3% |
Regression analysis | 2 | 2.3% |
Reporting bias | 2 | 2.3% |
Research methods | 2 | 2.3% |
Respiratory disease | 2 | 2.3% |
Reverse-transcriptase inhibitor | 2 | 2.3% |
Ritonavir | 2 | 2.3% |
Science | 2 | 2.3% |
Sepsis | 2 | 2.3% |
Simvastatin | 2 | 2.3% |
Social programs | 2 | 2.3% |
Streptococcus | 2 | 2.3% |
Streptococcus agalactiae | 2 | 2.3% |
Superficial vein thrombosis | 2 | 2.3% |
Sustainability | 2 | 2.3% |
Tooth decay | 2 | 2.3% |
Transient ischemic attack | 2 | 2.3% |
Uncertainty | 2 | 2.3% |
Validity (statistics) | 2 | 2.3% |
Viral load | 2 | 2.3% |
Web of Science | 2 | 2.3% |
2009 flu pandemic in the United Kingdom | 1 | 1.2% |
Abstract (summary) | 1 | 1.2% |
Academic degree | 1 | 1.2% |
Accountability | 1 | 1.2% |
Active surveillance of prostate cancer | 1 | 1.2% |
Acute kidney injury | 1 | 1.2% |
Acute lymphoblastic leukemia | 1 | 1.2% |
Adverse event | 1 | 1.2% |
Ageing | 1 | 1.2% |
Alcoholism | 1 | 1.2% |
Allopurinol | 1 | 1.2% |
Alpha-fetoprotein | 1 | 1.2% |
Amenorrhea | 1 | 1.2% |
Anal sex | 1 | 1.2% |
Analysis | 1 | 1.2% |
Anaphylaxis | 1 | 1.2% |
Anesthetic | 1 | 1.2% |
Angina | 1 | 1.2% |
Angiography | 1 | 1.2% |
Anthracycline | 1 | 1.2% |
Anti-Müllerian hormone | 1 | 1.2% |
Antibody | 1 | 1.2% |
Anticonvulsant | 1 | 1.2% |
Antigen | 1 | 1.2% |
Antimicrobial stewardship | 1 | 1.2% |
Antineoplastic and immunomodulating drugs | 1 | 1.2% |
Antineoplastic drugs | 1 | 1.2% |
Antiplatelet drug | 1 | 1.2% |
Antipsychotic | 1 | 1.2% |
Anxiolytic | 1 | 1.2% |
Apremilast | 1 | 1.2% |
Artery | 1 | 1.2% |
Artificial cardiac pacemaker | 1 | 1.2% |
Asbestos | 1 | 1.2% |
Asbestos-related diseases | 1 | 1.2% |
Asbestosis | 1 | 1.2% |
Aspirin | 1 | 1.2% |
Atezolizumab | 1 | 1.2% |
Atheroma | 1 | 1.2% |
Atorvastatin | 1 | 1.2% |
Atypical pneumonia | 1 | 1.2% |
Auckland | 1 | 1.2% |
Audiology | 1 | 1.2% |
Autoimmunity | 1 | 1.2% |
Automated external defibrillator | 1 | 1.2% |
Autonomy | 1 | 1.2% |
Avelumab | 1 | 1.2% |
BRCA mutation | 1 | 1.2% |
BRCA1 | 1 | 1.2% |
BRCA2 | 1 | 1.2% |
Bacteria | 1 | 1.2% |
Balance (ability) | 1 | 1.2% |
Barbiturate | 1 | 1.2% |
Baricitinib | 1 | 1.2% |
Basic life support | 1 | 1.2% |
Bayesian inference | 1 | 1.2% |
Behavior | 1 | 1.2% |
Benign tumor | 1 | 1.2% |
Bevacizumab | 1 | 1.2% |
Binimetinib | 1 | 1.2% |
Biofilm | 1 | 1.2% |
Biosafety | 1 | 1.2% |
Bipolar disorder | 1 | 1.2% |
Birth defect | 1 | 1.2% |
Bisphosphonate | 1 | 1.2% |
Bladder cancer | 1 | 1.2% |
Bleeding | 1 | 1.2% |
Blinatumomab | 1 | 1.2% |
Blood donation | 1 | 1.2% |
Blood vessel | 1 | 1.2% |
Bone marrow | 1 | 1.2% |
Bone resorption | 1 | 1.2% |
Brain metastasis | 1 | 1.2% |
Brain tumor | 1 | 1.2% |
Branches of science | 1 | 1.2% |
Breast cancer screening | 1 | 1.2% |
Breast milk | 1 | 1.2% |
Breathing | 1 | 1.2% |
Bronchiectasis | 1 | 1.2% |
Budesonide | 1 | 1.2% |
Budesonide/formoterol | 1 | 1.2% |
Burden of proof (law) | 1 | 1.2% |
CD19 | 1 | 1.2% |
CT scan | 1 | 1.2% |
Caesarean section | 1 | 1.2% |
Cancer immunotherapy | 1 | 1.2% |
Cancer research | 1 | 1.2% |
Cancer survivor | 1 | 1.2% |
Cancer treatments | 1 | 1.2% |
Cardiac arrest | 1 | 1.2% |
Cardiopulmonary resuscitation | 1 | 1.2% |
Cardiothoracic surgery | 1 | 1.2% |
Cardioversion | 1 | 1.2% |
Cattle | 1 | 1.2% |
Causes of death | 1 | 1.2% |
Cellulitis | 1 | 1.2% |
Cerebrovascular disease | 1 | 1.2% |
Cervical cancer | 1 | 1.2% |
Cervical screening | 1 | 1.2% |
Chest pain | 1 | 1.2% |
Chest radiograph | 1 | 1.2% |
Child | 1 | 1.2% |
Child mortality | 1 | 1.2% |
Chimeric antigen receptor T cell | 1 | 1.2% |
Chlamydia infection | 1 | 1.2% |
Cholecalciferol | 1 | 1.2% |
Chronic fatigue syndrome | 1 | 1.2% |
Chronic lymphocytic leukemia | 1 | 1.2% |
Chrysotile | 1 | 1.2% |
Circumcision and HIV | 1 | 1.2% |
Clinical commissioning group | 1 | 1.2% |
Clinical research | 1 | 1.2% |
Clopidogrel | 1 | 1.2% |
Clorazepate | 1 | 1.2% |
Coagulation | 1 | 1.2% |
Coefficient of determination | 1 | 1.2% |
Cohen's kappa | 1 | 1.2% |
Combined hormonal contraception | 1 | 1.2% |
Communication | 1 | 1.2% |
Community health | 1 | 1.2% |
Compression stockings | 1 | 1.2% |
Consent | 1 | 1.2% |
Consolidated Omnibus Budget Reconciliation Act of 1985 | 1 | 1.2% |
Continuing medical education | 1 | 1.2% |
Copanlisib | 1 | 1.2% |
Copyright | 1 | 1.2% |
Coronary artery bypass surgery | 1 | 1.2% |
Coronavirus | 1 | 1.2% |
Corticosteroid | 1 | 1.2% |
Cost–utility analysis | 1 | 1.2% |
Cough | 1 | 1.2% |
Creatinine | 1 | 1.2% |
Crizotinib | 1 | 1.2% |
Custirsen | 1 | 1.2% |
Cyclin-dependent kinase | 1 | 1.2% |
Cystatin C | 1 | 1.2% |
Cystic fibrosis | 1 | 1.2% |
Cystic fibrosis transmembrane conductance regulator | 1 | 1.2% |
DPT vaccine | 1 | 1.2% |
Dabigatran | 1 | 1.2% |
Daratumumab | 1 | 1.2% |
Database | 1 | 1.2% |
Death | 1 | 1.2% |
Decriminalizing sex work | 1 | 1.2% |
Defibrillation | 1 | 1.2% |
Demcizumab | 1 | 1.2% |
Dementia with Lewy bodies | 1 | 1.2% |
Demographic and Health Surveys | 1 | 1.2% |
Demography | 1 | 1.2% |
Dengue fever | 1 | 1.2% |
Denosumab | 1 | 1.2% |
Dental public health | 1 | 1.2% |
Depression (mood) | 1 | 1.2% |
Development aid | 1 | 1.2% |
Diabetic foot | 1 | 1.2% |
Diabetic nephropathy | 1 | 1.2% |
Diagnosis code | 1 | 1.2% |
Diagnosis-related group | 1 | 1.2% |
Diazepam | 1 | 1.2% |
Dietary supplement | 1 | 1.2% |
Dieting | 1 | 1.2% |
Difference in differences | 1 | 1.2% |
Diffuse large B-cell lymphoma | 1 | 1.2% |
Diffusion of innovations | 1 | 1.2% |
Disease management (health) | 1 | 1.2% |
Disease-modifying antirheumatic drug | 1 | 1.2% |
Docetaxel | 1 | 1.2% |
Dolutegravir | 1 | 1.2% |
Doxorubicin | 1 | 1.2% |
Dronedarone | 1 | 1.2% |
Drug development | 1 | 1.2% |
Drug injection | 1 | 1.2% |
Drug liberalization | 1 | 1.2% |
Drug resistance | 1 | 1.2% |
Drug user | 1 | 1.2% |
Dummy variable (statistics) | 1 | 1.2% |
ELISA | 1 | 1.2% |
Eclampsia | 1 | 1.2% |
Economics | 1 | 1.2% |
Edema | 1 | 1.2% |
Education | 1 | 1.2% |
Educational assessment | 1 | 1.2% |
Educational technology | 1 | 1.2% |
Effect size | 1 | 1.2% |
Electrocardiography | 1 | 1.2% |
Embolic stroke of undetermined source | 1 | 1.2% |
Embolism | 1 | 1.2% |
Employee Retirement Income Security Act of 1974 | 1 | 1.2% |
Endocrine system | 1 | 1.2% |
Endoscopic mucosal resection | 1 | 1.2% |
Endothelium | 1 | 1.2% |
Environmental health | 1 | 1.2% |
Epidermal growth factor receptor | 1 | 1.2% |
Epilepsy | 1 | 1.2% |
Ergocalciferol | 1 | 1.2% |
Essential health benefits | 1 | 1.2% |
Estrogen | 1 | 1.2% |
Etomidate | 1 | 1.2% |
Evaluation methods | 1 | 1.2% |
Evidence-based practice | 1 | 1.2% |
Exemestane | 1 | 1.2% |
Exhaled nitric oxide | 1 | 1.2% |
Expanded Program on Immunization | 1 | 1.2% |
Falls in older adults | 1 | 1.2% |
Family medicine | 1 | 1.2% |
Fecal occult blood | 1 | 1.2% |
Federally Qualified Health Center | 1 | 1.2% |
Fee | 1 | 1.2% |
Fertility | 1 | 1.2% |
Fever | 1 | 1.2% |
Fibrate | 1 | 1.2% |
Financial audit | 1 | 1.2% |
Fixed effects model | 1 | 1.2% |
Flurazepam | 1 | 1.2% |
Folate | 1 | 1.2% |
Follicle-stimulating hormone | 1 | 1.2% |
Foot | 1 | 1.2% |
Forecasting | 1 | 1.2% |
Frequentist inference | 1 | 1.2% |
Gangrene | 1 | 1.2% |
Genealogy | 1 | 1.2% |
General anaesthesia | 1 | 1.2% |
Generalized linear model | 1 | 1.2% |
Genetic counseling | 1 | 1.2% |
Geriatrics | 1 | 1.2% |
Glioblastoma | 1 | 1.2% |
Global Burden of Disease Study | 1 | 1.2% |
Glomerular filtration rate | 1 | 1.2% |
Glucose test | 1 | 1.2% |
Glucose tolerance test | 1 | 1.2% |
Gout | 1 | 1.2% |
Governance | 1 | 1.2% |
Gums | 1 | 1.2% |
Gynaecology | 1 | 1.2% |
HAS-BLED | 1 | 1.2% |
HIV and pregnancy | 1 | 1.2% |
HIV tropism | 1 | 1.2% |
Health belief model | 1 | 1.2% |
Health care in the United States | 1 | 1.2% |
Health data | 1 | 1.2% |
Health effects of sunlight exposure | 1 | 1.2% |
Health equity | 1 | 1.2% |
Health informatics | 1 | 1.2% |
Health insurance | 1 | 1.2% |
Health literacy | 1 | 1.2% |
Health maintenance organization | 1 | 1.2% |
Health research | 1 | 1.2% |
Healthcare Cost and Utilization Project | 1 | 1.2% |
Healthcare in Italy | 1 | 1.2% |
Hearing aid | 1 | 1.2% |
Hearing loss | 1 | 1.2% |
Heart arrhythmia | 1 | 1.2% |
Hematuria | 1 | 1.2% |
Hemoglobinopathy | 1 | 1.2% |
Hemostasis | 1 | 1.2% |
Heparin | 1 | 1.2% |
Hepatectomy | 1 | 1.2% |
Hepatitis C virus | 1 | 1.2% |
Hereditary nonpolyposis colorectal cancer | 1 | 1.2% |
Hierarchy of evidence | 1 | 1.2% |
Holter monitor | 1 | 1.2% |
Honiara | 1 | 1.2% |
Hospital-acquired condition | 1 | 1.2% |
Hot flash | 1 | 1.2% |
Human Development Index | 1 | 1.2% |
Human chorionic gonadotropin | 1 | 1.2% |
Human diseases and disorders | 1 | 1.2% |
Human papillomavirus infection | 1 | 1.2% |
Human parainfluenza viruses | 1 | 1.2% |
Human respiratory syncytial virus | 1 | 1.2% |
Human sexual activity | 1 | 1.2% |
Human sexuality | 1 | 1.2% |
Human tooth | 1 | 1.2% |
Hypercholesterolemia | 1 | 1.2% |
Hyperuricemia | 1 | 1.2% |
Hypothermia | 1 | 1.2% |
Hypoxemia | 1 | 1.2% |
Immigration | 1 | 1.2% |
Immune system | 1 | 1.2% |
Immunosuppressive drug | 1 | 1.2% |
Immunotherapy | 1 | 1.2% |
Impact factor | 1 | 1.2% |
Imputation (statistics) | 1 | 1.2% |
Indication (medicine) | 1 | 1.2% |
Infant mortality | 1 | 1.2% |
Infectious mononucleosis | 1 | 1.2% |
Influenza A virus subtype H3N2 | 1 | 1.2% |
Influenza vaccine | 1 | 1.2% |
Informed consent | 1 | 1.2% |
Inhaler | 1 | 1.2% |
Innovation | 1 | 1.2% |
Insomnia | 1 | 1.2% |
Insurance | 1 | 1.2% |
Integrated disease surveillance program | 1 | 1.2% |
Intensive care unit | 1 | 1.2% |
Intention-to-treat analysis | 1 | 1.2% |
Interleukin 17 | 1 | 1.2% |
International Classification of Diseases | 1 | 1.2% |
International Health Regulations | 1 | 1.2% |
Intervertebral disc | 1 | 1.2% |
Intima-media thickness | 1 | 1.2% |
Ipilimumab | 1 | 1.2% |
Join (SQL) | 1 | 1.2% |
Laboratory | 1 | 1.2% |
Legionella | 1 | 1.2% |
Legionnaires' disease | 1 | 1.2% |
Life expectancy | 1 | 1.2% |
Life satisfaction | 1 | 1.2% |
Life sciences industry | 1 | 1.2% |
Likelihood function | 1 | 1.2% |
Lithium (medication) | 1 | 1.2% |
Liver | 1 | 1.2% |
Liver cancer | 1 | 1.2% |
Logistic function | 1 | 1.2% |
Long-term effects of alcohol consumption | 1 | 1.2% |
Lorazepam | 1 | 1.2% |
Low-molecular-weight heparin | 1 | 1.2% |
Lung | 1 | 1.2% |
Lung cancer screening | 1 | 1.2% |
Lung nodule | 1 | 1.2% |
Lymphoma | 1 | 1.2% |
MTOR inhibitors | 1 | 1.2% |
Malnutrition | 1 | 1.2% |
MammaPrint | 1 | 1.2% |
Mammography | 1 | 1.2% |
Management of atrial fibrillation | 1 | 1.2% |
Marburg virus disease | 1 | 1.2% |
Marketing authorisation | 1 | 1.2% |
Marriage | 1 | 1.2% |
Maternal–fetal medicine | 1 | 1.2% |
Median | 1 | 1.2% |
Medical device | 1 | 1.2% |
Medical education | 1 | 1.2% |
Medical eligibility criteria for contraceptive use | 1 | 1.2% |
Medical emergencies | 1 | 1.2% |
Medical home | 1 | 1.2% |
Medical imaging | 1 | 1.2% |
Medical microbiology | 1 | 1.2% |
Medical record | 1 | 1.2% |
Medical research | 1 | 1.2% |
Medical school | 1 | 1.2% |
Medical technology | 1 | 1.2% |
Medical ultrasound | 1 | 1.2% |
Medicinal chemistry | 1 | 1.2% |
Melanoma | 1 | 1.2% |
Meningitis | 1 | 1.2% |
Menstrual cycle | 1 | 1.2% |
Menstruation | 1 | 1.2% |
Mergers and acquisitions | 1 | 1.2% |
Mesothelioma | 1 | 1.2% |
Metabolic syndrome | 1 | 1.2% |
Metastatic breast cancer | 1 | 1.2% |
Metered-dose inhaler | 1 | 1.2% |
Metformin | 1 | 1.2% |
Methicillin-resistant Staphylococcus aureus | 1 | 1.2% |
Methods of birth control | 1 | 1.2% |
Microalbuminuria | 1 | 1.2% |
Midazolam | 1 | 1.2% |
Middle East respiratory syndrome | 1 | 1.2% |
Molecular diagnostics | 1 | 1.2% |
Monitoring (medicine) | 1 | 1.2% |
Monoamine oxidase inhibitor | 1 | 1.2% |
Mouth | 1 | 1.2% |
Multilevel model | 1 | 1.2% |
Multimethodology | 1 | 1.2% |
Mycobacterium bovis | 1 | 1.2% |
Māori people | 1 | 1.2% |
NHS dentistry | 1 | 1.2% |
NHS health check | 1 | 1.2% |
Needle exchange programme | 1 | 1.2% |
Needlestick injury | 1 | 1.2% |
Neglected tropical diseases | 1 | 1.2% |
Neonatal intensive care unit | 1 | 1.2% |
Neoplasm | 1 | 1.2% |
Neurodegeneration | 1 | 1.2% |
Neurology | 1 | 1.2% |
Neuropathic arthropathy | 1 | 1.2% |
Neuropathic pain | 1 | 1.2% |
New Drug Application | 1 | 1.2% |
Newborn screening | 1 | 1.2% |
Nicotine replacement therapy | 1 | 1.2% |
Nightmare | 1 | 1.2% |
Nivolumab | 1 | 1.2% |
Non-governmental organization | 1 | 1.2% |
Non-small-cell lung carcinoma | 1 | 1.2% |
Nonsteroidal anti-inflammatory drug | 1 | 1.2% |
Norethisterone enanthate | 1 | 1.2% |
Nuchal scan | 1 | 1.2% |
Obstetric ultrasonography | 1 | 1.2% |
Obstructive lung disease | 1 | 1.2% |
Occupational safety and health | 1 | 1.2% |
Occupational therapist | 1 | 1.2% |
Odds ratio | 1 | 1.2% |
Off-label use | 1 | 1.2% |
Oral hygiene | 1 | 1.2% |
Organ transplantation | 1 | 1.2% |
Orthotics | 1 | 1.2% |
Oseltamivir | 1 | 1.2% |
Osteoarthritis | 1 | 1.2% |
Osteocyte | 1 | 1.2% |
Otoacoustic emission | 1 | 1.2% |
Outbreak | 1 | 1.2% |
Ovary | 1 | 1.2% |
Ownership | 1 | 1.2% |
Oxaliplatin | 1 | 1.2% |
Oxazepam | 1 | 1.2% |
Oxygen therapy | 1 | 1.2% |
PD-L1 | 1 | 1.2% |
Pain management | 1 | 1.2% |
Palbociclib | 1 | 1.2% |
Palliative care | 1 | 1.2% |
Pancreatic cancer | 1 | 1.2% |
Pancreatitis | 1 | 1.2% |
Pandemrix | 1 | 1.2% |
Parameter | 1 | 1.2% |
Parasomnia | 1 | 1.2% |
Parathyroid hormone | 1 | 1.2% |
Paresthesia | 1 | 1.2% |
Patient Protection and Affordable Care Act | 1 | 1.2% |
Pembrolizumab | 1 | 1.2% |
Pension | 1 | 1.2% |
Periodontal disease | 1 | 1.2% |
Periodontology | 1 | 1.2% |
Peripheral artery disease | 1 | 1.2% |
Personal protective equipment | 1 | 1.2% |
Peter C. Gøtzsche | 1 | 1.2% |
Phantom limb | 1 | 1.2% |
Pharmaceutical sciences | 1 | 1.2% |
Pharmaceutics | 1 | 1.2% |
Pharmacokinetics | 1 | 1.2% |
Pharyngitis | 1 | 1.2% |
Phenylketonuria | 1 | 1.2% |
Physical fitness | 1 | 1.2% |
Physiology | 1 | 1.2% |
Placebo-controlled study | 1 | 1.2% |
Pneumocystis pneumonia | 1 | 1.2% |
Podiatrist | 1 | 1.2% |
Podiatry | 1 | 1.2% |
Polio vaccine | 1 | 1.2% |
Polymerase chain reaction | 1 | 1.2% |
Polysomnography | 1 | 1.2% |
Population | 1 | 1.2% |
Positive and negative predictive values | 1 | 1.2% |
Positron emission tomography | 1 | 1.2% |
Posttraumatic stress disorder | 1 | 1.2% |
Poultry diseases | 1 | 1.2% |
Power (statistics) | 1 | 1.2% |
Pre-eclampsia | 1 | 1.2% |
Pre-exposure prophylaxis | 1 | 1.2% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 1 | 1.2% |
Premature ovarian failure | 1 | 1.2% |
Prenatal development | 1 | 1.2% |
Prenatal testing | 1 | 1.2% |
Pressure ulcer | 1 | 1.2% |
Primary care physician | 1 | 1.2% |
Primary healthcare | 1 | 1.2% |
Prior probability | 1 | 1.2% |
Procedural sedation and analgesia | 1 | 1.2% |
Professional degrees of public health | 1 | 1.2% |
Program optimization | 1 | 1.2% |
Programmed cell death protein 1 | 1 | 1.2% |
Proof of concept | 1 | 1.2% |
Propensity score matching | 1 | 1.2% |
Propofol | 1 | 1.2% |
Prostate cancer | 1 | 1.2% |
Prostatectomy | 1 | 1.2% |
Prosthesis | 1 | 1.2% |
Prostitution | 1 | 1.2% |
Prothrombin time | 1 | 1.2% |
Pseudomonas | 1 | 1.2% |
Pseudomonas aeruginosa | 1 | 1.2% |
Psoriasis | 1 | 1.2% |
Psoriatic arthritis | 1 | 1.2% |
Psychosis | 1 | 1.2% |
Psychotherapy | 1 | 1.2% |
Puberty | 1 | 1.2% |
Public services | 1 | 1.2% |
Pulmonary embolism | 1 | 1.2% |
Pulmonary rehabilitation | 1 | 1.2% |
Pulmonology | 1 | 1.2% |
Pulse wave velocity | 1 | 1.2% |
Q fever | 1 | 1.2% |
Quality | 1 | 1.2% |
Quality management | 1 | 1.2% |
Quality of life (healthcare) | 1 | 1.2% |
Quantitative computed tomography | 1 | 1.2% |
ROS1 | 1 | 1.2% |
Radiology | 1 | 1.2% |
Radiosurgery | 1 | 1.2% |
Ramucirumab | 1 | 1.2% |
Randomness | 1 | 1.2% |
Rapid eye movement sleep | 1 | 1.2% |
Rapid eye movement sleep behavior disorder | 1 | 1.2% |
Reference range | 1 | 1.2% |
Regulatory compliance | 1 | 1.2% |
Reinsurance | 1 | 1.2% |
Reuptake inhibitor | 1 | 1.2% |
Rheumatic fever | 1 | 1.2% |
Rheumatoid arthritis | 1 | 1.2% |
Rheumatology | 1 | 1.2% |
Risk ratio | 1 | 1.2% |
Robert Guthrie | 1 | 1.2% |
Rural health | 1 | 1.2% |
Schizophrenia | 1 | 1.2% |
Scientific method | 1 | 1.2% |
Secukinumab | 1 | 1.2% |
Sedation | 1 | 1.2% |
Self-esteem | 1 | 1.2% |
Self-insurance | 1 | 1.2% |
Serosorting | 1 | 1.2% |
Service industries | 1 | 1.2% |
Services sector of the economy | 1 | 1.2% |
Sex and drugs | 1 | 1.2% |
Shared decision-making in medicine | 1 | 1.2% |
Sickle cell disease | 1 | 1.2% |
Sleep | 1 | 1.2% |
Smoking | 1 | 1.2% |
Smoking cessation | 1 | 1.2% |
Social determinants of health | 1 | 1.2% |
Social support | 1 | 1.2% |
Software testing | 1 | 1.2% |
Sorafenib | 1 | 1.2% |
Sotalol | 1 | 1.2% |
Spinal disc herniation | 1 | 1.2% |
Spinal fusion | 1 | 1.2% |
Statistical classification | 1 | 1.2% |
Statistical process control | 1 | 1.2% |
Stavudine | 1 | 1.2% |
Student-centered learning | 1 | 1.2% |
Sulfonylurea | 1 | 1.2% |
Sunitinib | 1 | 1.2% |
Surveillance | 1 | 1.2% |
Survival analysis | 1 | 1.2% |
Sustainable Development Goals | 1 | 1.2% |
Swine influenza | 1 | 1.2% |
Systemic lupus erythematosus | 1 | 1.2% |
T cell | 1 | 1.2% |
TNF inhibitor | 1 | 1.2% |
Tamoxifen | 1 | 1.2% |
Tax | 1 | 1.2% |
Technology | 1 | 1.2% |
Telecare | 1 | 1.2% |
Telehealth | 1 | 1.2% |
Telenursing | 1 | 1.2% |
Temazepam | 1 | 1.2% |
Tetanus vaccine | 1 | 1.2% |
Tetraplegia | 1 | 1.2% |
The European Semester | 1 | 1.2% |
Thrombophilia | 1 | 1.2% |
Thrombosis prevention | 1 | 1.2% |
Time series | 1 | 1.2% |
Tisagenlecleucel | 1 | 1.2% |
Tobacco control | 1 | 1.2% |
Tobacco smoking | 1 | 1.2% |
Tocilizumab | 1 | 1.2% |
Toe | 1 | 1.2% |
Tofacitinib | 1 | 1.2% |
Trabecula | 1 | 1.2% |
Transtheoretical model | 1 | 1.2% |
Trastuzumab | 1 | 1.2% |
Triage | 1 | 1.2% |
Triglyceride | 1 | 1.2% |
Triple test | 1 | 1.2% |
Tumor microenvironment | 1 | 1.2% |
Tumor necrosis factor alpha | 1 | 1.2% |
Type I and type II errors | 1 | 1.2% |
Ulcer (dermatology) | 1 | 1.2% |
Ulipristal acetate | 1 | 1.2% |
Uric acid | 1 | 1.2% |
Urinary tract infection | 1 | 1.2% |
Ustekinumab | 1 | 1.2% |
Vaccination | 1 | 1.2% |
Varicose veins | 1 | 1.2% |
Veterinary medicine | 1 | 1.2% |
Visual impairment | 1 | 1.2% |
Vitamin | 1 | 1.2% |
WHO Framework Convention on Tobacco Control | 1 | 1.2% |
Waist–hip ratio | 1 | 1.2% |
Waitematā Harbour | 1 | 1.2% |
Weighted arithmetic mean | 1 | 1.2% |
Wheeze | 1 | 1.2% |
Wound | 1 | 1.2% |
Youth | 1 | 1.2% |
Zidovudine | 1 | 1.2% |
Zoledronic acid | 1 | 1.2% |
abs | rel | |
---|---|---|
Health | 89 | 97.8% |
Health sciences | 89 | 97.8% |
Medicine | 89 | 97.8% |
Medical specialties | 87 | 95.6% |
Clinical medicine | 84 | 92.3% |
Health care | 76 | 83.5% |
Public health | 39 | 42.9% |
Diseases and disorders | 30 | 33.0% |
Health economics | 27 | 29.7% |
Cardiovascular disease | 26 | 28.6% |
Preventive healthcare | 26 | 28.6% |
Randomized controlled trial | 24 | 26.4% |
Risk | 24 | 26.4% |
Epidemiology | 23 | 25.3% |
Hypertension | 23 | 25.3% |
Infection | 21 | 23.1% |
Adherence (medicine) | 18 | 19.8% |
Evidence-based medicine | 18 | 19.8% |
Myocardial infarction | 18 | 19.8% |
Clinical trial | 17 | 18.7% |
Health policy | 17 | 18.7% |
Major depressive disorder | 17 | 18.7% |
Medical guideline | 17 | 18.7% |
Blood pressure | 16 | 17.6% |
Cancer | 16 | 17.6% |
Coronary artery disease | 16 | 17.6% |
Medical diagnosis | 16 | 17.6% |
Medical humanities | 16 | 17.6% |
Systematic review | 16 | 17.6% |
HIV/AIDS | 15 | 16.5% |
Human activities | 15 | 16.5% |
Medication | 15 | 16.5% |
Chronic condition | 14 | 15.4% |
Disease | 14 | 15.4% |
Meta-analysis | 14 | 15.4% |
Stroke | 14 | 15.4% |
Statin | 13 | 14.3% |
Health professional | 12 | 13.2% |
Obesity | 12 | 13.2% |
Exercise | 11 | 12.1% |
Heart | 11 | 12.1% |
Immunology | 11 | 12.1% |
Low-density lipoprotein | 11 | 12.1% |
Sensitivity and specificity | 11 | 12.1% |
Tuberculosis | 11 | 12.1% |
Glycated hemoglobin | 10 | 11.0% |
High-density lipoprotein | 10 | 11.0% |
Sexually transmitted infection | 10 | 11.0% |
Therapy | 10 | 11.0% |
Atherosclerosis | 9 | 9.9% |
Cardiovascular system | 9 | 9.9% |
Caregiver | 9 | 9.9% |
Cholesterol | 9 | 9.9% |
Diabetes mellitus type 2 | 9 | 9.9% |
Hospital | 9 | 9.9% |
Antihypertensive drug | 8 | 8.8% |
Biology | 8 | 8.8% |
Childbirth | 8 | 8.8% |
Chronic kidney disease | 8 | 8.8% |
Diagnosis of HIV/AIDS | 8 | 8.8% |
Evaluation | 8 | 8.8% |
Health system | 8 | 8.8% |
Infectious diseases | 8 | 8.8% |
Medical treatments | 8 | 8.8% |
Public sphere | 8 | 8.8% |
Surgery | 8 | 8.8% |
Antimicrobial resistance | 7 | 7.7% |
Blinded experiment | 7 | 7.7% |
Body mass index | 7 | 7.7% |
Chemotherapy | 7 | 7.7% |
Cohort study | 7 | 7.7% |
Confidence interval | 7 | 7.7% |
Diabetes | 7 | 7.7% |
Dieting | 7 | 7.7% |
Electronic health record | 7 | 7.7% |
Hypercholesterolemia | 7 | 7.7% |
Management of HIV/AIDS | 7 | 7.7% |
Men who have sex with men | 7 | 7.7% |
Pain | 7 | 7.7% |
Patient | 7 | 7.7% |
Renal function | 7 | 7.7% |
Saturated fat | 7 | 7.7% |
Screening (medicine) | 7 | 7.7% |
Type 2 diabetes | 7 | 7.7% |
Vaccination | 7 | 7.7% |
Weight loss | 7 | 7.7% |
Adverse effect | 6 | 6.6% |
Blood sugar level | 6 | 6.6% |
Cardiology | 6 | 6.6% |
Dose (biochemistry) | 6 | 6.6% |
Drugs | 6 | 6.6% |
Healthy diet | 6 | 6.6% |
Internal medicine | 6 | 6.6% |
Life sciences | 6 | 6.6% |
Mental health | 6 | 6.6% |
Microbiology | 6 | 6.6% |
Physical therapy | 6 | 6.6% |
Phytosterol | 6 | 6.6% |
Pneumonia | 6 | 6.6% |
Post-exposure prophylaxis | 6 | 6.6% |
Pre-exposure prophylaxis | 6 | 6.6% |
Prevention of HIV/AIDS | 6 | 6.6% |
Quality-adjusted life year | 6 | 6.6% |
Thrombosis | 6 | 6.6% |
Angiology | 5 | 5.5% |
Anticoagulant | 5 | 5.5% |
Aspirin | 5 | 5.5% |
Circulatory system | 5 | 5.5% |
Diabetes management | 5 | 5.5% |
Diabetes mellitus | 5 | 5.5% |
Emergency department | 5 | 5.5% |
Fat | 5 | 5.5% |
HIV | 5 | 5.5% |
Hospital readmission | 5 | 5.5% |
Human reproduction | 5 | 5.5% |
Influenza | 5 | 5.5% |
Medicaid | 5 | 5.5% |
Medical imaging | 5 | 5.5% |
Mental disorder | 5 | 5.5% |
Methicillin-resistant Staphylococcus aureus | 5 | 5.5% |
Nursing | 5 | 5.5% |
Pharmacy | 5 | 5.5% |
Physical activity | 5 | 5.5% |
Prediabetes | 5 | 5.5% |
Pregnancy | 5 | 5.5% |
RTT | 5 | 5.5% |
Sepsis | 5 | 5.5% |
Transient ischemic attack | 5 | 5.5% |
Venous thrombosis | 5 | 5.5% |
Virus | 5 | 5.5% |
ACE inhibitor | 4 | 4.4% |
Acute coronary syndrome | 4 | 4.4% |
Alcoholism | 4 | 4.4% |
Angina | 4 | 4.4% |
Animal diseases | 4 | 4.4% |
Antibiotic | 4 | 4.4% |
Antiplatelet drug | 4 | 4.4% |
Atorvastatin | 4 | 4.4% |
Bipolar disorder | 4 | 4.4% |
Blood | 4 | 4.4% |
CT scan | 4 | 4.4% |
Canagliflozin | 4 | 4.4% |
Clopidogrel | 4 | 4.4% |
Combined oral contraceptive pill | 4 | 4.4% |
Community health | 4 | 4.4% |
Comorbidity | 4 | 4.4% |
Cost-effectiveness analysis | 4 | 4.4% |
Deep vein thrombosis | 4 | 4.4% |
Dementia | 4 | 4.4% |
Determinants of health | 4 | 4.4% |
Disorders of endocrine pancreas | 4 | 4.4% |
Ebola virus disease | 4 | 4.4% |
Fish oil | 4 | 4.4% |
GeneXpert MTB/RIF | 4 | 4.4% |
Heart failure | 4 | 4.4% |
Hyperglycemia | 4 | 4.4% |
Hypoglycemia | 4 | 4.4% |
Influenza A virus subtype H5N1 | 4 | 4.4% |
Medicare (United States) | 4 | 4.4% |
Metabolic syndrome | 4 | 4.4% |
Neoplasms | 4 | 4.4% |
Omega-3 fatty acid | 4 | 4.4% |
Ovarian cancer | 4 | 4.4% |
Patient Protection and Affordable Care Act | 4 | 4.4% |
Pediatrics | 4 | 4.4% |
Peripheral neuropathy | 4 | 4.4% |
Physical fitness | 4 | 4.4% |
Physician | 4 | 4.4% |
Physiology | 4 | 4.4% |
Psychiatry | 4 | 4.4% |
Psychotherapy | 4 | 4.4% |
Research | 4 | 4.4% |
Safe sex | 4 | 4.4% |
Schizophrenia | 4 | 4.4% |
Self-care | 4 | 4.4% |
Statistics | 4 | 4.4% |
Tissues (biology) | 4 | 4.4% |
Tobacco smoking | 4 | 4.4% |
Violence | 4 | 4.4% |
Zidovudine | 4 | 4.4% |
Adolescence | 3 | 3.3% |
Alcoholic drink | 3 | 3.3% |
Analgesic | 3 | 3.3% |
Anesthesia | 3 | 3.3% |
Angiotensin II receptor blocker | 3 | 3.3% |
Animal viral diseases | 3 | 3.3% |
Arthritis | 3 | 3.3% |
Asthma | 3 | 3.3% |
Best practice | 3 | 3.3% |
Birth control | 3 | 3.3% |
Bleeding | 3 | 3.3% |
Breast cancer | 3 | 3.3% |
Breastfeeding | 3 | 3.3% |
Bupropion | 3 | 3.3% |
CD4 | 3 | 3.3% |
Cardiovascular diseases | 3 | 3.3% |
Case management (US health system) | 3 | 3.3% |
Cigar | 3 | 3.3% |
Cigarette | 3 | 3.3% |
Cognitive behavioral therapy | 3 | 3.3% |
Condom | 3 | 3.3% |
Coronary artery bypass surgery | 3 | 3.3% |
Current Procedural Terminology | 3 | 3.3% |
Data analysis | 3 | 3.3% |
Diabetic retinopathy | 3 | 3.3% |
Diet (nutrition) | 3 | 3.3% |
Dietary supplement | 3 | 3.3% |
Disability | 3 | 3.3% |
Disease surveillance | 3 | 3.3% |
Dysmenorrhea | 3 | 3.3% |
Effect size | 3 | 3.3% |
Electrocardiography | 3 | 3.3% |
Electronic cigarette | 3 | 3.3% |
Endocrine system | 3 | 3.3% |
Epidemic | 3 | 3.3% |
Framingham Risk Score | 3 | 3.3% |
Gonorrhea | 3 | 3.3% |
Hematology | 3 | 3.3% |
Hepatitis | 3 | 3.3% |
Infection control | 3 | 3.3% |
Influenza A virus | 3 | 3.3% |
Influenza pandemic | 3 | 3.3% |
Influenza vaccine | 3 | 3.3% |
Influenza-like illness | 3 | 3.3% |
Insulin | 3 | 3.3% |
Insulin (medication) | 3 | 3.3% |
Intrauterine device | 3 | 3.3% |
Ischemia | 3 | 3.3% |
Lamivudine | 3 | 3.3% |
Lentiviruses | 3 | 3.3% |
Liraglutide | 3 | 3.3% |
Long-term effects of alcohol consumption | 3 | 3.3% |
Lymphoma | 3 | 3.3% |
MEDLINE | 3 | 3.3% |
Medical prescription | 3 | 3.3% |
Medical record | 3 | 3.3% |
Medical test | 3 | 3.3% |
Medicare dual eligible | 3 | 3.3% |
Mediterranean diet | 3 | 3.3% |
Metformin | 3 | 3.3% |
Multi-drug-resistant tuberculosis | 3 | 3.3% |
Nicotine | 3 | 3.3% |
Nicotine replacement therapy | 3 | 3.3% |
Off-label use | 3 | 3.3% |
Pandemic | 3 | 3.3% |
Parkinson's disease | 3 | 3.3% |
Passive smoking | 3 | 3.3% |
Pay for performance (healthcare) | 3 | 3.3% |
Percutaneous coronary intervention | 3 | 3.3% |
Pharmacology | 3 | 3.3% |
Placebo | 3 | 3.3% |
Placebo-controlled study | 3 | 3.3% |
Preventive medicine | 3 | 3.3% |
Primary care | 3 | 3.3% |
Prothrombin time | 3 | 3.3% |
Pulmonary embolism | 3 | 3.3% |
Reporting bias | 3 | 3.3% |
Reverse-transcriptase inhibitor | 3 | 3.3% |
Rivaroxaban | 3 | 3.3% |
SGLT2 inhibitor | 3 | 3.3% |
Safety | 3 | 3.3% |
Sensitivity analysis | 3 | 3.3% |
Sexual health | 3 | 3.3% |
Sexual intercourse | 3 | 3.3% |
Shortness of breath | 3 | 3.3% |
Simvastatin | 3 | 3.3% |
Smoking | 3 | 3.3% |
Smoking cessation | 3 | 3.3% |
Stanol ester | 3 | 3.3% |
Stavudine | 3 | 3.3% |
Study heterogeneity | 3 | 3.3% |
Tetanus | 3 | 3.3% |
Thrombophilia | 3 | 3.3% |
Tuberculosis management | 3 | 3.3% |
Unit of alcohol | 3 | 3.3% |
Vaccine | 3 | 3.3% |
Varenicline | 3 | 3.3% |
Vitamin | 3 | 3.3% |
Vitamin E | 3 | 3.3% |
Warfarin | 3 | 3.3% |
Acute myeloid leukemia | 2 | 2.2% |
Africa | 2 | 2.2% |
Amyotrophic lateral sclerosis | 2 | 2.2% |
Anatomical terms of motion | 2 | 2.2% |
Angiography | 2 | 2.2% |
Anti-diabetic medication | 2 | 2.2% |
Antimicrobial stewardship | 2 | 2.2% |
Antiviral drug | 2 | 2.2% |
Anxiety disorder | 2 | 2.2% |
Arrhythmia | 2 | 2.2% |
Atheroma | 2 | 2.2% |
Atrial fibrillation | 2 | 2.2% |
Attention | 2 | 2.2% |
Audiology | 2 | 2.2% |
Avian influenza | 2 | 2.2% |
BRCA mutation | 2 | 2.2% |
Balance (ability) | 2 | 2.2% |
Bariatric surgery | 2 | 2.2% |
Behavior | 2 | 2.2% |
Beta blocker | 2 | 2.2% |
Bias | 2 | 2.2% |
Biomarker | 2 | 2.2% |
Biopsy | 2 | 2.2% |
Blood glucose monitoring | 2 | 2.2% |
Body fluids | 2 | 2.2% |
Bone marrow | 2 | 2.2% |
CT pulmonary angiogram | 2 | 2.2% |
Cannabidiol | 2 | 2.2% |
Cannabinoid | 2 | 2.2% |
Cannabis (drug) | 2 | 2.2% |
Carbapenem-resistant enterobacteriaceae | 2 | 2.2% |
Cardiac muscle | 2 | 2.2% |
Cardiac stress test | 2 | 2.2% |
Cardiothoracic surgery | 2 | 2.2% |
Cerebrospinal fluid | 2 | 2.2% |
Cervical cancer | 2 | 2.2% |
Circumcision and HIV | 2 | 2.2% |
Clinical psychology | 2 | 2.2% |
Cochrane Library | 2 | 2.2% |
Cognition | 2 | 2.2% |
Colorectal cancer | 2 | 2.2% |
Community health worker | 2 | 2.2% |
Computed tomography angiography | 2 | 2.2% |
Confounding | 2 | 2.2% |
Contrast (vision) | 2 | 2.2% |
Cost–utility analysis | 2 | 2.2% |
Creatinine | 2 | 2.2% |
D-dimer | 2 | 2.2% |
Dabigatran | 2 | 2.2% |
Diabetic ketoacidosis | 2 | 2.2% |
Diagnosis-related group | 2 | 2.2% |
Dietary fiber | 2 | 2.2% |
Diffuse large B-cell lymphoma | 2 | 2.2% |
Disseminated intravascular coagulation | 2 | 2.2% |
Driving | 2 | 2.2% |
Dronabinol | 2 | 2.2% |
Echocardiography | 2 | 2.2% |
Emergency contraception | 2 | 2.2% |
Endocrine pancreas | 2 | 2.2% |
Endometriosis | 2 | 2.2% |
Epidural administration | 2 | 2.2% |
Executive functions | 2 | 2.2% |
Exenatide | 2 | 2.2% |
Extensively drug-resistant tuberculosis | 2 | 2.2% |
Familial hypercholesterolemia | 2 | 2.2% |
Flu season | 2 | 2.2% |
Follicular lymphoma | 2 | 2.2% |
Food | 2 | 2.2% |
Formulary (pharmacy) | 2 | 2.2% |
Fraction (mathematics) | 2 | 2.2% |
Gene expression | 2 | 2.2% |
Gestational diabetes | 2 | 2.2% |
Glucagon-like peptide-1 | 2 | 2.2% |
Glucose tolerance test | 2 | 2.2% |
Glycemic index | 2 | 2.2% |
Gynaecologic disorders | 2 | 2.2% |
Headache | 2 | 2.2% |
Health Level 7 | 2 | 2.2% |
Health care quality | 2 | 2.2% |
Health insurance | 2 | 2.2% |
Health insurance coverage in the United States | 2 | 2.2% |
Healthcare industry | 2 | 2.2% |
Healthcare management | 2 | 2.2% |
Healthcare quality | 2 | 2.2% |
Hearing | 2 | 2.2% |
Hearing loss | 2 | 2.2% |
Heart arrhythmia | 2 | 2.2% |
Heart failure with preserved ejection fraction | 2 | 2.2% |
Heart-type fatty acid binding protein | 2 | 2.2% |
Hematopoietic stem cell transplantation | 2 | 2.2% |
Hodgkin's lymphoma | 2 | 2.2% |
Homelessness | 2 | 2.2% |
Hormonal contraception | 2 | 2.2% |
Hospital-acquired infection | 2 | 2.2% |
Human papillomavirus infection | 2 | 2.2% |
Immunodeficiency | 2 | 2.2% |
Incremental cost-effectiveness ratio | 2 | 2.2% |
Incretin | 2 | 2.2% |
Influenza A virus subtype H7N9 | 2 | 2.2% |
Insulin analog | 2 | 2.2% |
Insulin degludec | 2 | 2.2% |
Insulin pump | 2 | 2.2% |
Intensive care unit | 2 | 2.2% |
International Health Regulations | 2 | 2.2% |
International Statistical Classification of Diseases and Related Health Problems | 2 | 2.2% |
Intravenous therapy | 2 | 2.2% |
Laparoscopy | 2 | 2.2% |
Leukemia | 2 | 2.2% |
Lithium (medication) | 2 | 2.2% |
Lixisenatide | 2 | 2.2% |
Lumbar puncture | 2 | 2.2% |
Magnetic resonance imaging | 2 | 2.2% |
Male genital disorders | 2 | 2.2% |
Mania | 2 | 2.2% |
Medical cannabis | 2 | 2.2% |
Medical history | 2 | 2.2% |
Medroxyprogesterone acetate | 2 | 2.2% |
Memory | 2 | 2.2% |
Menopause | 2 | 2.2% |
Middle East respiratory syndrome coronavirus | 2 | 2.2% |
Millennium Development Goals | 2 | 2.2% |
Molecular diagnostics | 2 | 2.2% |
Multiple sclerosis | 2 | 2.2% |
Mycobacterium bovis | 2 | 2.2% |
Nabiximols | 2 | 2.2% |
Needle exchange programme | 2 | 2.2% |
Neonatal alloimmune thrombocytopenia | 2 | 2.2% |
Nervous system | 2 | 2.2% |
Neurology | 2 | 2.2% |
Neuropathic pain | 2 | 2.2% |
Nevirapine | 2 | 2.2% |
Non-Hodgkin lymphoma | 2 | 2.2% |
Non-alcoholic fatty liver disease | 2 | 2.2% |
Occupational therapist | 2 | 2.2% |
Old age | 2 | 2.2% |
Ondansetron | 2 | 2.2% |
Organs (anatomy) | 2 | 2.2% |
Osteoarthritis | 2 | 2.2% |
Pain management | 2 | 2.2% |
Partner notification | 2 | 2.2% |
Pathology | 2 | 2.2% |
Patient safety | 2 | 2.2% |
Perception | 2 | 2.2% |
Peripheral artery disease | 2 | 2.2% |
Pharmaceutical sciences | 2 | 2.2% |
Platelet | 2 | 2.2% |
Platelet transfusion | 2 | 2.2% |
Poliomyelitis | 2 | 2.2% |
Poliomyelitis eradication | 2 | 2.2% |
Polypharmacy | 2 | 2.2% |
Positron emission tomography | 2 | 2.2% |
Posttraumatic stress disorder | 2 | 2.2% |
Pre-eclampsia | 2 | 2.2% |
Prescription drug | 2 | 2.2% |
Psychoactive drug | 2 | 2.2% |
Publication bias | 2 | 2.2% |
QT interval | 2 | 2.2% |
Real-time polymerase chain reaction | 2 | 2.2% |
Relative risk | 2 | 2.2% |
Rheumatoid arthritis | 2 | 2.2% |
Rheumatology | 2 | 2.2% |
Risk assessment | 2 | 2.2% |
Rosuvastatin | 2 | 2.2% |
Saxagliptin | 2 | 2.2% |
Sex worker | 2 | 2.2% |
Sexually transmitted diseases and infections | 2 | 2.2% |
Snellen chart | 2 | 2.2% |
Spasticity | 2 | 2.2% |
Spinal anaesthesia | 2 | 2.2% |
Substance abuse | 2 | 2.2% |
Surface epithelial-stromal tumor | 2 | 2.2% |
Syncope (medicine) | 2 | 2.2% |
Telehealth | 2 | 2.2% |
Test (assessment) | 2 | 2.2% |
Tetrahydrocannabinol | 2 | 2.2% |
Thrombocytopenia | 2 | 2.2% |
Tourette syndrome | 2 | 2.2% |
Traffic | 2 | 2.2% |
Traffic collision | 2 | 2.2% |
Traumatic brain injury | 2 | 2.2% |
Treatment as prevention | 2 | 2.2% |
Troponin | 2 | 2.2% |
Urinary incontinence | 2 | 2.2% |
Vein | 2 | 2.2% |
Veterinary medicine | 2 | 2.2% |
Virology | 2 | 2.2% |
Visual acuity | 2 | 2.2% |
Visual impairment | 2 | 2.2% |
Visual perception | 2 | 2.2% |
Waste | 2 | 2.2% |
Women's health | 2 | 2.2% |
Working memory | 2 | 2.2% |
World Wide Web | 2 | 2.2% |
Zoonosis | 2 | 2.2% |
2009 flu pandemic | 1 | 1.1% |
Abacavir | 1 | 1.1% |
Abdomen | 1 | 1.1% |
Abdominal obesity | 1 | 1.1% |
Adalimumab | 1 | 1.1% |
Adjustable gastric band | 1 | 1.1% |
Adjuvant therapy | 1 | 1.1% |
Aflibercept | 1 | 1.1% |
African Americans | 1 | 1.1% |
Alirocumab | 1 | 1.1% |
Allocation concealment | 1 | 1.1% |
Alpha-Linolenic acid | 1 | 1.1% |
Ambulance | 1 | 1.1% |
Aminoglycoside | 1 | 1.1% |
Amlodipine | 1 | 1.1% |
Amoxicillin | 1 | 1.1% |
Amphotericin B | 1 | 1.1% |
Ampicillin | 1 | 1.1% |
Analysis of variance | 1 | 1.1% |
Angiotensin-converting enzyme | 1 | 1.1% |
Animal virology | 1 | 1.1% |
Animals | 1 | 1.1% |
Animals and humans | 1 | 1.1% |
Anovulation | 1 | 1.1% |
Antibiotic prophylaxis | 1 | 1.1% |
Antibiotic sensitivity | 1 | 1.1% |
Anticonvulsant | 1 | 1.1% |
Antimicrobial | 1 | 1.1% |
Antiphospholipid syndrome | 1 | 1.1% |
Anxiety | 1 | 1.1% |
Aorta | 1 | 1.1% |
Aortic aneurysm | 1 | 1.1% |
Aortic dissection | 1 | 1.1% |
Aortic stenosis | 1 | 1.1% |
Aortic valve | 1 | 1.1% |
Aortic valve replacement | 1 | 1.1% |
Apixaban | 1 | 1.1% |
Apolipoprotein | 1 | 1.1% |
Artery | 1 | 1.1% |
Ascending cholangitis | 1 | 1.1% |
Assessment of kidney function | 1 | 1.1% |
Atrium (heart) | 1 | 1.1% |
Attentional control | 1 | 1.1% |
Autism spectrum | 1 | 1.1% |
Azacitidine | 1 | 1.1% |
Baby Friendly Hospital Initiative | 1 | 1.1% |
Bacteremia | 1 | 1.1% |
Bacteriuria | 1 | 1.1% |
Beef cattle | 1 | 1.1% |
Behaviour therapy | 1 | 1.1% |
Beta cell | 1 | 1.1% |
Beta thalassemia | 1 | 1.1% |
Beta-Sitosterol | 1 | 1.1% |
Beta-lactamase | 1 | 1.1% |
Bile duct | 1 | 1.1% |
Biomarker (medicine) | 1 | 1.1% |
Birth defect | 1 | 1.1% |
Bladder cancer | 1 | 1.1% |
Blood cell | 1 | 1.1% |
Blood lipids | 1 | 1.1% |
Blood transfusion | 1 | 1.1% |
Borderline personality disorder | 1 | 1.1% |
Borna disease | 1 | 1.1% |
Borrelia | 1 | 1.1% |
Bovine leukemia virus | 1 | 1.1% |
Breastfeeding and HIV | 1 | 1.1% |
Broad-spectrum antibiotic | 1 | 1.1% |
Brucella | 1 | 1.1% |
C-reactive protein | 1 | 1.1% |
CA-125 | 1 | 1.1% |
CHOP | 1 | 1.1% |
COX-3 | 1 | 1.1% |
Cancer Drugs Fund | 1 | 1.1% |
Cancer screening | 1 | 1.1% |
Cancer staging | 1 | 1.1% |
Capacity building | 1 | 1.1% |
Carbapenem | 1 | 1.1% |
Carcinogenesis | 1 | 1.1% |
Carcinoma | 1 | 1.1% |
Cardiac catheterization | 1 | 1.1% |
Cardiac imaging | 1 | 1.1% |
Cardiac magnetic resonance imaging | 1 | 1.1% |
Cardiac marker | 1 | 1.1% |
Cardiac monitoring | 1 | 1.1% |
Cardiac rehabilitation | 1 | 1.1% |
Cardiac surgery | 1 | 1.1% |
Cardiovascular physiology | 1 | 1.1% |
Case management (US healthcare system) | 1 | 1.1% |
Categorical variable | 1 | 1.1% |
Cattle | 1 | 1.1% |
Causes of death | 1 | 1.1% |
Ceftazidime | 1 | 1.1% |
Cephalosporin | 1 | 1.1% |
Cerebrovascular disease | 1 | 1.1% |
Cervical screening | 1 | 1.1% |
Change management | 1 | 1.1% |
Chikungunya | 1 | 1.1% |
Childhood | 1 | 1.1% |
Childhood obesity | 1 | 1.1% |
Chlamydia infection | 1 | 1.1% |
Chlortalidone | 1 | 1.1% |
Cholecystectomy | 1 | 1.1% |
Cholecystitis | 1 | 1.1% |
Chronic fatigue syndrome | 1 | 1.1% |
Chronic lymphocytic leukemia | 1 | 1.1% |
Chronic obstructive pulmonary disease | 1 | 1.1% |
Chronotype | 1 | 1.1% |
Ciprofloxacin | 1 | 1.1% |
Circadian rhythm | 1 | 1.1% |
Clinical pathology | 1 | 1.1% |
Clostridial infections | 1 | 1.1% |
Clostridioides difficile infection | 1 | 1.1% |
Clostridium difficile infection | 1 | 1.1% |
Coagulation | 1 | 1.1% |
Coenzyme Q10 | 1 | 1.1% |
Colonoscopy | 1 | 1.1% |
Common bile duct stone | 1 | 1.1% |
Community-acquired pneumonia | 1 | 1.1% |
Computerized physician order entry | 1 | 1.1% |
Confidentiality | 1 | 1.1% |
Copeptin | 1 | 1.1% |
Coronary CT angiography | 1 | 1.1% |
Coronary CT calcium scan | 1 | 1.1% |
Coronary catheterization | 1 | 1.1% |
Coronary circulation | 1 | 1.1% |
Coronavirus | 1 | 1.1% |
Creatine kinase | 1 | 1.1% |
Crohn's disease | 1 | 1.1% |
Cryptococcosis | 1 | 1.1% |
Culture | 1 | 1.1% |
Cure | 1 | 1.1% |
Cyclooxygenase | 1 | 1.1% |
Cystoscopy | 1 | 1.1% |
Cytopathology | 1 | 1.1% |
DNA sequencing | 1 | 1.1% |
Defined daily dose | 1 | 1.1% |
Depression (mood) | 1 | 1.1% |
Diabetes medication | 1 | 1.1% |
Diabetes mellitus type 1 | 1 | 1.1% |
Diabetic hypoglycemia | 1 | 1.1% |
Diabetic nephropathy | 1 | 1.1% |
Diabetic neuropathy | 1 | 1.1% |
Diastole | 1 | 1.1% |
Didanosine | 1 | 1.1% |
Dietitian | 1 | 1.1% |
Digestive diseases | 1 | 1.1% |
Digestive system | 1 | 1.1% |
Diltiazem | 1 | 1.1% |
Directly observed treatment, short-course | 1 | 1.1% |
Disability-adjusted life year | 1 | 1.1% |
Disease management (health) | 1 | 1.1% |
Docosahexaenoic acid | 1 | 1.1% |
Doctor of Medicine | 1 | 1.1% |
Dog | 1 | 1.1% |
Dopamine | 1 | 1.1% |
Drug-induced QT prolongation | 1 | 1.1% |
Dual diagnosis | 1 | 1.1% |
Dummy variable (statistics) | 1 | 1.1% |
Dyslipidemia | 1 | 1.1% |
ELISA | 1 | 1.1% |
Echinococcus multilocularis | 1 | 1.1% |
Economics of service industries | 1 | 1.1% |
Ectopic pregnancy | 1 | 1.1% |
Educational assessment | 1 | 1.1% |
Eicosapentaenoic acid | 1 | 1.1% |
Embolic stroke of undetermined source | 1 | 1.1% |
Emergency | 1 | 1.1% |
Emtricitabine/tenofovir | 1 | 1.1% |
Endocrine, nutritional and metabolic diseases | 1 | 1.1% |
Endometrial cancer | 1 | 1.1% |
Endoscopic retrograde cholangiopancreatography | 1 | 1.1% |
Epidemiology of HIV/AIDS | 1 | 1.1% |
Equianalgesic | 1 | 1.1% |
Eradication of infectious diseases | 1 | 1.1% |
Estrogen | 1 | 1.1% |
Estrogen (medication) | 1 | 1.1% |
Ethinylestradiol | 1 | 1.1% |
Eurasian beaver | 1 | 1.1% |
Exotic pet | 1 | 1.1% |
Expressed emotion | 1 | 1.1% |
Ezetimibe | 1 | 1.1% |
Ezetimibe/simvastatin | 1 | 1.1% |
Factor V Leiden | 1 | 1.1% |
Factor analysis | 1 | 1.1% |
Family planning | 1 | 1.1% |
Fecal occult blood | 1 | 1.1% |
Federally Qualified Health Center | 1 | 1.1% |
Fenofibrate | 1 | 1.1% |
Fibrate | 1 | 1.1% |
Field Epidemiology Training Program | 1 | 1.1% |
Field epidemiology | 1 | 1.1% |
Fine-needle aspiration | 1 | 1.1% |
Fluconazole | 1 | 1.1% |
Flucytosine | 1 | 1.1% |
Fludeoxyglucose (18F) | 1 | 1.1% |
Fluid replacement | 1 | 1.1% |
Fluorescence in situ hybridization | 1 | 1.1% |
Fluvastatin | 1 | 1.1% |
Forest plot | 1 | 1.1% |
Fresh frozen plasma | 1 | 1.1% |
Frozen section procedure | 1 | 1.1% |
G2 phase | 1 | 1.1% |
Gallstone | 1 | 1.1% |
Gastroenterology | 1 | 1.1% |
Gene | 1 | 1.1% |
Gene expression profiling | 1 | 1.1% |
General practitioner | 1 | 1.1% |
Generalized anxiety disorder | 1 | 1.1% |
Genetic counseling | 1 | 1.1% |
Genetics | 1 | 1.1% |
Gestational trophoblastic disease | 1 | 1.1% |
Gliflozin | 1 | 1.1% |
Global health | 1 | 1.1% |
Global warming | 1 | 1.1% |
Glomerular filtration rate | 1 | 1.1% |
Glucose test | 1 | 1.1% |
Glutaric aciduria type 1 | 1 | 1.1% |
Gun violence | 1 | 1.1% |
Gynaecology | 1 | 1.1% |
Hazard ratio | 1 | 1.1% |
Health equity | 1 | 1.1% |
Health human resources | 1 | 1.1% |
Health informatics | 1 | 1.1% |
Health literacy | 1 | 1.1% |
Health research | 1 | 1.1% |
Hearing aid | 1 | 1.1% |
Heart valve | 1 | 1.1% |
Helicobacter pylori | 1 | 1.1% |
Hematuria | 1 | 1.1% |
Henipavirus | 1 | 1.1% |
Heparin | 1 | 1.1% |
Hepatitis E | 1 | 1.1% |
Hepatocellular carcinoma | 1 | 1.1% |
Hereditary nonpolyposis colorectal cancer | 1 | 1.1% |
High-grade serous carcinoma | 1 | 1.1% |
Holter monitor | 1 | 1.1% |
Hormonal IUDs | 1 | 1.1% |
Hormone replacement therapy | 1 | 1.1% |
Hospital-acquired pneumonia | 1 | 1.1% |
Human body temperature | 1 | 1.1% |
Human respiratory syncytial virus | 1 | 1.1% |
Human sexual activity | 1 | 1.1% |
Hyperlipidemia | 1 | 1.1% |
Hypokinesia | 1 | 1.1% |
Hypothermia | 1 | 1.1% |
Ibrutinib | 1 | 1.1% |
Immigration | 1 | 1.1% |
Immunization | 1 | 1.1% |
Immunosuppressive drug | 1 | 1.1% |
Immunotherapy | 1 | 1.1% |
Implantable cardioverter-defibrillator | 1 | 1.1% |
Incidence (epidemiology) | 1 | 1.1% |
Infant | 1 | 1.1% |
Inferior vena cava | 1 | 1.1% |
Inferior vena cava filter | 1 | 1.1% |
Inflammatory bowel disease | 1 | 1.1% |
Infliximab | 1 | 1.1% |
Influenza A virus subtype H1N1 | 1 | 1.1% |
Influenza A virus subtype H3N2 | 1 | 1.1% |
Influenza research | 1 | 1.1% |
Infographic | 1 | 1.1% |
Information technology | 1 | 1.1% |
Innovation | 1 | 1.1% |
Insulin aspart | 1 | 1.1% |
Insulin lispro | 1 | 1.1% |
Insulin resistance | 1 | 1.1% |
Intensive insulin therapy | 1 | 1.1% |
Intention-to-treat analysis | 1 | 1.1% |
International Classification of Diseases | 1 | 1.1% |
International Prognostic Index | 1 | 1.1% |
Intraclass correlation | 1 | 1.1% |
Intravitreal administration | 1 | 1.1% |
Ipilimumab | 1 | 1.1% |
Islet cell transplantation | 1 | 1.1% |
Kidney disease | 1 | 1.1% |
Kidney failure | 1 | 1.1% |
Klebsiella pneumoniae | 1 | 1.1% |
Knowledge | 1 | 1.1% |
Laboratory | 1 | 1.1% |
Lassa fever | 1 | 1.1% |
Legionella | 1 | 1.1% |
Legionnaires' disease | 1 | 1.1% |
Leprosy | 1 | 1.1% |
Levofloxacin | 1 | 1.1% |
Likelihood function | 1 | 1.1% |
Linezolid | 1 | 1.1% |
Liver | 1 | 1.1% |
Local anesthetic | 1 | 1.1% |
Logic model | 1 | 1.1% |
Logistic regression | 1 | 1.1% |
Long QT syndrome | 1 | 1.1% |
Long-acting reversible contraception | 1 | 1.1% |
Lovastatin | 1 | 1.1% |
Low molecular weight heparin | 1 | 1.1% |
Low-molecular-weight heparin | 1 | 1.1% |
Luteinizing hormone | 1 | 1.1% |
Lyme disease | 1 | 1.1% |
Lymphadenectomy | 1 | 1.1% |
Lymphadenopathy | 1 | 1.1% |
MALT lymphoma | 1 | 1.1% |
Macular degeneration | 1 | 1.1% |
Major trauma | 1 | 1.1% |
Managed care | 1 | 1.1% |
Management of acute coronary syndrome | 1 | 1.1% |
Mantle cell lymphoma | 1 | 1.1% |
Measles | 1 | 1.1% |
Median | 1 | 1.1% |
Medical error | 1 | 1.1% |
Medical microbiology | 1 | 1.1% |
Medical research | 1 | 1.1% |
Medical ultrasound | 1 | 1.1% |
Melanoma | 1 | 1.1% |
Menstruation | 1 | 1.1% |
Mestranol | 1 | 1.1% |
Metabolic disorders | 1 | 1.1% |
Metabolic equivalent of task | 1 | 1.1% |
Metastasis | 1 | 1.1% |
Methodology | 1 | 1.1% |
MicroRNA | 1 | 1.1% |
Microalbuminuria | 1 | 1.1% |
Microvascular angina | 1 | 1.1% |
Mid-level practitioner | 1 | 1.1% |
Middle East respiratory syndrome | 1 | 1.1% |
Migraine | 1 | 1.1% |
Mindfulness-based cognitive therapy | 1 | 1.1% |
Minimally invasive procedure | 1 | 1.1% |
Minimally invasive procedures | 1 | 1.1% |
Missing data | 1 | 1.1% |
Monitoring (medicine) | 1 | 1.1% |
Monoclonal B-cell lymphocytosis | 1 | 1.1% |
Monounsaturated fat | 1 | 1.1% |
Mood disorder | 1 | 1.1% |
Morphine | 1 | 1.1% |
Motivational interviewing | 1 | 1.1% |
Multiple drug resistance | 1 | 1.1% |
Muriel Bowser | 1 | 1.1% |
Myc | 1 | 1.1% |
Myocardial perfusion imaging | 1 | 1.1% |
Needs assessment | 1 | 1.1% |
Nelfinavir | 1 | 1.1% |
Neonatal intensive care unit | 1 | 1.1% |
Neoplasm | 1 | 1.1% |
Newborn screening | 1 | 1.1% |
Non-communicable disease | 1 | 1.1% |
Non-governmental organization | 1 | 1.1% |
Nonsteroidal anti-inflammatory drug | 1 | 1.1% |
Norethisterone | 1 | 1.1% |
Norwegian language | 1 | 1.1% |
Number needed to treat | 1 | 1.1% |
Nurse practitioner | 1 | 1.1% |
Nursing home care | 1 | 1.1% |
Obstructive sleep apnea | 1 | 1.1% |
Occupational therapy | 1 | 1.1% |
Omega-3 acid ethyl esters | 1 | 1.1% |
Oncology | 1 | 1.1% |
Opioid | 1 | 1.1% |
Optimism | 1 | 1.1% |
Optimism bias | 1 | 1.1% |
Orthohantavirus | 1 | 1.1% |
Otitis media | 1 | 1.1% |
Otoacoustic emission | 1 | 1.1% |
Outcomes research | 1 | 1.1% |
Ovarian cyst | 1 | 1.1% |
Ovulation | 1 | 1.1% |
P-value | 1 | 1.1% |
PET-CT | 1 | 1.1% |
PHQ-9 | 1 | 1.1% |
Packed red blood cells | 1 | 1.1% |
Palliative care | 1 | 1.1% |
Palpitations | 1 | 1.1% |
Pancreas | 1 | 1.1% |
Pancreatic islets | 1 | 1.1% |
Pancreatitis | 1 | 1.1% |
Pandemic H1N1/09 virus | 1 | 1.1% |
Paracetamol | 1 | 1.1% |
Pathogen | 1 | 1.1% |
Patient participation | 1 | 1.1% |
Patient safety organization | 1 | 1.1% |
Patient-controlled analgesia | 1 | 1.1% |
Patient-reported outcome | 1 | 1.1% |
Pelvic inflammatory disease | 1 | 1.1% |
Percutaneous aortic valve replacement | 1 | 1.1% |
Perfusion | 1 | 1.1% |
Periodontology | 1 | 1.1% |
Perioperative | 1 | 1.1% |
Peritoneum | 1 | 1.1% |
Personalized medicine | 1 | 1.1% |
Pet | 1 | 1.1% |
Pharmacist | 1 | 1.1% |
Pharmacodynamics | 1 | 1.1% |
Pharmacokinetics | 1 | 1.1% |
Pharmacy benefit management | 1 | 1.1% |
Pharmacy management system | 1 | 1.1% |
Pharyngitis | 1 | 1.1% |
Phases of clinical research | 1 | 1.1% |
Phenylketonuria | 1 | 1.1% |
Physical examination | 1 | 1.1% |
Pioglitazone | 1 | 1.1% |
Plateletpheresis | 1 | 1.1% |
Point of care | 1 | 1.1% |
Polycystic ovary syndrome | 1 | 1.1% |
Polymerase chain reaction | 1 | 1.1% |
Polyp (medicine) | 1 | 1.1% |
Positive and negative predictive values | 1 | 1.1% |
Post-thrombotic syndrome | 1 | 1.1% |
Postpartum period | 1 | 1.1% |
Prasugrel | 1 | 1.1% |
Pravastatin | 1 | 1.1% |
Pre- and post-test probability | 1 | 1.1% |
Preterm birth | 1 | 1.1% |
Primary health care | 1 | 1.1% |
Primary healthcare | 1 | 1.1% |
Problem solving | 1 | 1.1% |
Procalcitonin | 1 | 1.1% |
Progestin | 1 | 1.1% |
Progestogen-only pill | 1 | 1.1% |
Program evaluation | 1 | 1.1% |
Propranolol | 1 | 1.1% |
Proteinuria | 1 | 1.1% |
Prothrombin G20210A | 1 | 1.1% |
Psychosis | 1 | 1.1% |
Psychosocial | 1 | 1.1% |
Puberty | 1 | 1.1% |
Public Health Emergency of International Concern | 1 | 1.1% |
Pulse | 1 | 1.1% |
Pulse oximetry | 1 | 1.1% |
Pulse pressure | 1 | 1.1% |
Pulse wave velocity | 1 | 1.1% |
Quality | 1 | 1.1% |
Quinolone antibiotic | 1 | 1.1% |
Rabbit haemorrhagic disease | 1 | 1.1% |
Race and ethnicity in the United States Census | 1 | 1.1% |
Radiation therapy | 1 | 1.1% |
Radiology | 1 | 1.1% |
Rat | 1 | 1.1% |
Receiver operating characteristic | 1 | 1.1% |
Recovery approach | 1 | 1.1% |
Regression analysis | 1 | 1.1% |
Reliability (statistics) | 1 | 1.1% |
Religious Freedom Restoration Act | 1 | 1.1% |
Reproductive health | 1 | 1.1% |
Reproductive medicine | 1 | 1.1% |
Research methods | 1 | 1.1% |
Residency (medicine) | 1 | 1.1% |
Respiratory disease | 1 | 1.1% |
Respiratory diseases | 1 | 1.1% |
Responsive web design | 1 | 1.1% |
Revised National Tuberculosis Control Program | 1 | 1.1% |
Richter's transformation | 1 | 1.1% |
Risk management | 1 | 1.1% |
Road traffic safety | 1 | 1.1% |
Robert Guthrie | 1 | 1.1% |
Rosiglitazone | 1 | 1.1% |
Rotavirus | 1 | 1.1% |
SWOT analysis | 1 | 1.1% |
Saline (medicine) | 1 | 1.1% |
Sampling (statistics) | 1 | 1.1% |
Sedentary lifestyle | 1 | 1.1% |
Selection bias | 1 | 1.1% |
Self-report study | 1 | 1.1% |
Serosorting | 1 | 1.1% |
Severe combined immunodeficiency | 1 | 1.1% |
Sickle cell disease | 1 | 1.1% |
Single-photon emission computed tomography | 1 | 1.1% |
Sinusitis | 1 | 1.1% |
Sleep | 1 | 1.1% |
Social distancing | 1 | 1.1% |
Social work | 1 | 1.1% |
Special education | 1 | 1.1% |
Specification (technical standard) | 1 | 1.1% |
Spinal cord | 1 | 1.1% |
Sputum | 1 | 1.1% |
Standard deviation | 1 | 1.1% |
Statistical hypothesis testing | 1 | 1.1% |
Stomach cancer | 1 | 1.1% |
Strategic management | 1 | 1.1% |
Strategic planning | 1 | 1.1% |
Strength training | 1 | 1.1% |
Stress (biology) | 1 | 1.1% |
Substance use disorder | 1 | 1.1% |
Substantia nigra | 1 | 1.1% |
Suicide | 1 | 1.1% |
Sulfonylurea | 1 | 1.1% |
Superficial thrombophlebitis | 1 | 1.1% |
Superficial vein thrombosis | 1 | 1.1% |
Supportive housing | 1 | 1.1% |
Suprachiasmatic nucleus | 1 | 1.1% |
Surveillance | 1 | 1.1% |
Sustainability | 1 | 1.1% |
Sustainable Development Goals | 1 | 1.1% |
Systematics | 1 | 1.1% |
Systemic lupus erythematosus | 1 | 1.1% |
Systole | 1 | 1.1% |
TNF inhibitor | 1 | 1.1% |
Takotsubo cardiomyopathy | 1 | 1.1% |
Targeted temperature management | 1 | 1.1% |
Technology | 1 | 1.1% |
Telecare | 1 | 1.1% |
Theiler's disease | 1 | 1.1% |
Thiazide | 1 | 1.1% |
Thromboelastography | 1 | 1.1% |
Thromboelastometry | 1 | 1.1% |
Thrombolysis | 1 | 1.1% |
Thrombosis prevention | 1 | 1.1% |
Ticagrelor | 1 | 1.1% |
Till Roenneberg | 1 | 1.1% |
Tomography | 1 | 1.1% |
Tooth decay | 1 | 1.1% |
Torsades de pointes | 1 | 1.1% |
Transfusion-related acute lung injury | 1 | 1.1% |
Transmission (medicine) | 1 | 1.1% |
Tumor necrosis factor alpha | 1 | 1.1% |
Tumors of the hematopoietic and lymphoid tissues | 1 | 1.1% |
Type 1 diabetes | 1 | 1.1% |
Uncertainty | 1 | 1.1% |
Unintended pregnancy | 1 | 1.1% |
Universal neonatal hearing screening | 1 | 1.1% |
Unsaturated fat | 1 | 1.1% |
Usability | 1 | 1.1% |
Vaccine-preventable diseases | 1 | 1.1% |
Vaginal ring | 1 | 1.1% |
Valvular heart disease | 1 | 1.1% |
Varicose veins | 1 | 1.1% |
Venetoclax | 1 | 1.1% |
Ventilator-associated pneumonia | 1 | 1.1% |
Ventricle (heart) | 1 | 1.1% |
Viral hemorrhagic fever | 1 | 1.1% |
Virtual reality | 1 | 1.1% |
Web of Science | 1 | 1.1% |
Website | 1 | 1.1% |
Weight management | 1 | 1.1% |
Whole grain | 1 | 1.1% |
Youth | 1 | 1.1% |
abs | rel | |
---|---|---|
Health | 94 | 98.9% |
Medicine | 92 | 96.8% |
Health sciences | 90 | 94.7% |
Medical specialties | 88 | 92.6% |
Clinical medicine | 87 | 91.6% |
Health care | 83 | 87.4% |
Public health | 44 | 46.3% |
Diseases and disorders | 38 | 40.0% |
Risk | 35 | 36.8% |
Clinical trial | 31 | 32.6% |
Systematic review | 29 | 30.5% |
Meta-analysis | 28 | 29.5% |
Randomized controlled trial | 28 | 29.5% |
Infection | 26 | 27.4% |
Epidemiology | 24 | 25.3% |
Evidence-based medicine | 24 | 25.3% |
Preventive healthcare | 23 | 24.2% |
Disease | 22 | 23.2% |
Cancer | 20 | 21.1% |
Medical guideline | 19 | 20.0% |
Surgery | 18 | 18.9% |
Immunology | 16 | 16.8% |
Medical diagnosis | 16 | 16.8% |
Medication | 15 | 15.8% |
Sensitivity and specificity | 15 | 15.8% |
Therapy | 15 | 15.8% |
Coronary artery disease | 14 | 14.7% |
Antimicrobial resistance | 13 | 13.7% |
Cardiovascular disease | 13 | 13.7% |
Hospital | 12 | 12.6% |
Hypertension | 12 | 12.6% |
Infectious diseases | 12 | 12.6% |
Myocardial infarction | 12 | 12.6% |
Pregnancy | 12 | 12.6% |
Adherence (medicine) | 11 | 11.6% |
Blinded experiment | 11 | 11.6% |
Blood pressure | 11 | 11.6% |
Heart | 11 | 11.6% |
Medical humanities | 11 | 11.6% |
Microbiology | 11 | 11.6% |
Stroke | 11 | 11.6% |
Tuberculosis | 11 | 11.6% |
Biology | 10 | 10.5% |
Confidence interval | 10 | 10.5% |
HIV/AIDS | 10 | 10.5% |
Health economics | 10 | 10.5% |
Health policy | 10 | 10.5% |
Screening (medicine) | 10 | 10.5% |
Chronic condition | 9 | 9.5% |
Neoplasms | 9 | 9.5% |
Research | 9 | 9.5% |
Vaccine | 9 | 9.5% |
Antibiotic | 8 | 8.4% |
Bias | 8 | 8.4% |
Breast cancer | 8 | 8.4% |
Cardiology | 8 | 8.4% |
Childbirth | 8 | 8.4% |
Life sciences | 8 | 8.4% |
Major depressive disorder | 8 | 8.4% |
Medical treatments | 8 | 8.4% |
Multi-drug-resistant tuberculosis | 8 | 8.4% |
Patient | 8 | 8.4% |
Quality-adjusted life year | 8 | 8.4% |
Cardiovascular system | 7 | 7.4% |
Cohort study | 7 | 7.4% |
Comorbidity | 7 | 7.4% |
Cost-effectiveness analysis | 7 | 7.4% |
Extensively drug-resistant tuberculosis | 7 | 7.4% |
Health professional | 7 | 7.4% |
Human reproduction | 7 | 7.4% |
Low-density lipoprotein | 7 | 7.4% |
Obesity | 7 | 7.4% |
Reporting bias | 7 | 7.4% |
Statistics | 7 | 7.4% |
Virus | 7 | 7.4% |
Circulatory system | 6 | 6.3% |
Diabetes mellitus | 6 | 6.3% |
Emergency department | 6 | 6.3% |
GeneXpert MTB/RIF | 6 | 6.3% |
Hepatitis | 6 | 6.3% |
Maternal health | 6 | 6.3% |
Medical imaging | 6 | 6.3% |
Miscarriage | 6 | 6.3% |
Pneumonia | 6 | 6.3% |
Statin | 6 | 6.3% |
Tuberculosis management | 6 | 6.3% |
Adverse effect | 5 | 5.3% |
Amniocentesis | 5 | 5.3% |
Antibody | 5 | 5.3% |
Anticoagulant | 5 | 5.3% |
Biotechnology | 5 | 5.3% |
Caregiver | 5 | 5.3% |
Chemotherapy | 5 | 5.3% |
Cholesterol | 5 | 5.3% |
Chronic kidney disease | 5 | 5.3% |
Confounding | 5 | 5.3% |
Dose (biochemistry) | 5 | 5.3% |
Drugs | 5 | 5.3% |
Evaluation | 5 | 5.3% |
Fetus | 5 | 5.3% |
Health system | 5 | 5.3% |
Lung cancer | 5 | 5.3% |
Measles | 5 | 5.3% |
Organ transplantation | 5 | 5.3% |
Ovarian cancer | 5 | 5.3% |
Poverty | 5 | 5.3% |
Prenatal development | 5 | 5.3% |
Prenatal testing | 5 | 5.3% |
Preterm birth | 5 | 5.3% |
RTT | 5 | 5.3% |
Receiver operating characteristic | 5 | 5.3% |
Sampling (statistics) | 5 | 5.3% |
Study heterogeneity | 5 | 5.3% |
Thrombosis | 5 | 5.3% |
Transmission (medicine) | 5 | 5.3% |
Vaccination | 5 | 5.3% |
Venous thrombosis | 5 | 5.3% |
Adjuvant therapy | 4 | 4.2% |
Angina | 4 | 4.2% |
Anti-diabetic medication | 4 | 4.2% |
Aortic stenosis | 4 | 4.2% |
Aspirin | 4 | 4.2% |
BRCA1 | 4 | 4.2% |
Birth defect | 4 | 4.2% |
Colorectal cancer | 4 | 4.2% |
Creative Commons license | 4 | 4.2% |
DNA sequencing | 4 | 4.2% |
Data analysis | 4 | 4.2% |
Deep vein thrombosis | 4 | 4.2% |
Down syndrome | 4 | 4.2% |
Effect size | 4 | 4.2% |
Glycated hemoglobin | 4 | 4.2% |
Heart failure | 4 | 4.2% |
High-density lipoprotein | 4 | 4.2% |
Human pregnancy | 4 | 4.2% |
Influenza | 4 | 4.2% |
Intensive care medicine | 4 | 4.2% |
Intensive care unit | 4 | 4.2% |
Internal medicine | 4 | 4.2% |
Kidney transplantation | 4 | 4.2% |
Latent tuberculosis | 4 | 4.2% |
MEDLINE | 4 | 4.2% |
MMR vaccine | 4 | 4.2% |
Magnetic resonance imaging | 4 | 4.2% |
Medicare (United States) | 4 | 4.2% |
Mental health | 4 | 4.2% |
Metastasis | 4 | 4.2% |
Nursing | 4 | 4.2% |
Obstetric ultrasonography | 4 | 4.2% |
Obstetrics | 4 | 4.2% |
Pharmacology | 4 | 4.2% |
Physician | 4 | 4.2% |
Placebo | 4 | 4.2% |
Positive and negative predictive values | 4 | 4.2% |
Public sphere | 4 | 4.2% |
Publication bias | 4 | 4.2% |
Reference range | 4 | 4.2% |
Renal function | 4 | 4.2% |
Rubella | 4 | 4.2% |
Sepsis | 4 | 4.2% |
Shared decision-making in medicine | 4 | 4.2% |
Sustainability | 4 | 4.2% |
Sustainable Development Goals | 4 | 4.2% |
Vein | 4 | 4.2% |
Zika fever | 4 | 4.2% |
Accountable care organization | 3 | 3.2% |
Angiography | 3 | 3.2% |
Angiology | 3 | 3.2% |
Antiviral drug | 3 | 3.2% |
Aortic valve | 3 | 3.2% |
Atheroma | 3 | 3.2% |
Atrial fibrillation | 3 | 3.2% |
Biomarker | 3 | 3.2% |
Biopsy | 3 | 3.2% |
CT scan | 3 | 3.2% |
Chickenpox | 3 | 3.2% |
Chikungunya | 3 | 3.2% |
Clinical commissioning group | 3 | 3.2% |
Cochrane Library | 3 | 3.2% |
Cornea | 3 | 3.2% |
DPT vaccine | 3 | 3.2% |
Decision-making | 3 | 3.2% |
Dialysis | 3 | 3.2% |
Drug development | 3 | 3.2% |
ELISA | 3 | 3.2% |
Electrocardiography | 3 | 3.2% |
Electronic health record | 3 | 3.2% |
Exercise | 3 | 3.2% |
Eye care | 3 | 3.2% |
Fever | 3 | 3.2% |
General practitioner | 3 | 3.2% |
Genetics | 3 | 3.2% |
Gestational age | 3 | 3.2% |
Gestational diabetes | 3 | 3.2% |
Health informatics | 3 | 3.2% |
Heart valve | 3 | 3.2% |
Hemodialysis | 3 | 3.2% |
Hepatitis B | 3 | 3.2% |
Hospital readmission | 3 | 3.2% |
Human activities | 3 | 3.2% |
Human papillomavirus infection | 3 | 3.2% |
Immunity (medical) | 3 | 3.2% |
Immunodeficiency | 3 | 3.2% |
Immunoglobulin G | 3 | 3.2% |
Incidence (epidemiology) | 3 | 3.2% |
Incremental cost-effectiveness ratio | 3 | 3.2% |
Influenza vaccine | 3 | 3.2% |
Intention-to-treat analysis | 3 | 3.2% |
International Statistical Classification of Diseases and Related Health Problems | 3 | 3.2% |
Intravenous therapy | 3 | 3.2% |
Ischemia | 3 | 3.2% |
Low molecular weight heparin | 3 | 3.2% |
Mammography | 3 | 3.2% |
Mantoux test | 3 | 3.2% |
Medicaid | 3 | 3.2% |
Medical research | 3 | 3.2% |
Medical ultrasound | 3 | 3.2% |
Millennium Development Goals | 3 | 3.2% |
Missing data | 3 | 3.2% |
Motherhood | 3 | 3.2% |
Neonatal intensive care unit | 3 | 3.2% |
Neutropenia | 3 | 3.2% |
Nuchal scan | 3 | 3.2% |
Ophthalmology | 3 | 3.2% |
Osteoporosis | 3 | 3.2% |
P-value | 3 | 3.2% |
Pancreatic cancer | 3 | 3.2% |
Pathology | 3 | 3.2% |
Pediatrics | 3 | 3.2% |
Pharmacovigilance | 3 | 3.2% |
Physiology | 3 | 3.2% |
Prenatal care | 3 | 3.2% |
Prostate cancer | 3 | 3.2% |
Prostate-specific antigen | 3 | 3.2% |
Prothrombin time | 3 | 3.2% |
Psychiatry | 3 | 3.2% |
Psychology | 3 | 3.2% |
Regression analysis | 3 | 3.2% |
Risk assessment | 3 | 3.2% |
Rivaroxaban | 3 | 3.2% |
Sample size determination | 3 | 3.2% |
Sensitivity analysis | 3 | 3.2% |
Septic shock | 3 | 3.2% |
Smoking cessation | 3 | 3.2% |
Spirometry | 3 | 3.2% |
Standard deviation | 3 | 3.2% |
Stillbirth | 3 | 3.2% |
Stomach cancer | 3 | 3.2% |
Tobacco smoking | 3 | 3.2% |
Transient ischemic attack | 3 | 3.2% |
Transplant rejection | 3 | 3.2% |
Tuberculosis diagnosis | 3 | 3.2% |
Vision | 3 | 3.2% |
Visual impairment | 3 | 3.2% |
Women's health | 3 | 3.2% |
Acute coronary syndrome | 2 | 2.1% |
Ageing | 2 | 2.1% |
Alirocumab | 2 | 2.1% |
Allergy | 2 | 2.1% |
Allocation concealment | 2 | 2.1% |
Alternative medicine | 2 | 2.1% |
Anaphylaxis | 2 | 2.1% |
Animal diseases | 2 | 2.1% |
Antihypertensive drug | 2 | 2.1% |
Antimicrobial | 2 | 2.1% |
Antimicrobial stewardship | 2 | 2.1% |
Arrhythmia | 2 | 2.1% |
Arthritis | 2 | 2.1% |
Artificial cardiac pacemaker | 2 | 2.1% |
Assay | 2 | 2.1% |
Asthma | 2 | 2.1% |
BRCA mutation | 2 | 2.1% |
Bacteremia | 2 | 2.1% |
Behavior | 2 | 2.1% |
Bendamustine | 2 | 2.1% |
Bevacizumab | 2 | 2.1% |
Biosimilar | 2 | 2.1% |
Bipolar disorder | 2 | 2.1% |
Birth weight | 2 | 2.1% |
Bleeding | 2 | 2.1% |
Blood | 2 | 2.1% |
Blood sugar level | 2 | 2.1% |
Blood transfusion | 2 | 2.1% |
Body mass index | 2 | 2.1% |
Bone density | 2 | 2.1% |
Bone fracture | 2 | 2.1% |
Branches of science | 2 | 2.1% |
Bundled payment | 2 | 2.1% |
C-reactive protein | 2 | 2.1% |
Cancer screening | 2 | 2.1% |
Carcinoma | 2 | 2.1% |
Cardiotocography | 2 | 2.1% |
Cardiovascular physiology | 2 | 2.1% |
Carotid artery stenosis | 2 | 2.1% |
Case–control study | 2 | 2.1% |
Cataract | 2 | 2.1% |
Cataract surgery | 2 | 2.1% |
Cell-free fetal DNA | 2 | 2.1% |
Central venous catheter | 2 | 2.1% |
Cervical cancer | 2 | 2.1% |
Coagulation | 2 | 2.1% |
Colonoscopy | 2 | 2.1% |
Confidentiality | 2 | 2.1% |
Contact lens | 2 | 2.1% |
Coronary circulation | 2 | 2.1% |
Cost–utility analysis | 2 | 2.1% |
Current Procedural Terminology | 2 | 2.1% |
Cytopathology | 2 | 2.1% |
Dabigatran | 2 | 2.1% |
Daclizumab | 2 | 2.1% |
Dengue fever | 2 | 2.1% |
Diabetes mellitus type 2 | 2 | 2.1% |
Diagnosis-related group | 2 | 2.1% |
Diphtheria vaccine | 2 | 2.1% |
Doppler ultrasonography | 2 | 2.1% |
Dual-energy X-ray absorptiometry | 2 | 2.1% |
Ebola virus disease | 2 | 2.1% |
Echocardiography | 2 | 2.1% |
Economic growth | 2 | 2.1% |
Economics | 2 | 2.1% |
Endophthalmitis | 2 | 2.1% |
Epidemic | 2 | 2.1% |
Ezetimibe | 2 | 2.1% |
Familial hypercholesterolemia | 2 | 2.1% |
Febrile neutropenia | 2 | 2.1% |
Fecal occult blood | 2 | 2.1% |
Flavivirus | 2 | 2.1% |
Fluconazole | 2 | 2.1% |
Framingham Risk Score | 2 | 2.1% |
Glaucoma | 2 | 2.1% |
Global health | 2 | 2.1% |
Gynaecology | 2 | 2.1% |
HER2/neu | 2 | 2.1% |
HPV vaccine | 2 | 2.1% |
Health care quality | 2 | 2.1% |
Hearing loss | 2 | 2.1% |
Heart rate | 2 | 2.1% |
Hepatitis B vaccine | 2 | 2.1% |
Hepatitis C | 2 | 2.1% |
Hepatocellular carcinoma | 2 | 2.1% |
Hib vaccine | 2 | 2.1% |
Hip fracture | 2 | 2.1% |
Hives | 2 | 2.1% |
Hormone replacement therapy | 2 | 2.1% |
Human diseases and disorders | 2 | 2.1% |
Human eye | 2 | 2.1% |
Hypercholesterolemia | 2 | 2.1% |
Hyperkalemia | 2 | 2.1% |
Hypoxia (medical) | 2 | 2.1% |
Hysterectomy | 2 | 2.1% |
Immune system | 2 | 2.1% |
Immunization | 2 | 2.1% |
Indigestion | 2 | 2.1% |
Influenza A virus subtype H7N9 | 2 | 2.1% |
Influenza pandemic | 2 | 2.1% |
Innovation | 2 | 2.1% |
Intraocular lens | 2 | 2.1% |
Intrauterine growth restriction | 2 | 2.1% |
Laparoscopy | 2 | 2.1% |
License | 2 | 2.1% |
Lymphoma | 2 | 2.1% |
MMRV vaccine | 2 | 2.1% |
Malaria | 2 | 2.1% |
Malnutrition | 2 | 2.1% |
Mammalian pregnancy | 2 | 2.1% |
Maternal death | 2 | 2.1% |
Maternal–fetal medicine | 2 | 2.1% |
Maturity onset diabetes of the young | 2 | 2.1% |
Medical device | 2 | 2.1% |
Medical specialty | 2 | 2.1% |
Medical test | 2 | 2.1% |
Medicare dual eligible | 2 | 2.1% |
Melanoma | 2 | 2.1% |
Meningitis | 2 | 2.1% |
Meningococcal vaccine | 2 | 2.1% |
Menopause | 2 | 2.1% |
Mental disorder | 2 | 2.1% |
Methicillin-resistant Staphylococcus aureus | 2 | 2.1% |
MicroRNA | 2 | 2.1% |
Mitral valve | 2 | 2.1% |
Mumps | 2 | 2.1% |
Neoplasm | 2 | 2.1% |
Neurology | 2 | 2.1% |
Nicotine | 2 | 2.1% |
Nicotine replacement therapy | 2 | 2.1% |
Nivolumab | 2 | 2.1% |
Organ donation | 2 | 2.1% |
Oxaliplatin | 2 | 2.1% |
PCSK9 | 2 | 2.1% |
Pandemic | 2 | 2.1% |
Pathogen | 2 | 2.1% |
Patient education | 2 | 2.1% |
Pay for performance (healthcare) | 2 | 2.1% |
Pembrolizumab | 2 | 2.1% |
Percutaneous aortic valve replacement | 2 | 2.1% |
Perinatal mortality | 2 | 2.1% |
Peripheral artery disease | 2 | 2.1% |
Peritoneal dialysis | 2 | 2.1% |
Personalized medicine | 2 | 2.1% |
Pharmacy | 2 | 2.1% |
Physical examination | 2 | 2.1% |
Physical therapy | 2 | 2.1% |
Pleural effusion | 2 | 2.1% |
Pneumococcal conjugate vaccine | 2 | 2.1% |
Pneumococcal vaccine | 2 | 2.1% |
Polio vaccine | 2 | 2.1% |
Polymerase chain reaction | 2 | 2.1% |
Positron emission tomography | 2 | 2.1% |
Post-transplant lymphoproliferative disorder | 2 | 2.1% |
Potassium | 2 | 2.1% |
Pre-eclampsia | 2 | 2.1% |
Precision medicine | 2 | 2.1% |
Prediabetes | 2 | 2.1% |
Prediction | 2 | 2.1% |
Prednisone | 2 | 2.1% |
Preventive medicine | 2 | 2.1% |
Primary care | 2 | 2.1% |
Probiotic | 2 | 2.1% |
Procalcitonin | 2 | 2.1% |
Psychiatric and mental health nursing | 2 | 2.1% |
Psychosocial | 2 | 2.1% |
Psychotherapy | 2 | 2.1% |
Pulse oximetry | 2 | 2.1% |
Pyrazinamide | 2 | 2.1% |
QT interval | 2 | 2.1% |
Qualitative research | 2 | 2.1% |
Radiation therapy | 2 | 2.1% |
Refractive surgery | 2 | 2.1% |
Reliability (statistics) | 2 | 2.1% |
Risk management | 2 | 2.1% |
Robust statistics | 2 | 2.1% |
Safe sex | 2 | 2.1% |
Salt | 2 | 2.1% |
Science | 2 | 2.1% |
Self-care | 2 | 2.1% |
Sexual intercourse | 2 | 2.1% |
Sexually transmitted infection | 2 | 2.1% |
Shock (circulatory) | 2 | 2.1% |
Smoking | 2 | 2.1% |
Specification (technical standard) | 2 | 2.1% |
Standard error | 2 | 2.1% |
Substance dependence | 2 | 2.1% |
Sugar | 2 | 2.1% |
Survey methodology | 2 | 2.1% |
Tetanus vaccine | 2 | 2.1% |
Thrombosis prevention | 2 | 2.1% |
Trastuzumab | 2 | 2.1% |
Type 2 diabetes | 2 | 2.1% |
Umbilical cord | 2 | 2.1% |
Vaccines | 2 | 2.1% |
Vagina | 2 | 2.1% |
Valvular heart disease | 2 | 2.1% |
Varicella vaccine | 2 | 2.1% |
Ventricle (heart) | 2 | 2.1% |
Warfarin | 2 | 2.1% |
White blood cell | 2 | 2.1% |
Zika virus | 2 | 2.1% |
100,000 Genomes Project | 1 | 1.1% |
3D bioprinting | 1 | 1.1% |
3D printing | 1 | 1.1% |
APACHE II | 1 | 1.1% |
Active surveillance of prostate cancer | 1 | 1.1% |
Acupressure | 1 | 1.1% |
Acute promyelocytic leukemia | 1 | 1.1% |
Adalimumab | 1 | 1.1% |
Adverse drug reaction | 1 | 1.1% |
Alectinib | 1 | 1.1% |
Alemtuzumab | 1 | 1.1% |
Allele | 1 | 1.1% |
Alpha-fetoprotein | 1 | 1.1% |
Aminoglycoside | 1 | 1.1% |
Amoxicillin | 1 | 1.1% |
Amphotericin B | 1 | 1.1% |
Analysis | 1 | 1.1% |
Anaplastic lymphoma kinase | 1 | 1.1% |
Andrew Wakefield | 1 | 1.1% |
Anesthesia | 1 | 1.1% |
Anesthesiology | 1 | 1.1% |
Aneuploidy | 1 | 1.1% |
Animal physiology | 1 | 1.1% |
Anterior chamber of eyeball | 1 | 1.1% |
Anthracycline | 1 | 1.1% |
Anti-thymocyte globulin | 1 | 1.1% |
Antidepressant | 1 | 1.1% |
Antihistamine | 1 | 1.1% |
Antimalarial medication | 1 | 1.1% |
Antioxidant | 1 | 1.1% |
Antiplatelet drug | 1 | 1.1% |
Antivenom | 1 | 1.1% |
Anxiety disorder | 1 | 1.1% |
Aortic insufficiency | 1 | 1.1% |
Aortic valve replacement | 1 | 1.1% |
Apixaban | 1 | 1.1% |
Appetite | 1 | 1.1% |
Aqueous humour | 1 | 1.1% |
Arsenic trioxide | 1 | 1.1% |
Asepsis | 1 | 1.1% |
Aspergillosis | 1 | 1.1% |
Assessment of kidney function | 1 | 1.1% |
Astigmatism | 1 | 1.1% |
Atezolizumab | 1 | 1.1% |
Atherosclerosis | 1 | 1.1% |
Atrial septal defect | 1 | 1.1% |
Atrium (heart) | 1 | 1.1% |
Avian influenza | 1 | 1.1% |
Aztreonam | 1 | 1.1% |
BRCA2 | 1 | 1.1% |
Back pain | 1 | 1.1% |
Bacterial vaginosis | 1 | 1.1% |
Bacteriuria | 1 | 1.1% |
Basal-cell carcinoma | 1 | 1.1% |
Bayley Scales of Infant Development | 1 | 1.1% |
Bedaquiline | 1 | 1.1% |
Behavior change method | 1 | 1.1% |
Benign tumor | 1 | 1.1% |
Best practice | 1 | 1.1% |
Beta blocker | 1 | 1.1% |
Beta distribution | 1 | 1.1% |
Beta-lactamase | 1 | 1.1% |
Biochemistry | 1 | 1.1% |
Biomarker (medicine) | 1 | 1.1% |
Biomedical waste | 1 | 1.1% |
Biopharmaceutical | 1 | 1.1% |
Biosafety | 1 | 1.1% |
Biosecurity | 1 | 1.1% |
Birds | 1 | 1.1% |
Birth | 1 | 1.1% |
Bladder cancer | 1 | 1.1% |
Blood cell | 1 | 1.1% |
Blood culture | 1 | 1.1% |
Blood donation | 1 | 1.1% |
Blood glucose monitoring | 1 | 1.1% |
Blood plasma | 1 | 1.1% |
Blood-borne disease | 1 | 1.1% |
Body fluids | 1 | 1.1% |
Bone | 1 | 1.1% |
Bone marrow | 1 | 1.1% |
Brain metastasis | 1 | 1.1% |
Brain tumor | 1 | 1.1% |
Breast cancer screening | 1 | 1.1% |
Breastfeeding | 1 | 1.1% |
Breathing | 1 | 1.1% |
Brigatinib | 1 | 1.1% |
Business | 1 | 1.1% |
CA-125 | 1 | 1.1% |
CE marking | 1 | 1.1% |
CHA2DS2–VASc score | 1 | 1.1% |
Caesarean section | 1 | 1.1% |
Calibration | 1 | 1.1% |
Cancer biomarker | 1 | 1.1% |
Cancer immunotherapy | 1 | 1.1% |
Cancer staging | 1 | 1.1% |
Cancer survivor | 1 | 1.1% |
Cancer-related fatigue | 1 | 1.1% |
Candida (fungus) | 1 | 1.1% |
Candida albicans | 1 | 1.1% |
Candida glabrata | 1 | 1.1% |
Candidiasis | 1 | 1.1% |
Carbohydrate | 1 | 1.1% |
Carcinoembryonic antigen | 1 | 1.1% |
Cardiac arrest | 1 | 1.1% |
Cardiac fibrosis | 1 | 1.1% |
Cardiac muscle | 1 | 1.1% |
Cardiac stress test | 1 | 1.1% |
Cardiac surgery | 1 | 1.1% |
Cardiopulmonary resuscitation | 1 | 1.1% |
Cardiothoracic surgery | 1 | 1.1% |
Cardiovascular diseases | 1 | 1.1% |
Carotid endarterectomy | 1 | 1.1% |
Carotid stenting | 1 | 1.1% |
Caspofungin | 1 | 1.1% |
Causes of death | 1 | 1.1% |
Ceftriaxone | 1 | 1.1% |
Cerebral hypoxia | 1 | 1.1% |
Cerebral palsy | 1 | 1.1% |
Ceritinib | 1 | 1.1% |
Cetuximab | 1 | 1.1% |
Chest tube | 1 | 1.1% |
Chlamydia infection | 1 | 1.1% |
Chlorhexidine | 1 | 1.1% |
Choice | 1 | 1.1% |
Cholera | 1 | 1.1% |
Chronic fatigue syndrome | 1 | 1.1% |
Chronic obstructive pulmonary disease | 1 | 1.1% |
Cigarette | 1 | 1.1% |
Ciprofloxacin | 1 | 1.1% |
Clinical urine tests | 1 | 1.1% |
Clopidogrel | 1 | 1.1% |
Clostridioides difficile infection | 1 | 1.1% |
Clotrimazole | 1 | 1.1% |
Clozapine | 1 | 1.1% |
Coefficient of determination | 1 | 1.1% |
Coefficient of variation | 1 | 1.1% |
Cognition | 1 | 1.1% |
Cognitive behavioral therapy | 1 | 1.1% |
Coma | 1 | 1.1% |
Committee | 1 | 1.1% |
Common cold | 1 | 1.1% |
Comparative genomic hybridization | 1 | 1.1% |
Congenital heart defect | 1 | 1.1% |
Consensus decision-making | 1 | 1.1% |
Contract | 1 | 1.1% |
Corneal pachymetry | 1 | 1.1% |
Corneal transplantation | 1 | 1.1% |
Coronary catheterization | 1 | 1.1% |
Coronavirus | 1 | 1.1% |
Correlation and dependence | 1 | 1.1% |
Cotinine | 1 | 1.1% |
Crizotinib | 1 | 1.1% |
Croup | 1 | 1.1% |
Cure | 1 | 1.1% |
Cyst | 1 | 1.1% |
Da Vinci Surgical System | 1 | 1.1% |
Data sharing | 1 | 1.1% |
Debridement (dental) | 1 | 1.1% |
Delirium | 1 | 1.1% |
Dementia | 1 | 1.1% |
Dengue vaccine | 1 | 1.1% |
Denosumab | 1 | 1.1% |
Dentistry | 1 | 1.1% |
Dependent and independent variables | 1 | 1.1% |
Dermatology Life Quality Index | 1 | 1.1% |
Diabetes management | 1 | 1.1% |
Diabetes mellitus type 1 | 1 | 1.1% |
Diabetic retinopathy | 1 | 1.1% |
Diarrhea | 1 | 1.1% |
Diastole | 1 | 1.1% |
Diet (nutrition) | 1 | 1.1% |
Dietary supplement | 1 | 1.1% |
Dieting | 1 | 1.1% |
Diffuse large B-cell lymphoma | 1 | 1.1% |
Disease management (health) | 1 | 1.1% |
Disorders of endocrine pancreas | 1 | 1.1% |
Disseminated intravascular coagulation | 1 | 1.1% |
Docetaxel | 1 | 1.1% |
Doctor of Philosophy | 1 | 1.1% |
Domperidone | 1 | 1.1% |
Drug nomenclature | 1 | 1.1% |
Ductal carcinoma in situ | 1 | 1.1% |
Early childhood intervention | 1 | 1.1% |
Ebola virus | 1 | 1.1% |
Ebola virus epidemic in Liberia | 1 | 1.1% |
Econometrics | 1 | 1.1% |
Economic development | 1 | 1.1% |
Economic model | 1 | 1.1% |
Edoxaban | 1 | 1.1% |
Educational assessment | 1 | 1.1% |
Egg allergy | 1 | 1.1% |
Ejection fraction | 1 | 1.1% |
Embolism | 1 | 1.1% |
Emergency | 1 | 1.1% |
Emergency management | 1 | 1.1% |
Emergency medical services | 1 | 1.1% |
Emergency medical technician | 1 | 1.1% |
Emergency medicine | 1 | 1.1% |
Emerging technologies | 1 | 1.1% |
Endocrine, nutritional and metabolic diseases | 1 | 1.1% |
Endoscopic mucosal resection | 1 | 1.1% |
Endoscopic submucosal dissection | 1 | 1.1% |
Enterovirus 71 | 1 | 1.1% |
Environmental enrichment | 1 | 1.1% |
Epidermal growth factor receptor | 1 | 1.1% |
Epigenetics | 1 | 1.1% |
Epigenomics | 1 | 1.1% |
Epilepsy | 1 | 1.1% |
Epstein–Barr virus | 1 | 1.1% |
Eradication of infectious diseases | 1 | 1.1% |
Erlotinib | 1 | 1.1% |
Errors and residuals | 1 | 1.1% |
Esophageal cancer | 1 | 1.1% |
Esophagus | 1 | 1.1% |
Evaluation methods | 1 | 1.1% |
Evaluation of binary classifiers | 1 | 1.1% |
Exome sequencing | 1 | 1.1% |
Experiment | 1 | 1.1% |
Eye | 1 | 1.1% |
FRAX | 1 | 1.1% |
Fatigue | 1 | 1.1% |
Fee-for-service | 1 | 1.1% |
Fetal movement | 1 | 1.1% |
Field Epidemiology Training Program | 1 | 1.1% |
Fifth disease | 1 | 1.1% |
Finasteride | 1 | 1.1% |
Fine-needle aspiration | 1 | 1.1% |
Fluid replacement | 1 | 1.1% |
Focal segmental glomerulosclerosis | 1 | 1.1% |
Formulary (pharmacy) | 1 | 1.1% |
Fresh frozen plasma | 1 | 1.1% |
Fulvestrant | 1 | 1.1% |
Funding of science | 1 | 1.1% |
Fundus photography | 1 | 1.1% |
GLUT1 | 1 | 1.1% |
Gadolinium | 1 | 1.1% |
Gallbladder | 1 | 1.1% |
Gastroesophageal reflux disease | 1 | 1.1% |
Gene | 1 | 1.1% |
Gene expression | 1 | 1.1% |
Gene expression profiling | 1 | 1.1% |
Gene silencing | 1 | 1.1% |
Gene therapy | 1 | 1.1% |
Generalized linear model | 1 | 1.1% |
Genetic disorder | 1 | 1.1% |
Genetic engineering | 1 | 1.1% |
Genital wart | 1 | 1.1% |
Genome-wide association study | 1 | 1.1% |
Genomics | 1 | 1.1% |
Genotype | 1 | 1.1% |
Geriatrics | 1 | 1.1% |
Glomerular filtration rate | 1 | 1.1% |
Glucose tolerance test | 1 | 1.1% |
Glut1 deficiency | 1 | 1.1% |
Glycemic index | 1 | 1.1% |
Gonorrhea | 1 | 1.1% |
Good manufacturing practice | 1 | 1.1% |
Governance | 1 | 1.1% |
Granulocyte colony-stimulating factor | 1 | 1.1% |
HBsAg | 1 | 1.1% |
HIV | 1 | 1.1% |
Hand washing | 1 | 1.1% |
Harm reduction | 1 | 1.1% |
Hazard ratio | 1 | 1.1% |
Head and neck cancer | 1 | 1.1% |
Health Insurance Portability and Accountability Act | 1 | 1.1% |
Health data | 1 | 1.1% |
Health insurance | 1 | 1.1% |
Health technology | 1 | 1.1% |
Heart arrhythmia | 1 | 1.1% |
Heart rate variability | 1 | 1.1% |
Hematology | 1 | 1.1% |
Hematopoietic stem cell transplantation | 1 | 1.1% |
Hemorrhoid | 1 | 1.1% |
Hemothorax | 1 | 1.1% |
Hepatectomy | 1 | 1.1% |
Hepatic arterial infusion | 1 | 1.1% |
Hepatitis C virus | 1 | 1.1% |
Hereditary nonpolyposis colorectal cancer | 1 | 1.1% |
Herpes simplex | 1 | 1.1% |
High-grade serous carcinoma | 1 | 1.1% |
High-risk pregnancy | 1 | 1.1% |
Histamine | 1 | 1.1% |
Hospital-acquired infection | 1 | 1.1% |
Human betaherpesvirus 5 | 1 | 1.1% |
Human chorionic gonadotropin | 1 | 1.1% |
Human development | 1 | 1.1% |
Human respiratory syncytial virus | 1 | 1.1% |
Hydroxyethyl starch | 1 | 1.1% |
Hygiene | 1 | 1.1% |
Hyperemesis gravidarum | 1 | 1.1% |
Hyperglycemia | 1 | 1.1% |
Hyperoxia | 1 | 1.1% |
Hypoglycemia | 1 | 1.1% |
Hypopnea | 1 | 1.1% |
Hypotension | 1 | 1.1% |
Hypothermia | 1 | 1.1% |
Idiopathic pulmonary fibrosis | 1 | 1.1% |
Immune thrombocytopenic purpura | 1 | 1.1% |
Immunoglobulin M | 1 | 1.1% |
Immunoglobulin therapy | 1 | 1.1% |
Immunosuppressive drug | 1 | 1.1% |
Immunotherapy | 1 | 1.1% |
Implantable cardioverter-defibrillator | 1 | 1.1% |
Incentive | 1 | 1.1% |
Index Medicus | 1 | 1.1% |
Infant | 1 | 1.1% |
Infection control | 1 | 1.1% |
Infection prevention and control | 1 | 1.1% |
Infectious mononucleosis | 1 | 1.1% |
Inflammation | 1 | 1.1% |
Infliximab | 1 | 1.1% |
Influenza A virus | 1 | 1.1% |
Influenza A virus subtype H1N1 | 1 | 1.1% |
Influenza A virus subtype H5N1 | 1 | 1.1% |
Influenza A virus subtype H5N8 | 1 | 1.1% |
Influenza A virus subtype H9N2 | 1 | 1.1% |
Inquiry | 1 | 1.1% |
Insomnia | 1 | 1.1% |
Insulin | 1 | 1.1% |
Insulin (medication) | 1 | 1.1% |
Insulin glargine | 1 | 1.1% |
Insulin resistance | 1 | 1.1% |
Inter-rater reliability | 1 | 1.1% |
International Health Regulations | 1 | 1.1% |
Intima-media thickness | 1 | 1.1% |
Intraductal papillary mucinous neoplasm | 1 | 1.1% |
Intraocular pressure | 1 | 1.1% |
Intrauterine hypoxia | 1 | 1.1% |
Intraventricular hemorrhage | 1 | 1.1% |
Invasive carcinoma of no special type | 1 | 1.1% |
Isolation (health care) | 1 | 1.1% |
Isoniazid | 1 | 1.1% |
Ivacaftor | 1 | 1.1% |
Janus kinase | 1 | 1.1% |
KRAS | 1 | 1.1% |
Keloid | 1 | 1.1% |
Kennel cough | 1 | 1.1% |
Kidney | 1 | 1.1% |
Kidney failure | 1 | 1.1% |
Klinefelter syndrome | 1 | 1.1% |
Labor induction | 1 | 1.1% |
Lactobacillus | 1 | 1.1% |
Lactobacillus acidophilus | 1 | 1.1% |
Lactobacillus fermentum | 1 | 1.1% |
Lactobacillus rhamnosus | 1 | 1.1% |
Laryngeal cancer | 1 | 1.1% |
Lassa fever | 1 | 1.1% |
Lateral flow test | 1 | 1.1% |
Lenalidomide | 1 | 1.1% |
Lentivirus | 1 | 1.1% |
Leukemia | 1 | 1.1% |
Levofloxacin | 1 | 1.1% |
Light therapy | 1 | 1.1% |
Likelihood function | 1 | 1.1% |
Likelihood ratios in diagnostic testing | 1 | 1.1% |
Linezolid | 1 | 1.1% |
Liver cancer | 1 | 1.1% |
Liver function tests | 1 | 1.1% |
Logistic regression | 1 | 1.1% |
Long QT syndrome | 1 | 1.1% |
Loratadine | 1 | 1.1% |
Low birth weight | 1 | 1.1% |
Low-carbohydrate diet | 1 | 1.1% |
Lower gastrointestinal series | 1 | 1.1% |
Lower respiratory tract infection | 1 | 1.1% |
Lymph node | 1 | 1.1% |
Lymphadenectomy | 1 | 1.1% |
Lymphatic system | 1 | 1.1% |
Lymphatic vessel | 1 | 1.1% |
MHealth | 1 | 1.1% |
MMR vaccine and autism | 1 | 1.1% |
MRI contrast agent | 1 | 1.1% |
MUC1 | 1 | 1.1% |
Macula of retina | 1 | 1.1% |
Magnetic resonance angiography | 1 | 1.1% |
MammaPrint | 1 | 1.1% |
Managed care | 1 | 1.1% |
Management of HIV/AIDS | 1 | 1.1% |
Management of depression | 1 | 1.1% |
Mastectomy | 1 | 1.1% |
Maximum likelihood estimation | 1 | 1.1% |
Mean | 1 | 1.1% |
Medical Subject Headings | 1 | 1.1% |
Medical emergencies | 1 | 1.1% |
Medical equipment | 1 | 1.1% |
Medical genetics | 1 | 1.1% |
Medical history | 1 | 1.1% |
Medical prescription | 1 | 1.1% |
Medical school | 1 | 1.1% |
Medical statistics | 1 | 1.1% |
Mediterranean diet | 1 | 1.1% |
Mefloquine | 1 | 1.1% |
Men who have sex with men | 1 | 1.1% |
Meningococcal disease | 1 | 1.1% |
Mentorship | 1 | 1.1% |
Mesothelioma | 1 | 1.1% |
Metastatic liver disease | 1 | 1.1% |
Metformin | 1 | 1.1% |
Methotrexate | 1 | 1.1% |
Microcephaly | 1 | 1.1% |
Microtia | 1 | 1.1% |
Middle East respiratory syndrome | 1 | 1.1% |
Middle East respiratory syndrome coronavirus | 1 | 1.1% |
Midwife | 1 | 1.1% |
Miliary tuberculosis | 1 | 1.1% |
Mitral insufficiency | 1 | 1.1% |
Model organism | 1 | 1.1% |
Molecular biology | 1 | 1.1% |
Molecular imaging | 1 | 1.1% |
Monitoring (medicine) | 1 | 1.1% |
Monoamine oxidase inhibitor | 1 | 1.1% |
Monoclonal antibody | 1 | 1.1% |
Monoclonal antibody therapy | 1 | 1.1% |
Mosquito-borne disease | 1 | 1.1% |
Motivation | 1 | 1.1% |
Motivational interviewing | 1 | 1.1% |
Multidrug-resistant tuberculosis | 1 | 1.1% |
Multiple drug resistance | 1 | 1.1% |
Multiple myeloma | 1 | 1.1% |
Muromonab-CD3 | 1 | 1.1% |
Musculoskeletal system | 1 | 1.1% |
Mutation | 1 | 1.1% |
Mycobacterium bovis | 1 | 1.1% |
Mycobacterium tuberculosis | 1 | 1.1% |
Myelofibrosis | 1 | 1.1% |
Myocardial perfusion imaging | 1 | 1.1% |
Nasopharynx cancer | 1 | 1.1% |
Natalizumab | 1 | 1.1% |
Natural killer cell | 1 | 1.1% |
Nausea | 1 | 1.1% |
Near-sightedness | 1 | 1.1% |
Necrotizing enterocolitis | 1 | 1.1% |
Neglected tropical diseases | 1 | 1.1% |
Neisseria meningitidis | 1 | 1.1% |
Nephrology | 1 | 1.1% |
Nephrotic syndrome | 1 | 1.1% |
Nervous system | 1 | 1.1% |
Neuroimaging | 1 | 1.1% |
Nicotine dependence | 1 | 1.1% |
Non-communicable disease | 1 | 1.1% |
Non-small-cell lung carcinoma | 1 | 1.1% |
Notified body | 1 | 1.1% |
Nutrition | 1 | 1.1% |
Obstructive sleep apnea | 1 | 1.1% |
Ocular tonometry | 1 | 1.1% |
Off-label use | 1 | 1.1% |
Oncology | 1 | 1.1% |
Oophorectomy | 1 | 1.1% |
Optic disc | 1 | 1.1% |
Optic nerve | 1 | 1.1% |
Optical coherence tomography | 1 | 1.1% |
Optometry | 1 | 1.1% |
Oral sex | 1 | 1.1% |
Organisms | 1 | 1.1% |
Organs (anatomy) | 1 | 1.1% |
Orphan drug | 1 | 1.1% |
Orthomyxoviridae | 1 | 1.1% |
Oseltamivir | 1 | 1.1% |
Outcomes research | 1 | 1.1% |
Outlier | 1 | 1.1% |
Ovarian cyst | 1 | 1.1% |
Ovary | 1 | 1.1% |
Oxygen saturation (medicine) | 1 | 1.1% |
Oxygen therapy | 1 | 1.1% |
PUVA therapy | 1 | 1.1% |
Palliative care | 1 | 1.1% |
Pancreas | 1 | 1.1% |
Pancreatic mucinous cystic neoplasm | 1 | 1.1% |
Panitumumab | 1 | 1.1% |
Paramedic | 1 | 1.1% |
Parameter | 1 | 1.1% |
Paratyphoid fever | 1 | 1.1% |
Parkinson's disease | 1 | 1.1% |
Passive smoking | 1 | 1.1% |
Patau syndrome | 1 | 1.1% |
Patent ductus arteriosus | 1 | 1.1% |
Patient participation | 1 | 1.1% |
Patient-reported outcome | 1 | 1.1% |
Penile cancer | 1 | 1.1% |
Percutaneous coronary intervention | 1 | 1.1% |
Periodontology | 1 | 1.1% |
Perioperative | 1 | 1.1% |
Peripheral neuropathy | 1 | 1.1% |
Personal protective equipment | 1 | 1.1% |
Phacoemulsification | 1 | 1.1% |
Pharmaceutical Benefits Scheme | 1 | 1.1% |
Pharmaceutical sciences | 1 | 1.1% |
Pharmacogenetics | 1 | 1.1% |
Pharmacogenomics | 1 | 1.1% |
Pharmacokinetics | 1 | 1.1% |
Pharmacopoeia | 1 | 1.1% |
Pharyngitis | 1 | 1.1% |
Piperacillin | 1 | 1.1% |
Piperaquine | 1 | 1.1% |
Placebo-controlled study | 1 | 1.1% |
Placenta | 1 | 1.1% |
Placental abruption | 1 | 1.1% |
Platelet | 1 | 1.1% |
Platelet transfusion | 1 | 1.1% |
Plateletpheresis | 1 | 1.1% |
Pleural empyema | 1 | 1.1% |
Pneumothorax | 1 | 1.1% |
Poliomyelitis | 1 | 1.1% |
Poliovirus | 1 | 1.1% |
Polyclonal B cell response | 1 | 1.1% |
Polyclonal antibodies | 1 | 1.1% |
Polycythemia vera | 1 | 1.1% |
Polysomnography | 1 | 1.1% |
Population health | 1 | 1.1% |
Positive airway pressure | 1 | 1.1% |
Post-exposure prophylaxis | 1 | 1.1% |
Postoperative nausea and vomiting | 1 | 1.1% |
Poultry | 1 | 1.1% |
Pre- and post-test probability | 1 | 1.1% |
Pre-exposure prophylaxis | 1 | 1.1% |
Prebiotic (nutrition) | 1 | 1.1% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 1 | 1.1% |
Premature ventricular contraction | 1 | 1.1% |
Prescription drug | 1 | 1.1% |
Prevention of HIV/AIDS | 1 | 1.1% |
Primary care physician | 1 | 1.1% |
Prison | 1 | 1.1% |
Privacy | 1 | 1.1% |
Programmed cell death protein 1 | 1 | 1.1% |
Prophylactic salpingectomy | 1 | 1.1% |
Prostatitis | 1 | 1.1% |
Proteomics | 1 | 1.1% |
Pseudoaneurysm | 1 | 1.1% |
Pseudoexfoliation syndrome | 1 | 1.1% |
Psoriasis | 1 | 1.1% |
Psoriatic arthritis | 1 | 1.1% |
Public health surveillance | 1 | 1.1% |
Public services | 1 | 1.1% |
Pulmonary edema | 1 | 1.1% |
Pyelonephritis | 1 | 1.1% |
Pyridoxine/doxylamine | 1 | 1.1% |
Quality of life | 1 | 1.1% |
Quality of life (healthcare) | 1 | 1.1% |
QuantiFERON | 1 | 1.1% |
Quantitative computed tomography | 1 | 1.1% |
Quantitative research | 1 | 1.1% |
Quinolone antibiotic | 1 | 1.1% |
ROS1 | 1 | 1.1% |
Ramucirumab | 1 | 1.1% |
Rare disease | 1 | 1.1% |
Real world evidence | 1 | 1.1% |
Recombinant DNA | 1 | 1.1% |
Relative risk | 1 | 1.1% |
Reproducibility | 1 | 1.1% |
Reproductive health | 1 | 1.1% |
Research Excellence Framework | 1 | 1.1% |
Research methods | 1 | 1.1% |
Residency (medicine) | 1 | 1.1% |
Respiratory disease | 1 | 1.1% |
Respiratory system | 1 | 1.1% |
Respiratory tract infection | 1 | 1.1% |
Retinopathy | 1 | 1.1% |
Retinopathy of prematurity | 1 | 1.1% |
Revised Cardiac Risk Index | 1 | 1.1% |
Rheumatoid arthritis | 1 | 1.1% |
Rifampicin | 1 | 1.1% |
Rituximab | 1 | 1.1% |
Roseola | 1 | 1.1% |
Ruxolitinib | 1 | 1.1% |
SOFA score | 1 | 1.1% |
Safety | 1 | 1.1% |
Salmonella | 1 | 1.1% |
Scanning laser ophthalmoscopy | 1 | 1.1% |
Scarlet fever | 1 | 1.1% |
Scientific method | 1 | 1.1% |
Seat belt | 1 | 1.1% |
Selection bias | 1 | 1.1% |
Self-control | 1 | 1.1% |
Senses | 1 | 1.1% |
Serology | 1 | 1.1% |
Severe acute respiratory syndrome | 1 | 1.1% |
Sexual anatomy | 1 | 1.1% |
Sharps waste | 1 | 1.1% |
Shingles | 1 | 1.1% |
Shortness of breath | 1 | 1.1% |
Sigmoidoscopy | 1 | 1.1% |
Simulation | 1 | 1.1% |
Single-nucleotide polymorphism | 1 | 1.1% |
Single-photon emission computed tomography | 1 | 1.1% |
Skin cancer | 1 | 1.1% |
Sleep | 1 | 1.1% |
Sleep and breathing | 1 | 1.1% |
Sleep apnea | 1 | 1.1% |
Sleep disorder | 1 | 1.1% |
Sleep medicine | 1 | 1.1% |
Slit lamp | 1 | 1.1% |
Small for gestational age | 1 | 1.1% |
Small interfering RNA | 1 | 1.1% |
Smokeless tobacco | 1 | 1.1% |
Smoking and pregnancy | 1 | 1.1% |
Smoking ban | 1 | 1.1% |
Snakebite | 1 | 1.1% |
Social programs | 1 | 1.1% |
Sofosbuvir | 1 | 1.1% |
Standardization | 1 | 1.1% |
Statistical hypothesis testing | 1 | 1.1% |
Stomach | 1 | 1.1% |
Stress hyperglycemia | 1 | 1.1% |
Subacute sclerosing panencephalitis | 1 | 1.1% |
Substance use disorder | 1 | 1.1% |
Sulfonylurea | 1 | 1.1% |
Supraventricular tachycardia | 1 | 1.1% |
Surrogate endpoint | 1 | 1.1% |
Surveillance | 1 | 1.1% |
Survival analysis | 1 | 1.1% |
Survival rate | 1 | 1.1% |
Symptom | 1 | 1.1% |
Syphilis | 1 | 1.1% |
Systemic inflammatory response syndrome | 1 | 1.1% |
T cell | 1 | 1.1% |
TNM staging system | 1 | 1.1% |
Tachycardia | 1 | 1.1% |
Technetium-99m | 1 | 1.1% |
Technology | 1 | 1.1% |
Telehealth | 1 | 1.1% |
Thalidomide | 1 | 1.1% |
Thematic analysis | 1 | 1.1% |
Thiomersal | 1 | 1.1% |
Thoracentesis | 1 | 1.1% |
Thoracotomy | 1 | 1.1% |
Thorax (human anatomy) | 1 | 1.1% |
Thrombocytopenia | 1 | 1.1% |
Thrombus | 1 | 1.1% |
Thymoglobulin | 1 | 1.1% |
Ticagrelor | 1 | 1.1% |
Ticlopidine | 1 | 1.1% |
Tigecycline | 1 | 1.1% |
Tissue plasminogen activator | 1 | 1.1% |
Tissues (biology) | 1 | 1.1% |
Torsades de pointes | 1 | 1.1% |
Trade-off | 1 | 1.1% |
Tramadol | 1 | 1.1% |
Transfusion-related acute lung injury | 1 | 1.1% |
Translational research | 1 | 1.1% |
Transposition of the great vessels | 1 | 1.1% |
Treatment of cancer | 1 | 1.1% |
Tretinoin | 1 | 1.1% |
Triage | 1 | 1.1% |
Trichomoniasis | 1 | 1.1% |
Triple test | 1 | 1.1% |
Troponin | 1 | 1.1% |
Trust (emotion) | 1 | 1.1% |
Tumors of the hematopoietic and lymphoid tissues | 1 | 1.1% |
Turner syndrome | 1 | 1.1% |
Twin-to-twin transfusion syndrome | 1 | 1.1% |
Type 1 diabetes | 1 | 1.1% |
Typhoid fever | 1 | 1.1% |
Urinary tract infection | 1 | 1.1% |
Urine | 1 | 1.1% |
Urine test strip | 1 | 1.1% |
Urology | 1 | 1.1% |
Utility | 1 | 1.1% |
Uveitis | 1 | 1.1% |
Vaginal discharge | 1 | 1.1% |
Vaginal flora | 1 | 1.1% |
Vaginal yeast infection | 1 | 1.1% |
Vaginitis | 1 | 1.1% |
Validity (statistics) | 1 | 1.1% |
Vancomycin | 1 | 1.1% |
Vancomycin-resistant Enterococcus | 1 | 1.1% |
Vandetanib | 1 | 1.1% |
Varenicline | 1 | 1.1% |
Ventricular hypertrophy | 1 | 1.1% |
Ventricular natriuretic peptide | 1 | 1.1% |
Vertebra | 1 | 1.1% |
Vertebral column | 1 | 1.1% |
Vertically transmitted infection | 1 | 1.1% |
Veterinary medicine | 1 | 1.1% |
Video-assisted thoracoscopic surgery | 1 | 1.1% |
VigiBase | 1 | 1.1% |
Viral vector | 1 | 1.1% |
Virtual colonoscopy | 1 | 1.1% |
Viruses | 1 | 1.1% |
Visual acuity | 1 | 1.1% |
Volume expander | 1 | 1.1% |
Web of Science | 1 | 1.1% |
Weight loss | 1 | 1.1% |
Welfare | 1 | 1.1% |
Welfare economics | 1 | 1.1% |
Whole genome sequencing | 1 | 1.1% |
Whooping cough | 1 | 1.1% |
Wound | 1 | 1.1% |
XYY syndrome | 1 | 1.1% |
Yellow fever | 1 | 1.1% |
Zoonosis | 1 | 1.1% |
Zygosity | 1 | 1.1% |
abs | rel | |
---|---|---|
Medicine | 110 | 98.2% |
Health | 109 | 97.3% |
Medical specialties | 103 | 92.0% |
Health sciences | 101 | 90.2% |
Clinical medicine | 97 | 86.6% |
Health care | 95 | 84.8% |
Public health | 49 | 43.8% |
Diseases and disorders | 44 | 39.3% |
Epidemiology | 34 | 30.4% |
Risk | 33 | 29.5% |
Infection | 32 | 28.6% |
Disease | 30 | 26.8% |
Randomized controlled trial | 28 | 25.0% |
Clinical trial | 25 | 22.3% |
Meta-analysis | 25 | 22.3% |
Systematic review | 24 | 21.4% |
Therapy | 23 | 20.5% |
Adherence (medicine) | 21 | 18.8% |
Medical diagnosis | 21 | 18.8% |
Preventive healthcare | 21 | 18.8% |
Evidence-based medicine | 19 | 17.0% |
Sensitivity and specificity | 19 | 17.0% |
HIV/AIDS | 18 | 16.1% |
Infectious diseases | 17 | 15.2% |
Blinded experiment | 15 | 13.4% |
Tuberculosis | 15 | 13.4% |
Cancer | 14 | 12.5% |
Chronic condition | 14 | 12.5% |
Medication | 14 | 12.5% |
Confidence interval | 13 | 11.6% |
Hypertension | 13 | 11.6% |
Immunology | 13 | 11.6% |
Hospital | 12 | 10.7% |
Patient | 12 | 10.7% |
Sexually transmitted infection | 12 | 10.7% |
Surgery | 12 | 10.7% |
Health economics | 11 | 9.8% |
Health policy | 11 | 9.8% |
Heart | 11 | 9.8% |
Medical humanities | 11 | 9.8% |
Pregnancy | 11 | 9.8% |
Antimicrobial resistance | 10 | 8.9% |
Biology | 10 | 8.9% |
Blood pressure | 10 | 8.9% |
Cardiovascular system | 10 | 8.9% |
Cohort study | 10 | 8.9% |
Management of HIV/AIDS | 10 | 8.9% |
Medical guideline | 10 | 8.9% |
Research | 10 | 8.9% |
Cardiovascular disease | 9 | 8.0% |
Human activities | 9 | 8.0% |
Life sciences | 9 | 8.0% |
Microbiology | 9 | 8.0% |
Receiver operating characteristic | 9 | 8.0% |
Screening (medicine) | 9 | 8.0% |
Tuberculosis management | 9 | 8.0% |
Diagnosis of HIV/AIDS | 8 | 7.1% |
Electronic health record | 8 | 7.1% |
Hepatitis | 8 | 7.1% |
Medical imaging | 8 | 7.1% |
Myocardial infarction | 8 | 7.1% |
Stroke | 8 | 7.1% |
Adverse effect | 7 | 6.2% |
Antibiotic | 7 | 6.2% |
Bisphosphonate | 7 | 6.2% |
Chemotherapy | 7 | 6.2% |
Dual-energy X-ray absorptiometry | 7 | 6.2% |
Health professional | 7 | 6.2% |
Health system | 7 | 6.2% |
Heart failure | 7 | 6.2% |
Major depressive disorder | 7 | 6.2% |
Multi-drug-resistant tuberculosis | 7 | 6.2% |
Neoplasms | 7 | 6.2% |
Osteoporosis | 7 | 6.2% |
Percutaneous coronary intervention | 7 | 6.2% |
Pneumonia | 7 | 6.2% |
Bone density | 6 | 5.4% |
Cardiology | 6 | 5.4% |
Caregiver | 6 | 5.4% |
Chronic kidney disease | 6 | 5.4% |
Cost-effectiveness analysis | 6 | 5.4% |
Data analysis | 6 | 5.4% |
Dose (biochemistry) | 6 | 5.4% |
Emergency department | 6 | 5.4% |
Exercise | 6 | 5.4% |
High-density lipoprotein | 6 | 5.4% |
Intravenous therapy | 6 | 5.4% |
Medicare (United States) | 6 | 5.4% |
Men who have sex with men | 6 | 5.4% |
Nursing | 6 | 5.4% |
Pharmacology | 6 | 5.4% |
Positive and negative predictive values | 6 | 5.4% |
Quality-adjusted life year | 6 | 5.4% |
Renal function | 6 | 5.4% |
Sepsis | 6 | 5.4% |
Transmission (medicine) | 6 | 5.4% |
Vitamin D | 6 | 5.4% |
Adjuvant therapy | 5 | 4.5% |
Anticoagulant | 5 | 4.5% |
Atrial fibrillation | 5 | 4.5% |
Bias | 5 | 4.5% |
Biomarker | 5 | 4.5% |
Bone | 5 | 4.5% |
Bone fracture | 5 | 4.5% |
Breast cancer | 5 | 4.5% |
Childbirth | 5 | 4.5% |
Colorectal cancer | 5 | 4.5% |
Current Procedural Terminology | 5 | 4.5% |
Diabetes | 5 | 4.5% |
Drugs | 5 | 4.5% |
Hepatitis C | 5 | 4.5% |
Human reproduction | 5 | 4.5% |
International Statistical Classification of Diseases and Related Health Problems | 5 | 4.5% |
Low-density lipoprotein | 5 | 4.5% |
Medicaid | 5 | 4.5% |
Medical test | 5 | 4.5% |
Obesity | 5 | 4.5% |
Osteopenia | 5 | 4.5% |
Pharmacy | 5 | 4.5% |
Polymerase chain reaction | 5 | 4.5% |
Reporting bias | 5 | 4.5% |
Sampling (statistics) | 5 | 4.5% |
Sensitivity analysis | 5 | 4.5% |
Sustainability | 5 | 4.5% |
Sustainable Development Goals | 5 | 4.5% |
Urinary tract infection | 5 | 4.5% |
Vaccination | 5 | 4.5% |
Vagina | 5 | 4.5% |
Accountable care organization | 4 | 3.6% |
Antiviral drug | 4 | 3.6% |
Biopsy | 4 | 3.6% |
Bipolar disorder | 4 | 3.6% |
Breastfeeding and HIV | 4 | 3.6% |
CD4 | 4 | 3.6% |
CT scan | 4 | 3.6% |
Chronic obstructive pulmonary disease | 4 | 3.6% |
Cirrhosis | 4 | 3.6% |
Colonoscopy | 4 | 3.6% |
Cost–utility analysis | 4 | 3.6% |
Creative Commons license | 4 | 3.6% |
Dementia | 4 | 3.6% |
Directly observed treatment, short-course | 4 | 3.6% |
Fecal occult blood | 4 | 3.6% |
GeneXpert MTB/RIF | 4 | 3.6% |
Glycated hemoglobin | 4 | 3.6% |
Gonorrhea | 4 | 3.6% |
HER2/neu | 4 | 3.6% |
Health informatics | 4 | 3.6% |
Hematuria | 4 | 3.6% |
Hepatocellular carcinoma | 4 | 3.6% |
Implantable cardioverter-defibrillator | 4 | 3.6% |
Innovation | 4 | 3.6% |
Kidney | 4 | 3.6% |
Kidney failure | 4 | 3.6% |
Medical Subject Headings | 4 | 3.6% |
Menopause | 4 | 3.6% |
Mental health | 4 | 3.6% |
Metastasis | 4 | 3.6% |
Pediatrics | 4 | 3.6% |
Physical therapy | 4 | 3.6% |
Placebo | 4 | 3.6% |
Post-exposure prophylaxis | 4 | 3.6% |
Preterm birth | 4 | 3.6% |
Publication bias | 4 | 3.6% |
Raloxifene | 4 | 3.6% |
Regression analysis | 4 | 3.6% |
Shortness of breath | 4 | 3.6% |
Statistics | 4 | 3.6% |
Teriparatide | 4 | 3.6% |
Thrombosis | 4 | 3.6% |
Urology | 4 | 3.6% |
Vaccine | 4 | 3.6% |
Vein | 4 | 3.6% |
Venous thrombosis | 4 | 3.6% |
Virus | 4 | 3.6% |
Zoledronic acid | 4 | 3.6% |
ACE inhibitor | 3 | 2.7% |
Alanine transaminase | 3 | 2.7% |
Alcoholism | 3 | 2.7% |
Allocation concealment | 3 | 2.7% |
Alzheimer's disease | 3 | 2.7% |
Anesthesia | 3 | 2.7% |
Anti-diabetic medication | 3 | 2.7% |
Asthma | 3 | 2.7% |
BCG vaccine | 3 | 2.7% |
Beta blocker | 3 | 2.7% |
Biotechnology | 3 | 2.7% |
Bronchitis | 3 | 2.7% |
Central venous catheter | 3 | 2.7% |
Cholesterol | 3 | 2.7% |
Comorbidity | 3 | 2.7% |
Condom | 3 | 2.7% |
Confounding | 3 | 2.7% |
Coronary artery disease | 3 | 2.7% |
Denosumab | 3 | 2.7% |
Diagnosis code | 3 | 2.7% |
Diagnosis-related group | 3 | 2.7% |
Dietary supplement | 3 | 2.7% |
EQ-5D | 3 | 2.7% |
Ejection fraction | 3 | 2.7% |
Epidemiology of HIV/AIDS | 3 | 2.7% |
Extensively drug-resistant tuberculosis | 3 | 2.7% |
Federally Qualified Health Center | 3 | 2.7% |
Gastroenterology | 3 | 2.7% |
HBsAg | 3 | 2.7% |
HIV | 3 | 2.7% |
Heart failure with preserved ejection fraction | 3 | 2.7% |
Hematology | 3 | 2.7% |
Hepatitis B | 3 | 2.7% |
Hepatitis B virus | 3 | 2.7% |
Hospital readmission | 3 | 2.7% |
Hyperlipidemia | 3 | 2.7% |
Incidence (epidemiology) | 3 | 2.7% |
Influenza | 3 | 2.7% |
Intensive care unit | 3 | 2.7% |
Internal medicine | 3 | 2.7% |
Kidney disease | 3 | 2.7% |
Lentiviruses | 3 | 2.7% |
Liver | 3 | 2.7% |
Liver biopsy | 3 | 2.7% |
Liver disease | 3 | 2.7% |
Liver function tests | 3 | 2.7% |
MEDLINE | 3 | 2.7% |
Machine learning | 3 | 2.7% |
Malaria | 3 | 2.7% |
MammaPrint | 3 | 2.7% |
Medical record | 3 | 2.7% |
Medical sign | 3 | 2.7% |
Medical treatments | 3 | 2.7% |
Methicillin-resistant Staphylococcus aureus | 3 | 2.7% |
Methylprednisolone | 3 | 2.7% |
Missing data | 3 | 2.7% |
Non-alcoholic fatty liver disease | 3 | 2.7% |
Odds ratio | 3 | 2.7% |
Organs (anatomy) | 3 | 2.7% |
Osteonecrosis of the jaw | 3 | 2.7% |
Patient participation | 3 | 2.7% |
Pay for performance (healthcare) | 3 | 2.7% |
Pediatric nursing | 3 | 2.7% |
Physician | 3 | 2.7% |
Poverty | 3 | 2.7% |
Prednisolone | 3 | 2.7% |
Prednisone | 3 | 2.7% |
Prevention of HIV/AIDS | 3 | 2.7% |
Preventive medicine | 3 | 2.7% |
Public sphere | 3 | 2.7% |
Safe sex | 3 | 2.7% |
Sex worker | 3 | 2.7% |
Specification (technical standard) | 3 | 2.7% |
Statin | 3 | 2.7% |
Strontium ranelate | 3 | 2.7% |
Study heterogeneity | 3 | 2.7% |
Substance use disorder | 3 | 2.7% |
Thrombocytopenia | 3 | 2.7% |
Transient ischemic attack | 3 | 2.7% |
Type 2 diabetes | 3 | 2.7% |
Urinary incontinence | 3 | 2.7% |
Vaginitis | 3 | 2.7% |
Vertebral augmentation | 3 | 2.7% |
Vitamin | 3 | 2.7% |
Women's health | 3 | 2.7% |
Abdomen | 2 | 1.8% |
Abscess | 2 | 1.8% |
Active surveillance of prostate cancer | 2 | 1.8% |
Adolescence | 2 | 1.8% |
Anatomical terms of location | 2 | 1.8% |
Angiology | 2 | 1.8% |
Angioplasty | 2 | 1.8% |
Angiotensin II receptor blocker | 2 | 1.8% |
Antibody | 2 | 1.8% |
Antihypertensive drug | 2 | 1.8% |
Arrhythmia | 2 | 1.8% |
Ascending cholangitis | 2 | 1.8% |
Assay | 2 | 1.8% |
Atrial flutter | 2 | 1.8% |
Atrial septal defect | 2 | 1.8% |
Atrium (heart) | 2 | 1.8% |
Atrophic vaginitis | 2 | 1.8% |
Autoimmune hepatitis | 2 | 1.8% |
Bacteria | 2 | 1.8% |
Bacterial vaginosis | 2 | 1.8% |
Bacteriuria | 2 | 1.8% |
Behavior | 2 | 1.8% |
Biochemistry | 2 | 1.8% |
Biosafety | 2 | 1.8% |
Biosafety level | 2 | 1.8% |
Birth defect | 2 | 1.8% |
Bleeding | 2 | 1.8% |
Blood | 2 | 1.8% |
Blood transfusion | 2 | 1.8% |
Bloodstream infections | 2 | 1.8% |
Botulinum toxin | 2 | 1.8% |
Brain natriuretic peptide | 2 | 1.8% |
Breast cancer classification | 2 | 1.8% |
Breastfeeding | 2 | 1.8% |
C-reactive protein | 2 | 1.8% |
CHA2DS2–VASc score | 2 | 1.8% |
Caesarean section | 2 | 1.8% |
Calcium supplement | 2 | 1.8% |
Cancer screening | 2 | 1.8% |
Cardiac catheterization | 2 | 1.8% |
Cardiopulmonary resuscitation | 2 | 1.8% |
Catheter ablation | 2 | 1.8% |
Cattle | 2 | 1.8% |
Cervical cancer | 2 | 1.8% |
Cervix | 2 | 1.8% |
Chickenpox | 2 | 1.8% |
Child | 2 | 1.8% |
Chlamydia | 2 | 1.8% |
Circumcision | 2 | 1.8% |
Coagulation | 2 | 1.8% |
Cochrane Library | 2 | 1.8% |
Complete blood count | 2 | 1.8% |
Coronary artery bypass surgery | 2 | 1.8% |
Creatinine | 2 | 1.8% |
Cross-validation (statistics) | 2 | 1.8% |
DNA sequencing | 2 | 1.8% |
DPT vaccine | 2 | 1.8% |
Deep vein thrombosis | 2 | 1.8% |
Defibrillation | 2 | 1.8% |
Delirium | 2 | 1.8% |
Dengue fever | 2 | 1.8% |
Digestive system | 2 | 1.8% |
Disability-adjusted life year | 2 | 1.8% |
Drug development | 2 | 1.8% |
Electrocardiography | 2 | 1.8% |
Emergency medical services | 2 | 1.8% |
Emergency medicine | 2 | 1.8% |
Endocrine system | 2 | 1.8% |
Endoscopy | 2 | 1.8% |
Engineering controls | 2 | 1.8% |
Epidural administration | 2 | 1.8% |
Equal opportunity | 2 | 1.8% |
Esophagus | 2 | 1.8% |
Estrogen receptor | 2 | 1.8% |
Fee-for-service | 2 | 1.8% |
Fever | 2 | 1.8% |
Function (mathematics) | 2 | 1.8% |
Gene expression profiling | 2 | 1.8% |
Gene expression profiling in cancer | 2 | 1.8% |
Gene signature | 2 | 1.8% |
Genetics | 2 | 1.8% |
Global health | 2 | 1.8% |
Gross domestic product | 2 | 1.8% |
Gynaecologic disorders | 2 | 1.8% |
Gynaecology | 2 | 1.8% |
HIV-positive people | 2 | 1.8% |
HIV/AIDS in Africa | 2 | 1.8% |
Health care quality | 2 | 1.8% |
Health technology in the United States | 2 | 1.8% |
Hematopoietic stem cell transplantation | 2 | 1.8% |
Hemodialysis | 2 | 1.8% |
Hepatitis B vaccine | 2 | 1.8% |
Hepatology | 2 | 1.8% |
Hip fracture | 2 | 1.8% |
Hormone replacement therapy | 2 | 1.8% |
Hypercholesterolemia | 2 | 1.8% |
Hyperglycemia | 2 | 1.8% |
Hypertrophic cardiomyopathy | 2 | 1.8% |
ICD-10 | 2 | 1.8% |
Immunodeficiency | 2 | 1.8% |
Implant (medicine) | 2 | 1.8% |
Infant | 2 | 1.8% |
Infection control | 2 | 1.8% |
Infertility | 2 | 1.8% |
Inflammation | 2 | 1.8% |
Information technology | 2 | 1.8% |
Ischemia | 2 | 1.8% |
Kidney transplantation | 2 | 1.8% |
Laboratory | 2 | 1.8% |
Lentigo maligna | 2 | 1.8% |
Likelihood ratios in diagnostic testing | 2 | 1.8% |
Logistic function | 2 | 1.8% |
Logistic regression | 2 | 1.8% |
MHealth | 2 | 1.8% |
Magnetic resonance imaging | 2 | 1.8% |
Major trauma | 2 | 1.8% |
Management of atrial fibrillation | 2 | 1.8% |
Mathematical optimization | 2 | 1.8% |
Medical microbiology | 2 | 1.8% |
Medical prescription | 2 | 1.8% |
Medical research | 2 | 1.8% |
Medical tests | 2 | 1.8% |
Melanoma | 2 | 1.8% |
Mental disorder | 2 | 1.8% |
Molecular diagnostics | 2 | 1.8% |
Mycobacterium bovis | 2 | 1.8% |
N-terminal prohormone of brain natriuretic peptide | 2 | 1.8% |
Neoplasm | 2 | 1.8% |
Nervous system | 2 | 1.8% |
Neurology | 2 | 1.8% |
Nevirapine | 2 | 1.8% |
Nevus | 2 | 1.8% |
Overactive bladder | 2 | 1.8% |
PCSK9 | 2 | 1.8% |
PHQ-9 | 2 | 1.8% |
Palliative care | 2 | 1.8% |
Personal protective equipment | 2 | 1.8% |
Personalized medicine | 2 | 1.8% |
Pharmaceutical sciences | 2 | 1.8% |
Physical examination | 2 | 1.8% |
Platelet | 2 | 1.8% |
Platelet transfusion | 2 | 1.8% |
Point of care | 2 | 1.8% |
Posttraumatic stress disorder | 2 | 1.8% |
Pre- and post-test probability | 2 | 1.8% |
Prediabetes | 2 | 1.8% |
Prediction | 2 | 1.8% |
Prescription drug | 2 | 1.8% |
Pressure ulcer | 2 | 1.8% |
Primary biliary cholangitis | 2 | 1.8% |
Primary health care | 2 | 1.8% |
Privacy | 2 | 1.8% |
Prostate cancer | 2 | 1.8% |
Prothrombin time | 2 | 1.8% |
Pulmonary embolism | 2 | 1.8% |
Pyelonephritis | 2 | 1.8% |
Quantitative computed tomography | 2 | 1.8% |
Radiation therapy | 2 | 1.8% |
Radiology | 2 | 1.8% |
Random forest | 2 | 1.8% |
Reference range | 2 | 1.8% |
Reproductive health | 2 | 1.8% |
Revised National Tuberculosis Control Program | 2 | 1.8% |
Rosuvastatin | 2 | 1.8% |
Sample size determination | 2 | 1.8% |
Selective estrogen receptor modulator | 2 | 1.8% |
Sexual intercourse | 2 | 1.8% |
Shingles | 2 | 1.8% |
Skin condition | 2 | 1.8% |
Slum | 2 | 1.8% |
Smoking cessation | 2 | 1.8% |
Social protection | 2 | 1.8% |
Spinal cord | 2 | 1.8% |
Standard deviation | 2 | 1.8% |
Substance abuse | 2 | 1.8% |
Tachycardia | 2 | 1.8% |
Tamoxifen | 2 | 1.8% |
Teledermatology | 2 | 1.8% |
Tissues (biology) | 2 | 1.8% |
Trauma center | 2 | 1.8% |
Traumatic brain injury | 2 | 1.8% |
Trichomonas vaginalis | 2 | 1.8% |
Trichomoniasis | 2 | 1.8% |
Triple-negative breast cancer | 2 | 1.8% |
Tropical medicine | 2 | 1.8% |
Urethra | 2 | 1.8% |
Urine test strip | 2 | 1.8% |
Vaginal discharge | 2 | 1.8% |
Ventricle (heart) | 2 | 1.8% |
Vertically transmitted infection | 2 | 1.8% |
Violence | 2 | 1.8% |
Viral load | 2 | 1.8% |
Virology | 2 | 1.8% |
Virtual colonoscopy | 2 | 1.8% |
Vital signs | 2 | 1.8% |
Vitamin D deficiency | 2 | 1.8% |
Wound | 2 | 1.8% |
Zika fever | 2 | 1.8% |
2009 flu pandemic | 1 | 0.9% |
3D modeling | 1 | 0.9% |
3D printing | 1 | 0.9% |
ABC (medicine) | 1 | 0.9% |
Abidjan | 1 | 0.9% |
Accuracy and precision | 1 | 0.9% |
Aclidinium bromide | 1 | 0.9% |
Acute prostatitis | 1 | 0.9% |
Adaptive immune system | 1 | 0.9% |
Adenoma | 1 | 0.9% |
Adenoviridae | 1 | 0.9% |
Adipose tissue | 1 | 0.9% |
Advanced trauma life support | 1 | 0.9% |
African trypanosomiasis | 1 | 0.9% |
Ailments of unknown cause | 1 | 0.9% |
Air pollution | 1 | 0.9% |
Albumin | 1 | 0.9% |
Alcoholic liver disease | 1 | 0.9% |
Algorithm | 1 | 0.9% |
Alkaline phosphatase | 1 | 0.9% |
Allergy | 1 | 0.9% |
Alzheimer's disease biomarkers | 1 | 0.9% |
Amiodarone | 1 | 0.9% |
Amplicon | 1 | 0.9% |
Amyloid beta | 1 | 0.9% |
Amyloidosis | 1 | 0.9% |
Anaphylaxis | 1 | 0.9% |
Anatomical Therapeutic Chemical Classification System | 1 | 0.9% |
Anatomical terms of motion | 1 | 0.9% |
Anemia | 1 | 0.9% |
Aneurysm | 1 | 0.9% |
Angina | 1 | 0.9% |
Angiography | 1 | 0.9% |
Angiotensin-converting enzyme | 1 | 0.9% |
Animal anatomy | 1 | 0.9% |
Ankle | 1 | 0.9% |
Anti-Müllerian hormone | 1 | 0.9% |
Anti-nuclear antibody | 1 | 0.9% |
Anti-social behaviour | 1 | 0.9% |
Antiarrhythmic agent | 1 | 0.9% |
Antifungal | 1 | 0.9% |
Antimicrobial | 1 | 0.9% |
Antimicrobial stewardship | 1 | 0.9% |
Antiplatelet drug | 1 | 0.9% |
Aorta | 1 | 0.9% |
Aortic aneurysm | 1 | 0.9% |
Apixaban | 1 | 0.9% |
Apnea | 1 | 0.9% |
Arm | 1 | 0.9% |
Artesunate | 1 | 0.9% |
Arthroscopy | 1 | 0.9% |
Artificial cardiac pacemaker | 1 | 0.9% |
Artificial intelligence | 1 | 0.9% |
Ascites | 1 | 0.9% |
Asepsis | 1 | 0.9% |
Aspirin | 1 | 0.9% |
Assessment of kidney function | 1 | 0.9% |
Asset | 1 | 0.9% |
Assisted living | 1 | 0.9% |
Assisted reproductive technology | 1 | 0.9% |
Asystole | 1 | 0.9% |
Atheroma | 1 | 0.9% |
Atherosclerosis | 1 | 0.9% |
Athletic heart syndrome | 1 | 0.9% |
Atorvastatin | 1 | 0.9% |
Atrial natriuretic peptide | 1 | 0.9% |
Attachment theory | 1 | 0.9% |
AutoPulse | 1 | 0.9% |
Autoantibody | 1 | 0.9% |
Autoimmunity | 1 | 0.9% |
Autopsy | 1 | 0.9% |
Avian influenza | 1 | 0.9% |
Bacillus anthracis | 1 | 0.9% |
Bacillus cereus | 1 | 0.9% |
Badger culling in the United Kingdom | 1 | 0.9% |
Baroreflex | 1 | 0.9% |
Basal-cell carcinoma | 1 | 0.9% |
Basic life support | 1 | 0.9% |
Bayesian inference | 1 | 0.9% |
Benign prostatic hyperplasia | 1 | 0.9% |
Benign tumor | 1 | 0.9% |
Best practice | 1 | 0.9% |
Beta distribution | 1 | 0.9% |
Beta-lactamase | 1 | 0.9% |
Beta-secretase 1 | 1 | 0.9% |
Big data | 1 | 0.9% |
Bilirubin | 1 | 0.9% |
Biobank | 1 | 0.9% |
Biomarker (medicine) | 1 | 0.9% |
Biosafety cabinet | 1 | 0.9% |
Bladder cancer | 1 | 0.9% |
Blepharoplasty | 1 | 0.9% |
Blockchain | 1 | 0.9% |
Blood culture | 1 | 0.9% |
Blood disorders | 1 | 0.9% |
Blood lipids | 1 | 0.9% |
Blood plasma | 1 | 0.9% |
Blood sugar level | 1 | 0.9% |
Blood-borne disease | 1 | 0.9% |
Body fluids | 1 | 0.9% |
Body mass index | 1 | 0.9% |
Bone cyst | 1 | 0.9% |
Bone resorption | 1 | 0.9% |
Booster dose | 1 | 0.9% |
Botulism | 1 | 0.9% |
Breast implant | 1 | 0.9% |
Breast milk | 1 | 0.9% |
Breast reconstruction | 1 | 0.9% |
Brisbane Diamantina Health Partners | 1 | 0.9% |
British National Formulary | 1 | 0.9% |
Bronchiolitis | 1 | 0.9% |
Bronchodilator | 1 | 0.9% |
Brucella | 1 | 0.9% |
Burkholderia | 1 | 0.9% |
Burkholderia mallei | 1 | 0.9% |
Burkholderia pseudomallei | 1 | 0.9% |
Business | 1 | 0.9% |
Ca2+/calmodulin-dependent protein kinase II | 1 | 0.9% |
Calcitriol | 1 | 0.9% |
Cancer research | 1 | 0.9% |
Candesartan | 1 | 0.9% |
Candidiasis | 1 | 0.9% |
Cannabis (drug) | 1 | 0.9% |
Capacity building | 1 | 0.9% |
Cardiac arrest | 1 | 0.9% |
Cardiac magnetic resonance imaging | 1 | 0.9% |
Cardiac muscle | 1 | 0.9% |
Cardiac rehabilitation | 1 | 0.9% |
Cardiac surgery | 1 | 0.9% |
Cardiac tamponade | 1 | 0.9% |
Cardiopulmonary rehabilitation | 1 | 0.9% |
Cardiothoracic surgery | 1 | 0.9% |
Cardiotocography | 1 | 0.9% |
Cardioversion | 1 | 0.9% |
Caring for people with dementia | 1 | 0.9% |
Case management (US health system) | 1 | 0.9% |
Case–control study | 1 | 0.9% |
Catheter | 1 | 0.9% |
Causes of death | 1 | 0.9% |
Cell culture | 1 | 0.9% |
Cellulitis | 1 | 0.9% |
Cerebral shunt | 1 | 0.9% |
Cerebrospinal fluid | 1 | 0.9% |
Cerebrovascular disease | 1 | 0.9% |
Cetuximab | 1 | 0.9% |
Child care | 1 | 0.9% |
Child mortality | 1 | 0.9% |
Childhood | 1 | 0.9% |
Chlamydia infection | 1 | 0.9% |
Chlamydia trachomatis | 1 | 0.9% |
Chlortalidone | 1 | 0.9% |
Cholecalciferol | 1 | 0.9% |
Cholestasis | 1 | 0.9% |
Choosing Wisely | 1 | 0.9% |
Cigarette | 1 | 0.9% |
Circulating tumor DNA | 1 | 0.9% |
Circulatory system | 1 | 0.9% |
Clavicle fracture | 1 | 0.9% |
Clinical commissioning group | 1 | 0.9% |
Clinical endpoint | 1 | 0.9% |
Clinical pathology | 1 | 0.9% |
ClinicalTrials.gov | 1 | 0.9% |
Cognitive disorders | 1 | 0.9% |
Common carotid artery | 1 | 0.9% |
Common cold | 1 | 0.9% |
Community | 1 | 0.9% |
Community health worker | 1 | 0.9% |
Community-acquired pneumonia | 1 | 0.9% |
Compartmental models in epidemiology | 1 | 0.9% |
Concussion | 1 | 0.9% |
Congenital hypothyroidism | 1 | 0.9% |
Conjunctivitis | 1 | 0.9% |
Consensus decision-making | 1 | 0.9% |
Contact tracing | 1 | 0.9% |
Controlled ovarian hyperstimulation | 1 | 0.9% |
Coronavirus | 1 | 0.9% |
Cost–benefit analysis | 1 | 0.9% |
Cotinine | 1 | 0.9% |
Crenezumab | 1 | 0.9% |
Crossover study | 1 | 0.9% |
Cryptococcosis | 1 | 0.9% |
D-dimer | 1 | 0.9% |
Da Vinci Surgical System | 1 | 0.9% |
Dabigatran | 1 | 0.9% |
Death | 1 | 0.9% |
Debridement | 1 | 0.9% |
Decision tree learning | 1 | 0.9% |
Dehydration | 1 | 0.9% |
Demographic and Health Surveys | 1 | 0.9% |
Dependent and independent variables | 1 | 0.9% |
Dermatitis | 1 | 0.9% |
Dermatophytosis | 1 | 0.9% |
Dermatoscopy | 1 | 0.9% |
Development aid | 1 | 0.9% |
Dexamethasone | 1 | 0.9% |
Diabetes mellitus | 1 | 0.9% |
Dialysis | 1 | 0.9% |
Diarrhea | 1 | 0.9% |
Diastole | 1 | 0.9% |
Digoxin | 1 | 0.9% |
Diphtheria | 1 | 0.9% |
Diphtheria vaccine | 1 | 0.9% |
Disease burden | 1 | 0.9% |
Diseases of poverty | 1 | 0.9% |
Dislocated shoulder | 1 | 0.9% |
Disorders of endocrine pancreas | 1 | 0.9% |
Disseminated intravascular coagulation | 1 | 0.9% |
Dominance (genetics) | 1 | 0.9% |
Ductal carcinoma in situ | 1 | 0.9% |
Dura mater | 1 | 0.9% |
Dysentery | 1 | 0.9% |
Dysplastic nevus | 1 | 0.9% |
EHealth | 1 | 0.9% |
Echocardiography | 1 | 0.9% |
Eclampsia | 1 | 0.9% |
Economic equilibrium | 1 | 0.9% |
Economic growth | 1 | 0.9% |
Economics of service industries | 1 | 0.9% |
Educational technology | 1 | 0.9% |
Effect size | 1 | 0.9% |
Efficacy | 1 | 0.9% |
Egg allergy | 1 | 0.9% |
Elastography | 1 | 0.9% |
Elbow | 1 | 0.9% |
Elderly care | 1 | 0.9% |
Embolism | 1 | 0.9% |
Embolization | 1 | 0.9% |
Emergency medical technician | 1 | 0.9% |
Endocrine diseases | 1 | 0.9% |
Endocrine pancreas | 1 | 0.9% |
Endocrine, nutritional and metabolic diseases | 1 | 0.9% |
Endocrinology | 1 | 0.9% |
Endovascular aneurysm repair | 1 | 0.9% |
Entecavir | 1 | 0.9% |
Enterococcus | 1 | 0.9% |
Enuresis | 1 | 0.9% |
Epilepsy | 1 | 0.9% |
Eplerenone | 1 | 0.9% |
Errors and residuals | 1 | 0.9% |
Escherichia coli | 1 | 0.9% |
Esophageal varices | 1 | 0.9% |
Estrogen | 1 | 0.9% |
Evaluation | 1 | 0.9% |
Exocrine system | 1 | 0.9% |
Expense | 1 | 0.9% |
Exponential distribution | 1 | 0.9% |
Ezetimibe | 1 | 0.9% |
Ezetimibe/simvastatin | 1 | 0.9% |
Fall prevention | 1 | 0.9% |
False positives and false negatives | 1 | 0.9% |
Fascia | 1 | 0.9% |
Fatty liver disease | 1 | 0.9% |
Fax | 1 | 0.9% |
Fecal incontinence | 1 | 0.9% |
Femoral fracture | 1 | 0.9% |
Fenofibrate | 1 | 0.9% |
Fetus | 1 | 0.9% |
Fibrinogen | 1 | 0.9% |
FibroTest | 1 | 0.9% |
Fibroadenoma | 1 | 0.9% |
Field triage | 1 | 0.9% |
Filariasis | 1 | 0.9% |
Finance | 1 | 0.9% |
Fine-needle aspiration | 1 | 0.9% |
Fish oil | 1 | 0.9% |
Fixed asset | 1 | 0.9% |
Flu season | 1 | 0.9% |
Fluconazole | 1 | 0.9% |
Flucytosine | 1 | 0.9% |
Fluid replacement | 1 | 0.9% |
Follicle-stimulating hormone | 1 | 0.9% |
Foot | 1 | 0.9% |
Forearm | 1 | 0.9% |
Forest plot | 1 | 0.9% |
Fosfomycin | 1 | 0.9% |
Fraction (mathematics) | 1 | 0.9% |
Frailty syndrome | 1 | 0.9% |
Francis Collins | 1 | 0.9% |
Free flap breast reconstruction | 1 | 0.9% |
Fresh frozen plasma | 1 | 0.9% |
Furosemide | 1 | 0.9% |
General practitioner | 1 | 0.9% |
Generic drug | 1 | 0.9% |
Genetic disorder | 1 | 0.9% |
Genetic testing | 1 | 0.9% |
Gene–environment interaction | 1 | 0.9% |
Genome-wide association study | 1 | 0.9% |
Geriatric psychiatry | 1 | 0.9% |
Geriatrics | 1 | 0.9% |
Gestational age | 1 | 0.9% |
Gestational hypertension | 1 | 0.9% |
Gilbert's syndrome | 1 | 0.9% |
Glands | 1 | 0.9% |
Glomerular filtration rate | 1 | 0.9% |
Glomerulonephritis | 1 | 0.9% |
Glomerulus (kidney) | 1 | 0.9% |
Glucocorticoid | 1 | 0.9% |
Glucose tolerance test | 1 | 0.9% |
Governance | 1 | 0.9% |
Group purchasing organization | 1 | 0.9% |
HAS-BLED | 1 | 0.9% |
HELLP syndrome | 1 | 0.9% |
HIV and pregnancy | 1 | 0.9% |
HPV-positive oropharyngeal cancer | 1 | 0.9% |
Hand | 1 | 0.9% |
Hand washing | 1 | 0.9% |
Hazard | 1 | 0.9% |
Hazard ratio | 1 | 0.9% |
Head and neck cancer | 1 | 0.9% |
Head injury | 1 | 0.9% |
Health care in the United States | 1 | 0.9% |
Health data | 1 | 0.9% |
Health equity | 1 | 0.9% |
Health literacy | 1 | 0.9% |
Health technology | 1 | 0.9% |
Healthcare industry | 1 | 0.9% |
Hemiparesis | 1 | 0.9% |
Heparin | 1 | 0.9% |
Hepatic encephalopathy | 1 | 0.9% |
Hernia | 1 | 0.9% |
Heuristics in judgment and decision-making | 1 | 0.9% |
Hib vaccine | 1 | 0.9% |
Hip | 1 | 0.9% |
Hormonal therapy (oncology) | 1 | 0.9% |
Hospital-acquired infection | 1 | 0.9% |
Household income in the United States | 1 | 0.9% |
Human anatomy | 1 | 0.9% |
Human female reproductive system | 1 | 0.9% |
Human leg | 1 | 0.9% |
Human metapneumovirus | 1 | 0.9% |
Human orthopneumovirus | 1 | 0.9% |
Human pregnancy | 1 | 0.9% |
Humerus | 1 | 0.9% |
Hydralazine | 1 | 0.9% |
Hygiene | 1 | 0.9% |
Hyperparathyroidism | 1 | 0.9% |
Hypertelorism | 1 | 0.9% |
Hypertensive disease of pregnancy | 1 | 0.9% |
Hypocalcemia | 1 | 0.9% |
Hypodermic needle | 1 | 0.9% |
Hypothermia | 1 | 0.9% |
Hypothyroidism | 1 | 0.9% |
Hypovolemic shock | 1 | 0.9% |
Ibandronic acid | 1 | 0.9% |
Icodextrin | 1 | 0.9% |
Immune system | 1 | 0.9% |
Immune thrombocytopenic purpura | 1 | 0.9% |
Immunity (medical) | 1 | 0.9% |
Immunoglobulin A | 1 | 0.9% |
Immunohistochemistry | 1 | 0.9% |
Immunotherapy | 1 | 0.9% |
Impetigo | 1 | 0.9% |
In vitro fertilisation | 1 | 0.9% |
Incentive | 1 | 0.9% |
Incremental cost-effectiveness ratio | 1 | 0.9% |
Indo-Fijians | 1 | 0.9% |
Industries | 1 | 0.9% |
Infant mortality | 1 | 0.9% |
Infection prevention and control | 1 | 0.9% |
Inflammatory cytokine | 1 | 0.9% |
Influenza A virus | 1 | 0.9% |
Influenza A virus subtype H1N1 | 1 | 0.9% |
Influenza A virus subtype H5N1 | 1 | 0.9% |
Influenza A virus subtype H7N9 | 1 | 0.9% |
Influenza vaccine | 1 | 0.9% |
Influenza-like illness | 1 | 0.9% |
Infrared | 1 | 0.9% |
Injection (medicine) | 1 | 0.9% |
Innate immune system | 1 | 0.9% |
Inspection | 1 | 0.9% |
Institutional review board | 1 | 0.9% |
Insulin resistance | 1 | 0.9% |
Insurance | 1 | 0.9% |
Intellectual disability | 1 | 0.9% |
Intensive care medicine | 1 | 0.9% |
Inter-rater reliability | 1 | 0.9% |
Interferon | 1 | 0.9% |
Interleukin-1 family | 1 | 0.9% |
International Classification of Diseases for Oncology | 1 | 0.9% |
International development | 1 | 0.9% |
Interoperability | 1 | 0.9% |
Interstitial cystitis | 1 | 0.9% |
Intracranial hemorrhage | 1 | 0.9% |
Intracytoplasmic sperm injection | 1 | 0.9% |
Intrauterine growth restriction | 1 | 0.9% |
Intravenous pyelogram | 1 | 0.9% |
Iodine deficiency | 1 | 0.9% |
Iron overload | 1 | 0.9% |
Iron-deficiency anemia | 1 | 0.9% |
Isolation (health care) | 1 | 0.9% |
Ivabradine | 1 | 0.9% |
Ivermectin | 1 | 0.9% |
Jaundice | 1 | 0.9% |
Joint dislocation | 1 | 0.9% |
KRAS | 1 | 0.9% |
Kaplan–Meier estimator | 1 | 0.9% |
Kegel exercise | 1 | 0.9% |
Kidney stone disease | 1 | 0.9% |
Knee | 1 | 0.9% |
Kt/V | 1 | 0.9% |
Labor induction | 1 | 0.9% |
Laboratory diagnosis of viral infections | 1 | 0.9% |
Lamivudine | 1 | 0.9% |
Laparoscopy | 1 | 0.9% |
Lassa fever | 1 | 0.9% |
Latent tuberculosis | 1 | 0.9% |
Le Fort fracture of skull | 1 | 0.9% |
Leishmaniasis | 1 | 0.9% |
Leprosy | 1 | 0.9% |
Leptospirosis | 1 | 0.9% |
Levothyroxine | 1 | 0.9% |
License | 1 | 0.9% |
Likelihood function | 1 | 0.9% |
Liver transplantation | 1 | 0.9% |
Local anesthetic | 1 | 0.9% |
Long-acting beta-adrenoceptor agonist | 1 | 0.9% |
Long-term care | 1 | 0.9% |
Low molecular weight heparin | 1 | 0.9% |
Lower respiratory tract infection | 1 | 0.9% |
Lumbar puncture | 1 | 0.9% |
Lumpectomy | 1 | 0.9% |
Lung cancer | 1 | 0.9% |
Lyme disease | 1 | 0.9% |
Lymphatic filariasis | 1 | 0.9% |
MMR vaccine | 1 | 0.9% |
MMRV vaccine | 1 | 0.9% |
Malnutrition | 1 | 0.9% |
Mammaplasty | 1 | 0.9% |
Managed care | 1 | 0.9% |
Management of dehydration | 1 | 0.9% |
Mandible | 1 | 0.9% |
Mandibular fracture | 1 | 0.9% |
Mani Menon | 1 | 0.9% |
Market (economics) | 1 | 0.9% |
Mass drug administration | 1 | 0.9% |
Mastectomy | 1 | 0.9% |
Mastopexy | 1 | 0.9% |
Maternal death | 1 | 0.9% |
Maternal health | 1 | 0.9% |
Maxilla | 1 | 0.9% |
Maximum likelihood estimation | 1 | 0.9% |
Mediastinitis | 1 | 0.9% |
Medical device | 1 | 0.9% |
Medical emergencies | 1 | 0.9% |
Medical history | 1 | 0.9% |
Medical ultrasound | 1 | 0.9% |
Medicare Advantage | 1 | 0.9% |
Medicare dual eligible | 1 | 0.9% |
Melanocytic nevus | 1 | 0.9% |
Melioidosis | 1 | 0.9% |
Meningitis | 1 | 0.9% |
Meningococcal disease | 1 | 0.9% |
Meningococcal vaccine | 1 | 0.9% |
Metabolic syndrome | 1 | 0.9% |
Metastatic breast cancer | 1 | 0.9% |
Metformin | 1 | 0.9% |
Metoclopramide | 1 | 0.9% |
Metolazone | 1 | 0.9% |
Metronidazole | 1 | 0.9% |
Microsimulation | 1 | 0.9% |
Middle East respiratory syndrome | 1 | 0.9% |
Middle East respiratory syndrome-related coronavirus | 1 | 0.9% |
Millennium Development Goals | 1 | 0.9% |
Molecular biology | 1 | 0.9% |
Monitoring and evaluation | 1 | 0.9% |
Mood disorder | 1 | 0.9% |
Mortality rate | 1 | 0.9% |
Motivational interviewing | 1 | 0.9% |
Multiple myeloma | 1 | 0.9% |
Musculoskeletal system | 1 | 0.9% |
Mutation | 1 | 0.9% |
Mycoplasma | 1 | 0.9% |
Myelofibrosis | 1 | 0.9% |
Myeloproliferative neoplasm | 1 | 0.9% |
Nanotechnology | 1 | 0.9% |
Natural reservoir | 1 | 0.9% |
Nausea | 1 | 0.9% |
Near-infrared spectroscopy | 1 | 0.9% |
Neglected tropical diseases | 1 | 0.9% |
Neisseria gonorrhoeae | 1 | 0.9% |
Neisseria meningitidis | 1 | 0.9% |
Neonatal alloimmune thrombocytopenia | 1 | 0.9% |
Neonatal intensive care unit | 1 | 0.9% |
Nephrectomy | 1 | 0.9% |
Nephrology | 1 | 0.9% |
Neuroimaging | 1 | 0.9% |
Neuroscience | 1 | 0.9% |
Neurostimulation | 1 | 0.9% |
Neurosurgery | 1 | 0.9% |
Newborn screening | 1 | 0.9% |
Nipple | 1 | 0.9% |
Nitrogen dioxide | 1 | 0.9% |
Non-communicable disease | 1 | 0.9% |
Non-governmental organization | 1 | 0.9% |
Nonsteroidal anti-inflammatory drug | 1 | 0.9% |
Normal distribution | 1 | 0.9% |
Norovirus | 1 | 0.9% |
Nucleic acid test | 1 | 0.9% |
Nursing home care | 1 | 0.9% |
Obeticholic acid | 1 | 0.9% |
Obstetrics | 1 | 0.9% |
Occupational safety and health | 1 | 0.9% |
Old age | 1 | 0.9% |
Onchocerciasis | 1 | 0.9% |
Open access | 1 | 0.9% |
Opioid use disorder | 1 | 0.9% |
Oral cancer | 1 | 0.9% |
Oral rehydration therapy | 1 | 0.9% |
Orbit (anatomy) | 1 | 0.9% |
Ordinary least squares | 1 | 0.9% |
Organ donation | 1 | 0.9% |
Organ transplantation | 1 | 0.9% |
Organic, including symptomatic, mental disorders | 1 | 0.9% |
Oseltamivir | 1 | 0.9% |
Osteotomy | 1 | 0.9% |
Otitis media | 1 | 0.9% |
Outcomes research | 1 | 0.9% |
Ovarian follicle | 1 | 0.9% |
Ovarian hyperstimulation syndrome | 1 | 0.9% |
Ovarian reserve | 1 | 0.9% |
Ovary | 1 | 0.9% |
Over-the-counter drug | 1 | 0.9% |
Ovulation induction | 1 | 0.9% |
Oxybutynin | 1 | 0.9% |
Oxygen therapy | 1 | 0.9% |
P-value | 1 | 0.9% |
Pain | 1 | 0.9% |
Pain management | 1 | 0.9% |
Palivizumab | 1 | 0.9% |
Panitumumab | 1 | 0.9% |
Panton–Valentine leukocidin | 1 | 0.9% |
Parameter | 1 | 0.9% |
Parathyroid hormone | 1 | 0.9% |
Particulates | 1 | 0.9% |
Passive smoking | 1 | 0.9% |
Pathogen | 1 | 0.9% |
Pathology | 1 | 0.9% |
Patient Protection and Affordable Care Act | 1 | 0.9% |
Patient safety | 1 | 0.9% |
Pelvic examination | 1 | 0.9% |
Pelvic inflammatory disease | 1 | 0.9% |
Pelvis | 1 | 0.9% |
Peramivir | 1 | 0.9% |
Percutaneous aortic valve replacement | 1 | 0.9% |
Percutaneous tibial nerve stimulation | 1 | 0.9% |
Performance indicator | 1 | 0.9% |
Pericardiocentesis | 1 | 0.9% |
Pericarditis | 1 | 0.9% |
Pericardium | 1 | 0.9% |
Perioperative | 1 | 0.9% |
Peritoneal dialysis | 1 | 0.9% |
Peritoneum | 1 | 0.9% |
Pertussis vaccine | 1 | 0.9% |
Pharmaceutical industry | 1 | 0.9% |
Pharmacist | 1 | 0.9% |
Pharmacogenetics | 1 | 0.9% |
Pharmacokinetics | 1 | 0.9% |
Pharmacovigilance | 1 | 0.9% |
Pharmacy (shop) | 1 | 0.9% |
Phases of clinical research | 1 | 0.9% |
Photovoltaics | 1 | 0.9% |
Physiology | 1 | 0.9% |
Placebo-controlled study | 1 | 0.9% |
Placenta | 1 | 0.9% |
Placental abruption | 1 | 0.9% |
Plateletpheresis | 1 | 0.9% |
Pneumococcal conjugate vaccine | 1 | 0.9% |
Pneumococcal vaccine | 1 | 0.9% |
Polyp (medicine) | 1 | 0.9% |
Portal hypertension | 1 | 0.9% |
Positron emission tomography | 1 | 0.9% |
Post-thrombotic syndrome | 1 | 0.9% |
Postpartum period | 1 | 0.9% |
Power (statistics) | 1 | 0.9% |
Power of a test | 1 | 0.9% |
Pre-clinical development | 1 | 0.9% |
Pre-eclampsia | 1 | 0.9% |
Pre-exposure prophylaxis | 1 | 0.9% |
Precision medicine | 1 | 0.9% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 1 | 0.9% |
Prelabor rupture of membranes | 1 | 0.9% |
Prenatal care | 1 | 0.9% |
Prenatal development | 1 | 0.9% |
Prevalence | 1 | 0.9% |
Pricing | 1 | 0.9% |
Primary care | 1 | 0.9% |
Primary sclerosing cholangitis | 1 | 0.9% |
Probability distribution | 1 | 0.9% |
Procalcitonin | 1 | 0.9% |
Professional degrees of public health | 1 | 0.9% |
Proof of concept | 1 | 0.9% |
Protected health information | 1 | 0.9% |
Proteinuria | 1 | 0.9% |
Pseudoaneurysm | 1 | 0.9% |
Psychological resilience | 1 | 0.9% |
Puberty | 1 | 0.9% |
Pulmonology | 1 | 0.9% |
Pulse | 1 | 0.9% |
Q fever | 1 | 0.9% |
Qualitative research | 1 | 0.9% |
RANKL | 1 | 0.9% |
RTT | 1 | 0.9% |
Race (human categorization) | 1 | 0.9% |
Radiofrequency ablation | 1 | 0.9% |
Radiography | 1 | 0.9% |
Radius (bone) | 1 | 0.9% |
Rare disease | 1 | 0.9% |
Relative risk | 1 | 0.9% |
Reliability (statistics) | 1 | 0.9% |
Renal sympathetic denervation | 1 | 0.9% |
Respiratory disease | 1 | 0.9% |
Reverse transcription polymerase chain reaction | 1 | 0.9% |
Rhinovirus | 1 | 0.9% |
Rhytidectomy | 1 | 0.9% |
Ribavirin | 1 | 0.9% |
Rifampicin | 1 | 0.9% |
Risk assessment | 1 | 0.9% |
Risk management | 1 | 0.9% |
Rivaroxaban | 1 | 0.9% |
Robot | 1 | 0.9% |
Robot-assisted surgery | 1 | 0.9% |
Robotics | 1 | 0.9% |
Rotator cuff | 1 | 0.9% |
Route of administration | 1 | 0.9% |
Rubella | 1 | 0.9% |
Rural health clinic | 1 | 0.9% |
Ryanodine receptor 2 | 1 | 0.9% |
SOFA score | 1 | 0.9% |
Sacubitril/valsartan | 1 | 0.9% |
Safety | 1 | 0.9% |
Salmeterol | 1 | 0.9% |
Scabies | 1 | 0.9% |
Schistosomiasis | 1 | 0.9% |
Science | 1 | 0.9% |
Selective laser sintering | 1 | 0.9% |
Selective serotonin reuptake inhibitor | 1 | 0.9% |
Self-care | 1 | 0.9% |
Self-harm | 1 | 0.9% |
Serology | 1 | 0.9% |
Severe acute respiratory syndrome coronavirus | 1 | 0.9% |
Sexual health | 1 | 0.9% |
Sexual reproduction | 1 | 0.9% |
Sexual violence | 1 | 0.9% |
Sexually transmitted diseases and infections | 1 | 0.9% |
Shock (circulatory) | 1 | 0.9% |
Shoulder | 1 | 0.9% |
Sigmoidoscopy | 1 | 0.9% |
Signs and symptoms | 1 | 0.9% |
Simulation | 1 | 0.9% |
Simvastatin | 1 | 0.9% |
Single-nucleotide polymorphism | 1 | 0.9% |
Sinusitis | 1 | 0.9% |
Sitosterolemia | 1 | 0.9% |
Sjögren syndrome | 1 | 0.9% |
Skin cancer | 1 | 0.9% |
Skin grafting | 1 | 0.9% |
Skull | 1 | 0.9% |
Skull fracture | 1 | 0.9% |
Sleep apnea | 1 | 0.9% |
Smoking | 1 | 0.9% |
Smoking ban | 1 | 0.9% |
Social competence | 1 | 0.9% |
Social exclusion | 1 | 0.9% |
Social group | 1 | 0.9% |
Social innovation | 1 | 0.9% |
Socioeconomic status | 1 | 0.9% |
Solanezumab | 1 | 0.9% |
Specialty (medicine) | 1 | 0.9% |
Spinal anaesthesia | 1 | 0.9% |
Spirometry | 1 | 0.9% |
Spironolactone | 1 | 0.9% |
Staphylococcus | 1 | 0.9% |
Staphylococcus aureus | 1 | 0.9% |
Sternum | 1 | 0.9% |
Stool test | 1 | 0.9% |
Strategic planning | 1 | 0.9% |
Strength training | 1 | 0.9% |
Streptococcus pyogenes | 1 | 0.9% |
Stress incontinence | 1 | 0.9% |
Student's t-test | 1 | 0.9% |
Subarachnoid hemorrhage | 1 | 0.9% |
Subdural hematoma | 1 | 0.9% |
Sudden infant death syndrome | 1 | 0.9% |
Supraspinatus muscle | 1 | 0.9% |
Supraventricular tachycardia | 1 | 0.9% |
Survival analysis | 1 | 0.9% |
Survival rate | 1 | 0.9% |
System | 1 | 0.9% |
Systemic inflammatory response syndrome | 1 | 0.9% |
Systemic lupus erythematosus | 1 | 0.9% |
Systole | 1 | 0.9% |
Targeted temperature management | 1 | 0.9% |
Technology | 1 | 0.9% |
Telehealth | 1 | 0.9% |
Temporomandibular joint | 1 | 0.9% |
Tenofovir disoproxil | 1 | 0.9% |
Terminal illness | 1 | 0.9% |
Tetanus | 1 | 0.9% |
Tetanus vaccine | 1 | 0.9% |
The Midlands | 1 | 0.9% |
Thematic analysis | 1 | 0.9% |
Thorax | 1 | 0.9% |
Thorax (human anatomy) | 1 | 0.9% |
Thrombolysis | 1 | 0.9% |
Thrombosis prevention | 1 | 0.9% |
Thrombus | 1 | 0.9% |
Thumb | 1 | 0.9% |
Thyroid | 1 | 0.9% |
Thyroid disease | 1 | 0.9% |
Thyroid hormones | 1 | 0.9% |
Thyroid-stimulating hormone | 1 | 0.9% |
Tissue engineering | 1 | 0.9% |
Tissue plasminogen activator | 1 | 0.9% |
Tobacco smoking | 1 | 0.9% |
Transfusion-related acute lung injury | 1 | 0.9% |
Transitional care | 1 | 0.9% |
Transplant rejection | 1 | 0.9% |
Trastuzumab | 1 | 0.9% |
Triage | 1 | 0.9% |
Tropical disease | 1 | 0.9% |
Tsetse fly | 1 | 0.9% |
Type I and type II errors | 1 | 0.9% |
Typhoid fever | 1 | 0.9% |
Ulcer (dermatology) | 1 | 0.9% |
Universal health care | 1 | 0.9% |
Unlicensed assistive personnel | 1 | 0.9% |
Uracil-DNA glycosylase | 1 | 0.9% |
Urethritis | 1 | 0.9% |
Urinary cast | 1 | 0.9% |
Urinary retention | 1 | 0.9% |
Urinary system | 1 | 0.9% |
Urination | 1 | 0.9% |
Ursodeoxycholic acid | 1 | 0.9% |
Vaccines | 1 | 0.9% |
Vaginal lubrication | 1 | 0.9% |
Valsartan | 1 | 0.9% |
Vancomycin-resistant Enterococcus | 1 | 0.9% |
Vector control | 1 | 0.9% |
Venipuncture | 1 | 0.9% |
Ventricular assist device | 1 | 0.9% |
Ventricular fibrillation | 1 | 0.9% |
Ventricular natriuretic peptide | 1 | 0.9% |
Vertebra | 1 | 0.9% |
Vertebral column | 1 | 0.9% |
Violence against women | 1 | 0.9% |
Viral hemorrhagic fever | 1 | 0.9% |
Viral load monitoring for HIV | 1 | 0.9% |
Visceral leishmaniasis | 1 | 0.9% |
Vitamin C | 1 | 0.9% |
Vitamin E | 1 | 0.9% |
Volunteering | 1 | 0.9% |
Warfarin | 1 | 0.9% |
Whole genome sequencing | 1 | 0.9% |
Whooping cough | 1 | 0.9% |
Working group | 1 | 0.9% |
Wrist | 1 | 0.9% |
Zanamivir | 1 | 0.9% |
Zidovudine | 1 | 0.9% |
Zika virus | 1 | 0.9% |
Zygomatic bone | 1 | 0.9% |
abs | rel | |
---|---|---|
Health | 102 | 99.0% |
Medical specialties | 101 | 98.1% |
Medicine | 101 | 98.1% |
Clinical medicine | 96 | 93.2% |
Health care | 95 | 92.2% |
Health sciences | 94 | 91.3% |
Diseases and disorders | 41 | 39.8% |
Public health | 35 | 34.0% |
Risk | 32 | 31.1% |
Infection | 29 | 28.2% |
Randomized controlled trial | 29 | 28.2% |
Cancer | 26 | 25.2% |
Epidemiology | 26 | 25.2% |
Evidence-based medicine | 25 | 24.3% |
Systematic review | 24 | 23.3% |
Preventive healthcare | 23 | 22.3% |
Disease | 22 | 21.4% |
Surgery | 20 | 19.4% |
Therapy | 20 | 19.4% |
Cardiovascular disease | 19 | 18.4% |
Medical diagnosis | 18 | 17.5% |
Adherence (medicine) | 17 | 16.5% |
Medication | 17 | 16.5% |
Research | 17 | 16.5% |
Biology | 16 | 15.5% |
Clinical trial | 16 | 15.5% |
Health economics | 16 | 15.5% |
Medical imaging | 16 | 15.5% |
Screening (medicine) | 16 | 15.5% |
Antimicrobial resistance | 15 | 14.6% |
Meta-analysis | 15 | 14.6% |
Coronary artery disease | 14 | 13.6% |
HIV/AIDS | 14 | 13.6% |
Heart | 14 | 13.6% |
Myocardial infarction | 14 | 13.6% |
Chronic condition | 13 | 12.6% |
Medical guideline | 13 | 12.6% |
Sensitivity and specificity | 13 | 12.6% |
Stroke | 13 | 12.6% |
Cohort study | 12 | 11.7% |
Hospital | 12 | 11.7% |
Hypertension | 12 | 11.7% |
Breast cancer | 11 | 10.7% |
Electronic health record | 11 | 10.7% |
Health policy | 11 | 10.7% |
Hepatitis | 11 | 10.7% |
Human activities | 11 | 10.7% |
Infectious diseases | 11 | 10.7% |
Life sciences | 11 | 10.7% |
Patient | 11 | 10.7% |
CT scan | 10 | 9.7% |
Immunology | 10 | 9.7% |
Medical treatments | 10 | 9.7% |
Tuberculosis | 10 | 9.7% |
Blinded experiment | 9 | 8.7% |
Cardiology | 9 | 8.7% |
Cardiovascular system | 9 | 8.7% |
Confidence interval | 9 | 8.7% |
Health professional | 9 | 8.7% |
Hepatitis C | 9 | 8.7% |
Medical humanities | 9 | 8.7% |
Obesity | 9 | 8.7% |
Receiver operating characteristic | 9 | 8.7% |
Antibiotic | 8 | 7.8% |
Blood pressure | 8 | 7.8% |
Cholesterol | 8 | 7.8% |
Drugs | 8 | 7.8% |
Pharmacy | 8 | 7.8% |
Smoking cessation | 8 | 7.8% |
Statin | 8 | 7.8% |
Tobacco smoking | 8 | 7.8% |
Angina | 7 | 6.8% |
Diabetes | 7 | 6.8% |
Emergency department | 7 | 6.8% |
Glycated hemoglobin | 7 | 6.8% |
Health system | 7 | 6.8% |
Low-density lipoprotein | 7 | 6.8% |
Major depressive disorder | 7 | 6.8% |
Mammography | 7 | 6.8% |
Medicare (United States) | 7 | 6.8% |
Multi-drug-resistant tuberculosis | 7 | 6.8% |
Neoplasms | 7 | 6.8% |
Prescription drug | 7 | 6.8% |
Quality-adjusted life year | 7 | 6.8% |
Radiation therapy | 7 | 6.8% |
Renal function | 7 | 6.8% |
Alzheimer's disease | 6 | 5.8% |
Antihypertensive drug | 6 | 5.8% |
Atherosclerosis | 6 | 5.8% |
Biomarker | 6 | 5.8% |
Chemotherapy | 6 | 5.8% |
Comorbidity | 6 | 5.8% |
General practitioner | 6 | 5.8% |
Hypercholesterolemia | 6 | 5.8% |
Machine learning | 6 | 5.8% |
Magnetic resonance imaging | 6 | 5.8% |
Medical prescription | 6 | 5.8% |
Microbiology | 6 | 5.8% |
Pharmacology | 6 | 5.8% |
Physician | 6 | 5.8% |
Placebo | 6 | 5.8% |
Radiology | 6 | 5.8% |
Type 2 diabetes | 6 | 5.8% |
Venous thrombosis | 6 | 5.8% |
Artificial intelligence | 5 | 4.9% |
Atheroma | 5 | 4.9% |
Biopsy | 5 | 4.9% |
Cancer screening | 5 | 4.9% |
Caregiver | 5 | 4.9% |
Cervical cancer | 5 | 4.9% |
Childbirth | 5 | 4.9% |
Chronic kidney disease | 5 | 4.9% |
Colorectal cancer | 5 | 4.9% |
Cost-effectiveness analysis | 5 | 4.9% |
Data analysis | 5 | 4.9% |
Decision-making | 5 | 4.9% |
Dementia | 5 | 4.9% |
Diabetes management | 5 | 4.9% |
Diabetes mellitus | 5 | 4.9% |
Exercise | 5 | 4.9% |
Hepatitis B | 5 | 4.9% |
High-density lipoprotein | 5 | 4.9% |
Innovation | 5 | 4.9% |
Mental disorder | 5 | 4.9% |
Metastasis | 5 | 4.9% |
Nursing | 5 | 4.9% |
Organ transplantation | 5 | 4.9% |
Physical examination | 5 | 4.9% |
Physical therapy | 5 | 4.9% |
Pneumonia | 5 | 4.9% |
Pre-exposure prophylaxis | 5 | 4.9% |
Prediction | 5 | 4.9% |
Psychotherapy | 5 | 4.9% |
Self-care | 5 | 4.9% |
Statistics | 5 | 4.9% |
Thrombosis | 5 | 4.9% |
Tuberculosis management | 5 | 4.9% |
Virus | 5 | 4.9% |
ACE inhibitor | 4 | 3.9% |
Adjuvant therapy | 4 | 3.9% |
Anticoagulant | 4 | 3.9% |
Aspirin | 4 | 3.9% |
BCG vaccine | 4 | 3.9% |
Bias | 4 | 3.9% |
Biotechnology | 4 | 3.9% |
Blood sugar level | 4 | 3.9% |
Body mass index | 4 | 3.9% |
Cancer immunotherapy | 4 | 3.9% |
Causes of death | 4 | 3.9% |
Chronic obstructive pulmonary disease | 4 | 3.9% |
Circulatory system | 4 | 3.9% |
Community health | 4 | 3.9% |
Coronary artery bypass surgery | 4 | 3.9% |
Cytopathology | 4 | 3.9% |
Fall prevention | 4 | 3.9% |
GeneXpert MTB/RIF | 4 | 3.9% |
Genetics | 4 | 3.9% |
Geriatrics | 4 | 3.9% |
Head and neck cancer | 4 | 3.9% |
Health care quality | 4 | 3.9% |
Hospital readmission | 4 | 3.9% |
Hospital-acquired infection | 4 | 3.9% |
Human papillomavirus infection | 4 | 3.9% |
Immune system | 4 | 3.9% |
Internal medicine | 4 | 3.9% |
Ischemia | 4 | 3.9% |
Laparoscopy | 4 | 3.9% |
Logistic regression | 4 | 3.9% |
Neoplasm | 4 | 3.9% |
Nicotine replacement therapy | 4 | 3.9% |
Organ donation | 4 | 3.9% |
Osteoporosis | 4 | 3.9% |
Patient safety | 4 | 3.9% |
Positive and negative predictive values | 4 | 3.9% |
Prostate cancer | 4 | 3.9% |
Prostate-specific antigen | 4 | 3.9% |
Psychiatry | 4 | 3.9% |
Public sphere | 4 | 3.9% |
Rifampicin | 4 | 3.9% |
Risk assessment | 4 | 3.9% |
Schizophrenia | 4 | 3.9% |
Shared decision-making in medicine | 4 | 3.9% |
Simvastatin | 4 | 3.9% |
Social programs | 4 | 3.9% |
Sustainable Development Goals | 4 | 3.9% |
Transient ischemic attack | 4 | 3.9% |
Transmission (medicine) | 4 | 3.9% |
Urinary tract infection | 4 | 3.9% |
Vaccine | 4 | 3.9% |
Addiction | 3 | 2.9% |
Adverse effect | 3 | 2.9% |
Anesthesia | 3 | 2.9% |
Angiography | 3 | 2.9% |
Antibody | 3 | 2.9% |
Asthma | 3 | 2.9% |
Atrial fibrillation | 3 | 2.9% |
Bacteria | 3 | 2.9% |
Best practice | 3 | 2.9% |
Birth defect | 3 | 2.9% |
Bisphosphonate | 3 | 2.9% |
Bone density | 3 | 2.9% |
Brain | 3 | 2.9% |
Breast cancer screening | 3 | 2.9% |
Breastfeeding | 3 | 2.9% |
Bupropion | 3 | 2.9% |
Cancer staging | 3 | 2.9% |
Cardiac catheterization | 3 | 2.9% |
Cardiac surgery | 3 | 2.9% |
Cervical screening | 3 | 2.9% |
Cigarette | 3 | 2.9% |
Cirrhosis | 3 | 2.9% |
Cognitive behavioral therapy | 3 | 2.9% |
DNA sequencing | 3 | 2.9% |
Dapagliflozin | 3 | 2.9% |
Denosumab | 3 | 2.9% |
Determinants of health | 3 | 2.9% |
Diabetes mellitus type 2 | 3 | 2.9% |
Diagnosis of HIV/AIDS | 3 | 2.9% |
Diarrhea | 3 | 2.9% |
Disease management (health) | 3 | 2.9% |
Dose (biochemistry) | 3 | 2.9% |
Echocardiography | 3 | 2.9% |
Education | 3 | 2.9% |
Electrocardiography | 3 | 2.9% |
Empagliflozin | 3 | 2.9% |
Endometrial cancer | 3 | 2.9% |
External beam radiotherapy | 3 | 2.9% |
Fecal occult blood | 3 | 2.9% |
Fee-for-service | 3 | 2.9% |
Gene | 3 | 2.9% |
Gene therapy | 3 | 2.9% |
Health insurance | 3 | 2.9% |
Heart failure | 3 | 2.9% |
Hematopoietic stem cell transplantation | 3 | 2.9% |
Hepatocellular carcinoma | 3 | 2.9% |
Hereditary nonpolyposis colorectal cancer | 3 | 2.9% |
Hormone replacement therapy | 3 | 2.9% |
Human reproduction | 3 | 2.9% |
Hyperlipidemia | 3 | 2.9% |
Incremental cost-effectiveness ratio | 3 | 2.9% |
Infection prevention and control | 3 | 2.9% |
Information | 3 | 2.9% |
International Statistical Classification of Diseases and Related Health Problems | 3 | 2.9% |
Kidney disease | 3 | 2.9% |
Kidney failure | 3 | 2.9% |
Kidney transplantation | 3 | 2.9% |
Lipoprotein | 3 | 2.9% |
Liver | 3 | 2.9% |
Lung cancer | 3 | 2.9% |
MammaPrint | 3 | 2.9% |
Management of HIV/AIDS | 3 | 2.9% |
Maternal health | 3 | 2.9% |
Medical Subject Headings | 3 | 2.9% |
Medical record | 3 | 2.9% |
Medical test | 3 | 2.9% |
Men who have sex with men | 3 | 2.9% |
Meningitis | 3 | 2.9% |
Menopause | 3 | 2.9% |
Metformin | 3 | 2.9% |
Millennium Development Goals | 3 | 2.9% |
Minimally invasive procedure | 3 | 2.9% |
Nephrology | 3 | 2.9% |
Nervous system | 3 | 2.9% |
Non-communicable disease | 3 | 2.9% |
Osteopenia | 3 | 2.9% |
Parameter | 3 | 2.9% |
Percutaneous coronary intervention | 3 | 2.9% |
Peripheral artery disease | 3 | 2.9% |
Post-exposure prophylaxis | 3 | 2.9% |
Prediabetes | 3 | 2.9% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 3 | 2.9% |
Pregnancy | 3 | 2.9% |
Preterm birth | 3 | 2.9% |
Primary health care | 3 | 2.9% |
Programmed cell death protein 1 | 3 | 2.9% |
Prostate cancer screening | 3 | 2.9% |
Prothrombin time | 3 | 2.9% |
Psychology | 3 | 2.9% |
Public services | 3 | 2.9% |
Raloxifene | 3 | 2.9% |
Random forest | 3 | 2.9% |
Saturated fat | 3 | 2.9% |
Sexually transmitted infection | 3 | 2.9% |
Statistical classification | 3 | 2.9% |
Study heterogeneity | 3 | 2.9% |
Substance abuse | 3 | 2.9% |
Survey methodology | 3 | 2.9% |
Sustainability | 3 | 2.9% |
T cell | 3 | 2.9% |
Thorax (human anatomy) | 3 | 2.9% |
Training, validation, and test sets | 3 | 2.9% |
Varenicline | 3 | 2.9% |
Warfarin | 3 | 2.9% |
Zoledronic acid | 3 | 2.9% |
Aboriginal Australians | 2 | 1.9% |
Abuse | 2 | 1.9% |
Accuracy and precision | 2 | 1.9% |
Acute coronary syndrome | 2 | 1.9% |
Ageing | 2 | 1.9% |
Algorithm | 2 | 1.9% |
Amos Tversky | 2 | 1.9% |
Analgesic | 2 | 1.9% |
Anesthesiology | 2 | 1.9% |
Anticonvulsant | 2 | 1.9% |
Antiplatelet drug | 2 | 1.9% |
Antipsychotic | 2 | 1.9% |
Antiviral drug | 2 | 1.9% |
Aortic stenosis | 2 | 1.9% |
Aortic valve | 2 | 1.9% |
Aortic valve replacement | 2 | 1.9% |
Apoptosis | 2 | 1.9% |
Artificial cardiac pacemaker | 2 | 1.9% |
Artificial neural network | 2 | 1.9% |
Assumption | 2 | 1.9% |
Atrial septal defect | 2 | 1.9% |
Autism | 2 | 1.9% |
Axon | 2 | 1.9% |
BRCA1 | 2 | 1.9% |
BRCA2 | 2 | 1.9% |
Behavior | 2 | 1.9% |
Behavioural sciences | 2 | 1.9% |
Biochemistry | 2 | 1.9% |
Bone | 2 | 1.9% |
Bone fracture | 2 | 1.9% |
Brain tumor | 2 | 1.9% |
Breast self-examination | 2 | 1.9% |
Bronchodilator | 2 | 1.9% |
CHA2DS2–VASc score | 2 | 1.9% |
Canagliflozin | 2 | 1.9% |
Capacity building | 2 | 1.9% |
Cardiac arrest | 2 | 1.9% |
Cardiac stress test | 2 | 1.9% |
Cardiothoracic surgery | 2 | 1.9% |
Carotid artery stenosis | 2 | 1.9% |
Case–control study | 2 | 1.9% |
Cell therapy | 2 | 1.9% |
Cervical intraepithelial neoplasia | 2 | 1.9% |
Cervix | 2 | 1.9% |
Chemicals in medicine | 2 | 1.9% |
Chlamydia | 2 | 1.9% |
Choosing Wisely | 2 | 1.9% |
Clinical commissioning group | 2 | 1.9% |
Clinical urine tests | 2 | 1.9% |
Clostridioides difficile infection | 2 | 1.9% |
Cognition | 2 | 1.9% |
Colonoscopy | 2 | 1.9% |
Colposcopy | 2 | 1.9% |
Comprehensive geriatric assessment | 2 | 1.9% |
Confounding | 2 | 1.9% |
Coronary catheterization | 2 | 1.9% |
Correlation and dependence | 2 | 1.9% |
Creatinine | 2 | 1.9% |
Creative Commons license | 2 | 1.9% |
Cryoablation | 2 | 1.9% |
DICOM | 2 | 1.9% |
Daniel Kahneman | 2 | 1.9% |
Deep learning | 2 | 1.9% |
Deep vein thrombosis | 2 | 1.9% |
Delirium | 2 | 1.9% |
Dentistry | 2 | 1.9% |
Dependent and independent variables | 2 | 1.9% |
Deprescribing | 2 | 1.9% |
Diabetes mellitus type 1 | 2 | 1.9% |
Dialysis | 2 | 1.9% |
Dietary supplement | 2 | 1.9% |
Digital health | 2 | 1.9% |
Disability | 2 | 1.9% |
Disorders of endocrine pancreas | 2 | 1.9% |
Donabedian model | 2 | 1.9% |
Doppler ultrasonography | 2 | 1.9% |
Dual diagnosis | 2 | 1.9% |
Dual-energy X-ray absorptiometry | 2 | 1.9% |
Ebola | 2 | 1.9% |
Economics | 2 | 1.9% |
Evaluation | 2 | 1.9% |
Expert | 2 | 1.9% |
Extensively drug-resistant tuberculosis | 2 | 1.9% |
Familial hypercholesterolemia | 2 | 1.9% |
Fetus | 2 | 1.9% |
Formulary (pharmacy) | 2 | 1.9% |
Fractional flow reserve | 2 | 1.9% |
Frailty syndrome | 2 | 1.9% |
Gastrointestinal tract | 2 | 1.9% |
Genetic testing | 2 | 1.9% |
Genome-wide association study | 2 | 1.9% |
Gentamicin | 2 | 1.9% |
Gerontological nursing | 2 | 1.9% |
Gestational diabetes | 2 | 1.9% |
Gonorrhea | 2 | 1.9% |
Governance | 2 | 1.9% |
HER2/neu | 2 | 1.9% |
HIV | 2 | 1.9% |
HPV vaccine | 2 | 1.9% |
Hazard | 2 | 1.9% |
Health informatics | 2 | 1.9% |
Health technology in the United States | 2 | 1.9% |
Heart valve | 2 | 1.9% |
Hepatectomy | 2 | 1.9% |
Hierarchy of evidence | 2 | 1.9% |
Home care in the United States | 2 | 1.9% |
Hygiene | 2 | 1.9% |
Implantable cardioverter-defibrillator | 2 | 1.9% |
Incentive | 2 | 1.9% |
Indigenous Australians | 2 | 1.9% |
Infective endocarditis | 2 | 1.9% |
Influenza | 2 | 1.9% |
Influenza A virus subtype H7N9 | 2 | 1.9% |
Inhaler | 2 | 1.9% |
Internet of things | 2 | 1.9% |
Ionizing radiation | 2 | 1.9% |
Isolation (health care) | 2 | 1.9% |
Kidney | 2 | 1.9% |
Lassa fever | 2 | 1.9% |
Lasso (statistics) | 2 | 1.9% |
Left atrial appendage occlusion | 2 | 1.9% |
Leukemia | 2 | 1.9% |
Liver cancer | 2 | 1.9% |
Liver transplantation | 2 | 1.9% |
Long-term care | 2 | 1.9% |
Lung | 2 | 1.9% |
Lymphoma | 2 | 1.9% |
Malaria | 2 | 1.9% |
Maternal death | 2 | 1.9% |
Medicaid | 2 | 1.9% |
Medical error | 2 | 1.9% |
Medical history | 2 | 1.9% |
Medical microbiology | 2 | 1.9% |
Medical specialty | 2 | 1.9% |
Medical tests | 2 | 1.9% |
Medical ultrasound | 2 | 1.9% |
Metabolic syndrome | 2 | 1.9% |
Methicillin-resistant Staphylococcus aureus | 2 | 1.9% |
Metronidazole | 2 | 1.9% |
Microsatellite instability | 2 | 1.9% |
Microwave ablation | 2 | 1.9% |
Miscarriage | 2 | 1.9% |
Model organism | 2 | 1.9% |
Monitoring (medicine) | 2 | 1.9% |
Moral hazard | 2 | 1.9% |
Mycobacterium | 2 | 1.9% |
Neuron | 2 | 1.9% |
Neuropathic pain | 2 | 1.9% |
Neuroscience | 2 | 1.9% |
Nicotine | 2 | 1.9% |
Nivolumab | 2 | 1.9% |
Non-small-cell lung carcinoma | 2 | 1.9% |
Nuchal scan | 2 | 1.9% |
Nursing home | 2 | 1.9% |
Nutrition | 2 | 1.9% |
Occam's razor | 2 | 1.9% |
Old age | 2 | 1.9% |
Oral cancer | 2 | 1.9% |
Ordinary least squares | 2 | 1.9% |
Osteonecrosis of the jaw | 2 | 1.9% |
Ovarian cancer | 2 | 1.9% |
Overdiagnosis | 2 | 1.9% |
Pain | 2 | 1.9% |
Pain management | 2 | 1.9% |
Pap test | 2 | 1.9% |
Patient Protection and Affordable Care Act | 2 | 1.9% |
Peptic ulcer disease | 2 | 1.9% |
Percutaneous aortic valve replacement | 2 | 1.9% |
Peripheral neuropathy | 2 | 1.9% |
Polymerase chain reaction | 2 | 1.9% |
Polyp (medicine) | 2 | 1.9% |
Polypharmacy | 2 | 1.9% |
Portal hypertension | 2 | 1.9% |
Precision medicine | 2 | 1.9% |
Predictive modelling | 2 | 1.9% |
Prenatal testing | 2 | 1.9% |
Primary care | 2 | 1.9% |
Publication bias | 2 | 1.9% |
Pyrazinamide | 2 | 1.9% |
Quality of life | 2 | 1.9% |
RTT | 2 | 1.9% |
Regression analysis | 2 | 1.9% |
Regularization (mathematics) | 2 | 1.9% |
Relative risk | 2 | 1.9% |
Reporting bias | 2 | 1.9% |
Representativeness heuristic | 2 | 1.9% |
Respiratory disease | 2 | 1.9% |
Retinoblastoma | 2 | 1.9% |
Rituximab | 2 | 1.9% |
Robot-assisted surgery | 2 | 1.9% |
Rosiglitazone | 2 | 1.9% |
Rosuvastatin | 2 | 1.9% |
Safety | 2 | 1.9% |
Selective estrogen receptor modulator | 2 | 1.9% |
Selective internal radiation therapy | 2 | 1.9% |
Sepsis | 2 | 1.9% |
Sexually transmitted diseases and infections | 2 | 1.9% |
Sickle cell disease | 2 | 1.9% |
Sievert | 2 | 1.9% |
Sigmoidoscopy | 2 | 1.9% |
Single-nucleotide polymorphism | 2 | 1.9% |
Single-payer healthcare | 2 | 1.9% |
Social work | 2 | 1.9% |
Sofosbuvir | 2 | 1.9% |
Sorafenib | 2 | 1.9% |
Spirometry | 2 | 1.9% |
Standard deviation | 2 | 1.9% |
Statistical model | 2 | 1.9% |
Stem cell | 2 | 1.9% |
Substance-related disorders | 2 | 1.9% |
Syphilis | 2 | 1.9% |
Systemic lupus erythematosus | 2 | 1.9% |
Technology | 2 | 1.9% |
Teriparatide | 2 | 1.9% |
Transcatheter arterial chemoembolization | 2 | 1.9% |
Translational research | 2 | 1.9% |
Treatment of cancer | 2 | 1.9% |
Troponin | 2 | 1.9% |
Urology | 2 | 1.9% |
Ventricle (heart) | 2 | 1.9% |
Ventricular tachycardia | 2 | 1.9% |
Vertebral augmentation | 2 | 1.9% |
Vertically transmitted infection | 2 | 1.9% |
Viral hemorrhagic fever | 2 | 1.9% |
Abacavir | 1 | 1.0% |
Abaloparatide | 1 | 1.0% |
Abdominal aortic aneurysm | 1 | 1.0% |
Aberrations of the eye | 1 | 1.0% |
Abortion | 1 | 1.0% |
Abscess | 1 | 1.0% |
Absorbed dose | 1 | 1.0% |
Accountable care organization | 1 | 1.0% |
Acetylcysteine | 1 | 1.0% |
Aciclovir | 1 | 1.0% |
Actigraphy | 1 | 1.0% |
Activities of daily living | 1 | 1.0% |
Acute exacerbation of chronic obstructive pulmonary disease | 1 | 1.0% |
Acute kidney injury | 1 | 1.0% |
Acute lymphoblastic leukemia | 1 | 1.0% |
Acute myeloid leukemia | 1 | 1.0% |
Adenosine | 1 | 1.0% |
Allele | 1 | 1.0% |
Allergen | 1 | 1.0% |
Allergen immunotherapy | 1 | 1.0% |
Allergy | 1 | 1.0% |
Ambulatory blood pressure | 1 | 1.0% |
Amikacin | 1 | 1.0% |
Aminoglycoside | 1 | 1.0% |
Amniocentesis | 1 | 1.0% |
Amoebiasis | 1 | 1.0% |
Amoxicillin | 1 | 1.0% |
Amphotericin B | 1 | 1.0% |
Ampicillin | 1 | 1.0% |
Ampicillin/sulbactam | 1 | 1.0% |
Amyloid beta | 1 | 1.0% |
Amyloid precursor protein | 1 | 1.0% |
Amyloid-beta precursor protein | 1 | 1.0% |
Anaerobic infection | 1 | 1.0% |
Anastrozole | 1 | 1.0% |
Anemia | 1 | 1.0% |
Aneuploidy | 1 | 1.0% |
Angiology | 1 | 1.0% |
Angiotensin II receptor blocker | 1 | 1.0% |
Animal bite | 1 | 1.0% |
Anthropometry of the upper arm | 1 | 1.0% |
Anti-diabetic medication | 1 | 1.0% |
Anti-dsDNA antibodies | 1 | 1.0% |
Anti-nuclear antibody | 1 | 1.0% |
Antibiotic prophylaxis | 1 | 1.0% |
Antibiotic sensitivity | 1 | 1.0% |
Antibiotics | 1 | 1.0% |
Antibody-drug conjugate | 1 | 1.0% |
Antidepressant | 1 | 1.0% |
Antifungal | 1 | 1.0% |
Antigen | 1 | 1.0% |
Antimicrobial stewardship | 1 | 1.0% |
Antioxidant | 1 | 1.0% |
Aortic insufficiency | 1 | 1.0% |
Apixaban | 1 | 1.0% |
Apolipoprotein E | 1 | 1.0% |
Appendectomy | 1 | 1.0% |
Appendicitis | 1 | 1.0% |
Applied behavior analysis | 1 | 1.0% |
Aromatase inhibitor | 1 | 1.0% |
Aromatic compounds | 1 | 1.0% |
Arrhythmia | 1 | 1.0% |
Artificial kidney | 1 | 1.0% |
Ascending cholangitis | 1 | 1.0% |
Aspergillosis | 1 | 1.0% |
Assay | 1 | 1.0% |
Astigmatism | 1 | 1.0% |
Atorvastatin | 1 | 1.0% |
Attention deficit hyperactivity disorder | 1 | 1.0% |
Attitude (psychology) | 1 | 1.0% |
Australian Organ Donor Register | 1 | 1.0% |
Autism spectrum | 1 | 1.0% |
Autism therapies | 1 | 1.0% |
Autoimmune disease | 1 | 1.0% |
Autoimmunity | 1 | 1.0% |
Autologous chondrocyte implantation | 1 | 1.0% |
Axicabtagene ciloleucel | 1 | 1.0% |
Azathioprine | 1 | 1.0% |
Azo dye | 1 | 1.0% |
B cell | 1 | 1.0% |
B1 cell | 1 | 1.0% |
BRCA mutation | 1 | 1.0% |
Balanced Budget Act of 1997 | 1 | 1.0% |
Bedaquiline | 1 | 1.0% |
Beta-Carotene | 1 | 1.0% |
Beta-catenin | 1 | 1.0% |
Big data | 1 | 1.0% |
Biochemical cascade | 1 | 1.0% |
Bipolar disorder | 1 | 1.0% |
Birth weight | 1 | 1.0% |
Bladder cancer | 1 | 1.0% |
Bleeding | 1 | 1.0% |
Blood culture | 1 | 1.0% |
Blood glucose monitoring | 1 | 1.0% |
Blood lipids | 1 | 1.0% |
Blood-borne disease | 1 | 1.0% |
Bloodstream infections | 1 | 1.0% |
Bone marrow | 1 | 1.0% |
Bone resorption | 1 | 1.0% |
Borderline personality disorder | 1 | 1.0% |
Brachytherapy | 1 | 1.0% |
Brain abscess | 1 | 1.0% |
Brain damage | 1 | 1.0% |
Brain ischemia | 1 | 1.0% |
Brain metastasis | 1 | 1.0% |
Branches of science | 1 | 1.0% |
Breast cancer classification | 1 | 1.0% |
Breast milk | 1 | 1.0% |
Bronchiectasis | 1 | 1.0% |
Brugada syndrome | 1 | 1.0% |
Budesonide | 1 | 1.0% |
Budesonide/formoterol | 1 | 1.0% |
Bullous pemphigoid | 1 | 1.0% |
Bumetanide | 1 | 1.0% |
Burn | 1 | 1.0% |
CCR5 | 1 | 1.0% |
CD135 | 1 | 1.0% |
CD19 | 1 | 1.0% |
CD4 | 1 | 1.0% |
CD4+ T cells and antitumor immunity | 1 | 1.0% |
CHEK2 | 1 | 1.0% |
CHOP | 1 | 1.0% |
California County Routes in zone G | 1 | 1.0% |
Cancer prevention | 1 | 1.0% |
Cancer registry | 1 | 1.0% |
Candidiasis | 1 | 1.0% |
Canon PowerShot G | 1 | 1.0% |
Carbamazepine | 1 | 1.0% |
Carcinogen | 1 | 1.0% |
Cardiac monitoring | 1 | 1.0% |
Cardiac muscle | 1 | 1.0% |
Cardiac rehabilitation | 1 | 1.0% |
Cardiogenic shock | 1 | 1.0% |
Cardiotocography | 1 | 1.0% |
Carotid endarterectomy | 1 | 1.0% |
Carotid stenting | 1 | 1.0% |
Cartilage | 1 | 1.0% |
Caspofungin | 1 | 1.0% |
Catheter | 1 | 1.0% |
Cattle | 1 | 1.0% |
Cefazolin | 1 | 1.0% |
Cefotaxime | 1 | 1.0% |
Ceftriaxone | 1 | 1.0% |
Cell biology | 1 | 1.0% |
Cell growth | 1 | 1.0% |
Cell signaling | 1 | 1.0% |
Cell-free fetal DNA | 1 | 1.0% |
Cellular respiration | 1 | 1.0% |
Central nervous system | 1 | 1.0% |
Cephalosporin | 1 | 1.0% |
Cerebrospinal fluid | 1 | 1.0% |
Chain of custody | 1 | 1.0% |
Chancroid | 1 | 1.0% |
Chest radiograph | 1 | 1.0% |
Children's Health Insurance Program | 1 | 1.0% |
Chimeric antigen receptor | 1 | 1.0% |
Cholecystectomy | 1 | 1.0% |
Chronic lymphocytic leukemia | 1 | 1.0% |
Chronic myelogenous leukemia | 1 | 1.0% |
Chronic pain | 1 | 1.0% |
Chylomicron | 1 | 1.0% |
Citalopram | 1 | 1.0% |
Clindamycin | 1 | 1.0% |
Clinic | 1 | 1.0% |
Clinical decision support system | 1 | 1.0% |
Clinical governance | 1 | 1.0% |
Clinical psychology | 1 | 1.0% |
Clostridioides difficile (bacteria) | 1 | 1.0% |
Co-stimulation | 1 | 1.0% |
Cochrane Library | 1 | 1.0% |
Coefficient of determination | 1 | 1.0% |
Coenzyme A | 1 | 1.0% |
Community health worker | 1 | 1.0% |
Competition | 1 | 1.0% |
Computer-aided diagnosis | 1 | 1.0% |
Concussion | 1 | 1.0% |
Condom | 1 | 1.0% |
Congenital cytomegalovirus infection | 1 | 1.0% |
Congenital heart defect | 1 | 1.0% |
Consent | 1 | 1.0% |
Control of Substances Hazardous to Health Regulations 2002 | 1 | 1.0% |
Coronary artery anomaly | 1 | 1.0% |
Coronary circulation | 1 | 1.0% |
CpG site | 1 | 1.0% |
Creutzfeldt–Jakob disease | 1 | 1.0% |
Cryptococcosis | 1 | 1.0% |
Current Procedural Terminology | 1 | 1.0% |
Cyberattack | 1 | 1.0% |
Cystic fibrosis transmembrane conductance regulator | 1 | 1.0% |
Cystoscopy | 1 | 1.0% |
Cytotoxic T cell | 1 | 1.0% |
DNA methylation | 1 | 1.0% |
Da Vinci Surgical System | 1 | 1.0% |
Dabigatran | 1 | 1.0% |
Data quality | 1 | 1.0% |
Death | 1 | 1.0% |
Defibrillation | 1 | 1.0% |
Deformation (mechanics) | 1 | 1.0% |
Dental implant | 1 | 1.0% |
Desmopressin | 1 | 1.0% |
Desogestrel | 1 | 1.0% |
Dexamethasone | 1 | 1.0% |
Diabetic cardiomyopathy | 1 | 1.0% |
Diabetic ketoacidosis | 1 | 1.0% |
Diabetic neuropathy | 1 | 1.0% |
Dieting | 1 | 1.0% |
Dietitian | 1 | 1.0% |
Diffuse large B-cell lymphoma | 1 | 1.0% |
Discrete trial training | 1 | 1.0% |
Docosahexaenoic acid | 1 | 1.0% |
Dog | 1 | 1.0% |
Domperidone | 1 | 1.0% |
Down syndrome | 1 | 1.0% |
Droperidol | 1 | 1.0% |
Drug brand names | 1 | 1.0% |
Drugs acting on the nervous system | 1 | 1.0% |
Duchenne muscular dystrophy | 1 | 1.0% |
Duloxetine | 1 | 1.0% |
EHealth | 1 | 1.0% |
ELISA | 1 | 1.0% |
EQ-5D | 1 | 1.0% |
Early-onset Alzheimer's disease | 1 | 1.0% |
Economic growth | 1 | 1.0% |
Economics of service industries | 1 | 1.0% |
Eicosapentaenoic acid | 1 | 1.0% |
Electroconvulsive therapy | 1 | 1.0% |
Electroencephalography | 1 | 1.0% |
Electronic prescribing | 1 | 1.0% |
Embolization | 1 | 1.0% |
Emergency medical services | 1 | 1.0% |
Emergency medical technician | 1 | 1.0% |
Employment | 1 | 1.0% |
Emtricitabine | 1 | 1.0% |
End Stage Renal Disease Program | 1 | 1.0% |
End-of-life care | 1 | 1.0% |
Endocrine system | 1 | 1.0% |
Endometriosis | 1 | 1.0% |
Endometrium | 1 | 1.0% |
Endoscopic mucosal resection | 1 | 1.0% |
Endoscopic submucosal dissection | 1 | 1.0% |
Enema | 1 | 1.0% |
Entamoeba | 1 | 1.0% |
Enterococcus | 1 | 1.0% |
Enterococcus faecalis | 1 | 1.0% |
Environmental factor | 1 | 1.0% |
Environmental social science | 1 | 1.0% |
Epidural administration | 1 | 1.0% |
Esophageal cancer | 1 | 1.0% |
Essential health benefits | 1 | 1.0% |
Estradiol (medication) | 1 | 1.0% |
Estrogen | 1 | 1.0% |
Eteplirsen | 1 | 1.0% |
Ethics | 1 | 1.0% |
Ethinylestradiol | 1 | 1.0% |
Ethyl eicosapentaenoic acid | 1 | 1.0% |
Evaluation of binary classifiers | 1 | 1.0% |
Evidence | 1 | 1.0% |
Exemestane | 1 | 1.0% |
External cephalic version | 1 | 1.0% |
Ezetimibe | 1 | 1.0% |
FRAX | 1 | 1.0% |
Familial adenomatous polyposis | 1 | 1.0% |
Fat | 1 | 1.0% |
Fatigue | 1 | 1.0% |
Fatty acid | 1 | 1.0% |
Febrile neutropenia | 1 | 1.0% |
Federally Qualified Health Center | 1 | 1.0% |
Feeling | 1 | 1.0% |
Fenofibrate | 1 | 1.0% |
Fentanyl | 1 | 1.0% |
Fetal movement | 1 | 1.0% |
Fibrate | 1 | 1.0% |
Fibrocystic breast changes | 1 | 1.0% |
Fidaxomicin | 1 | 1.0% |
Fine-needle aspiration | 1 | 1.0% |
Fluconazole | 1 | 1.0% |
Flucytosine | 1 | 1.0% |
Fluticasone propionate | 1 | 1.0% |
Fluvastatin | 1 | 1.0% |
Follicular lymphoma | 1 | 1.0% |
Food | 1 | 1.0% |
Food and drink | 1 | 1.0% |
Food energy | 1 | 1.0% |
Framingham Risk Score | 1 | 1.0% |
Frozen section procedure | 1 | 1.0% |
Functional groups | 1 | 1.0% |
Furosemide | 1 | 1.0% |
Gabapentin | 1 | 1.0% |
Galanin | 1 | 1.0% |
Ganciclovir | 1 | 1.0% |
Gardasil | 1 | 1.0% |
Gardner's syndrome | 1 | 1.0% |
Gastric bypass surgery | 1 | 1.0% |
Gastroenteritis | 1 | 1.0% |
Gastrointestinal bleeding | 1 | 1.0% |
Gene expression | 1 | 1.0% |
Generic drug | 1 | 1.0% |
Genetic counseling | 1 | 1.0% |
Genetic disorder | 1 | 1.0% |
Genetic linkage | 1 | 1.0% |
Genital wart | 1 | 1.0% |
Genome | 1 | 1.0% |
Genome editing | 1 | 1.0% |
Genomics | 1 | 1.0% |
Gestational age | 1 | 1.0% |
Glutathione | 1 | 1.0% |
Graft-versus-host disease | 1 | 1.0% |
Gynaecologic disorders | 1 | 1.0% |
HBB | 1 | 1.0% |
HIV-positive people | 1 | 1.0% |
Haematopoiesis | 1 | 1.0% |
Health Insurance Portability and Accountability Act | 1 | 1.0% |
Health and Social Care Act 2012 | 1 | 1.0% |
Health care brands | 1 | 1.0% |
Health care industry | 1 | 1.0% |
Health effects of tobacco | 1 | 1.0% |
Health literacy | 1 | 1.0% |
Health savings account | 1 | 1.0% |
Health technology | 1 | 1.0% |
Healthcare Effectiveness Data and Information Set | 1 | 1.0% |
Healthcare management | 1 | 1.0% |
Healthcare quality | 1 | 1.0% |
Healthy diet | 1 | 1.0% |
Hearing loss | 1 | 1.0% |
Heart failure with preserved ejection fraction | 1 | 1.0% |
Heart rate | 1 | 1.0% |
Helicobacter pylori | 1 | 1.0% |
Hemodialysis | 1 | 1.0% |
Hemoglobin | 1 | 1.0% |
Hepatitis B virus | 1 | 1.0% |
Hepatitis C virus | 1 | 1.0% |
Hepatotoxicity | 1 | 1.0% |
Hip fracture | 1 | 1.0% |
Histocompatibility | 1 | 1.0% |
Histoplasmosis | 1 | 1.0% |
Home hemodialysis | 1 | 1.0% |
Homelessness | 1 | 1.0% |
Human cytomegalovirus | 1 | 1.0% |
Human leukocyte antigen | 1 | 1.0% |
Human sexuality | 1 | 1.0% |
Hydronephrosis | 1 | 1.0% |
Hypercapnia | 1 | 1.0% |
Hyperglycemia | 1 | 1.0% |
Hyperinsulinemia | 1 | 1.0% |
Hypertriglyceridemia | 1 | 1.0% |
Hypertrophic cardiomyopathy | 1 | 1.0% |
Hypnotic | 1 | 1.0% |
Hypoglycemia | 1 | 1.0% |
Hypopnea | 1 | 1.0% |
Hysterectomy | 1 | 1.0% |
IL17A | 1 | 1.0% |
Ibandronic acid | 1 | 1.0% |
Immune thrombocytopenic purpura | 1 | 1.0% |
Immunodeficiency | 1 | 1.0% |
Immunoglobulin therapy | 1 | 1.0% |
Immunoprecipitation | 1 | 1.0% |
Immunosuppressive drug | 1 | 1.0% |
Immunotherapy | 1 | 1.0% |
Impact evaluation | 1 | 1.0% |
Implant (medicine) | 1 | 1.0% |
Incidence (epidemiology) | 1 | 1.0% |
Index Medicus | 1 | 1.0% |
Indigenous health in Australia | 1 | 1.0% |
Individualized Education Program | 1 | 1.0% |
Inflammation | 1 | 1.0% |
Influenza A virus | 1 | 1.0% |
Influenza A virus subtype H1N1 | 1 | 1.0% |
Influenza A virus subtype H3N2 | 1 | 1.0% |
Influenza pandemic | 1 | 1.0% |
Influenza vaccine | 1 | 1.0% |
Information privacy | 1 | 1.0% |
Information security | 1 | 1.0% |
Informed consent | 1 | 1.0% |
Insomnia | 1 | 1.0% |
Insulin | 1 | 1.0% |
Insulin (medication) | 1 | 1.0% |
Insulin analog | 1 | 1.0% |
Insulin glargine | 1 | 1.0% |
Insulin resistance | 1 | 1.0% |
Insurance | 1 | 1.0% |
Intention | 1 | 1.0% |
Interferon gamma | 1 | 1.0% |
Interleukin 15 | 1 | 1.0% |
Interleukin 2 | 1 | 1.0% |
Interleukin 6 | 1 | 1.0% |
International development | 1 | 1.0% |
Interoperability | 1 | 1.0% |
Irritable bowel syndrome | 1 | 1.0% |
Isoniazid | 1 | 1.0% |
Itraconazole | 1 | 1.0% |
Ivabradine | 1 | 1.0% |
KIT (gene) | 1 | 1.0% |
Kinase | 1 | 1.0% |
Lactate dehydrogenase | 1 | 1.0% |
Lamivudine | 1 | 1.0% |
Language interpretation | 1 | 1.0% |
Laxative | 1 | 1.0% |
Leadership | 1 | 1.0% |
Lentiviruses | 1 | 1.0% |
Lenvatinib | 1 | 1.0% |
Licensed behavior analyst | 1 | 1.0% |
Lidocaine | 1 | 1.0% |
Linezolid | 1 | 1.0% |
Linkage disequilibrium | 1 | 1.0% |
Lipids | 1 | 1.0% |
Lipoprotein(a) | 1 | 1.0% |
Liraglutide | 1 | 1.0% |
Lithium (medication) | 1 | 1.0% |
Liver biopsy | 1 | 1.0% |
Liver disease | 1 | 1.0% |
Li–Fraumeni syndrome | 1 | 1.0% |
Lobular carcinoma in situ | 1 | 1.0% |
Local anesthetic | 1 | 1.0% |
Long non-coding RNA | 1 | 1.0% |
Loop diuretic | 1 | 1.0% |
Low molecular weight heparin | 1 | 1.0% |
Low-carbohydrate diet | 1 | 1.0% |
Lung cancer screening | 1 | 1.0% |
Lung nodule | 1 | 1.0% |
Lymphadenectomy | 1 | 1.0% |
Lymphocyte | 1 | 1.0% |
Lymphogranuloma venereum | 1 | 1.0% |
MEDLINE | 1 | 1.0% |
MHealth | 1 | 1.0% |
MLH1 | 1 | 1.0% |
MSH2 | 1 | 1.0% |
MSH6 | 1 | 1.0% |
Macrogol | 1 | 1.0% |
Magnetic resonance angiography | 1 | 1.0% |
Major histocompatibility complex | 1 | 1.0% |
Malcolm B. Frost | 1 | 1.0% |
Male genital disorders | 1 | 1.0% |
Mammary tumor | 1 | 1.0% |
Managed care | 1 | 1.0% |
Mantoux test | 1 | 1.0% |
Marburg virus disease | 1 | 1.0% |
Maternal–fetal medicine | 1 | 1.0% |
Mean | 1 | 1.0% |
Medical device | 1 | 1.0% |
Medical research | 1 | 1.0% |
Medical statistics | 1 | 1.0% |
Medicare dual eligible | 1 | 1.0% |
Medicinal chemistry | 1 | 1.0% |
Medroxyprogesterone acetate | 1 | 1.0% |
Melanoma | 1 | 1.0% |
Mental health | 1 | 1.0% |
Mentorship | 1 | 1.0% |
Mesenchymal stem cell | 1 | 1.0% |
Mesothelioma | 1 | 1.0% |
Metabolism | 1 | 1.0% |
Metastasectomy | 1 | 1.0% |
Metastatic liver disease | 1 | 1.0% |
Metered-dose inhaler | 1 | 1.0% |
Methylprednisolone | 1 | 1.0% |
Midazolam | 1 | 1.0% |
Midostaurin | 1 | 1.0% |
Midwife | 1 | 1.0% |
Midwifery | 1 | 1.0% |
Miliary tuberculosis | 1 | 1.0% |
Missing data | 1 | 1.0% |
Mitochondrion | 1 | 1.0% |
MitraClip | 1 | 1.0% |
Mitral insufficiency | 1 | 1.0% |
Mitral valve | 1 | 1.0% |
Mitral valve repair | 1 | 1.0% |
Model for End-Stage Liver Disease | 1 | 1.0% |
Molecular biology | 1 | 1.0% |
Monoclonal antibody | 1 | 1.0% |
Monounsaturated fat | 1 | 1.0% |
Motion sickness | 1 | 1.0% |
Multiple drug resistance | 1 | 1.0% |
Muscular dystrophy | 1 | 1.0% |
Mutation | 1 | 1.0% |
Myc | 1 | 1.0% |
Mycobacteria | 1 | 1.0% |
Mycobacterium bovis | 1 | 1.0% |
Mycobacterium tuberculosis | 1 | 1.0% |
Mycophenolic acid | 1 | 1.0% |
Mycoplasma | 1 | 1.0% |
Natural reservoir | 1 | 1.0% |
Nausea | 1 | 1.0% |
Near-sightedness | 1 | 1.0% |
Nebulizer | 1 | 1.0% |
Needlestick injury | 1 | 1.0% |
Neglected tropical diseases | 1 | 1.0% |
Neisseria gonorrhoeae | 1 | 1.0% |
Neisseria meningitidis | 1 | 1.0% |
Neonatal intensive care unit | 1 | 1.0% |
Nerve | 1 | 1.0% |
Neuralgia | 1 | 1.0% |
Neuroimaging | 1 | 1.0% |
Neurology | 1 | 1.0% |
Neutropenia | 1 | 1.0% |
Niacin | 1 | 1.0% |
Nifedipine | 1 | 1.0% |
Non-alcoholic fatty liver disease | 1 | 1.0% |
Non-invasive ventilation | 1 | 1.0% |
Norethisterone | 1 | 1.0% |
Norgestimate | 1 | 1.0% |
Number needed to treat | 1 | 1.0% |
Nutrients | 1 | 1.0% |
Obstetric ultrasonography | 1 | 1.0% |
Obstetrics | 1 | 1.0% |
Obstructive sleep apnea | 1 | 1.0% |
Occupational disease | 1 | 1.0% |
Occupational safety and health | 1 | 1.0% |
Omalizumab | 1 | 1.0% |
Omega-3 fatty acid | 1 | 1.0% |
Omeprazole | 1 | 1.0% |
Oncology | 1 | 1.0% |
Oncolytic virus | 1 | 1.0% |
Ondansetron | 1 | 1.0% |
Oophorectomy | 1 | 1.0% |
Opioid | 1 | 1.0% |
Organ (anatomy) | 1 | 1.0% |
Organ (biology) | 1 | 1.0% |
Organ donation in Australia | 1 | 1.0% |
Organ procurement | 1 | 1.0% |
Organic compounds | 1 | 1.0% |
Organs (anatomy) | 1 | 1.0% |
Osteoclast | 1 | 1.0% |
Ototoxicity | 1 | 1.0% |
Outcomes research | 1 | 1.0% |
Outpatient surgery | 1 | 1.0% |
Ovarian cyst | 1 | 1.0% |
Oxidative stress | 1 | 1.0% |
P53 | 1 | 1.0% |
PCSK9 | 1 | 1.0% |
PD-L1 | 1 | 1.0% |
PHQ-9 | 1 | 1.0% |
PMS2 | 1 | 1.0% |
PSEN1 | 1 | 1.0% |
PTEN (gene) | 1 | 1.0% |
Palliative care | 1 | 1.0% |
Pancreatitis | 1 | 1.0% |
Pandemic | 1 | 1.0% |
Pandemic H1N1/09 virus | 1 | 1.0% |
Paracetamol | 1 | 1.0% |
Paramedic | 1 | 1.0% |
Parathyroid hormone | 1 | 1.0% |
Parenting | 1 | 1.0% |
Parkinson's disease | 1 | 1.0% |
Passive smoking | 1 | 1.0% |
Pathogen | 1 | 1.0% |
Pectus excavatum | 1 | 1.0% |
Pediatrics | 1 | 1.0% |
Peer review | 1 | 1.0% |
Pelvic inflammatory disease | 1 | 1.0% |
Pemphigoid | 1 | 1.0% |
Pemphigus | 1 | 1.0% |
Penicillin | 1 | 1.0% |
Performance appraisal | 1 | 1.0% |
Performance indicator | 1 | 1.0% |
Pericardiocentesis | 1 | 1.0% |
Pericardium | 1 | 1.0% |
Peritoneal dialysis | 1 | 1.0% |
Personal data | 1 | 1.0% |
Personal protective equipment | 1 | 1.0% |
Personality disorder | 1 | 1.0% |
Personalized medicine | 1 | 1.0% |
Pervasive developmental disorder | 1 | 1.0% |
Pervasive developmental disorder not otherwise specified | 1 | 1.0% |
Pharmaceutical sciences | 1 | 1.0% |
Physical activity | 1 | 1.0% |
Picture archiving and communication system | 1 | 1.0% |
Pioglitazone | 1 | 1.0% |
Piperacillin | 1 | 1.0% |
Pixantrone | 1 | 1.0% |
Placebo-controlled study | 1 | 1.0% |
Platelet | 1 | 1.0% |
Pleural effusion | 1 | 1.0% |
Pneumococcal conjugate vaccine | 1 | 1.0% |
Pneumococcal vaccine | 1 | 1.0% |
Pneumocystis pneumonia | 1 | 1.0% |
Point of care | 1 | 1.0% |
Policy | 1 | 1.0% |
Polypill | 1 | 1.0% |
Polysomnography | 1 | 1.0% |
Positron emission tomography | 1 | 1.0% |
Postherpetic neuralgia | 1 | 1.0% |
Postoperative nausea and vomiting | 1 | 1.0% |
Posttraumatic stress disorder | 1 | 1.0% |
Power of a test | 1 | 1.0% |
Prasugrel | 1 | 1.0% |
Pravastatin | 1 | 1.0% |
Pre-eclampsia | 1 | 1.0% |
Pregabalin | 1 | 1.0% |
Premium tax credit | 1 | 1.0% |
Prenatal care | 1 | 1.0% |
Prenatal development | 1 | 1.0% |
Preventive medicine | 1 | 1.0% |
Primaquine | 1 | 1.0% |
Privacy | 1 | 1.0% |
Promoter (genetics) | 1 | 1.0% |
Protein kinase | 1 | 1.0% |
Psychological concepts | 1 | 1.0% |
Psychological evaluation | 1 | 1.0% |
Psychosis | 1 | 1.0% |
Public health surveillance | 1 | 1.0% |
Pulmonary fibrosis | 1 | 1.0% |
Pulmonology | 1 | 1.0% |
Quality management | 1 | 1.0% |
Quetiapine | 1 | 1.0% |
RNA-Seq | 1 | 1.0% |
Rabies | 1 | 1.0% |
Radon | 1 | 1.0% |
Readability | 1 | 1.0% |
Real-time polymerase chain reaction | 1 | 1.0% |
Receptor antagonist | 1 | 1.0% |
Reference range | 1 | 1.0% |
Refugee | 1 | 1.0% |
Regenerative medicine | 1 | 1.0% |
Regulatory Flexibility Act | 1 | 1.0% |
Regulatory compliance | 1 | 1.0% |
Relapse | 1 | 1.0% |
Remote surgery | 1 | 1.0% |
Reperfusion injury | 1 | 1.0% |
Reperfusion therapy | 1 | 1.0% |
Respiratory tract | 1 | 1.0% |
Resting state fMRI | 1 | 1.0% |
Revised National Tuberculosis Control Program | 1 | 1.0% |
Rhabdomyolysis | 1 | 1.0% |
Rheumatic fever | 1 | 1.0% |
Rheumatoid arthritis | 1 | 1.0% |
Risk management | 1 | 1.0% |
Rivaroxaban | 1 | 1.0% |
Robot | 1 | 1.0% |
Rubella | 1 | 1.0% |
SGK1 | 1 | 1.0% |
SGLT2 inhibitor | 1 | 1.0% |
Safe sex | 1 | 1.0% |
Salbutamol | 1 | 1.0% |
Salt | 1 | 1.0% |
Sampling (statistics) | 1 | 1.0% |
Saxagliptin | 1 | 1.0% |
Schizoaffective disorder | 1 | 1.0% |
Science | 1 | 1.0% |
Selective serotonin reuptake inhibitor | 1 | 1.0% |
Sensitivity analysis | 1 | 1.0% |
Sensorineural hearing loss | 1 | 1.0% |
Seroconversion | 1 | 1.0% |
Serology | 1 | 1.0% |
Serum amyloid A1 | 1 | 1.0% |
Sex worker | 1 | 1.0% |
Sexual health | 1 | 1.0% |
Shortness of breath | 1 | 1.0% |
Signal transduction | 1 | 1.0% |
Simeprevir | 1 | 1.0% |
Sleep | 1 | 1.0% |
Sleep apnea | 1 | 1.0% |
Sleep disorder | 1 | 1.0% |
Smoking | 1 | 1.0% |
Social determinants of health | 1 | 1.0% |
Social science | 1 | 1.0% |
Software | 1 | 1.0% |
Southeast Asia | 1 | 1.0% |
Spanish flu | 1 | 1.0% |
Spontaneous bacterial peritonitis | 1 | 1.0% |
Squamous cell carcinoma | 1 | 1.0% |
Staphylococcus aureus | 1 | 1.0% |
Sternum | 1 | 1.0% |
Stool guaiac test | 1 | 1.0% |
Streptococcus agalactiae | 1 | 1.0% |
Streptomycin | 1 | 1.0% |
Sulfonylurea | 1 | 1.0% |
Surface epithelial-stromal tumor | 1 | 1.0% |
Surfactant protein B | 1 | 1.0% |
Symptoms and signs | 1 | 1.0% |
Symptoms and signs: General | 1 | 1.0% |
Synapse | 1 | 1.0% |
Syncope (medicine) | 1 | 1.0% |
T helper cell | 1 | 1.0% |
Tachycardia | 1 | 1.0% |
Tag SNP | 1 | 1.0% |
Talimogene laherparepvec | 1 | 1.0% |
Tamoxifen | 1 | 1.0% |
Tax | 1 | 1.0% |
Telehealth | 1 | 1.0% |
Telemedicine | 1 | 1.0% |
Tenofovir disoproxil | 1 | 1.0% |
Testosterone (medication) | 1 | 1.0% |
Tetraplegia | 1 | 1.0% |
Thalassemia | 1 | 1.0% |
Theory of planned behavior | 1 | 1.0% |
Threshold limit value | 1 | 1.0% |
Thrombocytopenia | 1 | 1.0% |
Thrombus | 1 | 1.0% |
Tibolone | 1 | 1.0% |
Tiotropium bromide | 1 | 1.0% |
Tisagenlecleucel | 1 | 1.0% |
Tissue plasminogen activator | 1 | 1.0% |
Tobacco control | 1 | 1.0% |
Tracheotomy | 1 | 1.0% |
Training | 1 | 1.0% |
Transcranial direct-current stimulation | 1 | 1.0% |
Transcription (biology) | 1 | 1.0% |
Transmissible spongiform encephalopathy | 1 | 1.0% |
Traumatic brain injury | 1 | 1.0% |
Treatment and control groups | 1 | 1.0% |
Treatment of lung cancer | 1 | 1.0% |
Trichomoniasis | 1 | 1.0% |
Tricyclic antidepressant | 1 | 1.0% |
Triglyceride | 1 | 1.0% |
Triple test | 1 | 1.0% |
Tuberculosis in relation to HIV | 1 | 1.0% |
Tubo-ovarian abscess | 1 | 1.0% |
Type I and type II errors | 1 | 1.0% |
United States budget sequestration in 2013 | 1 | 1.0% |
Unwarranted variation | 1 | 1.0% |
Ureter | 1 | 1.0% |
Urological conditions | 1 | 1.0% |
Uterine fibroid | 1 | 1.0% |
Uterine prolapse | 1 | 1.0% |
VKORC1 | 1 | 1.0% |
Vaccination | 1 | 1.0% |
Vaccines for Children Program | 1 | 1.0% |
Vaginal bleeding | 1 | 1.0% |
Vaginal yeast infection | 1 | 1.0% |
Vaginitis | 1 | 1.0% |
Valproate | 1 | 1.0% |
Valsartan | 1 | 1.0% |
Valvular heart disease | 1 | 1.0% |
Vancomycin | 1 | 1.0% |
Ventricular assist device | 1 | 1.0% |
Ventricular natriuretic peptide | 1 | 1.0% |
Very low-density lipoprotein | 1 | 1.0% |
Violence | 1 | 1.0% |
Viral load | 1 | 1.0% |
Viral replication | 1 | 1.0% |
Viral vector | 1 | 1.0% |
Virtual colonoscopy | 1 | 1.0% |
Virus latency | 1 | 1.0% |
Virus quantification | 1 | 1.0% |
Visual field test | 1 | 1.0% |
Visual impairment | 1 | 1.0% |
Visual perception | 1 | 1.0% |
Vitamin | 1 | 1.0% |
Vitamin A | 1 | 1.0% |
Vomiting | 1 | 1.0% |
Vulnerable plaque | 1 | 1.0% |
Wart | 1 | 1.0% |
Weight loss | 1 | 1.0% |
Wnt signaling pathway | 1 | 1.0% |
World Wide Web | 1 | 1.0% |
Wound | 1 | 1.0% |
Zygosity | 1 | 1.0% |
abs | rel | |
---|---|---|
Health | 111 | 96.5% |
Medicine | 110 | 95.7% |
Health sciences | 108 | 93.9% |
Medical specialties | 105 | 91.3% |
Clinical medicine | 101 | 87.8% |
Health care | 100 | 87.0% |
Diseases and disorders | 51 | 44.3% |
Public health | 51 | 44.3% |
Infection | 40 | 34.8% |
Disease | 37 | 32.2% |
Epidemiology | 37 | 32.2% |
Risk | 37 | 32.2% |
Coronavirus disease 2019 | 31 | 27.0% |
Cancer | 24 | 20.9% |
Clinical trial | 24 | 20.9% |
Therapy | 22 | 19.1% |
COVID-19 pandemic | 21 | 18.3% |
Hospital | 21 | 18.3% |
Randomized controlled trial | 21 | 18.3% |
Medical diagnosis | 20 | 17.4% |
Surgery | 20 | 17.4% |
Patient | 19 | 16.5% |
Preventive healthcare | 19 | 16.5% |
Infectious diseases | 18 | 15.7% |
Cardiovascular disease | 17 | 14.8% |
Diabetes | 16 | 13.9% |
Evidence-based medicine | 16 | 13.9% |
Research | 16 | 13.9% |
Medical humanities | 14 | 12.2% |
Medication | 14 | 12.2% |
Screening (medicine) | 14 | 12.2% |
Systematic review | 14 | 12.2% |
Biology | 13 | 11.3% |
Obesity | 13 | 11.3% |
Pregnancy | 13 | 11.3% |
Chronic condition | 12 | 10.4% |
Medical imaging | 12 | 10.4% |
Type 2 diabetes | 12 | 10.4% |
Health professional | 11 | 9.6% |
Hypertension | 11 | 9.6% |
Infection prevention and control | 11 | 9.6% |
Myocardial infarction | 11 | 9.6% |
Personal protective equipment | 11 | 9.6% |
Safety | 11 | 9.6% |
Sensitivity and specificity | 11 | 9.6% |
Transmission (medicine) | 11 | 9.6% |
Vaccine | 11 | 9.6% |
Virus | 11 | 9.6% |
Confidence interval | 10 | 8.7% |
HIV/AIDS | 10 | 8.7% |
Health economics | 10 | 8.7% |
Human activities | 10 | 8.7% |
Immunology | 10 | 8.7% |
Meta-analysis | 10 | 8.7% |
Nursing | 10 | 8.7% |
Severe acute respiratory syndrome coronavirus 2 | 10 | 8.7% |
COVID-19 | 9 | 7.8% |
CT scan | 9 | 7.8% |
Chronic kidney disease | 8 | 7.0% |
Comorbidity | 8 | 7.0% |
General practitioner | 8 | 7.0% |
Health policy | 8 | 7.0% |
Health system | 8 | 7.0% |
Heart | 8 | 7.0% |
Heart failure | 8 | 7.0% |
Magnetic resonance imaging | 8 | 7.0% |
Medical guideline | 8 | 7.0% |
Radiation therapy | 8 | 7.0% |
Radiology | 8 | 7.0% |
Receiver operating characteristic | 8 | 7.0% |
Telehealth | 8 | 7.0% |
Adverse effect | 7 | 6.1% |
Antimicrobial resistance | 7 | 6.1% |
Cardiology | 7 | 6.1% |
Cervical cancer | 7 | 6.1% |
Cohort study | 7 | 6.1% |
Diabetes management | 7 | 6.1% |
Kidney failure | 7 | 6.1% |
Life sciences | 7 | 6.1% |
Lung cancer | 7 | 6.1% |
Medical test | 7 | 6.1% |
Microbiology | 7 | 6.1% |
Pandemic | 7 | 6.1% |
Pathology | 7 | 6.1% |
Signs and symptoms | 7 | 6.1% |
Statistics | 7 | 6.1% |
Surgical mask | 7 | 6.1% |
Adherence (medicine) | 6 | 5.2% |
Antibiotic | 6 | 5.2% |
Bleeding | 6 | 5.2% |
Branches of science | 6 | 5.2% |
COVID-19 testing | 6 | 5.2% |
Cancer screening | 6 | 5.2% |
Caregiver | 6 | 5.2% |
Chronic obstructive pulmonary disease | 6 | 5.2% |
Coronary artery disease | 6 | 5.2% |
Glycated hemoglobin | 6 | 5.2% |
Human papillomavirus infection | 6 | 5.2% |
Immunodeficiency | 6 | 5.2% |
Infection control | 6 | 5.2% |
Intensive care unit | 6 | 5.2% |
Laparoscopy | 6 | 5.2% |
Machine learning | 6 | 5.2% |
Medical statistics | 6 | 5.2% |
Medical treatments | 6 | 5.2% |
Medical ultrasound | 6 | 5.2% |
Prostate cancer | 6 | 5.2% |
Stroke | 6 | 5.2% |
Symptom | 6 | 5.2% |
Transmission-based precautions | 6 | 5.2% |
Tuberculosis | 6 | 5.2% |
Urology | 6 | 5.2% |
Angina | 5 | 4.3% |
Biomarker | 5 | 4.3% |
Blood sugar level | 5 | 4.3% |
Body mass index | 5 | 4.3% |
Cardiovascular system | 5 | 4.3% |
Cervical screening | 5 | 4.3% |
Chemotherapy | 5 | 4.3% |
Childbirth | 5 | 4.3% |
Creative Commons license | 5 | 4.3% |
Dementia | 5 | 4.3% |
Dependent and independent variables | 5 | 4.3% |
Echocardiography | 5 | 4.3% |
Emergency department | 5 | 4.3% |
Exercise | 5 | 4.3% |
False positives and false negatives | 5 | 4.3% |
Food | 5 | 4.3% |
Health equity | 5 | 4.3% |
Human reproduction | 5 | 4.3% |
Influenza | 5 | 4.3% |
Maternal health | 5 | 4.3% |
Medical prescription | 5 | 4.3% |
Neoplasms | 5 | 4.3% |
Nephrology | 5 | 4.3% |
Occupational safety and health | 5 | 4.3% |
Physician | 5 | 4.3% |
Point of care | 5 | 4.3% |
Pulmonary embolism | 5 | 4.3% |
Regression analysis | 5 | 4.3% |
Respirator | 5 | 4.3% |
Risk assessment | 5 | 4.3% |
Shortness of breath | 5 | 4.3% |
Thrombosis | 5 | 4.3% |
Type I and type II errors | 5 | 4.3% |
Venous thrombosis | 5 | 4.3% |
Anesthesia | 4 | 3.5% |
Anticoagulant | 4 | 3.5% |
Artificial intelligence | 4 | 3.5% |
Asthma | 4 | 3.5% |
Atypical pneumonias | 4 | 3.5% |
Biopsy | 4 | 3.5% |
Blood | 4 | 3.5% |
Blood pressure | 4 | 3.5% |
Blood transfusion | 4 | 3.5% |
Breast cancer | 4 | 3.5% |
C-reactive protein | 4 | 3.5% |
Cancer survivor | 4 | 3.5% |
Cardiac magnetic resonance imaging | 4 | 3.5% |
Causes of death | 4 | 3.5% |
Colorectal cancer | 4 | 3.5% |
Coronavirus | 4 | 3.5% |
Cost-effectiveness analysis | 4 | 3.5% |
Deep vein thrombosis | 4 | 3.5% |
Doppler ultrasonography | 4 | 3.5% |
Dose (biochemistry) | 4 | 3.5% |
Electrocardiography | 4 | 3.5% |
Endoscopy | 4 | 3.5% |
Face masks during the COVID-19 pandemic | 4 | 3.5% |
Hand washing | 4 | 3.5% |
Health promotion | 4 | 3.5% |
Histopathology | 4 | 3.5% |
Human pregnancy | 4 | 3.5% |
Hygiene | 4 | 3.5% |
Hysterectomy | 4 | 3.5% |
Immunization | 4 | 3.5% |
Intensive care medicine | 4 | 3.5% |
Isolation (health care) | 4 | 3.5% |
Low-molecular-weight heparin | 4 | 3.5% |
Lymphoma | 4 | 3.5% |
Major depressive disorder | 4 | 3.5% |
Mental health | 4 | 3.5% |
Mortality rate | 4 | 3.5% |
Motherhood | 4 | 3.5% |
Non-communicable disease | 4 | 3.5% |
Ophthalmology | 4 | 3.5% |
Organs (anatomy) | 4 | 3.5% |
Physical therapy | 4 | 3.5% |
Prenatal development | 4 | 3.5% |
Prostatectomy | 4 | 3.5% |
Quality of life | 4 | 3.5% |
Radiography | 4 | 3.5% |
Renal function | 4 | 3.5% |
Respiratory disease | 4 | 3.5% |
Sarbecovirus | 4 | 3.5% |
Self-care | 4 | 3.5% |
Sensitivity analysis | 4 | 3.5% |
Social distancing | 4 | 3.5% |
Standard deviation | 4 | 3.5% |
Statin | 4 | 3.5% |
Technology | 4 | 3.5% |
Treatment of cancer | 4 | 3.5% |
Triage | 4 | 3.5% |
Vaccination | 4 | 3.5% |
2019–20 coronavirus outbreak | 3 | 2.6% |
Adolescence | 3 | 2.6% |
Anesthesiology | 3 | 2.6% |
Angiography | 3 | 2.6% |
Artificial intelligence in healthcare | 3 | 2.6% |
Atherosclerosis | 3 | 2.6% |
Bacteria | 3 | 2.6% |
Behavior | 3 | 2.6% |
Bias of an estimator | 3 | 2.6% |
Birth | 3 | 2.6% |
Blinded experiment | 3 | 2.6% |
Breastfeeding | 3 | 2.6% |
COVID-19 pandemic in Papua New Guinea | 3 | 2.6% |
CT pulmonary angiogram | 3 | 2.6% |
Cancer prevention | 3 | 2.6% |
Cardiothoracic surgery | 3 | 2.6% |
Chest radiograph | 3 | 2.6% |
Cholesterol | 3 | 2.6% |
Circulatory system | 3 | 2.6% |
Clinical commissioning group | 3 | 2.6% |
Cognition | 3 | 2.6% |
Confounding | 3 | 2.6% |
Correlation and dependence | 3 | 2.6% |
D-dimer | 3 | 2.6% |
Da Vinci Surgical System | 3 | 2.6% |
Dietary supplement | 3 | 2.6% |
Dieting | 3 | 2.6% |
Disease burden | 3 | 2.6% |
Education | 3 | 2.6% |
Elastography | 3 | 2.6% |
Endocrine system | 3 | 2.6% |
Enga Province | 3 | 2.6% |
Environmental social science | 3 | 2.6% |
Estimator | 3 | 2.6% |
Evaluation | 3 | 2.6% |
Gynaecology | 3 | 2.6% |
Hela Province | 3 | 2.6% |
Hematopoietic stem cell transplantation | 3 | 2.6% |
Hepatitis | 3 | 2.6% |
Human development | 3 | 2.6% |
Immunotherapy | 3 | 2.6% |
Incremental cost-effectiveness ratio | 3 | 2.6% |
Indication (medicine) | 3 | 2.6% |
Infant | 3 | 2.6% |
Innovation | 3 | 2.6% |
Insulin | 3 | 2.6% |
Insurance | 3 | 2.6% |
Internal medicine | 3 | 2.6% |
Kidney | 3 | 2.6% |
Kidney transplantation | 3 | 2.6% |
Laboratory | 3 | 2.6% |
Likelihood function | 3 | 2.6% |
Linear regression | 3 | 2.6% |
Logistic regression | 3 | 2.6% |
Malaria | 3 | 2.6% |
Mammography | 3 | 2.6% |
Mechanical filter (respirator) | 3 | 2.6% |
Medical device | 3 | 2.6% |
Medical tests | 3 | 2.6% |
Multi-drug-resistant tuberculosis | 3 | 2.6% |
Myocardial perfusion imaging | 3 | 2.6% |
Neoplasm | 3 | 2.6% |
Nephrectomy | 3 | 2.6% |
Non-alcoholic fatty liver disease | 3 | 2.6% |
Nuclear medicine | 3 | 2.6% |
Obstetrics | 3 | 2.6% |
Organ transplantation | 3 | 2.6% |
Pain | 3 | 2.6% |
Pap test | 3 | 2.6% |
Parameter | 3 | 2.6% |
Platelet | 3 | 2.6% |
Policy | 3 | 2.6% |
Positive and negative predictive values | 3 | 2.6% |
Pre-exposure prophylaxis | 3 | 2.6% |
Prediabetes | 3 | 2.6% |
Prediction | 3 | 2.6% |
Prescription drug | 3 | 2.6% |
Primary care | 3 | 2.6% |
Recovery approach | 3 | 2.6% |
Respiratory droplet | 3 | 2.6% |
Robot-assisted surgery | 3 | 2.6% |
Science | 3 | 2.6% |
Simulation | 3 | 2.6% |
Statistical classification | 3 | 2.6% |
Type 1 diabetes | 3 | 2.6% |
Urinary tract infection | 3 | 2.6% |
Women's health | 3 | 2.6% |
Accuracy and precision | 2 | 1.7% |
Active surveillance of prostate cancer | 2 | 1.7% |
Acute kidney injury | 2 | 1.7% |
Adjuvant therapy | 2 | 1.7% |
Alcoholism | 2 | 1.7% |
Alzheimer's disease | 2 | 1.7% |
Anatomy | 2 | 1.7% |
Angiology | 2 | 1.7% |
Animal testing | 2 | 1.7% |
Anti-diabetic medication | 2 | 1.7% |
Antigen | 2 | 1.7% |
Aorta | 2 | 1.7% |
Aspirin | 2 | 1.7% |
BCG vaccine | 2 | 1.7% |
Benign tumor | 2 | 1.7% |
Beta cell | 2 | 1.7% |
Biotechnology | 2 | 1.7% |
Birth control | 2 | 1.7% |
Birth weight | 2 | 1.7% |
Blood lead level | 2 | 1.7% |
Body fluids | 2 | 1.7% |
Bone fracture | 2 | 1.7% |
Brachytherapy | 2 | 1.7% |
Caesarean section | 2 | 1.7% |
Carcinogen | 2 | 1.7% |
Carcinogenesis | 2 | 1.7% |
Cardiac stress test | 2 | 1.7% |
Cardiac surgery | 2 | 1.7% |
Cardiotocography | 2 | 1.7% |
Childhood | 2 | 1.7% |
Cirrhosis | 2 | 1.7% |
Coagulation | 2 | 1.7% |
Cochrane Library | 2 | 1.7% |
Cognitive science | 2 | 1.7% |
Colonoscopy | 2 | 1.7% |
Complication (medicine) | 2 | 1.7% |
Computed tomography angiography | 2 | 1.7% |
Computer-aided diagnosis | 2 | 1.7% |
Contact tracing | 2 | 1.7% |
Convolutional neural network | 2 | 1.7% |
Coronary catheterization | 2 | 1.7% |
Cough | 2 | 1.7% |
Current Procedural Terminology | 2 | 1.7% |
Cystectomy | 2 | 1.7% |
Cystoscopy | 2 | 1.7% |
Cytopathology | 2 | 1.7% |
Data analysis | 2 | 1.7% |
Decision-making | 2 | 1.7% |
Deep learning | 2 | 1.7% |
Diabetic retinopathy | 2 | 1.7% |
Diagnosis of HIV/AIDS | 2 | 1.7% |
Dialysis | 2 | 1.7% |
Disability | 2 | 1.7% |
Disease management (health) | 2 | 1.7% |
Disinfectant | 2 | 1.7% |
Disorders of endocrine pancreas | 2 | 1.7% |
Dual-energy X-ray absorptiometry | 2 | 1.7% |
Ejection fraction | 2 | 1.7% |
Emergency management | 2 | 1.7% |
Emergency medicine | 2 | 1.7% |
Endocrinology | 2 | 1.7% |
Endovascular aneurysm repair | 2 | 1.7% |
Epidemic | 2 | 1.7% |
Esophagogastroduodenoscopy | 2 | 1.7% |
Eur-Lex | 2 | 1.7% |
Exhaled nitric oxide | 2 | 1.7% |
Experiment | 2 | 1.7% |
External beam radiotherapy | 2 | 1.7% |
Externality | 2 | 1.7% |
Extracorporeal membrane oxygenation | 2 | 1.7% |
Family medicine | 2 | 1.7% |
Fecal occult blood | 2 | 1.7% |
Fetus | 2 | 1.7% |
Frailty syndrome | 2 | 1.7% |
GeneXpert MTB/RIF | 2 | 1.7% |
General anaesthesia | 2 | 1.7% |
Gestational age | 2 | 1.7% |
Gestational diabetes | 2 | 1.7% |
Global health | 2 | 1.7% |
Goal | 2 | 1.7% |
HIV | 2 | 1.7% |
HPV vaccine | 2 | 1.7% |
Health care in the United States | 2 | 1.7% |
Health data | 2 | 1.7% |
Health informatics | 2 | 1.7% |
Health insurance | 2 | 1.7% |
Hematology | 2 | 1.7% |
Hematuria | 2 | 1.7% |
Hemodialysis | 2 | 1.7% |
Hepatitis C | 2 | 1.7% |
Hepatocellular carcinoma | 2 | 1.7% |
Hip fracture | 2 | 1.7% |
Hip replacement | 2 | 1.7% |
Homelessness | 2 | 1.7% |
Hormone replacement therapy | 2 | 1.7% |
Human anatomy | 2 | 1.7% |
Human diseases and disorders | 2 | 1.7% |
Human eye | 2 | 1.7% |
Hyperglycemia | 2 | 1.7% |
Hypoglycemia | 2 | 1.7% |
Hypothesis | 2 | 1.7% |
Immune system | 2 | 1.7% |
Immunosuppression | 2 | 1.7% |
Influenza vaccine | 2 | 1.7% |
Influenza-like illness | 2 | 1.7% |
Information | 2 | 1.7% |
Insulin (medication) | 2 | 1.7% |
Insulin resistance | 2 | 1.7% |
Interventional radiology | 2 | 1.7% |
Isoniazid | 2 | 1.7% |
Kidney disease | 2 | 1.7% |
Labor induction | 2 | 1.7% |
Laparoscopic radical prostatectomy | 2 | 1.7% |
Lead poisoning | 2 | 1.7% |
Leukemia | 2 | 1.7% |
Liver transplantation | 2 | 1.7% |
Low-density lipoprotein | 2 | 1.7% |
Lung | 2 | 1.7% |
MEDLINE | 2 | 1.7% |
Mammalian pregnancy | 2 | 1.7% |
Management of HIV/AIDS | 2 | 1.7% |
Medical Subject Headings | 2 | 1.7% |
Medical emergency | 2 | 1.7% |
Medical specialty | 2 | 1.7% |
Medicare (United States) | 2 | 1.7% |
Megakaryocyte | 2 | 1.7% |
Melanoma | 2 | 1.7% |
Men who have sex with men | 2 | 1.7% |
Metastasis | 2 | 1.7% |
Metformin | 2 | 1.7% |
Middle East respiratory syndrome | 2 | 1.7% |
Midwife | 2 | 1.7% |
Midwifery | 2 | 1.7% |
Minimally invasive procedure | 2 | 1.7% |
Miscarriage | 2 | 1.7% |
Monitoring (medicine) | 2 | 1.7% |
Mouse | 2 | 1.7% |
N95 respirator | 2 | 1.7% |
NIOSH air filtration rating | 2 | 1.7% |
Nerve | 2 | 1.7% |
Nervous system | 2 | 1.7% |
Nonsteroidal anti-inflammatory drug | 2 | 1.7% |
Nursing home | 2 | 1.7% |
Osteoarthritis | 2 | 1.7% |
Osteoporosis | 2 | 1.7% |
P-value | 2 | 1.7% |
Paracetamol | 2 | 1.7% |
Parenting | 2 | 1.7% |
Pathology of pregnancy, childbirth and the puerperium | 2 | 1.7% |
Patient safety | 2 | 1.7% |
Pediatrics | 2 | 1.7% |
Percutaneous coronary intervention | 2 | 1.7% |
Perinatal mortality | 2 | 1.7% |
Perioperative | 2 | 1.7% |
Perioperative mortality | 2 | 1.7% |
Perioperative nursing | 2 | 1.7% |
Personalized medicine | 2 | 1.7% |
Pharmaceutical industry | 2 | 1.7% |
Pharmacovigilance | 2 | 1.7% |
Phases of clinical research | 2 | 1.7% |
Physical examination | 2 | 1.7% |
Physiology | 2 | 1.7% |
Placebo | 2 | 1.7% |
Plasmodium vivax | 2 | 1.7% |
Platelet transfusion | 2 | 1.7% |
Pneumonia | 2 | 1.7% |
Positron emission tomography | 2 | 1.7% |
Prenatal care | 2 | 1.7% |
Preterm birth | 2 | 1.7% |
Prevalence | 2 | 1.7% |
Prevention | 2 | 1.7% |
Prevention of HIV/AIDS | 2 | 1.7% |
Projectional radiography | 2 | 1.7% |
Propensity score matching | 2 | 1.7% |
Prostate-specific antigen | 2 | 1.7% |
Prothrombin time | 2 | 1.7% |
Psychiatry | 2 | 1.7% |
Public Health Emergency of International Concern | 2 | 1.7% |
Public health surveillance | 2 | 1.7% |
Public sphere | 2 | 1.7% |
Pulmonary function testing | 2 | 1.7% |
Qualitative research | 2 | 1.7% |
Quality-adjusted life year | 2 | 1.7% |
Quarantine | 2 | 1.7% |
Rabies | 2 | 1.7% |
Radiographer | 2 | 1.7% |
Radiosurgery | 2 | 1.7% |
Reference range | 2 | 1.7% |
Relative risk | 2 | 1.7% |
Reproduction in mammals | 2 | 1.7% |
Research methods | 2 | 1.7% |
Respirator fit test | 2 | 1.7% |
Retinopathy | 2 | 1.7% |
Rubella | 2 | 1.7% |
Scenario analysis | 2 | 1.7% |
Scientific method | 2 | 1.7% |
Severe acute respiratory syndrome | 2 | 1.7% |
Severe acute respiratory syndrome coronavirus | 2 | 1.7% |
Single-photon emission computed tomography | 2 | 1.7% |
Sleep | 2 | 1.7% |
Smart city | 2 | 1.7% |
Smoking | 2 | 1.7% |
Smoking cessation | 2 | 1.7% |
Spirometry | 2 | 1.7% |
Stillbirth | 2 | 1.7% |
Sulfonylurea | 2 | 1.7% |
Surgical procedures and techniques | 2 | 1.7% |
Survival analysis | 2 | 1.7% |
Sustainable Development Goals | 2 | 1.7% |
Thorax | 2 | 1.7% |
Thrombocytopenia | 2 | 1.7% |
Thrombopoietin | 2 | 1.7% |
Thrombosis prevention | 2 | 1.7% |
Tissues (biology) | 2 | 1.7% |
Tobacco smoking | 2 | 1.7% |
Tomography | 2 | 1.7% |
Tracheal intubation | 2 | 1.7% |
Training | 2 | 1.7% |
Transient ischemic attack | 2 | 1.7% |
Transmission of COVID-19 | 2 | 1.7% |
Traumatic brain injury | 2 | 1.7% |
Tuberculosis management | 2 | 1.7% |
Unlicensed assistive personnel | 2 | 1.7% |
Urinary bladder | 2 | 1.7% |
Urinary incontinence | 2 | 1.7% |
Vascular surgery | 2 | 1.7% |
Ventricular natriuretic peptide | 2 | 1.7% |
Vitamin | 2 | 1.7% |
Vitamin D | 2 | 1.7% |
Warfarin | 2 | 1.7% |
Weight loss | 2 | 1.7% |
Women | 2 | 1.7% |
X-ray | 2 | 1.7% |
Zoonosis | 2 | 1.7% |
2,3,7,8-Tetrachlorodibenzodioxin | 1 | 0.9% |
ACE inhibitor | 1 | 0.9% |
ASA physical status classification system | 1 | 0.9% |
Abdomen | 1 | 0.9% |
Abdominal aortic aneurysm | 1 | 0.9% |
Accessibility | 1 | 0.9% |
Acetabular labrum | 1 | 0.9% |
Acromegaly | 1 | 0.9% |
Acute myeloid leukemia | 1 | 0.9% |
Acute respiratory distress syndrome | 1 | 0.9% |
Adalimumab | 1 | 0.9% |
Adaptive immune system | 1 | 0.9% |
Addiction | 1 | 0.9% |
Adenocarcinoma | 1 | 0.9% |
Adenoma | 1 | 0.9% |
Adenoviridae | 1 | 0.9% |
Adipose tissue | 1 | 0.9% |
Advanced practice nurse | 1 | 0.9% |
Aedes aegypti | 1 | 0.9% |
Aflibercept | 1 | 0.9% |
Ageing | 1 | 0.9% |
Air pollution | 1 | 0.9% |
Airborne transmission | 1 | 0.9% |
Airway management | 1 | 0.9% |
Alanine transaminase | 1 | 0.9% |
Alcohol advertising | 1 | 0.9% |
Alcohol and cancer | 1 | 0.9% |
Aldosterone | 1 | 0.9% |
Algorithm | 1 | 0.9% |
Allocation concealment | 1 | 0.9% |
Ambulance | 1 | 0.9% |
Anal sex | 1 | 0.9% |
Analgesic | 1 | 0.9% |
Analysis | 1 | 0.9% |
Analysis of variance | 1 | 0.9% |
Analytics | 1 | 0.9% |
Anatomical terms of location | 1 | 0.9% |
Anatomical terms of motion | 1 | 0.9% |
Androgen deprivation therapy | 1 | 0.9% |
Aneurysm | 1 | 0.9% |
Angiotensin | 1 | 0.9% |
Angiotensin II receptor blocker | 1 | 0.9% |
Angiotensin-converting enzyme | 1 | 0.9% |
Animal diseases | 1 | 0.9% |
Animal viral diseases | 1 | 0.9% |
Animal virology | 1 | 0.9% |
Animal welfare | 1 | 0.9% |
Anomaly scan | 1 | 0.9% |
Antenatal steroid | 1 | 0.9% |
Anthracycline | 1 | 0.9% |
Antibody | 1 | 0.9% |
Antifungal | 1 | 0.9% |
Antihypertensive drug | 1 | 0.9% |
Antimalarial medication | 1 | 0.9% |
Antimineralocorticoid | 1 | 0.9% |
Antiphospholipid syndrome | 1 | 0.9% |
Antiplatelet drug | 1 | 0.9% |
Antiserum | 1 | 0.9% |
Antivenom | 1 | 0.9% |
Aortic aneurysm | 1 | 0.9% |
Aortic dissection | 1 | 0.9% |
Aortic stenosis | 1 | 0.9% |
Apolipoprotein | 1 | 0.9% |
Apolipoprotein B | 1 | 0.9% |
Apolipoprotein L1 | 1 | 0.9% |
Appendectomy | 1 | 0.9% |
Appendicitis | 1 | 0.9% |
Application software | 1 | 0.9% |
Applied behavior analysis | 1 | 0.9% |
Arabs | 1 | 0.9% |
Arrhythmia | 1 | 0.9% |
Artemisinin | 1 | 0.9% |
Arthritis | 1 | 0.9% |
Arthrogram | 1 | 0.9% |
Arthroscopy | 1 | 0.9% |
Artificial cardiac pacemaker | 1 | 0.9% |
Artificial kidney | 1 | 0.9% |
Artificial neural network | 1 | 0.9% |
Asbestos | 1 | 0.9% |
Asperger syndrome | 1 | 0.9% |
Assay | 1 | 0.9% |
Assessment of kidney function | 1 | 0.9% |
Assisted living | 1 | 0.9% |
Assumption | 1 | 0.9% |
Atmosphere of Earth | 1 | 0.9% |
Atorvastatin | 1 | 0.9% |
Atrial septal defect | 1 | 0.9% |
Attention | 1 | 0.9% |
Autism | 1 | 0.9% |
Autism spectrum | 1 | 0.9% |
Autism therapies | 1 | 0.9% |
Autologous chondrocyte implantation | 1 | 0.9% |
Autonomic nervous system | 1 | 0.9% |
Avascular necrosis | 1 | 0.9% |
Average treatment effect | 1 | 0.9% |
Avian influenza | 1 | 0.9% |
BRCA mutation | 1 | 0.9% |
Basal metabolic rate | 1 | 0.9% |
Behavioural sciences | 1 | 0.9% |
Benjamin Netanyahu | 1 | 0.9% |
Best practice | 1 | 0.9% |
Bethesda system | 1 | 0.9% |
Bevacizumab | 1 | 0.9% |
Bias | 1 | 0.9% |
Biomedical waste | 1 | 0.9% |
Biopharmaceutical | 1 | 0.9% |
Biosafety | 1 | 0.9% |
Biosimilar | 1 | 0.9% |
Bipolar disorder | 1 | 0.9% |
Birth defect | 1 | 0.9% |
Black Death | 1 | 0.9% |
Blast injury | 1 | 0.9% |
Bleach | 1 | 0.9% |
Blepharoplasty | 1 | 0.9% |
Blood glucose monitoring | 1 | 0.9% |
Blood plasma | 1 | 0.9% |
Blood-borne disease | 1 | 0.9% |
Body composition | 1 | 0.9% |
Bone | 1 | 0.9% |
Borrelia | 1 | 0.9% |
Bourbon virus | 1 | 0.9% |
Brachial plexus | 1 | 0.9% |
Brain | 1 | 0.9% |
Brain metastasis | 1 | 0.9% |
Brassica | 1 | 0.9% |
Broccoli | 1 | 0.9% |
Bronchiectasis | 1 | 0.9% |
Bubonic plague | 1 | 0.9% |
COVID-19 Surveillance | 1 | 0.9% |
COVID-19 pandemic in New Jersey | 1 | 0.9% |
COVID-19 pandemic in the United Kingdom | 1 | 0.9% |
COVID-19 vaccine | 1 | 0.9% |
COX-2 inhibitor | 1 | 0.9% |
Calcium | 1 | 0.9% |
Canagliflozin | 1 | 0.9% |
Cancer immunotherapy | 1 | 0.9% |
Cancer rehabilitation | 1 | 0.9% |
Cancer staging | 1 | 0.9% |
Cancer syndrome | 1 | 0.9% |
Candidiasis | 1 | 0.9% |
Capacity building | 1 | 0.9% |
Carbon tax | 1 | 0.9% |
Carboplatin | 1 | 0.9% |
Carcinoma | 1 | 0.9% |
Cardiac imaging | 1 | 0.9% |
Cardiac muscle | 1 | 0.9% |
Cardiac rehabilitation | 1 | 0.9% |
Cardiomyopathy | 1 | 0.9% |
Carlos Finlay | 1 | 0.9% |
Cartilage | 1 | 0.9% |
Case–control study | 1 | 0.9% |
Causes of cancer | 1 | 0.9% |
Central nervous system | 1 | 0.9% |
Cerebral cortex | 1 | 0.9% |
Cerebrovascular disease | 1 | 0.9% |
Certified Registered Nurse Anesthetist | 1 | 0.9% |
Certified reference materials | 1 | 0.9% |
Cervical cerclage | 1 | 0.9% |
Cervical intraepithelial neoplasia | 1 | 0.9% |
Cervix | 1 | 0.9% |
Chalazion | 1 | 0.9% |
Chikungunya | 1 | 0.9% |
Childhood cancer | 1 | 0.9% |
Chimbu Province | 1 | 0.9% |
Chimeric antigen receptor T cell | 1 | 0.9% |
Chlamydia | 1 | 0.9% |
Chloroquine | 1 | 0.9% |
Chronic care | 1 | 0.9% |
Chronic care management | 1 | 0.9% |
Chronic myelomonocytic leukemia | 1 | 0.9% |
Chronic thromboembolic pulmonary hypertension | 1 | 0.9% |
Cigarette | 1 | 0.9% |
Cisplatin | 1 | 0.9% |
Cleaning agent | 1 | 0.9% |
Clinic | 1 | 0.9% |
Clinical decision support system | 1 | 0.9% |
Clinical pathology | 1 | 0.9% |
Clostridioides difficile infection | 1 | 0.9% |
Clotrimazole | 1 | 0.9% |
Coefficient of determination | 1 | 0.9% |
Colposcopy | 1 | 0.9% |
Combined oral contraceptive pill | 1 | 0.9% |
Community health worker | 1 | 0.9% |
Complexity | 1 | 0.9% |
Complications of diabetes | 1 | 0.9% |
Condom | 1 | 0.9% |
Congenital heart defect | 1 | 0.9% |
Content analysis | 1 | 0.9% |
Coronary CT angiography | 1 | 0.9% |
Coronary CT calcium scan | 1 | 0.9% |
Coronary artery bypass surgery | 1 | 0.9% |
Coronary circulation | 1 | 0.9% |
Coronaviridae | 1 | 0.9% |
Corticosteroid | 1 | 0.9% |
Cost–benefit analysis | 1 | 0.9% |
Cost–utility analysis | 1 | 0.9% |
Country of origin | 1 | 0.9% |
Creatinine | 1 | 0.9% |
Crush syndrome | 1 | 0.9% |
Curriculum | 1 | 0.9% |
Cushing's disease | 1 | 0.9% |
Cushing's syndrome | 1 | 0.9% |
Cystic fibrosis | 1 | 0.9% |
DNA sequencing | 1 | 0.9% |
Darbepoetin alfa | 1 | 0.9% |
Death | 1 | 0.9% |
Decompression sickness | 1 | 0.9% |
Dengue fever | 1 | 0.9% |
Depression (mood) | 1 | 0.9% |
Determinants of health | 1 | 0.9% |
Diabetes medication | 1 | 0.9% |
Diabetic ketoacidosis | 1 | 0.9% |
Diagnostic and Statistical Manual of Mental Disorders | 1 | 0.9% |
Diarrhea | 1 | 0.9% |
Diet (nutrition) | 1 | 0.9% |
Digital pathology | 1 | 0.9% |
Disability-adjusted life year | 1 | 0.9% |
Discrete trial training | 1 | 0.9% |
Disseminated intravascular coagulation | 1 | 0.9% |
Docetaxel | 1 | 0.9% |
Dog | 1 | 0.9% |
Dosimetry | 1 | 0.9% |
Drug | 1 | 0.9% |
Duodenum | 1 | 0.9% |
Dysglycemia | 1 | 0.9% |
EHealth | 1 | 0.9% |
Eating | 1 | 0.9% |
Ebola | 1 | 0.9% |
Ebola virus disease | 1 | 0.9% |
Economics | 1 | 0.9% |
Educational assessment | 1 | 0.9% |
Effect size | 1 | 0.9% |
Electroencephalography | 1 | 0.9% |
Electromyography | 1 | 0.9% |
Electronic cigarette | 1 | 0.9% |
Emergency medical services | 1 | 0.9% |
Emotional eating | 1 | 0.9% |
Empagliflozin | 1 | 0.9% |
Employee Retirement Income Security Act of 1974 | 1 | 0.9% |
Employment | 1 | 0.9% |
End-of-life care | 1 | 0.9% |
Endocrine pancreas | 1 | 0.9% |
Endometrial cancer | 1 | 0.9% |
Enoxaparin sodium | 1 | 0.9% |
Entropy | 1 | 0.9% |
Epidermal growth factor receptor | 1 | 0.9% |
Epididymis | 1 | 0.9% |
Epigenomics | 1 | 0.9% |
Epithelium | 1 | 0.9% |
Eradication of infectious diseases | 1 | 0.9% |
Erythrocyte sedimentation rate | 1 | 0.9% |
Erythropoietin | 1 | 0.9% |
Essential health benefits | 1 | 0.9% |
Estrous cycle | 1 | 0.9% |
European polecat | 1 | 0.9% |
Evaluation methods | 1 | 0.9% |
Everolimus | 1 | 0.9% |
Evidence | 1 | 0.9% |
Exercise prescription | 1 | 0.9% |
Exhalation | 1 | 0.9% |
Exophthalmos | 1 | 0.9% |
External validity | 1 | 0.9% |
Extracellular matrix | 1 | 0.9% |
Eye care | 1 | 0.9% |
Eye neoplasm | 1 | 0.9% |
Eye protection | 1 | 0.9% |
Eye surgery | 1 | 0.9% |
Eyelid | 1 | 0.9% |
Ezetimibe | 1 | 0.9% |
FFP standards | 1 | 0.9% |
Face shield | 1 | 0.9% |
Facial trauma | 1 | 0.9% |
Familial hypercholesterolemia | 1 | 0.9% |
Fatty liver disease | 1 | 0.9% |
Femoral artery | 1 | 0.9% |
Femoroacetabular impingement | 1 | 0.9% |
Fentanyl | 1 | 0.9% |
Ferret | 1 | 0.9% |
Fetal alcohol spectrum disorder | 1 | 0.9% |
Five Year Forward View | 1 | 0.9% |
Folate | 1 | 0.9% |
Food frequency questionnaire | 1 | 0.9% |
Fraction (mathematics) | 1 | 0.9% |
Fraction of inspired oxygen | 1 | 0.9% |
Fractional flow reserve | 1 | 0.9% |
Francisco Javier de Balmis | 1 | 0.9% |
Frozen section procedure | 1 | 0.9% |
Fructosamine | 1 | 0.9% |
Fundus photography | 1 | 0.9% |
Gastrointestinal bleeding | 1 | 0.9% |
Gastrointestinal tract | 1 | 0.9% |
Gaza Strip | 1 | 0.9% |
Gemcitabine | 1 | 0.9% |
Gene | 1 | 0.9% |
Gene therapy | 1 | 0.9% |
General surgery | 1 | 0.9% |
Genetic engineering | 1 | 0.9% |
Genetic testing | 1 | 0.9% |
Genetics | 1 | 0.9% |
Genotoxicity | 1 | 0.9% |
Geriatrics | 1 | 0.9% |
Germline mutation | 1 | 0.9% |
Gestational trophoblastic disease | 1 | 0.9% |
Giant-cell arteritis | 1 | 0.9% |
Glands | 1 | 0.9% |
Glasses | 1 | 0.9% |
Glaucoma | 1 | 0.9% |
Glove | 1 | 0.9% |
Glucagon-like peptide-1 | 1 | 0.9% |
Glucose | 1 | 0.9% |
Glucose test | 1 | 0.9% |
Glucose tolerance test | 1 | 0.9% |
Glucose-6-phosphate dehydrogenase deficiency | 1 | 0.9% |
Glutamate dehydrogenase | 1 | 0.9% |
Good manufacturing practice | 1 | 0.9% |
Government | 1 | 0.9% |
Granulocyte colony-stimulating factor | 1 | 0.9% |
Graves' ophthalmopathy | 1 | 0.9% |
Gray (unit) | 1 | 0.9% |
Greater trochanteric pain syndrome | 1 | 0.9% |
Ground-glass opacity | 1 | 0.9% |
Growth hormone | 1 | 0.9% |
Gunshot wound | 1 | 0.9% |
Gynaecologic disorders | 1 | 0.9% |
HER2/neu | 1 | 0.9% |
HIV-positive people | 1 | 0.9% |
Haemaphysalis longicornis | 1 | 0.9% |
Hazard ratio | 1 | 0.9% |
Head and neck cancer | 1 | 0.9% |
Health care quality | 1 | 0.9% |
Health education | 1 | 0.9% |
Health literacy | 1 | 0.9% |
Health reimbursement account | 1 | 0.9% |
Health technology | 1 | 0.9% |
Health technology assessment | 1 | 0.9% |
Health technology in the United States | 1 | 0.9% |
Healthcare industry | 1 | 0.9% |
Healthy diet | 1 | 0.9% |
Heart failure with preserved ejection fraction | 1 | 0.9% |
Heart valve | 1 | 0.9% |
Helicobacter | 1 | 0.9% |
Helicobacter pylori | 1 | 0.9% |
Hemofiltration | 1 | 0.9% |
Heparin | 1 | 0.9% |
Hepatitis B | 1 | 0.9% |
Herd immunity | 1 | 0.9% |
Herpes simplex | 1 | 0.9% |
Hierarchy of evidence | 1 | 0.9% |
High-density lipoprotein | 1 | 0.9% |
High-intensity focused ultrasound | 1 | 0.9% |
Hip arthroscopy | 1 | 0.9% |
Hip dislocation | 1 | 0.9% |
Hip pain | 1 | 0.9% |
Histology | 1 | 0.9% |
Hospital-acquired infection | 1 | 0.9% |
Human | 1 | 0.9% |
Human betaherpesvirus 5 | 1 | 0.9% |
Human chorionic gonadotropin | 1 | 0.9% |
Human orthopneumovirus | 1 | 0.9% |
Human sexuality | 1 | 0.9% |
Hypercholesterolemia | 1 | 0.9% |
Hyperkalemia | 1 | 0.9% |
Hyperlipidemia | 1 | 0.9% |
Hyperprolactinaemia | 1 | 0.9% |
Hyperthermia therapy | 1 | 0.9% |
Hypokalemia | 1 | 0.9% |
Hypopituitarism | 1 | 0.9% |
Hypoxemia | 1 | 0.9% |
ISO/IEC 27001 | 1 | 0.9% |
Ibuprofen | 1 | 0.9% |
Image scanner | 1 | 0.9% |
Immunoassay | 1 | 0.9% |
Immunoglobulin G | 1 | 0.9% |
Immunoglobulin M | 1 | 0.9% |
Immunosuppressive drug | 1 | 0.9% |
Imputation (statistics) | 1 | 0.9% |
Indigenous Australians | 1 | 0.9% |
Individualized Education Program | 1 | 0.9% |
Indole-3-carbinol | 1 | 0.9% |
Indoor tanning | 1 | 0.9% |
Infant mortality | 1 | 0.9% |
Inflammation | 1 | 0.9% |
Influenza pandemic | 1 | 0.9% |
Information security management | 1 | 0.9% |
Insect-borne diseases | 1 | 0.9% |
Intelligence quotient | 1 | 0.9% |
Intention-to-treat analysis | 1 | 0.9% |
Interleukin | 1 | 0.9% |
Intermittent preventive therapy | 1 | 0.9% |
Internal validity | 1 | 0.9% |
Intracranial pressure | 1 | 0.9% |
Intrauterine growth restriction | 1 | 0.9% |
Intravenous therapy | 1 | 0.9% |
Invasive species | 1 | 0.9% |
Ionizing radiation | 1 | 0.9% |
Ischemia | 1 | 0.9% |
Israeli settlement | 1 | 0.9% |
Issues in ethics | 1 | 0.9% |
Jejunum | 1 | 0.9% |
Jerusalem | 1 | 0.9% |
Kaplan–Meier estimator | 1 | 0.9% |
Knee | 1 | 0.9% |
Laboratory information management system | 1 | 0.9% |
Laboratory rat | 1 | 0.9% |
Laminoplasty | 1 | 0.9% |
Laparotomy | 1 | 0.9% |
Laser coagulation | 1 | 0.9% |
Lasso (statistics) | 1 | 0.9% |
Legislation | 1 | 0.9% |
Lenalidomide | 1 | 0.9% |
Lentiviruses | 1 | 0.9% |
License | 1 | 0.9% |
Licensure | 1 | 0.9% |
Likelihood ratios in diagnostic testing | 1 | 0.9% |
Lipoprotein | 1 | 0.9% |
Lipoprotein(a) | 1 | 0.9% |
Liraglutide | 1 | 0.9% |
Liver | 1 | 0.9% |
Logistics | 1 | 0.9% |
Long-term care | 1 | 0.9% |
Long-term effects of alcohol | 1 | 0.9% |
Long-term effects of alcohol consumption | 1 | 0.9% |
Loop diuretic | 1 | 0.9% |
Lung nodule | 1 | 0.9% |
Lupus | 1 | 0.9% |
Lyme disease | 1 | 0.9% |
Lymphadenectomy | 1 | 0.9% |
Lymphatic system | 1 | 0.9% |
Lymphatic vessel | 1 | 0.9% |
MMR vaccine | 1 | 0.9% |
Macular degeneration | 1 | 0.9% |
Magnesium | 1 | 0.9% |
Magnesium deficiency | 1 | 0.9% |
Magnetoencephalography | 1 | 0.9% |
Major trauma | 1 | 0.9% |
Male genital disorders | 1 | 0.9% |
Malignancy | 1 | 0.9% |
Management | 1 | 0.9% |
Management of COVID-19 | 1 | 0.9% |
Management of hypertension | 1 | 0.9% |
Mantoux test | 1 | 0.9% |
Manufacturing | 1 | 0.9% |
Manus Island | 1 | 0.9% |
Mass-casualty incident | 1 | 0.9% |
Maternal death | 1 | 0.9% |
Maternal–fetal medicine | 1 | 0.9% |
Mathematical and quantitative methods (economics) | 1 | 0.9% |
Median | 1 | 0.9% |
Medical cannabis | 1 | 0.9% |
Medical emergencies | 1 | 0.9% |
Medical equipment | 1 | 0.9% |
Medical laboratory | 1 | 0.9% |
Medical laboratory scientist | 1 | 0.9% |
Medical microbiology | 1 | 0.9% |
Medical physics | 1 | 0.9% |
Medical record | 1 | 0.9% |
Medical ventilator | 1 | 0.9% |
Memory | 1 | 0.9% |
Meningococcal disease | 1 | 0.9% |
Meningococcal vaccine | 1 | 0.9% |
Menopause | 1 | 0.9% |
Mental disorder | 1 | 0.9% |
Meralgia paraesthetica | 1 | 0.9% |
Meta-regression | 1 | 0.9% |
Metabolic syndrome | 1 | 0.9% |
Metabolomics | 1 | 0.9% |
Micronucleus | 1 | 0.9% |
Micronucleus test | 1 | 0.9% |
Midazolam | 1 | 0.9% |
Middle East respiratory syndrome-related coronavirus | 1 | 0.9% |
Middle East respiratory syndrome–related coronavirus | 1 | 0.9% |
Misoprostol | 1 | 0.9% |
Missing data | 1 | 0.9% |
Mitral valve replacement | 1 | 0.9% |
Model organism | 1 | 0.9% |
Morobe Province | 1 | 0.9% |
Mosquito | 1 | 0.9% |
Mosquito-borne disease | 1 | 0.9% |
Multidrug-resistant tuberculosis | 1 | 0.9% |
Multiple comparisons problem | 1 | 0.9% |
Multiple myeloma | 1 | 0.9% |
Mustelidae | 1 | 0.9% |
Mutagen | 1 | 0.9% |
Mutation | 1 | 0.9% |
Mycoplasma | 1 | 0.9% |
Myelodysplastic syndrome | 1 | 0.9% |
Myocarditis | 1 | 0.9% |
Myrosinase | 1 | 0.9% |
Naproxen | 1 | 0.9% |
Nasolacrimal duct obstruction | 1 | 0.9% |
National coverage determination | 1 | 0.9% |
National security | 1 | 0.9% |
Natural reservoir | 1 | 0.9% |
Naypyidaw | 1 | 0.9% |
Necrotizing fasciitis | 1 | 0.9% |
Neisseria meningitidis | 1 | 0.9% |
Neonatal intensive care unit | 1 | 0.9% |
Nerve compression syndrome | 1 | 0.9% |
Nerve conduction study | 1 | 0.9% |
Neural tube defect | 1 | 0.9% |
Neuroimaging | 1 | 0.9% |
Neuron | 1 | 0.9% |
Neuroplasticity | 1 | 0.9% |
Neuroscience | 1 | 0.9% |
Neurostimulation | 1 | 0.9% |
Neurosurgery | 1 | 0.9% |
Neutralizing antibody | 1 | 0.9% |
New Britain | 1 | 0.9% |
Nicotine | 1 | 0.9% |
Nidovirales | 1 | 0.9% |
Non-governmental organization | 1 | 0.9% |
Non-invasive ventilation | 1 | 0.9% |
Non-small-cell lung carcinoma | 1 | 0.9% |
Nuclear safety and security | 1 | 0.9% |
Null hypothesis | 1 | 0.9% |
Nurse practitioner | 1 | 0.9% |
Nutri-Score | 1 | 0.9% |
Nutrition | 1 | 0.9% |
Occult fracture | 1 | 0.9% |
Oculoplastics | 1 | 0.9% |
Omics | 1 | 0.9% |
Oncology | 1 | 0.9% |
Oncovirus | 1 | 0.9% |
Opioid | 1 | 0.9% |
Optic neuropathy | 1 | 0.9% |
Orbit (anatomy) | 1 | 0.9% |
Orbital blowout fracture | 1 | 0.9% |
Organ donation | 1 | 0.9% |
Organisms | 1 | 0.9% |
Osteopathy | 1 | 0.9% |
Otorhinolaryngology | 1 | 0.9% |
Ovarian cancer | 1 | 0.9% |
Over-the-counter drug | 1 | 0.9% |
Overdispersion | 1 | 0.9% |
Oxygen saturation (medicine) | 1 | 0.9% |
Oxygen therapy | 1 | 0.9% |
Ozone depletion | 1 | 0.9% |
PCSK9 | 1 | 0.9% |
PET-CT | 1 | 0.9% |
Paclitaxel | 1 | 0.9% |
Pain management | 1 | 0.9% |
Palestinian territories | 1 | 0.9% |
Pancreas | 1 | 0.9% |
Pancreaticoduodenectomy | 1 | 0.9% |
Pancreatitis | 1 | 0.9% |
Pandemics | 1 | 0.9% |
Papillomaviridae | 1 | 0.9% |
Paramedic | 1 | 0.9% |
Paresthesia | 1 | 0.9% |
Passive smoking | 1 | 0.9% |
Pathogen | 1 | 0.9% |
Patient Protection and Affordable Care Act | 1 | 0.9% |
Patiromer | 1 | 0.9% |
Pelvis | 1 | 0.9% |
Pembrolizumab | 1 | 0.9% |
Penetrating trauma | 1 | 0.9% |
Perception | 1 | 0.9% |
Perfusion | 1 | 0.9% |
Pericarditis | 1 | 0.9% |
Pericardium | 1 | 0.9% |
Peripheral artery disease | 1 | 0.9% |
Peripheral nervous system | 1 | 0.9% |
Pervasive developmental disorder | 1 | 0.9% |
Pervasive developmental disorder not otherwise specified | 1 | 0.9% |
Pesticide | 1 | 0.9% |
Pet | 1 | 0.9% |
Pharmacist | 1 | 0.9% |
Pharmacogenomics | 1 | 0.9% |
Pharmacy | 1 | 0.9% |
Physical fitness | 1 | 0.9% |
Physician Orders for Life-Sustaining Treatment | 1 | 0.9% |
Physician supply | 1 | 0.9% |
Pioglitazone | 1 | 0.9% |
Piperaquine | 1 | 0.9% |
Pituitary adenoma | 1 | 0.9% |
Placebo-controlled study | 1 | 0.9% |
Plain language | 1 | 0.9% |
Plasmodium | 1 | 0.9% |
Plasmodium falciparum | 1 | 0.9% |
Plasmodium knowlesi | 1 | 0.9% |
Plasmodium ovale | 1 | 0.9% |
Plastic surgery | 1 | 0.9% |
Point-of-care testing | 1 | 0.9% |
Poisson distribution | 1 | 0.9% |
Polio | 1 | 0.9% |
Polio eradication | 1 | 0.9% |
Polio vaccine | 1 | 0.9% |
Poliovirus | 1 | 0.9% |
Pollution | 1 | 0.9% |
Polymerase chain reaction | 1 | 0.9% |
Polysomnography | 1 | 0.9% |
Polystyrene sulfonate | 1 | 0.9% |
Positive airway pressure | 1 | 0.9% |
Post-exposure prophylaxis | 1 | 0.9% |
Post-thrombotic syndrome | 1 | 0.9% |
Potassium | 1 | 0.9% |
Potassium binder | 1 | 0.9% |
Poverty | 1 | 0.9% |
Powassan virus | 1 | 0.9% |
Power of a test | 1 | 0.9% |
Powered air-purifying respirator | 1 | 0.9% |
Pravastatin | 1 | 0.9% |
Pre-eclampsia | 1 | 0.9% |
Precision and recall | 1 | 0.9% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 1 | 0.9% |
Preventive medicine | 1 | 0.9% |
Primaquine | 1 | 0.9% |
Primary immunodeficiency | 1 | 0.9% |
Procalcitonin | 1 | 0.9% |
Prolactinoma | 1 | 0.9% |
Prolotherapy | 1 | 0.9% |
Proportional hazards model | 1 | 0.9% |
Prostate biopsy | 1 | 0.9% |
Prostate cancer screening | 1 | 0.9% |
Proton-pump inhibitor | 1 | 0.9% |
Protozoal diseases | 1 | 0.9% |
Pseudoaneurysm | 1 | 0.9% |
Psychiatric history | 1 | 0.9% |
Psychology | 1 | 0.9% |
Psychosis | 1 | 0.9% |
Psychotherapy | 1 | 0.9% |
Ptosis (eyelid) | 1 | 0.9% |
Public health genomics | 1 | 0.9% |
Public policy | 1 | 0.9% |
Public services | 1 | 0.9% |
Pulmonary fibrosis | 1 | 0.9% |
Pulmonology | 1 | 0.9% |
Pulse oximetry | 1 | 0.9% |
QRISK | 1 | 0.9% |
Quality and Outcomes Framework | 1 | 0.9% |
QuantiFERON | 1 | 0.9% |
RET proto-oncogene | 1 | 0.9% |
ROS1 | 1 | 0.9% |
Rabies in animals | 1 | 0.9% |
Rabies vaccine | 1 | 0.9% |
Rabies virus | 1 | 0.9% |
Radiation protection | 1 | 0.9% |
Radiomics | 1 | 0.9% |
Radiopharmaceutical | 1 | 0.9% |
Radon | 1 | 0.9% |
Ranibizumab | 1 | 0.9% |
Ratio | 1 | 0.9% |
Readability | 1 | 0.9% |
Regeneration (biology) | 1 | 0.9% |
Regulation | 1 | 0.9% |
Regulatory affairs | 1 | 0.9% |
Remote dispensing | 1 | 0.9% |
Renal cell carcinoma | 1 | 0.9% |
Renin | 1 | 0.9% |
Reperfusion therapy | 1 | 0.9% |
Reporting bias | 1 | 0.9% |
Residency (medicine) | 1 | 0.9% |
Respiratory system | 1 | 0.9% |
Respiratory therapist | 1 | 0.9% |
Retroviridae | 1 | 0.9% |
Reuse | 1 | 0.9% |
Revised Cardiac Risk Index | 1 | 0.9% |
Rhabdomyolysis | 1 | 0.9% |
Rheumatoid arthritis | 1 | 0.9% |
Rhinorrhea | 1 | 0.9% |
Rifampicin | 1 | 0.9% |
Risk management | 1 | 0.9% |
Rivaroxaban | 1 | 0.9% |
Robotics | 1 | 0.9% |
Robust statistics | 1 | 0.9% |
Rosuvastatin | 1 | 0.9% |
SARS-CoV-2 | 1 | 0.9% |
SGLT2 inhibitor | 1 | 0.9% |
Sacrum | 1 | 0.9% |
Safe sex | 1 | 0.9% |
Sample (statistics) | 1 | 0.9% |
Sample size determination | 1 | 0.9% |
Sampling (statistics) | 1 | 0.9% |
Sarcopenia | 1 | 0.9% |
Schizophrenia | 1 | 0.9% |
Self-assessment | 1 | 0.9% |
Sentence (linguistics) | 1 | 0.9% |
Sequential analysis | 1 | 0.9% |
Seroconversion | 1 | 0.9% |
Sexual anatomy | 1 | 0.9% |
Sexual health | 1 | 0.9% |
Sexual intercourse | 1 | 0.9% |
Sexually transmitted diseases and infections | 1 | 0.9% |
Sexually transmitted infection | 1 | 0.9% |
Shared decision-making in medicine | 1 | 0.9% |
Ship | 1 | 0.9% |
Shoulder | 1 | 0.9% |
Shoulder impingement syndrome | 1 | 0.9% |
Sideroblastic anemia | 1 | 0.9% |
Sigmoidoscopy | 1 | 0.9% |
Simvastatin | 1 | 0.9% |
Single-payer healthcare | 1 | 0.9% |
Sirolimus | 1 | 0.9% |
Skin cancer | 1 | 0.9% |
Sleep apnea | 1 | 0.9% |
Small for gestational age | 1 | 0.9% |
Small intestine | 1 | 0.9% |
Small-cell carcinoma | 1 | 0.9% |
Smallpox | 1 | 0.9% |
Snakebite | 1 | 0.9% |
Social isolation | 1 | 0.9% |
Social work | 1 | 0.9% |
Source control (respiratory disease) | 1 | 0.9% |
Spanish flu | 1 | 0.9% |
Specialty (medicine) | 1 | 0.9% |
Spinal fusion | 1 | 0.9% |
Statistical analysis | 1 | 0.9% |
Statistical hypothesis testing | 1 | 0.9% |
Statistical methods | 1 | 0.9% |
Statistical significance | 1 | 0.9% |
Stereotactic surgery | 1 | 0.9% |
Stomach cancer | 1 | 0.9% |
Strain (injury) | 1 | 0.9% |
Strength training | 1 | 0.9% |
Stress (biology) | 1 | 0.9% |
Stress hyperglycemia | 1 | 0.9% |
Subclavian artery | 1 | 0.9% |
Substance abuse | 1 | 0.9% |
Substance dependence | 1 | 0.9% |
Substance use disorder | 1 | 0.9% |
Sun tanning | 1 | 0.9% |
Supply chain management | 1 | 0.9% |
Support-vector machine | 1 | 0.9% |
Surveillance | 1 | 0.9% |
Sustainability | 1 | 0.9% |
Sympathetic nervous system | 1 | 0.9% |
Symptoms of COVID-19 | 1 | 0.9% |
System | 1 | 0.9% |
Systole | 1 | 0.9% |
Tabubil | 1 | 0.9% |
Tacrolimus | 1 | 0.9% |
Tattoo | 1 | 0.9% |
Telecommuting | 1 | 0.9% |
Telepharmacy | 1 | 0.9% |
Tendinopathy | 1 | 0.9% |
The Hallmarks of Cancer | 1 | 0.9% |
Thromboelastography | 1 | 0.9% |
Thromboelastometry | 1 | 0.9% |
Thrombophilia | 1 | 0.9% |
Thyroid-stimulating hormone | 1 | 0.9% |
Tibia | 1 | 0.9% |
Tick | 1 | 0.9% |
Tissue Doppler echocardiography | 1 | 0.9% |
Toilet | 1 | 0.9% |
Toxicity | 1 | 0.9% |
Tozinameran | 1 | 0.9% |
Transesophageal echocardiogram | 1 | 0.9% |
Transfusion medicine | 1 | 0.9% |
Transplant rejection | 1 | 0.9% |
Tree of life (biology) | 1 | 0.9% |
Tropical diseases | 1 | 0.9% |
Troponin | 1 | 0.9% |
Tuberculosis diagnosis | 1 | 0.9% |
Tyrosine kinase | 1 | 0.9% |
Ultraviolet | 1 | 0.9% |
United Nations Security Council Resolution 478 | 1 | 0.9% |
United States budget sequestration in 2013 | 1 | 0.9% |
Universal precautions | 1 | 0.9% |
Upper gastrointestinal series | 1 | 0.9% |
Urinary system | 1 | 0.9% |
Urological conditions | 1 | 0.9% |
VO2 max | 1 | 0.9% |
Vaccine efficacy | 1 | 0.9% |
Vagina | 1 | 0.9% |
Validity (statistics) | 1 | 0.9% |
Valvular heart disease | 1 | 0.9% |
Variance | 1 | 0.9% |
Vector (epidemiology) | 1 | 0.9% |
Vector control | 1 | 0.9% |
Vein | 1 | 0.9% |
Ventilator | 1 | 0.9% |
Ventricle (heart) | 1 | 0.9% |
Ventricular hypertrophy | 1 | 0.9% |
Verification and validation | 1 | 0.9% |
Vertebral column | 1 | 0.9% |
Veterinary medicine | 1 | 0.9% |
Viral diseases | 1 | 0.9% |
Viral vector | 1 | 0.9% |
Virology | 1 | 0.9% |
Viruses | 1 | 0.9% |
Vision | 1 | 0.9% |
Vital signs | 1 | 0.9% |
Vitamin D deficiency | 1 | 0.9% |
WASH | 1 | 0.9% |
Waste | 1 | 0.9% |
Wearable technology | 1 | 0.9% |
West Bank | 1 | 0.9% |
West Nile virus | 1 | 0.9% |
Western African Ebola virus epidemic | 1 | 0.9% |
Whole genome sequencing | 1 | 0.9% |
Whooping cough | 1 | 0.9% |
Zebrafish | 1 | 0.9% |
Zika fever | 1 | 0.9% |
Zika virus | 1 | 0.9% |
abs | rel | |
---|---|---|
Health | 111 | 98.2% |
Medicine | 110 | 97.3% |
Health sciences | 108 | 95.6% |
Health care | 107 | 94.7% |
Clinical medicine | 103 | 91.2% |
Medical specialties | 103 | 91.2% |
Diseases and disorders | 59 | 52.2% |
Public health | 58 | 51.3% |
Epidemiology | 39 | 34.5% |
Infection | 39 | 34.5% |
Risk | 35 | 31.0% |
Vaccine | 34 | 30.1% |
Disease | 31 | 27.4% |
Immunology | 31 | 27.4% |
Cancer | 27 | 23.9% |
Life sciences | 26 | 23.0% |
COVID-19 pandemic | 24 | 21.2% |
Severe acute respiratory syndrome coronavirus 2 | 24 | 21.2% |
Infectious diseases | 23 | 20.4% |
Hospital | 22 | 19.5% |
Screening (medicine) | 21 | 18.6% |
Chronic condition | 20 | 17.7% |
Clinical trial | 20 | 17.7% |
Biology | 19 | 16.8% |
Heart | 19 | 16.8% |
Medication | 19 | 16.8% |
Preventive healthcare | 19 | 16.8% |
Randomized controlled trial | 19 | 16.8% |
COVID-19 | 18 | 15.9% |
Evidence-based medicine | 18 | 15.9% |
Health policy | 18 | 15.9% |
Patient | 18 | 15.9% |
COVID-19 vaccine | 17 | 15.0% |
Cardiovascular disease | 17 | 15.0% |
Cohort study | 17 | 15.0% |
Coronavirus disease 2019 | 17 | 15.0% |
Health professional | 17 | 15.0% |
Hypertension | 17 | 15.0% |
Medical diagnosis | 17 | 15.0% |
Sensitivity and specificity | 17 | 15.0% |
Systematic review | 17 | 15.0% |
Adherence (medicine) | 16 | 14.2% |
Nursing | 16 | 14.2% |
Microbiology | 15 | 13.3% |
Pregnancy | 15 | 13.3% |
Stroke | 14 | 12.4% |
Diabetes | 13 | 11.5% |
Isolation (health care) | 13 | 11.5% |
Medical humanities | 13 | 11.5% |
Cardiology | 12 | 10.6% |
Cardiovascular system | 12 | 10.6% |
Health economics | 12 | 10.6% |
Health system | 12 | 10.6% |
Immunodeficiency | 12 | 10.6% |
Artificial intelligence | 11 | 9.7% |
Coronary artery disease | 11 | 9.7% |
Dose (biochemistry) | 11 | 9.7% |
HIV/AIDS | 11 | 9.7% |
Meta-analysis | 11 | 9.7% |
Obesity | 11 | 9.7% |
Pharmacy | 11 | 9.7% |
Radiology | 11 | 9.7% |
Surgery | 11 | 9.7% |
Therapy | 11 | 9.7% |
Vaccination | 11 | 9.7% |
Childbirth | 10 | 8.8% |
Medical guideline | 10 | 8.8% |
Primary care | 10 | 8.8% |
Research | 10 | 8.8% |
Tuberculosis | 10 | 8.8% |
Virus | 10 | 8.8% |
Breastfeeding | 9 | 8.0% |
Comorbidity | 9 | 8.0% |
Human activities | 9 | 8.0% |
Major depressive disorder | 9 | 8.0% |
Pandemic | 9 | 8.0% |
Personal protective equipment | 9 | 8.0% |
Transmission (medicine) | 9 | 8.0% |
Type 2 diabetes | 9 | 8.0% |
Asthma | 8 | 7.1% |
Breast cancer | 8 | 7.1% |
Cost-effectiveness analysis | 8 | 7.1% |
Drugs | 8 | 7.1% |
Face masks during the COVID-19 pandemic | 8 | 7.1% |
HIV | 8 | 7.1% |
Heart failure | 8 | 7.1% |
Immunization | 8 | 7.1% |
Infection prevention and control | 8 | 7.1% |
Influenza | 8 | 7.1% |
Medical imaging | 8 | 7.1% |
Medical statistics | 8 | 7.1% |
Physician | 8 | 7.1% |
Social distancing | 8 | 7.1% |
Adverse effect | 7 | 6.2% |
Antibody | 7 | 6.2% |
Antimicrobial resistance | 7 | 6.2% |
Blood pressure | 7 | 6.2% |
Health equity | 7 | 6.2% |
Health technology | 7 | 6.2% |
Lung | 7 | 6.2% |
Medical treatments | 7 | 6.2% |
Mental disorder | 7 | 6.2% |
Myocardial infarction | 7 | 6.2% |
Neutralizing antibody | 7 | 6.2% |
Pharmacology | 7 | 6.2% |
Phases of clinical research | 7 | 6.2% |
Positive and negative predictive values | 7 | 6.2% |
Quality-adjusted life year | 7 | 6.2% |
Safety | 7 | 6.2% |
Antibiotic | 6 | 5.3% |
Artificial cardiac pacemaker | 6 | 5.3% |
CT scan | 6 | 5.3% |
Caregiver | 6 | 5.3% |
Casirivimab/imdevimab | 6 | 5.3% |
Chronic obstructive pulmonary disease | 6 | 5.3% |
Diabetes management | 6 | 5.3% |
Emergency department | 6 | 5.3% |
Glycated hemoglobin | 6 | 5.3% |
Health care quality | 6 | 5.3% |
Hepatitis | 6 | 5.3% |
Immune system | 6 | 5.3% |
Management of HIV/AIDS | 6 | 5.3% |
Multidrug-resistant tuberculosis | 6 | 5.3% |
Non-communicable disease | 6 | 5.3% |
Palliative care | 6 | 5.3% |
Pediatrics | 6 | 5.3% |
Pfizer–BioNTech COVID-19 vaccine | 6 | 5.3% |
Pharmacovigilance | 6 | 5.3% |
Preterm birth | 6 | 5.3% |
Receiver operating characteristic | 6 | 5.3% |
Self-care | 6 | 5.3% |
Serology | 6 | 5.3% |
Signs and symptoms | 6 | 5.3% |
Angina | 5 | 4.4% |
Breast cancer screening | 5 | 4.4% |
Cancer screening | 5 | 4.4% |
Dexamethasone | 5 | 4.4% |
Electronic health record | 5 | 4.4% |
Hypogammaglobulinemia | 5 | 4.4% |
Immunoglobulin therapy | 5 | 4.4% |
Incremental cost-effectiveness ratio | 5 | 4.4% |
Infant | 5 | 4.4% |
Leukemia | 5 | 4.4% |
Lung cancer | 5 | 4.4% |
Mammography | 5 | 4.4% |
Maternal health | 5 | 4.4% |
Medical device | 5 | 4.4% |
Medical test | 5 | 4.4% |
Methicillin-resistant Staphylococcus aureus | 5 | 4.4% |
Moderna COVID-19 vaccine | 5 | 4.4% |
N95 respirator | 5 | 4.4% |
Percutaneous coronary intervention | 5 | 4.4% |
Preventive medicine | 5 | 4.4% |
Radiation therapy | 5 | 4.4% |
Remdesivir | 5 | 4.4% |
Respirator | 5 | 4.4% |
Respiratory disease | 5 | 4.4% |
Risk assessment | 5 | 4.4% |
Surgical mask | 5 | 4.4% |
Tocilizumab | 5 | 4.4% |
Vaccine adverse event | 5 | 4.4% |
Airborne transmission | 4 | 3.5% |
Allergy | 4 | 3.5% |
Assay | 4 | 3.5% |
Atrial fibrillation | 4 | 3.5% |
Autoimmunity | 4 | 3.5% |
Basic reproduction number | 4 | 3.5% |
Biotechnology | 4 | 3.5% |
Body mass index | 4 | 3.5% |
Booster dose | 4 | 3.5% |
Branches of science | 4 | 3.5% |
COVID-19 pandemic in the United Kingdom | 4 | 3.5% |
Cardiac catheterization | 4 | 3.5% |
Cervical cancer | 4 | 3.5% |
Chronic kidney disease | 4 | 3.5% |
Cirrhosis | 4 | 3.5% |
Clinical endpoint | 4 | 3.5% |
Compartmental models in epidemiology | 4 | 3.5% |
Copyright | 4 | 3.5% |
Environmental social science | 4 | 3.5% |
Exercise | 4 | 3.5% |
Expanded Program on Immunization | 4 | 3.5% |
Familial hypercholesterolemia | 4 | 3.5% |
GeneXpert MTB/RIF | 4 | 3.5% |
Governance | 4 | 3.5% |
Hospital-acquired infection | 4 | 3.5% |
Hypercholesterolemia | 4 | 3.5% |
Immunity (medical) | 4 | 3.5% |
Indication (medicine) | 4 | 3.5% |
Inflammation | 4 | 3.5% |
Informed consent | 4 | 3.5% |
Interventional radiology | 4 | 3.5% |
Intravenous therapy | 4 | 3.5% |
Johnson & Johnson COVID-19 vaccine | 4 | 3.5% |
Low-density lipoprotein | 4 | 3.5% |
Malaria | 4 | 3.5% |
Measles | 4 | 3.5% |
Natural reservoir | 4 | 3.5% |
Non-pharmaceutical intervention (epidemiology) | 4 | 3.5% |
Nursing home | 4 | 3.5% |
Occupational safety and health | 4 | 3.5% |
Patient safety | 4 | 3.5% |
Physical therapy | 4 | 3.5% |
Sepsis | 4 | 3.5% |
Shortness of breath | 4 | 3.5% |
Statin | 4 | 3.5% |
Technology | 4 | 3.5% |
Thorax (human anatomy) | 4 | 3.5% |
Tuberculosis management | 4 | 3.5% |
Type 1 diabetes | 4 | 3.5% |
Variants of SARS-CoV-2 | 4 | 3.5% |
Vein | 4 | 3.5% |
Acute coronary syndrome | 3 | 2.7% |
Adverse event | 3 | 2.7% |
Anaphylaxis | 3 | 2.7% |
Angiology | 3 | 2.7% |
Animal viral diseases | 3 | 2.7% |
Antigen | 3 | 2.7% |
Antipsychotic | 3 | 2.7% |
Antiviral drug | 3 | 2.7% |
Arrhythmia | 3 | 2.7% |
Aspirin | 3 | 2.7% |
Assessment of kidney function | 3 | 2.7% |
Avian influenza | 3 | 2.7% |
Biopsy | 3 | 2.7% |
Bipolar disorder | 3 | 2.7% |
Blood sugar level | 3 | 2.7% |
Bovine spongiform encephalopathy | 3 | 2.7% |
Breakthrough infection | 3 | 2.7% |
Bronchiectasis | 3 | 2.7% |
Cardiothoracic surgery | 3 | 2.7% |
Catheter | 3 | 2.7% |
Cholesterol | 3 | 2.7% |
Chronic lymphocytic leukemia | 3 | 2.7% |
Clinic | 3 | 2.7% |
Cloth face mask | 3 | 2.7% |
Cold chain | 3 | 2.7% |
Common variable immunodeficiency | 3 | 2.7% |
Computer-aided diagnosis | 3 | 2.7% |
Cost–utility analysis | 3 | 2.7% |
Creative Commons license | 3 | 2.7% |
DPT vaccine | 3 | 2.7% |
Diabetic retinopathy | 3 | 2.7% |
Diagnosis of HIV/AIDS | 3 | 2.7% |
Disease surveillance | 3 | 2.7% |
Disinfectant | 3 | 2.7% |
Ductal carcinoma in situ | 3 | 2.7% |
Dyslipidemia | 3 | 2.7% |
Education | 3 | 2.7% |
Emergency Use Authorization | 3 | 2.7% |
Emerging technologies | 3 | 2.7% |
Evaluation | 3 | 2.7% |
Expert | 3 | 2.7% |
Ezetimibe | 3 | 2.7% |
Gene | 3 | 2.7% |
General practitioner | 3 | 2.7% |
Gestational age | 3 | 2.7% |
Global health | 3 | 2.7% |
Health informatics | 3 | 2.7% |
Hematopoietic stem cell transplantation | 3 | 2.7% |
High-density lipoprotein | 3 | 2.7% |
Human diseases and disorders | 3 | 2.7% |
Hypoglycemia | 3 | 2.7% |
Immunoglobulin G | 3 | 2.7% |
Immunosuppressive drug | 3 | 2.7% |
Implant (medicine) | 3 | 2.7% |
Infant mortality | 3 | 2.7% |
Influenza A virus subtype H5N1 | 3 | 2.7% |
Innovation | 3 | 2.7% |
Insulin (medication) | 3 | 2.7% |
Ischemia | 3 | 2.7% |
Kidney | 3 | 2.7% |
Lipoprotein | 3 | 2.7% |
Lung cancer screening | 3 | 2.7% |
Lung nodule | 3 | 2.7% |
Machine learning | 3 | 2.7% |
Mechanical filter (respirator) | 3 | 2.7% |
Medical Subject Headings | 3 | 2.7% |
Medical record | 3 | 2.7% |
Medicare (United States) | 3 | 2.7% |
Mental health | 3 | 2.7% |
Multiple sclerosis | 3 | 2.7% |
Mutation | 3 | 2.7% |
Off-label use | 3 | 2.7% |
Overdiagnosis | 3 | 2.7% |
Oxford–AstraZeneca COVID-19 vaccine | 3 | 2.7% |
Pap test | 3 | 2.7% |
Pericardium | 3 | 2.7% |
Pharmaceutical sciences | 3 | 2.7% |
Pharmacist | 3 | 2.7% |
Physical examination | 3 | 2.7% |
Placebo | 3 | 2.7% |
Placebo-controlled study | 3 | 2.7% |
Policy | 3 | 2.7% |
Polio vaccine | 3 | 2.7% |
Positive airway pressure | 3 | 2.7% |
Postpartum period | 3 | 2.7% |
Prediabetes | 3 | 2.7% |
Prenatal care | 3 | 2.7% |
Primary health care | 3 | 2.7% |
Primary immunodeficiency | 3 | 2.7% |
Proteinuria | 3 | 2.7% |
Psychotherapy | 3 | 2.7% |
Public sphere | 3 | 2.7% |
Radiography | 3 | 2.7% |
Respiratory droplet | 3 | 2.7% |
Rubella | 3 | 2.7% |
SARS-CoV-2 Beta variant | 3 | 2.7% |
SARS-CoV-2 Delta variant | 3 | 2.7% |
Science | 3 | 2.7% |
Severe acute respiratory syndrome | 3 | 2.7% |
Severe combined immunodeficiency | 3 | 2.7% |
Shared decision-making in medicine | 3 | 2.7% |
Sleep apnea | 3 | 2.7% |
Smoking cessation | 3 | 2.7% |
Social determinants of health | 3 | 2.7% |
Source control (respiratory disease) | 3 | 2.7% |
Study heterogeneity | 3 | 2.7% |
Sustainable Development Goals | 3 | 2.7% |
Tetanus vaccine | 3 | 2.7% |
Tobacco smoking | 3 | 2.7% |
Training, validation, and test sets | 3 | 2.7% |
Transient ischemic attack | 3 | 2.7% |
Transmission-based precautions | 3 | 2.7% |
Variant Creutzfeldt–Jakob disease | 3 | 2.7% |
Venous thrombosis | 3 | 2.7% |
3D bioprinting | 2 | 1.8% |
3D printing | 2 | 1.8% |
Aboriginal Australians | 2 | 1.8% |
Abstract (summary) | 2 | 1.8% |
Accountability | 2 | 1.8% |
Adaptive immune system | 2 | 1.8% |
Adenoviridae | 2 | 1.8% |
Agriculture | 2 | 1.8% |
Air pollution | 2 | 1.8% |
Airborne diseases | 2 | 1.8% |
Alirocumab | 2 | 1.8% |
Analytics | 2 | 1.8% |
Anticoagulant | 2 | 1.8% |
Antiserum | 2 | 1.8% |
Aortic stenosis | 2 | 1.8% |
Aortic valve | 2 | 1.8% |
Aortic valve replacement | 2 | 1.8% |
Apolipoprotein | 2 | 1.8% |
Atheroma | 2 | 1.8% |
Atherosclerosis | 2 | 1.8% |
Atrial septal defect | 2 | 1.8% |
Atypical pneumonias | 2 | 1.8% |
Audit | 2 | 1.8% |
Augmented reality | 2 | 1.8% |
Australians | 2 | 1.8% |
B cell | 2 | 1.8% |
Back pain | 2 | 1.8% |
Baricitinib | 2 | 1.8% |
Bempedoic acid | 2 | 1.8% |
Beta blocker | 2 | 1.8% |
Biomarker | 2 | 1.8% |
Biosecurity | 2 | 1.8% |
Birth weight | 2 | 1.8% |
Bleeding | 2 | 1.8% |
Blinded experiment | 2 | 1.8% |
Blood plasma | 2 | 1.8% |
Blood transfusion | 2 | 1.8% |
Breast milk | 2 | 1.8% |
C-reactive protein | 2 | 1.8% |
COVID-19 pandemic in the United States | 2 | 1.8% |
Carcinoma | 2 | 1.8% |
Cardiac surgery | 2 | 1.8% |
Cardioversion | 2 | 1.8% |
Case–control study | 2 | 1.8% |
Causes of death | 2 | 1.8% |
Census in Australia | 2 | 1.8% |
Cerebrovascular disease | 2 | 1.8% |
Cervical intraepithelial neoplasia | 2 | 1.8% |
Chorioamnionitis | 2 | 1.8% |
Chronic pain | 2 | 1.8% |
Circulatory system | 2 | 1.8% |
Cognition | 2 | 1.8% |
Cognitive behavioral therapy | 2 | 1.8% |
Colorectal cancer | 2 | 1.8% |
Colposcopy | 2 | 1.8% |
Common cold | 2 | 1.8% |
Confidence interval | 2 | 1.8% |
CoronaVac | 2 | 1.8% |
DICOM | 2 | 1.8% |
Deep learning | 2 | 1.8% |
Defibrillation | 2 | 1.8% |
Dementia | 2 | 1.8% |
Deployment of COVID-19 vaccines | 2 | 1.8% |
Diabetes medication | 2 | 1.8% |
Diabetic ketoacidosis | 2 | 1.8% |
Dieting | 2 | 1.8% |
Disorders of endocrine pancreas | 2 | 1.8% |
Doxorubicin | 2 | 1.8% |
Ebola | 2 | 1.8% |
Echocardiography | 2 | 1.8% |
Electrocardiography | 2 | 1.8% |
Embolization | 2 | 1.8% |
Emergency medical services | 2 | 1.8% |
Emergency medical technician | 2 | 1.8% |
Emergency medicine | 2 | 1.8% |
Emerging infectious disease | 2 | 1.8% |
Employment | 2 | 1.8% |
Epidemic | 2 | 1.8% |
Epilepsy | 2 | 1.8% |
Eradication of infectious diseases | 2 | 1.8% |
Extensively drug-resistant tuberculosis | 2 | 1.8% |
FFP standards | 2 | 1.8% |
Family medicine | 2 | 1.8% |
Fat | 2 | 1.8% |
Fatty liver disease | 2 | 1.8% |
Fee-for-service | 2 | 1.8% |
Fetus | 2 | 1.8% |
Fraction | 2 | 1.8% |
Gestational diabetes | 2 | 1.8% |
Good manufacturing practice | 2 | 1.8% |
Graft-versus-host disease | 2 | 1.8% |
Group A streptococcal infection | 2 | 1.8% |
Group B streptococcal infection | 2 | 1.8% |
Hand washing | 2 | 1.8% |
Health data | 2 | 1.8% |
Health human resources | 2 | 1.8% |
Hepatitis B vaccine | 2 | 1.8% |
Histoplasmosis | 2 | 1.8% |
Homelessness | 2 | 1.8% |
Hospital readmission | 2 | 1.8% |
Human papillomavirus infection | 2 | 1.8% |
Human reproduction | 2 | 1.8% |
Hygiene | 2 | 1.8% |
Hyperglycemia | 2 | 1.8% |
Hypertrophic cardiomyopathy | 2 | 1.8% |
Image segmentation | 2 | 1.8% |
Indigenous Australians | 2 | 1.8% |
Influenza A virus | 2 | 1.8% |
Influenza A virus subtype H5N8 | 2 | 1.8% |
Influenza pandemic | 2 | 1.8% |
Information privacy | 2 | 1.8% |
Inspection | 2 | 1.8% |
International Classification of Diseases | 2 | 1.8% |
Kidney failure | 2 | 1.8% |
Lentiviruses | 2 | 1.8% |
Lineage B.1.1.7 | 2 | 1.8% |
Lineage B.1.351 | 2 | 1.8% |
Liver | 2 | 1.8% |
Livestock | 2 | 1.8% |
Low back pain | 2 | 1.8% |
Lymphocyte | 2 | 1.8% |
Mechanical ventilation | 2 | 1.8% |
MedDRA | 2 | 1.8% |
Medical error | 2 | 1.8% |
Medical research | 2 | 1.8% |
Metformin | 2 | 1.8% |
Middle East respiratory syndrome | 2 | 1.8% |
Middle East respiratory syndrome–related coronavirus | 2 | 1.8% |
Minimally invasive procedure | 2 | 1.8% |
Miscarriage | 2 | 1.8% |
Monitoring (medicine) | 2 | 1.8% |
Multiple birth | 2 | 1.8% |
Multisystem inflammatory syndrome in children | 2 | 1.8% |
Neonatal infection | 2 | 1.8% |
Neonatal intensive care unit | 2 | 1.8% |
Neonatal sepsis | 2 | 1.8% |
Neuromodulation (medicine) | 2 | 1.8% |
Neurostimulation | 2 | 1.8% |
Nightmare | 2 | 1.8% |
Notifiable disease | 2 | 1.8% |
Obstructive sleep apnea | 2 | 1.8% |
Organ transplantation | 2 | 1.8% |
Overactive bladder | 2 | 1.8% |
PCSK9 | 2 | 1.8% |
Pain | 2 | 1.8% |
Pain management | 2 | 1.8% |
Pandemics | 2 | 1.8% |
Particulates | 2 | 1.8% |
Pathogen | 2 | 1.8% |
Pectus excavatum | 2 | 1.8% |
Pericardiocentesis | 2 | 1.8% |
Personal data | 2 | 1.8% |
Pharmaceutical industry | 2 | 1.8% |
Philippine national identity card | 2 | 1.8% |
Physiology | 2 | 1.8% |
Picture archiving and communication system | 2 | 1.8% |
Pneumonia | 2 | 1.8% |
Point of care | 2 | 1.8% |
Polio | 2 | 1.8% |
Polio eradication | 2 | 1.8% |
Poultry | 2 | 1.8% |
Powered air-purifying respirator | 2 | 1.8% |
Prenatal development | 2 | 1.8% |
Prescription drug | 2 | 1.8% |
Primary care physician | 2 | 1.8% |
Privacy | 2 | 1.8% |
Protein | 2 | 1.8% |
Psychology | 2 | 1.8% |
Public Health Emergency of International Concern | 2 | 1.8% |
Public health surveillance | 2 | 1.8% |
Q fever | 2 | 1.8% |
Qualitative research | 2 | 1.8% |
Quality assurance | 2 | 1.8% |
Radiographer | 2 | 1.8% |
Regenerative medicine | 2 | 1.8% |
Regulatory compliance | 2 | 1.8% |
Reperfusion therapy | 2 | 1.8% |
Respiratory syncytial virus | 2 | 1.8% |
Retinopathy | 2 | 1.8% |
Rheumatic fever | 2 | 1.8% |
Rifampicin | 2 | 1.8% |
SARS-CoV-2 | 2 | 1.8% |
SARS-CoV-2 Alpha variant | 2 | 1.8% |
Schizophrenia | 2 | 1.8% |
Severe acute respiratory syndrome coronavirus | 2 | 1.8% |
Sexually transmitted infection | 2 | 1.8% |
Sinopharm BIBP COVID-19 vaccine | 2 | 1.8% |
Social work | 2 | 1.8% |
Statistics | 2 | 1.8% |
Stem cell | 2 | 1.8% |
Sternum | 2 | 1.8% |
Surveillance | 2 | 1.8% |
Survey methodology | 2 | 1.8% |
Swine influenza | 2 | 1.8% |
T cell | 2 | 1.8% |
Telehealth | 2 | 1.8% |
Thrombosis | 2 | 1.8% |
Tissue engineering | 2 | 1.8% |
Transcranial magnetic stimulation | 2 | 1.8% |
Transmissible spongiform encephalopathy | 2 | 1.8% |
Triage | 2 | 1.8% |
Type I and type II errors | 2 | 1.8% |
Unwarranted variation | 2 | 1.8% |
Urinary incontinence | 2 | 1.8% |
Usability | 2 | 1.8% |
Valvular heart disease | 2 | 1.8% |
Ventilator | 2 | 1.8% |
Ventricular fibrillation | 2 | 1.8% |
Verification and validation | 2 | 1.8% |
VigiBase | 2 | 1.8% |
Viral respiratory tract infections | 2 | 1.8% |
Viral vector | 2 | 1.8% |
Virtual reality | 2 | 1.8% |
Virus-like particle | 2 | 1.8% |
Vital signs | 2 | 1.8% |
Wearable technology | 2 | 1.8% |
Woman | 2 | 1.8% |
Zidovudine | 2 | 1.8% |
Zoonosis | 2 | 1.8% |
2009 swine flu pandemic | 1 | 0.9% |
Abiraterone acetate | 1 | 0.9% |
Access to COVID-19 Tools Accelerator | 1 | 0.9% |
Accessibility | 1 | 0.9% |
Accountable care organization | 1 | 0.9% |
Accuracy and precision | 1 | 0.9% |
Acute lymphoblastic leukemia | 1 | 0.9% |
Acute myeloid leukemia | 1 | 0.9% |
Acute respiratory distress syndrome | 1 | 0.9% |
Addiction | 1 | 0.9% |
Adjuvant therapy | 1 | 0.9% |
Advance healthcare directive | 1 | 0.9% |
Advertising | 1 | 0.9% |
Aegis Combat System | 1 | 0.9% |
Aerosol | 1 | 0.9% |
Affordable Care Act | 1 | 0.9% |
Alcoholic drink | 1 | 0.9% |
Allied health professions | 1 | 0.9% |
Alma Ata Declaration | 1 | 0.9% |
Alteplase | 1 | 0.9% |
Alzheimer's disease | 1 | 0.9% |
Amblyopia | 1 | 0.9% |
Ambulance | 1 | 0.9% |
Ambulatory care | 1 | 0.9% |
Amiodarone | 1 | 0.9% |
Anal fissure | 1 | 0.9% |
Analysis | 1 | 0.9% |
Anatomy | 1 | 0.9% |
Anesthesia | 1 | 0.9% |
Anesthesiology | 1 | 0.9% |
Animals and humans | 1 | 0.9% |
Anismus | 1 | 0.9% |
Anti-NMDA receptor encephalitis | 1 | 0.9% |
Anti-obesity medication | 1 | 0.9% |
Antiarrhythmic agent | 1 | 0.9% |
Anticonvulsant | 1 | 0.9% |
Antidepressant | 1 | 0.9% |
Antifungal | 1 | 0.9% |
Antigen-presenting cell | 1 | 0.9% |
Antihypertensive drug | 1 | 0.9% |
Antimicrobial | 1 | 0.9% |
Antimicrobial stewardship | 1 | 0.9% |
Antiplatelet drug | 1 | 0.9% |
Antiretroviral drugs | 1 | 0.9% |
Anxiety | 1 | 0.9% |
Anxiety disorder | 1 | 0.9% |
Apheresis | 1 | 0.9% |
Apixaban | 1 | 0.9% |
Appetite | 1 | 0.9% |
Artificial heart valve | 1 | 0.9% |
Artificial neural network | 1 | 0.9% |
Atezolizumab | 1 | 0.9% |
Atopy | 1 | 0.9% |
Atorvastatin | 1 | 0.9% |
Attention deficit hyperactivity disorder | 1 | 0.9% |
Attenuated vaccine | 1 | 0.9% |
Autoimmune disease | 1 | 0.9% |
Autoimmune hemolytic anemia | 1 | 0.9% |
Autonomy | 1 | 0.9% |
BCG vaccine | 1 | 0.9% |
BK virus | 1 | 0.9% |
Bag valve mask | 1 | 0.9% |
Bariatric surgery | 1 | 0.9% |
Bariatrics | 1 | 0.9% |
Behaviour therapy | 1 | 0.9% |
Belief | 1 | 0.9% |
Bempedoic acid/ezetimibe | 1 | 0.9% |
Bethesda system | 1 | 0.9% |
Biochemical cascade | 1 | 0.9% |
Biological globalization | 1 | 0.9% |
Biomarker (medicine) | 1 | 0.9% |
Biosafety | 1 | 0.9% |
Biosimilar | 1 | 0.9% |
Birth | 1 | 0.9% |
Birth control | 1 | 0.9% |
Blood | 1 | 0.9% |
Blood bank | 1 | 0.9% |
Blood donation | 1 | 0.9% |
Blood glucose monitoring | 1 | 0.9% |
Blood type | 1 | 0.9% |
Body fluids | 1 | 0.9% |
Bone | 1 | 0.9% |
Bone density | 1 | 0.9% |
Bone fracture | 1 | 0.9% |
Bone health | 1 | 0.9% |
Botulinum toxin | 1 | 0.9% |
Brilacidin | 1 | 0.9% |
Bronchoscopy | 1 | 0.9% |
Budget | 1 | 0.9% |
Bupropion | 1 | 0.9% |
CD135 | 1 | 0.9% |
CD4 | 1 | 0.9% |
CHA2DS2–VASc score | 1 | 0.9% |
COVID-19 drug development | 1 | 0.9% |
COVID-19 pandemic in Papua New Guinea | 1 | 0.9% |
COVID-19 testing | 1 | 0.9% |
COVID-19 vaccination in the United Kingdom | 1 | 0.9% |
Cancer immunotherapy | 1 | 0.9% |
Cancer prevention | 1 | 0.9% |
Capitation (healthcare) | 1 | 0.9% |
Carbohydrate | 1 | 0.9% |
Cardiac arrest | 1 | 0.9% |
Cardiac electrophysiology | 1 | 0.9% |
Cardiac rehabilitation | 1 | 0.9% |
Cardiac resynchronization therapy | 1 | 0.9% |
Cardiopulmonary resuscitation | 1 | 0.9% |
Cardiovascular diseases | 1 | 0.9% |
Cardiovascular physiology | 1 | 0.9% |
Case management (US healthcare system) | 1 | 0.9% |
Cattle | 1 | 0.9% |
Cefiderocol | 1 | 0.9% |
Cell (biology) | 1 | 0.9% |
Cell signaling | 1 | 0.9% |
Cell-mediated immunity | 1 | 0.9% |
Central venous catheter | 1 | 0.9% |
Cervical screening | 1 | 0.9% |
Cervix | 1 | 0.9% |
Chagas disease | 1 | 0.9% |
Chemicals in medicine | 1 | 0.9% |
Chemotherapy | 1 | 0.9% |
Chest radiograph | 1 | 0.9% |
Chickenpox | 1 | 0.9% |
Child | 1 | 0.9% |
Child development | 1 | 0.9% |
Chimeric antigen receptor T cell | 1 | 0.9% |
Chlorine dioxide | 1 | 0.9% |
Chronic fatigue syndrome | 1 | 0.9% |
Chronic inflammatory demyelinating polyneuropathy | 1 | 0.9% |
Cigarette | 1 | 0.9% |
Clinical commissioning group | 1 | 0.9% |
Clinical decision support system | 1 | 0.9% |
Clinical governance | 1 | 0.9% |
Clopidogrel | 1 | 0.9% |
Cloud computing | 1 | 0.9% |
Clozapine | 1 | 0.9% |
Coagulation | 1 | 0.9% |
Cochrane Library | 1 | 0.9% |
Cognitive science | 1 | 0.9% |
Colesevelam | 1 | 0.9% |
Colestyramine | 1 | 0.9% |
Colonoscopy | 1 | 0.9% |
Combination therapy | 1 | 0.9% |
Community health | 1 | 0.9% |
Competence (human resources) | 1 | 0.9% |
Computer vision | 1 | 0.9% |
Confidentiality | 1 | 0.9% |
Conjugate vaccine | 1 | 0.9% |
Constipation | 1 | 0.9% |
Continuous glucose monitor | 1 | 0.9% |
Continuous positive airway pressure | 1 | 0.9% |
Convolutional neural network | 1 | 0.9% |
Coronary artery bypass surgery | 1 | 0.9% |
Coronavirus spike protein | 1 | 0.9% |
Cough | 1 | 0.9% |
CpG site | 1 | 0.9% |
Creatinine | 1 | 0.9% |
Creutzfeldt–Jakob disease | 1 | 0.9% |
Crimean–Congo hemorrhagic fever | 1 | 0.9% |
Crohn's disease | 1 | 0.9% |
Cross-reactivity | 1 | 0.9% |
Cross-validation (statistics) | 1 | 0.9% |
Current events | 1 | 0.9% |
Cystatin C | 1 | 0.9% |
Cystic fibrosis | 1 | 0.9% |
Cytotoxic T cell | 1 | 0.9% |
DNA vaccination | 1 | 0.9% |
DNA vaccine | 1 | 0.9% |
Dabigatran | 1 | 0.9% |
Daratumumab | 1 | 0.9% |
Darunavir | 1 | 0.9% |
Dasatinib | 1 | 0.9% |
Data analysis | 1 | 0.9% |
Database | 1 | 0.9% |
Death | 1 | 0.9% |
Decision-making | 1 | 0.9% |
Defecation | 1 | 0.9% |
Demographic and Health Surveys | 1 | 0.9% |
Dendritic cell | 1 | 0.9% |
Dermatomyositis | 1 | 0.9% |
Diabetic foot ulcer | 1 | 0.9% |
Diabetic nephropathy | 1 | 0.9% |
Diagnosis | 1 | 0.9% |
Dietary supplement | 1 | 0.9% |
Diffuse large B-cell lymphoma | 1 | 0.9% |
Digital health | 1 | 0.9% |
Digital pathology | 1 | 0.9% |
Digoxin | 1 | 0.9% |
Diltiazem | 1 | 0.9% |
Diphtheria | 1 | 0.9% |
Diphtheria vaccine | 1 | 0.9% |
Disability | 1 | 0.9% |
Disability-adjusted life year | 1 | 0.9% |
Disease outbreaks | 1 | 0.9% |
Disease registry | 1 | 0.9% |
Drink | 1 | 0.9% |
Dronedarone | 1 | 0.9% |
Drug development | 1 | 0.9% |
Dystonia | 1 | 0.9% |
EHealth | 1 | 0.9% |
ELISA | 1 | 0.9% |
EQ-5D | 1 | 0.9% |
Eating | 1 | 0.9% |
Ebola vaccine | 1 | 0.9% |
Echinocandin | 1 | 0.9% |
Educational assessment | 1 | 0.9% |
Effect size | 1 | 0.9% |
Elastomeric respirator | 1 | 0.9% |
Elderly care | 1 | 0.9% |
Electroblotting | 1 | 0.9% |
Embolism | 1 | 0.9% |
Emergency | 1 | 0.9% |
Emergency management | 1 | 0.9% |
Encephalitis | 1 | 0.9% |
End-of-life care | 1 | 0.9% |
Endocrine pancreas | 1 | 0.9% |
Endocrine system | 1 | 0.9% |
Endocrine, nutritional and metabolic diseases | 1 | 0.9% |
Endocrinology | 1 | 0.9% |
Endometrial cancer | 1 | 0.9% |
Endoplasmic reticulum | 1 | 0.9% |
Endoscopy | 1 | 0.9% |
Enterovirus | 1 | 0.9% |
Epidemics | 1 | 0.9% |
Erlotinib | 1 | 0.9% |
Esophageal achalasia | 1 | 0.9% |
Estimand | 1 | 0.9% |
Exclusion of the null hypothesis | 1 | 0.9% |
Exhalation | 1 | 0.9% |
Exhaled nitric oxide | 1 | 0.9% |
Eye protection | 1 | 0.9% |
Factor VIII | 1 | 0.9% |
Factor X | 1 | 0.9% |
Fall prevention | 1 | 0.9% |
False positives and false negatives | 1 | 0.9% |
Family planning | 1 | 0.9% |
Fecal incontinence | 1 | 0.9% |
Fenofibrate | 1 | 0.9% |
Fever | 1 | 0.9% |
Fibrate | 1 | 0.9% |
Fibrinogen | 1 | 0.9% |
Filtering facepiece respirator | 1 | 0.9% |
Financial risk | 1 | 0.9% |
Fluoride therapy | 1 | 0.9% |
Fluvastatin | 1 | 0.9% |
Food | 1 | 0.9% |
Frailty syndrome | 1 | 0.9% |
Framingham Risk Score | 1 | 0.9% |
Fresh frozen plasma | 1 | 0.9% |
Fundus photography | 1 | 0.9% |
Galactose-1-phosphate uridylyltransferase deficiency | 1 | 0.9% |
Galactosemia | 1 | 0.9% |
Gender | 1 | 0.9% |
Gender equality | 1 | 0.9% |
Gene therapy | 1 | 0.9% |
Genetics | 1 | 0.9% |
Genomics | 1 | 0.9% |
Geriatrics | 1 | 0.9% |
Gerontological nursing | 1 | 0.9% |
Glasses | 1 | 0.9% |
Glomerular filtration rate | 1 | 0.9% |
Glucose meter | 1 | 0.9% |
Glucose tolerance test | 1 | 0.9% |
Glycemic index | 1 | 0.9% |
Gynaecology | 1 | 0.9% |
HPV vaccine | 1 | 0.9% |
HTTPS | 1 | 0.9% |
Haemophilia | 1 | 0.9% |
Haemophilia B | 1 | 0.9% |
Hand dryer | 1 | 0.9% |
Hand sanitizer | 1 | 0.9% |
Headache | 1 | 0.9% |
Health care prices in the United States | 1 | 0.9% |
Health disasters | 1 | 0.9% |
Health insurance | 1 | 0.9% |
Health issues in pregnancy | 1 | 0.9% |
Health law | 1 | 0.9% |
Health literacy | 1 | 0.9% |
Health promotion | 1 | 0.9% |
Health research | 1 | 0.9% |
Health security | 1 | 0.9% |
Healthcare industry | 1 | 0.9% |
Heart diseases | 1 | 0.9% |
Heart rate | 1 | 0.9% |
Heart valve | 1 | 0.9% |
Heated humidified high-flow therapy | 1 | 0.9% |
Hela Province | 1 | 0.9% |
Helminthiasis | 1 | 0.9% |
Hematology | 1 | 0.9% |
Heparin-induced thrombocytopenia | 1 | 0.9% |
Hepatitis B | 1 | 0.9% |
Hepatitis C | 1 | 0.9% |
Herd immunity | 1 | 0.9% |
Hereditary nonpolyposis colorectal cancer | 1 | 0.9% |
Hib vaccine | 1 | 0.9% |
Hierarchy of evidence | 1 | 0.9% |
Histopathology | 1 | 0.9% |
Holter monitor | 1 | 0.9% |
Human development | 1 | 0.9% |
Human pregnancy | 1 | 0.9% |
Human resource management | 1 | 0.9% |
Humoral immunity | 1 | 0.9% |
Hunger | 1 | 0.9% |
Hunger (physiology) | 1 | 0.9% |
Hydroxychloroquine | 1 | 0.9% |
Hyperhidrosis | 1 | 0.9% |
Hyperparameter optimization | 1 | 0.9% |
Hypopnea | 1 | 0.9% |
Hypothesis | 1 | 0.9% |
Hypothyroidism | 1 | 0.9% |
Hysterectomy | 1 | 0.9% |
ISO 9000 | 1 | 0.9% |
Idiopathic pulmonary fibrosis | 1 | 0.9% |
Illicit cigarette trade | 1 | 0.9% |
Imatinib | 1 | 0.9% |
Immune response | 1 | 0.9% |
Immune thrombocytopenic purpura | 1 | 0.9% |
Immunologic adjuvant | 1 | 0.9% |
Immunosenescence | 1 | 0.9% |
Immunotherapy | 1 | 0.9% |
Implantable cardioverter-defibrillator | 1 | 0.9% |
Incubation period | 1 | 0.9% |
Indiana vesiculovirus | 1 | 0.9% |
Influenza A virus subtype H1N1 | 1 | 0.9% |
Influenza vaccine | 1 | 0.9% |
Influenza-like illness | 1 | 0.9% |
Information | 1 | 0.9% |
Information system | 1 | 0.9% |
Innate immune system | 1 | 0.9% |
Insulin | 1 | 0.9% |
Insulin analog | 1 | 0.9% |
Insulin aspart | 1 | 0.9% |
Intellectual disability | 1 | 0.9% |
Intensive care medicine | 1 | 0.9% |
Internal medicine | 1 | 0.9% |
Internet | 1 | 0.9% |
Internet of Military Things | 1 | 0.9% |
Interoperability | 1 | 0.9% |
Interstitial lung disease | 1 | 0.9% |
Interview | 1 | 0.9% |
Ionizing radiation | 1 | 0.9% |
Issues in ethics | 1 | 0.9% |
JLENS | 1 | 0.9% |
Janssen COVID-19 vaccine | 1 | 0.9% |
Janus kinase | 1 | 0.9% |
Juvenile dermatomyositis | 1 | 0.9% |
KIT (gene) | 1 | 0.9% |
Kaposi's sarcoma-associated herpesvirus | 1 | 0.9% |
Kidney transplantation | 1 | 0.9% |
Kinase | 1 | 0.9% |
Laboratory | 1 | 0.9% |
Lambert–Eaton myasthenic syndrome | 1 | 0.9% |
Lamivudine | 1 | 0.9% |
Laparoscopy | 1 | 0.9% |
Large for gestational age | 1 | 0.9% |
Lassa fever | 1 | 0.9% |
Latent tuberculosis | 1 | 0.9% |
Leadership | 1 | 0.9% |
License | 1 | 0.9% |
Licensure | 1 | 0.9% |
Life-cycle assessment | 1 | 0.9% |
Likelihood function | 1 | 0.9% |
Lineage P.1 | 1 | 0.9% |
Liraglutide | 1 | 0.9% |
Lobular carcinoma in situ | 1 | 0.9% |
Logistic regression | 1 | 0.9% |
Long COVID | 1 | 0.9% |
Low birth weight | 1 | 0.9% |
Lymphoma | 1 | 0.9% |
MHealth | 1 | 0.9% |
MMR vaccine | 1 | 0.9% |
MMRV vaccine | 1 | 0.9% |
MRNA vaccine | 1 | 0.9% |
MRNA-1273 | 1 | 0.9% |
Macrophage | 1 | 0.9% |
Malignancy | 1 | 0.9% |
Malnutrition | 1 | 0.9% |
Mammalian pregnancy | 1 | 0.9% |
Managed care | 1 | 0.9% |
Management of atrial fibrillation | 1 | 0.9% |
Management of depression | 1 | 0.9% |
Management of obesity | 1 | 0.9% |
Mandibular advancement splint | 1 | 0.9% |
Mantoux test | 1 | 0.9% |
Marburg virus | 1 | 0.9% |
Mastocytosis | 1 | 0.9% |
Median | 1 | 0.9% |
Mediastinum | 1 | 0.9% |
Medicaid | 1 | 0.9% |
Medical Priority Dispatch System | 1 | 0.9% |
Medical education | 1 | 0.9% |
Medical microbiology | 1 | 0.9% |
Medical prescription | 1 | 0.9% |
Medical prevention | 1 | 0.9% |
Medical school | 1 | 0.9% |
Medical specialty | 1 | 0.9% |
Medicinal chemistry | 1 | 0.9% |
Meige's syndrome | 1 | 0.9% |
Memory B cell | 1 | 0.9% |
Memory T cell | 1 | 0.9% |
Men who have sex with men | 1 | 0.9% |
Men's health | 1 | 0.9% |
Meningitis | 1 | 0.9% |
Meningococcal vaccine | 1 | 0.9% |
Mental health professional | 1 | 0.9% |
Metabolic disorders | 1 | 0.9% |
Metabolic syndrome | 1 | 0.9% |
Metabolomics | 1 | 0.9% |
Metastasis | 1 | 0.9% |
Metered-dose inhaler | 1 | 0.9% |
Methylphenidate | 1 | 0.9% |
Metoprolol | 1 | 0.9% |
Midwife | 1 | 0.9% |
Migraine | 1 | 0.9% |
Missing data | 1 | 0.9% |
MitraClip | 1 | 0.9% |
Mitral regurgitation | 1 | 0.9% |
Mitral stenosis | 1 | 0.9% |
Mitral valve | 1 | 0.9% |
Mitral valve replacement | 1 | 0.9% |
Molecular diagnostics | 1 | 0.9% |
Monocyte | 1 | 0.9% |
Mood disorder | 1 | 0.9% |
Mood stabilizer | 1 | 0.9% |
Mortality rate | 1 | 0.9% |
Motherhood | 1 | 0.9% |
Motivation | 1 | 0.9% |
Motivational interviewing | 1 | 0.9% |
Multifocal motor neuropathy | 1 | 0.9% |
Multiomics | 1 | 0.9% |
Multiple myeloma | 1 | 0.9% |
Mumps | 1 | 0.9% |
Musicians from Florida | 1 | 0.9% |
Myasthenia gravis | 1 | 0.9% |
Mycobacteria | 1 | 0.9% |
Mycobacterium tuberculosis | 1 | 0.9% |
Myocarditis | 1 | 0.9% |
Naive T cell | 1 | 0.9% |
Naltrexone | 1 | 0.9% |
National Immunization Technical Advisory Group | 1 | 0.9% |
National Lung Screening Trial | 1 | 0.9% |
Natural killer cell | 1 | 0.9% |
Nebulizer | 1 | 0.9% |
Needlestick injury | 1 | 0.9% |
Neglected tropical diseases | 1 | 0.9% |
Neonatal alloimmune thrombocytopenia | 1 | 0.9% |
Neonatal tetanus | 1 | 0.9% |
Neoplasms | 1 | 0.9% |
Nephrology | 1 | 0.9% |
Nervous system | 1 | 0.9% |
Neurodegeneration | 1 | 0.9% |
Neurology | 1 | 0.9% |
Neutrophil | 1 | 0.9% |
Nevirapine | 1 | 0.9% |
Nicotine | 1 | 0.9% |
Nicotine replacement therapy | 1 | 0.9% |
Nilotinib | 1 | 0.9% |
Nintedanib | 1 | 0.9% |
Nirmatrelvir | 1 | 0.9% |
Nivolumab | 1 | 0.9% |
Non-alcoholic fatty liver disease | 1 | 0.9% |
Non-invasive ventilation | 1 | 0.9% |
Notified body | 1 | 0.9% |
Nutrition | 1 | 0.9% |
Obstetric labor complication | 1 | 0.9% |
Obstetrics | 1 | 0.9% |
Occupational therapist | 1 | 0.9% |
Olanzapine | 1 | 0.9% |
Ongoing events | 1 | 0.9% |
Opioid | 1 | 0.9% |
Opsoclonus myoclonus syndrome | 1 | 0.9% |
Organs (anatomy) | 1 | 0.9% |
Orlistat | 1 | 0.9% |
Oseltamivir | 1 | 0.9% |
Osteoarthritis | 1 | 0.9% |
Osteopenia | 1 | 0.9% |
Osteoporosis | 1 | 0.9% |
Outcomes research | 1 | 0.9% |
Overfitting | 1 | 0.9% |
P-value | 1 | 0.9% |
PANDAS | 1 | 0.9% |
PD-L1 | 1 | 0.9% |
PHQ-9 | 1 | 0.9% |
Palbociclib | 1 | 0.9% |
Palpitations | 1 | 0.9% |
Paramedic | 1 | 0.9% |
Pathology | 1 | 0.9% |
Pathology of pregnancy, childbirth and the puerperium | 1 | 0.9% |
Patient-reported outcome | 1 | 0.9% |
Pay for performance (healthcare) | 1 | 0.9% |
Pelvic floor | 1 | 0.9% |
Pelvic floor dysfunction | 1 | 0.9% |
Pembrolizumab | 1 | 0.9% |
Pemphigus | 1 | 0.9% |
Pentavalent vaccine | 1 | 0.9% |
Percentage | 1 | 0.9% |
Percutaneous aortic valve replacement | 1 | 0.9% |
Peripherally inserted central catheter | 1 | 0.9% |
Pertuzumab | 1 | 0.9% |
Phagocyte | 1 | 0.9% |
Phosphoinositide 3-kinase | 1 | 0.9% |
Physician Orders for Life-Sustaining Treatment | 1 | 0.9% |
Pirfenidone | 1 | 0.9% |
Piriformis syndrome | 1 | 0.9% |
Placental abruption | 1 | 0.9% |
Plain tobacco packaging | 1 | 0.9% |
Plasmapheresis | 1 | 0.9% |
Platelet | 1 | 0.9% |
Plateletpheresis | 1 | 0.9% |
Pneumococcal conjugate vaccine | 1 | 0.9% |
Pneumococcal vaccine | 1 | 0.9% |
Pneumothorax | 1 | 0.9% |
Point-of-care testing | 1 | 0.9% |
Poliovirus | 1 | 0.9% |
Population genetics | 1 | 0.9% |
Population health | 1 | 0.9% |
Positron emission tomography | 1 | 0.9% |
Post-exposure prophylaxis | 1 | 0.9% |
Postgraduate education | 1 | 0.9% |
Prasugrel | 1 | 0.9% |
Pre-eclampsia | 1 | 0.9% |
Pre-exposure prophylaxis | 1 | 0.9% |
Precision medicine | 1 | 0.9% |
Preclinical development | 1 | 0.9% |
Prediction | 1 | 0.9% |
Predictive analytics | 1 | 0.9% |
Premature ventricular contraction | 1 | 0.9% |
Prenatal testing | 1 | 0.9% |
Prevalence | 1 | 0.9% |
Prevalence of tobacco use | 1 | 0.9% |
Prevention of HIV/AIDS | 1 | 0.9% |
Prion | 1 | 0.9% |
Probability distribution | 1 | 0.9% |
Programmed cell death protein 1 | 1 | 0.9% |
Prolapse | 1 | 0.9% |
Propranolol | 1 | 0.9% |
Prostate cancer | 1 | 0.9% |
Prostate cancer screening | 1 | 0.9% |
Prostate-specific antigen | 1 | 0.9% |
Protein C | 1 | 0.9% |
Protein kinase | 1 | 0.9% |
Proteomics | 1 | 0.9% |
Prothrombin time | 1 | 0.9% |
Proton therapy | 1 | 0.9% |
Psychiatry | 1 | 0.9% |
Psychosis | 1 | 0.9% |
Public services | 1 | 0.9% |
Publication bias | 1 | 0.9% |
Public–private partnership | 1 | 0.9% |
Pulmonary alveolus | 1 | 0.9% |
Pulmonary fibrosis | 1 | 0.9% |
Pulmonology | 1 | 0.9% |
Pulse | 1 | 0.9% |
Pyrazinamide | 1 | 0.9% |
Quality (business) | 1 | 0.9% |
Quality management | 1 | 0.9% |
Quality management system | 1 | 0.9% |
Quality of life | 1 | 0.9% |
Quality of life (healthcare) | 1 | 0.9% |
QuantiFERON | 1 | 0.9% |
Quantitative research | 1 | 0.9% |
Quarantine | 1 | 0.9% |
Quitline | 1 | 0.9% |
RTT | 1 | 0.9% |
Radiofrequency ablation | 1 | 0.9% |
Raltegravir | 1 | 0.9% |
Recovery approach | 1 | 0.9% |
Rectocele | 1 | 0.9% |
Rectum | 1 | 0.9% |
Regression analysis | 1 | 0.9% |
Regurgitation (circulation) | 1 | 0.9% |
Reproduction | 1 | 0.9% |
Reproduction in mammals | 1 | 0.9% |
Reproductive health | 1 | 0.9% |
Republic | 1 | 0.9% |
Respiration | 1 | 0.9% |
Respiratory diseases | 1 | 0.9% |
Respiratory failure | 1 | 0.9% |
Respiratory system | 1 | 0.9% |
Retina | 1 | 0.9% |
Rheumatoid arthritis | 1 | 0.9% |
Rheumatology | 1 | 0.9% |
Risk–benefit ratio | 1 | 0.9% |
Ritonavir | 1 | 0.9% |
Rituximab | 1 | 0.9% |
Rivaroxaban | 1 | 0.9% |
Robot-assisted surgery | 1 | 0.9% |
Rosuvastatin | 1 | 0.9% |
Russian language | 1 | 0.9% |
SARS-CoV-2 Omicron variant | 1 | 0.9% |
Salt | 1 | 0.9% |
Self-determination theory | 1 | 0.9% |
Self-employment | 1 | 0.9% |
Semaglutide | 1 | 0.9% |
Sensitivity analysis | 1 | 0.9% |
Severe acute respiratory syndrome–related coronavirus | 1 | 0.9% |
Sexually transmitted diseases and infections | 1 | 0.9% |
Shortages related to the COVID-19 pandemic | 1 | 0.9% |
Simvastatin | 1 | 0.9% |
Smoking | 1 | 0.9% |
Smoking ban | 1 | 0.9% |
Social programs | 1 | 0.9% |
Sofosbuvir | 1 | 0.9% |
Soft drink | 1 | 0.9% |
Sotalol | 1 | 0.9% |
South Yorkshire | 1 | 0.9% |
Spasmodic torticollis | 1 | 0.9% |
Spasticity | 1 | 0.9% |
Specification (technical standard) | 1 | 0.9% |
Spreadsheet | 1 | 0.9% |
Standard error | 1 | 0.9% |
Statistical classification | 1 | 0.9% |
Statistical methods | 1 | 0.9% |
Stem cell factor | 1 | 0.9% |
Stillbirth | 1 | 0.9% |
Strategy | 1 | 0.9% |
Streptococcus agalactiae | 1 | 0.9% |
Subsidy | 1 | 0.9% |
Substance use disorder | 1 | 0.9% |
Sugar | 1 | 0.9% |
Sulfonylurea | 1 | 0.9% |
Supervised learning | 1 | 0.9% |
Surrogate endpoint | 1 | 0.9% |
Sustainability | 1 | 0.9% |
Swarm behaviour | 1 | 0.9% |
Sweetened beverage | 1 | 0.9% |
Symptoms of COVID-19 | 1 | 0.9% |
Syphilis | 1 | 0.9% |
System | 1 | 0.9% |
Systole | 1 | 0.9% |
T helper cell | 1 | 0.9% |
Tax | 1 | 0.9% |
Telecommuting | 1 | 0.9% |
Telenursing | 1 | 0.9% |
Telepathology | 1 | 0.9% |
Temporomandibular joint dysfunction | 1 | 0.9% |
Tenofovir disoproxil | 1 | 0.9% |
Terminal illness | 1 | 0.9% |
Tetanus | 1 | 0.9% |
Thiazide | 1 | 0.9% |
Thorax | 1 | 0.9% |
Thrombin | 1 | 0.9% |
Thrombocytopenia | 1 | 0.9% |
Ticagrelor | 1 | 0.9% |
Tirofiban | 1 | 0.9% |
Tissues (biology) | 1 | 0.9% |
Tobacco | 1 | 0.9% |
Tobacco control | 1 | 0.9% |
Tom Petty | 1 | 0.9% |
Toothpaste | 1 | 0.9% |
Torticollis | 1 | 0.9% |
Traceability | 1 | 0.9% |
Tracheal intubation | 1 | 0.9% |
Tracheotomy | 1 | 0.9% |
Traffic collision | 1 | 0.9% |
Transcriptomics technologies | 1 | 0.9% |
Transfusion medicine | 1 | 0.9% |
Transitional care | 1 | 0.9% |
Transmission of COVID-19 | 1 | 0.9% |
Transplant rejection | 1 | 0.9% |
Trastuzumab | 1 | 0.9% |
Trimethoprim/sulfamethoxazole | 1 | 0.9% |
Tropical disease | 1 | 0.9% |
Tuberculosis diagnosis | 1 | 0.9% |
Tyrosine kinase | 1 | 0.9% |
Ulipristal acetate | 1 | 0.9% |
Umbilical cord | 1 | 0.9% |
Unfolded protein response | 1 | 0.9% |
Universal health care | 1 | 0.9% |
Unsupervised learning | 1 | 0.9% |
Urinary system | 1 | 0.9% |
Urinary tract infection | 1 | 0.9% |
Urination | 1 | 0.9% |
Urogynecology | 1 | 0.9% |
Use case | 1 | 0.9% |
Uterus | 1 | 0.9% |
Vaccine Adverse Event Reporting System | 1 | 0.9% |
Vaccine Information Statement | 1 | 0.9% |
Vaccine hesitancy | 1 | 0.9% |
Vaccines | 1 | 0.9% |
Vagina | 1 | 0.9% |
Valproate | 1 | 0.9% |
Valsartan | 1 | 0.9% |
Vaporized hydrogen peroxide | 1 | 0.9% |
Varenicline | 1 | 0.9% |
Ventricular escape beat | 1 | 0.9% |
Verapamil | 1 | 0.9% |
Vertically transmitted infection | 1 | 0.9% |
Very low-density lipoprotein | 1 | 0.9% |
Veterinary medicine | 1 | 0.9% |
Viral hemorrhagic fever | 1 | 0.9% |
Viral load | 1 | 0.9% |
Viral vector vaccine | 1 | 0.9% |
Virology | 1 | 0.9% |
Visual impairment | 1 | 0.9% |
Vitamin | 1 | 0.9% |
Vitamin D | 1 | 0.9% |
WHO Framework Convention on Tobacco Control | 1 | 0.9% |
Warfarin | 1 | 0.9% |
Weight loss | 1 | 0.9% |
Weight management | 1 | 0.9% |
Welfare | 1 | 0.9% |
West Nile fever | 1 | 0.9% |
Western African Ebola virus epidemic | 1 | 0.9% |
Whole blood | 1 | 0.9% |
Women's health | 1 | 0.9% |
Working conditions | 1 | 0.9% |
Workplace | 1 | 0.9% |
X-linked agammaglobulinemia | 1 | 0.9% |
X-linked severe combined immunodeficiency | 1 | 0.9% |
Youth | 1 | 0.9% |
Zanamivir | 1 | 0.9% |
abs | rel | |
---|---|---|
Health | 57 | 98.3% |
Health sciences | 54 | 93.1% |
Medicine | 54 | 93.1% |
Clinical medicine | 53 | 91.4% |
Health care | 50 | 86.2% |
Medical specialties | 47 | 81.0% |
Diseases and disorders | 32 | 55.2% |
Epidemiology | 23 | 39.7% |
Public health | 22 | 37.9% |
Disease | 18 | 31.0% |
Cancer | 16 | 27.6% |
Clinical trial | 16 | 27.6% |
Medical diagnosis | 16 | 27.6% |
Preventive healthcare | 16 | 27.6% |
Risk | 16 | 27.6% |
Causes of death | 14 | 24.1% |
Evidence-based medicine | 13 | 22.4% |
Screening (medicine) | 13 | 22.4% |
Systematic review | 13 | 22.4% |
Therapy | 13 | 22.4% |
Patient | 12 | 20.7% |
Infection | 11 | 19.0% |
Health economics | 10 | 17.2% |
Breast cancer | 9 | 15.5% |
COVID-19 | 9 | 15.5% |
COVID-19 pandemic | 9 | 15.5% |
Immunology | 9 | 15.5% |
Infectious diseases | 9 | 15.5% |
Lung cancer | 9 | 15.5% |
Neoplasms | 9 | 15.5% |
Randomized controlled trial | 9 | 15.5% |
Research | 9 | 15.5% |
Social programs | 9 | 15.5% |
Health professional | 8 | 13.8% |
Hospital | 8 | 13.8% |
Life sciences | 8 | 13.8% |
Prostate cancer | 8 | 13.8% |
Tuberculosis | 8 | 13.8% |
Adherence (medicine) | 7 | 12.1% |
Artificial intelligence | 7 | 12.1% |
Branches of science | 7 | 12.1% |
HIV/AIDS | 7 | 12.1% |
Health policy | 7 | 12.1% |
Quality-adjusted life year | 7 | 12.1% |
Sensitivity and specificity | 7 | 12.1% |
Cancer screening | 6 | 10.3% |
Caregiver | 6 | 10.3% |
Cervical cancer | 6 | 10.3% |
Chronic condition | 6 | 10.3% |
Clinical endpoint | 6 | 10.3% |
Medical guideline | 6 | 10.3% |
Medical humanities | 6 | 10.3% |
Medical treatments | 6 | 10.3% |
Pharmacology | 6 | 10.3% |
Public services | 6 | 10.3% |
Public sphere | 6 | 10.3% |
Technology | 6 | 10.3% |
Vaccine | 6 | 10.3% |
Diabetes | 5 | 8.6% |
Emergency department | 5 | 8.6% |
Health informatics | 5 | 8.6% |
Health system | 5 | 8.6% |
Health technology | 5 | 8.6% |
Human papillomavirus infection | 5 | 8.6% |
Mammography | 5 | 8.6% |
Medical test | 5 | 8.6% |
Meta-analysis | 5 | 8.6% |
Shared decision-making in medicine | 5 | 8.6% |
Surgery | 5 | 8.6% |
CT scan | 4 | 6.9% |
Cardiovascular disease | 4 | 6.9% |
Chemotherapy | 4 | 6.9% |
Cohort study | 4 | 6.9% |
Colorectal cancer | 4 | 6.9% |
Comorbidity | 4 | 6.9% |
Drugs | 4 | 6.9% |
Heart | 4 | 6.9% |
Human activities | 4 | 6.9% |
Intensive care unit | 4 | 6.9% |
Lung cancer screening | 4 | 6.9% |
Machine learning | 4 | 6.9% |
Management of HIV/AIDS | 4 | 6.9% |
Medical imaging | 4 | 6.9% |
Medication | 4 | 6.9% |
Microbiology | 4 | 6.9% |
Multidrug-resistant tuberculosis | 4 | 6.9% |
Physical therapy | 4 | 6.9% |
Placebo | 4 | 6.9% |
Primary care | 4 | 6.9% |
Prostate cancer screening | 4 | 6.9% |
Prostate-specific antigen | 4 | 6.9% |
Pyrazinamide | 4 | 6.9% |
Radiology | 4 | 6.9% |
Statistical significance | 4 | 6.9% |
Stroke | 4 | 6.9% |
Tuberculosis management | 4 | 6.9% |
Type 2 diabetes | 4 | 6.9% |
Antimicrobial resistance | 3 | 5.2% |
Biomarker | 3 | 5.2% |
Bootstrapping (statistics) | 3 | 5.2% |
Breast cancer screening | 3 | 5.2% |
Cardiology | 3 | 5.2% |
Chest radiograph | 3 | 5.2% |
Childbirth | 3 | 5.2% |
Cost-effectiveness analysis | 3 | 5.2% |
Creative Commons license | 3 | 5.2% |
Decision tree learning | 3 | 5.2% |
Dependent and independent variables | 3 | 5.2% |
Econometrics | 3 | 5.2% |
Electronic health record | 3 | 5.2% |
Evaluation | 3 | 5.2% |
Experiment | 3 | 5.2% |
Extensively drug-resistant tuberculosis | 3 | 5.2% |
Fecal occult blood | 3 | 5.2% |
Guido Imbens | 3 | 5.2% |
Health insurance | 3 | 5.2% |
Insurance | 3 | 5.2% |
Isolation (health care) | 3 | 5.2% |
Lymphoma | 3 | 5.2% |
Managed care | 3 | 5.2% |
Mathematical optimization | 3 | 5.2% |
Medicaid | 3 | 5.2% |
National Lung Screening Trial | 3 | 5.2% |
Nursing | 3 | 5.2% |
Oregon Medicaid health experiment | 3 | 5.2% |
Overdiagnosis | 3 | 5.2% |
Percentile | 3 | 5.2% |
Phases of clinical research | 3 | 5.2% |
Physician | 3 | 5.2% |
Pneumonia | 3 | 5.2% |
Policy | 3 | 5.2% |
Pre-exposure prophylaxis | 3 | 5.2% |
Psychiatry | 3 | 5.2% |
Radiation therapy | 3 | 5.2% |
Random forest | 3 | 5.2% |
Rifampicin | 3 | 5.2% |
Science | 3 | 5.2% |
Scientific Advice Mechanism | 3 | 5.2% |
Shortness of breath | 3 | 5.2% |
Statin | 3 | 5.2% |
Statistical classification | 3 | 5.2% |
Statistics | 3 | 5.2% |
Stomach cancer | 3 | 5.2% |
Supplemental Nutrition Assistance Program | 3 | 5.2% |
Telehealth | 3 | 5.2% |
Adjuvant therapy | 2 | 3.4% |
Adverse event | 2 | 3.4% |
Airborne diseases | 2 | 3.4% |
Animal diseases | 2 | 3.4% |
Animal viral diseases | 2 | 3.4% |
Anticoagulant | 2 | 3.4% |
Asthma | 2 | 3.4% |
Atezolizumab | 2 | 3.4% |
Average treatment effect | 2 | 3.4% |
BCG vaccine | 2 | 3.4% |
Biopsy | 2 | 3.4% |
Bladder cancer | 2 | 3.4% |
Bone fracture | 2 | 3.4% |
Breast imaging | 2 | 3.4% |
COVID-19 testing | 2 | 3.4% |
COVID-19 vaccine | 2 | 3.4% |
Cancer immunotherapy | 2 | 3.4% |
Cerebral palsy | 2 | 3.4% |
Cerebrovascular disease | 2 | 3.4% |
Cervical intraepithelial neoplasia | 2 | 3.4% |
Cervical screening | 2 | 3.4% |
Chemicals in medicine | 2 | 3.4% |
Cholesterol | 2 | 3.4% |
Chronic myelogenous leukemia | 2 | 3.4% |
Cirrhosis | 2 | 3.4% |
Colonoscopy | 2 | 3.4% |
Copyright | 2 | 3.4% |
Coronavirus disease 2019 | 2 | 3.4% |
Cystic fibrosis | 2 | 3.4% |
Cytopathology | 2 | 3.4% |
Dense breast tissue | 2 | 3.4% |
Diabetes management | 2 | 3.4% |
Digital health | 2 | 3.4% |
Disease surveillance | 2 | 3.4% |
Dose (biochemistry) | 2 | 3.4% |
Education | 2 | 3.4% |
Environmental social science | 2 | 3.4% |
Epidermal growth factor receptor | 2 | 3.4% |
Foot | 2 | 3.4% |
Gardasil | 2 | 3.4% |
General practitioner | 2 | 3.4% |
Governance | 2 | 3.4% |
HIV | 2 | 3.4% |
HPV vaccine | 2 | 3.4% |
Health equity | 2 | 3.4% |
Heart failure | 2 | 3.4% |
Hematopoietic stem cell transplantation | 2 | 3.4% |
Hemodialysis | 2 | 3.4% |
Human diseases and disorders | 2 | 3.4% |
Human reproduction | 2 | 3.4% |
Hypercholesterolemia | 2 | 3.4% |
Hypertension | 2 | 3.4% |
Immunization | 2 | 3.4% |
Immunodeficiency | 2 | 3.4% |
Immunotherapy | 2 | 3.4% |
Incremental cost-effectiveness ratio | 2 | 3.4% |
Infant | 2 | 3.4% |
Informed consent | 2 | 3.4% |
Injection (medicine) | 2 | 3.4% |
Innovation | 2 | 3.4% |
Insulin (medication) | 2 | 3.4% |
Intensive care medicine | 2 | 3.4% |
Intention-to-treat analysis | 2 | 3.4% |
Intramuscular injection | 2 | 3.4% |
Isoniazid | 2 | 3.4% |
Lentiviruses | 2 | 3.4% |
Leukemia | 2 | 3.4% |
Local average treatment effect | 2 | 3.4% |
Loss function | 2 | 3.4% |
MEDLINE | 2 | 3.4% |
MHealth | 2 | 3.4% |
Mantoux test | 2 | 3.4% |
Maternal–fetal medicine | 2 | 3.4% |
Median | 2 | 3.4% |
Medical prescription | 2 | 3.4% |
Medical statistics | 2 | 3.4% |
Medical tests | 2 | 3.4% |
Men who have sex with men | 2 | 3.4% |
Mobile app | 2 | 3.4% |
Mobility aid | 2 | 3.4% |
Multiple myeloma | 2 | 3.4% |
Mycobacterium tuberculosis | 2 | 3.4% |
Neonatal intensive care unit | 2 | 3.4% |
Nivolumab | 2 | 3.4% |
Non-small-cell lung carcinoma | 2 | 3.4% |
Orthopedic surgery | 2 | 3.4% |
Orthotics | 2 | 3.4% |
Osimertinib | 2 | 3.4% |
Osteoporosis | 2 | 3.4% |
Ovarian cancer | 2 | 3.4% |
Palliative care | 2 | 3.4% |
Pandemic | 2 | 3.4% |
Pap test | 2 | 3.4% |
Pathology | 2 | 3.4% |
Pediatrics | 2 | 3.4% |
Pembrolizumab | 2 | 3.4% |
Personalized medicine | 2 | 3.4% |
Pharmaceutical industry | 2 | 3.4% |
Pharmaceutical sciences | 2 | 3.4% |
Pharmacokinetics | 2 | 3.4% |
Physical examination | 2 | 3.4% |
Pneumothorax | 2 | 3.4% |
Point of care | 2 | 3.4% |
Poverty | 2 | 3.4% |
Pregnancy | 2 | 3.4% |
Preterm birth | 2 | 3.4% |
Programmed cell death protein 1 | 2 | 3.4% |
Ptosis (eyelid) | 2 | 3.4% |
Pulmonary embolism | 2 | 3.4% |
Radiography | 2 | 3.4% |
Regression analysis | 2 | 3.4% |
Respiratory disease | 2 | 3.4% |
Rheumatology | 2 | 3.4% |
Risk assessment | 2 | 3.4% |
Robot-assisted surgery | 2 | 3.4% |
Self-care | 2 | 3.4% |
Sepsis | 2 | 3.4% |
Severe acute respiratory syndrome coronavirus 2 | 2 | 3.4% |
Sexually transmitted diseases and infections | 2 | 3.4% |
Sexually transmitted infection | 2 | 3.4% |
Signs and symptoms | 2 | 3.4% |
Smoking cessation | 2 | 3.4% |
Survival analysis | 2 | 3.4% |
Symptoms of COVID-19 | 2 | 3.4% |
Thrombosis | 2 | 3.4% |
Vaccination | 2 | 3.4% |
Vaccination schedule | 2 | 3.4% |
Viral diseases | 2 | 3.4% |
Viral respiratory tract infections | 2 | 3.4% |
ABC (medicine) | 1 | 1.7% |
ABVD | 1 | 1.7% |
Abaloparatide | 1 | 1.7% |
Acinetobacter | 1 | 1.7% |
Acromegaly | 1 | 1.7% |
Active surveillance of prostate cancer | 1 | 1.7% |
Acute myeloid leukemia | 1 | 1.7% |
Acute respiratory distress syndrome | 1 | 1.7% |
Adaptive clinical trial | 1 | 1.7% |
Adverse effect | 1 | 1.7% |
Alagille syndrome | 1 | 1.7% |
Algorithm | 1 | 1.7% |
Allergy | 1 | 1.7% |
Amyloidosis | 1 | 1.7% |
Anakinra | 1 | 1.7% |
Anaplastic lymphoma kinase | 1 | 1.7% |
Anatomical Therapeutic Chemical Classification System | 1 | 1.7% |
Anatomical terms of motion | 1 | 1.7% |
Anatomy | 1 | 1.7% |
Anesthesia | 1 | 1.7% |
Anesthesiology | 1 | 1.7% |
Angiography | 1 | 1.7% |
Angiology | 1 | 1.7% |
Angiotensin II receptor blocker | 1 | 1.7% |
Animal bite | 1 | 1.7% |
Anosmia | 1 | 1.7% |
Antibiotic | 1 | 1.7% |
Anticonvulsant | 1 | 1.7% |
Antineoplastic and immunomodulating drugs | 1 | 1.7% |
Antineoplastic drugs | 1 | 1.7% |
Antipsychotic | 1 | 1.7% |
Aortic valve | 1 | 1.7% |
Apixaban | 1 | 1.7% |
Arab world | 1 | 1.7% |
Artificial cardiac pacemaker | 1 | 1.7% |
Artificial intelligence in healthcare | 1 | 1.7% |
Ascending cholangitis | 1 | 1.7% |
Assessment of kidney function | 1 | 1.7% |
Atelectasis | 1 | 1.7% |
Atrophic vaginitis | 1 | 1.7% |
Attention deficit hyperactivity disorder | 1 | 1.7% |
Atypical pneumonias | 1 | 1.7% |
Augmented reality | 1 | 1.7% |
Automation | 1 | 1.7% |
Bachelor of Medicine, Bachelor of Surgery | 1 | 1.7% |
Barrett's esophagus | 1 | 1.7% |
Bedaquiline | 1 | 1.7% |
Behavior | 1 | 1.7% |
Best practice | 1 | 1.7% |
Bevacizumab | 1 | 1.7% |
Biological globalization | 1 | 1.7% |
Biopharmaceutical | 1 | 1.7% |
Biosimilar | 1 | 1.7% |
Birth control | 1 | 1.7% |
Birth defect | 1 | 1.7% |
Bisphosphonate | 1 | 1.7% |
Blastoma | 1 | 1.7% |
Blinded experiment | 1 | 1.7% |
Blood | 1 | 1.7% |
Blood pressure | 1 | 1.7% |
Blood sugar level | 1 | 1.7% |
Body fluids | 1 | 1.7% |
Bone | 1 | 1.7% |
Bone density | 1 | 1.7% |
Bone resorption | 1 | 1.7% |
Booster dose | 1 | 1.7% |
Bortezomib | 1 | 1.7% |
Breast milk | 1 | 1.7% |
Breastfeeding | 1 | 1.7% |
Breathing | 1 | 1.7% |
Brentuximab vedotin | 1 | 1.7% |
Canakinumab | 1 | 1.7% |
Cancer registry | 1 | 1.7% |
Cancer research | 1 | 1.7% |
Cancer staging | 1 | 1.7% |
Cancer treatments | 1 | 1.7% |
Cardiac amyloidosis | 1 | 1.7% |
Cardiac muscle | 1 | 1.7% |
Cardiothoracic surgery | 1 | 1.7% |
Cardiovascular system | 1 | 1.7% |
Carfilzomib | 1 | 1.7% |
Cataplexy | 1 | 1.7% |
Cataract | 1 | 1.7% |
Causality | 1 | 1.7% |
Cefiderocol | 1 | 1.7% |
Checkpoint inhibitor | 1 | 1.7% |
Child development | 1 | 1.7% |
Childhood | 1 | 1.7% |
Chimeric antigen receptor T cell | 1 | 1.7% |
Chronic lymphocytic leukemia | 1 | 1.7% |
Chronic obstructive pulmonary disease | 1 | 1.7% |
Circulating tumor DNA | 1 | 1.7% |
Circulatory system | 1 | 1.7% |
Clinic | 1 | 1.7% |
Clinical decision support system | 1 | 1.7% |
Cloth face mask | 1 | 1.7% |
Cognitive behavioral therapy | 1 | 1.7% |
Collaboration | 1 | 1.7% |
Computed tomography angiography | 1 | 1.7% |
Computer-aided diagnosis | 1 | 1.7% |
Condom | 1 | 1.7% |
Confounding | 1 | 1.7% |
Congenital pulmonary airway malformation | 1 | 1.7% |
Continuous positive airway pressure | 1 | 1.7% |
Convulsion | 1 | 1.7% |
Coronary artery disease | 1 | 1.7% |
Coronavirus-associated diseases | 1 | 1.7% |
Cost–benefit analysis | 1 | 1.7% |
Cost–utility analysis | 1 | 1.7% |
Cough | 1 | 1.7% |
Cushing's disease | 1 | 1.7% |
Cyclophosphamide | 1 | 1.7% |
DICOM | 1 | 1.7% |
DNA sequencing | 1 | 1.7% |
DPT vaccine | 1 | 1.7% |
Daratumumab | 1 | 1.7% |
Dasatinib | 1 | 1.7% |
Data analysis | 1 | 1.7% |
Deep learning | 1 | 1.7% |
Deep vein thrombosis | 1 | 1.7% |
Deferasirox | 1 | 1.7% |
Deferiprone | 1 | 1.7% |
Denosumab | 1 | 1.7% |
Dentistry | 1 | 1.7% |
Dermatology | 1 | 1.7% |
Dexamethasone | 1 | 1.7% |
Diabetic retinopathy | 1 | 1.7% |
Diagnosis of HIV/AIDS | 1 | 1.7% |
Dietary supplement | 1 | 1.7% |
Diffuse large B-cell lymphoma | 1 | 1.7% |
Disasters | 1 | 1.7% |
Disease outbreaks | 1 | 1.7% |
Doctor–patient relationship | 1 | 1.7% |
Dog | 1 | 1.7% |
Dravet syndrome | 1 | 1.7% |
Drug development | 1 | 1.7% |
Drug withdrawal | 1 | 1.7% |
Drug-induced QT prolongation | 1 | 1.7% |
Dual-energy X-ray absorptiometry | 1 | 1.7% |
Duchenne muscular dystrophy | 1 | 1.7% |
Dyspareunia | 1 | 1.7% |
ECTS grading scale | 1 | 1.7% |
EHealth | 1 | 1.7% |
EQ-5D | 1 | 1.7% |
Echinocandin | 1 | 1.7% |
Echocardiography | 1 | 1.7% |
Electrocardiography | 1 | 1.7% |
Electroconvulsive therapy | 1 | 1.7% |
Electrophysiology | 1 | 1.7% |
Emergency management | 1 | 1.7% |
Emergency medicine | 1 | 1.7% |
Emphysema | 1 | 1.7% |
Empowerment | 1 | 1.7% |
End-of-life care | 1 | 1.7% |
Endoscopy | 1 | 1.7% |
Enterovirus-associated diseases | 1 | 1.7% |
Epidemic | 1 | 1.7% |
Epidemics | 1 | 1.7% |
Epidemiology of HIV/AIDS | 1 | 1.7% |
Epilepsy | 1 | 1.7% |
Eradication of infectious diseases | 1 | 1.7% |
Erlotinib | 1 | 1.7% |
Esophageal cancer | 1 | 1.7% |
Esophagus | 1 | 1.7% |
Estradiol (medication) | 1 | 1.7% |
Everolimus | 1 | 1.7% |
Excessive daytime sleepiness | 1 | 1.7% |
Expanded Program on Immunization | 1 | 1.7% |
Expert | 1 | 1.7% |
Familial hypercholesterolemia | 1 | 1.7% |
Fatigue | 1 | 1.7% |
Frailty syndrome | 1 | 1.7% |
Gait analysis | 1 | 1.7% |
Gastroesophageal reflux disease | 1 | 1.7% |
GeneXpert MTB/RIF | 1 | 1.7% |
General practice | 1 | 1.7% |
Generic drug | 1 | 1.7% |
Genetic testing | 1 | 1.7% |
Geriatrics | 1 | 1.7% |
Global health | 1 | 1.7% |
Glomerular filtration rate | 1 | 1.7% |
Glycogen storage disease type II | 1 | 1.7% |
Gout | 1 | 1.7% |
Gynaecologic disorders | 1 | 1.7% |
HER2/neu | 1 | 1.7% |
HERG | 1 | 1.7% |
HIV-positive people | 1 | 1.7% |
Hazard ratio | 1 | 1.7% |
Health care management | 1 | 1.7% |
Health data | 1 | 1.7% |
Health disasters | 1 | 1.7% |
Health law | 1 | 1.7% |
Helicobacter pylori | 1 | 1.7% |
Hematology | 1 | 1.7% |
Hemophagocytic lymphohistiocytosis | 1 | 1.7% |
Hemosiderosis | 1 | 1.7% |
Hepatitis | 1 | 1.7% |
Hepatitis C | 1 | 1.7% |
Hierarchy of evidence | 1 | 1.7% |
Hip fracture | 1 | 1.7% |
Hip replacement | 1 | 1.7% |
Hives | 1 | 1.7% |
Hospital readmission | 1 | 1.7% |
Human development | 1 | 1.7% |
Human gender and sexuality | 1 | 1.7% |
Hydrops fetalis | 1 | 1.7% |
Hydroxychloroquine | 1 | 1.7% |
Hypersomnia | 1 | 1.7% |
Hypoglycemia | 1 | 1.7% |
Hypopnea | 1 | 1.7% |
Hypoxia (medical) | 1 | 1.7% |
Ibandronic acid | 1 | 1.7% |
Ibrutinib | 1 | 1.7% |
Idiopathic hypersomnia | 1 | 1.7% |
Improving Access to Psychological Therapies | 1 | 1.7% |
Indication (medicine) | 1 | 1.7% |
Infection prevention and control | 1 | 1.7% |
Inferior vena cava filter | 1 | 1.7% |
Information | 1 | 1.7% |
Information governance | 1 | 1.7% |
Insomnia | 1 | 1.7% |
Insulin | 1 | 1.7% |
International Classification of Diseases | 1 | 1.7% |
Interventional radiology | 1 | 1.7% |
Intrauterine growth restriction | 1 | 1.7% |
Intravenous therapy | 1 | 1.7% |
Iron overload | 1 | 1.7% |
Juvenile idiopathic arthritis | 1 | 1.7% |
Kangaroo care | 1 | 1.7% |
Knee replacement | 1 | 1.7% |
Latent tuberculosis | 1 | 1.7% |
Law of Canada | 1 | 1.7% |
Learning | 1 | 1.7% |
Lenalidomide | 1 | 1.7% |
Lennox–Gastaut syndrome | 1 | 1.7% |
Levofloxacin | 1 | 1.7% |
Lipid disorders | 1 | 1.7% |
Lipids | 1 | 1.7% |
Lisinopril | 1 | 1.7% |
Liver function tests | 1 | 1.7% |
Long QT syndrome | 1 | 1.7% |
Low-molecular-weight heparin | 1 | 1.7% |
Lung | 1 | 1.7% |
Lupus | 1 | 1.7% |
Lysosome | 1 | 1.7% |
Magnetic resonance imaging | 1 | 1.7% |
Major depressive disorder | 1 | 1.7% |
Male genital disorders | 1 | 1.7% |
Mandibular advancement splint | 1 | 1.7% |
Mechanical ventilation | 1 | 1.7% |
Medical device | 1 | 1.7% |
Medical education | 1 | 1.7% |
Medical error | 1 | 1.7% |
Medical privacy | 1 | 1.7% |
Medical school | 1 | 1.7% |
Medical ultrasound | 1 | 1.7% |
Medicinal chemistry | 1 | 1.7% |
Medium-chain acyl-coenzyme A dehydrogenase deficiency | 1 | 1.7% |
Membrane-active molecules | 1 | 1.7% |
Menopause | 1 | 1.7% |
Mental disorder | 1 | 1.7% |
Mental states | 1 | 1.7% |
Metabolic disorders | 1 | 1.7% |
Methylnaltrexone | 1 | 1.7% |
Methylphenidate | 1 | 1.7% |
Midwife | 1 | 1.7% |
Midwifery | 1 | 1.7% |
Migraine | 1 | 1.7% |
Minimally invasive procedure | 1 | 1.7% |
Mobile device | 1 | 1.7% |
Modafinil | 1 | 1.7% |
Monitoring (medicine) | 1 | 1.7% |
Motherhood | 1 | 1.7% |
Mycobacteria | 1 | 1.7% |
Mycoplasma | 1 | 1.7% |
Myelodysplastic syndrome | 1 | 1.7% |
Naldemedine | 1 | 1.7% |
Narcolepsy | 1 | 1.7% |
National TB Elimination Program (India) | 1 | 1.7% |
Neonatal hypoglycemia | 1 | 1.7% |
Neonatology | 1 | 1.7% |
Neurology | 1 | 1.7% |
Neurosurgery | 1 | 1.7% |
Nilotinib | 1 | 1.7% |
Niraparib | 1 | 1.7% |
Non-alcoholic fatty liver disease | 1 | 1.7% |
Non-communicable disease | 1 | 1.7% |
Null hypothesis | 1 | 1.7% |
Obeticholic acid | 1 | 1.7% |
Obstetrics | 1 | 1.7% |
Obstructive sleep apnea | 1 | 1.7% |
Octreotide | 1 | 1.7% |
Olaparib | 1 | 1.7% |
Omacetaxine mepesuccinate | 1 | 1.7% |
Omalizumab | 1 | 1.7% |
Ongoing events | 1 | 1.7% |
Oregon Health Plan | 1 | 1.7% |
Organ donation | 1 | 1.7% |
Orphan drug | 1 | 1.7% |
Osilodrostat | 1 | 1.7% |
Ospemifene | 1 | 1.7% |
PD-1 and PD-L1 inhibitors | 1 | 1.7% |
PD-L1 | 1 | 1.7% |
Palbociclib | 1 | 1.7% |
Pandemics | 1 | 1.7% |
Patient safety | 1 | 1.7% |
Patient safety organization | 1 | 1.7% |
Patient-reported outcome | 1 | 1.7% |
Peer review | 1 | 1.7% |
Periodic limb movement disorder | 1 | 1.7% |
Personal protective equipment | 1 | 1.7% |
Pertuzumab | 1 | 1.7% |
Pharmacist | 1 | 1.7% |
Pharmacodynamics | 1 | 1.7% |
Pharmacogenomics | 1 | 1.7% |
Pharmacy | 1 | 1.7% |
Physiology | 1 | 1.7% |
Picture archiving and communication system | 1 | 1.7% |
Pitolisant | 1 | 1.7% |
Placebo-controlled study | 1 | 1.7% |
Pleural effusion | 1 | 1.7% |
Point-of-care testing | 1 | 1.7% |
Polio | 1 | 1.7% |
Polio eradication | 1 | 1.7% |
Polio vaccine | 1 | 1.7% |
Poliovirus | 1 | 1.7% |
Population health | 1 | 1.7% |
Post-exposure prophylaxis | 1 | 1.7% |
Postpartum period | 1 | 1.7% |
Precision medicine | 1 | 1.7% |
Prediction | 1 | 1.7% |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses | 1 | 1.7% |
Pretomanid | 1 | 1.7% |
Prevention of HIV/AIDS | 1 | 1.7% |
Preventive medicine | 1 | 1.7% |
Price | 1 | 1.7% |
Primary biliary cholangitis | 1 | 1.7% |
Primary sclerosing cholangitis | 1 | 1.7% |
Probability | 1 | 1.7% |
Progressive familial intrahepatic cholestasis | 1 | 1.7% |
Provinces and territories of Canada | 1 | 1.7% |
Public Health Emergency of International Concern | 1 | 1.7% |
Public health surveillance | 1 | 1.7% |
Pulmonary sequestration | 1 | 1.7% |
QT interval | 1 | 1.7% |
Quality of life (healthcare) | 1 | 1.7% |
Quarantine | 1 | 1.7% |
Rabies | 1 | 1.7% |
Rabies vaccine | 1 | 1.7% |
Rabies virus | 1 | 1.7% |
Radiographer | 1 | 1.7% |
Radiosurgery | 1 | 1.7% |
Raloxifene | 1 | 1.7% |
Rare disease | 1 | 1.7% |
Real world evidence | 1 | 1.7% |
Receiver operating characteristic | 1 | 1.7% |
Refrigerator | 1 | 1.7% |
Refugee children | 1 | 1.7% |
Relative risk | 1 | 1.7% |
Retinopathy | 1 | 1.7% |
Ribociclib | 1 | 1.7% |
Rifapentine | 1 | 1.7% |
Rivaroxaban | 1 | 1.7% |
Robotics | 1 | 1.7% |
Romosozumab | 1 | 1.7% |
SARS-CoV-2 | 1 | 1.7% |
SOFA score | 1 | 1.7% |
Safe sex | 1 | 1.7% |
Sarcoma | 1 | 1.7% |
Scintigraphy | 1 | 1.7% |
Sclerostin | 1 | 1.7% |
Seizure | 1 | 1.7% |
Septic shock | 1 | 1.7% |
Serum free light-chain measurement | 1 | 1.7% |
Sexual health | 1 | 1.7% |
Sexual intercourse | 1 | 1.7% |
Single-photon emission computed tomography | 1 | 1.7% |
Sleep | 1 | 1.7% |
Sleep apnea | 1 | 1.7% |
Sleep disorder | 1 | 1.7% |
Social distancing | 1 | 1.7% |
Societal collapse | 1 | 1.7% |
Spastic cerebral palsy | 1 | 1.7% |
Spinal fusion | 1 | 1.7% |
Spinal muscular atrophy | 1 | 1.7% |
Spirometry | 1 | 1.7% |
Stargardt disease | 1 | 1.7% |
Stimulant | 1 | 1.7% |
Strontium ranelate | 1 | 1.7% |
Study heterogeneity | 1 | 1.7% |
Subcutaneous injection | 1 | 1.7% |
Sudden unexpected death in epilepsy | 1 | 1.7% |
Superficial thrombophlebitis | 1 | 1.7% |
Superficial vein thrombosis | 1 | 1.7% |
Surgical mask | 1 | 1.7% |
Syphilis | 1 | 1.7% |
Systemic inflammatory response syndrome | 1 | 1.7% |
Tafamidis | 1 | 1.7% |
Technetium-99m | 1 | 1.7% |
Teleradiology | 1 | 1.7% |
Telmisartan | 1 | 1.7% |
Temporary Assistance for Needy Families | 1 | 1.7% |
Teriparatide | 1 | 1.7% |
Tetanus vaccine | 1 | 1.7% |
The New England Journal of Medicine | 1 | 1.7% |
Thoracic diaphragm | 1 | 1.7% |
Thrombophilia | 1 | 1.7% |
Thrombosis prevention | 1 | 1.7% |
Tissues (biology) | 1 | 1.7% |
Tobacco smoking | 1 | 1.7% |
Tocilizumab | 1 | 1.7% |
Torsades de pointes | 1 | 1.7% |
Transmission (medicine) | 1 | 1.7% |
Transthyretin | 1 | 1.7% |
Trastuzumab | 1 | 1.7% |
Traumatic brain injury | 1 | 1.7% |
Treatment and management of COVID-19 | 1 | 1.7% |
Treatment as prevention | 1 | 1.7% |
Treatment of cancer | 1 | 1.7% |
Truenat | 1 | 1.7% |
Trust (social science) | 1 | 1.7% |
Tuberculosis diagnosis | 1 | 1.7% |
Type 1 diabetes | 1 | 1.7% |
Tyrosine kinase | 1 | 1.7% |
Ursodeoxycholic acid | 1 | 1.7% |
Vaccine adverse event | 1 | 1.7% |
Valproate | 1 | 1.7% |
Vein | 1 | 1.7% |
Venous thrombosis | 1 | 1.7% |
Vertically transmitted infection | 1 | 1.7% |
Viral infections of the central nervous system | 1 | 1.7% |
Virology | 1 | 1.7% |
Virtual reality | 1 | 1.7% |
Visual impairment | 1 | 1.7% |
Warfarin | 1 | 1.7% |
Weakness | 1 | 1.7% |
Whole genome sequencing | 1 | 1.7% |
Zoledronic acid | 1 | 1.7% |
abs | rel | |
---|---|---|
Clinical medicine | 5 | 100.0% |
Health | 5 | 100.0% |
Health sciences | 5 | 100.0% |
Medical specialties | 5 | 100.0% |
Medicine | 5 | 100.0% |
Health care | 4 | 80.0% |
Disease | 3 | 60.0% |
Diseases and disorders | 3 | 60.0% |
Adverse effect | 2 | 40.0% |
Cancer | 2 | 40.0% |
Cardiovascular disease | 2 | 40.0% |
Caregiver | 2 | 40.0% |
Chronic condition | 2 | 40.0% |
Evidence-based medicine | 2 | 40.0% |
Medication | 2 | 40.0% |
Myocardial infarction | 2 | 40.0% |
Pregnancy | 2 | 40.0% |
Preterm birth | 2 | 40.0% |
Preventive healthcare | 2 | 40.0% |
Psychotherapy | 2 | 40.0% |
Risk | 2 | 40.0% |
Aboriginal Australians | 1 | 20.0% |
Abortion | 1 | 20.0% |
Aciclovir | 1 | 20.0% |
Acute coronary syndrome | 1 | 20.0% |
Adherence (medicine) | 1 | 20.0% |
Ageing | 1 | 20.0% |
Alpha-Linolenic acid | 1 | 20.0% |
Anatomical terms of motion | 1 | 20.0% |
Angiology | 1 | 20.0% |
Attention | 1 | 20.0% |
Australians | 1 | 20.0% |
Bacterial vaginosis | 1 | 20.0% |
Bevacizumab | 1 | 20.0% |
Birth control | 1 | 20.0% |
Birth weight | 1 | 20.0% |
Blood pressure | 1 | 20.0% |
Breastfeeding | 1 | 20.0% |
C-reactive protein | 1 | 20.0% |
Caesarean section | 1 | 20.0% |
Cancer immunotherapy | 1 | 20.0% |
Cardiology | 1 | 20.0% |
Cardiovascular system | 1 | 20.0% |
Census in Australia | 1 | 20.0% |
Ceritinib | 1 | 20.0% |
Cervical cancer | 1 | 20.0% |
Cervical screening | 1 | 20.0% |
Chancroid | 1 | 20.0% |
Chemotherapy | 1 | 20.0% |
Childbirth | 1 | 20.0% |
Chlamydia infection | 1 | 20.0% |
Cholesterol | 1 | 20.0% |
Clinical psychology | 1 | 20.0% |
Clinical trial | 1 | 20.0% |
Cognition | 1 | 20.0% |
Combined oral contraceptive pill | 1 | 20.0% |
Condom | 1 | 20.0% |
Contrast (vision) | 1 | 20.0% |
Coronary artery disease | 1 | 20.0% |
Crizotinib | 1 | 20.0% |
Decision-making | 1 | 20.0% |
Dementia | 1 | 20.0% |
Diabetes | 1 | 20.0% |
Diabetic retinopathy | 1 | 20.0% |
Diagnosis of HIV/AIDS | 1 | 20.0% |
Dietary supplement | 1 | 20.0% |
Disability | 1 | 20.0% |
Docetaxel | 1 | 20.0% |
Docosahexaenoic acid | 1 | 20.0% |
Domestic violence | 1 | 20.0% |
Dose (biochemistry) | 1 | 20.0% |
Driving | 1 | 20.0% |
Echocardiography | 1 | 20.0% |
Efavirenz | 1 | 20.0% |
Eicosanoid | 1 | 20.0% |
Eicosapentaenoic acid | 1 | 20.0% |
Emergency contraception | 1 | 20.0% |
Epidemiology | 1 | 20.0% |
Epidermal growth factor receptor | 1 | 20.0% |
Erlotinib | 1 | 20.0% |
Essential fatty acid | 1 | 20.0% |
Evaluation | 1 | 20.0% |
Executive functions | 1 | 20.0% |
Family planning | 1 | 20.0% |
Fat | 1 | 20.0% |
Female condom | 1 | 20.0% |
Fertility | 1 | 20.0% |
Fish oil | 1 | 20.0% |
Genital herpes | 1 | 20.0% |
Genital wart | 1 | 20.0% |
Gonorrhea | 1 | 20.0% |
Group A streptococcal infection | 1 | 20.0% |
HIV | 1 | 20.0% |
HIV and pregnancy | 1 | 20.0% |
HIV/AIDS | 1 | 20.0% |
Hazard ratio | 1 | 20.0% |
Health policy | 1 | 20.0% |
Heart | 1 | 20.0% |
Heart arrhythmia | 1 | 20.0% |
Herpes simplex | 1 | 20.0% |
High-density lipoprotein | 1 | 20.0% |
Hormonal contraception | 1 | 20.0% |
Hospital | 1 | 20.0% |
Human activities | 1 | 20.0% |
Human papillomavirus infection | 1 | 20.0% |
Human reproduction | 1 | 20.0% |
Human sexual activity | 1 | 20.0% |
Human sexuality | 1 | 20.0% |
Hyperlipidemia | 1 | 20.0% |
Hypertension | 1 | 20.0% |
Indigenous Australians | 1 | 20.0% |
Infection | 1 | 20.0% |
Infectious diseases | 1 | 20.0% |
Infertility | 1 | 20.0% |
Intrauterine device | 1 | 20.0% |
Lamivudine | 1 | 20.0% |
Lipids | 1 | 20.0% |
Low-density lipoprotein | 1 | 20.0% |
Lung cancer | 1 | 20.0% |
Lutein | 1 | 20.0% |
Major depressive disorder | 1 | 20.0% |
Malaria | 1 | 20.0% |
Management of HIV/AIDS | 1 | 20.0% |
Maternal death | 1 | 20.0% |
Medical abortion | 1 | 20.0% |
Medical history | 1 | 20.0% |
Medical humanities | 1 | 20.0% |
Medical treatments | 1 | 20.0% |
Medicare (United States) | 1 | 20.0% |
Medroxyprogesterone acetate | 1 | 20.0% |
Memory | 1 | 20.0% |
Metastasis | 1 | 20.0% |
Mifepristone | 1 | 20.0% |
Miscarriage | 1 | 20.0% |
Misoprostol | 1 | 20.0% |
Motor skill | 1 | 20.0% |
Neoplasms | 1 | 20.0% |
Nevirapine | 1 | 20.0% |
Nivolumab | 1 | 20.0% |
Non-small-cell lung carcinoma | 1 | 20.0% |
Nursing | 1 | 20.0% |
Nutrient | 1 | 20.0% |
Nutrients | 1 | 20.0% |
Nutrition | 1 | 20.0% |
Obstetrics | 1 | 20.0% |
Occupational therapist | 1 | 20.0% |
Occupational therapy | 1 | 20.0% |
Old age | 1 | 20.0% |
Omega-3 acid ethyl esters | 1 | 20.0% |
Omega-3 fatty acid | 1 | 20.0% |
Organic compounds | 1 | 20.0% |
Osteoarthritis | 1 | 20.0% |
PD-L1 | 1 | 20.0% |
Pain | 1 | 20.0% |
Palpitations | 1 | 20.0% |
Pelvic inflammatory disease | 1 | 20.0% |
Pembrolizumab | 1 | 20.0% |
Pemetrexed | 1 | 20.0% |
Perception | 1 | 20.0% |
Percutaneous coronary intervention | 1 | 20.0% |
Pharmacy | 1 | 20.0% |
Physical therapy | 1 | 20.0% |
Physician | 1 | 20.0% |
Postpartum period | 1 | 20.0% |
Prenatal development | 1 | 20.0% |
Problem solving | 1 | 20.0% |
Programmed cell death protein 1 | 1 | 20.0% |
Public health | 1 | 20.0% |
RTT | 1 | 20.0% |
Randomized controlled trial | 1 | 20.0% |
Rape | 1 | 20.0% |
Reperfusion therapy | 1 | 20.0% |
Reproductive health | 1 | 20.0% |
Rheumatic fever | 1 | 20.0% |
Safe sex | 1 | 20.0% |
Safety | 1 | 20.0% |
Screening (medicine) | 1 | 20.0% |
Sensitivity and specificity | 1 | 20.0% |
Sexual health | 1 | 20.0% |
Sexual intercourse | 1 | 20.0% |
Sexually transmitted infection | 1 | 20.0% |
Shortness of breath | 1 | 20.0% |
Snellen chart | 1 | 20.0% |
Spermicide | 1 | 20.0% |
Stavudine | 1 | 20.0% |
Sterilization (medicine) | 1 | 20.0% |
Survey methodology | 1 | 20.0% |
Syncope (medicine) | 1 | 20.0% |
Syphilis | 1 | 20.0% |
Systematic review | 1 | 20.0% |
Test (assessment) | 1 | 20.0% |
Therapy | 1 | 20.0% |
Traffic | 1 | 20.0% |
Traffic collision | 1 | 20.0% |
Transmission (medicine) | 1 | 20.0% |
Traumatic brain injury | 1 | 20.0% |
Unintended pregnancy | 1 | 20.0% |
Urology | 1 | 20.0% |
Vacuum aspiration | 1 | 20.0% |
Vagina | 1 | 20.0% |
Vaginal discharge | 1 | 20.0% |
Vaginitis | 1 | 20.0% |
Vertically transmitted infection | 1 | 20.0% |
Violence | 1 | 20.0% |
Visual acuity | 1 | 20.0% |
Visual impairment | 1 | 20.0% |
Visual perception | 1 | 20.0% |
Wart | 1 | 20.0% |
Woman | 1 | 20.0% |
Women's health | 1 | 20.0% |
Working memory | 1 | 20.0% |
Zidovudine | 1 | 20.0% |